PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MILLSTEIN, SG; NIGHTINGALE, EO; PETERSEN, AC; MORTIMER, AM; HAMBURG, DA				MILLSTEIN, SG; NIGHTINGALE, EO; PETERSEN, AC; MORTIMER, AM; HAMBURG, DA			PROMOTING THE HEALTHY DEVELOPMENT OF ADOLESCENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									CARNEGIE CORP,NEW YORK,NY; UNIV MINNESOTA,GRAD SCH,OFF VICE PRESIDENT RES & DEAN,MINNEAPOLIS,MN 55455; CARNEGIE CORP,WASHINGTON,DC	University of Minnesota System; University of Minnesota Twin Cities	MILLSTEIN, SG (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DIV ADOLESCENT MED,400 PARNASSUS AVE,ROOM AC 01,BOX 0374,SAN FRANCISCO,CA 94143, USA.							Elster AB, 1993, GUIDELINES ADOLESCEN; Feldman SS, 1990, THRESHOLD DEV ADOLES; HAMBURG DA, 1992, TODAYS CHILDREN CREA; Hechinger F M, 1992, FATEFUL CHOICES HLTH; KICKBUSCH I, 1989, SOC SCI MED, V29, P125, DOI 10.1016/0277-9536(89)90160-3; Millstein S. G., 1993, PROMOTING HLTH ADOLE; 1989, TURNING POINTS PREPA; 1990, CODE BLUE UNITING HL; 1991, ADOLESCENT HLTH, V1	9	44	45	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1413	1415		10.1001/jama.269.11.1413	http://dx.doi.org/10.1001/jama.269.11.1413			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ857	8441218				2022-12-28	WOS:A1993KQ85700037
J	LEW, DJ; MARINI, NJ; REED, SI				LEW, DJ; MARINI, NJ; REED, SI			A SUPPRESSOR OF CLN3 FOR SIZE CONTROL	CELL			English	Article							CEREVISIAE				LEW, DJ (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.							GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3	3	4	4	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					488	489		10.1016/0092-8674(93)90068-2	http://dx.doi.org/10.1016/0092-8674(93)90068-2			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440017				2022-12-28	WOS:A1993KP16500004
J	PAFFENBARGER, RS; HYDE, RT; WING, AL; LEE, IM; JUNG, DL; KAMPERT, JB				PAFFENBARGER, RS; HYDE, RT; WING, AL; LEE, IM; JUNG, DL; KAMPERT, JB			THE ASSOCIATION OF CHANGES IN PHYSICAL-ACTIVITY LEVEL AND OTHER LIFE-STYLE CHARACTERISTICS WITH MORTALITY AMONG MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ALL-CAUSE MORTALITY; RISK-FACTORS; LEISURE-TIME; COLLEGE ALUMNI; DEATH; ATTACK; RATES	Background. Recent trends toward increasing physical exercise, stopping cigarette smoking, and avoiding obesity may increase longevity. We analyzed changes in the lifestyles of Harvard College alumni and the associations of these changes with mortality. Methods. Men who were 45 to 84 years of age in 1977 and who had reported no life-threatening disease on questionnaires completed in 1962 or 1966 and again in 1977 were classified according to changes in lifestyle characteristics between the first and second questionnaires. We analyzed changes in their level of physical activity, cigarette smoking, blood pressure, and body weight, and the relation of these factors to mortality between 1977 and 1985. Results. Of the 10,269 men, 476 died during this period (which totaled 90,650 man-years of observation). Beginning moderately vigorous sports activity (at an intensity of 4.5 or more metabolic equivalents) was associated with a 23 percent lower risk of death (95 percent confidence interval, 4 to 42 percent; P = 0.015) than not taking up moderately vigorous sports. Quitting cigarette smoking was associated with a 41 percent lower risk (95 percent confidence interval, 20 to 57 percent; P = 0.001) than continuing smoking, but with a 23 percent higher risk than constant nonsmoking. Men with recently diagnosed hypertension had a lower risk of death than those with long-term hypertension (relative risk, 0.75; 95 percent confidence interval, 0.55 to 1.02; P = 0.057), as did men with consistently normal blood pressure (relative risk, 0.52; 95 percent confidence interval, 0.40 to 0.68; P < 0.001). Maintenance of lean body mass was associated with a lower mortality rate than long-term, recent, or previous obesity. The associations between changes in lifestyle and mortality were independent and were largely undiminished by age. Our findings on death from coronary heart disease mirrored those on death from all causes. Conclusions. Beginning moderately vigorous sports activity, quitting cigarette smoking, maintaining normal blood pressure, and avoiding obesity were separately associated with lower rates of death from all causes and from coronary heart disease among middle-aged and older men.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	PAFFENBARGER, RS (corresponding author), STANFORD UNIV, MED CTR,SCH MED,DEPT HLTH RES & POLICY, DIV EPIDEMIOL,HRP BLDG, RM 113, STANFORD, CA 94305 USA.		Lee, I-Min/ABD-5409-2021		NCI NIH HHS [R01 CA 44854] Funding Source: Medline; NHLBI NIH HHS [R01 HL 34174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044854] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ARRAIZ GA, 1992, J CLIN EPIDEMIOL, V45, P419, DOI 10.1016/0895-4356(92)90043-M; BENFANTE RJ, 1989, J CLIN EPIDEMIOL, V42, P95, DOI 10.1016/0895-4356(89)90082-6; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; CASPERSEN CJ, 1991, AM J EPIDEMIOL, V133, P1078, DOI 10.1093/oxfordjournals.aje.a115821; CHAVE SPW, 1978, J EPIDEMIOL COMMUN H, V32, P239, DOI 10.1136/jech.32.4.239; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KARVONEN MJ, 1989, ANN MED, V21, P3, DOI 10.3109/07853898909149175; LEE IM, 1992, AM J EPIDEMIOL, V135, P915, DOI 10.1093/oxfordjournals.aje.a116387; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; LINDSTED KD, 1991, J CLIN EPIDEMIOL, V44, P355, DOI 10.1016/0895-4356(91)90074-J; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MORRIS JN, 1990, BRIT HEART J, V63, P325; MORRIS JN, IN PRESS MED SCI SPO; PAFFENBARGER RS, 1990, EXERCISE, FITNESS, AND HEALTH, P33; PAFFENBARGER RS, 1984, JAMA-J AM MED ASSOC, V252, P491, DOI 10.1001/jama.252.4.491; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P12; PAFFENBARGER RS, 1966, AM J PUBLIC HEALTH N, V56, P962, DOI 10.2105/AJPH.56.6.962; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PAFFENBARGER RS, IN PRESS PHYSICAL AC; PEKKANEN J, 1987, LANCET, V1, P1473, DOI 10.1016/S0140-6736(87)92218-5; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SHAPER AG, 1991, BRIT HEART J, V66, P384; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; [No title captured]; 1986, NEW ENGL J MED, V315, P399	31	1337	1374	3	107	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					538	545		10.1056/NEJM199302253280804	http://dx.doi.org/10.1056/NEJM199302253280804			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8426621				2022-12-28	WOS:A1993KP05300004
J	MCDONALD, GB; HINDS, MS; FISHER, LD; SCHOCH, HG; WOLFORD, JL; BANAJI, M; HARDIN, BJ; SHULMAN, HM; CLIFT, RA				MCDONALD, GB; HINDS, MS; FISHER, LD; SCHOCH, HG; WOLFORD, JL; BANAJI, M; HARDIN, BJ; SHULMAN, HM; CLIFT, RA			VENOOCCLUSIVE DISEASE OF THE LIVER AND MULTIORGAN FAILURE AFTER BONE-MARROW TRANSPLANTATION - A COHORT STUDY OF 355 PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						BONE MARROW TRANSPLANTATION; MULTIPLE ORGAN FAILURE; HEPATIC VENOOCCLUSIVE DISEASE; AMINOTRANSFERASES; VANCOMYCIN	TUMOR-NECROSIS-FACTOR; REGIMEN-RELATED TOXICITY; RESPIRATORY-DISTRESS SYNDROME; 2 IRRADIATION REGIMENS; VENOOCCLUSIVE DISEASE; VENOCCLUSIVE DISEASE; FACTOR-ALPHA; ENDOTHELIAL-CELLS; MYELOID-LEUKEMIA; RANDOMIZED TRIAL	Objective: To determine the incidence and clinical course of veno-occlusive disease of the liver (VOD) after bone marrow transplantation and to analyze risk factors for severe VOD. Design: Cohort study of 355 consecutive patients. Setting: A bone marrow transplantation center. Measurements: Each patient was prospectively evaluated for VOD, and many risk factors for severe VOD were analyzed using logistic regression models. The relation of VOD to renal and cardiopulmonary failure was analyzed using time-dependent proportional hazards models. Results: Veno-occlusive disease developed in 190 of 355 patients (54%; 95% CI, 48% to 59%): Fifty-four patients had severe VOD and 136 had mild or moderate VOD. Independent variables derived from a multivariate model for predicting severe VOD included elevated transaminase values before transplantation (relative risk, 4.6; P < 0.0001); vancomycin therapy during cytoreductive therapy (relative risk, 2.9; P = 0.003); cytoreductive therapy with a high-dose regimen (relative risk, 2.8; P = 0.01); acyclovir therapy before transplantation (relative risk, 4.8; P = 0.02); mismatched or unrelated donor marrow (relative risk, 2.4; P = 0.02); and previous radiation therapy to the abdomen (relative risk, 2.2; P = 0.04). Vancomycin therapy was a marker for persistent fever. Multiorgan failure was more frequent among patients with VOD and usually followed the onset of liver disease. Conclusions: Veno-occlusive disease, which developed in 54% of bone marrow transplant recipients, is frequently associated with renal and cardiopulmonary failure. Pretransplant transaminase elevations, use of high-dose cytoreductive therapy, and persistent fever during cytoreductive therapy are independent predictors of severe VOD.	UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	MCDONALD, GB (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.				NATIONAL CANCER INSTITUTE [P01CA018029, P30CA015704] Funding Source: NIH RePORTER; NCI NIH HHS [CA18029, CA15704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDUS T, 1991, HEPATOLOGY, V13, P364, DOI 10.1016/0270-9139(91)92454-G; [Anonymous], 1991, J Infect Dis, V163, P951; AURER I, 1991, BONE MARROW TRANSPL, V7, P255; BEARMAN SI, 1989, J CLIN ONCOL, V7, P1288, DOI 10.1200/JCO.1989.7.9.1288; BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BIANCO JA, 1991, BLOOD, V78, P1205; Birnbaum Z., 1974, RELIABILITY BIOMETRY, P441; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; CLIFT RA, 1990, BLOOD, V76, P1867; CLIFT RA, 1991, BLOOD, V77, P1660; ELMOUELHI M, 1986, HEPATOLOGY, V6, P450; ERIKSSON LS, 1990, HEPATOLOGY, V12, P1350, DOI 10.1002/hep.1840120616; ESSELL JH, 1992, BLOOD, V79, P2784; FAIONI EM, 1991, BLOOD S, V78, pA193; FOX ES, 1990, LAB INVEST, V63, P733; GALE RP, 1978, SCIENCE, V201, P937, DOI 10.1126/science.356266; GANEM G, 1988, INT J RADIAT ONCOL, V14, P879, DOI 10.1016/0360-3016(88)90009-0; GERLACH H, 1990, ANNU REV MED, V41, P15; GORDON B, 1991, BONE MARROW TRANSPL, V8, P497; GREVE JW, 1990, GASTROENTEROLOGY, V98, P478, DOI 10.1016/0016-5085(90)90841-N; GROCHOW LB, 1990, BLOOD, V75, P1723; GROCHOW LB, 1989, CANCER CHEMOTH PHARM, V25, P55, DOI 10.1007/BF00694339; HARPER PL, 1990, BONE MARROW TRANSPL, V5, P39; HASSAN M, 1991, CANCER CHEMOTH PHARM, V28, P130, DOI 10.1007/BF00689702; HILL HF, 1991, BLOOD, V78, pA243; HOLLER E, 1990, BLOOD, V75, P1011; ISHAWA T, 1986, TARGET ORGAN TOXICIT; JAATTELA M, 1991, LAB INVEST, V64, P724; JIRTLE RL, 1981, CANCER RES, V41, P3512; JOHNSON LK, 1982, ANAL QUANT CYTOL, V4, P188; JONES RJ, 1987, TRANSPLANTATION, V44, P778, DOI 10.1097/00007890-198712000-00011; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LOCASCIULLI A, 1989, TRANSPLANTATION, V48, P68, DOI 10.1097/00007890-198907000-00016; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; LUCARELLI G, 1987, NEW ENGL J MED, V316, P1050, DOI 10.1056/NEJM198704233161703; MATUSCHAK GM, 1987, J CRIT CARE, V2, P162, DOI 10.1016/0883-9441(87)90003-7; MATUSCHAK GM, 1988, CHEST, V94, P400, DOI 10.1378/chest.94.2.400; MCDONALD GB, 1984, HEPATOLOGY, V4, P116, DOI 10.1002/hep.1840040121; MCDONALD GB, 1985, TRANSPLANTATION, V39, P603, DOI 10.1097/00007890-198506000-00005; MEYERS JD, 1991, ANNU REV MED, V42, P179, DOI 10.1146/annurev.me.42.020191.001143; Mitchell J R, 1981, Semin Liver Dis, V1, P143, DOI 10.1055/s-2008-1040727; NASH RA, 1992, BLOOD, V80, P1838; NEVILL TJ, 1991, J CLIN ONCOL, V9, P1224, DOI 10.1200/JCO.1991.9.7.1224; OZKAYNAK MF, 1991, BONE MARROW TRANSPL, V7, P467; PINSKY MR, 1990, J CRIT CARE, V5, P108, DOI 10.1016/0883-9441(90)90056-F; RIO B, 1986, BLOOD, V67, P1773; ROBERTS DW, 1991, AM J PATHOL, V138, P359; SAKR MF, IN PRESS LIVER TRANS; SCOAZEC JY, 1991, HEPATOLOGY, V14, P789, DOI 10.1002/hep.1840140508; SCROBOHACI ML, 1991, THROMB RES, V63, P509, DOI 10.1016/0049-3848(91)90176-W; SHENEP JL, 1988, NEW ENGL J MED, V319, P1053, DOI 10.1056/NEJM198810203191604; SHULMAN HM, 1987, AM J PATHOL, V126, P114; SHULMAN HM, 1987, AM J PATHOL, V127, P549; SHULMAN HM, 1980, GASTROENTEROLOGY, V79, P1178; SOIFFER RJ, 1991, TRANSPLANTATION, V52, P1014, DOI 10.1097/00007890-199112000-00015; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; TEBOEKHORST T, 1988, J HEPATOL, V7, P111, DOI 10.1016/S0168-8278(88)80514-2; Thomas E. D., 1990, BONE MARROW TRANSPLA; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; TILNEY NL, 1973, ANN SURG, V178, P117, DOI 10.1097/00000658-197308000-00001; TOX U, 1991, HEPATOLOGY, V14, pA220; TRABER PG, 1988, GASTROENTEROLOGY, V95, P1130, DOI 10.1016/0016-5085(88)90194-1; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; VASSAL G, 1992, BLOOD, V79, P2475; VOLPES R, 1990, HEPATOLOGY, V12, P59, DOI 10.1002/hep.1840120110; VOLPES R, 1990, HEPATOLOGY, V12, P148, DOI 10.1002/hep.1840120123; VOLPES R, 1991, GASTROENTEROLOGY, V101, P200, DOI 10.1016/0016-5085(91)90478-4; WINGARD JR, 1989, BONE MARROW TRANSPL, V4, P685; WITHERSPOON RP, 1984, AM J HEMATOL, V17, P269, DOI 10.1002/ajh.2830170307; ZAGER RA, 1989, AM J KIDNEY DIS, V13, P210, DOI 10.1016/S0272-6386(89)80054-X; 1990, BMDP STATISTICAL SOF, V2, P1013	74	933	964	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					255	267		10.7326/0003-4819-118-4-199302150-00003	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00003			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420443				2022-12-28	WOS:A1993KL45700003
J	GLATT, CE; SNYDER, SH				GLATT, CE; SNYDER, SH			CLONING AND EXPRESSION OF AN ADENYLYL CYCLASE LOCALIZED TO THE CORPUS STRIATUM	NATURE			English	Article							MESSENGER-RNA; RAT-BRAIN; INSITU HYBRIDIZATION; LOCALIZATIONS	THE neurotransmitter dopamine acts through various receptor subtypes that are largely associated with enhancement or inhibition of adenylyl cyclases1,2. These dopamine-sensitive adenylyl cyclases are highly concentrated in the corpus striatum and associated limbic structures of the brain, where their levels exceed by orders of magnitude 3,4 those in other areas of the brain. Here we use in situ hybridization to show that messenger RNA for three of these adenylyl cyclases5-7 is not found in the corpus striatum. We have isolated and expressed a complementary DNA encoding new adenylyl cyclase whose selective concentration in the corpus striatum indicates that it may be responsible for the synaptic actions of dopamine.	JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University	GLATT, CE (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205, USA.							BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; Battey, 1986, BASIC METHODS MOL BI; DRINNAN S L, 1991, Molecular and Cellular Neuroscience, V2, P66, DOI 10.1016/1044-7431(91)90040-U; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GEHLERT DR, 1985, EUR J PHARMACOL, V106, P223; GORMAN CM, 1992, DNA PROT ENG TECHN, V2, P3; Grandy D K, 1992, Curr Opin Neurobiol, V2, P275, DOI 10.1016/0959-4388(92)90115-2; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LARGENT BL, 1988, P NATL ACAD SCI USA, V85, P2864, DOI 10.1073/pnas.85.8.2864; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; WORLEY PF, 1986, P NATL ACAD SCI USA, V83, P4053, DOI 10.1073/pnas.83.11.4053; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T	18	182	185	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					536	538		10.1038/361536a0	http://dx.doi.org/10.1038/361536a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429907				2022-12-28	WOS:A1993KL71400060
J	THEWISSEN, JGM; HUSSAIN, ST				THEWISSEN, JGM; HUSSAIN, ST			ORIGIN OF UNDERWATER HEARING IN WHALES	NATURE			English	Article							MAMMALS	ALL described fossil and Recent cetaceans have relatively similar ear bones (malleus, incus and stapes) that strongly diverge from those of land mammals1-4. Here we report that the hearing organ of the oldest whale, Pakicetus, is the only known intermediate between that of land mammals and aquatic cetaceans (whales, dolphins and porpoises). The incus of Pakicetus is intermediate with respect to inflation, crural proportions, and position of the mallear joint. The incus and mandible of Pakicetus indic-ate that the path of soundwaves to its ear resembled that of land mammals. These fossils suggest that the first whale was amphibious, and corroborate the hypothesis that artiodactyls (for example, pigs, camels and ruminants) are the closest extant relatives of cetaceans.	HOWARD UNIV, COLL MED, DEPT ANAT, WASHINGTON, DC 20059 USA	Howard University	THEWISSEN, JGM (corresponding author), DUKE UNIV, SCH MED, DEPT BIOL ANTHROPOL & ANAT, DURHAM, NC 27710 USA.			Thewissen, J. G. M./0000-0002-0973-4137				deHaan Reysenbach, 1957, ACTA OTO-LARYNGOL, V134, P1; Doran AHG., 1878, T LINN SOC LOND, V1:, P371, DOI DOI 10.1111/J.1096-3642.1878.TB00663.X; Fleischer G., 1978, Advances in Anatomy Embryology and Cell Biology, V55, P1; FRASER FC, 1960, PROC R SOC SER B-BIO, V152, P62, DOI 10.1098/rspb.1960.0024; GINGERICH P D, 1981, Contributions from the Museum of Paleontology University of Michigan, V25, P235; GINGERICH PD, 1983, SCIENCE, V200, P402; GOODMAN M, 1985, Cladistics, V1, P171, DOI 10.1111/j.1096-0031.1985.tb00420.x; Ketten D. R., 1991, BIOL HEARING, P717; Lancaster W.C., 1990, Journal of Vertebrate Paleontology, V10, P117; MCCORMICK J G, 1970, Journal of the Acoustical Society of America, V48, P1418, DOI 10.1121/1.1912302; MCMORMICK JG, 1980, ANIMAL SONAR SYSTEMS, P449; MOORE PWB, 1987, MAR MAMMAL SCI, V3, P31, DOI 10.1111/j.1748-7692.1987.tb00150.x; NORRIS KS, 1980, ANIMAL SONAR SYSTEMS, P495; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Oelschlager H.A., 1987, Gegenbaurs Morphologisches Jahrbuch, V133, P673; OELSCHLAGER HA, 1986, AM J ANAT, V177, P353, DOI 10.1002/aja.1001770306; Purves P.E., 1966, WHALES DOLPHINS PORP, P320; Purves P E, 1983, ECHOLOCATION WHALES, P1; RAMPRASHAD F, 1973, CAN J ZOOL, V51, P589, DOI 10.1139/z73-085; RAMPRASHAD F, 1971, CAN J ZOOLOG, V49, P241, DOI 10.1139/z71-034; Repenning C.A., 1972, P307; SLIJPER EJ, 1979, WHALES; VANVALEN L, 1966, B AM MUS NAT HIST, V132, P10; WATKINS WA, 1985, MAR MAMMAL SCI, V1, P219, DOI 10.1111/j.1748-7692.1985.tb00011.x; WEST RM, 1979, CONTRIBUTIONS BIOL G, V26, P1; WYSS A, 1990, NATURE, V347, P428, DOI 10.1038/347428a0; Wyss AR, 1987, AM MUS NAT HIST NOVI, V2871, P1	28	56	63	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 4	1993	361	6411					444	445		10.1038/361444a0	http://dx.doi.org/10.1038/361444a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8429882				2022-12-28	WOS:A1993KK71300058
J	LARRAZET, F; SPAULDING, C; LOBREAU, HJ; WEBER, S; GUERIN, F				LARRAZET, F; SPAULDING, C; LOBREAU, HJ; WEBER, S; GUERIN, F			POSSIBLE BROMOCRIPTINE-INDUCED MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Note						MYOCARDIAL INFARCTION; BROMOCRIPTINE; CORONARY VASOSPASM; PUERPERIUM	RECEIVING BROMOCRIPTINE; RECEPTORS; DOPAMINE	We report a case of a postpartum myocardial infarction in a 32-year-old multiparous woman receiving bromocriptine. The patient had an uncomplicated pregnancy. She had been sent home with bromocriptine to suppress lactation. Ten days postpartum, she presented with chest pain. Her electrocardiogram showed marked ST-segment elevation in leads II, III, and aVF. Coronary, angiography showed a total occlusion of the midportion of the right coronary artery. Angioplasty was immediately done, and the right coronary artery was reopened. One month later, she was tested with bromocriptine. At the peak of action of bromocriptine, a severe narrowing of the right coronary artery occurred, which probably corresponded to a bromocriptine-induced spasm. Bromocriptine is an ergopeptine derivative, and it should be considered as a possible etiologic agent causing postpartum myocardial infarction in patients with a predisposition to coronary vasospasm.	CHU COCHIN PORT ROYAL, SERV CARDIOL, 27 RUE FAUBOURG ST JAMES, F-75014 PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite								CEDARBAUM JM, 1990, PHARMACOL BASIS THER, P473; CREA F, 1986, CIRCULATION, V74, P262, DOI 10.1161/01.CIR.74.2.262; GIUDICI MC, 1989, AM HEART J, V118, P614, DOI 10.1016/0002-8703(89)90280-9; GOLDBERG LI, 1985, CIRCULATION, V72, P245, DOI 10.1161/01.CIR.72.2.245; IFFY L, 1986, AM J OBSTET GYNECOL, V155, P371, DOI 10.1016/0002-9378(86)90829-X; MISSALE C, 1988, J CARDIOVASC PHARM, V11, P643, DOI 10.1097/00005344-198806000-00003; RUCH A, 1989, OBSTET GYNECOL, V74, P448	7	21	21	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					199	200		10.7326/0003-4819-118-3-199302010-00008	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00008			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8417637				2022-12-28	WOS:A1993KJ43900008
J	HENGGEARONIS, R				HENGGEARONIS, R			SURVIVAL OF HUNGER AND STRESS - THE ROLE OF RPOS IN EARLY STATIONARY PHASE GENE-REGULATION IN ESCHERICHIA-COLI	CELL			English	Article							INDUCED CROSS PROTECTION; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; OSMOTIC-STRESS; KATF; TRANSCRIPTION; EXPRESSION; RESPONSES; IDENTIFICATION; RESISTANCE				HENGGEARONIS, R (corresponding author), UNIV CONSTANCE, DEPT BIOL, W-7750 CONSTANCE, GERMANY.		Hengge, Regine/AAE-7092-2021					ALDEA M, 1989, EMBO J, V8, P3923, DOI 10.1002/j.1460-2075.1989.tb08573.x; ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ATLUNG T, 1989, J BACTERIOL, V171, P1683, DOI 10.1128/jb.171.3.1683-1691.1989; BOOS W, 1987, J BIOL CHEM, V262, P13212; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; DASSA J, 1991, MOL GEN GENET, V229, P341, DOI 10.1007/BF00267454; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DIAZGUERRA L, 1989, J BACTERIOL, V171, P2906, DOI 10.1128/jb.171.5.2906-2908.1989; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; FOSTER PL, 1992, J BACTERIOL, V174, P1711, DOI 10.1128/jb.174.6.1711-1716.1992; GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988; GROAT RG, 1986, J BACTERIOL, V168, P486, DOI 10.1128/jb.168.2.486-493.1986; GROSS CA, 1990, STRESS PROTEINS BIOL, P167; HENGGEARONIS R, 1992, MOL MICROBIOL, V6, P1877, DOI 10.1111/j.1365-2958.1992.tb01360.x; HENGGEARONIS R, 1993, J BACTERIOL, V175, P259, DOI 10.1128/JB.175.1.259-265.1993; HENGGEARONIS R, 1993, IN PRESS STARVATION; JENKINS DE, 1988, J BACTERIOL, V170, P3910, DOI 10.1128/jb.170.9.3910-3914.1988; JENKINS DE, 1990, J BACTERIOL, V172, P2779, DOI 10.1128/jb.172.5.2779-2781.1990; JUNG JU, 1990, J BIOL CHEM, V265, P10574; KAASEN I, 1992, J BACTERIOL, V174, P889, DOI 10.1128/jb.174.3.889-898.1992; KOLTER R, 1992, ANNU REV MICROBIOL, V46, P141, DOI 10.1146/annurev.mi.46.100192.001041; LANGE R, 1991, J BACTERIOL, V173, P4474, DOI 10.1128/JB.173.14.4474-4481.1991; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; LOEWEN PC, 1985, ARCH BIOCHEM BIOPHYS, V243, P144, DOI 10.1016/0003-9861(85)90782-9; LOEWEN PC, 1984, J BACTERIOL, V160, P668, DOI 10.1128/JB.160.2.668-675.1984; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MATIN A, 1991, MOL MICROBIOL, V5, P3, DOI 10.1111/j.1365-2958.1991.tb01819.x; MCCANN MP, 1991, J BACTERIOL, V173, P4188, DOI 10.1128/jb.173.13.4188-4194.1991; MULVEY MR, 1989, NUCLEIC ACIDS RES, V17, P9979, DOI 10.1093/nar/17.23.9979; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; OLSEN A, 1993, MOL MICROBIOL; OZAKI M, 1991, MOL GEN GENET, V230, P17, DOI 10.1007/BF00290644; PREISS J, 1989, ADV MICROB PHYSIOL, V30, P183; Preiss J., 1989, BACTERIA NATURE, P189; ROMEO T, 1989, J BACTERIOL, V171, P2773, DOI 10.1128/jb.171.5.2773-2782.1989; SAK BD, 1989, P NATL ACAD SCI USA, V86, P3271, DOI 10.1073/pnas.86.9.3271; SAMMARTANO LJ, 1986, J BACTERIOL, V168, P13, DOI 10.1128/jb.168.1.13-21.1986; TOUATI E, 1991, RES MICROBIOL, V142, P29; TUVESON RW, 1980, PHOTOCHEM PHOTOBIOL, V32, P703, DOI 10.1111/j.1751-1097.1980.tb04044.x; VANLAERE A, 1989, FEMS MICROBIOL LETT, V63, P201, DOI 10.1016/0378-1097(89)90130-4; WADA A, 1990, P NATL ACAD SCI USA, V87, P2657, DOI 10.1073/pnas.87.7.2657; YIM HH, 1992, J BACTERIOL, V174, P3637, DOI 10.1128/JB.174.11.3637-3644.1992	42	476	487	0	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 29	1993	72	2					165	168		10.1016/0092-8674(93)90655-A	http://dx.doi.org/10.1016/0092-8674(93)90655-A			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	8425216				2022-12-28	WOS:A1993KK03800002
J	SINGER, PT; SMALAS, A; CARTY, RP; MANGEL, WF; SWEET, RM				SINGER, PT; SMALAS, A; CARTY, RP; MANGEL, WF; SWEET, RM			THE HYDROLYTIC WATER MOLECULE IN TRYPSIN, REVEALED BY TIME-RESOLVED LAUE CRYSTALLOGRAPHY	SCIENCE			English	Article							CRYSTAL-STRUCTURE; RESOLUTION	Crystals of bovine trypsin were acylated at the reactive residue, serine 195, to form the transiently stable p-guanidinobenzoate. Hydrolysis of this species was triggered in the crystals by a jump in pH. The hydrolysis was monitored by three-dimensional Laue crystallography, resulting in three x-ray diffraction structures, all from the same crystal and each representing approximately 5 seconds of x-ray exposure. The structures were analyzed at a nominal resolution of 1.8 angstroms and were of sufficient quality to reproduce subtle features in the electron-density maps for each of the structures. Comparison of the structures before and after the pH jump reveals that a water molecule has positioned itself to attack the acyl group in the initial step of the hydrolysis of this transient intermediate.	BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; ARGONNE NATL LAB,DEPT BIOL,ARGONNE,IL 60439; UNIV TROMSO,INST MATH & PHYS SCI,N-9000 TROMSO,NORWAY; SUNY HLTH SCI CTR,DEPT BIOCHEM,BROOKLYN,NY 11203	United States Department of Energy (DOE); Brookhaven National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; UiT The Arctic University of Tromso; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center			Smalås, Arne/C-4131-2016	Smalås, Arne/0000-0002-4651-9911				BARTUNIK HD, 1989, J MOL BIOL, V210, P813, DOI 10.1016/0022-2836(89)90110-1; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BRUNGER AT, X PLOR; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; HELLIWELL JR, 1989, J APPL CRYSTALLOGR, V22, P483, DOI 10.1107/S0021889889006564; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; MANGEL WF, 1990, BIOCHEMISTRY-US, V29, P8351, DOI 10.1021/bi00488a022; SACK JS, 1988, J MOL GRAPHICS, V6, P24; SINGER P, UNPUB; SINGER PT, 1992, PHILOS T ROY SOC A, V340, P285, DOI 10.1098/rsta.1992.0067; SWEET RM, 1974, BIOCHEMISTRY-US, V13, P4212, DOI 10.1021/bi00717a024	12	98	99	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					669	673		10.1126/science.8430314	http://dx.doi.org/10.1126/science.8430314			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430314				2022-12-28	WOS:A1993KJ68800039
J	ABERG, A; NORDLUND, P; EKLUND, H				ABERG, A; NORDLUND, P; EKLUND, H			UNUSUAL CLUSTERING OF CARBOXYL SIDE-CHAINS IN THE CORE OF IRON-FREE RIBONUCLEOTIDE REDUCTASE	NATURE			English	Article							CONCANAVALIN-A	THE principal driving forces of protein folding are the burial of hydrophobic residues in the interior of proteins and the exposure of charged residues at the surface1. Charged residues are only occasionally found in the interior, where they form hydrogen bonds to oppositely charged residues or main-chain atoms2. Ribonucleotide reductase, a key enzyme in DNA synthesis, catalyses the de novo production of deoxyribonucleotide precursors. It is composed of two different dimeric proteins R1 and R2 (refs 3-5). R2 subunits contain buried iron-centres with each centre formed by two ferric ions coordinated by four carboxylates and two histidine ligands6. Iron-free R2, apoR2, is a precursor of active R2 and folds into a stable protein which is transformed into active R2 by ferrous ions and molecular oxygen. Here we show that the iron-free protein does not undergo any major structural changes compared with the iron-containing R2. The effect of this is a clustering of four carboxyl side chains in the interior of the subunit, in contrast to the normal distribution of charged residues in proteins.	LAB MOLEC BIOPHYS, OXFORD OX1 3QH, ENGLAND; SWEDISH UNIV AGR SCI, CTR BIOMED, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN	University of Oxford; Swedish University of Agricultural Sciences	ABERG, A (corresponding author), UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN.							ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ATKIN CL, 1973, J BIOL CHEM, V248, P7664; ATTA M, 1992, J BIOL CHEM, V267, P20682; BAJORATH J, 1989, NATURE, V337, P481, DOI 10.1038/337481a0; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DAVIES D, 1989, A REV BIOPHYS CHEM, V19, P189; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; FONTECAVE M, 1992, ADV ENZYMOL, V65, P147; Honig B., 1992, CURR OPIN STRUC BIOL, V2, P40; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; NAR H, 1992, FEBS LETT, V306, P119, DOI 10.1016/0014-5793(92)80981-L; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; REEKE GN, 1978, P NATL ACAD SCI USA, V75, P2286, DOI 10.1073/pnas.75.5.2286; REES DC, 1983, P NATL ACAD SCI-BIOL, V80, P7151, DOI 10.1073/pnas.80.23.7151; SCHNEIDER G, 1983, P NATL ACAD SCI-BIOL, V80, P5289, DOI 10.1073/pnas.80.17.5289; SHOHAM M, 1979, J MOL BIOL, V131, P137, DOI 10.1016/0022-2836(79)90070-6; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; Stubbe J, 1991, CURR OPIN STRUC BIOL, V1, P788, DOI 10.1016/0959-440X(91)90180-2; Williams R.J.P., 1991, BIOL CHEM ELEMENTS	25	66	67	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1993	361	6409					276	278		10.1038/361276a0	http://dx.doi.org/10.1038/361276a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8423856				2022-12-28	WOS:A1993KH61400066
J	SINGH, J; KLAR, AJS				SINGH, J; KLAR, AJS			DNA POLYMERASE-ALPHA IS ESSENTIAL FOR MATING-TYPE SWITCHING IN FISSION YEAST	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; REPLICATION; GENES; CELLS; INITIATION; ASYMMETRY; STRANDS; PATTERN; SITE; MAT1	IN the fission yeast Schizosaccharomyces pombe, the double-stranded chromosomal break (DSB) at the mating-type locus (mat1) initiates recombination during mating-type switching1-3 . A constant DSB level is maintained throughout the cell-cycle'. In the strand-segregation model for mating-type switching, it was postulated that if the DSB is generated during or soon after mat1 replication4, one of the chromatids could be repaired and switched during replication in the next cell cycle, while the other chromatid inherits the break3-6. Here we report a molecular characterization of swi7, one of the genes required for DSB formation. Surprisingly, a gene complementing the swi7 mutation maps to chromosome I and encodes S. pombe DNA polymerase-alpha. Disruption of this gene is lethal in both switching and non-switching strains, as expected. S. pombe DNA polymerase-alpha must therefore play a role in generating the DSB at mat1, suggesting that DSB formation is coupled with DNA replication.	NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM,EUKARYOT GENE EXPRESS LAB, POB B,BLDG 539, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								ARCANGIOLI B, 1991, EMBO J, V10, P3025, DOI 10.1002/j.1460-2075.1991.tb07853.x; BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; BEACH DH, 1984, EMBO J, V3, P603, DOI 10.1002/j.1460-2075.1984.tb01855.x; DAMAGNEZ V, 1991, MOL GEN GENET, V226, P182, DOI 10.1007/BF00273602; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; EGEL R, 1984, CURR GENET, V8, P205, DOI 10.1007/BF00417817; EGEL R, 1984, P NATL ACAD SCI-BIOL, V81, P3481, DOI 10.1073/pnas.81.11.3481; EGEL R, 1987, CURR GENET, V12, P429, DOI 10.1007/BF00434820; ENGELKE U, 1987, CURR GENET, V12, P535, DOI 10.1007/BF00419563; FAN JB, 1991, NUCLEIC ACIDS RES, V19, P6289, DOI 10.1093/nar/19.22.6289; GUTZ H, 1985, CURR GENET, V9, P325, DOI 10.1007/BF00421601; KLAR AJS, 1991, GENETICS, V127, P489; KLAR AJS, 1990, EMBO J, V9, P1407, DOI 10.1002/j.1460-2075.1990.tb08256.x; KLAR AJS, 1987, NATURE, V326, P466, DOI 10.1038/326466a0; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MIYATA H, 1981, J GEN APPL MICROBIOL, V27, P365, DOI 10.2323/jgam.27.365; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Munz P, 1989, MOL BIOL FISSION YEA, P1; NIELSEN O, 1989, EMBO J, V8, P269, DOI 10.1002/j.1460-2075.1989.tb03373.x; PERKINS DD, 1949, GENETICS, V34, P607; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; RUSSELL P, 1989, MOL BIOL FISSION YEA, P244; Sambrook J, 1989, MOL CLONING LABORATO; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X	28	62	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1993	361	6409					271	273		10.1038/361271a0	http://dx.doi.org/10.1038/361271a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8423854				2022-12-28	WOS:A1993KH61400064
J	MULCAHY, D; FITZGERALD, M; WRIGHT, C; SPARROW, J; PEPPER, J; YACOUB, M; FOX, KM				MULCAHY, D; FITZGERALD, M; WRIGHT, C; SPARROW, J; PEPPER, J; YACOUB, M; FOX, KM			LONG-TERM FOLLOW-UP OF SEVERELY ILL PATIENTS WHO UNDERWENT URGENT CARDIAC TRANSPLANTATION	BRITISH MEDICAL JOURNAL			English	Article							HEART-TRANSPLANTATION; CYCLOSPORINE; RECIPIENTS; KIDNEY; DONOR	Objective-To assess long term survival (>5 years) and quality of life in severely ill patients referred for urgent cardiac transplantation. Setting-Tertiary referral centres: before transplantation at the National Heart Hospital (late 1984 to end 1986); after transplantation at Harefield Hospital. Subjects-Eighteen patients (15 men; three women) who had required intensive support in hospital before cardiac transplantation and were alive at short term follow up. Interventions-Intravenous infusions of cardiac drugs (mean 2.2 infusions), intravenous diuretics (17 patients), and many other drugs before transplantation. Intra-aortic balloon counterpulsation (four patients), temporary pacing (two), and rescusitation from cardiac arrest (three). Patients had specialised nursing care on a medical intensive care unit in almost every case. Main outcome measures-Long term survival in patients after urgent cardiac transplantation and perceived quality of life. Results-Of 18 patients who were alive at short term follow up (mean (range) 19.4 (10-33) months), 14 were still alive in 1992 (69 (61-83) months). Ten still worked full time, and 11 reported no restrictions in their daily activities. Three of four patients who died in the intervening period survived >5 years after transplantation. Overall, 17 of 18 patients survived at least 5 years. Conclusions-In severely ill patients who undergo urgent cardiac transplantation and survive in the short term, long term (5-7 year) survival and quality of life seem good.	HAREFIELD HOSP,HAREFIELD,MIDDX,ENGLAND	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital	MULCAHY, D (corresponding author), ROYAL BROMPTON NATL HEART & LUNG HOSP,LONDON SW3 6NP,ENGLAND.							BIROVLJEV S, 1992, J HEART LUNG TRANSPL, V11, P240; BUNZEL B, 1991, J HEART LUNG TRANSPL, V10, P455; DUMMER JS, 1983, TRANSPLANTATION, V36, P259, DOI 10.1097/00007890-198309000-00007; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; HARDESTY RL, 1986, ANN THORAC SURG, V41, P126, DOI 10.1016/S0003-4975(10)62651-3; HOSENPUD JD, 1992, J HEART LUNG TRANSPL, V11, P9; KRIETT JM, 1991, J HEART LUNG TRANSPL, V10, P491; LEWIS RM, 1991, J HEART LUNG TRANSPL, V10, P63; MENKIS AH, 1991, J HEART LUNG TRANSPL, V10, P28; MULCAHY D, 1988, BRIT MED J, V296, P817, DOI 10.1136/bmj.296.6625.817; OYER PE, 1983, TRANSPLANT P, V15, P2546; PFLUGFELDER PW, 1991, J HEART LUNG TRANSPL, V10, P394; REEDY JE, 1992, J HEART LUNG TRANSPL, V11, P246; VONSCHEIDT W, 1991, J HEART LUNG TRANSPL, V10, P342	14	11	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					98	101		10.1136/bmj.306.6870.98	http://dx.doi.org/10.1136/bmj.306.6870.98			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435650	Bronze, Green Published			2022-12-28	WOS:A1993KG46500018
J	GAUR, A; HASPEL, R; MAYER, JP; FATHMAN, CG				GAUR, A; HASPEL, R; MAYER, JP; FATHMAN, CG			REQUIREMENT FOR CD8+ CELLS IN T-CELL RECEPTOR PEPTIDE-INDUCED CLONAL UNRESPONSIVENESS	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; LAMBDA-REPRESSOR; ANTIGEN RECEPTOR; DEGRADATION; IDENTIFICATION; IMMUNIZATION; ANTIBODIES; ELEMENT; USAGE	T cell receptor (TCR) vaccination in rats prevents the development of experimental allergic encephalomyelitis (EAE), an animal model of multiple sclerosis. The mechanism of this potential immunotherapy was examined by vaccinating mice with an immunogenic peptide fragment of the variable region of the TCR V(beta)8.2 gene. Another immunogen that usually induces an immune response mediated by V(beta)8.2+ T cells was subsequently inhibited because specific clonal unresponsiveness (anergy) had been induced. Depletion of CD8+ cells before TCR peptide vaccination blocked such inhibition. Thus, the clonal anergy was dependent on CD8+ T cells, and such immunoregulatory T cells may participate in the normal course of EAE.	STANFORD UNIV, MED CTR,SCH MED,DEPT MED,DIV IMMUNOL & RHEUMATOL, STANFORD, CA 94305 USA; IMMULOG PHARMACEUT CORP, PALO ALTO, CA 94304 USA	Stanford University				RUBERTI, Giovina/0000-0003-2367-9709	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039959] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 27989] Funding Source: Medline; NIDDK NIH HHS [DK 39959] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; COHEN IR, 1989, COLD SPRING HARB SYM, V54, P879; DESQUENNECLARK L, 1991, P NATL ACAD SCI USA, V88, P7219, DOI 10.1073/pnas.88.16.7219; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; HASHIM GA, 1990, J IMMUNOL, V144, P4621; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; JIANG H, 1991, ANN NY ACAD SCI, V636, P28, DOI 10.1111/j.1749-6632.1991.tb33435.x; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KOH DR, 1992, SCIENCE, V256, P1210, DOI 10.1126/science.256.5060.1210; LAI MZ, 1988, J EXP MED, V168, P1081, DOI 10.1084/jem.168.3.1081; LAI MZ, 1990, J IMMUNOL, V144, P4851; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; OFFNER H, 1991, SCIENCE, V251, P430, DOI 10.1126/science.1989076; RUBERTI G, 1991, J EXP MED, V174, P83, DOI 10.1084/jem.174.1.83; TSE DB, 1986, J MOL CELL IMMUNOL, V2, P315; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WILSON DB, 1989, IMMUNOL REV, V107, P159, DOI 10.1111/j.1600-065X.1989.tb00008.x; WISNIEWSKI HM, 1977, ANN NEUROL, V1, P144, DOI 10.1002/ana.410010207	21	119	123	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 1	1993	259	5091					91	94		10.1126/science.8418501	http://dx.doi.org/10.1126/science.8418501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418501				2022-12-28	WOS:A1993KE60100036
J	HUBBARD, A				HUBBARD, A			A TRAVELING-WAVE AMPLIFIER MODEL OF THE COCHLEA	SCIENCE			English	Article							BASILAR-MEMBRANE; MOSSBAUER TECHNIQUE; MECHANICS; CHINCHILLA; VIBRATION; EMISSIONS; BASE	A two-mode model of the cochlea that uses active intermode feedback has been developed that quantitatively accounts for the motion of the basilar membrane in response to single tones and qualitatively accounts for cochlear emission phenomena. In contrast to existing single-mode models, this model amplifies the mechanical traveling wave in spatially localized cochlear regions where an approximate match occurs between the traveling-wave velocities of each of the two traveling-wave lines or modes.	BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA	Boston University	HUBBARD, A (corresponding author), BOSTON UNIV, COLL ENGN, BOSTON, MA 02215 USA.							ALLEN JB, 1992, J ACOUST SOC AM, V92, P178, DOI 10.1121/1.404281; AYASLI Y, 1984, IEEE T MICROW THEORY, V32, P290, DOI 10.1109/TMTT.1984.1132667; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; CODY AR, 1992, HEARING RES, V62, P166, DOI 10.1016/0378-5955(92)90182-M; DEBOER E, 1983, J ACOUST SOC AM, V73, P567, DOI 10.1121/1.389002; DEBOER E, 1990, LECT NOTES BIOMATH, V87, P333; GINZTON EL, 1948, P IRE, V36, P956, DOI 10.1109/JRPROC.1948.231624; Guinan JJ, 1990, MECH BIOPHYSICS HEAR, P170; HUBBARD A, IN PRESS 16TH MIDW M; HUBBARD AE, 1983, SCIENCE, V222, P510, DOI 10.1126/science.6623090; IWASA KH, 1992, J ACOUST SOC AM, V92, P3169, DOI 10.1121/1.404194; KEMP DT, 1978, J ACOUST SOC AM, V64, P1386, DOI 10.1121/1.382104; KHANNA SM, 1982, SCIENCE, V215, P305, DOI 10.1126/science.7053580; Kiang NYS, 1965, DISCHARGE PATTERNS S; PETERSON LC, 1950, J ACOUST SOC AM, V22, P369, DOI 10.1121/1.1906615; RHODE WS, 1971, J ACOUST SOC AM, V49, P1218, DOI 10.1121/1.1912485; ROBLES L, 1986, J ACOUST SOC AM, V80, P1364, DOI 10.1121/1.394389; RUGGERO MA, 1990, J ACOUST SOC AM, V87, P1612, DOI 10.1121/1.399409; RUGGERO MA, 1991, HEARING RES, V51, P215, DOI 10.1016/0378-5955(91)90038-B; RUSSELL I, 1986, J PHYSIOL-LONDON, V284, P261; SELLICK PM, 1982, J ACOUST SOC AM, V72, P131, DOI 10.1121/1.387996; SHINE D, 1991, THESIS BOSTON U; von Bekesy G, 1928, PHYS Z, V29, P793; WILSON JP, 1980, HEARING RES, V2, P233, DOI 10.1016/0378-5955(80)90060-X; ZWEIG G, 1991, J ACOUST SOC AM, V89, P1229, DOI 10.1121/1.400653; ZWICKER E, 1979, BIOL CYBERN, V35, P243, DOI 10.1007/BF00344207	26	101	102	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					68	71		10.1126/science.8418496	http://dx.doi.org/10.1126/science.8418496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418496				2022-12-28	WOS:A1993KE60100029
J	IGRA, V; MILLSTEIN, SG				IGRA, V; MILLSTEIN, SG			CURRENT STATUS AND APPROACHES TO IMPROVING PREVENTIVE SERVICES FOR ADOLESCENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE; HEALTH PROMOTION; PHYSICIANS; PRACTITIONERS; INTERNISTS; GUIDELINES; NEEDS				IGRA, V (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,DIV ADOLESCENT MED,BOX 0374,400 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.				PHS HHS [MC000978] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1989, GUIDE CLIN PREVENTIV; BELCHER D W, 1988, American Journal of Preventive Medicine, V4, P27; BLUM RW, 1990, J ADOLESCENT HEALTH, V11, P289, DOI 10.1016/0197-0070(90)90037-3; Carter W B, 1981, Med Care Rev, V38, P195, DOI 10.1177/107755878103800401; Elster AB, 1993, GUIDELINES ADOLESCEN; FOGLE S, 1991, J NIH RES, V3, P90; GANS GE, 1991, ADOLESCENT HLTH CARE, P19; GEMSON DH, 1986, AM J PREV MED, V2, P226; HAYES CD, 1987, RISKING FUTURE ADOLE; Henry R C, 1987, Fam Med, V19, P110; LALONDE M, 1975, NEW PERSPECTIVE HLTH; LEWIS CE, 1991, ANN INTERN MED, V114, P54, DOI 10.7326/0003-4819-114-1-54; Logsdon D N, 1984, J Ambul Care Manage, V7, P46; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; MARKS A, 1983, J PEDIATR-US, V102, P456, DOI 10.1016/S0022-3476(83)80677-5; MCPHEE SJ, 1987, AM J PUBLIC HEALTH, V77, P780, DOI 10.2105/AJPH.77.7.780; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; MCPHEE SJ, IN PRESS CANCER; MILLSTEIN SG, 1993, PROMOTING HLTH ADOLE, P97; ORLEANS CT, 1985, PREV MED, V14, P636, DOI 10.1016/0091-7435(85)90083-0; ORR DP, 1987, J ADOLESCENT HEALTH, V8, P239, DOI 10.1016/0197-0070(87)90427-X; RADECKI SE, 1986, PATIENT EDUC COUNS, V8, P165, DOI 10.1016/0738-3991(86)90087-X; Schappert SM, 1992, ADV DATA VITAL HLTH, V213; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; VALENTE C M, 1986, American Journal of Preventive Medicine, V2, P82; WECHSLER H, 1983, NEW ENGL J MED, V308, P97, DOI 10.1056/NEJM198301133080211; WOO B, 1985, JAMA-J AM MED ASSOC, V254, P1480, DOI 10.1001/jama.254.11.1480; WOODELL D, 1992, ADV DATA VITAL HLTH, V208; WOODELL D, 1992, ADV DATA VITAL HLTH, V209; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; 1991, MMWR, V40, P885; 1991, MMWR, V40, P617; 1991, OTAH468 OFF TECHN AS	33	83	83	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1408	1412		10.1001/jama.269.11.1408	http://dx.doi.org/10.1001/jama.269.11.1408			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ857	8441217				2022-12-28	WOS:A1993KQ85700036
J	EDELMAN, RR; WARACH, S				EDELMAN, RR; WARACH, S			MEDICAL PROGRESS .1. MAGNETIC-RESONANCE-IMAGING	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SURFACE COIL MR; GADOPENTETATE DIMEGLUMINE; MULTIPLE-SCLEROSIS; ENHANCED MR; MULTIFOCAL LEUKOENCEPHALOPATHY; PATHOLOGICAL CORRELATIONS; CEREBRAL INFARCTION; CLINICAL-TRIALS; TEMPORAL-LOBE; CT		BETH ISRAEL HOSP, DEPT NEUROL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	EDELMAN, RR (corresponding author), BETH ISRAEL HOSP, DEPT RADIOL, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.		Warach, Steven/R-5074-2019					ASHTARI M, 1991, AM J NEURORADIOL, V12, P941; AWAD IA, 1986, STROKE, V17, P1084, DOI 10.1161/01.STR.17.6.1084; BARKHOF F, 1992, NEUROLOGY, V42, P63, DOI 10.1212/WNL.42.1.63; BARKOVICH AJ, 1992, RADIOLOGY, V182, P493, DOI 10.1148/radiology.182.2.1732969; BLOCH F, 1946, PHYS REV, V69, P127, DOI 10.1103/PhysRev.69.127; BOTTOMLEY PA, 1987, MED PHYS, V14, P1, DOI 10.1118/1.596111; BOULLOCHE J, 1989, NEUROPEDIATRICS, V20, P173, DOI 10.1055/s-2008-1071286; BRONEN RA, 1991, AM J NEURORADIOL, V12, P933; BRYAN RN, 1991, AM J NEURORADIOL, V12, P611; BURNHAM JA, 1991, NEUROLOGY, V41, P1349, DOI 10.1212/WNL.41.9.1349; CASCINO GD, 1991, ANN NEUROL, V30, P31, DOI 10.1002/ana.410300107; CHAMBERLAIN MC, 1990, NEUROLOGY, V40, P435, DOI 10.1212/WNL.40.3_Part_1.435; CIRICILLO SF, 1990, J NEUROSURG, V73, P720, DOI 10.3171/jns.1990.73.5.0720; DAVIS PC, 1991, AM J NEURORADIOL, V12, P293; DINA TS, 1991, RADIOLOGY, V179, P823, DOI 10.1148/radiology.179.3.2027999; DOPPMAN JL, 1987, J NEUROSURG, V66, P830, DOI 10.3171/jns.1987.66.6.0830; EDELMAN RR, 1990, CLIN MAGNETIC RESONA, P16; ELSTER AD, 1990, RADIOLOGY, V177, P627, DOI 10.1148/radiology.177.3.2243961; FAZEKAS F, 1991, AM J NEURORADIOL, V12, P915; GOLDSTEIN HA, 1990, RADIOLOGY, V174, P17, DOI 10.1148/radiology.174.1.2403679; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; HARRIS JO, 1991, ANN NEUROL, V29, P548, DOI 10.1002/ana.410290515; HEIER LA, 1989, AM J NEURORADIOL, V10, P929; JACK CR, 1992, ANN NEUROL, V31, P138, DOI 10.1002/ana.410310204; JACKLER RK, 1990, OTOLARYNG HEAD NECK, V102, P670, DOI 10.1177/019459989010200608; JACOBS L, 1991, NEUROLOGY, V41, P15, DOI 10.1212/WNL.41.1.15; JARVIK JG, 1988, ARCH NEUROL-CHICAGO, V45, P731, DOI 10.1001/archneur.1988.00520310037014; JONES KM, 1992, AM J ROENTGENOL, V158, P1313, DOI 10.2214/ajr.158.6.1590133; KERTESZ A, 1988, ARCH NEUROL-CHICAGO, V45, P404, DOI 10.1001/archneur.1988.00520280050015; KILPATRICK CJ, 1991, EPILEPSIA, V32, P358, DOI 10.1111/j.1528-1157.1991.tb04664.x; KUCHARCZYK W, 1991, MAGNETIC RESONANCE I, P625; LAUFFER RB, 1987, CHEM REV, V87, P901, DOI 10.1021/cr00081a003; LAUTERBUR PC, 1973, NATURE, V242, P190, DOI 10.1038/242190a0; LIM V, 1990, AM J NEURORADIOL, V11, P975; MARK AS, 1989, RADIOLOGY, V173, P517, DOI 10.1148/radiology.173.2.2798883; MATSUBAYASHI K, 1992, STROKE, V23, P175, DOI 10.1161/01.STR.23.2.175; MAWAD ME, 1990, AM J NEURORADIOL, V11, P987; MODIC MT, 1986, AM J ROENTGENOL, V147, P757, DOI 10.2214/ajr.147.4.757; MODIC MT, 1986, RADIOLOGY, V161, P753, DOI 10.1148/radiology.161.3.3786728; NAYLER GL, 1986, J COMPUT ASSIST TOMO, V10, P715, DOI 10.1097/00004728-198609000-00001; NESBIT GM, 1991, RADIOLOGY, V180, P467, DOI 10.1148/radiology.180.2.2068314; PAUSHTER DM, 1985, RADIOL CLIN N AM, V23, P551; PHILLIPS ME, 1990, J COMPUT ASSIST TOMO, V14, P536, DOI 10.1097/00004728-199007000-00007; PURCELL EM, 1946, PHYS REV, V69, P37, DOI 10.1103/PhysRev.69.37; ROSS JS, 1987, AM J NEURORADIOL, V8, P885; ROSS JS, 1990, AM J NEURORADIOL, V11, P771; SANDHU FS, 1991, AM J NEURORADIOL, V12, P1087; SCHROTH G, 1987, NEUROLOGY, V37, P179, DOI 10.1212/WNL.37.2.179; SHELLOCK FG, 1991, RADIOLOGY, V180, P541, DOI 10.1148/radiology.180.2.2068325; SHUAIB A, 1992, NEUROLOGY, V42, P816, DOI 10.1212/WNL.42.4.816; TIEN RD, 1992, AM J ROENTGENOL, V158, P1325, DOI 10.2214/ajr.158.6.1590135; TIEN RD, 1991, AM J NEURORADIOL, V12, P283; TROTOT PM, 1990, J NEURORADIOLOGY, V17, P233; UNGER E, 1988, AM J ROENTGENOL, V150, P605, DOI 10.2214/ajr.150.3.605; WEINGARTEN K, 1992, AM J ROENTGENOL, V158, P645, DOI 10.2214/ajr.158.3.1739012; WEISSLEDER R, 1992, Magnetic Resonance Quarterly, V8, P55; YETKIN FZ, 1991, RADIOLOGY, V178, P447, DOI 10.1148/radiology.178.2.1987607; YUH WTC, 1991, AM J NEURORADIOL, V12, P621; ZERVAS NT, 1992, NEW ENGL J MED, V326, P816, DOI 10.1056/NEJM199203193261208; ZYED A, 1991, AM J NEURORADIOL, V12, P469	60	143	164	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1993	328	10					708	716		10.1056/NEJM199303113281008	http://dx.doi.org/10.1056/NEJM199303113281008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ861	8433731				2022-12-28	WOS:A1993KQ86100008
J	ZIJLSTRA, F; DEBOER, MJ; HOORNTJE, JCA; REIFFERS, S; REIBER, JHC; SURYAPRANATA, H				ZIJLSTRA, F; DEBOER, MJ; HOORNTJE, JCA; REIFFERS, S; REIBER, JHC; SURYAPRANATA, H			A COMPARISON OF IMMEDIATE CORONARY ANGIOPLASTY WITH INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; THROMBOLYTIC THERAPY; INTRACORONARY STREPTOKINASE; REPERFUSION THERAPY; RANDOMIZED TRIAL; FOLLOW-UP; ARTERY; CATHETERIZATION; TERM	Background. Despite the widespread use of intravenous thrombolytic therapy and of immediate percutaneous transluminal coronary angioplasty for the treatment of acute myocardial infarction, randomized comparisons of the two approaches to reperfusion are lacking. We report the results of a prospective, randomized trial comparing immediate coronary angioplasty (without previous thrombolytic therapy) with intravenous streptokinase treatment. Methods. A total of 142 patients with acute myocardial infarction were randomly assigned to receive one of the two treatments. The left ventricular ejection fraction was measured by radionuclide scanning before hospital discharge. Quantitative coronary angiography was performed to assess the degree of residual stenosis in the infarct-related arteries. Results. A total of 72 patients were assigned to receive streptokinase and 70 patients to undergo immediate angioplasty. Angioplasty was technically successful in 64 of the 65 patients who underwent the procedure. Infarction recurred in nine patients assigned to receive streptokinase, but in none of those assigned to receive angioplasty (P = 0.003 ). Fourteen patients in the streptokinase group had unstable angina after their infarction, but only four in the angioplasty group (P = 0.02). The mean (+/-SD) left ventricular ejection fraction as measured before discharge was 45+/-12 percent in the streptokinase group and 51+/-11 percent in the angioplasty group (P = 0.004). The infarct-related artery was patent in 68 percent of the patients in the streptokinase group and 91 percent of those in the angioplasty group (P = 0.001). Quantitative coronary angiography revealed stenosis of 36+/-20 percent of the luminal diameter in the angioplasty group, as compared with 76+/-19 percent in the streptokinase group (P<0.001). Conclusions. Immediate angioplasty after acute myocardial infarction was associated with a higher rate of patency of the infarct-related artery, a less severe residual stenotic lesion, better left ventricular function, and less recurrent myocardial ischemia and infarction than was intravenous streptokinase.	ZIEKENHUIS WEEZENLANDEN, DEPT NUCL MED, 8011 JW ZWOLLE, NETHERLANDS; LEIDEN UNIV HOSP, DEPT DIAGNOST RADIOL & NUCL MED, CLIN & EXPTL IMAGE PROC LAB, 2333 AA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	ZIJLSTRA, F (corresponding author), ZIEKENHUIS WEEZENLANDEN, DEPT CARDIOL, GROOT WEZENLAND 20, 8011 JW ZWOLLE, NETHERLANDS.		Suryapranata, H./H-8095-2014; de Boer, M.J./H-8014-2014					[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1990, Lancet, V336, P65; [Anonymous], 1986, Lancet, V1, P397; BORER JS, 1987, SEMIN NUCL MED, V17, P89, DOI 10.1016/S0001-2998(87)80014-4; BOUDREAU RJ, 1987, SEMIN NUCL MED, V17, P28, DOI 10.1016/S0001-2998(87)80005-3; CALIFF RM, 1990, CIRCULATION, V82, P1847, DOI 10.1161/01.CIR.82.5.1847; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; DEBONO DP, 1992, BRIT HEART J, V67, P122; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; GACIOCH GM, 1989, J AM COLL CARDIOL, V14, P1202, DOI 10.1016/0735-1097(89)90418-X; HUNT D, 1992, LANCET, V339, P753; JONES RH, 1987, SEMIN NUCL MED, V17, P95, DOI 10.1016/S0001-2998(87)80015-6; KAHN JK, 1990, CIRCULATION, V82, P1910, DOI 10.1161/01.CIR.82.6.1910; KENNEDY JW, 1985, NEW ENGL J MED, V312, P1073, DOI 10.1056/NEJM198504253121701; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; MEIER B, 1990, CIRCULATION, V82, P2243, DOI 10.1161/01.CIR.82.6.2243; NORRIS RM, 1988, LANCET, V1, P104; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; REIBER J H C, 1989, Medicamundi, V34, P89; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; REIBER JHC, 1992, ADV QUANTITATIVE COR, P75; REMKES PAJ, 1991, NED TIJDSCHR CARDIOL, V5, P178; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; SIMOONS ML, 1988, LANCET, V1, P199; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; SIMOONS ML, 1986, J AM COLL CARDIOL, V7, P717, DOI 10.1016/S0735-1097(86)80329-1; van der Zwet P M, 1990, Int J Card Imaging, V5, P75; WALLER BF, 1987, J AM COLL CARDIOL, V9, P785, DOI 10.1016/S0735-1097(87)80234-6	31	1014	1056	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1993	328	10					680	684		10.1056/NEJM199303113281002	http://dx.doi.org/10.1056/NEJM199303113281002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ861	8433726	Bronze			2022-12-28	WOS:A1993KQ86100002
J	HARTLEY, SB; COOKE, MP; FULCHER, DA; HARRIS, AW; CORY, S; BASTEN, A; GOODNOW, CC				HARTLEY, SB; COOKE, MP; FULCHER, DA; HARRIS, AW; CORY, S; BASTEN, A; GOODNOW, CC			ELIMINATION OF SELF-REACTIVE LYMPHOCYTES-B PROCEEDS IN 2 STAGES - ARRESTED DEVELOPMENT AND CELL-DEATH	CELL			English	Article							COMPLEMENT RECEPTOR TYPE-2; IMMUNOGLOBULIN MU-CHAIN; MOUSE BONE-MARROW; TRANSGENIC MICE; CLONAL DELETION; ANTIBODY-RESPONSES; T-CELLS; EXPRESSION; TOLERANCE; DIFFERENTIATION	In transgenic mice, self-reactive B lymphocytes are eliminated if they encounter membrane-bound self antigens during their development within the bone marrow. We show here that two separate and sequential events, arrested development and cell death, bring about B cell elimination. Developmental arrest is an early outcome of antigen binding in immature B cells, blocks acquisition of adhesion molecules and receptors important for B cell migration and activation, and is rapidly reversible by removal of antigen. Death of the arrested B cells occurs within 1 to 3 days and can be delayed by expression of a bcl-2 transgene, which results in escape of large numbers of self-reactive B cells from the bone marrow but fails to override the developmental arrest. These findings define a novel pathway for B cell elimination, involving an initial stage vulnerable to breakdown in autoimmune disease.	STANFORD UNIV, MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL, BECKMAN CTR, STANFORD, CA 94305 USA; UNIV SYDNEY, CENTENARY INST CANC MED & CELL BIOL, SYDNEY, NSW 2006, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	Stanford University; University of Sydney; Centenary Institute; Royal Melbourne Hospital; Walter & Eliza Hall Institute	HARTLEY, SB (corresponding author), STANFORD UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.		Goodnow, Christopher C/V-8108-2018; Cory, Suzanne/E-1642-2013	Goodnow, Christopher C/0000-0001-5296-6155; Cory, Suzanne/0000-0002-6818-3451	NCI NIH HHS [CA 43540] Funding Source: Medline; NIAID NIH HHS [AI-19512] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI019512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLATTNER FR, 1984, NATURE, V307, P417, DOI 10.1038/307417a0; BROMBACHER F, 1991, J EXP MED, V174, P1335, DOI 10.1084/jem.174.6.1335; CARTER RH, 1988, J IMMUNOL, V141, P457; CHEN SZ, 1990, BIOTECHNIQUES, V8, P32; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; Conrad D H, 1991, Monogr Allergy, V29, P9; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ERA T, 1991, EMBO J, V10, P337, DOI 10.1002/j.1460-2075.1991.tb07954.x; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FORD WL, 1975, PROG ALLERGY, V19, P1, DOI 10.1159/000313381; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GELFAND MC, 1974, J EXP MED, V139, P1125, DOI 10.1084/jem.139.5.1125; GLEICHMANN E, 1982, EUR J IMMUNOL, V12, P152, DOI 10.1002/eji.1830120210; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Gordon J, 1991, Monogr Allergy, V29, P156; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; KINOSHITA T, 1990, INT IMMUNOL, V2, P651, DOI 10.1093/intimm/2.7.651; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; LASKY LA, 1991, J CELL BIOCHEM, V45, P139, DOI 10.1002/jcb.240450204; Lawton A R 3rd, 1974, Contemp Top Immunobiol, V3, P193; MacLennan I C, 1989, Curr Top Pathol, V79, P37; MASON DY, 1992, INT IMMUNOL, V4, P163, DOI 10.1093/intimm/4.2.163; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; OSMOND DG, 1974, CELL IMMUNOL, V13, P132, DOI 10.1016/0008-8749(74)90233-0; PARKS DR, 1986, HDB EXPT IMMUNOLOGY, V1; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; PICKER LJ, 1992, ANN REV IMMUNOL, V10; PLAYFAIR JH, 1973, NATURE-NEW BIOL, V243, P213, DOI 10.1038/newbio243213a0; RAJEWSKY K, 1992, CURR OPIN IMMUNOL, V4, P171, DOI 10.1016/0952-7915(92)90008-3; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHEN FW, 1981, MONOCLONAL ANTIBODIE, P25; SPRENT J, 1973, CELL IMMUNOL, V7, P40, DOI 10.1016/0008-8749(73)90181-0; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TIMENS W, 1989, EUR J IMMUNOL, V19, P2163, DOI 10.1002/eji.1830191129; VANKRIEKEN JHJM, 1989, HUM PATHOL, V20, P320, DOI 10.1016/0046-8177(89)90040-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALDSCHMIDT TJ, 1991, INT IMMUNOL, V3, P305, DOI 10.1093/intimm/3.4.305; Weigle W O, 1973, Adv Immunol, V16, P61, DOI 10.1016/S0065-2776(08)60296-5; WIERSMA EJ, 1991, EUR J IMMUNOL, V21, P2501, DOI 10.1002/eji.1830211029; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YELLEN AJ, 1991, J IMMUNOL, V146, P1446	61	458	465	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					325	335		10.1016/0092-8674(93)90111-3	http://dx.doi.org/10.1016/0092-8674(93)90111-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431943				2022-12-28	WOS:A1993KM16200004
J	CROWLEY, TE; HOEY, T; LIU, JK; JAN, YN; JAN, LY; TJIAN, R				CROWLEY, TE; HOEY, T; LIU, JK; JAN, YN; JAN, LY; TJIAN, R			A NEW FACTOR RELATED TO TATA-BINDING PROTEIN HAS HIGHLY RESTRICTED EXPRESSION PATTERNS IN DROSOPHILA	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; NERVOUS-SYSTEM; INITIATION; COACTIVATORS; EMBRYOS	THE TATA-binding protein TBP is necessary for the transcription of eukaryotic genes. Multi-protein complexes formed by TBP and different TBP-associated factors are involved in the initiation of transcription by polymerases I and II, and probably ill as well1. During the formation of an active initiation complex, TBP makes specific contacts with other proteins, for example TFIIB and RNA polymerase II (refs 2-4). Here we describe the cloning and characterization of a Drosophila gene product with considerable sequence similarity to TBP and a highly restricted expression pattern in the embryo. This TBP-related factor is a DNA-binding protein but is not likely to be a basal transcription factor. Our results suggest that TBP-related factor is a sequence-specific transcription factor that shares the DNA-binding properties of TBP.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California Berkeley				Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Gill Grace, 1992, Current Biology, V2, P565, DOI 10.1016/0960-9822(92)90046-D; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; JACOBS JR, 1989, NEURON, V2, P1625; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; NASH HA, 1991, CELL, V67, P1037, DOI 10.1016/0092-8674(91)90280-C; PAPAZIAN DM, 1988, ANNU REV PHYSIOL, V50, P379; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SINK H, 1991, DEVELOPMENT, V112, P307; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223	26	104	106	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					557	561		10.1038/361557a0	http://dx.doi.org/10.1038/361557a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429912				2022-12-28	WOS:A1993KL71400068
J	QIAN, Z; GILBERT, ME; COLICOS, MA; KANDEL, ER; KUHL, D				QIAN, Z; GILBERT, ME; COLICOS, MA; KANDEL, ER; KUHL, D			TISSUE-PLASMINOGEN ACTIVATOR IS INDUCED AS AN IMMEDIATE EARLY GENE DURING SEIZURE, KINDLING AND LONG-TERM POTENTIATION	NATURE			English	Article							NERVE GROWTH-FACTOR; NEURITE OUTGROWTH; MESSENGER-RNA; EXPRESSION; HIPPOCAMPUS; RECEPTOR; PROTEIN; MEMORY; CELLS; RAT	THE requirement of protein and messenger RNA synthesis for long-term memory1,2 suggests that neural activity induced by learning initiates a cascade of gene expression3. Here we use differential screening to identify five immediate-early genes induced by neuronal activity. One of these is tissue-plasminogen activator (tPA), an extracellular serine protease, which is induced with different spatial patterns in the brain by three activity-dependent events: (1) convulsive seizure increases expression of tPA in the whole brain; (2) stimulation of the perforant path produces an epileptiform after-discharge that ultimately leads to kindling increases the levels of tPA throughout the hippocampus bilaterally; and (3) brief high-frequency stimulation of the perforant path that produces long-term potentiation (LTP) causes an NMDA (N-methyl-D-aspartate) receptor-mediated increase in the levels of tPA mRNA which is restricted to the granule cells of the ipsilateral dentate gyrus. As release of tPA is correlated with morphological differentiation4-6, the increased expression of tPA may play a role in the structural changes that accompany activity-dependent plasticity7-10.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; MANTECH ENVIRONM TECHNOL INC,RES TRIANGLE PK,NC 27709	Columbia University; Howard Hughes Medical Institute	QIAN, Z (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032, USA.		Kuhl, Dietmar/A-4689-2009	Kuhl, Dietmar/0000-0002-4772-6701				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; CARNEY DH, 1987, PROTEASES BIOL CONTR, P277; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FASELI MS, 1990, BRAIN RES, V521, P247; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GEINISMAN Y, 1992, BRAIN RES, V569, P342; GERARD RD, 1989, ANNU REV PHYSIOL, V51, P245, DOI 10.1146/annurev.physiol.51.1.245; GILBERT ME, 1990, BRAIN RES, V519, P89, DOI 10.1016/0006-8993(90)90064-I; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HAJJAR KA, 1991, J BIOL CHEM, V266, P21962; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; MCNAMARA JO, 1980, PROG NEUROBIOL, V15, P139, DOI 10.1016/0301-0082(80)90006-4; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NEUMAN T, 1989, J NEUROSCI RES, V23, P274, DOI 10.1002/jnr.490230305; PITTMAN RN, 1989, J NEUROSCI, V9, P4269; RACINE RJ, 1983, BRAIN RES, V260, P217, DOI 10.1016/0006-8993(83)90676-5; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P269, DOI 10.1016/0013-4694(72)90176-9; Sambrook J, 1989, MOL CLONING LABORATO; SHAW G, 1986, CELL, V24, P151; WALLACE CS, 1991, LONG TERM POTENTIATI, P189; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y	29	648	662	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					453	457		10.1038/361453a0	http://dx.doi.org/10.1038/361453a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8429885				2022-12-28	WOS:A1993KK71300062
J	VANDERLINDEN, PWG; STRUYVENBERG, A; KRAAIJENHAGEN, RJ; HACK, CE; VANDERZWAN, JK				VANDERLINDEN, PWG; STRUYVENBERG, A; KRAAIJENHAGEN, RJ; HACK, CE; VANDERZWAN, JK			ANAPHYLACTIC SHOCK AFTER INSECT-STING CHALLENGE IN 138 PERSONS WITH A PREVIOUS INSECT-STING REACTION	ANNALS OF INTERNAL MEDICINE			English	Article						ANAPHYLAXIS; INSECT BITES AND STINGS; HYMENOPTERA; CATECHOLAMINES; ANGIOTENSINS	WASP VENOM; HISTAMINE; ANGIOTENSIN; HYPERSENSITIVITY; MECHANISMS; RESPONSES; PEPTIDES; PLASMA; HEART	Objective: To study the rate and severity of anaphylactic reaction in relation to plasma levels of cardiovascular mediators in persons with a history of insect-sting anaphylactic shock who were rechallenged with a sting by the same insect. Design: A cohort study with measurements before and after intentional sting challenge. Setting: Intensive care unit of an 830-bed general hospital, a national center of insect-sting anaphylaxis in The Netherlands. Patients: A total of 138 patients referred after a previous anaphylactic reaction to a Hymenoptera sting; and 8 volunteers. Measurements: Signs of anaphylaxis and plasma levels of catecholamines and angiotensins. Main Results: Only 39 of 138 (28%) of patients with a previous insect-sting anaphylactic reaction developed anaphylactic symptoms after sting challenge. Values of cardiovascular mediators and mean arterial pressure did not differ after the challenge from initial values in the volunteers or in the patients with a mild or no reaction after challenge. In the 17 patients with anaphylactic shock, mean arterial pressure decreased from 97 +/- 11 (mean t SD) to 65 +/- 17 mm Hg (P < 0.001), epinephrine levels rose from a median of 0.3 nmol/L (range, 0.2 to 2.3 nmol/L) to 2.5 nmol/L (0.2 to 35.7 nmol/L; P < 0.05), norepinephrine from 1.5 nmol/L (0.5 to 6.7) to 5.9 nmol/L (1.6 to 30.9 nmol/L; P < 0.01), and angiotensin 11 from 61 pmol/L (7 to 217 pmol/L) to 105 pmol/L (11 to 286 pmol/L; P < 0.01), all within 5 minutes after the onset of anaphylactic symptoms. The rise of these mediators correlated with the drop in blood pressure (P < 0.001). Dopamine and angiotensin I levels did not change in any participants. Conclusions: A recurrent insect-sting anaphylactic reaction occurred in only 28% of patients with a previous reaction. During this recurrent reaction, plasma levels of endogenous epinephrine, norepinephrine, and angiotensin II rose in relation to hypotension.	UNIV UTRECHT HOSP,3511 GV UTRECHT,NETHERLANDS; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,AMSTERDAM,NETHERLANDS	Utrecht University; Utrecht University Medical Center	VANDERLINDEN, PWG (corresponding author), EEMLAND HOSP,DEPT INTERNAL MED,UTRECHTSEWEG 160,3818 ES AMERSFOORT,NETHERLANDS.		Levi, Marcel/AAZ-8559-2020					ANDERSON MW, 1990, J ALLERGY CLIN IMMUN, V85, P856, DOI 10.1016/0091-6749(90)90068-F; BLAAUW PK, 1985, J ALLERGY CLIN IMMUN, V75, P566; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785, DOI 10.1056/NEJM199106203242506; BRISTOW MR, 1982, AM J CARDIOL, V49, P249, DOI 10.1016/0002-9149(82)90298-3; Fisher M, 1989, UPDATE INTENSIVE CAR, P309; FISHER MM, 1986, ANAESTH INTENS CARE, V14, P17, DOI 10.1177/0310057X8601400105; HELLER LJ, 1990, INT ARCH ALLER A IMM, V91, P285, DOI 10.1159/000235129; HERMANN K, 1988, CLIN CHEM, V34, P1046; HERMANN K, 1990, CLIN EXP ALLERGY, V20, P566; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JOHNSON AR, 1977, J CLIN INVEST, V59, P684, DOI 10.1172/JCI108687; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; KIFOR I, 1987, CIRC RES, V60, P422, DOI 10.1161/01.RES.60.3.422; LANDSBERG L, 1987, HARRISONS PRINCIPLES, P358; Levi R., 1988, HUMAN INFLAMMATORY D, P93; MUELLER HL, 1966, J ASTHMA RES, V3, P331; NAGARATNAM N, 1988, J ROY SOC MED, V81, P420, DOI 10.1177/014107688808100722; PAVEK K, 1982, KLIN WOCHENSCHR, V60, P941, DOI 10.1007/BF01716952; PETSAS AA, 1973, CHEST, V64, P66, DOI 10.1378/chest.64.1.66; PIPER PJ, 1967, NATURE, V213, P838, DOI 10.1038/213838a0; RAPER RF, 1988, LANCET, V1, P386; SAXENA PR, 1990, J CARDIOVASC PHARM, V15, pS17, DOI 10.1097/00005344-199001001-00004; SCHELLENBERG RR, 1991, J ALLERGY CLIN IMMUN, V87, P499, DOI 10.1016/0091-6749(91)90008-C; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; VANDERZWAN JK, 1992, J ALLERGY CLIN IMMUN, V89, P293; VANE JR, 1990, NEW ENGL J MED, V323, P27; WALDHAUSEN E, 1987, ANAESTHESIST, V36, P150; WASSERMAN SI, 1986, J ALLERGY CLIN IMMUN, V77, P663, DOI 10.1016/0091-6749(86)90405-7; ZAVECZ JH, 1977, CIRC RES, V40, P15, DOI 10.1161/01.RES.40.1.15; ZIMMERMAN BG, 1981, CLIN SCI, V60, P343, DOI 10.1042/cs0600343	37	72	74	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					161	168		10.7326/0003-4819-118-3-199302010-00001	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8417633				2022-12-28	WOS:A1993KJ43900001
J	KARLIN, S; BRENDEL, V				KARLIN, S; BRENDEL, V			PATCHINESS AND CORRELATIONS IN DNA-SEQUENCES	SCIENCE			English	Article							METHYLATION; CHROMOSOME	The highly nonrandom character of genomic DNA can confound attempts at modeling DNA sequence variation by standard stochastic processes (including random walk or fractal models). In particular, the mosaic character of DNA consisting of patches of different composition can fully account for apparent long-range correlations in DNA.			KARLIN, S (corresponding author), STANFORD UNIV,DEPT MATH,STANFORD,CA 94305, USA.				NHGRI NIH HHS [HG00335-04] Funding Source: Medline; NIGMS NIH HHS [GM10452-29] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010452] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATO I, 1992, SCIENCE, V257, P747, DOI 10.1126/science.1496395; AMATO I, 1992, SCIENCE, V256, P1763, DOI 10.1126/science.1615321; BAKER GL, 1990, CHAOTIC DYNAMICS; Berg DE, 1989, MOBILE DNA; BERNARDI G, 1988, J MOL EVOL, V28, P7, DOI 10.1007/BF02143493; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; CASSANDRO M, 1978, ADV PHYS, V27, P913, DOI 10.1080/00018737800101504; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; FISZ M, 1963, PROBABILITY THEORY M, P512; GILSON E, 1991, NUCLEIC ACIDS RES, V19, P1375, DOI 10.1093/nar/19.7.1375; INMAN RB, 1966, J MOL BIOL, V18, P464, DOI 10.1016/S0022-2836(66)80037-2; JOSSE J, 1961, J BIOL CHEM, V236, P864; KARLIN S, 1992, NUCLEIC ACIDS RES, V20, P1363, DOI 10.1093/nar/20.6.1363; KARLIN S, 1992, SCIENCE, V257, P39, DOI 10.1126/science.1621093; Kimura M., 1983, NEUTRAL THEORY MOL E; KRAWIEC S, 1990, MICROBIOL REV, V54, P502, DOI 10.1128/MMBR.54.4.502-539.1990; LI W, 1992, EUROPHYS LETT, V17, P655, DOI 10.1209/0295-5075/17/7/014; MADDOX J, 1992, NATURE, V358, P103, DOI 10.1038/358103a0; MANDELBROT BB, 1968, SIAM REV, V10, P422, DOI 10.1137/1010093; NEE S, 1992, NATURE, V357, P450, DOI 10.1038/357450a0; NELSON M, 1991, NUCLEIC ACIDS RES, V19, P2045, DOI 10.1093/nar/19.suppl.2045; PENG CK, 1992, NATURE, V356, P168, DOI 10.1038/356168a0; PRABHU VV, 1992, NATURE, V359, P782, DOI 10.1038/359782a0; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; Sokal R. R., 1981, BIOMETRY; TAQQU MS, 1978, STOCHASTIC PROCESSES, V7, P55; VOSS RF, 1992, PHYS REV LETT, V68, P3805, DOI 10.1103/PhysRevLett.68.3805; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; [No title captured]	32	171	177	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					677	680		10.1126/science.8430316	http://dx.doi.org/10.1126/science.8430316			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430316				2022-12-28	WOS:A1993KJ68800041
J	KAY, GF; PENNY, GD; PATEL, D; ASHWORTH, A; BROCKDORFF, N; RASTAN, S				KAY, GF; PENNY, GD; PATEL, D; ASHWORTH, A; BROCKDORFF, N; RASTAN, S			EXPRESSION OF XIST DURING MOUSE DEVELOPMENT SUGGESTS A ROLE IN THE INITIATION OF X-CHROMOSOME INACTIVATION	CELL			English	Article							CONTROLLING ELEMENTS; FEMALE MOUSE; GERM-LINE; PREFERENTIAL INACTIVATION; GENE-EXPRESSION; YOLK-SAC; EMBRYOS; DIFFERENTIATION; CELLS; INVITRO	The mouse Xist gene maps to the X inactivation center (Xic) region and is expressed exclusively from the inactive X chromosome. It is thus a candidate gene for the Xic. We show that the onset of Xist expression in mouse development precedes X chromosome inactivation and may therefore be a cause rather than merely a consequence of X inactivation. The earliest Xist expression in morulae and blastocysts is imprinted, resulting in specific expression of the paternal Xist allele. Imprinted Xist expression may thus be the cause of nonrandom inactivation of the paternal X in trophectoderm. Strong Xce alleles can act to reduce the effect of imprinted Xist expression in the trophectoderm. The imprint on Xist expression is lost shortly before gastrulation when random X inactivation occurs. Our data support a direct role for Xist in the initiation of X inactivation.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	KAY, GF (corresponding author), CLIN RES CTR,MRC,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND.		Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				ADLER DA, 1977, NATURE, V267, P838, DOI 10.1038/267838a0; ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BROWN SW, 1973, P NATL ACAD SCI USA, V70, P195, DOI 10.1073/pnas.70.1.195; BUCHER T, 1985, GENET RES, V47, P43; Cattanach B. M., 1991, Mouse Genome, V89, P565; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; CATTANACH BM, 1969, GENET RES, V14, P233; CHAPMAN VM, 1976, NATURE, V259, P665, DOI 10.1038/259665a0; CHATOT CL, 1989, J REPROD FERTIL, V86, P679, DOI 10.1530/jrf.0.0860679; CHATOT CL, 1990, BIOL REPROD, V42, P432, DOI 10.1095/biolreprod42.3.432; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER DW, 1971, NATURE, V230, P292, DOI 10.1038/230292a0; EPSTEIN CJ, 1978, NATURE, V274, P500, DOI 10.1038/274500a0; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GARTLER SM, 1975, EXP CELL RES, V91, P454, DOI 10.1016/0014-4827(75)90127-5; GOETZ P, 1984, J CELL SCI, V65, P249; GUETHHALLONET C, 1992, TRENDS GENET, V8, P274, DOI 10.1016/0168-9525(92)90134-P; HOGAN BLM, 1981, J EMBRYOL EXP MORPH, V62, P379; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JOHNSTON PG, 1981, GENET RES, V37, P151, DOI 10.1017/S0016672300020127; KAY G, 1991, GENOMICS, V11, P651, DOI 10.1016/0888-7543(91)90072-M; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; KRATZER PG, 1981, P NATL ACAD SCI-BIOL, V78, P3093, DOI 10.1073/pnas.78.5.3093; KRATZER PG, 1978, NATURE, V274, P503, DOI 10.1038/274503a0; LEVAKSVA.B, 1969, EXPERIENTIA, V25, P1311, DOI 10.1007/BF01897519; LIFSCHYTZ E, 1972, P NATL ACAD SCI USA, V69, P182, DOI 10.1073/pnas.69.1.182; LYON MF, 1974, PROC R SOC SER B-BIO, V187, P243, DOI 10.1098/rspb.1974.0073; LYON MF, 1984, DIFFERENTIATION, V26, P63, DOI 10.1111/j.1432-0436.1984.tb01375.x; LYON MF, 1961, NATURE, V190, P373; LYON MF, 1989, GENETIC VARIANTS STA; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V74, P207; MCMAHON A, 1981, J EMBRYOL EXP MORPH, V64, P251; MONK M, 1981, J EMBRYOL EXP MORPH, V63, P75; MONK M, 1978, J EMBRYOL EXP MORPH, V46, P53; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; MONK M, 1977, NATURE, V270, P599, DOI 10.1038/270599a0; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1982, J EMBRYOL EXP MORPH, V71, P11; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1983, NATURE, V303, P635, DOI 10.1038/303635a0; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; ROBERTSON EJ, 1983, COLD SPRING HARBOR C, V10, P647; SACHS L, 1954, ANN EUGENIC, V18, P255; SCHERER SE, 1988, NUCLEIC ACIDS RES, V16, P1593, DOI 10.1093/nar/16.4.1593; SOLARI AJ, 1974, INT REV CYTOL, V38, P273, DOI 10.1016/S0074-7696(08)60928-6; SUGAWARA O, 1985, CYTOGENET CELL GENET, V39, P210, DOI 10.1159/000132137; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; TAKAGI N, 1982, CHROMOSOMA, V85, P275, DOI 10.1007/BF00294971; TAKAGI N, 1974, EXP CELL RES, V86, P127, DOI 10.1016/0014-4827(74)90657-0; TAKAGI N, 1978, CYTOGENET CELL GENET, V20, P240, DOI 10.1159/000130856; WEST JD, 1977, CELL, V12, P873, DOI 10.1016/0092-8674(77)90151-9; WILLISON K, 1987, TRENDS GENET, V3, P351, DOI 10.1016/0168-9525(87)90296-4	61	342	352	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					171	182		10.1016/0092-8674(93)90658-D	http://dx.doi.org/10.1016/0092-8674(93)90658-D			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	8425217				2022-12-28	WOS:A1993KK03800003
J	CRICK, F; JONES, E				CRICK, F; JONES, E			BACKWARDNESS OF HUMAN NEUROANATOMY	NATURE			English	Editorial Material									UNIV CALIF IRVINE,DEPT ANAT & NEUROBIOL,IRVINE,CA 92715	University of California System; University of California Irvine	CRICK, F (corresponding author), SALK INST,POB 85800,SAN DIEGO,CA 92186, USA.							BURKHALTER A, 1989, P NATL ACAD SCI USA, V86, P1071, DOI 10.1073/pnas.86.3.1071; CLARK VP, 1992, CEREB CORTEX, V2, P417, DOI 10.1093/cercor/2.5.417; EDELMAN RR, 1990, DISCUSS NEUROSCI, V7, P11; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; GODEMENT P, 1987, DEVELOPMENT, V101, P697; HARI R, 1989, SCIENCE, V244, P432, DOI 10.1126/science.2655083; HEIMER L, 1989, NEUROANATOMICAL TRAC, V2; JONES EG, 1992, NEUROSCI METH, V44, P133; RAICHLE ME, 1990, COLD SPRING HARB SYM, V55, P983; Tank D. W., 1992, Current Biology, V2, P525, DOI 10.1016/0960-9822(92)90011-X; WONG DF, 1986, SCIENCE, V234, P1558, DOI 10.1126/science.2878495	11	154	161	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					109	110		10.1038/361109a0	http://dx.doi.org/10.1038/361109a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421513				2022-12-28	WOS:A1993KG46600024
J	HOSTETLER, MD; DUNN, MI				HOSTETLER, MD; DUNN, MI			PERIOPERATIVE EVALUATION OF A PATIENT WITH ABDOMINAL AORTIC-ANEURYSM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CORONARY-ARTERY DISEASE; VASCULAR-SURGERY; CARDIAC RISK; COMPLICATIONS; MANAGEMENT				HOSTETLER, MD (corresponding author), UNIV KANSAS,MED CTR,SCH MED,KANSAS CITY,KS 66103, USA.							[Anonymous], 1982, LANCET, V2, P1173; AROUS EJ, 1984, ARCH SURG-CHICAGO, V119, P780; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; CAMPBELL JB, 1989, SOUTH MED J, V82, P458, DOI 10.1097/00007611-198904000-00013; CUTLER BS, 1991, AM J CARDIOL, V68, P593; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; MCPHAIL NV, 1989, J VASC SURG, V10, P51, DOI 10.1067/mva.1989.vs0100051; ROGER VL, 1989, J AM COLL CARDIOL, V14, P1245, DOI 10.1016/0735-1097(89)90423-3	10	9	9	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					295	295		10.1001/jama.269.2.295	http://dx.doi.org/10.1001/jama.269.2.295			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417248				2022-12-28	WOS:A1993KF40500037
J	COCKBURN, F; BARWELL, BE; BRENTON, DP; CHAPPLE, J; CLARK, B; CURZON, G; DAVIDSON, DC; HEELEY, AF; LAING, SC; LISTERCHEESE, JAF; MCDONALD, I; MALCOLM, S; POLLITT, RJ; QUINN, D; RYLANCE, G; SMITH, I; STEWART, A; SURTEES, R; THOMPSON, AJ; TYFIELD, L; WHITTLE, MJ; SCRIVER, CR; FREW, J				COCKBURN, F; BARWELL, BE; BRENTON, DP; CHAPPLE, J; CLARK, B; CURZON, G; DAVIDSON, DC; HEELEY, AF; LAING, SC; LISTERCHEESE, JAF; MCDONALD, I; MALCOLM, S; POLLITT, RJ; QUINN, D; RYLANCE, G; SMITH, I; STEWART, A; SURTEES, R; THOMPSON, AJ; TYFIELD, L; WHITTLE, MJ; SCRIVER, CR; FREW, J			PHENYLKETONURIA DUE TO PHENYLALANINE-HYDROXYLASE DEFICIENCY - AN UNFOLDING STORY	BRITISH MEDICAL JOURNAL			English	Article							EARLY-TREATED PHENYLKETONURIA; MATERNAL PHENYLKETONURIA; DIETARY-TREATMENT; NEUROLOGICAL DETERIORATION; FETAL DAMAGE; HYPERPHENYLALANINEMIA; INTELLIGENCE; CHILDREN; TERMINATION; BEHAVIOR	Efficient neonatal screening for phenylketonuria and the availability of complex diets for lifelong use have virtually eliminated severe mental handicap from the disease. Nevertheless, there remains a high risk of fetal damage in offspring of women with the disease, and the possibility that the diets themselves may be harmful cannot be excluded. Search for a preventive treatment for the disease has been greatly aided by advances in molecular genetics. For example, in mice modified liver cells have been implanted, which have not only corrected the phenylalanine defect but have remained healthy for the normal life span of the animal. Overall, however, prevention and treatment have not progressed as quickly as was hoped, and research and development must be pursued vigorously to take account of contemporary perceptions of the disorder.	INST CHILD HLTH,PHENYLKETONURIA REGISTER,LONDON WC1N 1EH,ENGLAND	University of London; University College London			Quinn, David/N-3730-2019; Thompson, Alan J/C-2654-2008	Quinn, David/0000-0002-1411-0417; Thompson, Alan J/0000-0002-4333-8496				BERRY HK, 1990, AM J DIS CHILD, V144, P539, DOI 10.1001/archpedi.1990.02150290033020; BICK U, 1991, EUR J PEDIATR, V150, P185, DOI 10.1007/BF01963563; BINEKSINGER P, 1982, BIOCHEM J, V206, P407, DOI 10.1042/bj2060407; BRUNNER RL, 1983, J PEDIATR-US, V102, P831, DOI 10.1016/S0022-3476(83)80007-9; CABALSKA B, 1977, EUR J PEDIATR, V126, P253, DOI 10.1007/BF00477051; DESONNEVILLE LHJ, 1990, EUR J PEDIATR, V5, P39; DOBSON JC, 1977, PEDIATRICS, V60, P822; DROGARI E, 1987, LANCET, V2, P927; FISCHLER K, 1987, AM J MENT DEFIC, V92, P65; FLYNN JR, 1984, PSYCHOL BULL, V95, P29, DOI 10.1037/0033-2909.95.1.29; FUGGLE PW, IN PRESS J CLIN PSYC; HOLTZMAN NA, 1986, NEW ENGL J MED, V314, P593, DOI 10.1056/NEJM198603063141001; HOMMES FA, 1982, J INHERIT METAB DIS, V5, P21, DOI 10.1007/BF01799750; HOSKINS JA, 1980, LANCET, V1, P392; JARUZELSKA J, 1991, HUM GENET, V86, P247; KAUFMAN S, 1989, J PEDIATR, V114, P95; KOCH R, 1982, J PEDIATR-US, V100, P870, DOI 10.1016/S0022-3476(82)80503-9; KOCH R, 1984, J INHERIT METAB DIS, V7, P86, DOI 10.1007/BF01805813; KONECKI DS, 1991, HUM GENET, V87, P377; KRAUSE W, 1985, J CLIN INVEST, V75, P40, DOI 10.1172/JCI111695; LENKE RR, 1980, NEW ENGL J MED, V303, P1202, DOI 10.1056/NEJM198011203032104; LEVY HL, 1983, NEW ENGL J MED, V309, P1269, DOI 10.1056/NEJM198311243092101; LOU HC, 1987, ACTA PAEDIATR SCAND, V76, P560, DOI 10.1111/j.1651-2227.1987.tb10521.x; MABRY CC, 1991, AM J DIS CHILD, V145, P33, DOI 10.1001/archpedi.1991.02160010035010; MALAMUD N, 1966, J NEUROPATH EXP NEUR, V25, P254, DOI 10.1097/00005072-196604000-00006; MCKEAN CM, 1968, J NEUROCHEM, V15, P235, DOI 10.1111/j.1471-4159.1968.tb06202.x; MELNICK CR, 1981, J PEDIATR-US, V98, P269, DOI 10.1016/S0022-3476(81)80658-0; Michel U, 1990, EUR J PEDIATR, V149, P34; OKANO Y, 1991, NEW ENGL J MED, V324, P232; PENNINGTON BF, 1985, AM J MENT DEF, V89, P467; SMITH I, 1991, BRIT MED J, V303, P333, DOI 10.1136/bmj.303.6798.333; SMITH I, 1988, J PEDIATR-US, V112, P403, DOI 10.1016/S0022-3476(88)80320-2; SMITH I, 1990, ARCH DIS CHILD, V65, P472, DOI 10.1136/adc.65.5.472; SMITH I, 1991, ARCH DIS CHILD, V66, P311, DOI 10.1136/adc.66.3.311; SMITH I, 1990, J INHERIT METAB DIS, V13, P651, DOI 10.1007/BF01799520; SMITH I, 1985, GENETIC METABOLIC DI, P166; SMITH I, 1978, BMJ, V3, P723; THOMPSON AJ, 1991, LANCET, V337, P1224, DOI 10.1016/0140-6736(91)92894-8; THOMPSON AJ, 1990, LANCET, V336, P602, DOI 10.1016/0140-6736(90)93401-A; VILLASANA D, 1989, J INHERIT METAB DIS, V12, P451, DOI 10.1007/BF01802042; WAISBREN SE, 1984, J PEDIATR-US, V105, P955, DOI 10.1016/S0022-3476(84)80088-8; WELSH MC, 1990, CHILD DEV, V61, P1697, DOI 10.2307/1130832; WOO SLC, 1989, BIOCHEMISTRY-US, V28, P1, DOI 10.1021/bi00427a001; IN PRESS ARCH DIS CH	44	67	67	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					115	119						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435608				2022-12-28	WOS:A1993KG46500026
J	STARZL, TE; DEMETRIS, AJ; TRUCCO, M; RICORDI, C; ILDSTAD, S; TERASAKI, PI; MURASE, N; KENDALL, RS; KOCOVA, M; RUDERT, WA; ZEEVI, A; VANTHIEL, D				STARZL, TE; DEMETRIS, AJ; TRUCCO, M; RICORDI, C; ILDSTAD, S; TERASAKI, PI; MURASE, N; KENDALL, RS; KOCOVA, M; RUDERT, WA; ZEEVI, A; VANTHIEL, D			CHIMERISM AFTER LIVER-TRANSPLANTATION FOR TYPE-IV GLYCOGEN-STORAGE-DISEASE AND TYPE-1 GAUCHERS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL HYPERCHOLESTEROLEMIA; HOST-DISEASE; GRAFT; IMMUNOGENICITY; REPLACEMENT; RECIPIENT; CELLS	Background. Liver transplantation for type IV glycogen storage disease (branching-enzyme deficiency) results in the resorption of extrahepatic deposits of amylopectin, but the mechanism of resorption is not known. Methods. We studied two patients with type IV glycogen storage disease 37 and 91 months after liver transplantation and a third patient with lysosomal glucocerebrosidase deficiency (type 1 Gaucher's disease), in whom tissue glucocerebroside deposition had decreased 26 months after liver replacement, to determine whether the migration of cells from the allograft (microchimerism) could explain the improved metabolism of enzyme-deficient tissues in the recipient. Samples of blood and biopsy specimens of the skin, lymph nodes, heart, bone marrow, or intestine were examined immunocytochemically with the use of donor-specific monoclonal anti-HLA antibodies and the polymerase chain reaction, with preliminary amplification specific to donor alleles of the gene for the beta chain of HLA-DR molecules, followed by hybridization with allele-specific oligonucleotide probes. Results. Histopathological examination revealed that the cardiac deposits of amylopectin in the patients with glycogen storage disease and the lymph-node deposits of glucocerebroside in the patient with Gaucher's disease were dramatically reduced after transplantation. Immunocytochemical analysis showed cells containing the HLA phenotypes of the donor in the heart and skin of the patients with glycogen storage disease and in the lymph nodes, but not the skin, of the patient with Gaucher's disease. Polymerase-chain-reaction analysis demonstrated donor HLA-DR DNA in the heart of both patients with glycogen storage disease, in the skin of one of them, and in the skin, intestine, blood, and bone marrow of the patient with Gaucher's disease. Conclusions. Systemic microchimerism occurs after liver allotransplantation and can ameliorate pancellular enzyme deficiencies.	UNIV CALIF LOS ANGELES, TISSUE TYPING LAB, LOS ANGELES, CA USA; MARY BRIDGE CHILDRENS HOSP, TACOMA, WA USA; UNIV PITTSBURGH, HLTH SCI CTR, PITTSBURGH TRANSPLANT INST, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, HLTH SCI CTR, DEPT PEDIAT, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, HLTH SCI CTR, DEPT MED, PITTSBURGH, PA 15213 USA	University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	STARZL, TE (corresponding author), UNIV PITTSBURGH, HLTH SCI CTR, DEPT SURG, 3601 5TH AVE, 5C FALK CLIN, PITTSBURGH, PA 15213 USA.		RICORDI, CAMILLO/AAA-4740-2019	Ricordi, Camillo/0000-0001-8092-7153	NIDDK NIH HHS [R01 DK029961-19, DK-29961] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029961, R01DK029961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BILHEIMER DW, 1984, NEW ENGL J MED, V311, P1658, DOI 10.1056/NEJM198412273112603; BRADY RO, 1966, J CLIN INVEST, V45, P1112, DOI 10.1172/JCI105417; BROWN BI, 1966, P NATL ACAD SCI USA, V56, P725, DOI 10.1073/pnas.56.2.725; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; COMENZO RL, 1992, NEW ENGL J MED, V326, P867, DOI 10.1056/NEJM199203263261305; DALOZE P, 1977, AM J MED GENET, V1, P229, DOI 10.1002/ajmg.1320010209; DEMETRIS AJ, 1992, LANCET, V339, P1610, DOI 10.1016/0140-6736(92)91875-9; DESNICK RJ, 1972, SURGERY, V72, P203; DUCERF C, 1992, TRANSPLANTATION, V53, P1141; FERRY GD, 1991, J PEDIATR GASTR NUTR, V12, P376, DOI 10.1097/00005176-199104000-00016; GOUW ASH, 1987, TRANSPLANTATION, V43, P291, DOI 10.1097/00007890-198702000-00025; HOWELL RR, 1991, NEW ENGL J MED, V324, P55, DOI 10.1056/NEJM199101033240111; HSIA S, 1992, IN PRESS TRANSPLANTA; JONES EA, 1982, LIVER BIOL PATHOBIOL, P507; LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31; NEUFELD EF, 1981, HARVEY LECT, V75, P41; PARKMAN R, 1986, SCIENCE, V232, P1373, DOI 10.1126/science.3520819; PORTER KA, 1969, EXPERIENCE HEPATIC T, P464; RAMSEY G, 1984, NEW ENGL J MED, V311, P1167, DOI 10.1056/NEJM198411013111807; RICORDI C, 1992, LANCET, V339, P1610, DOI 10.1016/0140-6736(92)91876-A; ROBERTS JP, 1991, HEPATOLOGY, V14, P274, DOI 10.1016/0270-9139(91)91415-W; SELBY R, 1991, NEW ENGL J MED, V324, P39, DOI 10.1056/NEJM199101033240107; STARZL TE, 1984, LANCET, V1, P1382; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; STARZL TE, IN PRESS TRANSPLANT; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415	29	174	179	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					745	749		10.1056/NEJM199303183281101	http://dx.doi.org/10.1056/NEJM199303183281101			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8437594	Green Accepted, Bronze			2022-12-28	WOS:A1993KR84800001
J	PETREK, JA; PETERS, M; CIRRINCIONE, C; RHODES, D; BAJORUNAS, D				PETREK, JA; PETERS, M; CIRRINCIONE, C; RHODES, D; BAJORUNAS, D			IS BODY-FAT TOPOGRAPHY A RISK FACTOR FOR BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; BODY COMPOSITION; WAIST-TO-HIP RATIO; BODY MASS INDEX; ADIPOSE TISSUE	ADIPOSE-TISSUE DISTRIBUTION; POSTMENOPAUSAL WOMEN; ENDOMETRIAL CANCER; HEALTH RISKS; OBESITY; METABOLISM; EPIDEMIOLOGY; CARCINOMA; PATTERNS; DISEASE	Objective: To determine whether body fat distribution is associated with the onset of breast cancer. Design: Case-control study. Setting. Memorial Sloan-Kettering Cancer Center, New York, New York. Patients: Three hundred thirteen healthy, white women, born in the United States. Measurements: Waist and hip circumferences were measured on the day before diagnostic breast surgery, and an extensive risk assessment of clinical and family history data was done. After the results of diagnostic breast surgery were obtained, study participants were divided into three groups: women with breast cancer (n = 156); controls (n = 126) with benign tissue at biopsy and an average risk for breast cancer; and high-risk women (n = 31), defined as being at a risk for breast cancer development of 1% per year, based on rigorous histologic or clinical criteria. Results- The waist-to-hip ratios (WHR) were identical (mean +/- SD) in case patients (0.80 +/- 0.06), controls (0.80 +/- 0.06), and high-risk women (0.80 +/- 0.08). Further, no trend could be detected between increasing WHR and breast cancer risk; the estimated relative risk for cancer incidence in women with WHR greater than or equal to 0.81 was 0.78 (95% CI, 0.36 to 1.71), compared with women with WHR of less than 0.73. No difference in WHR was noted between the case patients and controls when analyzed separately according to menopausal status, age, absolute weight, or relative weight. Conclusion: In the women studied, body fat topography as defined by WHR was not associated with breast cancer development.			PETREK, JA (corresponding author), MEM SLOAN KETTERING CANC CTR, 1275 YORK AVE, NEW YORK, NY 10021 USA.			Rhodes, Deborah/0000-0003-4408-6451				ADAMSCAMPBELL LL, 1990, J NATL MED ASSOC, V82, P573; ASHWELL M, 1982, INT J OBESITY, V6, P143; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; BEIJERINCK D, 1991, INT J OBESITY, V15, P89; Bjorntorp P, 1988, Acta Med Scand Suppl, V723, P121; BJORNTORP P, 1990, INFUSIONSTHERAPIE, V17, P24; Bouchard C, 1988, Acta Med Scand Suppl, V723, P135; BRAY GA, 1989, DM-DIS MON, V35, P451; CAMPAIGNE BN, 1990, MED SCI SPORT EXER, V22, P291; DENTONKELAAR I, 1990, INT J OBESITY, V14, P753; ELWOOD JM, 1977, J NATL CANCER I, V59, P1055, DOI 10.1093/jnci/59.4.1055; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; FOLSOM AR, 1989, AM J EPIDEMIOL, V130, P911, DOI 10.1093/oxfordjournals.aje.a115424; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; HAFFNER SM, 1988, CLIN RES, V36, pA482; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; KELLY PT, 1991, UNDERSTANDING BREAST, P29; KELSEY JL, 1991, CA-CANCER J CLIN, V41, P146, DOI 10.3322/canjclin.41.3.146; KELSEY JL, 1982, AM J EPIDEMIOL, V116, P333, DOI 10.1093/oxfordjournals.aje.a113417; KELSEY JL, 1983, BREAST GYNECOLOGIC C, P71; KILLINGER D W, 1987, Steroids, V50, P523, DOI 10.1016/0039-128X(87)90036-5; KIRSCHNER MA, 1990, J CLIN ENDOCR METAB, V70, P473, DOI 10.1210/jcem-70-2-473; KISSEBAH AH, 1982, J CLIN ENDOCR METAB, V54, P254, DOI 10.1210/jcem-54-2-254; KISSEBAH AH, 1989, DIABETES METAB REV, V5, P83, DOI 10.1002/dmr.5610050202; KISSEBAH AH, 1989, MED CLIN N AM, V73, P111, DOI 10.1016/S0025-7125(16)30695-2; KROTKIEWSKI M, 1978, J ENDOCRINOL INVEST, V1, P365, DOI 10.1007/BF03350985; LAPIDUS L, 1988, INT J OBESITY, V12, P361; Last JM, 1983, DICT EPIDEMIOLOGY; LEIBEL RL, 1989, ANNU REV NUTR, V9, P417, DOI 10.1146/annurev.nu.09.070189.002221; MILLER AB, 1991, BREAST DISEASES, V2, P119; OTTMAN R, 1983, LANCET, V2, P556; PAGE DL, 1991, B AM COLL SURG, V76, P16; Rebuffe-Scrive M., 1987, REC ADV OBES RES, V5, P82; REBUFFESCRIVE M, 1987, INT J OBESITY, V11, P347; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V266, P1808, DOI 10.1001/jama.266.13.1808; Seidell J C, 1988, Acta Med Scand Suppl, V723, P189; SEIDELL JC, 1989, AM J CLIN NUTR, V50, P269, DOI 10.1093/ajcn/50.2.269; SEIDELL JC, 1989, INFUSIONSTHERAPIE, V16, P276; SHIMOKATA H, 1989, J GERONTOL, V44, pM66, DOI 10.1093/geronj/44.2.M66; SONNICHSEN AC, 1990, ANN INTERN MED, V112, P882, DOI 10.7326/0003-4819-112-11-882_1; VERMEULEN A, 1969, J CLIN ENDOCR METAB, V29, P1470, DOI 10.1210/jcem-29-11-1470; WINCHESTER DP, 1986, B AM COLL SURG, V71, P29	43	36	37	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					356	362		10.7326/0003-4819-118-5-199303010-00006	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8430981				2022-12-28	WOS:A1993KN68800006
J	STRUHL, G; BASLER, K				STRUHL, G; BASLER, K			ORGANIZING ACTIVITY OF WINGLESS PROTEIN IN DROSOPHILA	CELL			English	Article							SEGMENT-POLARITY GENE; SITE-SPECIFIC RECOMBINATION; XENOPUS EMBRYOS; SPATIAL-DISTRIBUTION; REGULATORY ELEMENTS; ECTOPIC EXPRESSION; PATTERN-FORMATION; ENGRAILED GENE; IMAGINAL DISKS; BICOID PROTEIN	The adult appendages of Drosophila are formed from imaginal discs, sheets of epithelial cells that proliferate during larval development and differentiate during metamorphosis. wingless (wg, DWnt-1) protein, a putative signaling molecule, is expressed only in prospective ventral cells in each of the leg discs. To test the role of wg, we have generated randomly positioned clones of cells that express wg protein constitutively. Clones that arise in the prospective ventral portions of the leg discs develop normally. In contrast, dorsally situated clones give rise to ventrolateral patterns and exert a ventralizing influence on neighboring wild-type tissue. We propose that wg protein organizes leg pattern along the dorsoventral axis by conferring ventral positional information within the disc.			STRUHL, G (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.			Basler, Konrad/0000-0003-3534-1529				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1989, TRENDS GENET, V5, P262, DOI 10.1016/0168-9525(89)90099-1; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BOHN H, 1972, ROUX ARCH DEV BIOL, V170, P354, DOI 10.1007/BF01380624; BOHN H, 1972, J EMBRYOL EXP MORPH, V28, P185; BOHN H, 1965, ROUX ARCH DEV BIOL, V156, P449; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROACH JR, 1980, CELL, V21, P501, DOI 10.1016/0092-8674(80)90487-0; BROWER DL, 1986, EMBO J, V5, P2649, DOI 10.1002/j.1460-2075.1986.tb04547.x; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; BUSTURIA A, 1988, DEVELOPMENT, V104, P713; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHAN LN, 1971, P NATL ACAD SCI USA, V68, P2217, DOI 10.1073/pnas.68.9.2217; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; Dalcq A, 1938, FORM CAUSALITY EARLY; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FRENCH V, 1980, J EMBRYOL EXP MORPH, V59, P281; FRENCH V, 1981, PHILOS T R SOC B, V295, P601, DOI 10.1098/rstb.1981.0163; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; FRENCH V, 1978, J EMBRYOL EXP MORPH, V47, P53; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GEYER PK, 1987, GENE DEV, V1, P996, DOI 10.1101/gad.1.9.996; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HAMBURGER V, 1964, F EXPT EMBRYOLOGY, P146; HANNAH-ALAVA ALOHA, 1958, J MORPH, V103, P281, DOI 10.1002/jmor.1051030205; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JACOBSON AG, 1988, DEVELOPMENT, V104, P341; JAYARAM M, 1985, P NATL ACAD SCI USA, V82, P5875, DOI 10.1073/pnas.82.17.5875; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1982, EMBO J, V1, P827, DOI 10.1002/j.1460-2075.1982.tb01255.x; LAWRENCE PA, 1979, J EMBRYOL EXP MORPH, V51, P195; LAWRENCE PA, 1977, DEV BIOL, V56, P40, DOI 10.1016/0012-1606(77)90153-1; LAWRENCE PA, 1972, DEV SYSTEMS INSECTS, V2, P157; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; RIDDIHOUGH G, 1991, GENE DEV, V5, P840, DOI 10.1101/gad.5.5.840; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; RODRIGUEZ I, 1990, EMBO J, V9, P3583, DOI 10.1002/j.1460-2075.1990.tb07569.x; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; ROSE SM, 1952, AM NAT, V86, P337, DOI 10.1086/281743; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; Sander K, 1975, Ciba Found Symp, V0, P241; SCHALLER HC, 1981, P NATL ACAD SCI-BIOL, V78, P7000, DOI 10.1073/pnas.78.11.7000; SCHALLER HC, 1979, ROUX ARCH DEV BIOL, V186, P139, DOI 10.1007/BF00848175; SCHUBIGER G, 1971, DEV BIOL, V26, P277, DOI 10.1016/0012-1606(71)90127-8; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; Spemann H., 1938, EMBRYONIC DEV INDUCT; STEINER E, 1976, ROUX ARCH DEV BIOL, V178, P233; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	90	728	746	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 26	1993	72	4					527	540		10.1016/0092-8674(93)90072-X	http://dx.doi.org/10.1016/0092-8674(93)90072-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440019	Green Accepted			2022-12-28	WOS:A1993KP16500008
J	BRAUNSTEIN, GD				BRAUNSTEIN, GD			CURRENT CONCEPTS - GYNECOMASTIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; IDIOPATHIC GYNECOMASTIA; ADOLESCENT GYNECOMASTIA; PUBERTAL GYNECOMASTIA; HUMAN TESTIS; NORMAL MEN; ESTROGEN; FEMINIZATION; ANDROGENS; TAMOXIFEN		UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	BRAUNSTEIN, GD (corresponding author), CEDARS SINAI MED CTR, DEPT MED, 8700 BEVERLY BLVD, RM B118, LOS ANGELES, CA 90048 USA.							ALAGARATNAM TT, 1987, CLIN THER, V9, P483; ANDERSEN JA, 1982, ACTA PATH MICRO IM A, V90, P191; BERKOVITZ GD, 1985, J CLIN INVEST, V75, P1763, DOI 10.1172/JCI111888; BIDLINGMAIER F, 1973, Z KINDERHEILKD, V115, P89, DOI 10.1007/BF00438995; BIRO FM, 1990, J PEDIATR-US, V116, P450, DOI 10.1016/S0022-3476(05)82843-4; BOYDEN TW, 1983, ENDOCR REV, V4, P389, DOI 10.1210/edrv-4-4-389; BULARD J, 1987, J CLIN ENDOCR METAB, V64, P618, DOI 10.1210/jcem-64-3-618; CARLSON HE, 1980, NEW ENGL J MED, V303, P795, DOI 10.1056/NEJM198010023031405; COEN P, 1991, NEW ENGL J MED, V324, P317, DOI 10.1056/NEJM199101313240507; DIRAIMONDO CV, 1980, NEW ENGL J MED, V302, P1089; Edmondson HA, 1939, P SOC EXP BIOL MED, V42, P97; FARA GM, 1979, LANCET, V2, P295; FENTIMAN IS, 1990, DETECTION TREATMENT, P207; FINKELSTEIN JS, 1988, NEW ENGL J MED, V318, P961, DOI 10.1056/NEJM198804143181505; FOREST MG, 1979, J CLIN ENDOCR METAB, V49, P284, DOI 10.1210/jcem-49-2-284; GABRILOVE JL, 1974, MT SINAI J MED, V41, P636; GORDON GG, 1975, J CLIN ENDOCR METAB, V40, P1018, DOI 10.1210/jcem-40-6-1018; GOTTSWINTER JM, 1984, J ENDOCRINOL INVEST, V7, P383, DOI 10.1007/BF03351021; GROSSO DS, 1983, ANTIMICROB AGENTS CH, V23, P207, DOI 10.1128/AAC.23.2.207; GUPTA RK, 1988, EUR J SURG ONCOL, V14, P317; HALL PF, 1959, GYNAECOMASTIA; HARLAN WR, 1979, J PEDIATR-US, V95, P293; HARRINGTON J, 1978, ARCH ENVIRON HEALTH, V33, P12, DOI 10.1080/00039896.1978.10667301; HEMSELL DL, 1977, J CLIN INVEST, V60, P455, DOI 10.1172/JCI108796; JONES DJ, 1990, ANN ROY COLL SURG, V72, P296; JONES TM, 1978, J CLIN ENDOCR METAB, V47, P1368, DOI 10.1210/jcem-47-6-1368; JUNG FT, 1938, ILLINOIS MED J, V73, P115; KEW MC, 1977, NEW ENGL J MED, V296, P1084, DOI 10.1056/NEJM197705122961903; KIMBALL AM, 1981, LANCET, V1, P671; KUHN JM, 1983, CLIN ENDOCRINOL, V19, P513, DOI 10.1111/j.1365-2265.1983.tb00026.x; LEE PA, 1975, J PEDIATR-US, V86, P212, DOI 10.1016/S0022-3476(75)80470-7; LEROITH D, 1980, ACTA ENDOCRINOL-COP, V95, P177, DOI 10.1530/acta.0.0950177; LEY SB, 1980, CLIN RES, V28, pA24; MACDONALD PC, 1979, J CLIN ENDOCR METAB, V49, P905, DOI 10.1210/jcem-49-6-905; MCDERMOTT MT, 1990, SOUTHERN MED J, V83, P1283, DOI 10.1097/00007611-199011000-00013; MOORE DC, 1984, J CLIN ENDOCR METAB, V58, P492, DOI 10.1210/jcem-58-3-492; NEYZI O, 1975, ANN HUM BIOL, V2, P251, DOI 10.1080/03014467500000831; NICOLIS GL, 1971, J CLIN ENDOCR METAB, V32, P173, DOI 10.1210/jcem-32-2-173; NIEWOEHNER CB, 1984, AM J MED, V77, P633, DOI 10.1016/0002-9343(84)90353-X; NUTTALL FQ, 1979, J CLIN ENDOCR METAB, V48, P338, DOI 10.1210/jcem-48-2-338; NYDICK M, 1961, JAMA-J AM MED ASSOC, V178, P449, DOI 10.1001/jama.1961.03040440001001; PARKER LN, 1986, METABOLISM, V35, P705, DOI 10.1016/0026-0495(86)90237-4; PLOURDE PV, 1983, AM J DIS CHILD, V137, P1080, DOI 10.1001/archpedi.1983.02140370040013; RIFKA SM, 1978, J CLIN ENDOCR METAB, V46, P338, DOI 10.1210/jcem-46-2-338; ROCHEFORT H, 1983, PHARMACOL THERAPEUT, V23, P193, DOI 10.1016/0163-7258(83)90013-X; ROSE LI, 1977, ANN INTERN MED, V87, P398, DOI 10.7326/0003-4819-87-4-398; Schmidt-Voigt J, 1941, Z KINDERHEILKD, V62, P590; SMALS AGH, 1987, NETH J MED, V31, P47; STEPANAS AV, 1977, J PEDIATR-US, V90, P651, DOI 10.1016/S0022-3476(77)80394-6; TREVES N, 1958, CANCER, V11, P1083, DOI 10.1002/1097-0142(195811/12)11:6<1083::AID-CNCR2820110602>3.0.CO;2-9; WANG C, 1975, CLIN ENDOCRINOL, V4, P399, DOI 10.1111/j.1365-2265.1975.tb01547.x; WATERFALL NB, 1979, CLIN ONCOL, V5, P257; WEINSTEIN RL, 1974, J CLIN INVEST, V53, P1, DOI 10.1172/JCI107526; WILLIAMS MJ, 1963, AM J MED, V34, P103, DOI 10.1016/0002-9343(63)90044-5; Wilson J D, 1980, Adv Intern Med, V25, P1; Young V L, 1991, Mo Med, V88, P153; ZACHMANN M, 1986, ACTA ENDOCRINOL-COP, V113, P218, DOI 10.1530/acta.0.112S218	57	319	332	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1993	328	7					490	495						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM417	8421478				2022-12-28	WOS:A1993KM41700008
J	BORUKHOV, S; SAGITOV, V; GOLDFARB, A				BORUKHOV, S; SAGITOV, V; GOLDFARB, A			TRANSCRIPT CLEAVAGE FACTORS FROM ESCHERICHIA-COLI	CELL			English	Article							RNA-POLYMERASE-II; ELONGATION FACTOR-SII; ESCHERICHIA-COLI; GENE; INVITRO; TERMINATION; INITIATION; PROMOTER; SEQUENCE; SITES	Two transcription elongation factors (GreA and GreB) related in primary sequence were isolated from E. coli. Each factor induced cleavage of the nascent transcript in artificially halted elongation complexes followed by the loss of the 3' proximal fragment and resumption of elongation from the new 3' terminus. GreA induced cleavages 2 or 3 nt behind the terminus while GreB released longer oligonucleotides up to 9 nt in length. The pattern of cleavages characteristically changed as the transcription complex advanced, supporting the ''inchworm'' model of RNA polymerase propagation. In addition to attacking artificially halted complexes, both factors antagonized the action of natural elongation-arresting sites that occasionally trap the advancing complex. GreB rescued the arrested complexes via the transcript cleavage and restart pathway while GreA acted by an unknown mechanism, preventing the arrest only if added before the polymerase reached the arresting site.			BORUKHOV, S (corresponding author), PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016, USA.		Borukhov, Sergei/AAF-3195-2019	Borukhov, Sergei/0000-0002-3517-3003				BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN MJ, 1993, IN PRESS HARVEY LECT; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MARKS GL, 1992, NUCLEIC ACIDS RES, V20, P3785, DOI 10.1093/nar/20.14.3785; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; OHLSEN KL, 1992, J BIOL CHEM, V267, P19813; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPARKOWSKI J, 1990, NUCLEIC ACIDS RES, V18, P6443, DOI 10.1093/nar/18.21.6443; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WURTZEL ET, 1982, J BIOL CHEM, V257, P13685; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	25	319	328	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					459	466		10.1016/0092-8674(93)90121-6	http://dx.doi.org/10.1016/0092-8674(93)90121-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431948				2022-12-28	WOS:A1993KM16200014
J	CHUNG, HH; BENSON, DR; SCHULTZ, PG				CHUNG, HH; BENSON, DR; SCHULTZ, PG			PROBING THE STRUCTURE AND MECHANISM OF RAS PROTEIN WITH AN EXPANDED GENETIC-CODE	SCIENCE			English	Article							SITE-SPECIFIC INCORPORATION; UNNATURAL AMINO-ACIDS; TRIPHOSPHATE CONFORMATION; BIOCHEMICAL-PROPERTIES; CATALYTIC DOMAIN; GTP HYDROLYSIS; TRANSFER-RNAS; P21; PRODUCT; MUTANTS	Mutations in Ras protein at positions Gly12 and Gly13 (phosphate-binding loop L1) and at positions Ala59, Gly60, and Gln61 (loop L4) are commonly associated with oncogenic activation. The structural and catalytic roles of these residues were probed with a series of unnatural amino acids that have unusual main chain conformations, hydrogen bonding abilities, and steric features. The properties of wild-type and transforming Ras proteins previously thought to be uniquely associated with the structure of a single amino acid at these positions were retained by mutants that contained a variety of unnatural amino acids. This expanded set of functional mutants provides new insight into the role of loop L4 residues in switch function and suggests that loop L1 may participate in the activation of Ras protein by effector molecules.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; LAWRENCE BERKELEY LAB, CTR ADV MAT, DIV MAT SCI, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014165] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM14165] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIN JD, 1991, BIOCHEMISTRY-US, V30, P5411, DOI 10.1021/bi00236a013; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELOKON YN, 1988, J CHEM SOC PERK T 1, P2075, DOI 10.1039/p19880002075; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOS JL, 1989, CANCER RES, V49, P4682; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; ELLMAN JA, 1992, J AM CHEM SOC, V114, P7959, DOI 10.1021/ja00046a080; GAY NJ, 1983, NATURE, V301, P262, DOI 10.1038/301262a0; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HOOZ J, 1968, CAN J CHEMISTRY, V46, P86, DOI 10.1139/v68-017; JOHN J, 1988, J BIOL CHEM, V263, P11792; KASIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V95, P505; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LOWRY TH, 1976, MECHANISM THEORY ORG; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MATSUEDA R, 1981, CHEM LETT, P737, DOI 10.1246/cl.1981.737; MENDEL D, 1991, J AM CHEM SOC, V113, P2758, DOI 10.1021/ja00007a063; MENDEL D, 1992, SCIENCE, V256, P1798, DOI 10.1126/science.1615324; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIURA K, 1986, JPN J CANCER RES, V77, P45; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARTHASARATHY M, 1980, BIOPOLYMERS, V19, P1943; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RAE ID, 1979, INT J PEPT PROT RES, V13, P304; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHIH TY, 1982, J BIOL CHEM, V257, P1767; SPANDIDOS D. A., 1989, RAS ONCOGENES; SUICH DJ, 1992, THESIS U CALIFORNIA; TONG L, 1989, SCIENCE, V245, P244, DOI 10.1126/science.2665078; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WIBERG KB, 1987, J AM CHEM SOC, V109, P5935, DOI 10.1021/ja00254a006; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YOKAYAMA S, UNPUB	45	126	182	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					806	809		10.1126/science.8430333	http://dx.doi.org/10.1126/science.8430333			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430333				2022-12-28	WOS:A1993KL11000031
J	VOKES, EE; WEICHSELBAUM, RR; LIPPMAN, SM; HONG, WK				VOKES, EE; WEICHSELBAUM, RR; LIPPMAN, SM; HONG, WK			MEDICAL PROGRESS - HEAD AND NECK-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SQUAMOUS-CELL-CARCINOMA; RANDOMIZED CLINICAL-TRIAL; CALIFORNIA-ONCOLOGY-GROUP; ADVANCED RESECTABLE HEAD; EPIDERMAL GROWTH-FACTOR; TERM FOLLOW-UP; NASOPHARYNGEAL CARCINOMA; RADIATION-THERAPY; LARYNGEAL-CANCER; RISK-FACTORS		UNIV CHICAGO, DEPT RADIAT & CELLULAR ONCOL, CHICAGO, IL 60637 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT THORAC HEAD & NECK MED ONCOL, HOUSTON, TX 77025 USA	University of Chicago; University of Texas System; UTMD Anderson Cancer Center	VOKES, EE (corresponding author), UNIV CHICAGO, MED CTR,DEPT MED,HEMATOL ONCOL SECT, 5841 S MARYLAND AVE, MC-2115, CHICAGO, IL 60637 USA.		Vokes, Everett/Q-2146-2019					ADELSTEIN DJ, 1990, CANCER-AM CANCER SOC, V65, P1685, DOI 10.1002/1097-0142(19900415)65:8<1685::AID-CNCR2820650804>3.0.CO;2-S; ADELSTEIN DJ, 1990, AM J CLIN ONCOL-CANC, V13, P440, DOI 10.1097/00000421-199010000-00016; AMDUR RJ, 1989, INT J RADIAT ONCOL, V17, P279, DOI 10.1016/0360-3016(89)90440-9; ANG KK, 1990, INT J RADIAT ONCOL, V19, P1339, DOI 10.1016/0360-3016(90)90341-G; [Anonymous], 1986, EUR J SURG ONCOL, V12, P289; BACHAUD JM, 1991, INT J RADIAT ONCOL, V20, P243, DOI 10.1016/0360-3016(91)90098-O; BERENSON JR, 1989, ONCOGENE, V4, P1111; BLAKESLEE D, 1984, LARYNGOSCOPE, V94, P488, DOI 10.1288/00005537-198404000-00012; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BRACHMAN DG, 1992, CANCER RES, V52, P4832; BROWN B, 1989, CANCER, V64, P1195, DOI 10.1002/1097-0142(19890915)64:6<1195::AID-CNCR2820640606>3.0.CO;2-7; BROWN LM, 1988, CANCER RES, V48, P1960; CAREY TE, 1989, CANCER RES, V49, P6098; CASTELIJNS J A, 1991, Current Opinion in Oncology, V3, P512, DOI 10.1097/00001622-199106000-00011; CLARK JR, 1989, SEMIN ONCOL, V16, P44; COLLINS SL, 1987, COMPREHENSIVE MANAGE, V2, P1386; COOPER JS, 1989, INT J RADIAT ONCOL, V17, P449, DOI 10.1016/0360-3016(89)90094-1; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; DECKER J, 1982, NEW ENGL J MED, V306, P1151, DOI 10.1056/NEJM198205133061905; DESANTO LW, 1987, COMPREHENSIVE MANAGE, V1, P699; DEVATHAIRE F, 1988, INT J CANCER, V42, P176, DOI 10.1002/ijc.2910420206; DISCHE S, 1990, INT J RADIAT ONCOL, V19, P1317, DOI 10.1016/0360-3016(90)90251-E; DREYFUSS AI, 1990, ANN INTERN MED, V112, P167, DOI 10.7326/0003-4819-112-3-167; ENSLEY JF, 1984, CANCER, V54, P811, DOI 10.1002/1097-0142(19840901)54:5<811::AID-CNCR2820540508>3.0.CO;2-E; Eschwege F, 1988, NCI Monogr, P275; FALK RT, 1989, CANCER RES, V49, P4024; FEINMESSER R, 1992, NEW ENGL J MED, V326, P17, DOI 10.1056/NEJM199201023260103; FLETCHER GH, 1972, CANCER-AM CANCER SOC, V29, P1450, DOI 10.1002/1097-0142(197206)29:6<1450::AID-CNCR2820290605>3.0.CO;2-Q; FOOTE RL, 1990, INT J RADIAT ONCOL, V18, P1293, DOI 10.1016/0360-3016(90)90300-9; FORASTIERE AA, 1992, J CLIN ONCOL, V10, P1245, DOI 10.1200/JCO.1992.10.8.1245; FORASTIERE AA, 1991, HEMATOL ONCOL CLIN N, V5, P725, DOI 10.1016/S0889-8588(18)30412-X; FRANCESCHI S, 1990, J NATL CANCER I, V82, P1407, DOI 10.1093/jnci/82.17.1407; FU KK, 1987, J CLIN ONCOL, V5, P1410, DOI 10.1200/JCO.1987.5.9.1410; GASMI J, 1990, ANN ONCOL, V1, P245, DOI 10.1093/oxfordjournals.annonc.a057741; Gotay C C, 1992, Qual Life Res, V1, P5, DOI 10.1007/BF00435431; GUILLAMONDEGUI OM, 1980, AM J SURG, V140, P560, DOI 10.1016/0002-9610(80)90212-3; GUPTA NK, 1987, CLIN RADIOL, V38, P575, DOI 10.1016/S0009-9260(87)80327-6; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HAMASAKI V K, 1992, Current Opinion in Oncology, V4, P504, DOI 10.1097/00001622-199206000-00013; Haraf D J, 1988, Oncology (Williston Park), V2, P41; Harwood A R, 1982, J Otolaryngol Suppl, V11, P1; HENDERSON BE, 1976, NEW ENGL J MED, V295, P1101, DOI 10.1056/NEJM197611112952003; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HEO DS, 1989, CANCER RES, V49, P5167; HIRANO M, 1987, ANN OTO RHINOL LARYN, V96, P586, DOI 10.1177/000348948709600521; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HONG WK, 1983, NEW ENGL J MED, V308, P75, DOI 10.1056/NEJM198301133080204; HOPPE RT, 1978, INT J RADIAT ONCOL, V4, P199, DOI 10.1016/0360-3016(78)90138-4; HORIOT JC, 1990, EUR J CANCER, V26, P779, DOI 10.1016/0277-5379(90)90150-R; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; JACOBS C, 1990, J CLIN ONCOL, V8, P838, DOI 10.1200/JCO.1990.8.5.838; JACOBS C, 1992, J CLIN ONCOL, V10, P257, DOI 10.1200/JCO.1992.10.2.257; JACOBS C, 1990, ANN INTERN MED, V113, P771, DOI 10.7326/0003-4819-113-10-771; JACOBS C, 1987, CANCER, V60, P1178, DOI 10.1002/1097-0142(19870915)60:6<1178::AID-CNCR2820600604>3.0.CO;2-S; JACOBS CD, 1990, CARCINOMAS HEAD NECK, P265; JIN YH, 1990, GENE CHROMOSOME CANC, V2, P198, DOI 10.1002/gcc.2870020306; JIN YS, 1988, CANCER GENET CYTOGEN, V32, P93, DOI 10.1016/0165-4608(88)90315-9; KAMATA N, 1986, CANCER RES, V46, P1648; KARP DD, 1991, AM J CLIN ONCOL-CANC, V14, P273, DOI 10.1097/00000421-199108000-00001; KELKER W, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P264; KOUFMAN JA, 1986, OTOLARYNG HEAD NECK, V95, P531, DOI 10.1177/019459988609500502; LARAMORE GE, 1992, INT J RADIAT ONCOL, V23, P705, DOI 10.1016/0360-3016(92)90642-U; LATIF F, 1992, CANCER RES, V52, P1451; LAVECCHIA C, 1990, CANCER RES, V50, P4497; LINDBERG R, 1972, CANCER, V29, P1446, DOI 10.1002/1097-0142(197206)29:6<1446::AID-CNCR2820290604>3.0.CO;2-C; Lippman S M, 1992, Important Adv Oncol, P93; LIPPMAN SM, 1993, NEW ENGL J MED, V328, P15, DOI 10.1056/NEJM199301073280103; LIPPMAN SM, 1990, JNCI-J NATL CANCER I, V82, P555, DOI 10.1093/jnci/82.7.555; LO TCM, 1976, AM J ROENTGENOL, V126, P229, DOI 10.2214/ajr.126.2.229; LUND VJ, 1990, J LARYNGOL OTOL, V104, P544, DOI 10.1017/S002221510011312X; LUSINCHI A, 1989, INT J RADIAT ONCOL, V17, P273, DOI 10.1016/0360-3016(89)90439-2; MASHBERG A, 1977, NEW ENGL J MED, V297, P109, DOI 10.1056/NEJM197707142970212; MAZERON JJ, 1990, INT J RADIAT ONCOL, V18, P1299, DOI 10.1016/0360-3016(90)90301-Y; MCLAUGHLIN JK, 1988, J NATL CANCER I, V80, P1237, DOI 10.1093/jnci/80.15.1237; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; MEAD GM, 1982, AM J MED, V73, P582, DOI 10.1016/0002-9343(82)90339-4; MEDINA JE, 1989, HEAD NECK-J SCI SPEC, V11, P111, DOI 10.1002/hed.2880110203; MENDENHALL WM, 1988, HEAD NECK-J SCI SPEC, V10, P373, DOI 10.1002/hed.2890100603; MENDENHALL WM, 1992, PRINCIPLES PRACTICE, P790; MERLANO M, 1991, CANCER-AM CANCER SOC, V67, P915, DOI 10.1002/1097-0142(19910215)67:4<915::AID-CNCR2820670410>3.0.CO;2-8; MERLANO M, 1992, NEW ENGL J MED, V327, P1115, DOI 10.1056/NEJM199210153271602; MERRITT WD, 1990, ARCH OTOLARYNGOL, V116, P1394; MEYSKENS FL, 1990, NEW ENGL J MED, V323, P825, DOI 10.1056/NEJM199009203231210; MILLION RR, 1989, CANCER PRINCIPLES PR, V1, P488; MORTON RP, 1985, CANCER CHEMOTH PHARM, V15, P283; MUSCAT JE, 1992, CANCER, V69, P2244, DOI 10.1002/1097-0142(19920501)69:9&lt;2244::AID-CNCR2820690906&gt;3.0.CO;2-O; NAM JM, 1992, J NATL CANCER I, V84, P619, DOI 10.1093/jnci/84.8.619; NING JP, 1990, J NATL CANCER I, V82, P291, DOI 10.1093/jnci/82.4.291; OGURA JH, 1975, LARYNGOSCOPE, V85, P1808, DOI 10.1288/00005537-197511000-00002; OGURA JH, 1980, LARYNGOSCOPE, V90, P591; PAJAK TF, 1991, INT J RADIAT ONCOL, V20, P13, DOI 10.1016/0360-3016(91)90132-N; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PEREZ CA, 1991, HEAD NECK-J SCI SPEC, V13, P282, DOI 10.1002/hed.2880130404; PEREZ CA, 1992, PRINCIPLES PRACTICE, P617; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; PFISTER DG, 1991, J CLIN ONCOL, V9, P850, DOI 10.1200/JCO.1991.9.5.850; RICHARD JM, 1987, LARYNGOSCOPE, V97, P97; ROONEY M, 1985, CANCER, V55, P1123, DOI 10.1002/1097-0142(19850301)55:5<1123::AID-CNCR2820550530>3.0.CO;2-8; SACKS PG, 1988, CANCER RES, V48, P2858; SARANATH D, 1989, JPN J CANCER RES, V80, P430, DOI 10.1111/j.1349-7006.1989.tb02332.x; SCHANTZ SP, 1990, CANCER RES, V50, P4349; SCHANTZ SP, 1990, J NATL CANCER I, V82, P1773, DOI 10.1093/jnci/82.22.1773; SCHANTZ SP, 1989, JAMA-J AM MED ASSOC, V262, P3313, DOI 10.1001/jama.262.23.3313; SCHORNAGEL JH, 1992, ANN ONCOL, V3, P223; SCHULLER DE, 1988, LARYNGOSCOPE, V98, P1205; SHAH JP, 1987, COMPREHENSIVE MANAGE, V1, P551; SHAHA AR, 1984, AM J SURG, V148, P455, DOI 10.1016/0002-9610(84)90369-6; SHANTA V, 1980, CLIN RADIOL, V31, P617, DOI 10.1016/S0009-9260(80)80069-9; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SHILLITOE EJ, 1984, CANCER, V54, P266, DOI 10.1002/1097-0142(19840715)54:2<266::AID-CNCR2820540214>3.0.CO;2-#; SHKLAR G, 1986, NEW ENGL J MED, V315, P1544, DOI 10.1056/NEJM198612113152408; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SOMERS KD, 1990, ONCOGENE, V5, P915; SPIRO JD, 1989, ARCH OTOLARYNGOL, V115, P1186; SPITZ MR, 1989, CANCER RES, V49, P4626; STEWART JG, 1975, LARYNGOSCOPE, V85, P1477, DOI 10.1288/00005537-197509000-00008; TAYLOR SG, 1989, J CLIN ONCOL, V7, P846, DOI 10.1200/JCO.1989.7.7.846; TUPCHONG L, 1991, INT J RADIAT ONCOL, V20, P21, DOI 10.1016/0360-3016(91)90133-O; Urba S G, 1989, Oncology (Williston Park), V3, P79; Urba SG, 1989, ONCOLOGY WILLISTON P, V3, P90; Urba SG, 1989, ONCOLOGY WILLISTON P, V3, P97; Urken M L, 1988, Oncology (Williston Park), V2, P48; VLOCK DR, 1991, HEMATOL ONCOL CLIN N, V5, P797, DOI 10.1016/S0889-8588(18)30417-9; VOKES, 1990, J CLIN ONCOL, V8, P1447, DOI 10.1200/JCO.1990.8.8.1447; VOKES EE, 1989, J CLIN ONCOL, V7, P761, DOI 10.1200/JCO.1989.7.6.761; VOKES EE, 1990, J CLIN ONCOL, V8, P911, DOI 10.1200/JCO.1990.8.5.911; VOKES EE, 1991, HEMATOL ONCOL CLIN N, V5, P753, DOI 10.1016/S0889-8588(18)30414-3; VOKES EE, 1992, JNCI-J NATL CANCER I, V84, P877, DOI 10.1093/jnci/84.11.877; VOKES EE, 1991, J CLIN ONCOL, V9, P1376, DOI 10.1200/JCO.1991.9.8.1376; VOKES EE, 1992, CHEMOTHERAPY SOURCE, P918; Wang C C, 1991, Oncology (Williston Park), V5, P41; Wang CC, 1987, COMPREHENSIVE MANAGE, V1, P906; WATTS SL, 1991, ORAL SURG ORAL MED O, V71, P701, DOI 10.1016/0030-4220(91)90278-K; WEEMS DH, 1987, INT J RADIAT ONCOL, V13, P1483, DOI 10.1016/0360-3016(87)90315-4; WEICHSELBAUM RR, 1985, P NATL ACAD SCI USA, V82, P4732, DOI 10.1073/pnas.82.14.4732; WEICHSELBAUM RR, 1989, HEAD NECK-J SCI SPEC, V11, P437, DOI 10.1002/hed.2880110510; WEISSBERG JB, 1989, INT J RADIAT ONCOL, V17, P3, DOI 10.1016/0360-3016(89)90362-3; WENDT TG, 1989, J CLIN ONCOL, V7, P471, DOI 10.1200/JCO.1989.7.4.471; WINN DM, 1991, CANCER RES, V51, P3044; WINN DM, 1992, ADV EXP MED BIOL, V320, P39; WINN DM, 1981, NEW ENGL J MED, V304, P745, DOI 10.1056/NEJM198103263041301; WOLF G, 1992, CANCER MED, P121; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402; WOLF GT, 1990, JNCI-J NATL CANCER I, V82, P1566, DOI 10.1093/jnci/82.19.1566; WONG CS, 1989, INT J RADIAT ONCOL, V16, P657; WORSHAM MJ, 1990, AM J HUM GENET, V47, pA24; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZARBO RJ, 1988, SEMIN ONCOL, V15, P10; ZENG Y, 1982, INT J CANCER, V29, P139, DOI 10.1002/ijc.2910290204; ZHOU DJ, 1988, ONCOGENE, V2, P279; 1988, MANUAL STAGING CANCE	153	1519	1547	1	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1993	328	3					184	194		10.1056/NEJM199301213280306	http://dx.doi.org/10.1056/NEJM199301213280306			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG625	8417385				2022-12-28	WOS:A1993KG62500006
J	HENIKOFF, S; MENEELY, PM				HENIKOFF, S; MENEELY, PM			UNWINDING DOSAGE COMPENSATION	CELL			English	Review							DROSOPHILA-MELANOGASTER; GENE; HELICASE		FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	HENIKOFF, S (corresponding author), HOWARD HUGHES MED INST,SEATTLE,WA 98104, USA.			Henikoff, Steven/0000-0002-7621-8685				BIRCHLER JA, 1990, GENETICS, V124, P677; DEVLIN RH, 1988, GENETICS, V118, P87; GORMAN M, 1993, CELL, V72; JAFFE E, 1986, TRENDS GENET, V2, P316, DOI 10.1016/0168-9525(86)90287-8; KIM SH, 1992, EMBO J, V11, P2319, DOI 10.1002/j.1460-2075.1992.tb05291.x; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LAIN S, 1990, NUCLEIC ACIDS RES, V18, P7003, DOI 10.1093/nar/18.23.7003; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; SASS H, 1991, P NATL ACAD SCI USA, V88, P6795, DOI 10.1073/pnas.88.15.6795; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SHUMAN S, 1992, P NATL ACAD SCI USA, V89, P10935, DOI 10.1073/pnas.89.22.10935; STEINMETZ EJ, 1990, J BIOL CHEM, V265, P18408; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B	15	27	27	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					1	2		10.1016/0092-8674(93)90040-W	http://dx.doi.org/10.1016/0092-8674(93)90040-W			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422671				2022-12-28	WOS:A1993KG95500001
J	RIGBY, PWJ				RIGBY, PWJ			3 IN ONE AND ONE IN 3 - IT ALL DEPENDS ON TBP	CELL			English	Review							TRANSCRIPTIONAL ACTIVATION; MULTIPLE FACTORS; PROTEIN				RIGBY, PWJ (corresponding author), NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND.							BURATOWSKI S, 1992, CELL, V71, P21; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3	23	159	162	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					7	10		10.1016/0092-8674(93)90042-O	http://dx.doi.org/10.1016/0092-8674(93)90042-O			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422684				2022-12-28	WOS:A1993KG95500003
J	KRONICK, R; GOODMAN, DC; WENNBERG, J; WAGNER, E				KRONICK, R; GOODMAN, DC; WENNBERG, J; WAGNER, E			THE MARKETPLACE IN HEALTH-CARE REFORM - THE DEMOGRAPHIC LIMITATIONS OF MANAGED COMPETITION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. The theory of managed competition holds that the quality and economy of health care delivery will improve if independent provider groups compete for consumers. In sparsely populated areas where relatively few provider's are required, however, it is not feasible to divide the provider community into competing groups. We examined the demographic features of health markets in the United States to see what proportion of the population lives in areas that might successfully support managed competition. Methods. The ratios of physicians to enrollees in large staff-model health maintenance organizations were determined as an indicator of the staffing needs of an efficient health plan. These ratios were used to estimate the populations necessary to support health organizations with various ranges of specialty services. Metropolitan areas with populations large enough to support managed competition were identified. Results. We estimated that a health care services market with a population of 1.2 million could support three fully independent plans. A population of 360,000 could support three plans that independently provided most acute care hospital services, but the plans would need to share hospital facilities and contract for tertiary services. A population of 180,000 could support three plans that provided primary care and many basic specialty services but that shared inpatient cardiology and urology services. Health markets with populations greater than 180,000 would include 71 percent of the U.S. population; those with populations greater than 360,000, 63 percent; and those with populations greater than 1.2 million, 42 percent. Conclusions. Reform of the U.S. health care system through expansion of managed competition is feasible in medium-sized or large metropolitan areas. Smaller metropolitan areas and rural areas would require alternative forms of organization and regulation of health care providers to improve quality and economy.	DARTMOUTH COLL,HANOVER,NH 03755; GRP HLTH COOPERAT PUGET SOUND,SEATTLE,WA 98112	Dartmouth College; Group Health Cooperative	KRONICK, R (corresponding author), UNIV CALIF SAN DIEGO,DEPT COMMUNITY & FAMILY MED,LA JOLLA,CA 92093, USA.		Goodman, David/AAG-7497-2020		AHRQ HHS [HS 05745-05] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ENTHOVEN AC, 1991, JAMA-J AM MED ASSOC, V265, P2532, DOI 10.1001/jama.265.19.2532; Enthoven Alain C., 1988, THEORY PRACTICE MANA; FALTERMAYER E, 1992, FORTUNE         0323, P46; FREEMAN JL, 1991, EVALUATION REFINEMEN; GARLAND SB, 1991, BUSINESS WEEK   1007, P59; Hicks L L, 1989, J Health Care Mark, V9, P18; Kasper J F, 1992, QRB Qual Rev Bull, V18, P183; MULHAUSEN R, 1989, JAMA-J AM MED ASSOC, V261, P1930, DOI 10.1001/jama.261.13.1930; 1990, 252 DEP COMM BUR CEN; 1992, NY TIMES        0802, P16; 1991, HALF NATIONS POPULAT; 1991, CPH131 BUR CENS REP, pA8; 1992, TALKING POINTS HLTH	13	155	155	1	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1993	328	2					148	152		10.1056/NEJM199301143280225	http://dx.doi.org/10.1056/NEJM199301143280225			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KG467	8416437				2022-12-28	WOS:A1993KG46700032
J	CUTLER, NR; SRAMEK, JJ				CUTLER, NR; SRAMEK, JJ			TACRINE IN ALZHEIMERS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											CUTLER, NR (corresponding author), CALIF CLIN TRIALS,BEVERLY HILLS,CA 90211, USA.							DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; GROWDON JH, 1992, NEW ENGL J MED, V327, P1306, DOI 10.1056/NEJM199210293271810; SSMALL GW, 1992, JAMA-J AM MED ASSOC, V268, P2564	4	8	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					808	808						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8437603				2022-12-28	WOS:A1993KR84800014
J	ESCOBEDO, LG; MARCUS, SE; HOLTZMAN, D; GIOVINO, GA				ESCOBEDO, LG; MARCUS, SE; HOLTZMAN, D; GIOVINO, GA			SPORTS PARTICIPATION, AGE AT SMOKING INITIATION, AND THE RISK OF SMOKING AMONG UNITED-STATES HIGH-SCHOOL-STUDENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE-SMOKING; ADOLESCENT SMOKING; CHILDREN; TOBACCO; PREVENTION; POLICY	Objective.-To examine smoking patterns, smoking initiation, and the relationship of sports participation and age at smoking initiation to regular and heavy smoking among adolescents. Design.-Survey. Participants.-A nationally representative sample of US high school students. Outcome Measures.-Prevalences of smoking patterns, prevalence and incidence of smoking initiation, and prevalences and odds of regular and heavy smoking in relation to sports participation and age at smoking initiation. Results.-Seventy-two percent of students reported experimenting with, formerly, or ever smoking cigarettes, and 32% reported smoking in the past 30 days. Students who had participated in interscholastic sports were less likely to be regular and heavy smoker's than were others who had not participated. Smoking initiation rates increased rapidly after age 10 years and peaked at age 13 to 14 years. Students who began smoking at age 12 years or younger were more likely to be regular and heavy smokers than were students who began smoking at older ages. Conclusions.-These data suggest that smoking initiation at a young age can increase the risk of nicotine addiction during adolescence and that sports participation may influence smoking behavior. Interventions to prevent smoking should be available before age 12 years to help combat the smoking epidemic among youth.	CTR DIS CONTROL & PREVENT,DIV ADOLESCENT & SCH HLTH,ATLANTA,GA; CTR DIS CONTROL & PREVENT,OFF SMOKING & HLTH,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	ESCOBEDO, LG (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30333, USA.							BAUMRIND D, 1987, ADM871335 US DEP HLT, P13; BEST JA, 1988, ANNU REV PUBL HEALTH, V9, P161; BURCHFIEL CM, 1989, AM J EPIDEMIOL, V130, P410, DOI 10.1093/oxfordjournals.aje.a115349; CHASSIN L, 1990, HEALTH PSYCHOL, V9, P701, DOI 10.1037/0278-6133.9.6.701; CLEARY PD, 1988, MILBANK Q, V66, P137, DOI 10.2307/3349988; DAVIS RM, 1991, JAMA-J AM MED ASSOC, V266, P3186, DOI 10.1001/jama.266.22.3186; DIFRANZA JR, 1991, JAMA-J AM MED ASSOC, V266, P3149, DOI 10.1001/jama.266.22.3149; ECKERT P, 1983, AM J PUBLIC HEALTH, V73, P439, DOI 10.2105/AJPH.73.4.439; EPPS RP, 1991, PEDIATRICS, V88, P140; ERSHLER J, 1989, ADDICT BEHAV, V14, P365, DOI 10.1016/0306-4603(89)90024-5; ESCOBEDO LG, 1990, JAMA-J AM MED ASSOC, V264, P1550, DOI 10.1001/jama.264.12.1550; FEIGHERY E, 1991, JAMA-J AM MED ASSOC, V266, P3168; FLAY B, 1985, ANN BEHAVIORAL MED, V7, P9; FLAY BR, 1985, HEALTH PSYCHOL, V4, P449, DOI 10.1037/0278-6133.4.5.449; FLYNN BS, 1992, AM J PUBLIC HEALTH, V82, P827, DOI 10.2105/AJPH.82.6.827; FRANK E, 1991, JAMA-J AM MED ASSOC, V266, P3139, DOI 10.1001/jama.266.22.3139; GLYNN K, 1987, PREVENTION RES DETER, P130; GLYNN TJ, 1989, J SCHOOL HEALTH, V59, P181, DOI 10.1111/j.1746-1561.1989.tb04698.x; HARRELL FE, 1983, LOGIST PROCEDURE SUG, P181; KOLBE LJ, 1990, HLTH ED, V21, P44; LAGRECA MF, 1992, PEDIATR ANN, V21, P241; LEWIT EM, 1989, BRIT J ADDICT, V84, P1217; LUEPKER RV, 1989, AM J PUBLIC HEALTH, V79, P202, DOI 10.2105/AJPH.79.2.202; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCCARTHY WJ, 1987, ADM871334 US DEP HLT, P153; PIRIE PL, 1988, AM J PUBLIC HEALTH, V78, P176, DOI 10.2105/AJPH.78.2.176; REYNOLDS I, 1988, MED J AUSTRALIA, V149, P250, DOI 10.5694/j.1326-5377.1988.tb120597.x; ROBINSON TN, 1987, JAMA-J AM MED ASSOC, V258, P2072, DOI 10.1001/jama.258.15.2072; SHAH BV, 1984, 74 RES TRIANGL I FIN; SHAH BV, 1991, SESUDAAN STANDARD ER; SWAN AV, 1990, INT J EPIDEMIOL, V19, P323, DOI 10.1093/ije/19.2.323; TAIOLI E, 1991, NEW ENGL J MED, V325, P968; ZABIN LS, 1984, AM J PUBLIC HEALTH, V74, P261, DOI 10.2105/AJPH.74.3.261; [No title captured]; 1980, HLTH CONSEQUENCES SM; 1982, PHS8250179 US DEP HL; 1992, AM MED NEWS, V35, P11; 1964, PHS PUBLICATION, V1103; 1989, CDC898411 US DEP HLT	39	189	197	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1391	1395		10.1001/jama.269.11.1391	http://dx.doi.org/10.1001/jama.269.11.1391			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ857	8441214				2022-12-28	WOS:A1993KQ85700032
J	GERSTEIN, HC				GERSTEIN, HC			INCIDENCE OF POSTPARTUM THYROID-DYSFUNCTION IN PATIENTS WITH TYPE-I DIABETES-MELLITUS	ANNALS OF INTERNAL MEDICINE			English	Article						THYROID DISEASES; DIABETES-MELLITUS, INSULIN DEPENDENT; THYROIDITIS, AUTOIMMUNE; PUERPERIUM; GRAVES DISEASE	TERM FOLLOW-UP; CLINICAL COURSE; GRAVES-DISEASE; HYPERTHYROIDISM; HYPOTHYROIDISM; PREGNANCY; DELIVERY; HLA-DR4; ANTIGEN	Objective: To assess the incidence of postpartum thyroid dysfunction in women with type I diabetes. Design: Cohort study of consecutive patients, with clinical and biochemical assessments of thyroid dysfunction and glycemic control done during the first postpartum week and 3 and 6 months after delivery. Setting: University medical center providing obstetric care for more than 90% of the pregnant women in the region with type I diabetes. Patients: Fifty-one patients with type I diabetes who resided in the Hamilton, Ontario, catchment area and who delivered babies between May 1989 and June 1991, were not taking thyroid medication or thyroactive or immunosuppressive medications. Forty patients completed follow-up. Main Outcome Measures: Postpartum thyroid dysfunction was defined on the basis of thyroid function test results. Results: Postpartum thyroid dysfunction occurred in 10 of 40 patients (25%; 95% CI, 12.7% to 41.2%); postpartum thyroiditis developed in 9 patients and postpartum Graves disease developed in 1 patient during the first 6 months after delivery. The incidence could have varied between 19.6% and 41.2%, depending on whether none or all of the 11 nonparticipating eligible patients developed thyroid dysfunction. Glycemic control was not affected by thyroid dysfunction. Conclusions: Women with type I diabetes are at a high risk for symptomatic postpartum thyroid dysfunction and therefore may benefit from routine thyroid function screening at postpartum visits.	MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University			Gerstein, Hertzel/ABB-8781-2020; Gerstein, Hertzel C/B-1235-2013	Gerstein, Hertzel/0000-0001-8072-2836; Gerstein, Hertzel C/0000-0001-8072-2836				AMINO N, 1982, J CLIN ENDOCR METAB, V55, P108, DOI 10.1210/jcem-55-1-108; BECH K, 1991, ACTA ENDOCRINOL-COP, V124, P534, DOI 10.1530/acta.0.1240534; BILLEWICZ WZ, 1969, Q J MED, V38, P255; CHIOVATO L, 1988, ENDOCRINOLOGY, V123, P1140, DOI 10.1210/endo-123-2-1140; CROOKS J, 1959, Q J MED, V28, P211; FUNG HYM, 1988, BRIT MED J, V296, P241, DOI 10.1136/bmj.296.6617.241; GERSTEIN HC, 1990, ARCH INTERN MED, V150, P1397, DOI 10.1001/archinte.150.7.1397; HASHIZUME K, 1991, NEW ENGL J MED, V324, P947, DOI 10.1056/NEJM199104043241403; HAYSLIP CC, 1988, AM J OBSTET GYNECOL, V159, P203, DOI 10.1016/0002-9378(88)90522-4; JANSSON R, 1985, J CLIN ENDOCR METAB, V60, P168, DOI 10.1210/jcem-60-1-168; JANSSON R, 1988, BAILLIERE CLIN ENDOC, V2, P619, DOI 10.1016/S0950-351X(88)80056-9; JANSSON R, 1984, J CLIN ENDOCR METAB, V58, P681, DOI 10.1210/jcem-58-4-681; LERVANG HH, 1987, ACTA MED SCAND, V222, P369; LERVANG HH, 1984, TISSUE ANTIGENS, V23, P250; LESHIN M, 1985, AM J MED SCI, V290, P77, DOI 10.1097/00000441-198508000-00007; MCKENNA MJ, 1990, DIABETES CARE, V13, P801, DOI 10.2337/diacare.13.7.801; NIKOLAI TF, 1987, ARCH INTERN MED, V147, P221, DOI 10.1001/archinte.147.2.221; NIKOLAI TF, 1989, AM J MED SCI, V297, P18, DOI 10.1097/00000441-198901000-00005; OTHMAN S, 1990, CLIN ENDOCRINOL, V32, P559, DOI 10.1111/j.1365-2265.1990.tb00898.x; POP VJM, 1991, NEW ENGL J MED, V324, P1815; ROBERTON HEW, 1948, BMJ-BRIT MED J, V2, P2275; TACHI J, 1988, J CLIN ENDOCR METAB, V66, P480, DOI 10.1210/jcem-66-3-480; WALFISH PG, 1985, CLIN ENDOCRINOL META, V14, P417, DOI 10.1016/S0300-595X(85)80041-4	23	65	69	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					419	423		10.7326/0003-4819-118-6-199303150-00004	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439115				2022-12-28	WOS:A1993KR81700004
J	SLAYTER, MV				SLAYTER, MV			THE MESSENGERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					1054	1054		10.1001/jama.269.8.1054	http://dx.doi.org/10.1001/jama.269.8.1054			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM603	8429588				2022-12-28	WOS:A1993KM60300037
J	VISKIN, S; BELHASSEN, B; ROTH, A; REICHER, M; AVERBUCH, M; SHEPS, D; SHALABYE, E; LANIADO, S				VISKIN, S; BELHASSEN, B; ROTH, A; REICHER, M; AVERBUCH, M; SHEPS, D; SHALABYE, E; LANIADO, S			AMINOPHYLLINE FOR BRADYASYSTOLIC CARDIAC-ARREST REFRACTORY TO ATROPINE AND EPINEPHRINE	ANNALS OF INTERNAL MEDICINE			English	Note						AMINOPHYLLINE; CARDIAC ARREST; ASYSTOLE; BRADYARRHYTHMIAS	ATRIOVENTRICULAR-CONDUCTION; MYOCARDIAL-INFARCTION; ADENOSINE; ANTAGONISM; BLOCK	Endogenous adenosine, which accumulates during hypoxia and ischemia, may perpetuate asystole. Therefore, patients with cardiac arrest were prospectively studied to see if their immediate outcome could be improved with aminophylline, a competitive antagonist of adenosine. Fifteen consecutive patients with cardiac arrest due to asystole or to nonperfusing bradyarrhythmias, who failed to respond to intravenous atropine and epinephrine, were treated with aminophylline (rapid intravenous injection of 250 mg). Establishment of a stable heart rhythm with sufficient blood pressure to allow discontinuation of closed-chest cardiac massage was achieved in 11 of 15 (73%) patients. All these 11 patients were alive 60 minutes after resuscitation. One patient survived, without neurologic damage. We conclude that the immediate outcome of patients with asystole refractory to standard treatment may be improved with aminophylline. Further study is warranted to determine if earlier administration of aminophylline during cardiac arrest will improve long-term outcome.	TEL AVIV UNIV, SACKLER SCH MED, TEL AVIV, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	VISKIN, S (corresponding author), TEL AVIV MED CTR & SCH MED, DEPT CARDIOL, WEIZMAN ST 6, IL-64239 TEL AVIV, ISRAEL.							BELARDINELLI L, 1982, CIRC RES, V51, P569, DOI 10.1161/01.RES.51.5.569; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; HORI M, 1991, CIRCULATION, V84, P828, DOI 10.1161/01.CIR.84.2.828; LERMAN BB, 1988, J CLIN INVEST, V82, P2127, DOI 10.1172/JCI113834; PARADIS NA, 1990, ANN EMERG MED, V19, P1288, DOI 10.1016/S0196-0644(05)82289-9; PELLEG A, 1990, AM J PHYSIOL, V258, pH1815, DOI 10.1152/ajpheart.1990.258.6.H1815; ROBERTS D, 1990, CHEST, V97, P413, DOI 10.1378/chest.97.2.413; STRASBERG B, 1991, AM J CARDIOL, V67, P527, DOI 10.1016/0002-9149(91)90016-E; VESTAL RE, 1983, CIRCULATION, V67, P162, DOI 10.1161/01.CIR.67.1.162; WESLEY RC, 1986, J AM COLL CARDIOL, V8, P1232, DOI 10.1016/S0735-1097(86)80406-5; 1992, JAMA-J AM MED ASSOC, V268, P2199	11	46	52	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					279	281		10.7326/0003-4819-118-4-199302150-00006	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420445				2022-12-28	WOS:A1993KL45700006
J	MULLER, YA; SCHULZ, GE				MULLER, YA; SCHULZ, GE			STRUCTURE OF THE THIAMINE-DEPENDENT AND FLAVIN-DEPENDENT ENZYME PYRUVATE OXIDASE	SCIENCE			English	Article							MECHANISM; PROTEINS	Pyruvate oxidase from Lactobacillus plantarum is a tetrameric enzyme that decarboxylates pyruvate, producing hydrogen peroxide and the energy-storage metabolite acetylphosphate. Structure determination at 2.1 angstroms showed that the cofactors thiamine pyrophosphate (TPP) and flavin adenine dinucleotide (FAD) are bound at the carboxyl termini of six-stranded parallel beta sheets. The pyrophosphate moiety of TPP is bound to a metal ion and to a betaalphaalphabeta unit corresponding to an established sequence fingerprint. The spatial arrangement of TPP and FAD suggests that the oxidation of the oxyethyl intermediate does not occur by hydride displacement but rather by a two-step transfer of two electrons.	UNIV FREIBURG,INST ORGAN CHEM & BIOCHEM,W-7800 FREIBURG,GERMANY	University of Freiburg			Muller, Yves A/R-5397-2016	Muller, Yves A/0000-0003-0519-8928				BLAKE R, 1982, J BIOL CHEM, V257, P9605; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; GOETZ F, 1991, P286; GREEN JBA, 1989, FEBS LETT, V246, P1, DOI 10.1016/0014-5793(89)80241-8; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; RAWN DJ, 1983, BIOCHEMISTRY-US, P414; RISSE B, IN PRESS PROTEIN SCI; SCHELLENBERGER A, 1990, CHEM BER, V123, P1489, DOI 10.1002/cber.19901230709; SCHREUDER HA, 1990, BIOCHEMISTRY-US, V29, P3101, DOI 10.1021/bi00464a029; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SUNDSTROM M, 1992, FEBS LETT, V313, P229, DOI 10.1016/0014-5793(92)81197-T; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012	18	217	222	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					965	967		10.1126/science.8438155	http://dx.doi.org/10.1126/science.8438155			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438155				2022-12-28	WOS:A1993KL80000041
J	TAPPERO, JW; MOHLEBOETANI, J; KOEHLER, JE; SWAMINATHAN, B; BERGER, TG; LEBOIT, PE; SMITH, LL; WENGER, JD; PINNER, RW; KEMPER, CA; REINGOLD, AL				TAPPERO, JW; MOHLEBOETANI, J; KOEHLER, JE; SWAMINATHAN, B; BERGER, TG; LEBOIT, PE; SMITH, LL; WENGER, JD; PINNER, RW; KEMPER, CA; REINGOLD, AL			THE EPIDEMIOLOGY OF BACILLARY ANGIOMATOSIS AND BACILLARY PELIOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAT-SCRATCH DISEASE; ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED COMPLEX; EPITHELIOID ANGIOMATOSIS; INFECTION; PATHOGENS; AGENT	Objective.-To determine environmental risk factors for bacillary angiomatosis-bacillary peliosis (BAP), and to confirm infection with Rochalimaea species. Design.-Case-control study. Setting.-Community and university hospitals and clinics. Patients.-Case patients (N=48) had biopsy-confirmed BAP. Controls (N=94) were matched to patients by institution and by human immunodeficiency virus (HIV) serological status. Main Outcome Measures.-Clinical information was obtained from medical records. Subjects were queried about environmental exposures. Univariate odds ratios (ORs) with 95% confidence intervals (CIs) were determined. Bivariate analyses were performed on variables associated with disease by univariate analysis. DNA from 22 available case-patient tissues and from 22 control tissues was amplified with the polymerase chain reaction (PCR) using primers designed to detect Rochalimaea species. Results.-We identified five HIV-negative, immunocompetent case patients; one HIV-negative, immunodeficient case patient; and 42 HIV-positive case patients. There were no significant differences between case patients and controls by race, sex, age, or risk factors for HIV infection. Owning a cat (OR, 2.8; CI, 1.4 to 5.8) and history of a recent cat lick (OR, 1.95; CI, 1.0 to 3.8), cat scratch (OR, 3.7; CI, 1.7 to 8.0), or cat bite (OR, 3.9; CI, 1.8 to 8.9) were associated with disease in the univariate analysis. In bivariate analyses, only the variables representing traumatic contact with a cat (bite or scratch) remained associated with disease. No other environmental exposure was associated with disease. The PCR amplified a DNA fragment of the size expected for Rochalimaea species in all 22 case-patient tissue specimens. Conclusions.-These data suggest that BAP is a new zoonosis associated with both traumatic exposure to cats and infection with Rochalimaea species or a closely related organism.	UNIV CALIF SAN FRANCISCO,DEPT DERMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED & LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; CTR DIS CONTROL,MYCOT DIS BRANCH,ATLANTA,GA 30333; STANFORD UNIV,MED CTR,DIV INFECT DIS,STANFORD,CA 94305; SANTA CLARA VALLEY MED CTR,SAN JOSE,CA 95128; UNIV CALIF BERKELEY,SCH PUBL HLTH,EPIDEMIOL PROGRAM,BERKELEY,CA 94720	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA; Stanford University; Santa Clara Valley Medical Center; University of California System; University of California Berkeley	TAPPERO, JW (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333, USA.		Mohle-Boetani, Janet/AAH-4221-2019		NIAMS NIH HHS [AR07175-15] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007175] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AZAD AF, 1992, P NATL ACAD SCI USA, V89, P43, DOI 10.1073/pnas.89.1.43; BERGER TG, 1989, ARCH DERMATOL, V125, P1543, DOI 10.1001/archderm.125.11.1543; BRENNER DJ, 1991, J CLIN MICROBIOL, V29, P2450, DOI 10.1128/JCM.29.11.2450-2460.1991; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; CHAN JKC, 1991, AM J SURG PATHOL, V15, P430, DOI 10.1097/00000478-199105000-00002; COCKERELL CJ, 1987, LANCET, V2, P654; Dean A. G., 1990, EPI INFO VERSION 5 W; ENGLISH CK, 1988, JAMA-J AM MED ASSOC, V259, P1347, DOI 10.1001/jama.259.9.1347; HELLER MJ, 1991, BIOTECHNIQUES, V11, P372; Hertig Marshall, 1942, AMER JOUR TROP MED SUPPL, V22, P1; KEMPER CA, 1990, AM J MED, V89, P216, DOI 10.1016/0002-9343(90)90301-S; KOEHLER JE, 1988, ANN INTERN MED, V109, P449, DOI 10.7326/0003-4819-109-6-449; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; LEBOIT PE, 1988, LANCET, V1, P960; LUCEY D, 1992, CLIN INFECT DIS, V14, P683, DOI 10.1093/clinids/14.3.683; OCONNOR SP, 1991, J CLIN MICROBIOL, V29, P2144, DOI 10.1128/JCM.29.10.2144-2150.1991; PERKINS BA, 1992, NEW ENGL J MED, V327, P1599, DOI 10.1056/NEJM199211263272215; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1992, MOL MICROBIOL, V6, P1801, DOI 10.1111/j.1365-2958.1992.tb01352.x; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; SPACH DH, 1992, ANN INTERN MED, V116, P740, DOI 10.7326/0003-4819-116-9-740; SPENCER L, 1992, J AM VET MED ASSOC, V201, P1669; Spink WW, 1956, NATURE BRUCELLOSIS; STOLER MH, 1983, AM J CLIN PATHOL, V80, P714, DOI 10.1093/ajcp/80.5.714; STRONG RP, 1918, TRENCH FEVER REPORT; TAPPERO JW, 1991, JAMA-J AM MED ASSOC, V266, P1938, DOI 10.1001/jama.1991.03470140050020; TAPPERO JW, 1991, 7TH INT C AIDS FLOR, V1, P340; TAPPERO JW, 1960, AM J MED, V28, P504; WEAR DJ, 1983, SCIENCE, V221, P1403, DOI 10.1126/science.6612349; WEISBURG WG, 1985, SCIENCE, V230, P556, DOI 10.1126/science.3931222; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; 1992, SAS RELEASE 6 07	36	165	172	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					770	775		10.1001/jama.269.6.770	http://dx.doi.org/10.1001/jama.269.6.770			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423659				2022-12-28	WOS:A1993KK54400030
J	DEVLIN, B; RISCH, N; ROEDER, K				DEVLIN, B; RISCH, N; ROEDER, K			STATISTICAL EVALUATION OF DNA FINGERPRINTING - A CRITIQUE OF THE NRCS REPORT	SCIENCE			English	Article							HARDY-WEINBERG EQUILIBRIUM; F-STATISTICS; TESTS; LOCI		YALE UNIV,DEPT STAT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Yale University; Yale University	DEVLIN, B (corresponding author), YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510, USA.			Roeder, Kathryn/0000-0002-8869-6254	NATIONAL CANCER INSTITUTE [R01CA045052] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000648] Funding Source: NIH RePORTER; NCI NIH HHS [CA45052] Funding Source: Medline; NHGRI NIH HHS [HG00648] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		[Anonymous], 1992, DNA TECHNOLOGY FOREN; BALAZS I, 1992, GENETICS, V131, P191; BALAZS I, IN PRESS 2ND INT C D; BAUR MP, 1986, AM J HUM GENET, V39, P528; Berry DA, 1992, APPL STAT, V41, P499, DOI 10.1111/j.1467-9876.1992/tb02418.x; Berry DA, 1991, STAT SCI, V6, P175; BUDOWLE B, 1991, AM J HUM GENET, V48, P841; BUDOWLE B, UNPUB; BUDOWLE B, UNPUB 1992 P S HUM I; CHAKRABORTY R, 1991, SCIENCE, V254, P1735, DOI 10.1126/science.1763323; CHAKRABORTY R, 1992, ANN HUM GENET, V56, P45, DOI 10.1111/j.1469-1809.1992.tb01128.x; CHAKRABORTY R, 1992, HUM GENET, V88, P267, DOI 10.1007/BF00197257; CHAKRABORTY RN, UNPUB; COCKERHAM CC, 1969, EVOLUTION, V23, P72, DOI 10.1111/j.1558-5646.1969.tb03496.x; COCKERHAM CC, 1972, GENETICS, V76, P679; COHEN JE, 1990, AM J HUM GENET, V46, P358; COHEN JE, 1992, AM J HUM GENET, V51, P1165; DEVLIN B, 1990, SCIENCE, V249, P1416, DOI 10.1126/science.2205919; DEVLIN B, 1992, AM J HUM GENET, V51, P534; DEVLIN B, 1991, SCIENCE, V253, P1039, DOI 10.1126/science.253.5023.1039; DEVLIN B, 1992, J AM STAT ASSOC, V87, P337; DEVLIN B, 1992, AM J HUM GENET, V51, P549; DEVLIN BA, UNPUB; EDRON B, 1991, SCIENCE, V253, P390; EVETT IW, 1992, CHANCE, V4, P19; EVETT IW, IN PRESS AM J HUM GE; GOODMAN LA, 1960, J AM STAT ASSOC, V55, P708, DOI 10.2307/2281592; GOODMAN LA, 1962, J AM STAT ASSOC, V57, P54; GREEN P, 1991, SCIENCE, V253, P1038, DOI 10.1126/science.253.5023.1038; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; Kennedy RJR, 1944, AM J SOCIOL, V49, P331, DOI 10.1086/219427; Kennedy RJR, 1952, AM J SOCIOL, V58, P56, DOI 10.1086/221073; LANDER ES, 1991, AM J HUM GENET, V48, P819; LANDER ES, 1989, NATURE, V339, P501, DOI 10.1038/339501a0; LATTER BDH, 1980, AM NAT, V116, P220, DOI 10.1086/283624; Lewontin R.C., 1972, EVOL BIOL, P381, DOI [10.1007/978-1-4684-9063-3_14, DOI 10.1007/978-1-4684-9063-3_14]; LEWONTIN RC, 1991, SCIENCE, V254, P1745, DOI 10.1126/science.1845040; LONG JC, 1986, GENETICS, V112, P629; LONG JC, 1987, GENETICS, V117, P223; LYNCH M, 1991, SCIENCE, V253, P1037; MITTON JB, 1978, AM NAT, V112, P1142, DOI 10.1086/283359; MORTON N, IN PRESS P NATL ACAD; MORTON NE, IN PRESS EUR J HUM G, P2556; NEEL JV, 1981, AM NAT, V117, P83, DOI 10.1086/283687; NEI M, 1982, EVOL BIOL, V14, P1; NEI M, 1981, AM NAT, V117, P88, DOI 10.1086/283688; RISCH N, 1992, SCIENCE, V256, P174; RISCH NJ, 1992, SCIENCE, V255, P717, DOI 10.1126/science.1738844; SMOUSE PE, 1982, AM NAT, V119, P445, DOI 10.1086/283925; SMOUSE PE, 1986, AM J HUM GENET, V38, P918; SPUHLER JN, 1961, HUM BIOL, V33, P223; WEIR BS, 1992, AM J HUM GENET, V50, P869; WEIR BS, 1992, GENETICS, V130, P873; WEIR BS, 1992, P NATL ACAD SCI USA, V89, P11654, DOI 10.1073/pnas.89.24.11654; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI [10.2307/2408641, 10.1111/j.1558-5646.1984.tb05657.x]; WEIR BS, 1992, AM J HUM GENET, V51, P992; WEIR BS, IN PRESS AM J HUM GE; 1983, WEBSTERS 9TH NEW COL	58	46	46	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 5	1993	259	5096					748	&		10.1126/science.8430323	http://dx.doi.org/10.1126/science.8430323			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430323				2022-12-28	WOS:A1993KL11000006
J	STENMAN, S; MELANDER, A; GROOP, PH; GROOP, LC				STENMAN, S; MELANDER, A; GROOP, PH; GROOP, LC			WHAT IS THE BENEFIT OF INCREASING THE SULFONYLUREA DOSE	ANNALS OF INTERNAL MEDICINE			English	Article						SULFONYLUREA COMPOUNDS; GLIPIZIDE; DIABETES-MELLITUS, NONINSULIN-DEPENDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; INSULIN	GLIPIZIDE; PHARMACOKINETICS; DRUGS; SERUM	Objective: To study the clinical benefit of increasing the dose of the sulfonylurea, glipizide, from 10 to 40 mg per day. Design: A placebo-controlled, double-blind, cross-over study. Setting: An outpatient clinic at the Helsinki University Hospital, Finland. Patients: Twenty-three patients with noninsulin-dependent diabetes mellitus. Methods: Patients were given glipizide in three different dose schedules for 3 months each: 10 mg in the morning or 10 mg or 20 mg in the morning and the evening. Glycemic control was followed by HbA1c measurements and blood glucose monitoring at home. Beta cell function was assessed by measuring insulin responses to a test meal. Results: Mean home-monitored blood glucose was 12.4 mmol/L during placebo treatment, and it was 9.6, 9.2, and 8.9 mmol/L after treatment with glipizide, 10, 20, or 40 mg, respectively. The levels of blood glucose and HbA1c differed after all treatment groups from placebo (P < 0.001) but not among themselves. The insulin response to a test meal was greatest after 10 mg of glipizide and weakest after 40 mg/d (P = 0.02 compared with the 10-mg dose). All treatments stimulated insulin secretion more than placebo (P < 0.001). Conclusions: Increasing the glipizide dose to more than 10 mg once daily produces little or no benefit and may reduce beta-cell function.	UNIV LUND, S-21401 MALMO, SWEDEN	Lund University	STENMAN, S (corresponding author), UNIV HELSINKI, CENT HOSP, DEPT MED 4, SF-00170 HELSINKI 17, FINLAND.							BALANT L, 1981, CLIN PHARMACOKINET, V6, P215, DOI 10.2165/00003088-198106030-00003; BOYD AE, 1988, DIABETES, V37, P847, DOI 10.2337/diabetes.37.7.847; FINLEY PR, 1978, CLIN CHEM, V24, P931; GROOP L, 1987, DIABETES CARE, V10, P671, DOI 10.2337/diacare.10.6.671; GROOP LC, 1991, ACTA DIABETOL, V28, P162, DOI 10.1007/BF00579720; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; JACKSON JE, 1981, DRUGS, V22, P211, DOI 10.2165/00003495-198122030-00003; KARAM JH, 1986, DIABETES, V35, P1314, DOI 10.2337/diabetes.35.12.1314; OSTMAN J, 1981, ACTA MED SCAND, V210, P173; WAHLINBOLL E, 1982, EUR J CLIN PHARMACOL, V22, P21, DOI 10.1007/BF00606420; WAHLINBOLL E, 1979, J CHROMATOGR, V164, P541, DOI 10.1016/S0378-4347(00)81560-1; WAHLINBOLL E, 1982, CLIN PHARMACOKINET, V7, P363, DOI 10.2165/00003088-198207040-00006; WAHLINBOLL E, 1986, EUR J CLIN PHARMACOL, V31, P95, DOI 10.1007/BF00870994	13	79	80	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					169	172		10.7326/0003-4819-118-3-199302010-00002	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00002			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8417634				2022-12-28	WOS:A1993KJ43900002
J	HARKNESS, MR; MCDERMOTT, JB; ABRAMOWICZ, DA; SALVO, JJ; FLANAGAN, WP; STEPHENS, ML; MONDELLO, FJ; MAY, RJ; LOBOS, JH; CARROLL, KM; BRENNAN, MJ; BRACCO, AA; FISH, KM; WARNER, GL; WILSON, PR; DIETRICH, DK; LIN, DT; MORGAN, CB; GATELY, WL				HARKNESS, MR; MCDERMOTT, JB; ABRAMOWICZ, DA; SALVO, JJ; FLANAGAN, WP; STEPHENS, ML; MONDELLO, FJ; MAY, RJ; LOBOS, JH; CARROLL, KM; BRENNAN, MJ; BRACCO, AA; FISH, KM; WARNER, GL; WILSON, PR; DIETRICH, DK; LIN, DT; MORGAN, CB; GATELY, WL			INSITU STIMULATION OF AEROBIC PCB BIODEGRADATION IN HUDSON RIVER SEDIMENTS	SCIENCE			English	Article							POLYCHLORINATED BIPHENYL METABOLISM; ALCALIGENES-EUTROPHUS H850; ANAEROBIC MICROORGANISMS; DEGRADATION; DECHLORINATION; SORPTION; HYDROCARBONS; STRAINS; SOILS	A 73-day field study of in situ aerobic biodegradation of polychlorinated biphenyls (PCBs) in the Hudson River shows that indigenous aerobic microorganisms can degrade the lightly chlorinated PCBs present in these sediments. Addition of inorganic nutrients, biphenyl, and oxygen enhanced PCB biodegradation, as indicated both by a 37 to 55 percent loss of PCBs and by the production of chlorobenzoates, intermediates in the PCB biodegradation pathway. Repeated inoculation with a purified PCB-degrading bacterium failed to improve biodegradative activity. Biodegradation was also observed under mixed but unamended conditions, which suggests that this process may occur commonly in river sediments, with implications for PCB fate models and risk assessments.	GE,CTR CORP RES & DEV,SCHENECTADY,NY 12301	General Electric								ABRAMOWICZ DA, 1990, CRIT REV BIOTECHNOL, V10, P241, DOI 10.3109/07388559009038210; ABRAMOWICZ DA, 1992, 1991 IN SITU HUDSON; AHMED M, 1973, CAN J MICROBIOL, V19, P47, DOI 10.1139/m73-007; ATLAS RM, 1981, MICROBIOL REV, V45, P180, DOI 10.1128/MMBR.45.1.180-209.1981; BEDARD DL, 1990, ADV AP BIOT, V4, P369; BEDARD DL, 1990, MICROBIAL ECOL, V20, P87, DOI 10.1007/BF02543870; BEDARD DL, 1987, APPL ENVIRON MICROB, V53, P1094, DOI 10.1128/AEM.53.5.1094-1102.1987; BEDARD DL, 1986, APPL ENVIRON MICROB, V51, P761, DOI 10.1128/AEM.51.4.761-768.1986; BEDARD DL, 1987, APPL ENVIRON MICROB, V53, P1103, DOI 10.1128/AEM.53.5.1103-1112.1987; BROWN JF, 1990, ENVIRON TOXICOL CHEM, V9, P1215, DOI 10.1002/etc.5620091001; BROWN JF, 1987, ENVIRON TOXICOL CHEM, V6, P579, DOI 10.1897/1552-8618(1987)6[579:EDOP]2.0.CO;2; BROWN JF, 1987, SCIENCE, V236, P709, DOI 10.1126/science.236.4802.709; Clesceri LS, 1989, STANDARD METHODS EXA; CLIFTON MJ, 1986, J APPL ELECTROCHEM, V16, P812, DOI 10.1007/BF01006526; Coates JT, 1986, J CONTAM HYDROL, V1, P191; DUNNIVANT FM, 1988, THESIS CLEMSON U; FISCHER R, 1988, FRESEN Z ANAL CHEM, V332, P441, DOI 10.1007/BF00499265; FLANAGAN WP, UNPUB; FOCHT DD, 1985, APPL ENVIRON MICROB, V50, P1058, DOI 10.1128/AEM.50.4.1058-1063.1985; FURUKAWA K, 1978, AGR BIOL CHEM TOKYO, V42, P543, DOI 10.1080/00021369.1978.10863017; FURUKAWA K, 1982, BIODEGRADATION DETOX, P33; HATZIKONSTANTINOU H, 1978, BIOCHEM J, V174, P893, DOI 10.1042/bj1740893; HERNANDEZ BS, 1991, APPL ENVIRON MICROB, V57, P3361, DOI 10.1128/AEM.57.11.3361-3366.1991; HICKEY WJ, 1990, APPL ENVIRON MICROB, V56, P3842, DOI 10.1128/AEM.56.12.3842-3850.1990; Karickhoff S.W., 1980, CONTAMINANTS SEDIMEN, P193; KARICKHOFF SW, 1985, ENVIRON TOXICOL CHEM, V4, P469; KAWAHARA FK, 1968, ANAL CHEM, V40, P2073, DOI 10.1021/ac60269a044; LAKE JL, 1992, MAR ENVIRON RES, V33, P31, DOI 10.1016/0141-1136(92)90004-6; LARSSON P, 1992, ENVIRON SCI TECHNOL, V26, P346, DOI 10.1021/es00026a016; MADSEN EL, 1991, ENVIRON SCI TECHNOL, V25, P1663, DOI 10.1021/es00022a001; MEANS JC, 1980, ENVIRON SCI TECHNOL, V14, P1524, DOI 10.1021/es60172a005; MONDELLO FJ, 1989, J BACTERIOL, V171, P1725, DOI 10.1128/jb.171.3.1725-1732.1989; PIGNATELLO JJ, 1990, ENVIRON TOXICOL CHEM, V9, P1107, DOI 10.1002/etc.5620090901; Pourbaix M, 1974, ATLAS ELECTROCHEMICA, P309; PRITCHARD PH, 1991, ENVIRON SCI TECHNOL, V25, P372, DOI 10.1021/es00015a002; QUENSEN JF, 1988, SCIENCE, V242, P752, DOI 10.1126/science.242.4879.752; Sediak DL, 1991, ENVIRON SCI TECHNOL, V25, P1419; SUNDSTROM G, 1976, CHEMOSPHERE, V5, P267, DOI 10.1016/0045-6535(76)90002-3; VANDORT HM, 1991, APPL ENVIRON MICROB, V57, P1576, DOI 10.1128/AEM.57.5.1576-1578.1991	39	148	157	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					503	507		10.1126/science.8424172	http://dx.doi.org/10.1126/science.8424172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424172				2022-12-28	WOS:A1993KJ07900031
J	OSMOND, DH; PADIAN, NS; SHEPPARD, HW; GLASS, S; SHIBOSKI, SC; REINGOLD, A				OSMOND, DH; PADIAN, NS; SHEPPARD, HW; GLASS, S; SHIBOSKI, SC; REINGOLD, A			RISK-FACTORS FOR HEPATITIS-C VIRUS SEROPOSITIVITY IN HETEROSEXUAL COUPLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-B-HEPATITIS; HUMAN-IMMUNODEFICIENCY-VIRUS; NON-A-HEPATITIS; SEXUAL TRANSMISSION; UNITED-STATES; DRUG-USERS; ANTIBODIES; HEMOPHILIACS; PREVALENCE; INFECTION	Objectives.-To determine the risk of heterosexual transmission of hepatitis C virus (HCV) and to identify other risk factors for HCV seropositivity in heterosexual couples. Design.-Retrospective cross-sectional study comparing HCV-seropositive and HCV-seronegative heterosexual men and women. Setting.-Couples recruited from the community and screened for participation in a study of the heterosexual transmission of human immunodeficiency virus. Participants.-A total of 340 subjects, 170 men and 170 women in sexual partnerships, aged 18 through 61 years. Main Outcome Measure.-Seropositivity for HCV antibodies. Results.-Overall, 31 (18%) of the 170 women and 56 (33%) of the 170 men were positive by a four-antigen HCV immunoblot. Injection drug use and hemophilia were strongly associated with HCV seropositivity. Sixty-four percent of injection drug users were positive (odds ratio [OR], 27.0; 95% confidence interval [CI], 13.4 to 56.1; P<.0001), as were all four hemophiliacs in the study. History of blood transfusion was significantly associated with HCV seropositivity (OR, 2.7; 95% CI, 1.1 to 7.0; P=.02). Positivity for HCV was not associated with measures of sexual behavior within couples or with numbers of other sexual partners, history of sexually transmitted diseases, or human immunodeficiency virus seropositivity. However, two of the 31 women without parenteral risk but with a long-term HCV-positive male partner were HCV seropositive compared with none of 81 women with an HCV-negative male partner (P=.07). Conclusions.-These results provide little evidence of HCV sexual transmission but are consistent with infrequent sexual transmission. They corroborate the importance of injection drug use and transfusion of blood or blood products in transmitting HCV and underscore the importance of ascertaining parenteral exposures when examining sexual transmission of HCV.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; CALIF DEPT HLTH SERV,VIRAL & RICKETTSIAL DIS LAB,BERKELEY,CA; UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720	University of California System; University of California San Francisco; California Department of Health Care Services; University of California System; University of California Berkeley	OSMOND, DH (corresponding author), SAN FRANCISCO GEN HOSP,DIV EPIDEMIOL,WARD 95 995 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1989, NEW ENGL J MED, V321, P1538, DOI 10.1056/NEJM198911303212208; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1987, AM J EPIDEMIOL, V125, P132; BENAMOUZIG R, 1990, ANN INTERN MED, V113, P638, DOI 10.7326/0003-4819-113-8-638_1; BLOSSER JW, 1991, 3RD INT S HCV STRASB; CARLSON JR, 1985, JAMA-J AM MED ASSOC, V253, P3405, DOI 10.1001/jama.253.23.3405; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DEPALMA M, 1991, 3RD INT S HCV STRASB; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; EVANS CS, 1991, 3RD INT S HCV STRASB; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; EYSTER ME, 1991, ANN INTERN MED, V115, P764, DOI 10.7326/0003-4819-115-10-764; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MAZZOTTA F, 1991, 3RD INT S HCV STRASB; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; MORTIMER PP, 1989, LANCET, V2, P798; MOSELEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77; NELSON KE, 1991, 3RD INT S HCV STRASB; PACHUCKI CT, 1991, J INFECT DIS, V164, P820, DOI 10.1093/infdis/164.4.820; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; RUMI MG, 1990, ANN INTERN MED, V112, P379, DOI 10.7326/0003-4819-112-5-379; Schlesselman J. J, 1982, CASE CONTROL STUDIES, P207; SIMMONDS P, 1990, LANCET, V336, P1469, DOI 10.1016/0140-6736(90)93179-S; TEDDER RS, 1991, BRIT MED J, V302, P1302; TOR J, 1990, BRIT MED J, V301, P1130, DOI 10.1136/bmj.301.6761.1130; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; 1987, SAS STAT GUIDE PERSO; 1989, EGRET USERS MANUAL 3, P43	34	150	149	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					361	365		10.1001/jama.269.3.361	http://dx.doi.org/10.1001/jama.269.3.361			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418342				2022-12-28	WOS:A1993KG38100027
J	BENHAR, I; ENGELBERGKULKA, H				BENHAR, I; ENGELBERGKULKA, H			FRAMESHIFTING IN THE EXPRESSION OF THE ESCHERICHIA-COLI TRPR GENE OCCURS BY THE BYPASSING OF A SEGMENT OF ITS CODING SEQUENCE	CELL			English	Article							POLYMERASE-III HOLOENZYME; CHAIN RELEASE FACTORS; ESCHERICHIA-COLI; GAMMA-SUBUNIT; STRUCTURAL GENE; MESSENGER-RNA; PROTEIN; PEPTIDE; REPRESSOR; YEAST	The E. coli trpR gene encodes the 108 amino acid long trp repressor. We have previously shown that a +1 frameshifting event occurs during the expression of trpR. Here we show that the transition from the 0 to the +1 frame of trpR occurs by the bypassing of a 55 nt long segment of the trpR+1-lacZ mRNA. This bypassing event is not pretranslational, and it probably takes place during translation. Two adjacent elements are required: a specific sequence of trpR, which must be preceded by a nonspecific 5' end longer than 10 translatable codons. Unique to trpR-lacZ bypassing is that the 55 nt long region must be translated in frame 0 to enable bypassing into the +1 frame. Translational bypassing as a newly discovered mechanism of gene expression is discussed, and the possible existence of translational introns is suggested.			BENHAR, I (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOLEC BIOL,IL-91010 JERUSALEM,ISRAEL.			Benhar, Itai/0000-0002-0824-7177				ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BARRY G, 1980, P NATL ACAD SCI-BIOL, V77, P3331, DOI 10.1073/pnas.77.6.3331; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BENHAR I, 1992, MOL MICROBIOL, V6, P2777, DOI 10.1111/j.1365-2958.1992.tb01457.x; BENHAR I, 1991, GENE, V103, P79, DOI 10.1016/0378-1119(91)90394-Q; BENHAR I, 1990, POSTTRANSCRIPTIONAL, P591; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BOGOSIAN G, 1981, J MOL BIOL, V149, P821, DOI 10.1016/0022-2836(81)90361-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CRAIGEN WJ, 1987, CELL, V50, P1, DOI 10.1016/0092-8674(87)90652-0; CRAIGEN WJ, 1987, BIOCHIMIE, V69, P1031, DOI 10.1016/0300-9084(87)90003-4; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CRAIGEN WJ, 1985, P NATL ACAD SCI USA, V82, P3616, DOI 10.1073/pnas.82.11.3616; ENGELBERGKULKA H, 1988, TRENDS BIOCHEM SCI, V13, P419, DOI 10.1016/0968-0004(88)90209-5; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GIMBLE P, 1992, NATURE, V357, P301; GROVE CL, 1987, J BACTERIOL, V169, P2158, DOI 10.1128/jb.169.5.2158-2164.1987; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HEATWOLE VM, 1991, J BACTERIOL, V173, P3601, DOI 10.1128/jb.173.11.3601-3604.1991; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANG C, 1985, J MOL BIOL, V181, P241, DOI 10.1016/0022-2836(85)90088-9; Maniatis T., 1982, MOL CLONING; Miller J.H., 1972, EXPT MOL GENETICS; OCONNOR M, 1989, EMBO J, V8, P4315, DOI 10.1002/j.1460-2075.1989.tb08618.x; PARKER J, 1989, MICROBIOL REV, V53, P273, DOI 10.1128/MMBR.53.3.273-298.1989; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; ROEDER W, 1979, MOL GEN GENET, V176, P361, DOI 10.1007/BF00333098; ROSE JK, 1973, NATURE-NEW BIOL, V245, P133, DOI 10.1038/newbio245133a0; SARSERO JP, 1991, J BACTERIOL, V173, P4133, DOI 10.1128/jb.173.13.4133-4143.1991; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; WEISS RB, 1990, CELL, V62, P117, DOI 10.1016/0092-8674(90)90245-A; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WONG SC, 1990, J BACTERIOL, V172, P630, DOI 10.1128/jb.172.2.630-642.1990; YANOFSKY C, 1987, ESCHERICHIA COLI SAL, P1453; ZURAWSKI G, 1981, J MOL BIOL, V145, P47, DOI 10.1016/0022-2836(81)90334-X	38	40	40	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					121	130		10.1016/0092-8674(93)90056-V	http://dx.doi.org/10.1016/0092-8674(93)90056-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422674				2022-12-28	WOS:A1993KG95500016
J	GORMAN, M; KURODA, MI; BAKER, BS				GORMAN, M; KURODA, MI; BAKER, BS			REGULATION OF THE SEX-SPECIFIC BINDING OF THE MALELESS DOSAGE COMPENSATION PROTEIN TO THE MALE X-CHROMOSOME IN DROSOPHILA	CELL			English	Article							FEMALE-SPECIFIC LETHAL; SACCHAROMYCES-CEREVISIAE; TRANSFORMER GENE; SPLICE SITE; MELANOGASTER; EXPRESSION; RNA; DIFFERENTIATION; SNF5; PRODUCT	In Drosophila, the single male X chromosome is transcribed at twice the rate of a single female X chromosome. This hypertranscription requires the functions of at least four autosomal male-specific lethal genes (msls) and is under the control of the Sex-lethal (Sxl) gene. One of the msls, the maleless (mle) gene, encodes a protein that is associated with the male X chromosome. To investigate how dosage compensation is regulated, we have determined whether Sxl and the other msls are required for mle X chromosome binding. We have found that in females, Sxl functions to prevent mle from binding to the two X chromosomes. Additionally, we have found that mle X chromosome binding requires wild-type msl1, msl2, and msl3 functions. These data support a model whereby the activity of the mle protein is regulated through its association with one or more of the other msl proteins.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine	GORMAN, M (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.							ABRAMS E, 1986, MOL CELL BIOL, V6, P3643, DOI 10.1128/MCB.6.11.3643; BAKER BS, 1983, ANNU REV GENET, V17, P345, DOI 10.1146/annurev.ge.17.120183.002021; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BELOTE JM, 1980, GENETICS, V96, P165; BIRCHLER JA, 1982, GENETICS, V102, P525; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BREEN TR, 1986, GENETICS, V112, P483; CLINE TW, 1986, GENETICS, V113, P641; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1980, GENETICS, V96, P903; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CLINE TW, 1979, DEV BIOL, V72, P266, DOI 10.1016/0012-1606(79)90117-9; CLINE TW, 1985, ORIGIN EVOLUTION SEX, P301; CLINE TW, 1982, GENETICS S, V100, P13; CLINE TW, 1988, EVOLUTIONARY MECHANI, P23; CLINE TW, 1986, GENETICS, V114, P345; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DOBZHANSKY T, 1957, CHROMOSOMA, V8, P691; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; FUKUNAGA A, 1975, GENETICS, V81, P135; GANGULY R, 1985, GENE, V35, P91, DOI 10.1016/0378-1119(85)90161-1; GERGEN JP, 1987, GENETICS, V117, P477; GOLUBOVSKY MD, 1972, DROS INF SERV, V49, P117; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HAPPEL AM, 1991, GENETICS, V128, P69; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; HOLMQUIST G, 1972, CHROMOSOMA, V36, P413, DOI 10.1007/BF00336796; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; JAFFE E, 1986, TRENDS GENET, V2, P316, DOI 10.1016/0168-9525(86)90287-8; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LINDSLEY DL, 1992, GENOME DORSOPHILA ME; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; LUCCHESI JC, 1982, GENETICS, V100, P42; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MUKHERJEE AS, 1965, NATURE, V207, P785, DOI 10.1038/207785a0; MUKHERJEE AS, 1966, NUCLEUS CALCUTTA, V9, P83; MULLER HJ, 1960, GENETICS, V45, P1001; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; NEIGEBORN L, 1984, GENETICS, V108, P845; OKUNO T, 1984, JPN J GENET, V59, P237, DOI 10.1266/jjg.59.237; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SANCHEZ L, 1982, ROUX ARCH DEV BIOL, V186, P235; SKRIPSKY T, 1982, DEV BIOL, V94, P153, DOI 10.1016/0012-1606(82)90078-1; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; UCHIDA S, 1981, JPN J GENET, V56, P523, DOI 10.1266/jjg.56.523; UENOYAMA T, 1982, GENETICS, V102, P233	59	85	85	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 15	1993	72	1					39	49		10.1016/0092-8674(93)90048-U	http://dx.doi.org/10.1016/0092-8674(93)90048-U			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422681				2022-12-28	WOS:A1993KG95500008
J	RUSTICI, A; VELUCCHI, M; FAGGIONI, R; SIRONI, M; GHEZZI, P; QUATAERT, S; GREEN, B; PORRO, M				RUSTICI, A; VELUCCHI, M; FAGGIONI, R; SIRONI, M; GHEZZI, P; QUATAERT, S; GREEN, B; PORRO, M			MOLECULAR MAPPING AND DETOXIFICATION OF THE LIPID-A BINDING-SITE BY SYNTHETIC PEPTIDES	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; BORDETELLA-PERTUSSIS ENDOTOXIN; POLYMYXIN-B; HUMAN-MONOCYTES; SEPTIC SHOCK; FACTOR-ALPHA; LIPOPOLYSACCHARIDE; INTERLEUKIN-1; EXPRESSION; ANTIBODIES	Endotoxin [lipopolysaccharide (LPS)], the major antigen of the outer membrane of Gram-negative bacteria, consists of a variable-size carbohydrate chain that is covalently linked to N,O-acylated beta-1,6-D-glucosamine disaccharide 1,4'-bisphosphate (lipid A). The toxic activity of LPS resides in the lipid A structure. The structural features of synthetic peptides that bind to lipid A with high affinity, detoxify LPS in vitro, and prevent LPS-induced cytokine release and lethality in vivo were defined. The binding thermodynamics were comparable to that of an antigen-antibody reaction. Such synthetic peptides may provide a strategy for prophylaxis and treatment of LPS-mediated diseases.	RAPOLANO TERME,BIOSYNTH RES LABS,I-53040 SIENA,ITALY; LEDERLE PRAXIS BIOL,ROCHESTER,NY 14623; MARIO NEGRI INST PHARMACOL RES,I-20157 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS			sironi, marina/AAB-5757-2020	sironi, marina/0000-0002-3342-1149; Ghezzi, Pietro/0000-0003-0911-8358				AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; ARNDT B, 1991, IMMUNOBIOLOGY PROTEI, V6, P129; Atherton E., 1981, J CHEM SOC P1, V1, P538; BERZOFSKY JA, 1978, CLIN CHEM, V24, P419; BROWN SE, 1984, J IMMUNOL METHODS, V72, P41, DOI 10.1016/0022-1759(84)90431-9; CAROFF M, 1983, CARBOHYD RES, V114, P95, DOI 10.1016/0008-6215(83)88176-2; CAROFF M, 1986, INFECT IMMUN, V54, P465, DOI 10.1128/IAI.54.2.465-471.1986; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CAVAILLON JM, 1986, MOL IMMUNOL, V23, P965, DOI 10.1016/0161-5890(86)90127-6; CRAIG WA, 1974, INFECT IMMUN, V10, P287, DOI 10.1128/IAI.10.2.287-292.1974; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; DINARELLO CA, 1991, J INFECT DIS, V163, P1177, DOI 10.1093/infdis/163.6.1177; DINARELLO CA, 1983, AGENTS ACTIONS, V13, P470, DOI 10.1007/BF02176419; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; KOTANI S, 1985, INFECT IMMUN, V49, P225, DOI 10.1128/IAI.49.1.225-237.1985; LOPPNOW H, 1990, INFECT IMMUN, V58, P3743, DOI 10.1128/IAI.58.11.3743-3750.1990; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; NESTEL FP, 1992, J EXP MED, V175, P405, DOI 10.1084/jem.175.2.405; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; PORRO M, 1986, MOL IMMUNOL, V23, P385, DOI 10.1016/0161-5890(86)90136-7; PORRO M, 1985, MOL IMMUNOL, V22, P907, DOI 10.1016/0161-5890(85)90077-X; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RIFKIND D, 1967, J BACTERIOL, V93, P1463, DOI 10.1128/JB.93.4.1463-1464.1967; SHIMOZATO T, 1990, INFECT IMMUN, V58, P1384, DOI 10.1128/IAI.58.5.1384-1390.1990; SIRONI M, 1989, J IMMUNOL, V142, P549; SPEAR GT, 1984, J IMMUNOL METHODS, V73, P321, DOI 10.1016/0022-1759(84)90407-1; STOKES DC, 1989, J INFECT DIS, V160, P52, DOI 10.1093/infdis/160.1.52; ULICH TR, 1989, AM J PATHOL, V134, P11; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WESTPHAL O, 1952, Z NATURFORSCH B, V7, P148, DOI 10.1515/znb-1952-0303; WRIGHT SD, 1991, SCIENCE, V252, P1321, DOI 10.1126/science.252.5010.1321-a; YOCKOCHI T, 1990, J IMMUNOL, V144, P3106; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1985, US PHARMACOPEIA, V21	34	143	169	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					361	365		10.1126/science.8420003	http://dx.doi.org/10.1126/science.8420003			5	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8420003				2022-12-28	WOS:A1993KG62400032
J	ADAMS, WG; DEAVER, KA; COCHI, SL; PLIKAYTIS, BD; ZELL, ER; BROOME, CV; WENGER, JD				ADAMS, WG; DEAVER, KA; COCHI, SL; PLIKAYTIS, BD; ZELL, ER; BROOME, CV; WENGER, JD			DECLINE OF CHILDHOOD HAEMOPHILUS-INFLUENZAE TYPE-B (HIB) DISEASE IN THE HIB VACCINE ERA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPSULAR POLYSACCHARIDE VACCINE; UNITED-STATES CHILDREN; BACTERIAL-MENINGITIS; CONJUGATE VACCINE; EFFICACY; SURVEILLANCE; AGE	Objective.-Effective Haemophilus influenzae type b (Hib) conjugate vaccines were first licensed for use in US children at least 18 months old in December 1987 and for infants at least 2 months old in October 1990. We evaluated trends in Hib disease associated with licensure of Hib conjugate vaccines. Design.-Data from two sources, an intensive laboratory-based active surveillance system and the National Bacterial Meningitis Reporting System (NBMRS), were used separately to evaluate disease incidence. Data from vaccine manufacturers on Hib vaccine doses distributed in the United States were compared with trends in Hib disease incidence. Results.-The age-specific incidence of Hib disease among children less than 5 years old decreased by 71 % from 37 per 100 000 persons in 1989 to 11 per 100 000 persons in 1991 (active surveillance data). Haemophilus influenzae meningitis incidence decreased by 82% between 1985 and 1991 (NBMRS data). Increases in doses of Hib vaccine distributed in the United States coincided with steep declines in Hib disease. Both surveillance systems showed decreased rates of Hib disease in infants less than 1 year old before vaccine was licensed for use in this age group. Haemophilus influenzae type b disease incidence in persons at least 12 years old and pneumococcal meningitis incidence in children less than 5 years old did not change substantially during the same period; therefore, decreased Hib disease in children less than 5 years old is not likely to be explained solely by changes in surveillance sensitivity or decreases in bacterial disease due to changes in medical practice. Conclusion.-Our data suggest that conjugate vaccines have already had a marked impact on the incidence of Hib disease in the United States, preventing an estimated 10000 to 16000 cases of Hib disease in 1991. The decline of disease in infants less than 1 year old before licensure for this age group warrants further investigation.	CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,BIOSTAT & INFORMAT MANAGEMENT BRANCH,ATLANTA,GA; CTR DIS CONTROL & PREVENT,NATL CTR PREVENT DIS,DIV IMMUNIZAT,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	ADAMS, WG (corresponding author), NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,MENINGITIS & SPECIAL PATHOGENS BRANCH,ATLANTA,GA 30333, USA.			Adams, William/0000-0002-5330-0010				BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; COCHI SL, 1985, JAMA-J AM MED ASSOC, V253, P521, DOI 10.1001/jama.253.4.521; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; DEAN AG, 1990, EPIINFO VERSION 5 WO; GREENBERG DP, 1991, JAMA-J AM MED ASSOC, V265, P987, DOI 10.1001/jama.265.8.987; LEPEL MH, 1988, NEW ENGL J MED, V319, P964; LOUGHLIN AM, 1992, PEDIATR INFECT DIS J, V11, P374, DOI 10.1097/00006454-199205000-00007; OSTERHOLM MT, 1991, 31ST INT C ANT AG CH; PELTOLA H, 1984, NEW ENGL J MED, V310, P1561, DOI 10.1056/NEJM198406143102404; PELTOLA H, 1977, PEDIATRICS, V60, P730; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; SELL SH, 1983, PEDIATR INFECT DIS J, V2, P90, DOI 10.1097/00006454-198303000-00003; SHAPIRO ED, 1991, EPIDEMIOL REV, V13, P113, DOI 10.1093/oxfordjournals.epirev.a036066; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; WENGER JD, 1991, LANCET, V338, P395; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; 1985, MMWR, V34, P201; 1990, MMWR, V39, P232; 1989, MMWR, V38, P32; 1989, MMWR, V38, P14; 1991, MMWR, V40, P1; 1991, PEDIATRICS, V88, P169; 1992, 93 US DEP HLTH HUM S, P4; 1988, MMWR, V37, P13; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1985, NEW VACCINE DEV ESTA; 1990, MMWR, V39, P698	28	534	546	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					221	226		10.1001/jama.269.2.221	http://dx.doi.org/10.1001/jama.269.2.221			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417239				2022-12-28	WOS:A1993KF40500027
J	PERRING, TM; COOPER, AD; RODRIGUEZ, RJ; FARRAR, CA; BELLOWS, TS				PERRING, TM; COOPER, AD; RODRIGUEZ, RJ; FARRAR, CA; BELLOWS, TS			IDENTIFICATION OF A WHITEFLY SPECIES BY GENOMIC AND BEHAVIORAL-STUDIES	SCIENCE			English	Article							BEMISIA-TABACI	An introduced whitefly species, responsible for over a half billion dollars in damage to U.S. agricultural production in 1991, is morphologically indistinguishable from Bemisia tabaci (Gennadius). However, with the use of polymerase chain reaction-based DNA differentiation tests, allozymic frequency analyses, crossing experiments, and mating behavior studies, the introduced whitefly is found to be a distinct species. Recognition of this new species, the silverleaf whitefly, is critical in the search for management options.	UNIV CALIF RIVERSIDE,DEPT PLANT PATHOL,RIVERSIDE,CA 92521	University of California System; University of California Riverside	PERRING, TM (corresponding author), UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521, USA.							AYALA FJ, 1985, POPULATION EVOLUTION; BETHKE JA, 1991, ANN ENTOMOL SOC AM, V84, P401; BHARATHAN N, 1990, PLANT PATHOL, V39, P530, DOI 10.1111/j.1365-3059.1990.tb02530.x; BREADY E, 1991, TEX VEG ASS PESTIC R, V1, P1; BROWN JK, 1992, PLANT DIS, V76, P220, DOI 10.1094/PD-76-0220; Byrne Daragh, COMMUNICATION; BYRNE DN, 1991, ANNU REV ENTOMOL, V36, P431, DOI 10.1146/annurev.en.36.010191.002243; BYRNE DN, 1990, WHITEFLIES : THEIR BIONOMICS, PEST STATUS AND MANAGEMENT, P227; BYRNE DN, 1990, J INSECT PHYSIOL, V36, P433, DOI 10.1016/0022-1910(90)90061-J; Cock M.J.W., 1986, BEMISIA TABACI LIT S; COHEN S, 1992, PHYTOPATHOLOGY, V82, P86, DOI 10.1094/Phyto-82-86; COSTA HS, 1991, ENTOMOL EXP APPL, V61, P211, DOI 10.1007/BF00187724; CULOTTA E, 1991, SCIENCE, V254, P1445, DOI 10.1126/science.254.5037.1445; DIEHL SR, 1984, ANNU REV ENTOMOL, V29, P471, DOI 10.1146/annurev.en.29.010184.002351; EPPLEN J, 1989, J HERED, V79, P409; FAUST RM, 1992, C REPORT 5 YEAR NATI; Gennadius P., 1889, ELLENIKE GEORGIA, V5, P1; GILL RJ, 1992, PAN-PAC ENTOMOL, V68, P144; Greathead D. J., 1981, Biocontrol News and Information, V2, P7; GUPTA M, 1991, INT SOC PLANT BIOL; LI TY, 1989, ENVIRON ENTOMOL, V18, P800, DOI 10.1093/ee/18.5.800; Mound L. A., 1963, Proceedings of the Royal Entomological Society of London (A), V38, P171; Mound L.A., 1983, P305; Mound L.A., 1978, WHITEFLY WORLD; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Nei M., 1976, P723; OWEN J L, 1991, Animal Biotechnology, V2, P107, DOI 10.1080/10495399109525753; Perring T. M., 1991, California Agriculture, V45, P10; PERRING TM, 1992, J ECON ENTOMOL, V85, P1278, DOI 10.1093/jee/85.4.1278; POWELL DA, 1992, ENVIRON ENTOMOL, V21, P359, DOI 10.1093/ee/21.2.359; Price J.F., 1987, GREENHOUSE GROWER, V35, P55; QUAINTANCE AL, 1900, TECH SER BUR ENTOMOL, V8, P9; RODRIGUEZ RJ, 1991, EXP MYCOL, V15, P232, DOI 10.1016/0147-5975(91)90025-9; Russell L.M, 1975, Co-operative Economic Insect Report, V25, P229; Sambrook J, 1989, MOL CLONING LABORATO; SCHUSTER DI, COMMUNICATION; WEISING K, 1989, NUCLEIC ACIDS RES, V17, P10128, DOI 10.1093/nar/17.23.10128	37	382	475	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					74	77		10.1126/science.8418497	http://dx.doi.org/10.1126/science.8418497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418497				2022-12-28	WOS:A1993KE60100031
J	PETERSDORF, RG				PETERSDORF, RG			FINANCING MEDICAL-EDUCATION - A UNIVERSAL BERRY PLAN FOR MEDICAL-STUDENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											PETERSDORF, RG (corresponding author), ASSOC AMER MED COLL,WASHINGTON,DC 20037, USA.							BERRY B, 1976, B NY ACAD MED, V52, P278; CLINTON B, 1992, NEW ENGL J MED, V327, P804, DOI 10.1056/NEJM199209103271112; DESMARAIS HR, 1992, KEYS HLTH CARE REFOR; HUGHES RG, 1991, NEW ENGL J MED, V325, P404, DOI 10.1056/NEJM199108083250606; KASSEBAUM DG, 1992, ACAD MED, V67, P700, DOI 10.1097/00001888-199210000-00018; PETERSDORF RG, 1991, ACAD MED, V66, P61, DOI 10.1097/00001888-199102000-00001; PETERSDORF RG, 1989, ACAD MED, V64, P512; PETERSDORF RG, 1992, FEB P MAC C GRAD MED; SULLIVAN LW, 1992, NEW ENGL J MED, V327, P801, DOI 10.1056/NEJM199209103271111; 1992, 3RD REPORT IMPROVING	10	30	30	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1993	328	9					651	654		10.1056/NEJM199303043280911	http://dx.doi.org/10.1056/NEJM199303043280911			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KP680	8429859				2022-12-28	WOS:A1993KP68000011
J	DOLAN, MJ; WONG, MT; REGNERY, RL; JORGENSEN, JH; GARCIA, M; PETERS, J; DREHNER, D				DOLAN, MJ; WONG, MT; REGNERY, RL; JORGENSEN, JH; GARCIA, M; PETERS, J; DREHNER, D			SYNDROME OF ROCHALIMAEA-HENSELAE ADENITIS SUGGESTING CAT SCRATCH DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						CAT-SCRATCH DISEASE; LYMPHADENITIS; ROCHALIMAEA-HENSELAE; AFIPIA-FELIS	ACQUIRED IMMUNODEFICIENCY SYNDROME; BACILLARY ANGIOMATOSIS; PELIOSIS HEPATIS; TRENCH FEVER; AGENT; IDENTIFICATION; BACTEREMIA; INFECTION; ORGANISM; CULTURE	Objective: To describe a clinical syndrome of cat scratch disease caused by Rochalimaea henselae, including methods for isolation of the organism from tissue and for identification. Design: Case series. Setting: U.S. Air Force referral hospital infectious diseases clinic. Patients: Two previously healthy patients. Main Measurements and Results: Two immunocompetent patients who had handled cats developed unilateral upper-extremity adenitis associated with a distal papular lesion and fever. The adenitis and distal lesions persisted and progressively worsened. Cultures of the involved lymph nodes from both patients grew R. henselae, a recently described organism associated with bacillary angiomatosis and peliosis hepatis in human immunodeficiency virus-infected patients and with bacteremia in immunocompromised and immunocompetent hosts. The organism was characterized as oxidase negative and X-factor dependent and had a characteristic pattern in analysis of whole-cell fatty acids differing from Afipia felis, a bacterium that has been associated with cat scratch disease. The identity of the isolate was confirmed by analysis of whole-cell fatty acids using gas chromatography and by amplification of the citrate synthetase gene sequence and analysis of the polymerase chain reaction-amplified product. The organisms were broadly susceptible to a variety of antimicrobials by broth microdilution; however in-vitro resistance to first-generation cephalosporins correlated with clinical failure of therapy. Conclusion: Rochalimaea henselae can be a cause of cat scratch disease in immunocompetent patients.	CTR DIS CONTROL, ATLANTA, GA 30333 USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA	Centers for Disease Control & Prevention - USA; University of Texas System; University of Texas Health San Antonio	DOLAN, MJ (corresponding author), WILFORD HALL USAF MED CTR, DEPT INFECT DIS, LACKLAND AFB, TX 78236 USA.							BIRTLES RJ, 1991, NEW ENGL J MED, V325, P1447; BRENNER DJ, 1991, J CLIN MICROBIOL, V29, P2450, DOI 10.1128/JCM.29.11.2450-2460.1991; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; CARITHERS HA, 1991, AM J DIS CHILD, V145, P98, DOI 10.1001/archpedi.1991.02160010104026; DELAHOUSSAYE PM, 1990, J INFECT DIS, V161, P71, DOI 10.1093/infdis/161.1.71; ENGLISH CK, 1988, JAMA-J AM MED ASSOC, V259, P1347, DOI 10.1001/jama.259.9.1347; FISCHER GW, 1990, PRINCIPLES PRACTICE, P1874; Howe C, 1943, ARCH INTERN MED, V72, P147, DOI 10.1001/archinte.1943.00210080003001; JORGENSEN JH, 1987, J CLIN MICROBIOL, V25, P2105, DOI 10.1128/JCM.25.11.2105-2113.1987; KATZ M, 1989, PARASITIC DISEASES, P245; KOEHLER JE, 1988, ANN INTERN MED, V109, P449, DOI 10.7326/0003-4819-109-6-449; LOGAN JS, 1989, ULSTER MED J, V58, P83; LUCEY D, 1992, CLIN INFECT DIS, V14, P683, DOI 10.1093/clinids/14.3.683; MARGILETH AM, 1987, J INFECT DIS, V155, P390, DOI 10.1093/infdis/155.3.390; MARGILETH AW, 1984, JAMA-J AM MED ASSOC, V252, P928, DOI 10.1001/jama.252.7.928; MERRELL BR, 1978, J BACTERIOL, V135, P633, DOI 10.1128/JB.135.2.633-640.1978; MOSS CW, 1990, J CLIN MICROBIOL, V28, P1071, DOI 10.1128/JCM.28.5.1071-1074.1990; MYERS WF, 1984, ANTIMICROB AGENTS CH, V25, P690, DOI 10.1128/AAC.25.6.690; NAJI AF, 1962, AM J CLIN PATHOL, V38, P513; OSBORNE BM, 1987, AM J CLIN PATHOL, V87, P739, DOI 10.1093/ajcp/87.6.739; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; PSHENICHKOV AV, 1957, J MICROBIOL EPIDEMIO, V28, P1392; REGNERY R, 1992, LANCET, V340, P557, DOI 10.1016/0140-6736(92)91760-6; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; REGNERY RL, 1991, J BACTERIOL, V173, P1576, DOI 10.1128/jb.173.5.1576-1589.1991; RELMAN DA, 1991, NEW ENGL J MED, V324, P1514; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; RUDIKOFF D, 1989, ARCH DERMATOL, V125, P706, DOI 10.1001/archderm.125.5.706b; SCHLOSSBERG D, 1989, ARCH INTERN MED, V149, P1437, DOI 10.1001/archinte.149.6.1437; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; SLATER LN, 1992, ARCH INTERN MED, V152, P602, DOI 10.1001/archinte.152.3.602; Swift HF, 1920, ARCH INTERN MED, V26, P76, DOI 10.1001/archinte.1920.00100010079006; VARELA G, 1969, AM J TROP MED HYG, V18, P708, DOI 10.4269/ajtmh.1969.18.708; VINSON JW, 1961, PATHOL MICROBIOL, V24, P152, DOI 10.1159/000161254; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; 1990, M7A2 NAT COMM CLIN L	37	268	273	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					331	336		10.7326/0003-4819-118-5-199303010-00002	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8430978				2022-12-28	WOS:A1993KN68800002
J	LINSKENS, M; TYERS, M; FUTCHER, B				LINSKENS, M; TYERS, M; FUTCHER, B			CLN3 FUNCTIONS IN BOTH DAUGHTER AND MOTHER CELLS OF SACCHAROMYCES-CEREVISIAE	CELL			English	Article											LINSKENS, M (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		Tyers, Michael/ABE-3194-2021					CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x	3	5	5	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					487	488		10.1016/0092-8674(93)90067-Z	http://dx.doi.org/10.1016/0092-8674(93)90067-Z			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440016	Green Published			2022-12-28	WOS:A1993KP16500003
J	STEWART, CB				STEWART, CB			THE POWERS AND PITFALLS OF PARSIMONY	NATURE			English	Review							EVOLUTION; PHYLOGENY; MONKEY; TREES; TESTS; GENE; DNA	Parsimony analysis is a powerful tool for the study of biological evolution. It is used to construct phylogenetic trees, to evaluate alternative hypotheses objectively, and to study evolutionary pattern and process. Yet, as comparative data sets expand, the pitfalls of parsimony analysis are catching experts and novices alike.			STEWART, CB (corresponding author), SUNY ALBANY, DEPT BIOL SCI, ALBANY, NY 12222 USA.							ATCHLEY WR, 1991, SCIENCE, V254, P554, DOI 10.1126/science.1948030; Brooks DR, 1991, PHYLOGENY ECOLOGY BE; CAVALLISFORZA LL, 1967, EVOLUTION, V21, P550, DOI 10.1111/j.1558-5646.1967.tb03411.x; Colbert E., 1991, HIST BACKBONED ANIMA; CORNISHBOWDEN A, 1983, J THEOR BIOL, V101, P317, DOI 10.1016/0022-5193(83)90343-0; Darwin C., 1877, ORIGIN SPECIES; DAYHOFF MO, 1966, ATLAS PROTEIN SEQUEN, V2; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; DOYLE JJ, 1992, SYST BOT, V17, P144, DOI 10.2307/2419070; Eldredge N., 1980, PHYLOGENETIC PATTERN; FARRIS JS, 1970, SYST ZOOL, V19, P83, DOI 10.2307/2412028; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Fitch W.M., 1984, P221; FITCH WM, 1977, AM NAT, V111, P223, DOI 10.1086/283157; FITCH WM, 1991, PHYLOGENETIC ANALYSIS OF DNA SEQUENCES, P147; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Gillespie J.H., 1992, CAUSES MOL EVOLUTION; GOULD SJ, 1992, NAT HIST, V92, P14; GRAUR D, 1991, NATURE, V351, P649, DOI 10.1038/351649a0; Haas Otto, 1946, PROC AMER PHIL SOC, V90, P319; Harvey P.H., 1991, COMP METHOD EVOLUTIO; HENNIG W, 1999, PHYLOGENETIC SYSTEMA; HILLIS DM, 1992, SCIENCE, V255, P589, DOI 10.1126/science.1736360; HILLIS DM, 1991, PHYLOGENETIC ANALYSIS OF DNA SEQUENCES, P278; Hull D. L., 1988, SCI PROCESS; HULL DL, 1989, INT CONGR SER, V824, P3; IRWIN DM, 1992, MAMMALIAN PHYLOGENY, P257; LI WH, 1991, FUNDAMENTALS MOL EVO; LI WH, 1990, METHOD ENZYMOL, V183, P645; MADDISON DR, 1992, SYST BIOL, V41, P111, DOI 10.2307/2992510; Maddison W.P., 1992, ANAL PHYLOGENY CHARA; MADDISON WP, 1989, FOLIA PRIMATOL, V53, P190, DOI 10.1159/000156416; NEI M, 1991, PHYLOGENETIC ANALYSIS OF DNA SEQUENCES, P90; Nelson G., 1981, SYSTEMATICS BIOGEORA; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; PATTERSON C, 1989, INT CONGR SER, V824, P471; PATTERSON C, 1988, MOL BIOL EVOL, V5, P603; PEACOCK D, 1975, J MOL BIOL, V95, P513, DOI 10.1016/0022-2836(75)90314-9; PENNY D, 1991, PHYLOGENETIC ANALYSIS OF DNA SEQUENCES, P155; SANKOFF D, 1982, NUCLEIC ACIDS RES, V10, P421, DOI 10.1093/nar/10.1.421; SHAW JP, 1989, P NATL ACAD SCI USA, V86, P1312, DOI 10.1073/pnas.86.4.1312; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; SOBER E, 1988, RECONSTRUCTING PAST; STACKHOUSE J, 1990, FEBS LETT, V262, P104, DOI 10.1016/0014-5793(90)80164-E; STEWART CB, 1987, NATURE, V330, P401, DOI 10.1038/330401a0; STEWART CB, IN PRESS METH ENZYM; SWANSON KW, 1991, J MOL EVOL, V33, P418, DOI 10.1007/BF02103133; Swofford D., 1992, PAUP PHYLOGENETIC AN; Swofford D.L., 1993, P186; Swofford David L., 1990, P411; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WILEY EO, 1991, PHYLOGENETICS; WILEY EO, 1991, U KANSAS MUSEUM NATU, V19; WILSON AC, 1989, INT CONGR SER, V824, P407; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041	56	163	167	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 18	1993	361	6413					603	607		10.1038/361603a0	http://dx.doi.org/10.1038/361603a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8437621				2022-12-28	WOS:A1993KM77600053
J	NICOLELIS, MAL; LIN, RCS; WOODWARD, DJ; CHAPIN, JK				NICOLELIS, MAL; LIN, RCS; WOODWARD, DJ; CHAPIN, JK			INDUCTION OF IMMEDIATE SPATIOTEMPORAL CHANGES IN THALAMIC NETWORKS BY PERIPHERAL BLOCK OF ASCENDING CUTANEOUS INFORMATION	NATURE			English	Article							ADULT FLYING-FOX; SOMATOSENSORY CORTEX; DIGIT DENERVATION; RECEPTIVE-FIELDS; RAT; DEAFFERENTATION; MONKEYS; REORGANIZATION; PLASTICITY; RESPONSES	PERIPHERAL sensory deprivation induces reorganization within the somatosensory cortex of adult animals1-6. Although most studies have focused on the somatosensory cortex1-6, changes at subcortical levels (for example the thalamus) could also play a fundamental role in sensory plasticity7-11. To investigate this, we made chronic simultaneous recordings of large numbers of single neurons across the ventral posterior medial thalamus (VPM) in adult rats. This allowed a continuous and quantitative evaluation of the receptive fields of the same sample of single VPM neurons per animal, before and after sensory deprivation. Local anaesthesia in the face induced an immediate and reversible reorganization of a large portion of the VPM map. This differentially affected the short latency (4-6 ms) responses (SLRs) and long latency (15-25 ms) responses (LLRs) of single VPM neurons. The SLRs and LLRs normally define spatiotemporally complex receptive fields in the VPM12. Here we report that 73% of single neurons whose original receptive fields included the anaesthetized zone showed immediate unmasking of SLRs in response to stimulation of adjacent cutaneous regions, and/or loss of SLRs with preservation or enhancement of LLRs in response to stimulation of regions just surrounding the anaesthetized zone. This thalamic reorganization demonstrates that peripheral sensory deprivation may induce immediate plastic changes at multiple levels of the somatosensory system. Further, its spatiotemporally complex character suggests a disruption of the normal dynamic equilibrium between multiple ascending and descending influences on the VPM.	UNIV SAO PAULO,DEPT PATHOL,BR-01246 SAO PAULO,BRAZIL; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PHYSIOL & PHARMACOL,WINSTON SALEM,NC 27103	Universidade de Sao Paulo; Wake Forest University; Wake Forest Baptist Medical Center	NICOLELIS, MAL (corresponding author), HAHNEMANN UNIV,DEPT PHYSIOL & BIOPHYS,BROAD & VINE ST,PHILADELPHIA,PA 19102, USA.							CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CALFORD MB, 1991, J NEUROPHYSIOL, V65, P178, DOI 10.1152/jn.1991.65.2.178; CALFORD MB, 1991, SOMATOSENS MOT RES, V8, P249, DOI 10.3109/08990229109144748; CHMIELOWSKA J, 1989, J COMP NEUROL, V285, P325, DOI 10.1002/cne.902850304; GARRAGHTY PE, 1992, NEUROREPORT, V2, P747; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; MERZENICH MM, 1983, NEUROSCIENCE, V10, P639, DOI 10.1016/0306-4522(83)90208-7; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; Nakahama H, 1966, Prog Brain Res, V21, P180; NICOLELIS MAL, 1991, BRAIN RES, V561, P344, DOI 10.1016/0006-8993(91)91614-7; NICOLELIS MAL, IN PRESS P NATN ACAD; PESCHANSKI M, 1983, BRAIN RES, V278, P240, DOI 10.1016/0006-8993(83)90245-7; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAUSELL E, 1992, P NATL ACAD SCI USA, V89, P2571, DOI 10.1073/pnas.89.7.2571; RHOADES RW, 1987, J NEUROPHYSIOL, V57, P1577, DOI 10.1152/jn.1987.57.5.1577; WAITE PME, 1973, J PHYSIOL-LONDON, V228, P541, DOI 10.1113/jphysiol.1973.sp010099; WALL PD, 1971, NATURE, V232, P542, DOI 10.1038/232542a0	17	185	196	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					533	536		10.1038/361533a0	http://dx.doi.org/10.1038/361533a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429906				2022-12-28	WOS:A1993KL71400059
J	DIZHOOR, AM; CHEN, CK; OLSHEVSKAYA, E; SINELNIKOVA, VV; PHILLIPOV, P; HURLEY, JB				DIZHOOR, AM; CHEN, CK; OLSHEVSKAYA, E; SINELNIKOVA, VV; PHILLIPOV, P; HURLEY, JB			ROLE OF THE ACYLATED AMINO TERMINUS OF RECOVERIN IN CA2+-DEPENDENT MEMBRANE INTERACTION	SCIENCE			English	Article							ROD OUTER SEGMENTS; FREE CALCIUM-CONCENTRATION; BINDING PROTEIN; GUANYLATE-CYCLASE; PLASMA-MEMBRANE; MYRISTOYLATION; SUBUNITS; KINASE	Recoverin, a calcium ion (Ca2+)-binding protein of vertebrate photoreceptors, binds to photoreceptor membranes when the Ca2+ concentration is greater than 1 micromolar. This interaction requires a fatty acyl residue covalently linked to the recoverin amino (NH2)-terminus. Removal of the acyl residue, either by proteolytic cleavage of the NH2-terminus or by production of nonacylated recoverin, prevented recoverin from binding to membranes. The acylated recoverin NH2-terminus could be cleaved by trypsin only when Ca2+ was bound to recoverin. These results suggest that the hydrophobic NH2-terminus is constrained in Ca2+-free recoverin and liberated by Ca2+ binding. The hydrophobic acyl moiety of recoverin may interact with the membrane only when recoverin binds Ca2+.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA; MOSCOW MV LOMONOSOV STATE UNIV, INST PHYSICOCHEM BIOL, MOSCOW 119899, RUSSIA; UNIV WASHINGTON, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; Lomonosov Moscow State University; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle			Philippov, Pavel P/A-8939-2012	Dizhoor, Alexander/0000-0001-6770-9186	NATIONAL EYE INSTITUTE [R01EY006641] Funding Source: NIH RePORTER; NEI NIH HHS [EYO6641, R01 EY006641] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; DIZHOOR AM, UNPUB; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAUPP UB, 1992, ANN REV PHYS, V54, P15; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KAWAMURA S, 1992, BIOCHEM BIOPH RES CO, V186, P411, DOI 10.1016/S0006-291X(05)80823-X; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KORENBROT JI, 1989, VISION RES, V29, P939, DOI 10.1016/0042-6989(89)90108-9; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; POLANS AS, 1991, J CELL BIOL, V112, P981, DOI 10.1083/jcb.112.5.981; RATTO GM, 1988, J NEUROSCI, V8, P3240; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STRYER L, 1991, J BIOL CHEM, V266, P10711; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	29	177	181	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					829	832		10.1126/science.8430337	http://dx.doi.org/10.1126/science.8430337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430337				2022-12-28	WOS:A1993KL11000038
J	HEALY, B				HEALY, B			THE PACE OF HUMAN GENE-TRANSFER RESEARCH QUICKENS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					567	567						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421352				2022-12-28	WOS:A1993KJ44400005
J	FAN, ST; LAI, ECS; MOK, FPT; LO, CM; ZHENG, SS; WONG, J				FAN, ST; LAI, ECS; MOK, FPT; LO, CM; ZHENG, SS; WONG, J			EARLY TREATMENT OF ACUTE BILIARY PANCREATITIS BY ENDOSCOPIC PAPILLOTOMY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE GALLSTONE PANCREATITIS; SURGICAL TREATMENT; SURGERY; TRACT; SEVERITY; MANAGEMENT; PREDICTION; TRIAL	Background. Most patients with acute biliary pancreatitis have stones in the biliary tract or ampulla of Vater. Because these stones may be passed spontaneously soon after a patient is admitted to the hospital, the importance of early operative removal is not known. We tested the hypothesis that endoscopic papillotomy within 24 hours of admission decreased the incidence of complications in patients with acute biliary pancreatitis. Methods. We studied 195 patients with acute pancreatitis who were randomly assigned to one of two groups: 97 patients underwent within 24 hours after admission emergency endoscopic retrograde cholangiopancreatography (ERCP) followed by endoscopic papillotomy for ampullary and common-bile-duct stones, and 98 patients received initial conservative treatment and selective ERCP with or without endoscopic papillotomy only if their condition deteriorated. Results. One hundred twenty-seven patients ultimately proved to have biliary stones. Emergency ERCP with or without endoscopic papillotomy resulted in a reduction in biliary sepsis as compared with conservative treatment (0 of 97 patients vs. 12 of 98 patients, P = 0.001). The decrease in biliary sepsis occurred both in patients predicted to have mild pancreatitis (0 of 56 patients in the group that received emergency ERCP vs. 4 of 58 patients in the conservative-treatment group, P = 0.14) and in patients predicted to have severe pancreatitis (0 of 41 patients vs. 8 of 40 patients, P = 0.008). In all patients who had unrelenting biliary sepsis, persistent ampullary or common-bile-duct stones were identified. There were no major differences in the incidence of local complications (10 patients in the group that received emergency ERCP vs. 12 patients in the conservative-treatment group) or systemic complications (10 patients vs. 14 patients) of acute pancreatitis between the two groups, but the hospital mortality rate was slightly lower in the group undergoing emergency ERCP with or without endoscopic papillotomy (5 patients vs. 9 patients, P = 0.4). Conclusions. Emergency ERCP with or without endoscopic papillotomy is indicated in the treatment of patients with acute pancreatitis.			FAN, ST (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT SURG,HONG KONG,HONG KONG.		Fan, Sheung Tat/C-4138-2009					ACOSTA JM, 1974, NEW ENGL J MED, V290, P484, DOI 10.1056/NEJM197402282900904; ACOSTA JM, 1980, SURGERY, V88, P118; ACOSTA JM, 1978, SURGERY, V83, P367; ARMSTRONG CP, 1985, BRIT J SURG, V72, P551, DOI 10.1002/bjs.1800720718; DIXON JA, 1970, AM J SURG, V120, P371; FAN ST, 1988, BRIT J SURG, V75, P463, DOI 10.1002/bjs.1800750520; FAN ST, 1989, GUT, V30, P1591, DOI 10.1136/gut.30.11.1591; FAN ST, 1989, AM J SURG, V157, P544, DOI 10.1016/0002-9610(89)90695-8; FEINSTEIN AR, 1977, CLIN BIOSTATISTICS; IMRIE CW, 1975, BRIT J SURG, V62, P490, DOI 10.1002/bjs.1800620615; KELLY TR, 1988, SURGERY, V104, P600; KELLY TR, 1980, SURGERY, V88, P345; LAWSON DW, 1970, ANN SURG, V172, P605, DOI 10.1097/00000658-197010000-00007; MCMAHON MJ, 1980, BRIT J SURG, V67, P22, DOI 10.1002/bjs.1800670107; NEOPTOLEMOS JP, 1988, LANCET, V2, P979, DOI 10.1016/S0140-6736(88)90740-4; OSBORNE DH, 1981, BRIT J SURG, V68, P758, DOI 10.1002/bjs.1800681103; PALOYAN D, 1975, SURG GYNECOL OBSTET, V141, P737; POSTON GJ, 1990, BRIT J SURG, V77, P5, DOI 10.1002/bjs.1800770104; RANSON JHC, 1979, ANN SURG, V189, P654, DOI 10.1097/00000658-197905000-00016; SEMEL L, 1983, ARCH SURG-CHICAGO, V118, P901; STONE HH, 1981, ANN SURG, V194, P305, DOI 10.1097/00000658-198109000-00008; TRAPNELL JE, 1967, ANN SURG, V165, P49; WILLIAMSON RCN, 1984, GUT, V25, P1331, DOI 10.1136/gut.25.12.1331; WILSON C, 1988, GUT, V29, P782, DOI 10.1136/gut.29.6.782; ZIMMON D, 1990, AM J GASTROENTEROL, V85, P9; 1988, LANCET, V1, P915	26	569	603	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1993	328	4					228	232		10.1056/NEJM199301283280402	http://dx.doi.org/10.1056/NEJM199301283280402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ442	8418402	Green Submitted			2022-12-28	WOS:A1993KJ44200002
J	REYNOLDS, EH; HELLER, AJ; CHADWICK, D				REYNOLDS, EH; HELLER, AJ; CHADWICK, D			VALPROATE VERSUS CARBAMAZEPINE FOR SEIZURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							PHENYTOIN		WALTON HOSP,LIVERPOOL L9 1AE,MERSEYSIDE,ENGLAND	Walton Centre	REYNOLDS, EH (corresponding author), UNIV LONDON KINGS COLL HOSP,LONDON SE5 9RS,ENGLAND.							CALLAGHAN N, 1985, J NEUROL NEUROSUR PS, V48, P639, DOI 10.1136/jnnp.48.7.639; DESILVA M, 1989, EPILEPSIA, V30, P662; HELLER A J, 1989, Epilepsia, V30, P648; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; TURNBULL DM, 1985, BRIT MED J, V290, P815, DOI 10.1136/bmj.290.6471.815	5	11	11	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1993	328	3					207	208						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG625	8417389				2022-12-28	WOS:A1993KG62500010
J	HAIN, R; REIF, HJ; KRAUSE, E; LANGEBARTELS, R; KINDL, H; VORNAM, B; WIESE, W; SCHMELZER, E; SCHREIER, PH; STOCKER, RH; STENZEL, K				HAIN, R; REIF, HJ; KRAUSE, E; LANGEBARTELS, R; KINDL, H; VORNAM, B; WIESE, W; SCHMELZER, E; SCHREIER, PH; STOCKER, RH; STENZEL, K			DISEASE RESISTANCE RESULTS FROM FOREIGN PHYTOALEXIN EXPRESSION IN A NOVEL PLANT	NATURE			English	Article							STILBENE SYNTHASE; RESVERATROL; GENE; GRAPEVINES; BOTRYTIS; VITIS	ALTHOUGH phytoalexins1,2 have long been inferred to be important in the defence of plants against fungal infection1,2, there are few reports showing that they provide resistance to infection. Several plants, including grapevine, synthesize the stilbene-type phytoalexin resveratrol3-7 when attacked by pathogens. Stilbenes with fungicidal potential are formed in several unrelated plant species, such as peanut (Arachis hypogaea), grapevine (Vitis vinifera) and pine (Pinus sylvestris)3,5,11-15. Stilbene biosynthesis only specifically requires the presence of stilbene synthase 6,9. Furthermore, the precursor molecules for the formation of hydroxystilbenes are malonyl-CoA and p-coumaroyl-CoA, both present in plants9. To investigate the potential of stilbene biosynthetic genes in a strategy of engineering pathogen resistance, we isolated stilbene synthase genes from grapevine, where they are expressed at a high level, and transferred them into tobacco10. We report here that regenerated tobacco plants containing these genes are more resistant to infection by Botrytis cinerea. This is, to our knowledge, the first report of increased disease resistance in transgenic plants based on an additional foreign phytoalexin.	UNIV MARBURG,FACHBEREICH CHEM,W-3550 MARBURG,GERMANY; MAX PLANCK INST ZUCHTUNGSFORSCH,W-5000 COLOGNE 30,GERMANY	Philipps University Marburg; Max Planck Society	HAIN, R (corresponding author), BAYER AG,PF-E-FU,INST BIOTECHNOL,W-5090 LEVERKUSEN 1,GERMANY.							BEDBROOK J, 1981, PLANT MOL BIOL NEWSL, V2, P24; Cuypers B., 1988, Molecular Plant-Microbe Interactions, V1, P157, DOI 10.1094/MPMI-1-157; DERCKS W, 1989, PHYSIOL MOL PLANT P, V34, P189, DOI 10.1016/0885-5765(89)90043-X; EBEL J, 1986, ANNU REV PHYTOPATHOL, V24, P235; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; Gorham J., 1980, Progress in phytochemistry. Volume 6., P203; HAIN R, 1990, PLANT MOL BIOL, V15, P325, DOI 10.1007/BF00036918; HAIN R, 1985, MOL GEN GENET, V199, P161, DOI 10.1007/BF00330254; INGHAM J, 1972, BOT REV, V38, P3432; INGHAM JL, 1976, PHYTOCHEMISTRY, V15, P1791, DOI 10.1016/S0031-9422(00)97494-6; LANGCAKE P, 1976, PHYSIOL PLANT PATHOL, V9, P77, DOI 10.1016/0048-4059(76)90077-1; LANGCAKE P, 1977, PHYTOCHEMISTRY, V16, P1193, DOI 10.1016/S0031-9422(00)94358-9; LANGCAKE P, 1977, EXPERIENTIA, V33, P151, DOI 10.1007/BF02124034; LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x; MELCHIOR F, 1991, ARCH BIOCHEM BIOPHYS, V288, P552, DOI 10.1016/0003-9861(91)90234-A; PONT V, 1990, J PHYTOPATHOL, V130, P1, DOI 10.1111/j.1439-0434.1990.tb01147.x; SCHAFER W, 1989, SCIENCE, V246, P247, DOI 10.1126/science.246.4927.247; SCHMELZER E, 1989, PLANT CELL, V1, P993, DOI 10.1105/tpc.1.10.993; SCHOPPNER A, 1979, FEBS LETT, V108, P345; SCHRODER G, 1988, EUR J BIOCHEM, V172, P161, DOI 10.1111/j.1432-1033.1988.tb13868.x; STEIN U, 1985, VITIS, V24, P75; TEGTMEIER KJ, 1982, PHYTOPATHOLOGY, V72, P608, DOI 10.1094/Phyto-72-608	22	465	555	3	69	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					153	156		10.1038/361153a0	http://dx.doi.org/10.1038/361153a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421520				2022-12-28	WOS:A1993KG46600059
J	GOSTIN, LO				GOSTIN, LO			CONTROLLING THE RESURGENT TUBERCULOSIS EPIDEMIC - A 50-STATE SURVEY OF TB STATUTES AND PROPOSALS FOR REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; ISSUES; AIDS				GOSTIN, LO (corresponding author), AMER SOC LAW MED & ETH,OFF EXECUT DIRECTOR,765 COMMONWEALTH AVE,16TH FLOOR,BOSTON,MA 02215, USA.							BARNES M, 1992, COMMUNICATION   1116; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; Bayer R., 1991, PRIVATE ACTS SOCIAL; Bayer Ronald, 1992, TUBERCULOSIS REVIVAL; BRAKEL SJ, 1985, MENTALLY DISABLED LA; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; Burris Scott, 1985, Yale Law Policy Rev, V3, P479; COWLEY G, 1992, NEWSWEEK        0316, P53; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; EDGAR H, 1990, AM J LAW MED, V16, P155; GOLDSMITH MF, 1990, JAMA-J AM MED ASSOC, V264, P165, DOI 10.1001/jama.264.2.165; GOLDSMITH MF, 1992, JAMA-J AM MED ASSOC, V268, P174, DOI 10.1001/jama.268.2.174; Gostin L. O., 1987, AM J LAW MED, V12, P461; GOSTIN LO, 1992, HEALTH AFFAIR, V11, P248, DOI 10.1377/hlthaff.11.3.248; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PARMET WE, 1989, J HEALTH POLIT POLIC, V14, P741, DOI 10.1215/03616878-14-4-741; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SHERMAN R, 1992, NATL LAW J, V14, P32; SHERMAN R, 1992, NATL LAW J, V14, P1; SKOLNICK A, 1989, JAMA-J AM MED ASSOC, V262, P3249, DOI 10.1001/jama.262.23.3249; SMALL PM, 1991, AM REV RESPIR DIS, V144, P745; SNIDER DE, 1989, JAMA-J AM MED ASSOC, V261, P436, DOI 10.1001/jama.261.3.436; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; 1991, MMWR, V40, P649; 1992, TUBERCULOSIS CONTROL; 1992, NATIONAL ACTION PLAN; 1986, TREATMENT TUBERCULOS; 1992, NIOSH RECOMMENDED GU; 1992, MMWR SRR5, V41, P1; 1990, MMWR, V39, P718; 1991, MMWR, V40, P585; 1989, MMWR SS3, V38, P1; 1992, MMWR SRR10, V41, P1; 1991, MMWR, V40, P869; 1990, MMWR SRR18, V39, P1; 1991, TUBERCULOSIS STATIST; 1989, OHIO ST LAW J, V49, P1017; 1990, MMWR SRR10, V39, P7	39	63	63	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					255	261		10.1001/jama.269.2.255	http://dx.doi.org/10.1001/jama.269.2.255			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417246				2022-12-28	WOS:A1993KF40500034
J	DUPON, M; MALOU, M; ROGUES, AM; LACUT, JY				DUPON, M; MALOU, M; ROGUES, AM; LACUT, JY			ACUTE EOSINOPHILIC PNEUMONIA INDUCED BY INHALED PENTAMIDINE ISETHIONATE	BRITISH MEDICAL JOURNAL			English	Letter											DUPON, M (corresponding author), HOP PELLEGRIN,F-33076 BORDEAUX,FRANCE.							CONTE JE, 1988, ANTIMICROB AGENTS CH, V32, P1490, DOI 10.1128/AAC.32.10.1490; DAUTZENBERG B, 1991, PRESSE MED, V230, P1117; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HOLMBERG L, 1980, AM J MED, V69, P733, DOI 10.1016/0002-9343(80)90443-X; MILLER RF, 1989, LANCET, V1, P1271	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					109	109		10.1136/bmj.306.6870.109-a	http://dx.doi.org/10.1136/bmj.306.6870.109-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435603	Bronze, Green Published			2022-12-28	WOS:A1993KG46500022
J	KAY, AB				KAY, AB			ALTERNATIVE ALLERGY AND THE GENERAL MEDICAL COUNCIL	BRITISH MEDICAL JOURNAL			English	Article								In July 1992 Dr Keith Mumby, a clinical ecologist, appeared before the professional conduct committee of the General Medical Council on five charges to do with his practice of clinical ecology. He was found guilty of two of the charges-touting for publicity and failing to give a patient adequate medical attention-and admonished. The GMC failed, however, to address the issue of the nature of Mumby's treatments-Clinical ecology itself. This is based on the idea that some patients are unusually susceptible to their environment, the diagnosis and treatment are based on an unstandardised provocation-neutralisation test. A variety of medical bodies have failed to find scientific foundation for the technique. The GMC's policy on advertising services to patients is inconsistent, and in this case it has shown a regrettable reluctance to deal with the issue of treatments that are not scientifically validated.			KAY, AB (corresponding author), NAT HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6LY,ENGLAND.							JEWETT DL, 1990, NEW ENGL J MED, V323, P429, DOI 10.1056/NEJM199008163230701; MILLER JB, 1972, FOOD ALLERGY PROVOCA, P7; RAWLINS MD, 1988, REGULATORY CONTROL S, P147; WATSON J, 1991, MIRACLE ALLERGY CURE; WOOD B, 1992, KEEP TAKING TABLOIDS; 1992, ALLERGY CONVENTIONAL; 1986, J ALLERGY CLIN IMMUN, V78, P269; 1989, ANN INTERN MED, V111, P168; 1986, W J MED, V144, P239; 1986, BMJ, V293, P948; 1983, FED REGISTER, V48, P37716	11	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					122	124		10.1136/bmj.306.6870.122	http://dx.doi.org/10.1136/bmj.306.6870.122			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435610	Green Published, Bronze			2022-12-28	WOS:A1993KG46500028
J	WILLIAMS, MH; BOWIE, C				WILLIAMS, MH; BOWIE, C			RETRACTED: EVIDENCE OF UNMET NEED IN THE CARE OF SEVERELY PHYSICALLY DISABLED ADULTS (RETRACTED ARTICLE. SEE VOL 316, PG 1700, 1998)	BMJ-BRITISH MEDICAL JOURNAL			English	Article; Retracted Publication								Objective-To identify unmet needs in the care of severely disabled people aged Design-Detailed personal interview and physical assessment of physically disabled adults; personal or telephone interview with carers. Setting-Somerset Health District. Subjects-181 severely disabled adults and their carers. Main outcome measures-Independence in activities of daily living; identity of requirements for assessing communication disorders; appropriate provision of services and allowances. Results-53 (29.3%) of the 181 disabled subjects had unmet needs for aids to allow independence in activities of daily living-namely, 43% of subjects (41/95) with progressive disorders and 14% of subjects (12/86) with non-progressive disorders. The prevalence of unmet need was higher among subjects whose sole regular professional contact was with health services personnel (48 (40.3%) of 119 subjects). Only 18 (31.6%) of the 57 subjects with communication disorders had ever been assessed by a speech therapist. Conclusions-This study shows that the needs of severely physically disabled adults in the community -especially those with progressive disorders-are being monitored inadequately by health professionals.	SOMERSET HLTH AUTHOR, TAUNTON TA2 7PQ, ENGLAND		WILLIAMS, MH (corresponding author), UNIV BRISTOL, HLTH CARE EVALUAT UNIT, BRISTOL BS8 2PR, ENGLAND.							BEARDSHAW V, 1988, 3 RES REP; BLAXTER M, 1979, CMND7615; BRADSHAW J, 1972, PROBLMS PROGR MED CA; BRECHIN A, 1981, LOOK IT THIS WAY NEW; Buchan H, 1990, Health Serv J, V100, P240; CAMPBELL MJ, 1984, J NEUROL SCI, V64, P65, DOI 10.1016/0022-510X(84)90056-X; CANTRELL E, 1985, PRISONERS HANDICAP; CULYER AJ, 1976, NEED NATIONAL HLTH S; EDWARDS FC, 1990, HLTH SERVICES ADULTS; MARTIN J, 1988, OPCS SURVEYS DISABIL; Patrick D L, 1982, J R Coll Gen Pract, V32, P429; Robinson T, 1978, WORLDS APART; THOMAS A, 1985, DEV MED CHILD NEUR S, V4, P50; Williams A, 1978, EC ASPECTS HLTH SERV; 1989, CARING PEOPLE; 1990, NHS COMMUNITY CARE A	16	22	22	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 9	1993	306	6870					95	98		10.1136/bmj.306.6870.95	http://dx.doi.org/10.1136/bmj.306.6870.95			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435649	Green Published, Bronze			2022-12-28	WOS:A1993KG46500017
J	TANG, AM; AMAGAI, M; GRANGER, LG; STANLEY, JR; UDEY, MC				TANG, AM; AMAGAI, M; GRANGER, LG; STANLEY, JR; UDEY, MC			ADHESION OF EPIDERMAL LANGERHANS CELLS TO KERATINOCYTES MEDIATED BY E-CADHERIN	NATURE			English	Article							DENDRITIC CELLS; BONE-MARROW; MOLECULES; FAMILY; EXPRESSION; DIFFERENTIATION; GLYCOPROTEIN; DESMOCOLLINS; DESMOGLEIN; MEMBER	LANGERHANS cells (LC) are the principal accessory cells present in epidermis1. Because LC have limited capacity for self-renewal2, epidermis is continually repopulated by as-yet uncharacterized bone marrow-derived LC progenitors3,4. In addition, although LC persist in epidermis for extended periods, LC are induced to migrate from skin to regional lymph nodes after antigen exposure5. To begin to elucidate mechanisms involved in LC trafficking, we characterized LC-keratinocyte (KC) interactions. Here we report that fresh murine LC express cadherins, and that LC adhere to KC in vitro through E-cadherin. Cultured LC (which may bear a phenotypic and functional relationship to LC that have migrated to lymph nodes6,7) express lower levels of E-cadherin and exhibit decreased affinity for KC. These results suggest that expression of E-cadherin by LC promotes persistence of these cells in epidermis, and that cadherins may play important and unanticipated roles in interactions between leukocytes and epithelia.	NCI,DERMATOL BRANCH,BETHESDA,MD 20892; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Amagai, Masayuki/K-5325-2013	Amagai, Masayuki/0000-0003-3314-7052				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; BREATHNACH SM, 1991, EPIDERMAL LANGERHANS, P23; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; DONALIES M, 1991, P NATL ACAD SCI USA, V88, P8024, DOI 10.1073/pnas.88.18.8024; FRELINGER JG, 1979, NATURE, V282, P321, DOI 10.1038/282321a0; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; HAUSER C, 1989, EUR J IMMUNOL, V19, P245, DOI 10.1002/eji.1830190205; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; KATZ SI, 1979, NATURE, V282, P324, DOI 10.1038/282324a0; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; RASANEN L, 1986, J INVEST DERMATOL, V86, P9, DOI 10.1111/1523-1747.ep12283693; RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533, DOI 10.1093/nar/19.23.6533; ROMANI N, 1989, J INVEST DERMATOL, V93, P600, DOI 10.1111/1523-1747.ep12319727; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; STINGL G, 1978, J IMMUNOL, V121, P2005; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1990, REV BIOCH, V59, P237; TANG AM, 1991, J IMMUNOL, V146, P3347; TANG AM, 1992, EUR J IMMUNOL, V22, P581, DOI 10.1002/eji.1830220242; WITSELL AL, 1990, BIOTECHNIQUES, V9, P318; YOSHIDANORO C, 1984, DEV BIOL, V101, P19, DOI 10.1016/0012-1606(84)90112-X; YUSPA SH, 1985, METHODS SKIN RES, P213	29	405	411	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					82	85		10.1038/361082a0	http://dx.doi.org/10.1038/361082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421498				2022-12-28	WOS:A1993KF71800054
J	ROBINSON, R				ROBINSON, R			COUNTDOWN TO COMMUNITY CARE .3. MOVING AHEAD - COMMUNITY CARE IN GWENT	BRITISH MEDICAL JOURNAL			English	Article																		BROWNING D, 1992, BRIT MED J, V305, P1415, DOI 10.1136/bmj.305.6866.1415; GROVES T, 1992, BRIT MED J, V305, P1489, DOI 10.1136/bmj.305.6867.1489; PATHY MSJ, 1992, LANCET, V340, P890, DOI 10.1016/0140-6736(92)93294-W; 1992, ALL WALSH MENTAL HAN; 1992, CARING PEOPLE GWENT; [No title captured]; 1991, PATHFINDER STRATEGIE; 1989, MENTAL ILLNESS SERVI	8	4	4	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1993	306	6869					44	47		10.1136/bmj.306.6869.44	http://dx.doi.org/10.1136/bmj.306.6869.44			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435580	Green Published, Bronze			2022-12-28	WOS:A1993KE98400030
J	BANDTLOW, CE; SCHMIDT, MF; HASSINGER, TD; SCHWAB, ME; KATER, SB				BANDTLOW, CE; SCHMIDT, MF; HASSINGER, TD; SCHWAB, ME; KATER, SB			ROLE OF INTRACELLULAR CALCIUM IN NI-35-EVOKED COLLAPSE OF NEURONAL GROWTH CONES	SCIENCE			English	Article							CENTRAL NERVOUS-SYSTEM; CELL-ADHESION MOLECULES; NEURITE GROWTH; NEUROTROPHIC FACTORS; INOSITOL PHOSPHATES; NEURAL DEVELOPMENT; MYELIN; HOMEOSTASIS; ACTIVATION; RECEPTORS	A myelin-associated protein from the central nervous system, the neurite growth inhibitor NI-35, inhibits regeneration of lesioned neuronal fiber tracts in vivo and growth of neurites in vitro. Growth cones of cultured rat dorsal root ganglion neurons arrested their growth and collapsed when exposed to liposomes containing NI-35. Before morphological changes, the concentration of free intracellular calcium ([Ca2+]i) showed a rapid and large increase.in growth cones exposed to liposomes containing NI-35. Neither an increase in [Ca2+]i nor collapse of growth cones was detected in the presence of antibodies to NI-35. Dantrolene, an inhibitor of calcium release from caffeine-sensitive intracellular calcium stores, protected growth cones from collapse evoked by NI-35. Depletion of these caffeine-sensitive intracellular calcium stores prevented the increase in [Ca2+]i evoked by NI-35. The NI-35-evoked cascade of intracellular messengers that mediates collapse of growth cones includes the crucial step of calcium release from intracellular stores.	COLORADO STATE UNIV,DEPT ANAT & NEUROBIOL,PROGRAM NEURONAL GROWTH & DEV,FT COLLINS,CO 80523	Colorado State University	BANDTLOW, CE (corresponding author), UNIV ZURICH,BRAIN RES INST,CH-8029 ZURICH,SWITZERLAND.		Schwab, Martin E/B-6818-2016; Schmidt, Marc/B-1597-2008		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS028323, R01NS024683] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28323, NS24683] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTONICEK H, 1988, J NEUROSCI, V8, P2961; BANDTLOW CE, 1990, J NEUROSCI, V10, P3937; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRIDGMAN PC, 1989, J CELL BIOL, V108, P95, DOI 10.1083/jcb.108.1.95; BRUNNER J, 1978, J BIOL CHEM, V235, P7538; CADELLI D, 1991, EUR J NEUROSCI, V3, P825, DOI 10.1111/j.1460-9568.1991.tb00093.x; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; COHAN CS, 1987, J NEUROSCI, V7, P3588; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; COX EC, 1990, NEURON, V2, P31; DAVIES JA, 1990, NEURON, V2, P11; DESMEDT JE, 1977, J PHYSIOL-LONDON, V265, P565, DOI 10.1113/jphysiol.1977.sp011731; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; FICHARD A, 1991, DEV BIOL, V148, P1, DOI 10.1016/0012-1606(91)90312-Q; GOLDBERG DJ, 1988, J NEUROSCI, V8, P2596; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGIWARA S, 1981, ANNU REV NEUROSCI, V4, P69, DOI 10.1146/annurev.ne.04.030181.000441; HAYDON PG, 1984, SCIENCE, V226, P561, DOI 10.1126/science.6093252; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JOHNSON P, 1990, INT J BIOCHEM, V22, P811, DOI 10.1016/0020-711X(90)90284-A; KATER SB, 1991, J NEUROSCI, V11, P891; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; KUBA K, 1980, J PHYSIOL-LONDON, V298, P251, DOI 10.1113/jphysiol.1980.sp013079; LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229; LANKFORD KL, 1988, P NATL ACAD SCI USA, V85, P2839, DOI 10.1073/pnas.85.8.2839; LIBSCOMBE D, 1988, NEURON, V1, P355; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; LUECKHOFF A, 1992, NATURE, V355, P356; MCBURNEY RN, 1987, TRENDS NEUROSCI, V10, P164, DOI 10.1016/0166-2236(87)90042-7; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MELDOLESI J, 1991, TRENDS PHARMACOL SCI, V12, P289, DOI 10.1016/0165-6147(91)90577-F; MILLER RJ, 1988, TRENDS NEUROSCI, V11, P415, DOI 10.1016/0166-2236(88)90191-9; MILLS LR, 1990, NEURON, V4, P149, DOI 10.1016/0896-6273(90)90451-K; NEERING JR, 1984, NATURE, V309, P158; PALADE P, 1989, MOL PHARMACOL, V36, P673; PFEIFFER DR, 1978, ANN NY ACAD SCI, V307, P403; POLOTORAK M, 1987, J CELL BIOL, V105, P1893; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; QUARLES RH, 1984, DEV NEUROSCI-BASEL, V6, P285; RAPER JA, 1990, NEURON, V2, P21; REHDER V, UNPUB; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SCHLIWA M, 1981, P NATL ACAD SCI-BIOL, V78, P1037, DOI 10.1073/pnas.78.2.1037; SCHMIDT M F, 1991, Society for Neuroscience Abstracts, V17, P927; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; SNOW DM, 1991, DEVELOPMENT, V113, P1437; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAYLOR CW, 1990, TRENDS PHARMACOL SCI, V11, P271; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; YAMAMOTO H, 1983, J NEUROCHEM, V41, P1119, DOI 10.1111/j.1471-4159.1983.tb09060.x; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4	61	244	251	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					80	83		10.1126/science.8418499	http://dx.doi.org/10.1126/science.8418499			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418499				2022-12-28	WOS:A1993KE60100033
J	STEVENS, CM				STEVENS, CM			HEALTH-CARE COST CONTAINMENT - SOME IMPLICATIONS OF GLOBAL BUDGETS	SCIENCE			English	Article							CHOICE				STEVENS, CM (corresponding author), REED COLL,PORTLAND,OR 97202, USA.							AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P105, DOI 10.1001/jama.265.1.105; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; Holoweiko M, 1992, Med Econ, V69, P64; HOLOWEIKO M, 1992, MED ECON, V69, P75; JENKS S, 1991, HLTH CARE FINAN REV, P1; LEVINSKY NG, 1984, NEW ENGL J MED, V311, P1537; REINHARDT U, 1990, SOCIAL POLICY STUDIE, V7, P107; SALTMAN RB, 1992, JAMA-J AM MED ASSOC, V268, P774, DOI 10.1001/jama.268.6.774; SOMERVILLE J, 1989, AM MED NEWS     0407, P37; SOMERVILLE J, 1992, AM MED NEWS     0511, P39; SONNEFELD S, 1991, HLTH CARE FINAN REV, V13, P7; VALLSPINOSA A, 1991, AM J PUBLIC HEALTH, V81, P1569; WEINER JM, 1992, BROOKINGS REV, V10, P26; 1991, NY TIMES        0430, pA8	16	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					16	&		10.1126/science.8418489	http://dx.doi.org/10.1126/science.8418489			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418489				2022-12-28	WOS:A1993KE60100009
J	BLANKSON, ML; CLIVER, SP; GOLDENBERG, RL; HICKEY, CA; JIN, J; DUBARD, MB				BLANKSON, ML; CLIVER, SP; GOLDENBERG, RL; HICKEY, CA; JIN, J; DUBARD, MB			HEALTH BEHAVIOR AND OUTCOMES IN SEQUENTIAL PREGNANCIES OF BLACK-AND-WHITE ADOLESCENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; INFANT-MORTALITY; TEENAGE MOTHERS; UNITED-STATES; PRENATAL-CARE; CHILDREN; GROWTH; AGE	Objective.-To examine the relationships among parity, preterm delivery, fetal growth retardation, and prenatal care utilization in first and second adolescent pregnancies. Design.-A longitudinal, retrospective study in which obstetric, behavioral, and sociodemographic data were used to examine birth outcomes of 737 low-income black (80%) and white (20%) teenagers delivering first and second singleton infants at 20 or more weeks' gestation. Setting.-Public health clinics in Jefferson County, Alabama, between January 1983 and February 1990. Main Outcome Measures.-Mean birth weight, preterm delivery, fetal growth retardation, Apgar scores, and perinatal mortality. Main Results.-In their second pregnancies, adolescents presented 2.8 weeks later for care ((P=.0001) and made fewer total clinic visits. Mean infant birth weight increased by 91 g (P=.0005). This increase was significantly associated with an increase in maternal prepregnancy body mass index. The rate of fetal growth retardation decreased (P=.0001) and the rate of preterm delivery increased (P<.02) in the second pregnancy. The rate of recurrence of fetal growth retardation was 13% and the rate of preterm delivery was 46%. Conclusions.-Poorer utilization of prenatal care and high risk for recurrence of adverse outcomes are characteristic of adolescents' second pregnancies and should be considered in teenage pregnancy intervention programs.	UNIV ALABAMA,DEPT OBSTET & GYNECOL,PERINATAL EPIDEMIOL UNIT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	BLANKSON, ML (corresponding author), UNIV ALABAMA,SCH PUBL HLTH,MATERNAL & CHILD HLTH PROGRAM,BIRMINGHAM,AL 35294, USA.				AHRQ HHS [HHS-282-92-0055] Funding Source: Medline; PHS HHS [MCJ 9040] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; BROOKSGUNN J, 1986, DEV REV, V6, P224, DOI 10.1016/0273-2297(86)90013-4; ELSTER AB, 1984, AM J OBSTET GYNECOL, V149, P845, DOI 10.1016/0002-9378(84)90602-1; ELSTER AB, 1983, PEDIATRICS, V71, P494; FORD K, 1983, FAM PLANN PERSPECT, V15, P268, DOI 10.2307/2135292; GOLDENBERG RL, 1992, WOMEN HEALTH, V19, P133, DOI 10.1300/J013v19n02_08; Graham D, 1981, Birth Defects Orig Artic Ser, V17, P49; HOFFMAN LW, 1987, SOC BEHAV, V2, P123; JEKEL JF, 1975, AM J PUBLIC HEALTH, V65, P370, DOI 10.2105/AJPH.65.4.370; KALISZER M, 1981, SOC SCI MED-MED GEOG, V15, P421, DOI 10.1016/0160-8002(81)90061-7; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; LAWRENCE RA, 1983, PREMATURE ADOLESCENT; LEPPERT PC, 1986, J ADOLESCENT HEALTH, V7, P112, DOI 10.1016/S0197-0070(86)80006-7; MCANARNEY ER, 1985, PEDIATRICS, V75, P973; MCCORMICK MC, 1984, AM J PUBLIC HEALTH, V74, P18, DOI 10.2105/AJPH.74.1.18; PARK CB, 1986, AM J PUBLIC HEALTH, V76, P995, DOI 10.2105/AJPH.76.8.995; POLIT DF, 1986, AM J PUBLIC HEALTH, V76, P167, DOI 10.2105/AJPH.76.2.167; STEVENSSIMON C, 1990, J ADOLESCENT HEALTH, V11, P114, DOI 10.1016/0197-0070(90)90019-X; Stickle G, 1981, Birth Defects Orig Artic Ser, V17, P5; SWEENEY PJ, 1989, AM J OBSTET GYNECOL, V160, P1361, DOI 10.1016/0002-9378(89)90856-9; WEN SW, 1990, AM J OBSTET GYNECOL, V162, P213; 1988, SAS USERS GUIDE VERS	22	55	57	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1401	1403		10.1001/jama.269.11.1401	http://dx.doi.org/10.1001/jama.269.11.1401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ857	8441215				2022-12-28	WOS:A1993KQ85700034
J	RANSOHOFF, DF; LANG, CA				RANSOHOFF, DF; LANG, CA			SIGMOIDOSCOPIC SCREENING IN THE 1990S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLORECTAL-CANCER; SURVEILLANCE; COLONOSCOPY; POLYPS		COLORADO PERMANENTE MED GRP,DENVER,CO; UNIV COLORADO,DEPT MED,DENVER,CO 80202	Permanente Medical Groups; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	RANSOHOFF, DF (corresponding author), UNIV N CAROLINA,SCH MED,DEPT MED,CB 7105,CHAPEL HILL,NC 27599, USA.							ACHKAR E, 1988, ANN INTERN MED, V109, P880, DOI 10.7326/0003-4819-109-11-880; AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; BOLAND CR, 1989, GASTROINTESTINAL DIS, P1483; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; LEVIN B, 1992, CA-CANCER J CLIN, V42, P296, DOI 10.3322/canjclin.42.5.296; LIEBERMAN DA, 1991, AM J GASTROENTEROL, V86, P946; LILLARD LA, 1986, RAND JR3266HCFA PUBL; LIMBERG B, 1992, NEW ENGL J MED, V327, P65, DOI 10.1056/NEJM199207093270201; LUK GD, 1990, CURRENT THERAPY GAST, P387; MACCARTY RL, 1992, MAYO CLIN PROC, V67, P253, DOI 10.1016/S0025-6196(12)60102-5; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; OW CL, 1989, J GEN INTERN MED, V4, P209, DOI 10.1007/BF02599525; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; RANSOHOFF DF, IN PRESS DIGESTIVE D; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; SCHAPIRO M, 1984, DIGEST DIS SCI, V29, P159, DOI 10.1007/BF01317058; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P595; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1993, ANN INTERN MED, V118, P1294; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SPIRO HM, 1988, MT SINAI J MED, V55, P251; STJOHN DGB, IN PRESS ANN INTERN; WEISS NS, 1983, AM J EPIDEMIOL, V118, P457; 1989, SUMMARY CURRENT GUID; 1990, SCREENING COLORECTAL; 1987, WORKING GUIDELINES E; 1989, BLUE SHEET      1018, P3	31	78	78	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1278	1281		10.1001/jama.269.10.1278	http://dx.doi.org/10.1001/jama.269.10.1278			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437306				2022-12-28	WOS:A1993KP88500027
J	REID, IR; AMES, RW; EVANS, MC; GAMBLE, GD; SHARPE, SJ				REID, IR; AMES, RW; EVANS, MC; GAMBLE, GD; SHARPE, SJ			EFFECT OF CALCIUM SUPPLEMENTATION ON BONE LOSS IN POSTMENOPAUSAL WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MIDDLE-AGED WOMEN; PHYSICAL-ACTIVITY; DIETARY CALCIUM; HIP FRACTURE; OSTEOPOROSIS; POPULATION; ESTROGEN; BALANCE; DENSITY; TRIAL	Background. The use of calcium supplements slows bone loss in the forearm and has a beneficial effect on the axial bone density of women in late menopause whose calcium intake is less than 400 mg per day. However, the effect of a calcium supplement of 1000 mg per day on the axial bone density of postmenopausal women with higher calcium intakes is not known. Methods. We studied 122 normal women at least three years after they had reached menopause who had a mean dietary calcium intake of 750 mg per day. The women were randomly assigned to treatment with either calcium (1000 mg per day) or placebo for two years. The bone mineral density of the total body, lumbar spine, and proximal femur was measured every six months by dual-energy x-ray absorptiometry. Serum and urine indexes of calcium metabolism were measured at base line and after 3, 12, and 24 months. Results. The mean (+/-SE) rate of loss of total-body bone mineral density was reduced by 43 percent in the calcium group (-0.0055+/-0.0010 g per square centimeter per year) as compared with the placebo group (-0.0097+/-0.0010 g per square centimeter per year, P = 0.005). The rate of loss of bone mineral density was reduced by 35 percent in the legs (P = 0.02), and loss was eliminated in the trunk (P = 0.04). Calcium use was of significant benefit in the lumbar spine (P = 0.04), and in Ward's triangle the rate of loss was reduced by 67 percent (P = 0.04). Calcium supplementation had a similar effect whether dietary calcium intake was above or below the mean value for the group. Serum parathyroid hormone concentrations tended to be lower in the calcium group, as were urinary hydroxyproline excretion and serum alkaline phosphatase concentrations. Conclusions. Calcium supplementation significantly slowed axial and appendicular bone loss in normal post-menopausal women.			REID, IR (corresponding author), UNIV AUCKLAND,DEPT MED,AUCKLAND,NEW ZEALAND.			Gamble, Greg/0000-0003-0412-3203				BARAN D, 1990, J CLIN ENDOCR METAB, V70, P264, DOI 10.1210/jcem-70-1-264; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; ELDERS PJM, 1991, J CLIN ENDOCR METAB, V73, P533, DOI 10.1210/jcem-73-3-533; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; HEANEY RP, 1978, J LAB CLIN MED, V92, P953; HEANEY RP, 1977, AM J CLIN NUTR, V30, P1603, DOI 10.1093/ajcn/30.10.1603; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; HORSMAN A, 1977, BRIT MED J, V2, P789, DOI 10.1136/bmj.2.6090.789; KANIS JA, 1989, BRIT MED J, V298, P137, DOI 10.1136/bmj.298.6667.137; KANIS JA, 1989, BRIT MED J, V298, P205, DOI 10.1136/bmj.298.6668.205; LAU E, 1988, BRIT MED J, V297, P1441, DOI 10.1136/bmj.297.6661.1441; MATKOVIC V, 1979, AM J CLIN NUTR, V32, P540, DOI 10.1093/ajcn/32.3.540; NORDIN BEC, 1990, BMJ-BRIT MED J, V300, P1056, DOI 10.1136/bmj.300.6731.1056; NORDIN BEC, 1980, BRIT MED J, V1, P451; ORWOLL ES, 1990, ANN INTERN MED, V112, P29, DOI 10.7326/0003-4819-112-1-29; ORWOLL ES, 1990, J CLIN ENDOCR METAB, V70, P1202, DOI 10.1210/jcem-70-4-1202; PARFITT AM, 1980, MINER ELECTROL METAB, V4, P273; PRINCE RL, 1991, NEW ENGL J MED, V325, P1189, DOI 10.1056/NEJM199110243251701; RECKER RR, 1977, ANN INTERN MED, V87, P649, DOI 10.7326/0003-4819-87-6-649; REID IR, 1986, AUST NZ J MED, V16, P193, DOI 10.1111/j.1445-5994.1986.tb01147.x; REID IR, 1992, J CLIN ENDOCR METAB, V75, P45, DOI 10.1210/jc.75.1.45; RIIS B, 1987, NEW ENGL J MED, V316, P173, DOI 10.1056/NEJM198701223160401; SMITH EL, 1989, AM J CLIN NUTR, V50, P833, DOI 10.1093/ajcn/50.4.833; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; WILSON PWF, 1986, AM HEART J, V111, P1177, DOI 10.1016/0002-8703(86)90022-0; 1985, SAS USERS GUIDE STAT	26	417	426	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1993	328	7					460	464		10.1056/NEJM199302183280702	http://dx.doi.org/10.1056/NEJM199302183280702			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM417	8421475				2022-12-28	WOS:A1993KM41700002
J	BELONGIA, EA; OSTERHOLM, MT; SOLER, JT; AMMEND, DA; BRAUN, JE; MACDONALD, KL				BELONGIA, EA; OSTERHOLM, MT; SOLER, JT; AMMEND, DA; BRAUN, JE; MACDONALD, KL			TRANSMISSION OF ESCHERICHIA-COLI O157-H7 INFECTION IN MINNESOTA CHILD DAY-CARE FACILITIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOLYTIC-UREMIC SYNDROME; HEMORRHAGIC COLITIS; WASHINGTON-STATE; O157-H7; OUTBREAK; EPIDEMIOLOGY; DIARRHEA; SHIGELLOSIS; SEROTYPE	Objective.-Escherichia coli O157:H7 infection can cause hemorrhagic colitis and hemolytic uremic syndrome. Since 1988 the Minnesota Department of Health has carried out surveillance for this infection. To assess the occurrence of person-to-person transmission within day-care facilities, we investigated facilities where an infected child attended after onset of symptoms. Design.-Parents of children less than 5 years old with E coli O157:H7 infection were interviewed from July 1988 through December 1989. If the child attended day care after onset, stool cultures were obtained from other children in attendance and their parents were interviewed. If there was presumptive evidence of ongoing E coli O157:H7 transmission in a facility, all preschool children were excluded from attending day-care facilities until two consecutive stool cultures were negative. Results.-Sixty-eight cases of E coli O157:H7 infection were identified in Minnesota during the 18-month period, including 29 cases identified through investigations at nine day-care facilities. There was evidence of person-to-person transmission in all nine facilities. The median number of infected children per facility was two (range, two to 18), and the median attack rate was 22% (range, 3% to 38%). The median age of the primary case at each facility was 26 months (range, 12 to 59 months). There was no evidence of further transmission at facilities where children were temporarily excluded until two consecutive stool cultures were negative. Conclusion.-Person-to-person transmission of E coli O157:H7 is common when infected preschool children attend day care while symptomatic. The number of unrecognized day-care outbreaks in the United States may be substantial due to the lack of routine testing for this pathogen in stool cultures, the absence of public health surveillance in many regions, and incomplete follow-up of infected children. Temporary exclusion of all children was an effective control strategy in this population, but additional investigations are needed to determine the optimal intervention.	HENNEPIN CTY COMMUNITY HLTH DEPT, MINNEAPOLIS, MN USA; CTR DIS CONTROL & PREVENT, EPIDEMIOL PROGRAM OFF, DIV FIELD EPIDEMIOL, ACUTE DIS EPIDEMIOL SECT, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA	BELONGIA, EA (corresponding author), MINNESOTA DEPT HLTH, ACUTE DIS EPIDEMIOL SECT, 717 SE DELAWARE ST, BOX 9441, MINNEAPOLIS, MN 55440 USA.			Belongia, Edward/0000-0001-7478-0415				BELONGIA EA, 1991, J INFECT DIS, V164, P338, DOI 10.1093/infdis/164.2.338; CLEARY TG, 1988, PEDIATR CLIN N AM, V35, P485; Ewing WH, 1986, IDENTIFICATION ENTER; GOODMAN RA, 1984, PEDIATRICS, V74, P134; HASKINS R, 1989, B NEW YORK ACAD MED, V65, P319; HOFFMAN RE, 1990, AM J DIS CHILD, V144, P219, DOI 10.1001/archpedi.1990.02150260099038; KARMALI MA, 1988, LANCET, V1, P526; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; LERMAN Y, 1992, J CLIN MICROBIOL, V30, P520, DOI 10.1128/JCM.30.2.520-521.1992; LOPEZ EL, 1991, PEDIATR INFECT DIS J, V10, P20, DOI 10.1097/00006454-199101000-00005; MACDONALD KL, 1988, JAMA-J AM MED ASSOC, V259, P3567, DOI 10.1001/jama.259.24.3567; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; MARTIN DL, 1990, NEW ENGL J MED, V323, P1161, DOI 10.1056/NEJM199010253231703; MARTIN ML, 1986, LANCET, V2, P1043; Ostroff S M, 1991, MMWR CDC Surveill Summ, V40, P1; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; OSTROFF SM, 1989, JAMA-J AM MED ASSOC, V262, P355, DOI 10.1001/jama.262.3.355; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; PICKERING LK, 1986, REV INFECT DIS, V8, P539; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; ROGERS MF, 1986, AM J EPIDEMIOL, V123, P137, DOI 10.1093/oxfordjournals.aje.a114207; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; TARR PI, 1987, PEDIATRICS, V80, P41; TAUXE RV, 1986, AM J PUBLIC HEALTH, V76, P627, DOI 10.2105/AJPH.76.6.627; WELLS JG, 1983, J CLIN MICROBIOL, V18, P512, DOI 10.1128/JCM.18.3.512-520.1983; 1987, CDWR, V13, P5	28	189	194	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					883	888		10.1001/jama.269.7.883	http://dx.doi.org/10.1001/jama.269.7.883			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL474	8426447				2022-12-28	WOS:A1993KL47400026
J	HAFNEREATON, C				HAFNEREATON, C			PHYSICIAN UTILIZATION DISPARITIES BETWEEN THE UNINSURED AND INSURED - COMPARISONS OF THE CHRONICALLY ILL, ACUTELY ILL, AND WELL NONELDERLY POPULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; UNITED-STATES; MEDICAL-CARE; INSURANCE; REFORM; TERMINATION; ACCESS	Background.-This study examines the associations between lack of health insurance coverage and physician utilization for the chronically ill, acutely ill, and well nonelderly populations in the United States. Methods.-Cross-sectional data from the 1989 National Health Interview Survey, conducted by the National Center for Health Statistics, were analyzed for the nonelderly population using a correlational, two-group design (N=102 055). Analytic models, using multiple logistic regression, were tested to predict the odds and likelihood of physician utilization for the uninsured and insured in the three subpopulations (ie, chronically ill, acutely ill, and well), controlling for health status, number of conditions, and geographic, sociodemographic, and economic factors. Disparities in utilization were then calculated between the uninsured and insured for each subpopulation. Results.-The nonelderly uninsured were consistently less likely than the insured to have received any health care within 12 months. Moreover, there were differential effects of being uninsured on utilization depending on whether an individual was chronically ill, acutely ill, or well. Whereas chronically ill and well uninsured persons were half as likely to have seen a physician as their insured counterparts (odds ratio, 0.50), acutely ill uninsured persons were almost two thirds as likely to receive physician care (odds ratio, 0.62). Thus, the disparity in physician utilization between the uninsured and insured was larger for the chronically ill and well than for the acutely ill; uninsured acutely ill were less likely to go without care. Of the three populations, those in the well population had average disparities with the largest magnitude (40%), compared with disparities of the chronically ill (20%) and acutely ill (10%). Conclusions.-These disparities represent large inequities in utilization of care by the uninsured, particularly for the chronically ill and well. Whether these disparities result from lower access or individual choice cannot be determined from this study. When viewed in light of other studies examining the impact of utilization on health status, these results provide support for the development of comprehensive health insurance packages with universal coverage and better inclusion of chronic and preventive care models in benefit packages.	UNIV CALIF LOS ANGELES, CTR HLTH POLICY STUDY, RAND, LOS ANGELES, CA USA	RAND Corporation; University of California System; University of California Los Angeles	HAFNEREATON, C (corresponding author), OREGON STATE UNIV, DEPT PUBL HLTH, 318 WALDO HALL, CORVALLIS, OR 97331 USA.							ADAY LA, 1988, INTRO HLTH SERVICES, P54; Aday LA, 1980, HLTH CARE US EQUITAB; AFIFI AA, 1984, COMPUTER AIDED MULTI, P218; BLUMENTHAL D, 1991, MED CARE, V29, P502, DOI 10.1097/00005650-199106000-00010; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; Brook RH, 1984, RAND HLTH INSURANCE, P1; Brown E R, 1983, J Public Health Policy, V4, P335, DOI 10.2307/3342113; Brown ER, 1992, JAMA-J AM MED ASSOC, V267, P552; BROWN ER, 1990, MED CARE REV, V46, P4; CLEARY PD, 1984, MED CARE, V22, P796, DOI 10.1097/00005650-198409000-00003; CORNELIUS L, 1991, 11 DEP HLTH HUM SERV, P4; COTTON P, 1991, JAMA-J AM MED ASSOC, V265, P2451; DAVIS K, 1983, MILBANK FUND Q, V61, P149, DOI 10.2307/3349903; ENTHOVEN AC, 1991, JAMA-J AM MED ASSOC, V265, P2532, DOI 10.1001/jama.265.19.2532; EVASHWICK CJ, 1988, INTRO HLTH SERVICES, P212; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P6, DOI 10.1377/hlthaff.6.1.6; FRIEDMAN E, 1991, JAMA-J AM MED ASSOC, V265, P2491, DOI 10.1001/jama.265.19.2491; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P274; HOLAHAN J, 1991, JAMA-J AM MED ASSOC, V265, P2537, DOI 10.1001/jama.265.19.2537; HOLLEMAN MC, 1991, MED CARE, V29, P654, DOI 10.1097/00005650-199107000-00005; HOSMER DW, 1989, WILEY SERIES PROBABI, P1; HUBBELL FA, 1989, AM J MED, V87, P127; Kahn HA, 1989, STATISTICAL METHODS, P137; KOVAR MG, 1984, P SECTION SURVEY RES, P2; LEPKOWSKI JM, 1987, MED CARE, V25, P705, DOI 10.1097/00005650-198708000-00004; LEWIS C E, 1988, American Journal of Preventive Medicine, V4, P9; LILLARD LA, 1986, RAND HLTH INSURANCE; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; OHSFELDT RL, 1985, MED CARE, V23, P1338, DOI 10.1097/00005650-198512000-00003; PLATEK R, 1983, INCOMPLETE DATA SAMP, V2, P249; POPE GC, 1988, HEALTH SERV RES, V22, P859; ROSENSTOCK IM, 1966, MILBANK FUND Q, V44, P94, DOI 10.2307/3348967; ROSS CE, 1982, J HEALTH SOC BEHAV, V23, P119, DOI 10.2307/2136509; ROYBAL ER, 1991, JAMA-J AM MED ASSOC, V265, P2545, DOI 10.1001/jama.265.19.2545; RUSSELL LB, 1986, IS PREVENTION BETTER, P1; SCHLESINGER M, 1986, MILBANK Q, V64, P189, DOI 10.2307/3349970; SHAH BV, 1989, SOFTWARE SURVEY DATA; THORNBERRY OT, 1988, WILEY S PRO, P25; VALDEZ RB, 1991, DOES HLTH SYSTEM SER; WEISBER S, 1985, APPLIED LINEAR REGRE, P248; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; 1991, UNIVERSAL HLTH INSUR, P1; 1988, HLTH INSURANCE UNINS, P1; 1991, NATIONAL HLTH INTERV; 1990, SAS STAT USERS GUIDE, P1; VITAL STATISTICS	47	128	128	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					787	792		10.1001/jama.269.6.787	http://dx.doi.org/10.1001/jama.269.6.787			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423663				2022-12-28	WOS:A1993KK54400034
J	CREDITOR, MC				CREDITOR, MC			HAZARDS OF HOSPITALIZATION OF THE ELDERLY	ANNALS OF INTERNAL MEDICINE			English	Article						HOSPITALIZATION; GERIATRIC ASSESSMENT; BED REST; ACTIVITIES OF DAILY LIVING; SOCIAL ENVIRONMENT	PROSPECTIVE PAYMENT SYSTEM; NURSING-HOME CARE; HIP FRACTURE; BED REST; UNIT	For many older persons, hospitalization results in functional decline despite cure or repair of the condition for which they were admitted. Hospitalization can result in complications unrelated to the problem that caused admission or to its specific treatment for reasons that are explainable and avoidable. Usual aging is often associated with functional change, such as a decline in muscle strength and aerobic capacity; vasomotor instability; reduced bone density; diminished pulmonary ventilation; altered sensory continence, appetite, and thirst; and a tendency toward urinary incontinence. Hospitalization and bed rest superimpose factors such as enforced immobilization, reduction of plasma volume, accelerated bone loss, increased closing volume, and sensory deprivation. Any of these factors may thrust vulnerable older persons into a state of irreversible functional decline. The factors that contribute to a cascade to dependency are identifiable and can be avoided by modification of the usual acute hospital environment by deemphasizing bed rest, removing the hazard of the high hospital bed with rails, and actively facilitating ambulation and socialization. The relationships among physicians, nurses, and other health professionals must reflect the importance of interdisciplinary care and the implementation of shared objectives.			CREDITOR, MC (corresponding author), UNIV KANSAS, MED CTR, 3901 RAINBOW BLVD, KANSAS CITY, KS 66160 USA.				NIA NIH HHS [5K07 AG-00413-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K07AG000413] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOOTH FW, 1987, CLIN ORTHOP RELAT R, P15; Boyer N, 1986, Nurs Manage, V17, P22; DOWNS FS, 1974, AM J NURS, V74, P434, DOI 10.2307/3469621; DRUZ WS, 1981, J APPL PHYSIOL, V51, P1552, DOI 10.1152/jappl.1981.51.6.1552; FITZGERALD JF, 1988, NEW ENGL J MED, V319, P1392, DOI 10.1056/NEJM198811243192106; FURSTENBERG AL, 1988, AM J APPLIED GERONTO, V7, P193; GREENLEAF JE, 1983, AVIAT SPACE ENVIR MD, V54, P696; HARPER CM, 1988, J AM GERIATR SOC, V36, P1047, DOI 10.1111/j.1532-5415.1988.tb04375.x; HIRSCH CH, 1990, J AM GERIATR SOC, V38, P1296, DOI 10.1111/j.1532-5415.1990.tb03451.x; HOENIG HM, 1991, J AM GERIATR SOC, V39, P220, DOI 10.1111/j.1532-5415.1991.tb01632.x; Huber M, 1991, J Gerontol Nurs, V17, P20; JETTE AM, 1987, ARCH PHYS MED REHAB, V68, P735; KELLIE SE, 1990, AM J PUBLIC HEALTH, V80, P326, DOI 10.2105/AJPH.80.3.326; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KROLNER B, 1983, CLIN SCI, V64, P537, DOI 10.1042/cs0640537; LAKATTA EG, 1990, HDB BIOL AGING, P195; LAMONT CT, 1983, J AM GERIATR SOC, V31, P282, DOI 10.1111/j.1532-5415.1983.tb04872.x; LEBLANC P, 1970, J APPL PHYSIOL, V28, P448, DOI 10.1152/jappl.1970.28.4.448; MEISSNER P, 1989, GERONTOLOGIST, V29, P524, DOI 10.1093/geront/29.4.524; Mobily P R, 1991, J Gerontol Nurs, V17, P5; MULLER E A, 1970, Archives of Physical Medicine and Rehabilitation, V51, P449; PALMER RM, 1989, ARCH INTERN MED, V149, P2237, DOI 10.1001/archinte.149.10.2237; PALMER RM, 1991, J AM GERIATR SOC, V39, pA62; RESNICK NM, 1985, NEW ENGL J MED, V313, P800, DOI 10.1056/NEJM198509263131307; SAUNDERS RH, 1983, J AM GERIATR SOC, V31, P685, DOI 10.1111/j.1532-5415.1983.tb04155.x; SLOANE PD, 1985, J AM GERIATR SOC, V33, P864, DOI 10.1111/j.1532-5415.1985.tb05442.x; VOGT FB, 1967, AEROSPACE MED, V38, P21; WARD RJ, 1966, GERIATRICS, V21, P139; ZUBEK JP, 1963, SCIENCE, V140, P306, DOI 10.1126/science.140.3564.306	29	919	930	0	46	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					219	223		10.7326/0003-4819-118-3-199302010-00011	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8417639				2022-12-28	WOS:A1993KJ43900011
J	LIPPMAN, ME				LIPPMAN, ME			THE DEVELOPMENT OF BIOLOGICAL THERAPIES FOR BREAST-CANCER	SCIENCE			English	Editorial Material											LIPPMAN, ME (corresponding author), GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007, USA.								0	62	67	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					631	632		10.1126/science.8430312	http://dx.doi.org/10.1126/science.8430312			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430312				2022-12-28	WOS:A1993KJ68800030
J	JIA, ZC; VANDONSELAAR, M; QUAIL, JW; DELBAERE, LTJ				JIA, ZC; VANDONSELAAR, M; QUAIL, JW; DELBAERE, LTJ			ACTIVE-CENTER TORSION-ANGLE STRAIN REVEALED IN 1.6 ANGSTROM-RESOLUTION STRUCTURE OF HISTIDINE-CONTAINING PHOSPHOCARRIER PROTEIN	NATURE			English	Article							ESCHERICHIA-COLI; MACROMOLECULAR CRYSTALLOGRAPHY; PHOSPHOTRANSFERASE SYSTEM; TERTIARY STRUCTURE; HPR; H-1-NMR; PHOSPHOENOLPYRUVATE; ASSIGNMENTS; RESONANCE; SECONDARY	THE histidine-containing phosphocarrier protein (HPr) is a central component of the phosphoenolpyruvate: sugar phosphotransferase system that transports carbohydrates across the cell membrane of bacteria1. A typical phosphotransfer sequence is phosphoenolpyruvate --> enzyme I --> HPr --> enzyme II/III(sugar) -->. This is thermodynamically favourable owing to the participation of the high-energy phosphoenolpyruvate. We report here the structure of HPr from Streptococcus faecalis determined at 1.6 angstrom resolution. Remarkable disallowed Ramachandran torsion angles at the active centre, revealed by the X-ray structure, demonstrate a unique example of torsion-angle strain that is probably directly involved in protein function. During phosphorylation, the active-centre torsion-angle strain should facilitate the phosphotransfer reaction by lowering the activation-energy barrier. A recently reported Bacillus subtilis HPr structure2, which represents the phosphorylated state of HPr with no torsion-angle strain, provides direct evidence supporting our hypothesis that torsion-angle strain plays a direct part in the function of HPr. An HPr phosphotransfer cycling mechanism is proposed, based primarily on the structures of HPr and other phosphotransferase system proteins.	UNIV SASKATCHEWAN,DEPT BIOCHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA	University of Saskatchewan	JIA, ZC (corresponding author), UNIV SASKATCHEWAN,DEPT CHEM,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA.							AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DICKERSO.RE, 1968, ACTA CRYSTALL B-STRU, VB 24, P997, DOI 10.1107/S0567740868003626; ELKABBANI OAL, 1987, J BIOL CHEM, V262, P12926; EVANS SV, IN PRESS J MOL GRAPH; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; HAMMEN PK, 1991, BIOCHEMISTRY-US, V30, P11842, DOI 10.1021/bi00115a014; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KALBITZER HR, 1991, BIOCHEMISTRY-US, V30, P11186, DOI 10.1021/bi00110a024; KALBITZER HR, 1982, BIOCHEMISTRY-US, V21, P2879, DOI 10.1021/bi00541a012; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; LIAO D, 1991, BIOCHEMISTRY-US, V90, P9583; MEADOW ND, 1990, REV BIOCH, V59, P495; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; SHARMA S, 1991, P NATL ACAD SCI USA, V88, P4877, DOI 10.1073/pnas.88.11.4877; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANNULAND NAJ, 1992, EUR J BIOCHEM, V203, P483; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WITTEKIND M, 1990, BIOCHEMISTRY-US, V29, P7191, DOI 10.1021/bi00483a006; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382	25	62	64	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					94	97		10.1038/361094a0	http://dx.doi.org/10.1038/361094a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421502				2022-12-28	WOS:A1993KF71800058
J	PFLUGL, G; KALLEN, J; SCHIRMER, T; JANSONIUS, JN; ZURINI, MGM; WALKINSHAW, MD				PFLUGL, G; KALLEN, J; SCHIRMER, T; JANSONIUS, JN; ZURINI, MGM; WALKINSHAW, MD			X-RAY STRUCTURE OF A DECAMERIC CYCLOPHILIN CYCLOSPORINE CRYSTAL COMPLEX	NATURE			English	Article							BINDING; PROTEIN; ISOMERASE	HUMAN cyclophilin A (CypA), a ubiquitous intracellular protein of 165 amino acids, is the major receptor for the cyclic undecapeptide immunosuppressant drug cyclosporin A (CsA)1,2, which pre vents allograft rejection after transplant surgery3,4 and is efficacious in the field of autoimmune diseases5. CsA prevents T-cell proliferation by blocking the calcium-activated pathway leading to interleukin-2 transcription. Besides their ability to bind CsA, the cyclophilin isoforms6-8 also have peptidyl-prolyl isomerase activity9-11 and enhance the rate of protein folding12,13. The macrolide FK506 acts similarly to CsA and its cognate receptor FKBP also has peptidyl-prolyl isomerase activity14. Inhibition of this enzymatic activity alone is not sufficient to achieve immunosuppression15,16. A direct molecular interaction between the drug-immunophilin complex (CsA-CypA, or FK506-FKBP) and the phosphatase calcineurin, is responsible for modulating the T-cell receptor signal transduction pathway17,18. Here we describe the crystal structure of a decameric CypA-CsA complex. The crystallographic asymmetric unit is composed of a pentamer of 1 : 1 cyclophilin-cyclosporin complexes of rather exact non-crystallographic fivefold symmetry. The 2.8 angstrom electron density map is of high quality. The five independent cyclosporin molecules are clearly identifiable, providing an unambiguous picture of the detailed interactions between a peptide drug and its receptor. It broadly confirms the results of previous NMR, X-ray and modelling studies, but provides further important structural details which will be of use in the design of drugs that are analogues of CsA.	SANDOZ PHARMA AG,PRECLIN RES,CH-4002 BASEL,SWITZERLAND; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND	Novartis; Sandoz; University of Basel			walkinshaw, malcolm/AAB-7497-2019	walkinshaw, malcolm/0000-0001-5955-9325				BOREL JF, 1989, PHARMACOL REV, V41, P259; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CALNE RY, 1978, LANCET, V2, P1323; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FESIK SW, 1992, J AM CHEM SOC, V114, P3165, DOI 10.1021/ja00034a087; FEUTREN G, 1992, TRANSPLANT P, V24, P55; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRANSSON C, 1992, FEBS LETT, V296, P90, DOI 10.1016/0014-5793(92)80410-I; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GALLION S, 1992, PROTEIN ENG, V5, P391, DOI 10.1093/protein/5.5.391; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HARRISON RK, 1992, J AM CHEM SOC, V114, P3464, DOI 10.1021/ja00035a046; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LINDQVIST Y, 1989, J MOL BIOL, V209, P151, DOI 10.1016/0022-2836(89)90178-2; MYLES DAA, 1990, J MOL BIOL, V216, P491, DOI 10.1016/0022-2836(90)90373-T; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; ROSEN MK, 1992, ANGEW CHEM, V104, P413; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WOOD SP, 1988, J MOL BIOL, V202, P169, DOI 10.1016/0022-2836(88)90529-3; ZURINI M, 1990, FEBS LETT, V276, P63, DOI 10.1016/0014-5793(90)80507-F	33	195	202	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					91	94		10.1038/361091a0	http://dx.doi.org/10.1038/361091a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421501				2022-12-28	WOS:A1993KF71800057
J	HULLEY, SB; NEWMAN, TB; GRADY, D; GARBER, AM; BARON, RB; BROWNER, WS				HULLEY, SB; NEWMAN, TB; GRADY, D; GARBER, AM; BARON, RB; BROWNER, WS			SHOULD WE BE MEASURING BLOOD CHOLESTEROL LEVELS IN YOUNG-ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SECONDARY PREVENTION; COST-EFFECTIVENESS; MYOCARDIAL-INFARCTION; LOWERING CHOLESTEROL; LIFE EXPECTANCY; MORTALITY; TRIALS; RISK; REDUCTION	Should we measure blood cholesterol levels in all adults, or only in those at high risk of coronary heart disease (CHD)? Most men under the age of 35 years and women under the age of 45 years-roughly half the adult population-are at very low short-term risk of CHD. One consequence is that drug treatment to lower high blood cholesterol levels in the average young adult is an extremely expensive means of prolonging life; the estimated $1 million to $10 million per year of life is 100 to 1000 times the cost of other approaches. Individualized dietary treatment is somewhat cheaper but relatively ineffective. Another consequence of the low CHD risk in young adults is the greater likelihood that intervention may have harmful effects that outweigh the benefits. Meta-analyses of primary prevention trials in middle-aged men reveal an increase in non-CHD deaths among those randomized to cholesterol interventions, an unexpected finding that is more substantial than the decrease in CHD deaths. This raises the possibility that one or more of the cholesterol interventions could have very serious adverse effects among young adults, whose risk of non-CHD death is normally 100 times their risk of CHD death. We conclude that the policy of screening and treating high blood cholesterol levels in young adults is neither cost-effective,nor does it satisfy ethical standards requiring strong evidence that preventive interventions do more good than harm. Fortunately, cholesterol screening in young adults is also not necessary: most CHD events associated with high blood cholesterol levels in this population will not occur for decades and can be prevented by treatment that is begun in middle age. Cholesterol screening and treatment in young adults should be limited to individuals with known coronary disease or other unusual factors that place them at high short-term risk of CHD death.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PEDIAT,DIV GEN PEDIAT,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,DEPT MED,GEN INTERNAL MED SECT,SAN FRANCISCO,CA; DEPT VET AFFAIRS MED CTR,PALO ALTO,CA; STANFORD UNIV,DEPT MED,DIV GEN INTERNAL MED,STANFORD,CA 94305	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University	HULLEY, SB (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,BOX 0886,SAN FRANCISCO,CA 94143, USA.		Garber, Alan M/F-1476-2010		NHLBI NIH HHS [HL-46297] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRETT AS, 1989, NEW ENGL J MED, V321, P676, DOI 10.1056/NEJM198909073211009; BROWN MA, 1989, ENERG BUILDINGS, V13, P51, DOI 10.1016/0378-7788(89)90017-0; CRIQUI MH, 1991, ANN INTERN MED, V115, P973, DOI 10.7326/0003-4819-115-12-973; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; DUFFY MA, 1993, PHYSICIANS DESK REFE; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GOLDMAN L, 1992, CIRCULATION, V85, P1930; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; HULLEY SB, 1980, NEW ENGL J MED, V302, P1383, DOI 10.1056/NEJM198006193022503; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JACOBS DR, IN PRESS ANN REV PUB; KAPLAN JR, 1991, PSYCHOSOM MED, V53, P634, DOI 10.1097/00006842-199111000-00005; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; KRAHN M, 1991, ANN INTERN MED, V115, P248, DOI 10.7326/0003-4819-115-4-248; KRISTIANSEN IS, 1991, BRIT MED J, V302, P1119, DOI 10.1136/bmj.302.6785.1119; MASON RP, 1991, J MOL CELL CARDIOL, V23, P1339, DOI 10.1016/0022-2828(91)90091-Y; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; NEWMAN TB, 1992, JAMA-J AM MED ASSOC, V267, P100, DOI 10.1001/jama.267.1.100; NEWMAN TB, 1990, JAMA-J AM MED ASSOC, V264, P3039, DOI 10.1001/jama.264.23.3039; NEWMAN TB, 1993, NEW ENGL J MED, V328, P139; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P393, DOI 10.1136/bmj.304.6824.393; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; ROSSOUW JE, 1991, NEW ENGL J MED, V325, P1813; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, P163; SIEGEL D, 1988, ANN INTERN MED, V109, P213, DOI 10.7326/0003-4819-109-3-213; SILBERBERG JS, 1991, MED J AUSTRALIA, V155, P665, DOI 10.5694/j.1326-5377.1991.tb93956.x; SMITH GD, 1992, BRIT MED J, V304, P913, DOI 10.1136/bmj.304.6831.913-a; TAYLOR WC, 1987, ANN INTERN MED, V106, P605, DOI 10.7326/0003-4819-106-4-605; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; Weinstein M C, 1981, Med Decis Making, V1, P309, DOI 10.1177/0272989X8100100403; YUSUF S, 1987, ATHEROSCLEROSIS, P389; 1990, J CLIN EPIDEMIOL, V43, P1029; 1970, JAMA-J AM MED ASSOC, V214, P1303; 1988, ARCH INTERN MED, V148, P36; 1984, JAMA-J AM MED ASSOC, V251, P365; 1990, STATISTICAL ABSTRACT; 1972, JAMA-J AM MED ASSOC, V220, P996; 1991, VITAL STATISTICS US, V2	45	74	74	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1416	1419		10.1001/jama.269.11.1416	http://dx.doi.org/10.1001/jama.269.11.1416			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ857	8441219				2022-12-28	WOS:A1993KQ85700038
J	WARE, JA; HEISTAD, DD				WARE, JA; HEISTAD, DD			PLATELET-ENDOTHELIUM INTERACTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROTEIN-KINASE-C; ATHEROSCLEROTIC CORONARY-ARTERIES; DEPENDENT VASCULAR RELAXATION; CHOLESTEROL-FED RABBITS; VONWILLEBRAND-FACTOR; ESSENTIAL-HYPERTENSION; SMOOTH-MUSCLE; NITRIC-OXIDE; BLOOD-FLOW; CELLS		HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,THORNDIKE LABS,BOSTON,MA 02215; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHARMACOL,IOWA CITY,IA 52242	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Iowa; University of Iowa	WARE, JA (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV CARDIOVASC,RW-453,330 BROOKLINE AVE,BOSTON,MA 02215, USA.			Heistad, Donald/0000-0001-8843-4628	NHLBI NIH HHS [HL38820, HL16066] Funding Source: Medline; NIDA NIH HHS [DA06363] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038820, R37HL016066, R01HL038820, R01HL016066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R18DA006363] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; ADELMAN B, 1985, BLOOD, V65, P32; ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BOWEN R, 1991, J CARDIOVASC PHARM, V17, P424, DOI 10.1097/00005344-199103000-00011; BREZINSKI DA, 1992, CIRCULATION, V86, P56, DOI 10.1161/01.CIR.86.1.56; CHANG JD, 1992, CLIN RES, V40, pA225; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; CUNNINGHAM LD, 1992, J CLIN INVEST, V89, P878, DOI 10.1172/JCI115667; CURWEN KD, 1980, LAB INVEST, V42, P366; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; DITTMAN WA, 1990, BLOOD, V75, P329; DORN GW, 1990, CIRCULATION, V81, P212, DOI 10.1161/01.CIR.81.1.212; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; DURANTE W, 1992, BLOOD, V79, P110; ERNE P, 1984, NEW ENGL J MED, V310, P1084, DOI 10.1056/NEJM198404263101705; FIORE S, 1990, J EXP MED, V172, P1451, DOI 10.1084/jem.172.5.1451; FITZGERALD GA, 1984, NEW ENGL J MED, V310, P1065, DOI 10.1056/NEJM198404263101701; FOLTS JD, 1982, CIRCULATION, V65, P248, DOI 10.1161/01.CIR.65.2.248; FREIMAN PC, 1986, CIRC RES, V58, P783, DOI 10.1161/01.RES.58.6.783; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GIRERD XJ, 1990, CIRC RES, V67, P1301, DOI 10.1161/01.RES.67.6.1301; GOLINO P, 1991, NEW ENGL J MED, V324, P641, DOI 10.1056/NEJM199103073241001; HAMBURGER SA, 1990, BLOOD, V75, P550; HAMILTON KK, 1987, J CLIN INVEST, V79, P600, DOI 10.1172/JCI112853; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; HASHEMI S, 1990, BIOCHIM BIOPHYS ACTA, V1052, P63, DOI 10.1016/0167-4889(90)90058-L; HEISTAD DD, 1984, CIRC RES, V54, P711, DOI 10.1161/01.RES.54.6.711; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HOUSTON DS, 1986, J CLIN INVEST, V78, P539, DOI 10.1172/JCI112606; JOHNSTONE MT, 1990, CIRCULATION, V82, P2142, DOI 10.1161/01.CIR.82.6.2142; KAUL S, 1992, STROKE, V23, P153; KENT KC, 1992, CIRCULATION, V86, P289; KENT KC, IN PRESS CIRC RES; KOYAMA H, 1989, LANCET, V1, P991; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; LOSCALZO J, 1987, J CLIN INVEST, V79, P1749, DOI 10.1172/JCI113015; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MANNUCCI PM, 1988, BLOOD, V72, P1449; MARCUS AJ, 1990, BLOOD, V76, P1903; MARCUS AJ, 1991, J CLIN INVEST, V88, P1690, DOI 10.1172/JCI115485; MCFADDEN EP, 1991, NEW ENGL J MED, V324, P648, DOI 10.1056/NEJM199103073241002; MEADE CJ, 1991, BIOCHEM PHARMACOL, V41, P657, DOI 10.1016/0006-2952(91)90064-C; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUGGE A, 1991, CIRC RES, V69, P1293, DOI 10.1161/01.RES.69.5.1293; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NGUYEN BL, 1991, AM J PHYSIOL, V261, pH1043, DOI 10.1152/ajpheart.1991.261.4.H1043; NOLTE C, 1991, J BIOL CHEM, V266, P14808; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PEDERSEN AK, 1984, NEW ENGL J MED, V311, P1206, DOI 10.1056/NEJM198411083111902; PENNY WF, 1992, BLOOD, V79, P91; PENNY WF, 1991, CIRCULATION, V83, P1630, DOI 10.1161/01.CIR.83.5.1630; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; REIS GJ, 1989, LANCET, V2, P1036; ROMANO M, 1992, BIOCHEMISTRY-US, V31, P8269, DOI 10.1021/bi00150a021; SAITO Y, 1990, NEW ENGL J MED, V322, P205; SARREL PM, 1990, LANCET, V336, P1030, DOI 10.1016/0140-6736(90)92490-9; SCHAFER AI, 1984, J CLIN INVEST, V73, P1105, DOI 10.1172/JCI111296; SERHAN CN, 1990, J CLIN INVEST, V85, P772, DOI 10.1172/JCI114503; SHANKAR R, 1992, AM J PHYSIOL, V262, pC199, DOI 10.1152/ajpcell.1992.262.1.C199; TESFAMARIAM B, 1991, J CLIN INVEST, V87, P1643, DOI 10.1172/JCI115179; VALLANCE P, 1992, LANCET, V339, P572; VANE JR, 1990, NEW ENGL J MED, V323, P27; WARE JA, 1989, BLOOD, V73, P172; WEBB DJ, 1991, TRENDS PHARMACOL SCI, V12, P43, DOI 10.1016/0165-6147(91)90492-B; WILLERSON JT, 1991, P NATL ACAD SCI USA, V88, P10624, DOI 10.1073/pnas.88.23.10624; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; WILLIAMS JK, 1989, J CEREBR BLOOD F MET, V9, P111, DOI 10.1038/jcbfm.1989.15; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614; YAMAMOTO H, 1988, J CLIN INVEST, V81, P1752, DOI 10.1172/JCI113516; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YAO SK, 1992, CIRC RES, V70, P39, DOI 10.1161/01.RES.70.1.39; YAO SK, 1991, J MOL CELL CARDIOL, V23, P473, DOI 10.1016/0022-2828(91)90171-H	79	228	230	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1993	328	9					628	635						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP680	8429855				2022-12-28	WOS:A1993KP68000007
J	DAVENPORT, RW; DOU, P; REHDER, V; KATER, SB				DAVENPORT, RW; DOU, P; REHDER, V; KATER, SB			A SENSORY ROLE FOR NEURONAL GROWTH CONE FILOPODIA	NATURE			English	Article							CALCIUM; GENERATION; CONTACTS; AXONS; DEGENERATION; MORPHOLOGY; SEROTONIN; TARGETS; PATHWAY; CULTURE	THE dynamic nature of neuronal growth cone filopodia led to the suggestion that the primary function of filopodia is to sample their immediate environment1-3, responding to and transducing environmental signals that affect growth cone behaviour4-6 and shape7-11. Filopodia seem well suited to serve as antenna-like sensors, their broad span allows sampling of information over a greatly enhanced radius, and forward-projecting filopodia encounter potential cues in the molecular terrain long before the advancing growth cone itself12. Filopodia in culture can serve structural roles13, exert mechanical tension14-16 and selectively adhere to their surrounding17-20. Whether or not filopodia have a general sensory role has not been tested directly, largely because of their small size, which limits an electrophysiological approach, and their integral relationship with the parent growth cone, which prevents resolution of their different functions. Here we use surgical procedures to isolate individual filopodia from their parent growth cone and, by monitoring their morphology and calcium second messenger systems, we show that neuronal growth cone filopodia contain signal transduction mechanisms that allow autonomous responses and the transmission of distant environmental information to their parent growth cone.	COLORADO STATE UNIV,DEPT ANAT & NEUROBIOL,PROGRAM NEURONAL GROWTH & DEV,FT COLLINS,CO 80523	Colorado State University								BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BEDLACK RS, 1992, NEURON, V9, P393, DOI 10.1016/0896-6273(92)90178-G; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; BOVOLENTA P, 1987, J NEUROSCI, V7, P1447; BRAY D, 1973, NATURE, V244, P93, DOI 10.1038/244093a0; BRAY D, 1979, J CELL SCI, V37, P391; COHAN CS, 1987, J NEUROSCI, V7, P3588; DAVENPORT RW, 1992, NEURON, V9, P405, DOI 10.1016/0896-6273(92)90179-H; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; GOLDBERG DJ, 1986, J CELL BIOL, V103, P1921, DOI 10.1083/jcb.103.5.1921; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNDERSEN RW, 1988, J NEUROSCI RES, V21, P298, DOI 10.1002/jnr.490210222; HAMMARBACK JA, 1986, DEV BIOL, V117, P655, DOI 10.1016/0012-1606(86)90334-9; HAYDON PG, 1988, NEURON, V1, P919, DOI 10.1016/0896-6273(88)90149-3; HAYDON PG, 1984, SCIENCE, V226, P561, DOI 10.1126/science.6093252; HEIDEMANN SR, 1990, J CELL BIOL, V111, P1949, DOI 10.1083/jcb.111.5.1949; HOLT CE, 1989, J NEUROSCI, V9, P3123; LETOURNEAU PC, 1989, DEVELOPMENT, V105, P505; LETOURNEAU PC, 1991, NERVE GROWTH CONE, P1; LIPSCOMBE D, 1988, P NATL ACAD SCI USA, V85, P2398, DOI 10.1073/pnas.85.7.2398; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MATTSON MP, 1989, BRAIN RES, V478, P337, DOI 10.1016/0006-8993(89)91514-X; MCCOBB DP, 1988, NEURON, V1, P377, DOI 10.1016/0896-6273(88)90187-0; MILLS LR, 1990, NEURON, V4, P149, DOI 10.1016/0896-6273(90)90451-K; NAKAI J, 1959, Z ZELLFORSCH MIK ANA, V51, P108, DOI 10.1007/BF00345083; OCONNOR TP, 1990, J NEUROSCI, V10, P3935, DOI 10.1523/JNEUROSCI.10-12-03935.1990; REHDER V, 1992, J NEUROSCI, V12, P3175, DOI 10.1523/JNEUROSCI.12-08-03175.1992; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; TAGHERT PH, 1982, DEV BIOL, V94, P391, DOI 10.1016/0012-1606(82)90356-6; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TOSNEY KW, 1985, J NEUROSCI, V5, P2345; UTO A, 1991, CELL CALCIUM, V12, P29, DOI 10.1016/0143-4160(91)90082-P; WONG RG, 1981, J NEUROSCI, V1, P1008	34	183	185	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					721	724		10.1038/361721a0	http://dx.doi.org/10.1038/361721a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441465				2022-12-28	WOS:A1993KN78900055
J	FAWZI, WW; CHALMERS, TC; HERRERA, MG; MOSTELLER, F				FAWZI, WW; CHALMERS, TC; HERRERA, MG; MOSTELLER, F			VITAMIN-A SUPPLEMENTATION AND CHILD-MORTALITY - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SOUTHERN INDIA; TRIAL; MEASLES; MORBIDITY; PROPHYLAXIS; PLACEBO	Objective.-A two-part meta-analysis of studies examining the relationship of v Data Sources.-We identified studies by searching the MEDLARS database from 1966 through 1992 and by scanning Current Contents and bibliographies of pertinent articles. Study Selection.-All 12 vitamin A controlled trials with data on mortality identified in the search were used in the analysis. Data Extraction.-Data were independently extracted by two investigators who also assessed the quality of each study using a previously described method. Data Synthesis.-We formally tested for heterogeneity across studies. We pooled studies using the Mantel-Haenszel and the DerSimonian and Laird methods and adjusted for the effect of cluster assignment of treatment groups in community-based studies. Vitamin A supplementation to hospitalized measles patients was highly protective against mortality (DerSimonian and Laird odds ratio, 0.39; 95% confidence interval, 0.22 to 0.66; P=.0004) (part 1 of the meta-analysis). Supplementation was also protective against overall mortality in community-based studies (DerSimonian and Laird odds ratio, 0.70; clustering-adjusted 95% confidence interval, 0.56 to 0.87; P=.001) (part 2 of the meta-analysis). Conclusions.-Vitamin A supplements are associated with a significant reduction in mortality when given periodically to children at the community level. Factors that affect the bioavailability of large doses of vitamin A need to be studied further. Vitamin A supplements should be given to all measles patients in developing countries whether or not they have symptoms of vitamin A deficiency.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, TECHNOL ASSESSMENT GRP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	FAWZI, WW (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.				AHRQ HHS [R01 HS-05936] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABDELJABER MH, 1991, AM J PUBLIC HEALTH, V81, P1654, DOI 10.2105/AJPH.81.12.1654; ARRIETA AC, 1992, J PEDIATR-US, V121, P75, DOI 10.1016/S0022-3476(05)82545-4; ARROYAVE G, 1977, GUIDELINES ERADICATI; ARTHUR P, 1992, LANCET, V339, P361, DOI 10.1016/0140-6736(92)91677-Z; BARCLAY AJG, 1987, BMJ-BRIT MED J, V294, P294, DOI 10.1136/bmj.294.6567.294; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; COUTSOUDIS A, 1991, AM J CLIN NUTR, V54, P890, DOI 10.1093/ajcn/54.5.890; COUTSOUDIS A, 1991, INT J VITAM NUTR RES, V61, P199; DAULAIRE NMP, 1992, BMJ-BRIT MED J, V304, P207, DOI 10.1136/bmj.304.6821.207; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; Ellison JB, 1932, BRIT MED J, V1932, P708, DOI 10.1136/bmj.2.3745.708; FRIEDEN TR, 1992, AM J DIS CHILD, V146, P182, DOI 10.1001/archpedi.1992.02160140048019; HERRERA MG, 1992, LANCET, V340, P267, DOI 10.1016/0140-6736(92)92357-L; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; KOTHARI G, 1991, J TROP PEDIATRICS, V37, P141, DOI 10.1093/tropej/37.3.141; MAHALANABIS D, 1979, AM J CLIN NUTR, V32, P313, DOI 10.1093/ajcn/32.2.313; MAJIA LA, 1986, VITAMIN A DEFICIENCY; MUHILAL, 1988, AM J CLIN NUTR, V48, P1271, DOI 10.1093/ajcn/48.5.1271; NAUSS KM, 1986, VITAMIN A DEFICIENCY; RAHMATHULLAH L, 1990, NEW ENGL J MED, V323, P929, DOI 10.1056/NEJM199010043231401; RAHMATHULLAH L, 1991, AM J CLIN NUTR, V54, P568, DOI 10.1093/ajcn/54.3.568; Rothman K, 1986, MODERN EPIDEMIOLOGY; SIVAKUMAR B, 1972, BRIT J NUTR, V27, P299, DOI 10.1079/BJN19720094; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1982, NUTRITIONAL BLINDNES; UNDERWOOD BA, 1990, NUTR REV, V48, P265, DOI 10.1111/j.1753-4887.1990.tb02955.x; VIJAYARAGHAVAN K, 1990, LANCET, V336, P1342, DOI 10.1016/0140-6736(90)92895-O; WEST KP, 1991, LANCET, V338, P67, DOI 10.1016/0140-6736(91)90070-6; Wolbach SB, 1933, J EXP MED, V57, P511, DOI 10.1084/jem.57.3.511; 1987, WKLY EPIDEMIOL REC, V62, P133; 1991, STATE WORLDS CHILDRE	32	306	315	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					898	903		10.1001/jama.269.7.898	http://dx.doi.org/10.1001/jama.269.7.898			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL474	8426449				2022-12-28	WOS:A1993KL47400029
J	GOSTIN, LO; BRANDT, AM				GOSTIN, LO; BRANDT, AM			CRITERIA FOR EVALUATING A BAN ON THE ADVERTISEMENT OF CIGARETTES - BALANCING PUBLIC-HEALTH BENEFITS WITH CONSTITUTIONAL BURDENS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REDUCING TOBACCO CONSUMPTION; MAGAZINE COVERAGE; SMOKING; POLICY; 1ST-AMENDMENT; RECOGNITION; CALIFORNIA; PROMOTION; PRODUCTS; CHILDREN		HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	GOSTIN, LO (corresponding author), AMER SOC LAW MED & ETH,765 COMMONWEALTH AVE,16TH FLOOR,BOSTON,MA 02215, USA.							AITKEN PP, 1990, BRIT J ADDICT, V85, P399; AITKEN PP, 1991, BRIT J ADDICT, V86, P383; AITKEN PP, 1985, SOC SCI MED, V21, P785, DOI 10.1016/0277-9536(85)90127-3; ALBRIGHT CL, 1988, HEALTH EDUC QUART, V15, P225, DOI 10.1177/109019818801500207; BAL DG, 1990, JAMA-J AM MED ASSOC, V264, P1570, DOI 10.1001/jama.264.12.1570; BLASI V, 1986, JAMA-J AM MED ASSOC, V256, P502, DOI 10.1001/jama.256.4.502; BODDEWYN JJ, 1989, BRIT J ADDICT, V84, P1255; BODDEWYN JJ, 1989, BR J ADDICT, V84, P1263; BRANDT AM, 1990, DAEDALUS-US, V119, P155; CHAPMAN S, 1990, AM J PUBLIC HEALTH, V80, P537, DOI 10.2105/AJPH.80.5.537; DAVIS RM, 1987, NEW ENGL J MED, V316, P725, DOI 10.1056/NEJM198703193161206; DIFRANZA JR, 1991, JAMA-J AM MED ASSOC, V266, P3149, DOI 10.1001/jama.266.22.3149; ELLIOT S, 1992, NY TIMES        0203, pD1; ERICKSON AC, 1990, PUBLIC HEALTH REP, V105, P239; FIELDING JE, 1985, NEW ENGL J MED, V313, P491, DOI 10.1056/NEJM198508223130807; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; FRITSCHLER AL, 1969, SMOKING POLITICS POL; GOLDSTEIN AO, 1987, J PEDIATR-US, V110, P488, DOI 10.1016/S0022-3476(87)80523-1; GOSTIN L, 1992, RESTRICTIONS ADVERTI; GOSTIN LO, 1991, JAMA-J AM MED ASSOC, V266, P3178, DOI 10.1001/jama.266.22.3178; HAMILTON JL, 1975, 3RD P WORLD C SMOK H; ILE ML, 1990, JAMA-J AM MED ASSOC, V264, P1593, DOI 10.1001/jama.264.12.1593; KLITZNER M, 1991, BRIT J ADDICT, V86, P287; LEVIT EM, 1981, J LAW ECON, V24, P545; NEUBERGER MB, 1963, SMOKE SCREEN TOBACCO, P49; PETERSON DE, 1992, AM J PUBLIC HEALTH, V82, P94, DOI 10.2105/AJPH.82.1.94; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; REDISH MH, 1990, VANDERBILT LAW REV, V43, P1433; REDISH MH, 1987, HEARING SUBCOMMITTEE; REUIJL JC, 1982, DETERMINATION ADVERT; ROGOTTI NA, 1991, JAMA-J AM MED ASSOC, V266, P3162; SCHNEIDER L, 1981, J LAW ECON, V24, P575, DOI 10.1086/467001; SELDON BJ, 1989, REV ECON STAT, V71, P673, DOI 10.2307/1928110; WARNER K E, 1989, Journal of Public Health Policy, V10, P32, DOI 10.2307/3342942; WARNER KE, 1987, NEW ENGL J MED, V316, P745, DOI 10.1056/NEJM198703193161210; WARNER KE, 1992, NEW ENGL J MED, V326, P305, DOI 10.1056/NEJM199201303260505; WARNER KE, 1986, J HEALTH POLIT POLIC, V11, P367, DOI 10.1215/03616878-11-3-367; WARNER KE, 1986, SELLING SMOKE CIGARE; WHELAN EM, 1984, SMOKING GUN; 1986, HARVARD LAW REV, V100, P172; 1964, 99113 TRAD REG PREV; 1989, 10898411 US DEP HLTH; 1986, HLTH CONSEQUENCES IN; 1987, UCLA LAW REV, V34, P1139; 1989, DDEC INT M HON; 1990, CDC878396 US DEP HLT; 1976, 425US7748 VIRG STAT, P762; 1991, NY TIMES        0201, pA9; 1990, MMWR, V39, P261	49	14	14	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					904	909		10.1001/jama.269.7.904	http://dx.doi.org/10.1001/jama.269.7.904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KL474	8426450				2022-12-28	WOS:A1993KL47400030
J	ADAMS, CC; WORKMAN, JL				ADAMS, CC; WORKMAN, JL			NUCLEOSOME DISPLACEMENT IN TRANSCRIPTION	CELL			English	Review							TUMOR VIRUS PROMOTER; CHROMATIN; INVIVO; GENE; RECEPTOR; DOMAINS; GAL4; RNA		PENN STATE UNIV,DEPT MOLEC & CELL BIOL,UNIV PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	ADAMS, CC (corresponding author), PENN STATE UNIV,CTR GENE REGULAT,UNIV PK,PA 16802, USA.							ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEE MS, 1991, P NATL ACAD SCI USA, V88, P9675, DOI 10.1073/pnas.88.21.9675; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PHAM TA, 1991, J BIOL CHEM, V266, P18179; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TURNER BM, 1991, J CELL SCI, V99, P13; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613	24	149	149	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					305	308		10.1016/0092-8674(93)90109-4	http://dx.doi.org/10.1016/0092-8674(93)90109-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431942				2022-12-28	WOS:A1993KM16200002
J	IGLEHART, JK				IGLEHART, JK			THE AMERICAN HEALTH-CARE SYSTEM - THE END STAGE RENAL-DISEASE PROGRAM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEMODIALYSIS; MORTALITY; DIALYSIS											ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; BRUNNER FP, 1992, KIDNEY INT, V42, pS4; COOPER H, 1992, WALL STREET J   1005, pB8; EGGERS PW, 1990, DHHS PHS901214 PUBL, P121; GREER JW, 1992, MEDICARE PAYMENT REC; HELD PJ, 1990, AM J KIDNEY DIS, V15, P441, DOI 10.1016/S0272-6386(12)70362-1; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1992, KIDNEY INT, V42, pS16; HULL AR, 1990, AM J KIDNEY DIS, V15, P375, DOI 10.1016/S0272-6386(12)70354-2; IGLEHART JK, 1992, NEW ENGL J MED, V326, P962, DOI 10.1056/NEJM199204023261426; IGLEHART JK, 1992, NEW ENGL J MED, V326, P1715, DOI 10.1056/NEJM199206183262526; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; KASSIRER JP, 1992, NEW ENGL J MED, V326, P945, DOI 10.1056/NEJM199204023261408; MCCLELLAN WM, 1992, ANN INTERN MED, V117, P332, DOI 10.7326/0003-4819-117-4-332; POWE NR, 1992, JAMA-J AM MED ASSOC, V268, P1434, DOI 10.1001/jama.268.11.1434; PRICE CA, 1992, NEPHROLOGY NEWS  FEB, P18; Rettig RA, 1991, BIOMEDICAL POLITICS, P176; Rettig RA, 1991, KIDNEY FAILURE FEDER; VONALBERTINI B, 1991, AM J NEPHROL, V11, P169, DOI 10.1159/000168298; 1992, C9204 C REP; 1992, 1992 GREEN BOOK; 1980, HLTH CARE FINANCING; 1992, GAOHRD9331 GEN ACC O	23	60	63	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					366	371		10.1056/NEJM199302043280528	http://dx.doi.org/10.1056/NEJM199302043280528			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8419833				2022-12-28	WOS:A1993KK24700029
J	AMATI, B; BROOKS, MW; LEVY, N; LITTLEWOOD, TD; EVAN, GI; LAND, H				AMATI, B; BROOKS, MW; LEVY, N; LITTLEWOOD, TD; EVAN, GI; LAND, H			ONCOGENIC ACTIVITY OF THE C-MYC PROTEIN REQUIRES DIMERIZATION WITH MAX	CELL			English	Article							LOOP-HELIX PROTEIN; LEUCINE ZIPPER PROTEINS; DNA-BINDING; ACTIVATES TRANSCRIPTION; COILED-COIL; BASIC REGION; CELLS; GENE; EXPRESSION; DOMAINS	c-Myc (Myc) and Max proteins dimerize and bind DNA through basic-helix-loop-helix-leucine zipper motifs (b-HLH-LZ). Using a genetic approach, we demonstrate that binding to Max is essential for Myc transforming activity and that Myc homodimers are inactive. Mutants of Myc and Max that bind efficiently to each other but not to their wild-type partners were generated by either exchanging the HLH-LZ domains or reciprocally modifying LZ dimerization specificities. While transformation defective on their own, complementary mutants restore Myc transforming activity when coexpressed in cells. The HLH-LZ exchange mutants also have dominant negative activity on wild-type Myc function. In addition, wild-type max antagonizes myc function in a dose-dependent manner, presumably through competition of Max-Max and Myc-Max dimers for common target DNA sites. Therefore, Max can function as both suppressor and activator of Myc. A general model for the role of Myc and Max in growth control is discussed.	IMPERIAL CANC RES FUND, BIOCHEM CELL NUCLEUS LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	AMATI, B (corresponding author), IMPERIAL CANC RES FUND, GROWTH CONTROL & DEV LAB, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Amati, Bruno/AAM-3418-2020	Levy-Strumpf, Naomi/0000-0002-5454-8800; Amati, Bruno/0000-0002-2958-1799				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEAN M, 1986, J BIOL CHEM, V261, P9161; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISHER F, 1991, ONCOGENE, V6, P1099; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1988, ANTIBODIES; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MOORE JP, 1987, ONCOGENE RES, V2, P65; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Penn L J, 1990, Semin Cancer Biol, V1, P69; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WATERS CM, 1991, ONCOGENE, V6, P797; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	66	479	485	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 29	1993	72	2					233	245		10.1016/0092-8674(93)90663-B	http://dx.doi.org/10.1016/0092-8674(93)90663-B			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	8425220				2022-12-28	WOS:A1993KK03800008
J	MACLEOD, DIA; HE, S				MACLEOD, DIA; HE, S			VISIBLE FLICKER FROM INVISIBLE PATTERNS	NATURE			English	Article							MONKEY MACACA-FASCICULARIS; SENSITIVITY; ADAPTATION; VISION; CONES	USING a laser interferometer we can create grating patterns of high optical contrast (interference fringes) directly on the retina1-3. With coarse fringe patterns, the alternating light and dark bars of the pattern can be seen, but the bars of the finest fringes are not subjectively resolved. We report here that when we rapidly modulate the contrast of a fine fringe pattern (keeping overall luminance constant), observers experience flicker, even if the fringes are too finely spaced to be perceived as a grating. For this flicker to be seen, the pattern needs to be resolvable by the photoreceptors themselves, but not necessarily by later stages of visual processing. It can be explained if, in man, signals associated with individual cone receptors do not depend linearly on light intensity, but instead are scaled by a fast sensitivity-regulating or light-adaptation mechanism. Contrast-modulation flicker is not demonstrable in rod vision; rod vision therefore lacks such a local adaptation process.			MACLEOD, DIA (corresponding author), UNIV CALIF SAN DIEGO,DEPT PSYCHOL,LA JOLLA,CA 92093, USA.							BAYLOR DA, 1984, J PHYSIOL-LONDON, V357, P575, DOI 10.1113/jphysiol.1984.sp015518; BOYNTON RM, 1970, SCIENCE, V170, P1423, DOI 10.1126/science.170.3965.1423; BURTON GJ, 1973, VISION RES, V13, P1211, DOI 10.1016/0042-6989(73)90198-3; CAMPBELL FW, 1965, J PHYSIOL-LONDON, V414, P89; KELLY DH, 1971, J OPT SOC AM, V61, P537, DOI 10.1364/JOSA.61.000537; MACLEOD DIA, 1989, VISION RES, V29, P965, DOI 10.1016/0042-6989(89)90111-9; MACLEOD DIA, 1992, VISION RES, V32, P347, DOI 10.1016/0042-6989(92)90144-8; MACLEOD DIA, 1992, INVEST OPHTH VIS SCI, V33, P1136; MILLER WH, 1983, VISION RES, V23, P1365, DOI 10.1016/0042-6989(83)90147-5; Polyak S. L., 1941, RETINA-J RET VIT DIS; RUSHTON WAH, 1965, PROC R SOC SER B-BIO, V162, P20, DOI 10.1098/rspb.1965.0024; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; TRANCHINA D, 1988, VISUAL NEUROSCI, V1, P339, DOI 10.1017/S0952523800004119; WILLIAMS DR, 1985, VISION RES, V25, P195, DOI 10.1016/0042-6989(85)90113-0	14	40	40	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 21	1993	361	6409					256	258		10.1038/361256a0	http://dx.doi.org/10.1038/361256a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8423852				2022-12-28	WOS:A1993KH61400058
J	SKOOG, I; NILSSON, L; PALMERTZ, B; ANDREASSON, LA; SVANBORG, A				SKOOG, I; NILSSON, L; PALMERTZ, B; ANDREASSON, LA; SVANBORG, A			A POPULATION-BASED STUDY OF DEMENTIA IN 85-YEAR-OLDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; DIFFERENTIAL-DIAGNOSIS; CLINICAL-DIAGNOSIS; PREVALENCE; DISORDERS; COMMUNITY; PEOPLE	Background. The aim of this study was to investigate the causes, severity, and prevalence of dementia in a representative sample of 494 85-year-olds living in Gothenburg, Sweden. Methods. The study included a psychiatric interview, neuropsychological and physical examinations, comprehensive laboratory tests, electrocardiography, chest radiography, computed tomography (CT) of the head, and analysis of cerebrospinal fluid. A person close to each subject was also interviewed. Dementia was defined according to the criteria proposed in the Diagnostic and Statistical Manual of Mental Disorders (third edition, revised), Alzheimer's disease according to the criteria of the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association, and vascular dementia according to recently proposed criteria that incorporate information from CT scanning and the patient's neurologic history. Results. The prevalence of dementia was 29.8 percent (147 subjects). The condition was mild in 8.3 percent, moderate in 10.3 percent, and severe in 11.1 percent. There were no significant sex-related differences in prevalence or severity. Of the subjects with dementia, 43.5 percent had Alzheimer's disease, 46.9 percent had vascular dementia (multi-infarct dementia in 34.6 percent, dementia related to cerebral hypoperfusion in 4.1 percent, and mixed dementia in 8.2 percent), and 9.5 percent had dementia due to other causes. The three-year mortality rate was 23.1 percent in the subjects without dementia, 42.2 percent in the patients with Alzheimer's disease, and 66.7 percent in the patients with vascular dementia. Infarcts detected by CT scanning were significantly more common in the subjects with dementia than in those without it (27.9 percent vs. 12.6 percent). Conclusions. Dementia was present in nearly a third of unselected 85-year-olds in Sweden. Almost half these subjects appeared to have vascular dementia, which may currently be more amenable to prevention or treatment than Alzheimer's disease.	OSTRA HOSP, DEPT RADIOL, S-41685 GOTHENBURG, SWEDEN; UNIV ILLINOIS, DEPT MED, GERIATR MED SECT, CHICAGO, IL 60680 USA	Sahlgrenska University Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	SKOOG, I (corresponding author), SAHLGRENS UNIV HOSP, DEPT PSYCHIAT, S-41345 GOTHENBURG, SWEDEN.							ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; BRUN A, 1990, CLIN SCI GERIATRICS, P1; BRUST JCM, 1988, ARCH NEUROL-CHICAGO, V45, P799, DOI 10.1001/archneur.1988.00520310117026; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cox DR, 1974, THEORETICAL STATISTI; CUMMINGS JL, 1987, PSYCHOSOMATICS, V28, P117, DOI 10.1016/S0033-3182(87)72553-5; DELSER T, 1990, J NEUROL SCI, V96, P1, DOI 10.1016/0022-510X(90)90052-O; ERKINJUNTTI T, 1987, ACTA NEUROL SCAND, V76, P433, DOI 10.1111/j.1600-0404.1987.tb03599.x; ERKINJUNTTI T, 1988, J NEUROL NEUROSUR PS, V51, P1037, DOI 10.1136/jnnp.51.8.1037; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FOLSTEIN M, 1985, J AM GERIATR SOC, V33, P228, DOI 10.1111/j.1532-5415.1985.tb07109.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Glatt S, 1984, Annu Rev Gerontol Geriatr, V4, P61; HACHINSKI V, 1992, LANCET, V340, P645; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HACHINSKI VC, 1990, CAN MED ASSOC J, V142, P107; HARSCH HH, 1988, ARCH NEUROL-CHICAGO, V45, P375, DOI 10.1001/archneur.1988.00520280017010; HENDERSON AS, 1987, PSYCHOL MED, V17, P549, DOI 10.1017/S0033291700025800; JELLINGER K, 1990, J NEUROL SCI, V95, P239, DOI 10.1016/0022-510X(90)90072-U; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; JORM AF, 1990, EPIDEMIOLOGY ALZHEIM; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LARSON EB, 1985, J GERONTOL, V40, P536, DOI 10.1093/geronj/40.5.536; LIVINGSTON G, 1990, PSYCHOL MED, V20, P881, DOI 10.1017/S0033291700036588; LOEB C, 1990, DEMENTIA, V1, P175; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MCLEAN S, 1987, AUST NZ J PSYCHIAT, V21, P142, DOI 10.3109/00048678709160910; MORTIMER JA, 1981, EPIDEMIOLOGY DEMENTI, P173; NILSSON LV, 1984, ACTA PSYCHIAT SCAND, V69, P519, DOI 10.1111/j.1600-0447.1984.tb02526.x; OBRIEN MD, 1988, ARCH NEUROL-CHICAGO, V45, P797, DOI 10.1001/archneur.1988.00520310115025; RINDER L, 1975, ACTA MED SCAND, V198, P397, DOI 10.1111/j.0954-6820.1975.tb19563.x; ROCCA WA, 1990, NEUROLOGY, V40, P626, DOI 10.1212/WNL.40.4.626; ROTH M, 1981, EPIDEMIOLOGY DEMENTI, P24; SVANBORG A, 1977, ACTA MED SCAND, P5; TOMLINSON BE, 1970, J NEUROL SCI, V11, P205, DOI 10.1016/0022-510X(70)90063-8; UEMURA K, 1988, EUR HEART J, V9, P1; WALLIN A, 1991, ALZ DIS ASSOC DIS, V5, P91, DOI 10.1097/00002093-199100520-00006; 1987, DIAGNOSTIC STATISTIC	40	606	614	1	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1993	328	3					153	158		10.1056/NEJM199301213280301	http://dx.doi.org/10.1056/NEJM199301213280301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG625	8417380				2022-12-28	WOS:A1993KG62500001
J	GOLDSTEIN, AO				GOLDSTEIN, AO			SOCIAL ... SECURITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					412	412						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418352				2022-12-28	WOS:A1993KG38100038
J	RABINDRAN, SK; HAROUN, RI; CLOS, J; WISNIEWSKI, J; WU, C				RABINDRAN, SK; HAROUN, RI; CLOS, J; WISNIEWSKI, J; WU, C			REGULATION OF HEAT-SHOCK FACTOR TRIMER FORMATION - ROLE OF A CONSERVED LEUCINE ZIPPER	SCIENCE			English	Article							DNA-BINDING; TRANSCRIPTION FACTOR; ACTIVATION; CLONING; GENE	The human and Drosophila heat shock transcription factors (HSFs) are multi-zipper proteins with high-affinity binding to DNA that is regulated by heat shock-induced trimerization. Formation of HSF trimers is dependent on hydrophobic heptad repeats located in the amino-terminal region of the protein. Two subregions at the carboxyl-terminal end of human HSF1 were identified that maintain the monomeric form of the protein under normal conditions. One of these contains a leucine zipper motif that is conserved between vertebrate and insect HSFs. These results suggest that the carboxyl-terminal zipper may suppress formation of trimers by the amino-terminal HSF zipper elements by means of intramolecular coiled-coil interactions that are sensitive to heat shock.	NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; CLOS J, UNPUB; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIS JT, IN PRESS TRANSCRIPTI; Morimoto RI, 1990, STRESS PROTEINS BIOL; NOVER L, 1984, BIOL ZBL, V103, P357; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PETERANDERL R, IN PRESS BIOCHEMISTR; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, UNPUB; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SZENTGYORGYI C, 1987, J MOL BIOL, V193, P71, DOI 10.1016/0022-2836(87)90628-0; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WESTWOOD JT, UNPUB HYDRODYNAMIC S; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WU C, 1990, STRESS PROTEINS BIOL, P429; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	38	411	435	2	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					230	234		10.1126/science.8421783	http://dx.doi.org/10.1126/science.8421783			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	8421783				2022-12-28	WOS:A1993KF71900032
J	PATTERSON, PH; NAWA, H				PATTERSON, PH; NAWA, H			NEURONAL DIFFERENTIATION FACTORS CYTOKINES AND SYNAPTIC PLASTICITY	CELL			English	Review							LONG-TERM POTENTIATION; LEUKEMIA-INHIBITORY FACTOR; RAT SYMPATHETIC NEURONS; NERVE GROWTH-FACTOR; CORTICOTROPIN-RELEASING-FACTOR; NEUROPEPTIDE GENE-EXPRESSION; MESSENGER-RNA EXPRESSION; CIRCADIAN TIMING SYSTEM; CELL CONDITIONED MEDIUM; SUBSTANCE-P		COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory	PATTERSON, PH (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							ABE K, 1992, BRAIN RES, V587, P102, DOI 10.1016/0006-8993(92)91433-F; ABE K, 1991, BRAIN RES, V547, P171; AKESSON TR, 1987, NEUROENDOCRINOLOGY, V45, P257, DOI 10.1159/000124737; AKWA Y, 1991, J STEROID BIOCHEM, V40, P71, DOI 10.1016/0960-0760(91)90169-6; ALBERS HE, 1990, MOL BRAIN RES, V7, P85, DOI 10.1016/0169-328X(90)90077-Q; ALBERS HE, 1991, J NEUROSCI, V11, P846; ALTIN JG, 1992, NEUROTROPHIC FACTORS, P129; ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANDERSON DJ, 1991, J NEUROSCI, V11, P3507; ARAKI M, 1992, DEV BRAIN RES, V65, P85, DOI 10.1016/0165-3806(92)90011-K; ARAKI M, 1990, CELL DIFFER DEV, V31, P129, DOI 10.1016/0922-3371(90)90016-P; ARAKI M, 1992, DEV BIOL, V149, P440, DOI 10.1016/0012-1606(92)90298-U; ATTARDI B, 1981, ENDOCRINOLOGY, V108, P1487, DOI 10.1210/endo-108-4-1487; AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BALDINO F, 1988, SYNAPSE, V2, P317, DOI 10.1002/syn.890020322; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BENVENISTE EN, 1992, NEUROIMMUNOENDOCRINO, V52, P106; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; BIENENSTOCK J, 1987, INT ARCH ALLER A IMM, V82, P238, DOI 10.1159/000234197; BINDONI M, 1988, BRAIN RES, V462, P10, DOI 10.1016/0006-8993(88)90578-1; BLACK IB, 1987, SCIENCE, V236, P1263, DOI 10.1126/science.2884727; BOSCH EP, 1989, J NEUROSCI, V9, P3690; BROWN ER, 1991, P NATL ACAD SCI USA, V88, P1222, DOI 10.1073/pnas.88.4.1222; CARNAHAN JF, 1991, DEV BIOL, V148, P552, DOI 10.1016/0012-1606(91)90273-6; CARNAHAN JF, 1991, J NEUROSCI, V11, P3520; CARNAHAN JF, 1991, J NEUROSCI, V11, P3493; CARTER DA, 1989, MOL BRAIN RES, V6, P233, DOI 10.1016/0169-328X(89)90069-7; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CHAMAK B, 1987, J NEUROSCI, V7, P3163; CHUN LLY, 1977, J CELL BIOL, V75, P694, DOI 10.1083/jcb.75.3.694; CLARK CR, 1982, J ENDOCRINOL, V93, P339, DOI 10.1677/joe.0.0930339; COHEN S, 1974, CELL IMMUNOL, V12, P150, DOI 10.1016/0008-8749(74)90066-5; COULOMBE JN, 1991, J NEUROSCI, V11, P553; COZENS PJ, 1987, IMMUNOBIOLOGY, V175, P7; DARCANGELO G, 1991, BRAIN RES, V564, P245, DOI 10.1016/0006-8993(91)91459-E; DEVRIES GJ, 1990, J NEUROENDOCRINOL, V2, P1, DOI 10.1111/j.1365-2826.1990.tb00385.x; DIMITRIADOU V, 1991, NEUROSCIENCE, V44, P97; DOBREA GM, 1992, DEV BRAIN RES, V66, P209, DOI 10.1016/0165-3806(92)90082-8; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; DULAC C, 1988, NEURON, V1, P211, DOI 10.1016/0896-6273(88)90141-9; EARNEST DJ, 1986, BRAIN RES, V382, P129, DOI 10.1016/0006-8993(86)90119-8; ERICSSON A, 1987, P NATL ACAD SCI USA, V84, P5585, DOI 10.1073/pnas.84.16.5585; FERGUSON IA, 1990, J NEUROSCI, V10, P2176; FERNS MJ, 1992, CELL, V70, P1, DOI 10.1016/0092-8674(92)90525-H; FITZGERALD M, 1989, TRENDS NEUROSCI, V12, P86, DOI 10.1016/0166-2236(89)90161-6; FOREMAN JC, 1987, BRIT MED BULL, V43, P386, DOI 10.1093/oxfordjournals.bmb.a072189; FREIDIN M, 1991, P NATL ACAD SCI USA, V88, P3200, DOI 10.1073/pnas.88.8.3200; FRENCH KA, 1992, TRENDS NEUROSCI, V15, P169, DOI 10.1016/0166-2236(92)90168-8; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; FUKADA K, 1985, P NATL ACAD SCI USA, V82, P8795, DOI 10.1073/pnas.82.24.8795; FUKADA K, 1980, NATURE, V287, P553, DOI 10.1038/287553a0; GALL C, 1990, PROG BRAIN RES, V83, P371; GARCIAARRARAS JE, 1991, DEV BRAIN RES, V60, P19, DOI 10.1016/0165-3806(91)90151-8; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GOUGH NM, 1989, CANCER CELL-MON REV, V1, P77; GOULD E, 1990, J NEUROSCI, V10, P1286; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; GREENOUGH WT, 1990, BIOL MEMORY, V23, P159; GUENARD V, 1991, J NEUROSCI RES, V29, P396, DOI 10.1002/jnr.490290315; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HALL AK, 1992, TRENDS NEUROSCI, V15, P35, DOI 10.1016/0166-2236(92)90022-Z; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HAMILL RW, 1990, J NEUROBIOL, V21, P731, DOI 10.1002/neu.480210507; HART RP, 1991, J NEUROSCI RES, V29, P282, DOI 10.1002/jnr.490290303; Hartung H P, 1989, Int Rev Immunol, V4, P229, DOI 10.3109/08830188909054420; HENDRY IA, 1992, J NEUROSCI, V12, P3427; HILTON DJ, 1988, ANAL BIOCHEM, V173, P359, DOI 10.1016/0003-2697(88)90200-X; HISAJIMA H, 1992, J NEUROSCI RES, V31, P549, DOI 10.1002/jnr.490310319; IMAKI T, 1991, J NEUROSCI, V11, P585; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; ISHII DN, 1992, NEUROTROPHIC FACTORS, P415; ISHIYAMA J, 1991, NEUROSCI RES, V12, P403, DOI 10.1016/0168-0102(91)90071-6; JESSEN KR, 1991, GLIA, V4, P185, DOI 10.1002/glia.440040210; JOHNSON MI, 1989, DEV BRAIN RES, V47, P289, DOI 10.1016/0165-3806(89)90184-3; JONAKAIT GM, 1981, DEV BIOL, V88, P288, DOI 10.1016/0012-1606(81)90172-X; JONAKAIT GM, 1990, J NEUROSCI RES, V26, P24, DOI 10.1002/jnr.490260104; KASPER S, 1992, ENDOCRINOLOGY, V130, P1796, DOI 10.1210/en.130.4.1796; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KIMBALL ES, 1990, ANN NY ACAD SCI, V594, P293; KIMBALL ES, 1988, J IMMUNOL, V141, P3564; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; KOWALSKI ML, 1988, J IMMUNOL, V140, P3905; LAMBRACHTHALL M, 1990, DEV BRAIN RES, V56, P151, DOI 10.1016/0165-3806(90)90077-C; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; LANDIS SC, 1983, DEV BIOL, V98, P349, DOI 10.1016/0012-1606(83)90365-2; LAURENZI MA, 1990, SCAND J IMMUNOL, V31, P529, DOI 10.1111/j.1365-3083.1990.tb02801.x; LEHMAN MN, 1987, J NEUROSCI, V7, P1626; LEROITH D, 1992, NEUROTROPHIC FACTORS, P391; LESLIE FM, 1992, NEUROTROPHIC FACTORS, P565; LEUNG DW, 1992, NEURON, V8, P1045, DOI 10.1016/0896-6273(92)90126-X; LEVINE JD, 1986, J NEUROSCI, V6, P3423; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LINDHOLM D, 1992, EUR J NEUROSCI, V4, P404, DOI 10.1111/j.1460-9568.1992.tb00889.x; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; LOTZ M, 1992, J CLIN INVEST, V90, P888, DOI 10.1172/JCI115964; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MANTHORPE M, 1992, NEUROTROPHIC FACTORS, P443; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MCGINNIS MY, 1981, NEUROENDOCRINOLOGY, V33, P158, DOI 10.1159/000123222; MCLENNAN IS, 1980, NATURE, V283, P206, DOI 10.1038/283206a0; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MERCHENTHALER I, 1991, ENDOCRINOLOGY, V129, P1977, DOI 10.1210/endo-129-4-1977; MERCHENTHALER I, 1990, P NATL ACAD SCI USA, V87, P6326, DOI 10.1073/pnas.87.16.6326; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; METCALF D, 1992, CIBA F S, V167; MILLER RH, 1991, DEVELOPMENT, V113, P353; MINAMI M, 1991, BIOCHEM BIOPH RES CO, V176, P593, DOI 10.1016/S0006-291X(05)80225-6; MOORE RY, 1990, ANN NY ACAD SCI, V611, P247; MORRISON R, 1992, NEUROTROPHIC FACTORS, P339; MUDGE AW, 1984, NATURE, V309, P367, DOI 10.1038/309367a0; MURAKAMI N, 1991, BRAIN RES, V545, P347, DOI 10.1016/0006-8993(91)91312-O; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; MUSASHI M, 1991, P NATL ACAD SCI USA, V88, P765, DOI 10.1073/pnas.88.3.765; NARUSE I, 1990, DEV BRAIN RES, V51, P253, DOI 10.1016/0165-3806(90)90283-5; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NAWA H, 1990, COLD SH Q B, V55, P247; NAWA H, 1990, NEURON, V4, P269, DOI 10.1016/0896-6273(90)90101-K; NAWA H, 1993, IN PRESS J NEUROCHEM; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NYSTROM B, 1986, NEUROCHEM INT, V9, P55, DOI 10.1016/0197-0186(86)90031-8; OJEDA SR, 1992, FRONT NEUROENDOCRIN, V13, P120; OKAMOTO S, 1991, HISTOCHEMISTRY, V95, P525, DOI 10.1007/BF00315750; OLAGUE PH, 1974, P NATL ACAD SCI USA, V71, P3602, DOI 10.1073/pnas.71.9.3602; OOMURA Y, 1989, J CELL BIOCHEM, V13, P227; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; ORO AE, 1988, NEUROENDOCRINOLOGY, V47, P225, DOI 10.1159/000124916; PATTERSO.PH, 1974, P NATL ACAD SCI USA, V71, P3607, DOI 10.1073/pnas.71.9.3607; Patterson P., 1992, INTRO MOL NEUROBIOLO, P388; Patterson P H, 1992, Curr Opin Neurobiol, V2, P94, DOI 10.1016/0959-4388(92)90169-L; PATTERSON PH, 1992, CIBA F SYMP, V167, P125; PATTERSON PH, 1977, DEV BIOL, V56, P263, DOI 10.1016/0012-1606(77)90269-X; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PATTERSON PH, 1978, ANNU REV NEUROSCI, V1, P1, DOI 10.1146/annurev.ne.01.030178.000245; PATTERSON PH, 1992, DEV REGENERATION PLA, P231; PATTERSON PH, 1992, NEUROTROPHIC FACTORS, P527; PAYAN DG, 1989, HOSP PRACT, V24, P67; PERRY VH, 1992, BIOESSAYS, V14, P401, DOI 10.1002/bies.950140610; PRESTA M, 1991, J NEUROCHEM, V56, P1087, DOI 10.1111/j.1471-4159.1991.tb02034.x; RABINOVSKY ED, 1992, J NEUROSCI RES, V31, P188, DOI 10.1002/jnr.490310124; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; RAO M, 1992, DEV BIOL, V153, P411, DOI 10.1016/0012-1606(92)90127-3; RAO MS, 1992, NEUROREPORT, V3, P865, DOI 10.1097/00001756-199210000-00011; RAO MS, 1990, NEURON, V5, P899, DOI 10.1016/0896-6273(90)90350-O; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; RAO MS, 1990, DEV BIOL, V139, P65, DOI 10.1016/0012-1606(90)90279-R; RAO MS, 1992, IN PRESS DEVELOPMENT; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; REPPERT SM, 1981, SCIENCE, V213, P1256, DOI 10.1126/science.7268432; ROACH A, 1987, P NATL ACAD SCI USA, V84, P5078, DOI 10.1073/pnas.84.14.5078; ROHRER H, 1992, DEVELOPMENT, V114, P689; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RUDEL C, 1992, DEVELOPMENT, V115, P519; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; Rupp F, 1992, Curr Opin Neurobiol, V2, P88, DOI 10.1016/0959-4388(92)90168-K; RYDHSTROM H, 1990, NEUROENDOCRINOLOGY, V52, P332, DOI 10.1159/000125616; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SASTRY BR, 1988, NEUROSCI LETT, V91, P101, DOI 10.1016/0304-3940(88)90256-X; SCARBOROUGH DE, 1989, ENDOCRINOLOGY, V124, P549, DOI 10.1210/endo-124-1-549; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLINGER BA, 1992, P NATL ACAD SCI USA, V89, P7650, DOI 10.1073/pnas.89.16.7650; SCHOTZINGER RJ, 1988, NATURE, V335, P637, DOI 10.1038/335637a0; SCHWARTZ LB, 1987, ANN ALLERGY, V58, P226; SELVERSTON AI, 1985, ANNU REV PHYSIOL, V47, P29; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENIUK N, 1992, BRAIN RES, V572, P300, DOI 10.1016/0006-8993(92)90489-V; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; SHINODA H, 1989, SCIENCE, V245, P415, DOI 10.1126/science.2569236; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SILVER R, 1992, J NEUROENDOCRINOL, V4, P207, DOI 10.1111/j.1365-2826.1992.tb00160.x; SIMERLY RB, 1989, P NATL ACAD SCI USA, V86, P4766, DOI 10.1073/pnas.86.12.4766; SIMERLY RB, 1990, TRENDS NEUROSCI, V13, P104, DOI 10.1016/0166-2236(90)90186-E; SMITH GD, 1992, NEUROSCI LETT, V137, P257, DOI 10.1016/0304-3940(92)90417-6; SMITH GD, 1991, BRAIN RES, V564, P27, DOI 10.1016/0006-8993(91)91347-4; SPIEGEL K, 1990, NEURON, V4, P303, DOI 10.1016/0896-6273(90)90104-N; STANTON PK, 1984, J NEUROSCI, V4, P3080; STEAD RH, 1990, NEUROENDOCRINE IMMUN, P19; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; STRAND FL, 1991, PHYSIOL REV, V71, P1017, DOI 10.1152/physrev.1991.71.4.1017; SUZUE T, 1990, NEURON, V5, P421, DOI 10.1016/0896-6273(90)90081-P; SWANSON LW, 1983, TRENDS NEUROSCI, V6, P294, DOI 10.1016/0166-2236(83)90140-6; SWANSON LW, 1991, PROG BRAIN RES, V87, P181; TAKAHASHI JS, 1987, COMP ASPETS CIRCADIA, P3; TANCREDI V, 1992, IN PRESS NEUROSCI LE; TERLAU H, 1990, EUR J NEUROSCI, V2, P973, DOI 10.1111/j.1460-9568.1990.tb00009.x; TERLAU H, 1989, BRAIN RES, V484, P352, DOI 10.1016/0006-8993(89)90380-6; THEOHARIDES TC, 1990, LIFE SCI, V46, P607, DOI 10.1016/0024-3205(90)90129-F; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TROPEA M, 1988, GLIA, V1, P380, DOI 10.1002/glia.440010605; TSAGARAKIS S, 1989, NEUROENDOCRINOLOGY, V49, P98, DOI 10.1159/000125096; TUBLITZ N, 1991, TRENDS NEUROSCI, V14, P254, DOI 10.1016/0166-2236(91)90126-F; UHL GR, 1986, SCIENCE, V232, P390, DOI 10.1126/science.3961487; UNDEM BJ, 1989, NEUROIMMUNE NETWORKS, P155; UNSICKER K, 1992, NEUROTROPHIC FACTORS, P313; UNSICKER K, 1992, REST NEUROL NEUROSCI, V4, P174; UNSICKER K, 1990, MOL ASPECTS DEV AGIN, P63; UNSICKER K, 1992, IN PRESS CURR OPIN N, V2; UNSICKER K, 1993, IN PRESS NEUROSCIENC; VANDESANDE F, 1975, CELL TISSUE RES, V156, P377, DOI 10.1007/BF00225365; WATTS AG, 1989, ENDOCRINOLOGY, V125, P1734, DOI 10.1210/endo-125-3-1734; WEEKS JC, 1990, ANNU REV NEUROSCI, V13, P183, DOI 10.1146/annurev.ne.13.030190.001151; WEIHE E, 1989, NEUROSCIENCE, V31, P77, DOI 10.1016/0306-4522(89)90031-6; WESTERMANN R, 1990, J NEUROCHEM, V55, P285, DOI 10.1111/j.1471-4159.1990.tb08850.x; WONG V, 1987, P NATL ACAD SCI USA, V84, P8726, DOI 10.1073/pnas.84.23.8726; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; XIE Z, 1991, NEUROSCIENCE, V43, P11, DOI 10.1016/0306-4522(91)90411-G; YAMAMORI T, 1991, P NATL ACAD SCI USA, V88, P7298, DOI 10.1073/pnas.88.16.7298; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037; ZEISE ML, 1992, REGUL PEPTIDES, V39, P1, DOI 10.1016/0167-0115(92)90002-C; ZIGMOND RE, 1992, P NATL ACAD SCI USA, V89, P1507, DOI 10.1073/pnas.89.4.1507; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215; ZURAWSKI G, 1986, SCIENCE, V232, P772, DOI 10.1126/science.2938259	231	273	275	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN	1993	72			S			123	137		10.1016/S0092-8674(05)80032-7	http://dx.doi.org/10.1016/S0092-8674(05)80032-7			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KL707	8428374				2022-12-28	WOS:A1993KL70700008
J	TROJAN, J; JOHNSON, TR; RUDIN, SD; ILAN, J; TYKOCINSKI, ML; ILAN, J				TROJAN, J; JOHNSON, TR; RUDIN, SD; ILAN, J; TYKOCINSKI, ML; ILAN, J			TREATMENT AND PREVENTION OF RAT GLIOBLASTOMA BY IMMUNOGENIC C6 CELLS EXPRESSING ANTISENSE INSULIN-LIKE GROWTH FACTOR-I RNA	SCIENCE			English	Article							FACTOR IGF RECEPTORS; BREAST-CANCER; WILMS-TUMORS; GENE; LINES	Rat C6 glioma cells express insulin-like growth factor I (IGF-I) and form rapidly growing tumors in syngeneic animals. When transfected with an episome-based vector encoding antisense IGF-I complementary DNA, these cells lost tumorigenicity. Subcutaneous injection of IGF-I antisense-transfected C6 cells into rats prevented formation of both subcutaneous tumors and brain tumors induced by nontransfected C6 cells. The antisense-transfected cells also caused regression of established brain glioblastomas when injected at a point distal to the tumor. These antitumor effects result from a glioma-specific immune response involving CD8+ lymphocytes. Antisense blocking of IGF-I expression may reverse a phenotype that allows C6 glioma cells to evade the immune system.	CASE WESTERN RESERVE UNIV,DEPT REPROD BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT ANAT,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEV GENET & MOLEC BIOL LAB,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,CTR CANC,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106; INSERM,F-75005 PARIS,FRANCE	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Institut National de la Sante et de la Recherche Medicale (Inserm)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025004, R01HD018271] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43703] Funding Source: Medline; NICHD NIH HHS [HD-18271, HD-25004] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BLATT J, 1984, BIOCHEM BIOPH RES CO, V123, P373, DOI 10.1016/0006-291X(84)90423-6; BOEHM KD, 1989, P NATL ACAD SCI USA, V86, P656, DOI 10.1073/pnas.86.2.656; BREWER Y, 1990, P ANN M AM ASS CANCE, V31, pA247; BRUNNER N, 1990, Breast Cancer Research and Treatment, V16, P148; COLOUSCOU JM, 1987, INT J CANCER, V40, P646; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DRUCKREY H, 1965, Z KREBSFORSCH KLIN O, V66, P389, DOI 10.1007/BF00525737; FEARON ER, 1988, CANCER RES, V48, P2975; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FOEKENS JA, 1989, CANCER, V63, P2139, DOI 10.1002/1097-0142(19890601)63:11<2139::AID-CNCR2820631112>3.0.CO;2-D; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; GANSLER T, 1988, AM J PATHOL, V130, P431; HALL TC, 1988, P AM ASSOC CANC RES, V29, pA802; HAMBOR JE, 1988, P NATL ACAD SCI USA, V85, P4010, DOI 10.1073/pnas.85.11.4010; HELDIN CH, 1989, EUR J BIOCHEM, V184, P487, DOI 10.1111/j.1432-1033.1989.tb15041.x; HEWETT HB, 1976, BRIT J CANCER, V33, P241; HUFF KK, 1986, CANCER RES, V46, P4613; JING NH, 1991, IN VITRO CELL DEV B, V27, P864; MACAULAY VM, 1990, CANCER RES, V50, P2511; MINUTO F, 1988, CANCER RES, V48, P3716; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; ROHOLL PJM, 1990, HISTOPATHOLOGY, V16, P455; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SHOOTER EM, 1991, MODERN CONCEPTS INSU, P297; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; TROJAN J, 1984, DEV NEUROSCI-BASEL, V6, P251; TROJAN J, UNPUB; WILLIAMS DW, 1989, MOL CELL ENDOCRINOL, V61, P139, DOI 10.1016/0303-7207(89)90199-8; YANG DY, 1991, CARCINOGENESIS, V12, P1983	32	338	374	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					94	97		10.1126/science.8418502	http://dx.doi.org/10.1126/science.8418502			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418502				2022-12-28	WOS:A1993KE60100037
J	AHLQUIST, DA; WIEAND, HS; MOERTEL, CG; MCGILL, DB; LOPRINZI, CL; OCONNELL, MJ; MAILLIARD, JA; GERSTNER, JB; PANDYA, K; ELLEFSON, RD				AHLQUIST, DA; WIEAND, HS; MOERTEL, CG; MCGILL, DB; LOPRINZI, CL; OCONNELL, MJ; MAILLIARD, JA; GERSTNER, JB; PANDYA, K; ELLEFSON, RD			ACCURACY OF FECAL OCCULT BLOOD SCREENING FOR COLORECTAL NEOPLASIA - A PROSPECTIVE-STUDY USING HEMOCCULT AND HEMOQUANT TESTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYMPTOMATIC PATIENTS; CONTROLLED TRIAL; CHEMICAL-TESTS; CANCER; SENSITIVITY; SPECIFICITY; HEMOGLOBIN; PATTERNS	Objectives.-To define the validity of fecal blood as a marker for colorectal neoplasia in the screening setting and to compare yields by Hemoccult and HemoQuant fecal occult blood screening tests. Design.-A multicenter masked comparison of fecal blood test results against structural colorectal evaluations and longitudinal follow-up, serving as criterion standards, in nonreferred subjects at risk for colorectal neoplasia. Setting.-Communities, primary care centers, referral centers. Participants.-Two groups: (1) 1217 patients aged at least 18 years undergoing routine structural surveillance evaluations following curative resection of a colorectal tumor and (2) 12312 relatives of colorectal cancer patients aged at least 50 years. Interventions.-Blinded Hemoccult II and HemoQuant testing on three mailed-in stool samples per subject. Main Outcome Measure.-Sensitivity of fecal blood tests for colorectal neoplasia. Results.-In the postresection group, surveillance evaluations revealed 46 malignant colorectal neoplasms and 402 polyps. At matched specificity, sensitivity of either test for cancer was 26% (95% confidence interval, 13% to 39%). Hemoccult was positive in 21% of intraluminal recurrences, 33% of all new primary tumors, and 29% of Dukes A or B cancers; HemoQuant was elevated in 24%, 28%, and 29%, respectively. Sensitivity for polyps 1.0 cm or larger was 13% by Hemoccult and 11 % by HemoQuant. In the group of relatives, estimated sensitivity for cancer at 1 to 3 years of follow-up was 25% to 33% by Hemoccult, not significantly different from the 29% to 43% by HemoQuant. Conclusions.-Based on our observations in the screening setting, fecal blood appears to be a poor marker for colorectal neoplasia. Most cancers and the vast majority of polyps will be missed. Hemoccult and HemoQuant are similarly insensitive.	MAYO CLIN & MAYO FDN,N CENT CANC TREATMENT GRP,ROCHESTER,MN 55905; AMC CANC CTR,EASTERN COOPERAT ONCOL GRP,DENVER,CO; MAYO CLIN & MAYO FDN,DIV ONCOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV LAB MED,ROCHESTER,MN 55905	Mayo Clinic; AMC Cancer Research Center; Mayo Clinic; Mayo Clinic	AHLQUIST, DA (corresponding author), MAYO CLIN & MAYO FDN,DIV GASTROENTEROL,ROCHESTER,MN 55905, USA.				NATIONAL CANCER INSTITUTE [U10CA025224, R01CA039765, U10CA037404] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39765, CA 37404, CA 25224] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGREZ M, 1990, AUST NZ J SURG, V60, P451, DOI 10.1111/j.1445-2197.1990.tb07401.x; AHLQUIST DA, 1992, CANCER, V70, P1259, DOI 10.1002/1097-0142(19920901)70:3+<1259::AID-CNCR2820701511>3.0.CO;2-D; AHLQUIST DA, 1984, ANN INTERN MED, V101, P297, DOI 10.7326/0003-4819-101-3-297; AHLQUIST DA, 1988, ANN INTERN MED, V108, P609, DOI 10.7326/0003-4819-108-4-609; AHLQUIST DA, 1985, NEW ENGL J MED, V312, P1422, DOI 10.1056/NEJM198505303122204; AHLQUIST DA, 1989, CANCER, V63, P1826; AHLQUIST DA, 1991, TXB GASTROENTEROLOGY, P616; ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; BANG KM, 1986, J OCCUP ENVIRON MED, V28, P709, DOI 10.1097/00043764-198608000-00033; BEAM CA, 1991, BIOMETRICS, V47, P907, DOI 10.2307/2532648; CHAMBERLAIN J, 1990, BRIT J CANCER, V62, P1, DOI 10.1038/bjc.1990.216; CROWLEY ML, 1983, J CLIN GASTROENTEROL, V5, P127, DOI 10.1097/00004836-198304000-00007; DYBDAHL JH, 1984, SCAND J GASTROENTERO, V19, P245, DOI 10.1080/00365521.1984.12005716; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1987, GASTROENTEROLOGY, V92, P682, DOI 10.1016/0016-5085(87)90018-7; ELLEFSON RD, 1986, CLIN CHEM, V32, P1142; Frank J W, 1985, Am J Prev Med, V1, P18; FROMMER DJ, 1990, GASTROENTEROLOGY, V99, P607, DOI 10.1016/0016-5085(90)91063-C; GNAUCK R, 1977, LEBER MAGEN DARM, V7, P32; GOLDSCHMIEDT M, 1988, DIGEST DIS SCI, V33, P605, DOI 10.1007/BF01798364; HARDCASTLE JD, 1989, LANCET, V1, P1160; ILLINGWORTH BG, 1965, GUT, V6, P595; Iwase T., 1992, FECAL OCCULT BLOOD T, P90; JAFFE RM, 1975, ANN INTERN MED, V83, P824, DOI 10.7326/0003-4819-83-6-824; JAHN H, 1992, DIS COLON RECTUM, V35, P253, DOI 10.1007/BF02051018; KEWENTER J, 1988, CANCER, V62, P645, DOI 10.1002/1097-0142(19880801)62:3<645::AID-CNCR2820620333>3.0.CO;2-#; KNIGHT KK, 1989, JAMA-J AM MED ASSOC, V261, P587; KRONBORG O, 1989, SCAND J GASTROENTERO, V24, P599, DOI 10.3109/00365528909093096; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P899; MACRAE FA, 1982, GASTROENTEROLOGY, V82, P891; MANDEL JS, 1989, GASTROENTEROLOGY, V97, P597, DOI 10.1016/0016-5085(89)90629-X; MCGILL DB, 1987, GASTROEN CLIN BIOL, V11, P191; MORRIS JB, 1991, AM J SURG, V161, P101, DOI 10.1016/0002-9610(91)90368-N; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; OSTROW JD, 1973, AM J DIG DIS, V18, P930, DOI 10.1007/BF01072436; PYE G, 1990, BRIT J SURG, V77, P630, DOI 10.1002/bjs.1800770612; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; SCHENTAG JJ, 1980, NEW ENGL J MED, V303, P110; SCHWARTZ S, 1983, CLIN CHEM, V29, P2061; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; SONGSTER CL, 1980, CANCER, V45, P1099, DOI 10.1002/1097-0142(19800315)45:5+<1099::AID-CNCR2820451312>3.0.CO;2-T; STJOHN DJB, 1992, ANN INTERN MED, V117, P376, DOI 10.7326/0003-4819-117-5-376; STROEHLEIN JR, 1976, MAYO CLIN PROC, V51, P548; TATE JJT, 1990, BRIT J SURG, V77, P523, DOI 10.1002/bjs.1800770516; 1989, CA-CANCER J CLIN, V40, P77; 1989, JAMA-J AM MED ASSOC, V261, P586	50	271	290	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1262	1267		10.1001/jama.269.10.1262	http://dx.doi.org/10.1001/jama.269.10.1262			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437303				2022-12-28	WOS:A1993KP88500024
J	PERNEGER, TV; KLAG, MJ; FELDMAN, HI; WHELTON, PK				PERNEGER, TV; KLAG, MJ; FELDMAN, HI; WHELTON, PK			PROJECTIONS OF HYPERTENSION-RELATED RENAL-DISEASE IN MIDDLE-AGED RESIDENTS OF THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; ANTIHYPERTENSIVE TREATMENT; DECLINE; ASSOCIATION; PREVALENCE; MORTALITY; STROKE; HEALTH; RISK	Objective.-To establish nationwide projections for hypertension-related renal disease among middle-aged residents of the United States and compare disease burden in demographic subgroups. Design.-Integrated analysis of data from the US Census, the National Health and Nutrition Examination Survey of 1976 through 1980 (NHANES II), the 1971 through 1975 NHANES I Epidemiologic Follow-up Study, the Hypertension Detection and Follow-up Program trial, and the US Renal Data System. Population.-African-American and white residents of the United States, aged 30 to 69 years. Main Outcome Measures.-Incidence rates and counts of hypertension, hypertension-related hypercreatinemia, and hypertension-related end-stage renal disease (ESRD). Results.-Each year, approximately 1.8 million middle-aged Americans develop hypertension, 140000 develop hypertension-related hypercreatinemia, and 5300 develop hypertension-related ESRD. African Americans are at increased risk for hypertension (relative risk [RR], 1.6; population-attributable risk [PAR], 5%), hypercreatinemia if hypertensive (RR, 2.4; PAR, 18%), ESRD if hypertensive with hypercreatinemia (RR, 2.7; PAR, 32%), and hypertension-related ESRD overall (RR, 8.0; PAR, 44%). Compared with women, men are at increased risk for hypertension (RR, 1.3; PAR, 13%) and hypertension-related ESRD (RR, 1.6; PAR, 23%). Most cases of hypercreatinemia in hypertensives (73%) occur among those with mild hypertension. Conclusions.-Progression to ESRD is rare in persons with hypertension-related renal disease, and factors other than blood pressure probably play an important role. A large proportion of hypertension-related renal disease cases occur among population subgroups considered to be at low risk. Interventions that favorably influence factors associated with the progression of hypertension-related renal disease in African Americans, in men, and in persons with mild hypertension, hold the greatest potential for reducing the population burden of hypertension-related ESRD.	JOHNS HOPKINS UNIV, WELCH CTR PREVENT EPIDEMIOL & CLIN RES, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21218 USA; UNIV PENN, MED CTR, CTR CLIN EPIDEMIOL & BIOSTAT, PHILADELPHIA, PA 19104 USA; UNIV GENEVA, INST SOCIAL & PREVENT MED, CH-1211 GENEVA 4, SWITZERLAND	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Pennsylvania; University of Geneva					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00035, 5MOIRR00722] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CAMPESE VM, 1991, SEMIN NEPHROL, V11, P549; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; DRIZD T, 1986, VITAL HLTH STAT, V11; FELDMAN HI, 1992, AM J KIDNEY DIS, V19, P397, DOI 10.1016/S0272-6386(12)80945-0; FREEMAN J, 1980, AM J EPIDEMIOL, V112, P707, DOI 10.1093/oxfordjournals.aje.a113043; HOY W, 1988, AM J KIDNEY DIS, V12, P454, DOI 10.1016/S0272-6386(88)80046-5; KLAG MJ, 1989, STROKE, V20, P14, DOI 10.1161/01.STR.20.1.14; KLAG MJ, 1990, HYPERTENSION, V16, P700, DOI 10.1161/01.HYP.16.6.700; LINDEMAN RD, 1984, KIDNEY INT, V26, P861, DOI 10.1038/ki.1984.229; LUKE RG, 1991, HYPERTENSION, V18, P139; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MCCLELLAN W, 1988, AM J KIDNEY DIS, V12, P285, DOI 10.1016/S0272-6386(88)80221-X; PARVING HH, 1983, LANCET, V1, P1175; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; ROCCELLA EJ, 1991, ARCH INTERN MED, V151, P1280; ROSANSKY SJ, 1990, ARCH INTERN MED, V150, P2073, DOI 10.1001/archinte.150.10.2073; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; TUOMILEHTO J, 1986, BRIT MED J, V293, P1068, DOI 10.1136/bmj.293.6554.1068; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268; WEISSTUCH JM, 1992, KIDNEY INT, V41, pS33; WHELTON PK, 1992, J HYPERTENS, V10, pS77; WHELTON PK, 1984, J HYPERTENSION S2, V2, P3; WHELTON PK, 1989, HYPERTENSION S1, V13, P19, DOI DOI 10.1161/HYPERTENSIONAHA.113.02250; WHITTLE JC, 1991, ARCH INTERN MED, V151, P1359, DOI 10.1001/archinte.151.7.1359; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; 1990, CURRENT POPULATION P, V25; 1991, USRDS1991 NIH NAT I	30	75	78	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1272	1277		10.1001/jama.269.10.1272	http://dx.doi.org/10.1001/jama.269.10.1272			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437305				2022-12-28	WOS:A1993KP88500026
J	WELCH, WP; MILLER, ME; WELCH, HG; FISHER, ES; WENNBERG, JE				WELCH, WP; MILLER, ME; WELCH, HG; FISHER, ES; WENNBERG, JE			GEOGRAPHIC-VARIATION IN EXPENDITURES FOR PHYSICIANS SERVICES IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMALL AREA VARIATIONS; HEALTH-CARE DELIVERY; NEW-HAVEN; POPULATION; PROPOSAL; BOSTON; RATES	Background. The national volume-performance standard recently implemented by Medicare does not account for geographic variation in expenditures for physicians' services. To study this variation, we examined expenditures for physicians' services in all metropolitan areas in the United States. Methods. We used Medicare claims data for 1989 to measure rates of service use for beneficiaries living in the 317 U.S. metropolitan statistical areas (MSAs). The variables investigated were rates of admission to the hospital, payments to physicians for inpatient care per admission and per beneficiary, payments to physicians for outpatient care per beneficiary, and overall payments to physicians per beneficiary. Expenditures were measured in terms of allowed charges as adjusted to reflect prevailing charges in each MSA. Rates of use were adjusted for age and sex, with the exception of the variable for payments to physicians for inpatient care per admission, which was adjusted for case mix. Results. Expenditures for the delivery of physicians' services to Medicare beneficiaries varied markedly among MSAs, with those for the areas with the lowest and the highest rates differing at least twofold on each measure. The measures for specific areas varied in parallel: areas with high rates of admission tended to have high levels of payment to physicians for inpatient care per admission, and areas with high payments for inpatient services tended to have high payments for outpatient services. Expenditures were not related to the number of physicians per capita but were lower in MSAs with a high proportion of primary care practitioners. The variation persisted when the 25 largest MSAs were examined; for total payments to physicians per beneficiary, there was a twofold difference between the area with the lowest rate and that with the highest, San Francisco ($872) and Miami ($1,874). The states with the highest overall payments to physicians per beneficiary were Florida, Louisiana, and Michigan. Conclusions. The marked variation among metropolitan areas in payments to physicians underscores the lack of consensus among physicians about which services are required. Moreover, the practice style in a given community appears to be influenced not by the aggregate supply of physicians but rather by the mixture of primary care physicians and specialists.	VET AFFAIRS MED CTR,WHITE RIVER JCT,VT; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,CTR EVALUAT CLIN SCI,HANOVER,NH 03756	US Department of Veterans Affairs; Veterans Health Administration (VHA); Dartmouth College	WELCH, WP (corresponding author), URBAN INST,2100 M ST NW,WASHINGTON,DC 20037, USA.							CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CONNELL FA, 1984, MED CARE, V22, P939, DOI 10.1097/00005650-198410000-00006; FISHER ES, 1992, JAMA-J AM MED ASSOC, V267, P1925, DOI 10.1001/jama.267.14.1925; HIMMELSTEIN DU, 1989, NEW ENGL J MED, V320, P102, DOI 10.1056/NEJM198901123200206; HOLAHAN J, 1990, HEALTH AFFAIR, V9, P166, DOI 10.1377/hlthaff.9.4.166; Lazenby H C, 1990, Health Care Financ Rev, V12, P1; MILLER ME, 1992, MED CARE, V30, P630, DOI 10.1097/00005650-199207000-00005; MITCHELL JB, 1992, HEALTH AFFAIR, V11, P224, DOI 10.1377/hlthaff.11.1.224; POPE GC, 1988, INDEX MED PREVAILING; RICE T, 1990, MILBANK Q, V68, P295, DOI 10.2307/3350108; ROOS NP, 1982, MED CARE, V20, P945, DOI 10.1097/00005650-198209000-00007; WELCH WP, 1989, HEALTH AFFAIR, V8, P34, DOI 10.1377/hlthaff.8.1.34; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; Wennberg J E, 1984, Health Manage Q, P6, DOI 10.1377/hlthaff.3.2.6; WENNBERG JE, 1987, MED CARE, V25, P354, DOI 10.1097/00005650-198704000-00008; WENNBERG JE, 1977, J MAINE MED ASSOC, V68, P275; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; 1990, SOURCE BOOK HLTH INS, P86; 1986, NEW ENGL J MED, V314, P310; 1989, FED REGISTER, V54, P53818	23	319	331	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1993	328	9					621	627		10.1056/NEJM199303043280906	http://dx.doi.org/10.1056/NEJM199303043280906			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP680	8429854				2022-12-28	WOS:A1993KP68000006
J	DEVITA, VT; HUBBARD, SM				DEVITA, VT; HUBBARD, SM			DRUG-THERAPY - HODGKINS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BONE-MARROW TRANSPLANTATION; COMBINED MODALITY TREATMENT; HIGH-DOSE CHEMOTHERAPY; PROSPECTIVE RANDOMIZED TRIAL; COMBINATION CHEMOTHERAPY; RADIATION-THERAPY; MOPP CHEMOTHERAPY; SALVAGE CHEMOTHERAPY; COMPLETE REMISSION; HYBRID PROGRAM		NCI, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	DEVITA, VT (corresponding author), MEM SLOAN KETTERING CANC CTR, 1275 YORK AVE, NEW YORK, NY 10021 USA.							ANDERSON JR, 1990, 4TH INT C MAL LYMPH; BAKEMEIER RF, 1984, ANN INTERN MED, V101, P447, DOI 10.7326/0003-4819-101-4-447; BITI GP, 1992, J CLIN ONCOL, V10, P378, DOI 10.1200/JCO.1992.10.3.378; BONADONNA G, 1986, ANN INTERN MED, V104, P739, DOI 10.7326/0003-4819-104-6-739; BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7; BOOKMAN MA, 1986, CANCER TREAT REV, V13, P77, DOI 10.1016/0305-7372(86)90015-0; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; CARDE P, 1983, J CLIN ONCOL, V1, P146, DOI 10.1200/JCO.1983.1.2.146; CARELLA AM, 1988, J CLIN ONCOL, V6, P1411, DOI 10.1200/JCO.1988.6.9.1411; COLEMAN CN, 1977, NEW ENGL J MED, V297, P1249, DOI 10.1056/NEJM197712082972303; CROWTHER D, 1984, J CLIN ONCOL, V2, P892, DOI 10.1200/JCO.1984.2.8.892; DEVEREAUX S, 1989, BONE MARROW TRANSPL, V4, P49; DEVITA VT, 1980, ANN INTERN MED, V92, P587, DOI 10.7326/0003-4819-92-5-587; DEVITA VT, 1991, ANN ONCOL, V2, P93, DOI 10.1093/oxfordjournals.annonc.a057892; DEVITA VT, 1987, CANCER RES, V47, P5810; DONALDSON SS, 1987, J CLIN ONCOL, V5, P742, DOI 10.1200/JCO.1987.5.5.742; EKERT H, 1988, J CLIN ONCOL, V6, P1845, DOI 10.1200/JCO.1988.6.12.1845; FISHER RI, 1979, ANN INTERN MED, V90, P761, DOI 10.7326/0003-4819-90-5-761; FOX KA, 1987, J CLIN ONCOL, V5, P38, DOI 10.1200/JCO.1987.5.1.38; GLICK J, 1990, BLOOD S, V76, pA351; GLICK J, 1991, P AN M AM SOC CLIN, V10, P271; GLICK JH, 1978, INT J RADIAT ONCOL, V4, P909, DOI 10.1016/0360-3016(78)90055-X; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; GRIBBEN JG, 1989, BLOOD, V73, P340; GULATI SC, 1991, CURR PROB CANCER, V15, P5; HELLMAN S, 1989, CANCER PRINCIPLES PR, V2, P1696; HOPPE RT, 1982, BLOOD, V59, P455; HORNING SJ, 1988, J CLIN ONCOL, V6, P1822, DOI 10.1200/JCO.1988.6.12.1822; Hryniuk W M, 1988, Important Adv Oncol, P121; JAGANNATH S, 1989, J CLIN ONCOL, V7, P179, DOI 10.1200/JCO.1989.7.2.179; JONES RJ, 1990, J CLIN ONCOL, V8, P527, DOI 10.1200/JCO.1990.8.3.527; KESSINGER A, 1989, BLOOD, V74, P1260; KLIMO P, 1985, J CLIN ONCOL, V3, P1174, DOI 10.1200/JCO.1985.3.9.1174; KLIMO P, 1988, SEMIN HEMATOL, V25, P34; LISTER TA, 1983, J CLIN ONCOL, V1, P745, DOI 10.1200/JCO.1983.1.12.745; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; LONGO DL, 1991, J CLIN ONCOL, V9, P906, DOI 10.1200/JCO.1991.9.6.906; LONGO DL, 1992, J CLIN ONCOL, V10, P210, DOI 10.1200/JCO.1992.10.2.210; LONGO DL, 1991, J CLIN ONCOL, V9, P1409, DOI 10.1200/JCO.1991.9.8.1409; LONGO DL, 1991, J CLIN ONCOL, V9, P227, DOI 10.1200/JCO.1991.9.2.227; LONGO DL, 1986, J CLIN ONCOL, V4, P1295, DOI 10.1200/JCO.1986.4.9.1295; MAUCH P, 1987, J CLIN ONCOL, V5, P544, DOI 10.1200/JCO.1987.5.4.544; MAUCH P, 1978, CANCER-AM CANCER SOC, V42, P1039, DOI 10.1002/1097-0142(197809)42:3<1039::AID-CNCR2820420302>3.0.CO;2-R; MAUCH P, 1985, J CLIN ONCOL, V3, P1166, DOI 10.1200/JCO.1985.3.9.1166; MCELWAIN TJ, 1977, BRIT J CANCER, V36, P276, DOI 10.1038/bjc.1977.187; OREILLY SE, 1991, ANN ONCOL, V2, P17, DOI 10.1093/annonc/2.suppl_1.17; PEDERSENBJERGAARD J, 1987, LANCET, V2, P83, DOI 10.1016/S0140-6736(87)92744-9; PHILIP T, 1986, BRIT J CANCER, V53, P737, DOI 10.1038/bjc.1986.127; PHILLIPS GL, 1989, BLOOD, V73, P2086; PROSNITZ LR, 1988, J CLIN ONCOL, V6, P603, DOI 10.1200/JCO.1988.6.4.603; SANTORO A, 1982, NEW ENGL J MED, V306, P770, DOI 10.1056/NEJM198204013061303; SANTORO A, 1982, ANN INTERN MED, V96, P139, DOI 10.7326/0003-4819-96-2-139; SUTCLIFFE SB, 1978, BRIT MED J, V1, P679, DOI 10.1136/bmj.1.6114.679; TAYLOR KM, 1989, J CLIN ONCOL, V7, P1791, DOI 10.1200/JCO.1989.7.12.1791; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VANRIJSWIJK REN, 1989, J CLIN ONCOL, V7, P1776, DOI 10.1200/JCO.1989.7.12.1776; VIVIANI S, 1990, ANN ONCOL, V1, P123, DOI 10.1093/oxfordjournals.annonc.a057689; VOSE J, 1988, AM J CLIN ONCOL-CANC, V11, P423, DOI 10.1097/00000421-198808000-00001; VOSE JM, 1990, SEMIN ONCOL, V17, P749; WIERNIK PH, 1988, J CANCER RES CLIN, V114, P105, DOI 10.1007/BF00390494; ZULIAN GB, 1989, BRIT J CANCER, V59, P631, DOI 10.1038/bjc.1989.128	61	101	102	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					560	565						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8426624				2022-12-28	WOS:A1993KP05300008
J	HALL, WH; GOLLAN, JL; BULKLEY, GB; DIEHL, AM; ELASHOFF, JD; FEDERLE, MP; HENDERSON, JM; HOGAN, WJ; KELLY, KA; MASSANARI, DL; POWELL, DW; RIKKERS, LF; SORRELL, M; THIEL, TK; WILSON, JAP				HALL, WH; GOLLAN, JL; BULKLEY, GB; DIEHL, AM; ELASHOFF, JD; FEDERLE, MP; HENDERSON, JM; HOGAN, WJ; KELLY, KA; MASSANARI, DL; POWELL, DW; RIKKERS, LF; SORRELL, M; THIEL, TK; WILSON, JAP			GALLSTONES AND LAPAROSCOPIC CHOLECYSTECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV GASTROENTEROL, BOSTON, MA 02115 USA; JOHNS HOPKINS MED INST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV GASTROENTEROL, BALTIMORE, MD 21205 USA; CEDARS SINAI MED CTR, DEPT MED, DIV BIOSTAT, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, MED CTR, LOS ANGELES, CA USA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA; CLEVELAND CLIN EDUC FDN, DEPT GEN SURG, CLEVELAND, OH 44106 USA; MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA; FROEDBERT MEM LUTHERAN HOSP, DIV GASTROENTEROL, MILWAUKEE, WI USA; MAYO CLIN & MAYO FDN, MAYO MED SCH, DEPT SURG, ROCHESTER, MN 55905 USA; SANFORD FAMILY HLTH CARE PA, SANFORD, ME USA; UNIV TEXAS, MED BRANCH, DEPT INTERNAL MED, GALVESTON, TX 77550 USA; UNIV NEBRASKA, MED CTR, DEPT SURG, OMAHA, NE 68105 USA; UNIV NEBRASKA, MED CTR, LIVER TRANSPLANT PROGRAM, OMAHA, NE 68105 USA; AMER LIVER FDN, CEDAR GROVE, NJ USA; DUKE UNIV, MED CTR, DIV GASTROENTEROL, OUTPATIENT SERV, DURHAM, NC 27710 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cleveland Clinic Foundation; Medical College of Wisconsin; Mayo Clinic; University of Texas System; University of Texas Medical Branch Galveston; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Duke University	HALL, WH (corresponding author), NIH, OFF MED APPLICAT RES, FED BLDG, ROOM 618, BETHESDA, MD 20892 USA.		Powell, Don W/K-4774-2014						0	248	256	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					1018	1024		10.1001/jama.1993.03500080066034	http://dx.doi.org/10.1001/jama.1993.03500080066034			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM603	8429583				2022-12-28	WOS:A1993KM60300031
J	SONNICHSEN, FD; SYKES, BD; CHAO, H; DAVIES, PL				SONNICHSEN, FD; SYKES, BD; CHAO, H; DAVIES, PL			THE NONHELICAL STRUCTURE OF ANTIFREEZE PROTEIN TYPE-III	SCIENCE			English	Article							MACROZOARCES-AMERICANUS; POLAR FISHES; OCEAN POUT; PEPTIDES; GLYCOPEPTIDES; POLYPEPTIDE; ADSORPTION; INHIBITION; DIVERSITY; SURFACE	Antifreeze proteins (AFPs) are present in the blood of some marine fishes and inhibit the growth of ice crystals at subzero temperatures by adsorption to the ice lattice. The solution structure of a Type III AFP was determined by two-dimensional nuclear magnetic resonance spectroscopy. These measurements indicate that this 66-residue protein has an unusual fold in which eight beta strands form two sheets of three antiparallel strands and one sheet of two antiparallel strands, and the triple-stranded sheets are packed orthogonally into a beta sandwich. This structure is completely different from the amphipathic, helical structure observed for Type I AFPs.	UNIV ALBERTA,CTR EXCELLENCE,PROT ENGN NETWORK,EDMONTON T6G 2S2,AB,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2S2,AB,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA	University of Alberta; University of Alberta; Queens University - Canada			Sönnichsen, Frank D/D-8408-2011	Sönnichsen, Frank D/0000-0002-4539-3755				ANANTHANARAYANAN VS, 1986, BIOCHIM BIOPHYS ACTA, V870, P154, DOI 10.1016/0167-4838(86)90019-1; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; CHOTHIA C, 1982, BIOCHEMISTRY-US, V21, P3955, DOI 10.1021/bi00260a009; CHOU KC, 1992, J MOL BIOL, V223, P509, DOI 10.1016/0022-2836(92)90666-8; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DEVRIES AL, 1984, PHILOS T R SOC B, V304, P575; DEVRIES AL, 1983, ANNU REV PHYSIOL, V45, P245, DOI 10.1146/annurev.ph.45.030183.001333; Feeney R E, 1978, Adv Protein Chem, V32, P191, DOI 10.1016/S0065-3233(08)60576-8; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P45; HAYES PH, 1989, J BIOL CHEM, V264, P18761; HEW CL, 1988, J BIOL CHEM, V263, P12049; HEW CL, 1992, EUR J BIOCHEM, V203, P33, DOI 10.1111/j.1432-1033.1992.tb19824.x; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; SLAUGHTER D, 1981, J BIOL CHEM, V256, P2022; SONNICHSEN FD, UNPUB; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WEN DY, 1992, J BIOL CHEM, V267, P14102; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0	24	98	102	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 19	1993	259	5098					1154	1157		10.1126/science.8438165	http://dx.doi.org/10.1126/science.8438165			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8438165				2022-12-28	WOS:A1993KM91700037
J	ONEK, LU				ONEK, LU			THE EAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					918	918						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL474	8426453				2022-12-28	WOS:A1993KL47400034
J	HURLEY, JH; FABER, HR; WORTHYLAKE, D; MEADOW, ND; ROSEMAN, S; PETTIGREW, DW; REMINGTON, SJ				HURLEY, JH; FABER, HR; WORTHYLAKE, D; MEADOW, ND; ROSEMAN, S; PETTIGREW, DW; REMINGTON, SJ			STRUCTURE OF THE REGULATORY COMPLEX OF ESCHERICHIA-COLI III(GLC) WITH GLYCEROL KINASE	SCIENCE			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; PHOSPHOCARRIER PROTEIN-IIIGLC; SIGNAL-TRANSDUCING PROTEIN; SHOCK COGNATE PROTEIN; 3-DIMENSIONAL STRUCTURE; SALMONELLA-TYPHIMURIUM; ISOCITRATE DEHYDROGENASE; SECONDARY STRUCTURE; ATPASE FRAGMENT; SUGAR-TRANSPORT	The phosphocarrier protein III(Glc) is an integral component of the bacterial phosphotransferase (PTS) system. Unphosphorylated III(Glc) inhibits non-PTS carbohydrate transport systems by binding to diverse target proteins. The crystal structure at 2.6 angstrom resolution of one of the targets, glycerol kinase (GK), in complex with unphosphorylated III(Glc), glycerol, and adenosine diphosphate was determined. GK contains a region that is topologically identical to the adenosine triphosphate binding domains of hexokinase, the 70-kD heat shock cognate, and actin. III(Glc) binds far from the catalytic site of GK, indicating that long-range conformational changes mediate the inhibition of GK by III(Glc). GK and III(Glc) are bound by hydrophobic and electrostatic interactions, with only one hydrogen bond involving an uncharged group. The phosphorylation site of III(Glc), His90, is buried in a hydrophobic environment formed by the active site region of III(Glc) and a 3(10) helix of GK, suggesting that phosphorylation prevents III(Glc) binding to GK by directly disrupting protein-protein interactions.	UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA; UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA; TEXAS A&M UNIV SYST, DEPT BIOCHEM & BIOPHYS, COLL STN, TX 77843 USA	University of Oregon; University of Oregon; Johns Hopkins University; Johns Hopkins University; Texas A&M University System; Texas A&M University College Station					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042618, R37GM038759] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-R37 GM38759, GM 42618-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; BENNETT WS, 1980, J MOL BIOL, V140, P183, DOI 10.1016/0022-2836(80)90102-3; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLORE GM, 1989, J BIOL CHEM, V264, P18907; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; DERIEL JK, 1978, BIOCHEMISTRY-US, V17, P5146, DOI 10.1021/bi00617a012; DERIEL JK, 1978, BIOCHEMISTRY-US, V17, P5134, DOI 10.1021/bi00617a010; FABER HR, 1989, J MOL BIOL, V207, P637, DOI 10.1016/0022-2836(89)90473-7; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FROHLICH KU, 1985, GENE, V36, P105, DOI 10.1016/0378-1119(85)90074-5; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOEFFKEN HW, 1988, J MOL BIOL, V204, P417, DOI 10.1016/0022-2836(88)90586-4; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P7774, DOI 10.1021/bi00371a073; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEADOW ND, 1986, J BIOL CHEM, V261, P3504; NOVOTNY MJ, 1985, J BACTERIOL, V162, P810, DOI 10.1128/JB.162.2.810-816.1985; PELTON JG, 1991, P NATL ACAD SCI USA, V88, P3479, DOI 10.1073/pnas.88.8.3479; PELTON JG, 1992, BIOCHEMISTRY-US, V31, P5215, DOI 10.1021/bi00137a017; PELTON JG, 1991, BIOCHEMISTRY-US, V30, P10043, DOI 10.1021/bi00105a032; PELTON JG, IN PRESS PROTEIN SCI; PETTIGREW DW, UNPUB; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; POSTMA PW, 1984, J BACTERIOL, V158, P351, DOI 10.1128/JB.158.1.351-353.1984; PRESPER KA, 1989, P NATL ACAD SCI USA, V86, P4052, DOI 10.1073/pnas.86.11.4052; REIZER J, 1992, J BIOL CHEM, V267, P9158; ROSEMAN S, 1990, J BIOL CHEM, V265, P2993; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; SCHMID MF, 1981, ACTA CRYSTALLOGR A, V37, P701, DOI 10.1107/S0567739481001587; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; THORNER JW, 1973, J BIOL CHEM, V248, P3922; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382	52	215	219	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1993	259	5095					673	677		10.1126/science.8430315	http://dx.doi.org/10.1126/science.8430315			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430315				2022-12-28	WOS:A1993KJ68800040
J	GALLI, SJ				GALLI, SJ			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - NEW CONCEPTS ABOUT THE MAST-CELL	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NECROSIS-FACTOR-ALPHA; ONCOGENE C-KIT; LEUKOCYTE ADHESION MOLECULE-1; TYROSINE KINASE RECEPTOR; CONNECTIVE-TISSUE TYPE; DEFICIENT W/WV MICE; FC-EPSILON-RI; TNF-ALPHA; SI-LOCUS; ALLERGIC REACTIONS		HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	GALLI, SJ (corresponding author), BETH ISRAEL HOSP,DEPT PATHOL,DIV EXPTL PATHOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NIAID NIH HHS [AI 31982, AI 22674, AI 23990] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031982, R01AI023990, R37AI023990, R01AI022674] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ASKENASE PW, 1980, SPRINGER SEMIN IMMUN, V2, P417, DOI 10.1007/BF01857177; BIENENSTOCK J, 1989, MAST CELL BASOPHIL D, P275; BIENENSTOCK J, 1986, MAST CELL DIFFERENTI, P391; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BROWN SJ, 1982, J IMMUNOL, V129, P790; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Church M. RC. B. PH. R. MA. L., 1989, MAST CELL BASOPHIL D, P161; CIRILLO R, 1990, J IMMUNOL, V144, P3891; CLAMAN HN, 1989, JAMA-J AM MED ASSOC, V262, P1206, DOI 10.1001/jama.262.9.1206; COHAN VL, 1989, MAST CELL BASOPHIL D, P149; COLUMBO M, 1992, J IMMUNOL, V149, P599; DELPOZO V, 1990, J IMMUNOL, V144, P3117; Ehrlich P., 1878, THESIS U LEIPZIG LEI; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GALLI SJ, 1990, LAB INVEST, V62, P5; GALLI SJ, 1991, CURR OPIN IMMUNOL, V3, P865, DOI 10.1016/S0952-7915(05)80005-6; GALLI SJ, 1984, PROG ALLERGY, V34, P1; GALLI SJ, 1988, ALLERGY PRINCIPLES P, P106; GALLI SJ, IN PRESS J CLIN INVE; GALLI SJ, IN PRESS EOSINOPHILS; GALLI SJ, 1992, ROLE MAST CELL HLTH, P129; GALLI SJ, IN PRESS BLOOD PRINC; GEISSLER EN, 1990, CELL, V63, P175; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1991, FASEB J, V5, pA1009; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; HATFIELD SM, 1992, J PHARMACOL EXP THER, V260, P680; HOLGATE ST, 1988, ALLERGY PRINCIPLES P, P135; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; ISHIZAKA T, 1992, FASEB J, V6, pA1403; Ishizaka T, 1988, ALLERGY PRINCIPLES P, P71; JARRETT EEE, 1982, PROG ALLERGY, V31, P178; KAY AB, 1992, AM REV RESPIR DIS, V145, pS22, DOI 10.1164/ajrccm/145.2_Pt_2.S22; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; KIRSCHENBAUM AS, 1989, MAST CELL BASOPHIL D, P317; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; KLEIN LM, 1989, P NATL ACAD SCI USA, V86, P8972, DOI 10.1073/pnas.86.22.8972; KLUINNELEMANS HC, 1992, NEW ENGL J MED, V326, P619, DOI 10.1056/NEJM199202273260907; LEMANSKE RF, 1988, ALLERGY PRINCIPLES P, P224; LERNER NB, 1991, BLOOD, V77, P1876; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; MACQUEEN G, 1989, SCIENCE, V243, P83, DOI 10.1126/science.2911721; MARSH D, 1988, ALLERGY PRINCIPLES P, P94; MATSUDA H, 1990, J IMMUNOL, V144, P259; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NILSSON G, 1992, FASEB J, V6, pA1722; PERDUE MH, 1991, J CLIN INVEST, V87, P687, DOI 10.1172/JCI115047; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; SCHWARTZ LB, 1989, MAST CELL BASOPHIL D, P93; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; SEKIDO Y, 1991, CANCER RES, V51, P2416; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; Selye H, 1965, MAST CELLS; SLIFMAN NR, 1988, ALLERGY PRINCIPLES P, P179; STEEVES EBT, 1990, INT J PARASITOL, V20, P655, DOI 10.1016/0020-7519(90)90124-6; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; STROHMEYER T, 1991, CANCER RES, V51, P1811; TRAVIS WD, 1990, MEDICINE, V69, P34; TRIGGIANI M, 1989, INT ARCH ALLER A IMM, V88, P253, DOI 10.1159/000234801; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; VALENT P, 1990, INT ARCH ALLER A IMM, V91, P198, DOI 10.1159/000235115; VALENT P, 1990, CRIT REV ONCOL HEMAT, V10, P327, DOI 10.1016/1040-8428(90)90009-H; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; WANG C, 1989, LEUKEMIA, V3, P699; WASSERMAN SI, 1988, ALLERGY PRINCIPLES P, P1365; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WERSHIL BK, 1992, J EXP MED, V175, P245, DOI 10.1084/jem.175.1.245; WERSHIL BK, 1992, FASEB J, V6, pA1716; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WONG DTW, 1991, BLOOD, V78, P2702; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	89	895	936	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1993	328	4					257	265						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ442	8418407				2022-12-28	WOS:A1993KJ44200008
J	COUSO, JP; BATE, M; MARTINEZARIAS, A				COUSO, JP; BATE, M; MARTINEZARIAS, A			A WINGLESS-DEPENDENT POLAR COORDINATE SYSTEM IN DROSOPHILA IMAGINAL DISKS	SCIENCE			English	Article							PATTERN-FORMATION; MOUSE DEVELOPMENT; LIMB DEVELOPMENT; CONTAINING GENES; ENGRAILED GENE; EXPRESSION; DISKS; MELANOGASTER; MUTATION; EMBRYOS	The patterning of the imaginal discs in Drosophila melanogaster is a progressive process that, like the patterning of the larval epidermis during embryogenesis, requires the activity of segment polarity genes. One segment polarity gene, wingless, encodes a homolog of the mouse proto-oncogene Wnt-1 and plays a prominent role in the patterning of the larval epidermis and the imaginal discs. However, whereas the function of wingless in the embryo is initially associated with a pattern of stripes along the anteroposterior axis that are part of a Cartesian coordinate system, it is shown here that during imaginal development wingless is associated with a pattern of sectors that provide references for a polar coordinate system homologous to that postulated in a well-known model for the regeneration of insect and vertebrate limbs.			COUSO, JP (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, CAMBRIDGE CB2 3EJ, ENGLAND.		Couso, Juan Pablo/ABH-5860-2020; Martinez Arias, Alfonso/F-1966-2010		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARIAS AM, 1989, TRENDS GENET, V5, P262, DOI 10.1016/0168-9525(89)90099-1; Ashburner M., 1989, DROSOPHILA LAB MANUA, P165; Auerbach C., 1936, Transactions of the Royal Society of Edinburgh, V58, P787; BAKER NE, 1988, DEVELOPMENT, V102, P489; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BATE M, 1991, DEVELOPMENT, V112, P755; BATE M, 1991, DEVELOPMENT, V113, P79; BATE M, 1990, DEVELOPMENT, V110, P791; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BODENSTEIN D, 1953, BIOL DROSOPHILA, P275; BROWER DL, 1986, EMBO J, V5, P2649, DOI 10.1002/j.1460-2075.1986.tb04547.x; BRYANT SV, 1986, TRENDS GENET, V2, P153, DOI 10.1016/0168-9525(86)90210-6; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COUSO JP, UNPUB; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GARCIABELLIDO A, 1972, GENETICS, V72, P87; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GELBART WM, 1989, DEVELOPMENT, V107, P65; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JAMES AA, 1981, DEV BIOL, V85, P39, DOI 10.1016/0012-1606(81)90234-7; KARLSSON J, 1980, J EMBRYOL EXP MORPH, V59, P315; KASSIS JA, IN PRESS P NATL ACAD; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LAWRENCE PA, 1977, DEV BIOL, V56, P40, DOI 10.1016/0012-1606(77)90153-1; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; MARTINEZARIAS A, IN PRESS DEV DROSOPH; MEINHARDT H, 1982, DEV ORDER ITS ORIGIN, P439; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PESACRETA TC, 1989, J CELL BIOL, V108, P1697, DOI 10.1083/jcb.108.5.1697; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; SANG J, 1984, GENETICS DEV, P295; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SIMCOX AA, 1989, DEVELOPMENT, V107, P715; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2; WHITELEY M, 1992, MECH DEVELOP, V36, P117, DOI 10.1016/0925-4773(92)90063-P; Whittle J R, 1990, Semin Cell Biol, V1, P241; WILKINS AS, 1991, DEV BIOL, V145, P1, DOI 10.1016/0012-1606(91)90208-K	50	248	250	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 22	1993	259	5094					484	489		10.1126/science.8424170	http://dx.doi.org/10.1126/science.8424170			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424170				2022-12-28	WOS:A1993KJ07900025
J	LEHMAN, N; JOYCE, GF				LEHMAN, N; JOYCE, GF			EVOLUTION INVITRO OF AN RNA ENZYME WITH ALTERED METAL DEPENDENCE	NATURE			English	Article							GROUP-I INTRONS; SECONDARY STRUCTURE; CATALYTIC RNA; ACTIVE-SITE; TETRAHYMENA; REQUIREMENTS; AMPLIFICATION; RIBOZYME	THE Tetrahymena group I ribozyme catalyses a sequence-specific phosphodiester cleavage reaction on an external RNA oligonucleotide substrate in the presence of a divalent metal cation cofactor1. This reaction proceeds readily with either Mg2+ or Mn2+, but no detectable reaction has been reported when other divalent cations are used as the sole cofactor2-5. Cations such as Ca2+, Sr2+ and Ba2+ can stabilize the correct folded conformation of the ribozyme, thereby partially alleviating the Mg2+ or Mn2+ requirement2. But catalysis by the ribozyme involves coordination of either Mg2+ or Mn2+ at the active site, resulting in an overall requirement for one of these two cations5. Here we use an in vitro evolution process6,7 to obtain variants of the Tetrahymena ribozyme that are capable of cleaving an RNA substrate in reaction mixtures containing Ca2+ as the divalent cation. These findings extend the range of different chemical environments available to RNA enzymes and illustrate the power of in vitro evolution in generating macromolecular catalysts with desired properties.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	LEHMAN, N (corresponding author), SCRIPPS RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Lehman, Niles/ABF-7609-2021; Lehman, Niles/A-3434-2008	Lehman, Niles/0000-0002-9056-6600; 				BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BEAUDRY AA, 1990, BIOCHEMISTRY-US, V29, P6534, DOI 10.1021/bi00479a027; BURKE JM, 1988, GENE, V73, P273, DOI 10.1016/0378-1119(88)90493-3; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; Fisher R.A., 1930, GENETICAL THEORY NAT; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUATELLI JC, 1990, P NATL ACAD SCI USA, V87, P1874, DOI 10.1073/pnas.87.5.1874; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; JOYCE GF, 1992, ANTISENSE RNA DNA, P353; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PRICE JV, 1985, NUCLEIC ACIDS RES, V13, P1871, DOI 10.1093/nar/13.6.1871; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; SZOSTAK JW, 1986, NATURE, V322, P83, DOI 10.1038/322083a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	22	163	187	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					182	185		10.1038/361182a0	http://dx.doi.org/10.1038/361182a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421526				2022-12-28	WOS:A1993KG46600069
J	DRAPER, GJ; STILLER, CA; CARTWRIGHT, RA; CRAFT, AW; VINCENT, TJ				DRAPER, GJ; STILLER, CA; CARTWRIGHT, RA; CRAFT, AW; VINCENT, TJ			CANCER IN CUMBRIA AND IN THE VICINITY OF THE SELLAFIELD NUCLEAR INSTALLATION, 1963-90	BRITISH MEDICAL JOURNAL			English	Article							WEST CUMBRIA; CHILDHOOD LEUKEMIA; CHILDREN BORN; ENGLAND; WALES; SEASCALE; BRITISH; FOLLOW; COHORT	Objective-To reappraise the epidemiological findings reported by the Black Advisory Group concerning a possible excess of malignant disease, particularly of childhood acute lymphoid leukaemia and non-Hodgkin lymphomas, in the vicinity of the Sellafield nuclear installation, and to determine whether any excess of malignant disease had occurred among people aged 0-24 years in the area in the years after the Black report-that is, from 1984 to 1990. Design-Calculation of incidence of cancer using data from population based cancer registries and special surveys. Setting-England and Wales; county of Cumbria; county districts Allerdale and Copeland within Cumbria; Seascale ward within Copeland. Subjects-All residents under the age of 75 years in the above areas, but with particular reference to those aged 0-24 years. Main outcome measures-Numbers of cases and incidence particularly of lymphoid leukaemia and non-Hodgkin lymphomas in those aged 0-24 years, but including other cancers and age groups. Results-Previous reports of an increased incidence of cancer, especially of leukaemia, among those aged 0-24 years in Seascale during the period up to and including 1983 are confirmed. During 1984-90 there was an excess of total cancer among those aged 0-24 years. This was based on four cases including two cases of non-Hodgkin lymphoma but none of leukaemia. There was an increased, but non-significant, incidence of other cancers, based on two cases (one pinealoma and one Hodgkin's disease) occurring among those aged 15-24 years during 1984-90. This was not observed in the younger age group or in previous years. For the immediately surrounding area-that is, the county districts of Allerdale and Copeland excluding Seascale and in the remainder of Cumbria-there was no evidence of an increased incidence of cancer among those aged 0-24 years in either period. Conclusions-During 1963-83 and 1984-90 the incidence of malignant disease, particularly lymphoid leukaemia and non-Hodgkin lymphomas, in young people aged 0-24 in Seascale was higher than would be expected on the basis of either national rates or those for the surrounding areas. Although this increased risk is unlikely to be due to chance, the reasons for it are still unknown.	UNIV LEEDS,LEUKAEMIA RES FUND CTR CLIN EPIDEMIOL,LEEDS LS2 9NG,W YORKSHIRE,ENGLAND; ROYAL VICTORIA INFIRM,DEPT CHILDRENS,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	University of Leeds; Newcastle University - UK	DRAPER, GJ (corresponding author), UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND.			Stiller, Charles/0000-0002-3006-7869				ALEXANDER FE, 1990, LANCET, V336, P1461, DOI 10.1016/0140-6736(90)93176-P; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; BIRCH JM, 1988, IARC SCI PUBL, V87, P299; BITHELL JF, 1975, BRIT J CANCER, V31, P271, DOI 10.1038/bjc.1975.62; BLACK D, 1984, INVESTIGATION POSSIB; CARTWRIGHT RA, 1990, LEUKAEMIA LYMPHOMA A; COOKMOZAFFARI PJ, 1989, BRIT J CANCER, V59, P476, DOI 10.1038/bjc.1989.99; CRAFT AW, 1987, BRIT J CANCER, V56, P853, DOI 10.1038/bjc.1987.305; CRAFT AW, IN PRESS J EPIDEMIOL; Draper G.J., 1991, OPCS STUDIES MED POP, V53, P37; GARDNER MJ, 1987, BRIT MED J, V295, P819, DOI 10.1136/bmj.295.6602.819; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; MCLAUGHLIN JR, 1992, OCCUPATIONAL EXPOSUR; STILLER CA, 1991, OPCS STUDIES MED POP, V53, P7; SWERDLOW AJ, 1986, J ROY STAT SOC A STA, V149, P146, DOI 10.2307/2981527; 1986, IMPLICATIONS NEW DAT; 1988, COMARE2ND COMM MED A; 1989, COMARE3RD COMM MED A	21	72	74	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					89	94		10.1136/bmj.306.6870.89	http://dx.doi.org/10.1136/bmj.306.6870.89			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435648	Green Published, Bronze			2022-12-28	WOS:A1993KG46500016
J	NUTBEAM, D; MACASKILL, P; SMITH, C; SIMPSON, JM; CATFORD, J				NUTBEAM, D; MACASKILL, P; SMITH, C; SIMPSON, JM; CATFORD, J			EVALUATION OF 2 SCHOOL SMOKING EDUCATION-PROGRAMS UNDER NORMAL CLASSROOM CONDITIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							6-YEAR FOLLOW-UP; PREVENTION PROGRAMS; CIGARETTE-SMOKING; ADOLESCENTS; ONSET	Objectives-To assess the effectiveness of two school based smoking education projects in delaying onset of smoking behaviour and in improving health knowledge, beliefs, and values. Design-Cluster randomised controlled trial of two projects taught under normal classroom conditions. Schools were allocated to one of four groups to receive the family smoking education project (FSE); the smoking and me project (SAM); both projects in sequence (FSE/SAM); or no intervention at all. Setting-39 schools in Wales and England matched for size and catchment profile. Subjects-All first year pupils in the schools were included and were assessed on three occasions (4538 before teaching (1988), 3930 immediately after teaching (1989), 3786 at one year follow up (1990)). Main outcome measures-Self reported smoking behaviour (backed by saliva sample) and change in relevant health knowledge, beliefs, and values. Results-No consistent significant differences in smoking behaviour, health knowledge, beliefs, or values were found between the four groups. For never smokers at baseline the rate of remaining never smokers in 1990 was 74% (594/804) in the control group, 65% (455/704) in the FSE group, 70% (440/625) in the SAM group, and 69% (549/791) in the FSE/SAM group (chi(adj)2=6.1, df=3, p=0.1). Knowledge about effects of smoking rose in all groups from a mean score of 5.4 in 1988 to 6.4 in 1989 and 6.5 in 1990. Conclusions-More comprehensive interventions than school health education alone will be needed to reduce teenage smoking. Other measures including further restrictions on access to cigarettes and on the promotion of tobacco products need to be considered. Further research will be needed to develop effective school based health education projects, which should be formally field tested under normal conditions before widespread dissemination.	HLTH PROMOT AUTHOR WALES, CARDIFF CF2 1EB, WALES		NUTBEAM, D (corresponding author), UNIV SYDNEY, DEPT PUBL HLTH, SYDNEY, NSW 2006, AUSTRALIA.		Nutbeam, Don/AAU-1571-2021	Macaskill, Petra/0000-0001-5879-6193; Nutbeam, Don/0000-0001-6497-2827				AARO LE, 1983, SCAND J PSYCHOL, V24, P277; AARO LE, 1989, HLTH BEHAVIOUR SCHOO; AITKEN M, 1989, STATISTICAL MODELLIN; Aitken P., 1986, HLTH ED RES, V1, P203, DOI DOI 10.1093/her/1.3.203; ARKIN RM, 1981, J SCHOOL HEALTH, V51, P611, DOI 10.1111/j.1746-1561.1981.tb02246.x; Bewley B R, 1980, Community Med, V2, P186; BLACKWELL SE, 1988, ASSESSING EFFECTIVEN; BOTVIN GJ, 1980, PREV MED, V9, P135, DOI 10.1016/0091-7435(80)90064-X; BRIER SS, 1980, BIOMETRIKA, V67, P591; BYNNER JM, 1969, YOUNG SMOKER SMOKING; CHAPMAN S, 1980, PUSHING SMOKE TOBACC, P39; CHARLTON A, 1990, MANUAL TOBACCO YOUNG; DOBBS J, 1985, SMOKING SECONDARY SC; DOBBS J, 1983, SMOKING SECONDARY SC; DONALD A, 1987, STAT MED, V6, P491, DOI 10.1002/sim.4780060408; EVANS RI, 1981, J APPL PSYCHOL, V66, P399, DOI 10.1037/0021-9010.66.4.399; FLAY BR, 1989, AM J PUBLIC HEALTH, V79, P1371, DOI 10.2105/AJPH.79.10.1371; GLYNN TJ, 1989, J SCHOOL HEALTH, V59, P181, DOI 10.1111/j.1746-1561.1989.tb04698.x; GODDARD E, 1987, SMOKING SECONDARY SC; GODDARD E, 1989, SMOKING SECONDARY SC; KISHCHUK N, 1990, J SCHOOL HEALTH, V60, P448, DOI 10.1111/j.1746-1561.1990.tb05973.x; LADER D, 1991, SMOKING SECONDARY SC; LAWRENCE D, 1981, BRIT J EDUC PSYCHOL, V51, P245, DOI 10.1111/j.2044-8279.1981.tb02481.x; MALES M, 1990, J SCHOOL HEALTH, V60, P505, DOI 10.1111/j.1746-1561.1990.tb05891.x; MCKENNELL AC, 1980, INT J EPIDEMIOL, V9, P167, DOI 10.1093/ije/9.2.167; MURRAY DM, 1989, J BEHAV MED, V12, P207, DOI 10.1007/BF00846551; MURRAY DM, 1992, MINNESOTA WISCONSIN; MURRAY M, 1983, INT J EPIDEMIOL, V12, P185, DOI 10.1093/ije/12.2.185; MURRAY M, 1988, EVALUATION DIFFERENT; Newman R, 1991, HLTH ED J, V50, P107; NEWMAN R, 1989, HLTH ED J, V48, P9; NUTBEAM D, 1989, PLANNING SMOKE FREE; NUTBEAM D, 1988, ED HLTH, V6, P52; PECHACEK TF, 1984, BEHAVIORAL HLTH HDB, P729; Potts H., 1986, HLTH ED RES, V1, P195, DOI DOI 10.1093/HER/1.3.195; RAWBONE RG, 1982, ARCH DIS CHILD, V57, P352, DOI 10.1136/adc.57.5.352; Ross J. G., 1991, Morbidity and Mortality Weekly Report, V40, P113; TELL GS, 1984, PREV MED, V13, P256, DOI 10.1016/0091-7435(84)90083-5; THOMPSON EL, 1978, AM J PUBLIC HEALTH, V68, P250, DOI 10.2105/AJPH.68.3.250; TOWNSEND J, 1989, TOBACCO PRICE SMOKIN, P52; VARTIAINEN E, 1983, B WORLD HEALTH ORGAN, V61, P529; 1991, FAMILY SMOKING ED PR; 1991, SMOKING ME SMOKING E; 1992, SMOKING YOUNG REPORT; [No title captured]; 1990, BMDP STATISTICAL SOF, V2; 1989, HLTH TOBACCO END TOB; 1989, DHHS CDC898411 PUB	48	86	87	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 9	1993	306	6870					102	107		10.1136/bmj.306.6870.102	http://dx.doi.org/10.1136/bmj.306.6870.102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435601	Green Published, Bronze			2022-12-28	WOS:A1993KG46500019
J	ZHANG, JY; TEMIN, HM				ZHANG, JY; TEMIN, HM			RATE AND MECHANISM OF NONHOMOLOGOUS RECOMBINATION DURING A SINGLE CYCLE OF RETROVIRAL REPLICATION	SCIENCE			English	Article							VIRUS; DNA; VECTORS; RNA; TRANSDUCTION; CELLS; CONSTRUCTION; SEQUENCE; CLONING; GENOMES	Oncogenes discovered in retroviruses such as Rous sarcoma virus were generated by transduction of cellular proto-oncogenes into the viral genome. Several different kinds of junctions between the viral and proto-oncogene sequences have been found in different viruses. A system of retrovirus vectors and a protocol that mimicked this transduction during a single cycle of retrovirus replication was developed. The transduction involved the formation of a chimeric viral-cellular RNA, strand switching of the reverse transcription growing point from an infectious retrovirus to the chimeric RNA, and often a subsequent deletion during the rest of viral DNA synthesis. A short region of sequence identity was frequently used for the strand switching. The rate of this process was about 0.1 to 1 percent of the rate of homologous retroviral recombination.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P01CA022443, P30CA007175] Funding Source: NIH RePORTER; NCI NIH HHS [CA-07175, CA-22443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DORNBURG R, 1988, MOL CELL BIOL, V8, P2328, DOI 10.1128/MCB.8.6.2328; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMBRETSON JE, 1987, J VIROL, V61, P3454, DOI 10.1128/JVI.61.11.3454-3462.1987; GOODRICH DW, 1988, P NATL ACAD SCI USA, V85, P3733, DOI 10.1073/pnas.85.11.3733; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P3604, DOI 10.1073/pnas.87.9.3604; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; HU WS, IN PRESS REVERSE TRA; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; JUNGHANS RP, 1982, CELL, V30, P53, DOI 10.1016/0092-8674(82)90011-3; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; MILLER AD, 1991, J VIROL, V65, P2220, DOI 10.1128/JVI.65.5.2220-2224.1991; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MURNANE JP, 1990, NUCLEIC ACIDS RES, V18, P2733, DOI 10.1093/nar/18.9.2733; OLSON P, 1992, J VIROL, V66, P1336, DOI 10.1128/JVI.66.3.1336-1343.1992; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAPP UR, 1988, HDB ONCOGENES, P213; STUHLMANN H, 1990, J VIROL, V64, P5783, DOI 10.1128/JVI.64.12.5783-5796.1990; SWAIN A, 1992, SCIENCE, V255, P841, DOI 10.1126/science.1371365; TEMIN HM, 1984, CANCER SURV, V3, P229; TEMIN HM, 1989, BIOCHEM INT, V18, P1; WANG JYJ, 1984, CELL, V36, P349; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; ZHANG J, IN PRESS J VIROL; ZHANG J, UNPUB	27	139	144	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					234	238		10.1126/science.8421784	http://dx.doi.org/10.1126/science.8421784			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	8421784				2022-12-28	WOS:A1993KF71900033
J	LOWRY, S				LOWRY, S			MEDICAL-EDUCATION .5. ASSESSMENT OF STUDENTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STRUCTURED CLINICAL EXAMINATION; COMPETENCE; PERFORMANCE; RELIABILITY											ENDE J, 1983, JAMA-J AM MED ASSOC, V250, P777, DOI 10.1001/jama.250.6.777; FELETTI GI, 1980, MED J AUSTRALIA, V1, P79, DOI 10.5694/j.1326-5377.1980.tb134633.x; HARDEN RM, 1979, MED EDUC, V13, P41; HARDEN RM, 1975, BRIT MED J, V1, P447, DOI 10.1136/bmj.1.5955.447; JOLLY B, IN PRESS CERTIFICATI; LEVINE HG, 1970, AM EDUC RES J, V7, P69, DOI 10.2307/1162085; MALIK SL, 1988, MED EDUC, V22, P40, DOI 10.1111/j.1365-2923.1988.tb00407.x; NEWBLE DI, 1981, MED EDUC, V15, P46, DOI 10.1111/j.1365-2923.1981.tb02315.x; NEWBLE DI, 1988, MED EDUC, V22, P200, DOI 10.1111/j.1365-2923.1988.tb00007.x; NEWBLE DI, 1983, MED EDUC, V17, P165, DOI 10.1111/j.1365-2923.1983.tb00657.x; Osler W, 1913, LANCET, V2, P1047; Painvin C, 1979, Annu Conf Res Med Educ, V18, P73; PALLIE W, 1987, MED TEACH, V9, P59, DOI 10.3109/01421598709028981; PETRUSA ER, 1987, AM J MED, V83, P34, DOI 10.1016/0002-9343(87)90494-3; ROBERTS J, 1990, MED EDUC, V24, P219, DOI 10.1111/j.1365-2923.1990.tb00004.x; TOOTH D, 1989, MED EDUC, V23, P416, DOI 10.1111/j.1365-2923.1989.tb00896.x; TOWLE A, 1991, CRITICAL THINKING FU; TURNBULL JM, 1989, MED TEACH, V11, P145, DOI 10.3109/01421598909146317; VERWIJNEN GM, 1982, ASSESS EVAL HIGH EDU, V3, P225; 1980, RECOMMENDATIONS BASI	20	36	40	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 2	1993	306	6869					51	54		10.1136/bmj.306.6869.51	http://dx.doi.org/10.1136/bmj.306.6869.51			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435583	Green Published, Bronze			2022-12-28	WOS:A1993KE98400032
J	SIBBALD, B; ADDINGTONHALL, J; BRENNEMAN, D; FREELING, P				SIBBALD, B; ADDINGTONHALL, J; BRENNEMAN, D; FREELING, P			COUNSELORS IN ENGLISH AND WELSH GENERAL PRACTICES - THEIR NATURE AND DISTRIBUTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY CARE	Objective-To establish the prevalence of counselling services in English and Welsh general practices and factors associated with their distribution; to describe qualifications, working arrangements, and case mix of ''counsellors.'' Design-Postal questionnaire and telephone interview survey of a sample of about one in 20 general practitioners in England and Wales. Setting-English and Welsh general practices. Subject-1880 general practitioners, of whom 1542 (82%) completed questionnaires. Main outcome measures-Prevalence and distribution of practice counselling services; counsellors' qualifications and funding; types of patients referred. Results-586 counsellors were distributed among 484 of the 1542 practices. Three types of counsellor predominated: community psychiatric nurses (187); ''practice counsellors'' (145); and clinical psychologists (95). Practice characteristics which independently predicted the presence of a counsellor were for community psychiatric nurses four or more partners (odds=1.72, 95% confidence interval 1.18 to 2.26); for practice counsellors stress clinic (odds = 2.22; 1.83 to 2.61), training practice (odds=1.70; 1.24 to 2.16), and health region (chi2=55.94; df=14; p<0.001); and for clinical psychologists list size of greater-than-or-equal-to 10 500 (odds=1.79; 1.09 to 2.49), training practice (odds=1.78; 1.31 to 2.25), health region (chi2=48.31; df=14; p<0.001). 197 counsellors had training in counseling. The qualifications of 85 were unknown to the general practitioner. The principal source of funding was the district health authority for community psychiatric nurses (150) and clinical psychologists (58) and the family health services authority for practice counsellors (76). All counsellors were referred a wide range of problems. Conclusions-Counselling services are widespread in general practice, but a high proportion of counsellors lack qualifications, and many may be referred problems outside their knowledge.	UCL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND	University of London; University College London	SIBBALD, B (corresponding author), ST GEORGE HOSP, SCH MED, DIV GEN PRACTICE & PRIMARY CARE, LONDON SW17 0RE, ENGLAND.							CORNEY RH, 1990, J ROY SOC MED, V83, P253, DOI 10.1177/014107689008300416; DEANS HG, 1992, J ROY SOC MED, V85, P83; EASTMAN C, 1982, BRIT J CLIN PSYCHOL, V21, P85, DOI 10.1111/j.2044-8260.1982.tb00536.x; Fallowfield L., 1992, PSYCHOL HEALTH, V6, P107; GATH D, 1986, J PSYCHOSOM RES, V30, P381, DOI 10.1016/0022-3999(86)90017-6; LONG CG, 1987, J ROY COLL GEN PRACT, V37, P199; MACLEOD J, 1988, 37 ROYAL COLL GEN PR; MARTIN E, 1988, BRIT MED J, V297, P637, DOI 10.1136/bmj.297.6649.637; MITCHELL ARK, 1989, PSYCHIATR B, V13, P135; ROBSON MH, 1984, BRIT MED J, V288, P1805, DOI 10.1136/bmj.288.6433.1805; ROWLAND N, 1989, J ROY COLL GEN PRACT, V39, P118; SCOTT AIF, 1992, BRIT MED J, V304, P883, DOI 10.1136/bmj.304.6831.883; STRATHDEE G, 1987, GEN HOSP PSYCHIAT, V9, P102, DOI 10.1016/0163-8343(87)90021-1; THOMAS RVR, 1992, BRIT J GEN PRACT, V42, P358; TREPKA C, 1987, J ROY COLL GEN PRACT, V37, P215; TYRER P, 1984, BRIT J PSYCHIAT, V145, P9, DOI 10.1192/bjp.145.1.9; 1988, HLTH PERSONAL SOCIAL	17	90	89	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 2	1993	306	6869					29	33		10.1136/bmj.306.6869.29	http://dx.doi.org/10.1136/bmj.306.6869.29			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435574	Green Published, Bronze			2022-12-28	WOS:A1993KE98400023
J	FROGUEL, P; ZOUALI, H; VIONNET, N; VELHO, G; VAXILLAIRE, M; SUN, F; LESAGE, S; STOFFEL, M; TAKEDA, J; PASSA, P; PERMUTT, MA; BECKMANN, JS; BELL, GI; COHEN, D				FROGUEL, P; ZOUALI, H; VIONNET, N; VELHO, G; VAXILLAIRE, M; SUN, F; LESAGE, S; STOFFEL, M; TAKEDA, J; PASSA, P; PERMUTT, MA; BECKMANN, JS; BELL, GI; COHEN, D			FAMILIAL HYPERGLYCEMIA DUE TO MUTATIONS IN GLUCOKINASE - DEFINITION OF A SUBTYPE OF DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DNA; GENE; AMPLIFICATION; POLYMERASE	Background and Methods. Non-insulin-dependent diabetes mellitus (NIDDM) is a genetically heterogeneous disorder. Maturity-onset diabetes of the young, a form of NIDDM with an early age of onset and autosomal dominant inheritance, can result from mutations in glucokinase, a key enzyme of glucose metabolism in beta cells and the liver. We studied 32 French families with maturity-onset diabetes of the young as well as 21 families with late-onset NIDDM to determine the frequency and clinical features of mutations of glucokinase. Fasting plasma glucose concentrations and oral glucose-tolerance tests were used to determine metabolic status. DNA was isolated from lymphocytes, and DNA polymorphisms in the glucokinase gene were tested for linkage with diabetes. Individual exons of the glucokinase gene from one affected member in each family were amplified by the polymerase chain reaction and screened for mutations by analysis of the conformation-dependent polymorphisms of single-stranded DNA and by DNA sequencing. Results. We found substantial evidence of linkage between the glucokinase locus and maturity-onset diabetes of the young but not between this locus and late-onset NIDDM. Sixteen mutations were identified in 18 of the 32 families with maturity-onset diabetes of the young, but none were found in families with late-onset NIDDM. They included 1 0 mutations that resulted in an amino acid substitution, 3 that resulted in the synthesis of a truncated protein, and 3 that affected RNA processing. The affected subjects with glucokinase mutations usually had mild hyperglycemia that began during childhood, whereas in subjects with maturity-onset diabetes of the young not due to glucokinase mutations, hyperglycemia usually appeared after puberty. Conclusions. Mutations in glucokinase are the primary cause of hyperglycemia in a substantial fraction of French patients with maturity-onset diabetes of the young and result in a relatively mild form of NIDDM that can be diagnosed in childhood.	HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE; WASHINGTON UNIV,SCH MED,DIV METAB,ST LOUIS,MO 63110; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Washington University (WUSTL); Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago	FROGUEL, P (corresponding author), CTR ETUD POLYMORPHISME HUMAIN,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.		Beckmann, Jacques S/A-9772-2008; FROGUEL, Philippe/O-6799-2017; Velho, Gilberto/Q-6724-2017; Vionnet, Nathalie/N-6302-2017	Beckmann, Jacques S/0000-0002-9741-1900; FROGUEL, Philippe/0000-0003-2972-0784; Velho, Gilberto/0000-0001-8811-363X; Stoffel, Markus/0000-0003-1304-5817	NIDDK NIH HHS [DK-20595, DK-44840, DK-16746] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, R01DK016746, P01DK044840, R37DK016746] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; CHIU KC, 1992, DIABETES, V41, P843, DOI 10.2337/diabetes.41.7.843; CHIU KC, 1992, DIABETOLOGIA, V35, P632, DOI 10.1007/BF00400254; COOPER DN, 1990, HUM GENET, V85, P55; FAJANS SS, 1990, DIABETES CARE, V13, P49, DOI 10.2337/diacare.13.1.49; FAJANS SS, 1990, DIABETES CARE, V13, P910; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1991, DIABETOLOGIA, V34, P685, DOI 10.1007/BF00401001; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; KOBBERLING J, 1982, SERONO S, V47, P201; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LESTRADET H, 1989, ARCH FR PEDIATR, V46, P19; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; ORAHILLY S, 1988, DIABETOLOGIA, V31, P407, DOI 10.1007/BF00271584; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Ott J., 1991, ANAL HUMAN GENETIC L; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; STOFFEL M, 1992, P NATL ACAD SCI USA, V89, P7698, DOI 10.1073/pnas.89.16.7698; TAYLOR SI, 1991, J CLIN ENDOCR METAB, V73, P1158, DOI 10.1210/jcem-73-6-1158; TCHOBROUTSKY G, 1991, DIABETOLOGIA, V34, P67, DOI 10.1007/BF00500374; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; 1980, WHO TECH REP SER, V646, P1	31	658	697	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1993	328	10					697	702		10.1056/NEJM199303113281005	http://dx.doi.org/10.1056/NEJM199303113281005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ861	8433729				2022-12-28	WOS:A1993KQ86100005
J	LACOMBE, M				LACOMBE, M			WHAT IS INTERNAL-MEDICINE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIAN-PATIENT RELATIONS; JOB SATISFACTION; CAREER CHOICE; PHYSICIANS, FAMILY		On internist's view of what internal medicine comprises. Or should.			LACOMBE, M (corresponding author), OXFORD HILLS INTERNAL MED GRP, 23 WINTER ST, NORWAY, ME 04268 USA.								0	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					384	387		10.7326/0003-4819-118-5-199303010-00010	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8430984				2022-12-28	WOS:A1993KN68800010
J	ANNAS, GJ				ANNAS, GJ			CONTROL OF TUBERCULOSIS - THE LAW AND THE PUBLICS HEALTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				Bayer Ronald, 1992, TUBERCULOSIS REVIVAL; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; CALIFANO J, 1992, WASHINGTON POST 1221, pA21; Dubos R, 1952, WHITE PLAGUE TUBERCU; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; HINGSON R, 1981, SICKNESS HLTH SOCIAL, P142; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; Lederberg J., 1992, EMERGING INFECTIONS; MAHON W, 1992, DEV SYSTEM TB PREVEN; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V268, P3177, DOI 10.1001/jama.268.22.3177; 1992, MMWR MORB MORTAL WKL, V41; 1992, RECOMMENDATIONS MASS	14	64	66	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					585	588		10.1056/NEJM199302253280825	http://dx.doi.org/10.1056/NEJM199302253280825			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8426636	Green Published			2022-12-28	WOS:A1993KP05300028
J	FRIEND, SH				FRIEND, SH			GENETIC MODELS FOR STUDYING CANCER SUSCEPTIBILITY	SCIENCE			English	Editorial Material									HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School	FRIEND, SH (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,DIV MOLEC GENET,BOSTON,MA 02129, USA.							ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ANDERS F, 1991, PIGM CELL RES, V3, P7; BREIDER H, 1952, STRAHLENTHERAPIE, V88, P618; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CANNONALBRIGHT LA, COMMUNICATION; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOLDSTEIN A, IN PRESS AM J HUM GE; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NEVINS JP, 1992, NATURE, V358, P357; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0	15	22	23	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 5	1993	259	5096					774	775		10.1126/science.8430329	http://dx.doi.org/10.1126/science.8430329			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430329				2022-12-28	WOS:A1993KL11000020
J	LONERGAN, KM; GRAY, MW				LONERGAN, KM; GRAY, MW			EDITING OF TRANSFER-RNAS IN ACANTHAMOEBA-CASTELLANII MITOCHONDRIA	SCIENCE			English	Article							AUG INITIATION CODONS; CYTOCHROME-C-OXIDASE; ENCODE GUIDE RNAS; MESSENGER-RNA; TRYPANOSOMA-BRUCEI; OENOTHERA MITOCHONDRIA; PLANT-MITOCHONDRIA; KINETOPLASTID MITOCHONDRIA; NADH DEHYDROGENASE; MAJOR DETERMINANT	With the discovery of RNA editing, a process whereby the primary sequence of RNA is altered after transcription, traditional concepts of genetic information transfer had to be revised. The known RNA editing systems act mainly on messenger RNAs, introducing sequence changes that alter their coding properties. An editing system that acts on transfer RNAs is described here. In the mitochondria of Acanthamoeba castellanii, an amoeboid protozoan, certain transfer RNAs differ in sequence from the genes that encode them. The changes consist of single-nucleotide conversions (U to A, U to G, and A to G) that appear to arise posttranscriptionally, are localized in the acceptor stem, and have the effect of correcting mismatched base pairs. Editing thus restores the base pairing expected of a normal transfer RNA in this region.	DALHOUSIE UNIV, CANADIAN INST ADV RES, DEPT BIOCHEM, PROGRAM EVOLUT BIOL, HALIFAX B3H 4H7, NS, CANADA	Canadian Institute for Advanced Research (CIFAR); Dalhousie University				Gray, Michael/0000-0001-7125-2625				ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BEGU D, 1990, PLANT CELL, V2, P1283, DOI 10.1105/tpc.2.12.1283; BEIER H, 1992, NUCLEIC ACIDS RES, V20, P2679, DOI 10.1093/nar/20.11.2679; BENNE R, 1989, BIOCHIM BIOPHYS ACTA, V1007, P131, DOI 10.1016/0167-4781(89)90031-6; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BYERS TJ, 1986, INT REV CYTOL, V99, P311; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHAPDELAINE Y, 1991, CELL, V65, P465, DOI 10.1016/0092-8674(91)90464-A; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CONKLIN PL, 1991, GENE DEV, V5, P1407, DOI 10.1101/gad.5.8.1407; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; COVELLO PS, 1990, FEBS LETT, V268, P5, DOI 10.1016/0014-5793(90)80958-L; COVELLO PS, 1990, NUCLEIC ACIDS RES, V18, P5189, DOI 10.1093/nar/18.17.5189; DEBORDE DC, 1986, ANAL BIOCHEM, V157, P275, DOI 10.1016/0003-2697(86)90626-3; DIAMOND AM, 1990, NUCLEIC ACIDS RES, V18, P6727, DOI 10.1093/nar/18.22.6727; DIRHEIMER G, 1990, J CHROMATOGRAPHY L B, V45, pB197; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; GELIEBTER J, 1987, FOCUS, V9, P5; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HOCH B, 1991, NATURE, V353, P178, DOI 10.1038/353178a0; HOU YM, 1989, BIOCHEMISTRY-US, V28, P6800, DOI 10.1021/bi00443a003; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JUNG G, 1989, GENE, V82, P269, DOI 10.1016/0378-1119(89)90052-8; KEMPKEN F, 1991, CURR GENET, V20, P417, DOI 10.1007/BF00317071; Kim S H, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P279; Kim S H, 1976, Prog Nucleic Acid Res Mol Biol, V17, P181, DOI 10.1016/S0079-6603(08)60070-7; KNOOP V, 1991, EMBO J, V10, P3483, DOI 10.1002/j.1460-2075.1991.tb04912.x; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; KUDLA J, 1992, EMBO J, V11, P1099, DOI 10.1002/j.1460-2075.1992.tb05149.x; LONERGAN KM, UNPUB; MAHENDRAN R, 1991, NATURE, V349, P434, DOI 10.1038/349434a0; MAIER RM, 1992, PLANT CELL, V4, P609, DOI 10.1105/tpc.4.5.609; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P9272, DOI 10.1073/pnas.88.20.9272; Neff R.J., 1964, METHODS CELL BIOL, V1, P55, DOI [10.1016/S0091-679X(08)62086-5, DOI 10.1016/S0091-679X(08)62086-5]; NOWAK C, 1990, NUCLEIC ACIDS RES, V18, P7164, DOI 10.1093/nar/18.23.7164; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RICH A, 1976, ANNU REV BIOCHEM, V45, P805, DOI 10.1146/annurev.bi.45.070176.004105; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SCHUSTER W, 1990, NUCLEIC ACIDS RES, V18, P229, DOI 10.1093/nar/18.2.229; SCHUSTER W, 1991, FEBS LETT, V295, P97, DOI 10.1016/0014-5793(91)81394-N; SCHUSTER W, 1990, FEBS LETT, V268, P252, DOI 10.1016/0014-5793(90)81021-F; SCHUSTER W, 1991, CURR GENET, V20, P397, DOI 10.1007/BF00317068; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1990, SCIENCE, V250, P512, DOI 10.1126/science.1700474; SINGHAL RP, 1979, PROG NUCLEIC ACID RE, V23, P228; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; STUART K, 1991, TRENDS BIOCHEM SCI, V16, P68, DOI 10.1016/0968-0004(91)90027-S; STUART K, 1989, GENE, V82, P155, DOI 10.1016/0378-1119(89)90040-1; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x; WINTZ H, 1991, CURR GENET, V19, P61, DOI 10.1007/BF00362089; WISSINGER B, 1991, CELL, V65, P473, DOI 10.1016/0092-8674(91)90465-B; ZEFF RA, 1987, FOCUS, V9, P1	68	144	147	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					812	816		10.1126/science.8430334	http://dx.doi.org/10.1126/science.8430334			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430334				2022-12-28	WOS:A1993KL11000033
J	PASIC, M; GALLINO, A; CARREL, T; MAGGIORINI, M; LASKE, A; VONSEGESSER, L; TURINA, M				PASIC, M; GALLINO, A; CARREL, T; MAGGIORINI, M; LASKE, A; VONSEGESSER, L; TURINA, M			REUSE OF A TRANSPLANTED HEART	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							INTERNATIONAL SOCIETY; LUNG TRANSPLANTATION; OFFICIAL REPORT; DONOR HEARTS; RETRANSPLANTATION; SURVIVAL; REGISTRY				PASIC, M (corresponding author), UNIV HOSP ZURICH, CARDIOVASC SURG CLIN, RAMISTR 100, CH-8091 ZURICH, SWITZERLAND.			Maggiorini, Marco/0000-0001-8180-2117				BILLINGHAM ME, 1990, J HEART TRANSPLANT, V9, P587; COSTANZONORDIN MR, 1991, J HEART LUNG TRANSPL, V10, P717; DEBOER J, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92822-J; KRIETT JM, 1990, J HEART TRANSPLANT, V9, P323; KRIETT JM, 1991, J HEART LUNG TRANSPL, V10, P491; MENKIS AH, 1991, J HEART LUNG TRANSPL, V10, P28; MULLINS P, 1991, LANCET, V337, P1552, DOI 10.1016/0140-6736(91)93251-4; MULLINS PA, 1991, AM J CARDIOL, V68, P408, DOI 10.1016/0002-9149(91)90844-B; PFLUGFELDER PW, 1991, J HEART LUNG TRANSPL, V10, P394; STEVENSON LW, 1991, J AM COLL CARDIOL, V18, P919, DOI 10.1016/0735-1097(91)90747-W; YACOUB MH, 1990, J HEART TRANSPLANT, V9, P459	11	27	28	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					319	320		10.1056/NEJM199302043280505	http://dx.doi.org/10.1056/NEJM199302043280505			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8419818				2022-12-28	WOS:A1993KK24700005
J	SOMERS, VK; DYKEN, ME; MARK, AL; ABBOUD, FM				SOMERS, VK; DYKEN, ME; MARK, AL; ABBOUD, FM			SYMPATHETIC-NERVE ACTIVITY DURING SLEEP IN NORMAL SUBJECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN CARDIAC DEATH; CIRCADIAN VARIATION; MYOCARDIAL-INFARCTION; ARTERIAL-PRESSURE; MORNING INCREASE; BLOOD-PRESSURE; ONSET; FREQUENCY; OUTFLOW; MUSCLE	Background. The early hours of the morning after awakening are associated with an increased frequency of events such as myocardial infarction and ischemic stroke. The triggering mechanisms for these events are not clear. We investigated whether autonomic changes occurring during sleep, particularly rapid-eye-movement (REM) sleep, contribute to the initiation of such events. Methods. We measured blood pressure, heart rate, and sympathetic-nerve activity (using microneurography, which provides direct measurements of efferent sympathetic-nerve activity related to muscle blood vessels) in eight normal subjects while they were awake and while in the five stages of sleep. Results. The mean (+/-SE)amplitude of bursts of sympathetic-nerve activity and levels of blood pressure and heart rate declined significantly (P<0.001), from 100+/-9 percent, 90+/-4 mm Hg, and 64+/-2 beats per minute, respectively, during wakefulness to 41+/-9 percent, 80+/-4 mm Hg, and 59+/-2 beats per minute, respectively, during stage 4 ot non-REM sleep. Arousal stimuli during stage 2 sleep elicited high-amplitude deflections on the electroencephalogram (called ''K complexes''), which were frequently associated with bursts of sympathetic-nerve activity and transient increases in blood pressure. During REM sleep, sympathetic-nerve activity increased significantly (to 215+/-11 percent; P<0.001) and the blood pressure and heart rate returned to levels similar to those during wakefulness. Momentary restorations of muscle tone during REM sleep (REM twitches) were associated with cessation of sympathetic-nerve discharge and surges in blood pressure. Conclusions. REM sleep is associated with profound sympathetic activation in normal subjects, possibly linked to changes in muscle tone. The hemodynamic and sympathetic changes during REM sleep could play a part in triggering ischemic events in patients with vascular disease.	UNIV IOWA,COLL MED,DEPT NEUROL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,CTR CARDIOVASC,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; University of Iowa				Abboud, Francois/0000-0002-7284-9148; Dyken, Mark/0000-0002-6252-581X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL024962, R01HL024962] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24962, HL-14388] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACCELLI G, 1974, CIRC RES, V35, P625, DOI 10.1161/01.RES.35.4.625; COCCAGNA G, 1971, ELECTROEN CLIN NEURO, V31, P277, DOI 10.1016/0013-4694(71)90098-8; CONWAY J, 1983, HYPERTENSION, V5, P746, DOI 10.1161/01.HYP.5.5.746; DEMENT W, 1957, ELECTROEN CLIN NEURO, V9, P673, DOI 10.1016/0013-4694(57)90088-3; FAGIUS J, 1985, BRAIN, V108, P423, DOI 10.1093/brain/108.2.423; FURLAN R, 1989, J HYPERTENS, V7, pS30, DOI 10.1097/00004872-198900076-00012; FURLAN R, 1990, CIRCULATION, V81, P537, DOI 10.1161/01.CIR.81.2.537; GEORGE CF, 1985, CLIN CHEST MED, V6, P595; HORNYAK M, 1991, BRAIN, V114, P1281, DOI 10.1093/brain/114.3.1281; Kelly D. D., 1991, PRINCIPLES NEURAL SC, P792; KHATRI IM, 1967, J APPL PHYSIOL, V22, P867, DOI 10.1152/jappl.1967.22.5.867; KING MJ, 1973, AM J MED SCI, V265, P419, DOI 10.1097/00000441-197305000-00009; KIRBY DA, 1989, PHYSIOL BEHAV, V45, P1017, DOI 10.1016/0031-9384(89)90231-X; MANCIA G, 1971, AM J PHYSIOL, V220, P1086, DOI 10.1152/ajplegacy.1971.220.4.1086; MANCIA G, 1980, RES TOPICS PHYSL, V3, P2; MARK AL, 1985, CIRC RES, V57, P461, DOI 10.1161/01.RES.57.3.461; MARK AL, 1990, J HYPERTENS, V8, pS67; MARLER JR, 1989, STROKE, V20, P473, DOI 10.1161/01.STR.20.4.473; MION D, 1988, J HYPERTENS, V6, pS74, DOI 10.1097/00004872-198812040-00019; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; MULLER JE, 1989, CIRCULATION, V79, P733, DOI 10.1161/01.CIR.79.4.733; NOWLIN JB, 1965, ANN INTERN MED, V63, P1040, DOI 10.7326/0003-4819-63-6-1040; OKADA H, 1991, NEUROLOGY, V41, P1961, DOI 10.1212/WNL.41.12.1961; PAGANI M, 1988, HYPERTENSION, V12, P600, DOI 10.1161/01.HYP.12.6.600; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; RECHTSTAFFEN A, 1968, MANUAL STANDARDIZED; REIS DJ, 1969, AM J PHYSIOL, V217, P541, DOI 10.1152/ajplegacy.1969.217.2.541; SMYTH HS, 1969, CIRC RES, V24, P109, DOI 10.1161/01.RES.24.1.109; SNEDECOR GW, 1980, STATISTICAL METHODS, P265; SNYDER F, 1964, J APPL PHYSIOL, V19, P417, DOI 10.1152/jappl.1964.19.3.417; STJERNBERG L, 1986, BRAIN, V109, P695, DOI 10.1093/brain/109.4.695; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; Wesseling K.H., 1986, BIOLOGICAL PSYCHOL F, P355, DOI [10.1007/978-3-642-71234-0_22, DOI 10.1007/978-3-642-71234-0_22]; [No title captured]	35	1058	1087	1	46	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					303	307		10.1056/NEJM199302043280502	http://dx.doi.org/10.1056/NEJM199302043280502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8419815	Bronze			2022-12-28	WOS:A1993KK24700002
J	CALMAN, NS				CALMAN, NS			NO SHATTERED VISION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					638	638						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421370				2022-12-28	WOS:A1993KJ44400034
J	BUZZELLI, DE				BUZZELLI, DE			THE DEFINITION OF MISCONDUCT IN SCIENCE - A VIEW FROM NSF	SCIENCE			English	Article											BUZZELLI, DE (corresponding author), NATL SCI FDN,OFF INSPECT GEN,1800 G ST NW,WASHINGTON,DC 20550, USA.							ANDERSON RM, 1988, J LAW TECHNOL, V3, P129; 1992, RESPONSIBLE SCI ENSU, V1	2	44	51	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					584	&		10.1126/science.8430300	http://dx.doi.org/10.1126/science.8430300			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430300				2022-12-28	WOS:A1993KJ68800012
J	DIETZ, HC; VALLE, D; FRANCOMANO, CA; KENDZIOR, RJ; PYERITZ, RE; CUTTING, GR				DIETZ, HC; VALLE, D; FRANCOMANO, CA; KENDZIOR, RJ; PYERITZ, RE; CUTTING, GR			THE SKIPPING OF CONSTITUTIVE EXONS INVIVO INDUCED BY NONSENSE MUTATIONS	SCIENCE			English	Article							PRE-MESSENGER RNA; MARFAN-SYNDROME; SPLICE-SITE; GENE; SEQUENCES; INTRON; IDENTIFICATION; TRANSCRIPTS; PRECURSORS; FIBRILLIN	Nonsense mutations create a premature signal for the termination of translation of messenger RNA. Such mutations have been observed to cause a severe reduction in the amount of mutant allele transcript or to generate a peptide truncated at the carboxyl end. Analysis of fibrillin transcript from a patient with Marfan syndrome revealed the skipping of a constitutive exon containing a nonsense mutation. Similar results were observed for two nonsense mutations in the gene encoding ornithine delta-aminotransferase from patients with gyrate atrophy. All genomic DNA sequences flanking these exons that are known to influence RNA splicing were unaltered, which suggests that nonsense mutations can after splice site selection in vivo.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Johns Hopkins University	DIETZ, HC (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,HOWARD HUGHES MED INST,BALTIMORE,MD 21205, USA.		Pyeritz, Reed/A-1364-2010		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000373] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00722] Funding Source: Medline; NHGRI NIH HHS [HG-00373] Funding Source: Medline; NIAMS NIH HHS [AR-41135] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BOND RW, 1990, P NATL ACAD SCI USA, V87, P8771, DOI 10.1073/pnas.87.22.8771; CHAIN AC, 1991, MOL CELL BIOL, V11, P1538, DOI 10.1128/MCB.11.3.1538; COOPER TA, 1992, J BIOL CHEM, V267, P5330; DIETZ H, UNPUB; DIETZ HC, 1992, J CLIN INVEST, V89, P1674, DOI 10.1172/JCI115766; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; DIETZ HC, IN PRESS HUM MUTAT; DOMENJOUD L, 1991, MOL CELL BIOL, V11, P4581, DOI 10.1128/MCB.11.9.4581; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MATSUO M, 1991, J CLIN INVEST, V87, P2127, DOI 10.1172/JCI115244; MICHAUD J, 1992, GENOMICS, V13, P389, DOI 10.1016/0888-7543(92)90258-T; MITCHELL GA, 1988, J BIOL CHEM, V263, P14288; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; OSHIMA Y, 1987, J MOL BIOL, V195, P247; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RICKETTS MH, 1987, P NATL ACAD SCI USA, V84, P3181, DOI 10.1073/pnas.84.10.3181; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SOMASEKHAR MB, 1985, NUCLEIC ACIDS RES, V13, P5591, DOI 10.1093/nar/13.15.5591; TSAI AYM, 1989, MOL CELL BIOL, V9, P4550, DOI 10.1128/MCB.9.10.4550; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VALLE D, UNPUB; WAKAMATSU N, 1992, J BIOL CHEM, V267, P2406	32	405	414	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					680	683		10.1126/science.8430317	http://dx.doi.org/10.1126/science.8430317			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430317				2022-12-28	WOS:A1993KJ68800042
J	HENDERSON, M				HENDERSON, M			CURRENT APPROACHES TO BREAST-CANCER PREVENTION	SCIENCE			English	Editorial Material											HENDERSON, M (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.								0	17	17	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					630	631		10.1126/science.8430311	http://dx.doi.org/10.1126/science.8430311			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430311				2022-12-28	WOS:A1993KJ68800029
J	MATHIAS, S; YOUNES, A; KAN, CC; ORLOW, I; JOSEPH, C; KOLESNICK, RN				MATHIAS, S; YOUNES, A; KAN, CC; ORLOW, I; JOSEPH, C; KOLESNICK, RN			ACTIVATION OF THE SPHINGOMYELIN SIGNALING PATHWAY IN INTACT EL4 CELLS AND IN A CELL-FREE SYSTEM BY IL-1-BETA	SCIENCE			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; GH3 PITUITARY-CELLS; NECROSIS-FACTOR-ALPHA; PHORBOL ESTERS; IL-1 RECEPTOR; INTERLEUKIN-1 RECEPTOR; PLASMA-MEMBRANE; THYMOMA CELLS; GTP-BINDING	The mechanism of interleukin-1 (IL-1) signaling is unknown. Tumor necrosis factor-alpha uses a signal transduction pathway that involves sphingomyelin hydrolysis to ceramide and stimulation of a ceramide-activated protein kinase. In intact EL4 thymoma cells, IL-1beta similarly stimulated a rapid decrease of sphingomyelin and an elevation of ceramide, and enhanced ceramide-activated protein kinase activity. This cascade was also activated by IL-1beta in a cell-free system, demonstrating tight coupling to the receptor. Exogenous sphingomyelinase, but not phospholipases A2, C, or D, in combination with phorbol ester replaced IL-1beta to stimulate IL-2 secretion. Thus, IL-1beta signals through the sphingomyelin pathway.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA042385] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1-CA-42385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P288, DOI 10.1016/0167-4838(84)90034-7; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; CHEDID M, 1989, J IMMUNOL, V142, P4301; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DORNAND J, 1987, IMMUNOL LETT, V16, P101, DOI 10.1016/0165-2478(87)90115-5; DORNAND J, 1992, J CELL PHYSIOL, V151, P71, DOI 10.1002/jcp.1041510112; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GUY GR, 1991, J BIOL CHEM, V266, P14343; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KIM MY, 1991, J BIOL CHEM, V266, P484; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; LEWIS C, 1990, EUR J IMMUNOL, V20, P207, DOI 10.1002/eji.1830200130; LOWENTHAL JW, 1986, J IMMUNOL, V137, P1226; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MCINTYRE KW, 1991, J EXP MED, V173, P931, DOI 10.1084/jem.173.4.931; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MCMANNIS JD, 1985, P NATL ACAD SCI USA, V82, P1513, DOI 10.1073/pnas.82.5.1513; MUNOZ E, 1990, J IMMUNOL, V144, P964; NETA R, 1992, TUMOR NECROSIS FACTO, P499; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; ONEILL LAJ, 1990, J BIOL CHEM, V265, P3146; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; PREISS J, 1986, J BIOL CHEM, V261, P8597; RANGNEKAR VM, 1988, J BIOL CHEM, V263, P16408; RAO BG, 1976, J LIPID RES, V17, P506; REBECCHI MJ, 1983, J BIOL CHEM, V258, P227; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; VONHOEGEN I, 1989, EUR J IMMUNOL, V19, P329; WHITEHEAD TP, 1983, NATURE, V305, P158, DOI 10.1038/305158a0; YODOI J, 1985, J IMMUNOL, V134, P1623; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	52	429	440	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					519	522		10.1126/science.8424175	http://dx.doi.org/10.1126/science.8424175			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424175				2022-12-28	WOS:A1993KJ07900036
J	SHOULSON, I; FAHN, S; OAKES, D; KIEBURTZ, K; LANG, A; LANGSTON, JW; LEWITT, P; OLANOW, CW; PENNEY, JB; TANNER, C; RUDOLPH, A; PELUSIO, RM				SHOULSON, I; FAHN, S; OAKES, D; KIEBURTZ, K; LANG, A; LANGSTON, JW; LEWITT, P; OLANOW, CW; PENNEY, JB; TANNER, C; RUDOLPH, A; PELUSIO, RM			EFFECTS OF TOCOPHEROL AND DEPRENYL ON THE PROGRESSION OF DISABILITY IN EARLY PARKINSONS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REQUIRING PROLONGED OBSERVATION; MONOAMINE OXIDASE-A; SELEGILINE; DESIGN; CAROTENE; PATIENT; TRIAL; BRAIN	Background and Methods. In 1987 we began a multicenter controlled clinical trial of deprenyl (a monoamine oxidase inhibitor) and tocopherol (a component of vitamin E that traps free radicals) in the treatment of early Parkinson's disease. We randomly assigned 800 patients to one of four treatments: placebo, active tocopherol and deprenyl placebo, active deprenyl and tocopherol placebo, or both active drugs. The primary end point was the onset of disability prompting the clinical decision to begin administering levodopa. An interim analysis showed that deprenyl was beneficial (N Engl J Med 1989;321:136471). We report the results of tocopherol treatment after a mean (+/-SD) follow-up of 14+/-6 months, as well as the follow-up results for deprenyl. Results. There was no beneficial effect of tocopherol or any interaction between tocopherol and deprenyl. The beneficial effects of deprenyl, which occurred largely during the first 12 months of treatment, remained strong and significantly delayed the onset of disability requiring levodopa therapy (hazard ratio, 0.50; 95 percent confidence interval, 0.41 to 0.62; P<0.001). The difference in the estimated median time to the end point was about nine months. The ratings for Parkinson's disease improved during the first three months of deprenyl treatment; the motor performance of deprenyl-treated patients worsened after the treatments were withdrawn. Conclusions. Deprenyl (10 mg per day) but not tocopherol (2000 IU per day) delays the onset of disability associated with early, otherwise untreated Parkinson's disease. The action of deprenyl that accounts for its beneficial effects remains unclear.	COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA; TORONTO GEN HOSP, TORONTO M5G 1L7, ONTARIO, CANADA; CALIF PARKINSONS FDN, SAN JOSE, CA USA; SINAI HOSP, DETROIT, MI 48235 USA; UNIV S FLORIDA, TAMPA, FL 33620 USA; UNIV MICHIGAN, ANN ARBOR, MI 48109 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CHICAGO, IL 60612 USA	Columbia University; NewYork-Presbyterian Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; State University System of Florida; University of South Florida; University of Michigan System; University of Michigan; Rush University	SHOULSON, I (corresponding author), UNIV ROCHESTER, MED CTR, DEPT NEUROL, BOX 673, 601 ELMWOOD AVE, ROCHESTER, NY 14642 USA.		LeWitt, Peter/AAW-4988-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645, M01RR000847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024778] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00645, RR00847] Funding Source: Medline; NINDS NIH HHS [NS24778] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLAIN H, 1991, ACTA NEUROL SCAND, V84, P73, DOI 10.1111/j.1600-0404.1991.tb05024.x; ARMITAGE P, 1987, STATISTICAL METHODS, P205; BIRKMAYER W, 1985, J NEURAL TRANSM, V64, P113, DOI 10.1007/BF01245973; Birkmayer W, 1983, Mod Probl Pharmacopsychiatry, V19, P170; CHRISP P, 1991, Drugs and Aging, V1, P228, DOI 10.2165/00002512-199101030-00006; COX DR, 1972, J R STAT SOC B, V34, P187; COX DR, 1984, MONOGRAPHS STATISTIC, V21; CSANDA E, 1983, ACTA NEUROL SCAND, V68, P117, DOI 10.1111/j.1600-0404.1983.tb01525.x; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2, P795; EISLER T, 1981, NEUROLOGY, V31, P19, DOI 10.1212/WNL.31.1.19; FAHN S, 1989, ANN NY ACAD SCI, V570, P186; GOLBE LI, 1989, NEUROLOGY, V39, P1109, DOI 10.1212/WNL.39.8.1109; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KONRADI C, 1989, NEUROSCIENCE, V33, P383, DOI 10.1016/0306-4522(89)90218-2; Lang A. E. T., 1989, QUANTIFICATION NEURO, P285; MYLLYLA VV, 1992, NEUROLOGY, V42, P339, DOI 10.1212/WNL.42.2.339; OAKES D, 1990, Neurology, V40, P370; OAKES D, 1990, CONTROLLED CLIN TRIA, V11, P284; PARKES JD, 1975, J NEUROL NEUROSUR PS, V38, P232, DOI 10.1136/jnnp.38.3.232; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RIEDERER P, 1986, J NEUROCHEM, V46, P1359, DOI 10.1111/j.1471-4159.1986.tb01747.x; RINNE JO, 1991, NEUROLOGY, V41, P859, DOI 10.1212/WNL.41.6.859; SHOULSON I, 1989, NEW ENGL J MED, V321, P1364; SHOULSON I, 1989, ARCH NEUROL-CHICAGO, V46, P1052, DOI 10.1001/archneur.1989.00520460028009; STAMPFER MJ, 1985, STAT MED, V4, P111, DOI 10.1002/sim.4780040202; Stern G M, 1983, Mod Probl Pharmacopsychiatry, V19, P215; TERAVAINEN H, 1990, ACTA NEUROL SCAND, V81, P333; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WILLSON RL, 1983, CIBA F SYMP, V101, P19; 1992, MOV DISORD, V7, P293	34	918	941	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1993	328	3					176	183						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG625	8417384				2022-12-28	WOS:A1993KG62500005
J	MICHEL, S; GEUSZ, ME; ZARITSKY, JJ; BLOCK, GD				MICHEL, S; GEUSZ, ME; ZARITSKY, JJ; BLOCK, GD			CIRCADIAN-RHYTHM IN MEMBRANE CONDUCTANCE EXPRESSED IN ISOLATED NEURONS	SCIENCE			English	Article							CHICK PINEAL CELLS; CELLULAR ANALYSIS; PACEMAKER SYSTEM; BULLA; EYE; LIGHT; LOCALIZATION; OSCILLATION; RELEASE; APLYSIA	Although isolated neurons can generate rhythmic activity, they have not yet been shown to generate rhythms with a period in the circadian range (near 24 hours). The eye of the mollusk Bulla gouldiana expresses a circadian rhythm in optic nerve impulses that is generated by electrically coupled cells known as basal retinal neurons (BRNs). Daily fluctuations in the membrane potential of the BRNs appear to be driven by a rhythm in membrane conductance. Isolated BRNs exhibited spontaneous conductance changes similar to those observed in the intact retina. Membrane conductance was high in the late subjective night and decreased approximately twofold near projected dawn during at least two circadian cycles in culture. The persistence of daily conductance changes in isolated BRNs indicates that individual neurons can function as circadian pacemakers.	UNIV VIRGINIA, DEPT BIOL, NATL SCI FDN, CTR BIOL TIMING, CHARLOTTESVILLE, VA 22901 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008806, R01NS015264] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15264, NS08806] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOCK GD, 1983, BRAIN RES, V265, P134, DOI 10.1016/0006-8993(83)91343-4; BLOCK GD, 1981, J COMP PHYSIOL, V142, P403, DOI 10.1007/BF00605452; BLOCK GD, 1982, SCIENCE, V217, P155, DOI 10.1126/science.217.4555.155; BLOCK GD, 1984, J COMP PHYSIOL, V155, P387, DOI 10.1007/BF00610592; DEGUCHI T, 1979, NATURE, V282, P94, DOI 10.1038/282094a0; ESKIN A, 1979, FED PROC, V38, P2573; ESKIN A, 1977, COMP BIOCHEM PHYS A, V57, P443, DOI 10.1016/0300-9629(77)90143-8; GEUSZ ME, 1991, J COMP PHYSIOL A, V168, P565, DOI 10.1007/BF00215078; GEUSZ ME, 1992, J BIOL RHYTHM, V7, P255, DOI 10.1177/074873049200700306; JACKLET JW, 1983, J NEUROCYTOL, V12, P673, DOI 10.1007/BF01181530; JACKLET JW, 1969, SCIENCE, V164, P562, DOI 10.1126/science.164.3879.562; JACKLET JW, 1989, NEURONAL CELLULAR OS, P483; KHALSA S B S, 1991, Society for Neuroscience Abstracts, V17, P1240; MCMAHON DG, 1984, J COMP PHYSIOL, V155, P379, DOI 10.1007/BF00610591; MCMAHON DG, 1987, J COMP PHYSIOL A, V161, P335, DOI 10.1007/BF00603959; MCMAHON DG, 1986, THESIS U VIRGINIA; MURAKAMI N, 1991, BRAIN RES, V545, P347, DOI 10.1016/0006-8993(91)91312-O; RALPH MR, 1990, J COMP PHYSIOL A, V166, P589; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TUREK FW, 1985, ANNU REV PHYSIOL, V47, P49, DOI 10.1146/annurev.ph.47.030185.000405; ZATZ M, 1988, BRAIN RES, V438, P199, DOI 10.1016/0006-8993(88)91339-X	22	177	178	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1993	259	5092					239	241		10.1126/science.8421785	http://dx.doi.org/10.1126/science.8421785			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	8421785	Green Submitted			2022-12-28	WOS:A1993KF71900034
J	WILLIAMS, N; CHELL, J; KAPILA, L				WILLIAMS, N; CHELL, J; KAPILA, L			WHY ARE CHILDREN REFERRED FOR CIRCUMCISION	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT PAEDIAT SURG,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								ESCALA JM, 1989, BRIT J UROL, V63, P196, DOI 10.1111/j.1464-410X.1989.tb05164.x; GAIRDNER D, 1949, BMJ-BRIT MED J, V2, P1433, DOI 10.1136/bmj.2.4642.1433; MCKINLEY GA, 1988, BRIT MED J, V297, P590; RICKWOOD AMK, 1989, ANN ROY COLL SURG, V71, P275; STRINGER MD, 1991, BRIT MED J, V302, P292, DOI 10.1136/bmj.302.6771.292-a	5	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1993	306	6869					28	28		10.1136/bmj.306.6869.28	http://dx.doi.org/10.1136/bmj.306.6869.28			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435573	Green Published, Bronze			2022-12-28	WOS:A1993KE98400022
J	LEVY, R				LEVY, R			TACRINE IN ALZHEIMERS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											LEVY, R (corresponding author), INST PSYCHIAT,LONDON SE5 8AF,ENGLAND.							EAGGER SA, 1991, LANCET, V337, P989, DOI 10.1016/0140-6736(91)92656-M	1	1	1	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					808	808						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8437604				2022-12-28	WOS:A1993KR84800015
J	PELLEGRINO, ED				PELLEGRINO, ED			THE METAMORPHOSIS OF MEDICAL-ETHICS - A 30-YEAR RETROSPECTIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											PELLEGRINO, ED (corresponding author), GEORGETOWN UNIV,MED CTR,CTR ADV STUDY ETH,WASHINGTON,DC 20007, USA.							Beauchamp T, 1989, PRINCIPLES BIOMEDICA; BEAUCHAMP TL, 1984, MED ETHICS MORAL RES, P22; Callahan S., 1991, GOOD CONSCIENCE REAS; CARRICK P, 1985, MED ETHICS ANTIQUITY, P163; CLOUSER KD, 1990, J MED PHILOS, V15, P219, DOI 10.1093/jmp/15.2.219; ENGELHARDT HT, 1988, NEW ENGL J MED, V319, P1086, DOI 10.1056/NEJM198810203191610; ENGELHARDT HT, 1986, F BIOETHICS; Flanagan Owen, 1991, VARIETIES MORAL PERS; Gilligan Carol., 1983, DIFFERENT VOICE; GREGORY J, 1772, LECTURES DUTIES QUAL; HOOKER W, 1972, PHYSICIAN PATIENT PR; JAEGER W, 1945, PAIDEA IDEALS GREEK, V3, P3; Jaspers K., 1963, PHILOS WORLD SELECTE, P153; JONES WHL, 1981, HIPPOCRATES, V2, P185; JONES WHL, 1972, HIPPOCRATES, V1, P289; JONES WHL, 1981, HIPPOCRATES, V2, P279; Jonsen A. R., 1988, ABUSE CASUISTRY HIST; MACINTYRE A, 1980, KNOWING VALUING, P18; MACINTYRE A, 1992, AM CATH PHIL Q, V66, P1; MacIntyre A., 1990, 3 RIVAL VERSIONS MOR, P139; MacIntyre Alasdair, 1988, AFTER VIRTUE; MADISON GB, 1992, PHIL TODAY       SPR, P3; MILLER W, 1975, CICERO, V21, P1; MILLER W, 1975, CICERO, P21; MOON RO, 1923, HIPPOCRATES HIS SUCC, P91; Nelson H L, 1992, J Clin Ethics, V3, P8; Noddings N., 1984, HAPPINESS ED; Pellegrino E., 1988, PATIENTS GOOD RESTOR; Pellegrino E D, 1991, J Clin Ethics, V2, P5; PELLEGRINO ED, 1988, LIT MED, V7, P22, DOI 10.1353/lm.2011.0164; PELLEGRINO ED, IN PRESS TRANSCULTUR; PELLEGRINO ED, IN PRESS PRINCIPLES; Percival T, 1803, MED ETHICS; Rawls J., 1971, THEORY JUSTICE, P302; Rorty Richard, 1979, PHILOS MIRROR NATURE; Ross W. D., 1988, RIGHT GOOD, p[19, 28]; Temkin O., 1991, HIPPOCRATES WORLD PA; WILDES KM, IN PRESS J MED PHIL; Williams B., 1985, ETHICS LIMITS PHILOS; Williams B., 1981, MORAL LUCK; Wiredu K., 1992, AFRICAN AM PERSPECTI; 1990, J MED PHILOS, V15, P1	42	147	150	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1158	1162		10.1001/jama.269.9.1158	http://dx.doi.org/10.1001/jama.269.9.1158			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	KN611	8433472				2022-12-28	WOS:A1993KN61100034
J	GRUMET, GW				GRUMET, GW			PANDEMONIUM IN THE MODERN HOSPITAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NOISE ANNOYANCE; HEALTH; SPEECH				GRUMET, GW (corresponding author), ROCHESTER GEN HOSP, ROCHESTER, NY 14621 USA.							AITKEN RJ, 1982, ARCH ENVIRON HEALTH, V37, P361, DOI 10.1080/00039896.1982.10667592; ARVIDSSON O, 1978, ARCH ENVIRON HEALTH, V33, P159, DOI 10.1080/00039896.1978.10667328; Baker C F, 1984, CCQ, V6, P66; BARON RA, 1970, TYYRANNY NOISE; Beranek LL, 1960, NOISE REDUCTION; BERLAND T, 1970, FIGHT QUIET; Broadbent D.E., 1958, PERCEPTION COMMUNICA; BROADBENT DE, 1963, Q J EXP PSYCHOL, V15, P205, DOI 10.1080/17470216308416325; Cohen S, 1984, NOISE SOC, P221; DENGERINK HA, 1982, J ACOUST SOC AM, V72, P276, DOI 10.1121/1.387991; DENZEL HA, 1964, SCIENCE, V143, P992, DOI 10.1126/science.143.3610.992; FALK SA, 1973, NEW ENGL J MED, V289, P774, DOI 10.1056/NEJM197310112891504; FIFE D, 1976, AM J PUBLIC HEALTH, V66, P680, DOI 10.2105/AJPH.66.7.680; Frankenhaeuser M, 1974, Biol Psychol, V2, P127, DOI 10.1016/0301-0511(74)90020-9; GARDNER WJ, 1960, SCIENCE, V132, P32, DOI 10.1126/science.132.3418.32; Gaze H, 1987, NURS TIMES, V83, P18; GEEN RG, 1971, PSYCHOL REP, V28, P983, DOI 10.2466/pr0.1971.28.3.983; Glass DC., 1972, URBAN STRESS EXPT NO; GRUMET GW, 1985, PSYCHIATRY, V48, P180, DOI 10.1080/00332747.1985.11024278; HANSELL HN, 1984, HEART LUNG, V13, P59; HILTON A, 1987, AM J NURS, V87, pA59; Hilton B A, 1986, Can Nurse, V82, P24; HOCKEY R, 1973, J EXP PSYCHOL, V101, P35, DOI 10.1037/h0035467; HODGE B, 1990, LANCET, V335, P891, DOI 10.1016/0140-6736(90)90486-O; HUGHJONES P, 1964, BRIT MED J, V2, P660, DOI 10.1136/bmj.2.5410.660; JONES DM, 1984, NOISE SOC, P125; KESTIN IG, 1988, ANESTHESIOLOGY, V69, P106, DOI 10.1097/00000542-198807000-00018; Knudsen Vern O., 1955, NOISE CONTROL, V1, P11; Kryter KD, 1985, EFFECTS NOISE MAN, V2nd; Loeb M., 1986, NOISE HUMAN EFFICIEN; LOVALLO WR, 1980, PSYCHOPHYSIOLOGY, V17, P29, DOI 10.1111/j.1469-8986.1980.tb02455.x; LUKAS JS, 1975, J ACOUST SOC AM, V58, P1232, DOI 10.1121/1.380805; MCINTYRE J W R, 1985, International Journal of Clinical Monitoring and Computing, V2, P47, DOI 10.1007/BF02915873; MCLEAN EK, 1977, PSYCHOL MED, V7, P19, DOI 10.1017/S0033291700023138; MILGRAM S, 1970, SCIENCE, V167, P1461, DOI 10.1126/science.167.3924.1461; MILLER GA, 1947, PSYCHOL BULL, V44, P105, DOI 10.1037/h0055960; MILLER JD, 1974, J ACOUST SOC AM, V56, P729, DOI 10.1121/1.1903322; MINCKLEY BB, 1968, NURS RES, V17, P247; MOREIRA NM, 1972, J SOUND VIB, V21, P449, DOI 10.1016/0022-460X(72)90829-2; NAISBITT N, 1982, MEGATRENDS 10 NEW DI; NOLEN WA, 1973, NEW ENGL J MED, V289, P803, DOI 10.1056/NEJM197310112891512; PEKKARINEN E, 1990, AUDIOLOGY, V29, P219; POLLACK I, 1957, J ACOUST SOC AM, V29, P1262, DOI 10.1121/1.1919140; PRAGAY DA, 1981, CLIN BIOCHEM, V14, P157, DOI 10.1016/S0009-9120(81)90351-9; SALAME P, 1982, J VERB LEARN VERB BE, V21, P150, DOI 10.1016/S0022-5371(82)90521-7; SCHULTZ TJ, 1978, J ACOUST SOC AM, V64, P377, DOI 10.1121/1.382013; SHAPIRO RA, 1972, NEW ENGL J MED, V287, P1236, DOI 10.1056/NEJM197212142872407; SOUTAR RL, 1986, BRIT MED J, V292, P305, DOI 10.1136/bmj.292.6516.305; STATHAM C, 1960, JAMA-J AM MED ASSOC, V172, P1080; TARNOPOLSKY A, 1980, AIRCRAFT NOISE PREVA; TEICHNER WH, 1963, ERGONOMICS, V6, P83, DOI 10.1080/00140136308930678; TOPF M, 1988, HEART LUNG, V17, P567; Topf M, 1988, Hosp Top, V66, P30; WARNAKA GE, 1989, NOISE NEWS, V18, P73; WEBB JM, 1977, HOSPITALS, V51, P93; WEINSTEIN ND, 1978, J APPL PSYCHOL, V63, P458, DOI 10.1037/0021-9010.63.4.458; 1976, B BUREAU LABOR STATI, V1905, P327; 1988, NOISE NEWS, V17, P11; 1974, EPA550974004 REP; [No title captured]	60	57	60	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					433	437		10.1056/NEJM199302113280612	http://dx.doi.org/10.1056/NEJM199302113280612			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8421463				2022-12-28	WOS:A1993KL58400012
J	SMITH, WC; KNECHT, AK; WU, M; HARLAND, RM				SMITH, WC; KNECHT, AK; WU, M; HARLAND, RM			SECRETED NOGGIN PROTEIN MIMICS THE SPEMANN ORGANIZER IN DORSALIZING XENOPUS MESODERM	NATURE			English	Article							MESSENGER-RNA; INSITU HYBRIDIZATION; LAEVIS EMBRYOS; LOCALIZATION; EXPRESSION; AXIS	A DORSALIZING signal acts during gastrulation to change the specification of lateral mesodermal tissues from ventral (blood, mesenchyme) to more dorsal fates (muscle, heart, pronephros)1-3. This signal, from Spemann's organizer, cannot be mimicked by the mesoderm inducers activin and fibroblast growth factor2. The gene noggin is expressed in the organizer 4, and could be the dorsalizing signal. Here we show that soluble noggin protein added to ventral marginal zones during gastrulation induces muscle, but that activin does not. Dorsal pattern can be partially rescued in ventralized embryos by injection of a plasmid that expresses noggin during gastrulation. The results suggest that the noggin product may be the dorsalizing signal from the organizer.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,401 BARKER HALL,BERKELEY,CA 94720	University of California System; University of California Berkeley								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BOLCE ME, 1992, DEVELOPMENT, V115, P681; CHRISTIAN JL, IN PRESS GENES DEV; CONDIE BG, 1987, DEVELOPMENT, V101, P93; DALE L, 1987, DEVELOPMENT, V100, P279; DWORKINRASTL E, 1986, J EMBRYOL EXP MORPH, V91, P153; HARLAND R, 1988, DEVELOPMENT, V102, P837; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LETTICE LA, 1993, DEVELOPMENT, V117, P263; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PENG HB, 1991, METHOD CELL BIOL, V36, P661; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STEWART RM, 1990, DEVELOPMENT, V109, P363; VIZE PD, 1991, METHOD CELL BIOL, V36, P361	20	326	336	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					547	549		10.1038/361547a0	http://dx.doi.org/10.1038/361547a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429909				2022-12-28	WOS:A1993KL71400064
J	WALDO, GS; LING, JS; SANDERSLOEHR, J; THEIL, EC				WALDO, GS; LING, JS; SANDERSLOEHR, J; THEIL, EC			FORMATION OF AN FE(III)-TYROSINATE COMPLEX DURING BIOMINERALIZATION OF H-SUBUNIT FERRITIN	SCIENCE			English	Article							HORSE SPLEEN APOFERRITIN; CONSERVATION; GENE; IDENTIFICATION; PSEUDOGENE; EXPRESSION; SEQUENCES; PROTEINS; FAMILY	An iron(III)-tyrosinate complex was identified in ferritin by ultraviolet-visible and resonance Raman spectroscopies. Previously, a specific amino acid side chain coordinated to iron in ferritin was not known. Ferritin protein was overexpressed in Escherichia coli from complementary DNA sequences of bullfrog red cell ferritin. The purple iron(III)-tyrosinate intermediate that formed during the first stages of iron uptake was replaced by the amber multinuclear iron(III)-oxo complexes of fully mineralized ferritin. Only the H subunit formed detectable amounts of the iron(III)-tyrosinate complex, which may explain the faster rates of iron biomineralization in H- compared to L-type ferritin.	N CAROLINA STATE UNIV, DEPT BIOCHEM, RALEIGH, NC 27695 USA; OREGON GRAD INST, DEPT CHEM & BIOL SCI, BEAVERTON, OR 97006 USA; N CAROLINA STATE UNIV, DEPT PHYS, RALEIGH, NC 27695 USA	University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020251, R56DK020251, R37DK020251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018865] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-20251] Funding Source: Medline; NIGMS NIH HHS [GM-18865] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVERILL BA, 1987, J AM CHEM SOC, V109, P3760, DOI 10.1021/ja00246a039; BAUMINGER ER, 1989, BIOCHEMISTRY-US, V28, P5486, DOI 10.1021/bi00439a025; BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; BOYD D, 1985, J BIOL CHEM, V260, P1755; DANIELSMCQUEEN S, 1988, NUCLEIC ACIDS RES, V16, P7741, DOI 10.1093/nar/16.15.7741; DICKEY LF, 1987, J BIOL CHEM, V262, P7901; GROSSMAN MJ, 1992, P NATL ACAD SCI USA, V89, P2419, DOI 10.1073/pnas.89.6.2419; HANNA PM, 1991, BIOCHEMISTRY-US, V30, P9210, DOI 10.1021/bi00102a012; Harrison P.M., 1989, IRON CARRIERS IRON P, P123; HEUSTERSPREUTE M, 1981, FEBS LETT, V129, P322, DOI 10.1016/0014-5793(81)80193-7; Joo M S, 1990, Biol Met, V3, P171, DOI 10.1007/BF01140575; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEIBOLD EA, 1987, J BIOL CHEM, V262, P7335; LOEHR TM, IN PRESS METHODS ENZ; MURRAY MT, 1987, P NATL ACAD SCI USA, V84, P7438, DOI 10.1073/pnas.84.21.7438; OHLENDORF DH, 1988, NATURE, V336, P403, DOI 10.1038/336403a0; PYRZ JW, 1985, J AM CHEM SOC, V107, P614, DOI 10.1021/ja00289a013; QUE L, 1981, BIOCHEMISTRY-US, V20, P2545, DOI 10.1021/bi00512a028; QUE L, 1983, COORDIN CHEM REV, V50, P73, DOI 10.1016/0010-8545(83)85027-9; QUE L, 1989, IRON CARRIERS IRON P, P457; Que L, 1988, BIOL APPLICATIONS RA, P491; RAGLAND M, 1990, J BIOL CHEM, V265, P18339; RICE DW, 1983, ADV INORG BIOCHEM, V5, P39; STEVENS PW, 1987, MOL CELL BIOL, V7, P1751, DOI 10.1128/MCB.7.5.1751; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEIL EC, 1990, ADV ENZYMOL RAMB, V63, P421; WADE VJ, 1991, J MOL BIOL, V221, P1443, DOI 10.1016/0022-2836(91)80137-J; YABLONSKI MJ, 1992, BIOCHEMISTRY-US, V31, P9680, DOI 10.1021/bi00155a022; YANG CY, 1987, BIOCHEMISTRY-US, V26, P497, DOI 10.1021/bi00376a023	29	87	87	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					796	798		10.1126/science.8430332	http://dx.doi.org/10.1126/science.8430332			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430332				2022-12-28	WOS:A1993KL11000027
J	ENQUIST, M; ARAK, A				ENQUIST, M; ARAK, A			SELECTION OF EXAGGERATED MALE TRAITS BY FEMALE AESTHETIC SENSES	NATURE			English	Article							SEXUAL SELECTION; PREFERENCES; EVOLUTION	DARWIN1 suggested that many apparently deleterious secondary sexual characters in males, such as bright colours, elaborate ornaments and conspicuous displays, evolved as a result of female choice. Darwin never tried to explain the crucial agent of selection, that females have preferences for exaggerated male traits. Rather, he took it for granted that females of many species possess a 'sense of the beautiful', akin to the aesthetic sense in humans. The question of why such preferences evolve remains a controversial issue2,3 . Here we report that mechanisms concerned with signal recognition possess inevitable biases in response that act as important agents of selection on signal form. The existence of such biases may be sufficient to explain the evolution of exaggerated male secondary sexual traits, and elaborate signals in general.			ENQUIST, M (corresponding author), UNIV STOCKHOLM,DEPT ZOOL,S-10691 STOCKHOLM,SWEDEN.							BASOLO AL, 1990, SCIENCE, V250, P808, DOI 10.1126/science.250.4982.808; BASOLO AL, 1991, SCIENCE, V253, P1426, DOI 10.1126/science.253.5026.1426-b; Caudill M, 1990, NATURALLY INTELLIGEN; Darwin C., 1871, P475; EBERHART RC, 1990, NEURAL NETWORK PC TO; HUXLEY J, 1966, PHILOS T ROY SOC B, V251, P249, DOI 10.1098/rstb.1966.0010; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; RYAN MJ, 1990, NATURE, V343, P66, DOI 10.1038/343066a0; RYAN MJ, 1991, OXFORD SURVEYS EVOLU, V7, P156; SMITH JM, 1991, TRENDS ECOL EVOL, V6, P146, DOI 10.1016/0169-5347(91)90055-3; Spence KW, 1937, PSYCHOL REV, V44, P430, DOI 10.1037/h0062885; Tinbergen N., 1948, Wilson Bulletin, V60, P6	13	148	151	0	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					446	448		10.1038/361446a0	http://dx.doi.org/10.1038/361446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	KK713	8429883				2022-12-28	WOS:A1993KK71300059
J	TITTIGER, C; WHYARD, S; WALKER, VK				TITTIGER, C; WHYARD, S; WALKER, VK			A NOVEL INTRON SITE IN THE TRIOSEPHOSPHATE ISOMERASE GENE FROM THE MOSQUITO CULEX-TARSALIS	NATURE			English	Article							ACID SEQUENCE DATA; DROSOPHILA-MELANOGASTER; STRUCTURAL UNITS; PIECES; TPI	THE origin and function of introns in eukaryotic genes has provoked considerable debate since their discovery in 1977. Central to this issue are studies on the highly conserved enzyme, triosephosphate isomerase (TPI, EC 5.3.1.1). The 'introns early' argument suggests that introns are as old as the genes themselves and that the apparent correlation of many of the intron sites in plant, animal and fungal TPI genes with the boundaries of modules1 is evidence of the assembly of ancient proteins by exon shuffling2-4. In contrast, the 'introns late' view holds that ancient genomes contained few if any introns; introns were inserted into pre-existing genes during the last billion years5,6. We have found that the TPI gene from the mosquito, Culex tarsalis, contains an intron in a unique position that was predicted by W. Gilbert2 and the exon shuffling hypothesis.			TITTIGER, C (corresponding author), QUEENS UNIV,DEPT BIOL,KINGSTON K7L 3N6,ONTARIO,CANADA.			Whyard, Steve/0000-0002-9874-7780				BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BROWN JR, 1985, MOL CELL BIOL, V5, P1964; CAVELIERSMITH T, 1985, NATURE, V315, P283; CHIA W, 1985, J MOL BIOL, V186, P689, DOI 10.1016/0022-2836(85)90389-4; CRAIG LC, 1991, GENE, V99, P217, DOI 10.1016/0378-1119(91)90130-4; DALY HV, 1978, INTRO INSECT BIOL DI, P268; DOOLITTLE WF, 1978, NATURE, V272, P581, DOI 10.1038/272581a0; FUTUYAMA DJ, 1986, EVOLUTIONARY BIOL, P323; GILBERT W, 1985, SCIENCE, V228, P823, DOI 10.1126/science.4001923; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GO M, 1987, COLD SPRING HARB SYM, V52, P915, DOI 10.1101/SQB.1987.052.01.100; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; HICKEY DA, 1989, J THEOR BIOL, V137, P41, DOI 10.1016/S0022-5193(89)80148-1; MARCHIONNI M, 1986, CELL, V46, P133, DOI 10.1016/0092-8674(86)90867-6; MCNIGHT GM, 1986, CELL, V46, P143; OLD SE, 1988, NUCLEIC ACIDS RES, V16, P9055, DOI 10.1093/nar/16.18.9055; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; Sambrook J, 1989, MOL CLONING LABORATO; SHAWLEE RL, 1991, MOL GEN GENET, V230, P225, DOI 10.1007/BF00290672; STRAUS D, 1985, MOL CELL BIOL, V5, P3497, DOI 10.1128/MCB.5.12.3497; ZIEGLER R, 1987, PESTIC BIOCHEM PHYS, V28, P279, DOI 10.1016/0048-3575(87)90026-5	24	51	53	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					470	472		10.1038/361470a0	http://dx.doi.org/10.1038/361470a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8429888				2022-12-28	WOS:A1993KK71300067
J	PERNEGER, TV; NIETO, FJ; WHELTON, PK; KLAG, MJ; COMSTOCK, GW; SZKLO, M				PERNEGER, TV; NIETO, FJ; WHELTON, PK; KLAG, MJ; COMSTOCK, GW; SZKLO, M			A PROSPECTIVE-STUDY OF BLOOD-PRESSURE AND SERUM CREATININE - RESULTS FROM THE CLUE STUDY AND THE ARIC STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL-FUNCTION; DISEASE; HYPERTENSION; ASSOCIATION; REGRESSION; DECLINE; KIDNEY; WOMEN	Objectives.-To describe associations of past and current blood pressure levels with serum creatinine levels and hypercreatinemia in the general population. Population.-1399 middle-aged residents of Washington County, Maryland, who had their blood pressure measured during a cancer screening campaign in 1974 (the ''Clue'' Study) and had their blood pressure and serum creatinine level measured in an atherosclerosis risk factors study from 1986 through 1989 (the Atherosclerosis Risk in Communities [ARIC] Study). Design.-Nonconcurrent prospective study. The outcome variables were serum creatinine level and hypercreatinemia (serum creatinine >115 mumol/L in men, >97 mumol/L in women) measured from 1986 through 1989. Main predictors were 1986-1989 blood pressure values (cross-sectional association) and 1974 blood pressure values (longitudinal association). Gender-adjusted associations were assessed and compared by linear and logistic regression. Results.-Both serum creatinine and hypercreatinemia were better predicted by past than by current blood pressure values. Creatinine values exhibited a gradual and statistically significant association with blood pressure levels measured in 1974, even across ''normal'' values of blood pressure and creatinine. The association with 1986-1989 blood pressure measurements was weaker and nonsignificant. The odds of hypercreatinemia in 1986-1989 were increased 1.5-fold to twofold, with a 20 mm Hg increment in 1974 blood pressure values, but the odds remained constant across 1986-1989 blood pressure values. Conclusions.-Blood pressure and creatinine level are associated in the general population. The observed association was stronger when a number of years had elapsed between the assessments of blood pressure and creatinine level. These findings are consistent with the hypothesis that blood pressure elevations, even below the hypertensive range, may induce early renal damage.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD 21218 USA; UNIV GENEVA, INST SOCIAL & PREVENT MED, CH-1211 GENEVA 4, SWITZERLAND	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Geneva				Szklo, Moyses/0000-0001-9433-6266	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NCRR NIH HHS [5MOIRR00722, RR00035] Funding Source: Medline; NHLBI NIH HHS [HL 21670] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Becker RA, 1988, NEW S LANGUAGE PROGR; BOICE JD, 1977, J NATL CANCER I, V59, P823, DOI 10.1093/jnci/59.3.823; BRIGHT R, 1836, GUYS HOSP REP, V1, P366; BROOKMEYER A, 1988, EPIDEMIOLOGY HLTH RI, P178; CHASIS H, 1966, CIRCULATION, V34, P921, DOI 10.1161/01.CIR.34.5.921; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; COMSTOCK GW, 1988, AM J EPIDEMIOL, V127, P114, DOI 10.1093/oxfordjournals.aje.a114771; DOOLAN PD, 1962, AM J MED, V32, P65, DOI 10.1016/0002-9343(62)90183-3; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KIM KE, 1972, CIRCULATION, V46, P456, DOI 10.1161/01.CIR.46.3.456; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; KLAHR S, 1989, NEW ENGL J MED, V320, P731, DOI 10.1056/NEJM198903163201110; LINDEMAN RD, 1984, KIDNEY INT, V26, P861, DOI 10.1038/ki.1984.229; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAHOMED FA, 1879, GUYS HOSP REP, V24, P363; MAMDANI BH, 1974, NEW ENGL J MED, V291, P1343, DOI 10.1056/NEJM197412192912509; NAGEE JN, 1964, AM J MED, V36, P795; PARVING HH, 1983, LANCET, V1, P1175; PETTINGER WA, 1989, HYPERTENSION, V13, P766, DOI 10.1161/01.HYP.13.6.766; ROSANSKY SJ, 1990, ARCH INTERN MED, V150, P2073, DOI 10.1001/archinte.150.10.2073; Rothman K, 1986, MODERN EPIDEMIOLOGY, P7; SCHOTTSTAEDT MF, 1953, AM HEART J, V45, P331, DOI 10.1016/0002-8703(53)90147-1; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; SHURTLEFF D, 1973, UUS DHEW NIH74599 PU; STAMLER J, 1989, HYPERTENSION S1, V13, P12; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; WALLACH J, 1986, INTERPRETATION DIAGN; WEISBERG S, 1985, APPLIED LINEAR REGRE; Whelton PK., 1989, HYPERTENSION, V13, P119; WHELTON PK, 1984, J HYPERTENSION S2, V2, P3; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; WRIGHT BM, 1970, LANCET, V1, P337; 1991, 1991 USRDS NAT I DIA; 1989, SAS STAT USERS GUIDE, P1	36	133	134	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					488	493		10.1001/jama.269.4.488	http://dx.doi.org/10.1001/jama.269.4.488			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8419668				2022-12-28	WOS:A1993KH38500032
J	JANDA, KD; SHEVLIN, CG; LERNER, RA				JANDA, KD; SHEVLIN, CG; LERNER, RA			ANTIBODY CATALYSIS OF A DISFAVORED CHEMICAL TRANSFORMATION	SCIENCE			English	Article							POLYETHER ANTIBIOTICS; STEREOCONTROLLED SYNTHESIS; TETRAHYDROPYRAN SYSTEMS; EPOXIDE OPENINGS; CONSTRUCTION; CYCLIZATION; STRATEGY; MONENSIN; SPECIFICITY; ACTIVATION	Organic reactions are often limited by stereoelectronic constrains that appear along the reaction coordinate. An antibody has been generated that overcomes these constraints and catalyzes a highly disfavored chemical transformation. The antibody facilitates the difficult 6-endo-tet ring closure of an epoxy-alcohol to form a tetrahydropyran. The catalyzed process is in formal violation of what has become known as Baldwin's rules for ring-closure reactions. In addition to controlling the regiochemistry of the disfavored cyclization reaction, these catalytic antibodies resolve enantiomeric substrates to afford a stereochemically pure product. The principles demonstrated in this study may be applicable to other disfavored chemical processes.	SCRIPPS RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute	JANDA, KD (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.							ASHLEY JA, IN PRESS J ORG CHEM; BALDWIN JE, 1976, J CHEM SOC CHEM COMM, P734, DOI 10.1039/c39760000734; BALDWIN JE, 1982, TETRAHEDRON, V19, P2929; BALDWIN JE, 1977, J CHEM SOC CHEM COMM, P253; BARTLETT PA, 1986, J ORG CHEM, V51, P2230, DOI 10.1021/jo00362a014; BEAK P, 1992, ACCOUNTS CHEM RES, V25, P215, DOI 10.1021/ar00017a002; BOIVIN TLB, 1987, TETRAHEDRON, V43, P3309, DOI 10.1016/S0040-4020(01)81626-4; CRUICKSHANK PA, 1969, J ORG CHEM, V34, P4060, DOI 10.1021/jo01264a066; DANISHEFSKY S, 1974, J AM CHEM SOC, V96, P1256, DOI 10.1021/ja00811a068; DANISHEFSKY SJ, 1987, J AM CHEM SOC, V109, P1572, DOI 10.1021/ja00239a049; DOLLE RE, 1985, J AM CHEM SOC, V107, P1691, DOI 10.1021/ja00292a038; Engvall E, 1980, Methods Enzymol, V70, P419; FUKUYAMA T, 1979, J AM CHEM SOC, V101, P260, DOI 10.1021/ja00495a065; FUKUYAMA T, 1979, J AM CHEM SOC, V101, P262, DOI 10.1021/ja00495a066; HOGG DR, 1970, J CHEM SOC C, P2142, DOI 10.1039/j39700002142; HOYE TR, 1985, J AM CHEM SOC, V107, P5312, DOI 10.1021/ja00304a068; HOYE TR, 1987, J AM CHEM SOC, V109, P6196, DOI 10.1021/ja00254a056; JANDA KD, 1991, J AM CHEM SOC, V113, P5427, DOI 10.1021/ja00014a039; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JANDA KD, 1991, TETRAHEDRON, V47, P2503, DOI 10.1016/S0040-4020(01)81784-1; JANDA KD, 1988, SCIENCE, V241, P1188, DOI 10.1126/science.3413482; JANDA KD, 1990, BIOTECHNOL PROGR, V6, P178, DOI 10.1021/bp00003a002; JANDA KD, 1987, 198TH NAT M AM CHEM; KLUMPP GW, 1982, REACTIVITY ORGANIC C; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOLB HC, IN PRESS TETRAHEDRON; KOZIKOWSKI AP, 1985, J ORG CHEM, V50, P3017, DOI 10.1021/jo00216a049; LEWIS C, 1991, SCIENCE, V253, P1019, DOI 10.1126/science.1887215; MARCH J, 1985, ADV ORG CHEM, P187; MOORE JW, 1981, KINETICS MECHANISM; NAKATA T, 1978, J AM CHEM SOC, V100, P2933, DOI 10.1021/ja00477a081; NICOLAOU KC, 1985, J CHEM SOC CHEM COMM, P1359, DOI 10.1039/c39850001359; NICOLAOU KC, 1989, J AM CHEM SOC, V111, P5330, DOI 10.1021/ja00196a043; NICOLAOU KC, 1989, J AM CHEM SOC, V111, P5355; OVERMAN LE, 1986, J AM CHEM SOC, V108, P3516, DOI 10.1021/ja00272a062; PAQUETTE LA, 1981, TETRAHEDRON LETT, V22, P291, DOI 10.1016/0040-4039(81)80078-0; PATERSON I, 1987, TETRAHEDRON LETT, V28, P5205, DOI 10.1016/S0040-4039(00)95630-2; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; PRESSMAN D, 1953, J AM CHEM SOC, V75, P686, DOI 10.1021/ja01099a052; PRESSMAN D, 1946, J AM CHEM SOC, V68, P250, DOI 10.1021/ja01206a031; RAO AS, 1983, TETRAHEDRON, V39, P2323, DOI 10.1016/S0040-4020(01)91961-1; RUSSELL ST, 1986, J CHEM SOC CHEM COMM, P351; SCHMID G, 1979, J AM CHEM SOC, V101, P259, DOI 10.1021/ja00495a064; SCHREIBER SL, 1986, J AM CHEM SOC, V108, P2106, DOI 10.1021/ja00268a070; SCHULTZ WJ, 1980, J AM CHEM SOC, V102, P7981, DOI 10.1021/ja00547a049; SHARPLESS KB, 1992, J ORG CHEM, V57, P2768, DOI 10.1021/jo00036a003; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; STILL WC, 1986, J AM CHEM SOC, V108, P2105, DOI 10.1021/ja00268a069; STORK G, 1974, J AM CHEM SOC, V96, P5268, DOI 10.1021/ja00823a052; TAWFIK DS, 1990, BIOCHEMISTRY-US, V29, P9916, DOI 10.1021/bi00494a023; Tenud L., 1970, HELV CHIM ACTA, V53, P2059, DOI [10.1002/hlca.19700530816, DOI 10.1002/HLCA.19700530816]; TIETZE LF, 1981, TETRAHEDRON LETT, V22, P219, DOI 10.1016/0040-4039(81)80059-7; UNO T, 1992, J AM CHEM SOC, V114, P6573, DOI 10.1021/ja00042a055; WATT RM, 1980, MOL IMMUNOL, V17, P1237, DOI 10.1016/0161-5890(80)90020-6; WUTS PGM, 1984, J ORG CHEM, V49, P2582, DOI 10.1021/jo00188a014; [No title captured]	56	156	159	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					490	493		10.1126/science.8424171	http://dx.doi.org/10.1126/science.8424171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	KJ079	8424171				2022-12-28	WOS:A1993KJ07900026
J	LAINE, C; GOLDMAN, L; SOUKUP, JR; HAYES, JG				LAINE, C; GOLDMAN, L; SOUKUP, JR; HAYES, JG			THE IMPACT OF A REGULATION RESTRICTING MEDICAL HOUSE STAFF WORKING HOURS ON THE QUALITY OF PATIENT-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESIDENT PERFORMANCE; SLEEP-DEPRIVATION; NEW-YORK	Objective.-To examine the impact on patient care of a New York State regulation that restricted house staff working hours. Design.-Retrospective cohort study. Setting.-General medical service of an urban teaching hospital. Patients.-A total of 263 (94%) of 281 patients discharged from the study service during October 1988 and 263 (93%) of 283 patients discharged from the same service during October 1989. Interventions.-On July 1, 1989, New York State enacted a new regulation, Code 405, which limited residents' working hours and specified levels of supervision and ancillary support. Main Outcome Measures.-In-hospital mortality, transfers to intensive care units, cardiopulmonary resuscitation attempts, discharge disposition, length of stay, medical complications, and house staff delays in ordering tests and procedures. Results.-Although the cohorts were comparable in severity of illness measures, more patients in 1989 suffered at least one medical complication (91 [35%] vs 59 [22%]; P=.002) and experienced at least one diagnostic test delay because of house staff (44 [17%] vs 4 [2%]; P<.001). These significant differences persisted after controlling for potential confounders in multivariate analyses. However, we found no significant differences in more serious outcomes: in-hospital mortality, transfer to intensive care unit, discharge disposition, or length of stay. Conclusions.-These results suggest that restricted house staff working hours were associated with delayed test ordering by house staff and increased in-hospital complications. While these potentially deleterious effects on the quality of care did not result in statistically significant differences in more serious outcomes, further study at other hospitals is warranted to determine staffing strategies that optimize quality of care for patients, as well as medical education and quality of life for house officers.	BETH ISRAEL HOSP,DEPT MED,DIV GEN MED,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT MED,DIV CLIN EPIDEMIOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; CORNELL UNIV,MED CTR,NEW YORK HOSP,COLL MED,DEPT MED,NEW YORK,NY 10021	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Cornell University; NewYork-Presbyterian Hospital								ASCH DA, 1988, NEW ENGL J MED, V318, P771, DOI 10.1056/NEJM198803243181209; ASKEN MJ, 1983, J MED EDUC, V58, P382; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHOLLAR S, 1991, NEW PHYSICIAN    JUL, P18; CHRISTENSEN EE, 1977, RADIOLOGY, V125, P103, DOI 10.1148/125.1.103; Condon R E, 1989, Curr Surg, V46, P361; DAVIDSON SM, 1981, NTIS PB81213803; DEACONSON TF, 1988, JAMA-J AM MED ASSOC, V260, P1721, DOI 10.1001/jama.260.12.1721; Denisco R A, 1987, J Clin Monit, V3, P22, DOI 10.1007/BF00770879; DIETRICH AJ, 1982, J FAM PRACTICE, V5, P929; FOLSE R, 1989, Current Surgery, V46, P193; GLICKMAN RM, 1988, NEW ENGL J MED, V318, P780, DOI 10.1056/NEJM198803243181212; GOTTLIEB DJ, 1991, ARCH INTERN MED, V151, P2065, DOI 10.1001/archinte.151.10.2065; HJORTDAHL P, 1990, FAM MED, V5, P361; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P512; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEVINSKY NG, 1988, NEW ENGL J MED, V318, P778, DOI 10.1056/NEJM198803243181211; MCCALL TB, 1988, NEW ENGL J MED, V318, P775, DOI 10.1056/NEJM198803243181210; PIVER CJ, 1991, NEW ENGL J MED, V324, P273; REINER SC, 1990, N Y STATE J MED, V90, P39; ROBBINS J, 1990, WESTERN J MED, V152, P82; THORPE KE, 1990, JAMA-J AM MED ASSOC, V263, P3177, DOI 10.1001/jama.263.23.3177; TRONTELL MC, 1991, J GEN INTERN MED, V6, P445, DOI 10.1007/BF02598169; YEDIDIA M, 1990, FACTORS INFLUENCING; 1986, REPORT 4TH GRAND  50	25	186	187	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					374	378		10.1001/jama.269.3.374	http://dx.doi.org/10.1001/jama.269.3.374			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418344				2022-12-28	WOS:A1993KG38100029
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC WARNING ABOUT HERBAL PRODUCT CHAPARRAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					328	328						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418328				2022-12-28	WOS:A1993KG38100004
J	SUH, WC; ROSS, W; RECORD, MT				SUH, WC; ROSS, W; RECORD, MT			2 OPEN COMPLEXES AND A REQUIREMENT FOR MG2+ TO OPEN THE LAMBDA-P(R) TRANSCRIPTION START SITE	SCIENCE			English	Article							COLI RNA-POLYMERASE; LAC UV5 PROMOTER; SINGLE-STRANDED REGIONS; ESCHERICHIA-COLI; MECHANISM INVIVO; PR PROMOTER; DNA; ACTIVATION; KINETICS	Potassium permanganate (KMnO4) footprinting in the absence and presence of magnesium (Mg2+) at the lambdaP(R) promoter identified two different open complexes with Escherichia coli Esigma70 RNA polymerase (designated RP(o1) and RP(o2). The single-stranded region in RP(o1), (formed in the absence of Mg2+) was at most 12 bases long, whereas that in RP(o2) (formed in the presence of Mg2+) spanned at least 14 bases. Only in RP(o2) did the single-stranded region extend to the start point of transcription (+1, +2). These results provide a structural basis for the requirement for uptake of Mg2+ in the formation of RP(o2) from RP(o1), as deduced from kinetic studies at this promoter.	UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM23467, GM37048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023467, R37GM037048, R01GM037048, R37GM023467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BUC H, 1989, NUCLEIC ACIDS MOL BI, V1, P186; BUCKLE M, 1989, BIOCHEMISTRY-US, V28, P4388, DOI 10.1021/bi00436a040; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KIRKEGAARD K, 1983, P NATL ACAD SCI-BIOL, V80, P2544, DOI 10.1073/pnas.80.9.2544; KLADDE MP, IN PRESS J MOL BIOL; KOREN R, 1977, BIOCHEMISTRY-US, V16, P241, DOI 10.1021/bi00621a013; LEIRMO S, 1990, NUCLEIC ACIDS MOL BI, V4, P123; LUSK JE, 1968, J BIOL CHEM, V243, P2618; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; ROE JH, 1985, BIOCHEMISTRY-US, V24, P4721, DOI 10.1021/bi00339a002; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; ROE JH, 1985, J MOL BIOL, V184, P444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; SUH WC, 1992, BIOCHEMISTRY-US, V31, P7815, DOI 10.1021/bi00149a011; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WU CW, 1969, BIOCHEMISTRY-US, V8, P4458, DOI 10.1021/bi00839a035; ZWIEB C, IN PRESS MOL BIOL	30	95	96	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					358	361		10.1126/science.8420002	http://dx.doi.org/10.1126/science.8420002			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8420002				2022-12-28	WOS:A1993KG62400031
J	CHALFIN, DB; HOLBEIN, MEB; FEIN, AM; CARLON, GC				CHALFIN, DB; HOLBEIN, MEB; FEIN, AM; CARLON, GC			COST-EFFECTIVENESS OF MONOCLONAL-ANTIBODIES TO GRAM-NEGATIVE ENDOTOXIN IN THE TREATMENT OF GRAM-NEGATIVE SEPSIS IN ICU PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAGNOSIS-RELATED GROUPS; CRITICALLY ILL PATIENTS; INTENSIVE-CARE; PROSPECTIVE PAYMENT; BACTEREMIA; CHARGES; IMPACT; HEALTH; SHOCK; TRIAL	Objective-To evaluate the fiscal impact and the cost-effectiveness of monoclonal antibodies against gram-negative endotoxin (MAbGNE) in the treatment of presumed gram-negative sepsis. Design.-A decision analysis model was developed from (1) data from two phase ill trials that studied the E5 or HA-1A MAbGNE, and (2) financial data from 1405 septic patients who required intensive care at a large tertiary hospital. Setting.-Intensive care unit (ICU) patients with presumed gram-negative sepsis. Patients.-The E5 trial evaluated 468 patients, and the HA-1A study enrolled 543 patients with presumed gram-negative sepsis. Interventions.-The addition of MAbGNE to standard regimens or standard regimens alone. Main Outcome Measures.-Total expected charges and the expected probability of survival were determined for each option. Cost-effectiveness and marginal cost-effectiveness ratios were also derived. Multiple sensitivity and Monte Carlo analyses were performed to test the underlying assumptions. Results.-MAbGNE therapy always resulted in higher expected charges; however, these differences were less than its acquisition cost by $870. The cost-effectiveness ratio for MAbGNE, for $2000 and $4000 acquisition costs, was $71 674 and $74 900 per probability of survival, respectively. Sensitivity analysis showed that cost-effectiveness was most affected by diagnostic accuracy, patient selection, and acquisition cost. Monte Carlo analysis showed that MAbGNE was more costly for 71 % of simulations, yet the most efficacious option for 79% of simulations. Conclusions.-From the perspective of acute care institutions, MAbGNE is expensive and cannot be justified on a cost-saving basis. However, it may be cost-effective throughout a reasonable range of assumptions.	WINTHROP UNIV HOSP,PULM RES INST,MINEOLA,NY; PRESBYTERIAN MED CTR,DEPT INTERNAL MED,DALLAS,TX; SUNY STONY BROOK,HLTH SCI CTR,SURG INTENS CARE UNIT,STONY BROOK,NY 11794; SUNY STONY BROOK,HLTH SCI CTR,DIV PULM & CRIT CARE MED,STONY BROOK,NY 11794; CORNELL UNIV,MED CTR,COLL MED,CRIT CARE MED SERV,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT ANESTHESIOL,NEW YORK,NY 10021	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cornell University; Cornell University	CHALFIN, DB (corresponding author), WINTHROP UNIV HOSP,DIV PULM & CRIT CARE MED,222 STN PLAZA N,SUITE 400,MINEOLA,NY 11501, USA.							AHMAD M, 1988, CHEST, V93, P176, DOI 10.1378/chest.93.1.176; BECK JR, 1982, AM J MED, V73, P883, DOI 10.1016/0002-9343(82)90786-0; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BEKES C, 1988, CRIT CARE MED, V16, P478, DOI 10.1097/00003246-198805000-00003; BOGARD WC, 1987, INFECT IMMUN, V55, P899, DOI 10.1128/IAI.55.4.899-908.1987; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BONE RC, 1991, ARCH INTERN MED, V151, P1061, DOI 10.1001/archinte.151.6.1061; BUTLER PW, 1985, CHEST, V87, P228; CERRA FB, 1990, HOSP PRACT, V25, P169; CHALFIN DB, 1989, CRIT CARE MED S, V17, pS86; CULLEN DJ, 1976, NEW ENGL J MED, V294, P982, DOI 10.1056/NEJM197604292941805; CULLEN DJ, 1977, ANESTHESIOLOGY, V47, P203, DOI 10.1097/00000542-197708000-00011; CUNNION RE, 1992, CRIT CARE MED, V20, P721, DOI 10.1097/00003246-199206000-00001; DEGROOT MH, 1986, PROBABILITY STATISTI; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; ENGLEBERG NC, 1984, NEW ENGL J MED, V311, P892, DOI 10.1056/NEJM198410043111406; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; GOETZLER RM, 1991, ARCH INTERN MED, V151, P1537, DOI 10.1001/archinte.151.8.1537; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HARKONEN S, 1988, ANTIMICROB AGENTS CH, V32, P710, DOI 10.1128/AAC.32.5.710; HOLLENBERG J, 1985, SMLTREE ALL PURPOSE; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; KASSIRER JP, 1987, ANN INTERN MED, V106, P275, DOI 10.7326/0003-4819-106-2-275; LAFFEL GL, 1987, J AM COLL CARDIOL, V10, pB79, DOI 10.1016/S0735-1097(87)80432-1; MARTY AT, 1977, ANN THORAC SURG, V24, P409, DOI 10.1016/S0003-4975(10)63433-9; OYE RK, 1991, CHEST, V99, P6875; PARILLO J E, 1990, Annals of Internal Medicine, V113, P227; SCHULMAN KA, 1991, JAMA-J AM MED ASSOC, V266, P3466, DOI 10.1001/jama.266.24.3466; SCHWARTZ WB, 1991, NEW ENGL J MED, V324, P1037, DOI 10.1056/NEJM199104113241506; Shepherd M F, 1992, Clin Pharm, V11, P257; SLOAN FA, 1988, MED CARE, V26, P837, DOI 10.1097/00005650-198809000-00004; SOX HC, 1988, MED DECIS MAKING, P27; SPIVACK D, 1987, AM REV RESPIR DIS, V136, P1007, DOI 10.1164/ajrccm/136.4.1007; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WEINSTEIN MC, 1980, CLIN DECISION ANAL, P12; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; WILKINSON L, 1989, SYSTAT SYSTEM STATIS; WILLARD KE, 1986, MED DECIS MAKING, V6, P85; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1990, MMWR, V39, P31	43	58	59	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					249	254		10.1001/jama.269.2.249	http://dx.doi.org/10.1001/jama.269.2.249			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417245				2022-12-28	WOS:A1993KF40500033
J	JANSSEN, HLA; BROUWER, JT; NEVENS, F; SANCHEZTAPIAS, JM; CRAXI, A; HADZIYANNIS, S				JANSSEN, HLA; BROUWER, JT; NEVENS, F; SANCHEZTAPIAS, JM; CRAXI, A; HADZIYANNIS, S			FATAL HEPATIC DECOMPENSATION ASSOCIATED WITH INTERFERON ALFA	BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED TRIAL		UNIV HOSP LEUVEN,DEPT HEPATOGASTROENTEROL,LOUVAIN,BELGIUM; HOSP CLIN I PROVENCIAL,LIVEN UNIT,BARCELONA,SPAIN; UNIV PADUA,DIV MED INTERNA,I-35100 PADUA,ITALY; HIPPOKRAT GEN HOSP,ACAD DEPT MED,ATHENS,GREECE	KU Leuven; University Hospital Leuven; University of Padua	JANSSEN, HLA (corresponding author), UNIV HOSP DIJKZIGT,DEPT INTERNAL MED 2,3015 GD ROTTERDAM,NETHERLANDS.							DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DURAND JM, 1991, LANCET, V338, P1268; KASSIANIDES C, 1988, VIRAL HEPATITIS LIVE, P840; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; SHEEN IS, 1985, GASTROENTEROLOGY, V89, P732, DOI 10.1016/0016-5085(85)90566-9	5	51	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					107	108		10.1136/bmj.306.6870.107	http://dx.doi.org/10.1136/bmj.306.6870.107			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435602	Bronze, Green Published			2022-12-28	WOS:A1993KG46500020
J	DIAMOND, GA; DENTON, TA				DIAMOND, GA; DENTON, TA			ALTERNATIVE PERSPECTIVES ON THE BIASED FOUNDATIONS OF MEDICAL TECHNOLOGY-ASSESSMENT	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						TECHNOLOGY ASSESSMENT, BIOMEDICAL; HEALTH POLICY; DECISION MAKING; COST-BENEFIT ANALYSIS	RANDOMIZED CLINICAL-TRIALS; CORONARY-ARTERY DISEASE; CHRONIC STABLE ANGINA; HEALTH-CARE; ANGIOPLASTY; PHYSICIANS; DECISIONS; SURVIVAL; QUALITY; LIFE	Medical technology assessment seeks to improve the care of individual patients (the conventional unit of clinical practice) through evaluation studies conducted in groups of patients (the conventional unit of clinical investigation). This distinction between individuals and groups has practical relevance to the design, analysis, and clinical applicability of technology assessment studies. We define several biased perspectives about technology assessment that derive from the distinction between individuals and groups: a misguided emphasis on efficacy versus effectiveness, on statistical significance versus clinical importance, and on objective versus subjective outcomes. In each case, we contrast these alternative perspectives and speculate on their implications for health care policy.	UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	DIAMOND, GA (corresponding author), CEDARS SINAI MED CTR, DIV CARDIOL, 8700 BEVERLY BLVD, LOS ANGELES, CA 90048 USA.							AMOORE JE, 1964, SCI AM, V210, P42, DOI 10.1038/scientificamerican0264-42; [Anonymous], 1986, LANCET, V1, P397; BARNOON S, 1972, MEASURING EFFECTIVEN, P74; BENTHAM J, 1907, INTRO PRINCIPLES MOR, P31; BLENDON RJ, 1984, NEW ENGL J MED, V311, P613, DOI 10.1056/NEJM198408303110938; BRAITMAN LE, 1991, ANN INTERN MED, V114, P515, DOI 10.7326/0003-4819-114-6-515; BROOK RH, 1976, ANN INTERN MED, V85, P809, DOI 10.7326/0003-4819-85-6-809; BUSH JW, 1984, ASSESSMENT QUALITY L, P118; Castro J, 1991, Time, V138, P34; CLANCY CM, 1988, AM J MED, V84, P283, DOI 10.1016/0002-9343(88)90426-3; Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; DANS PE, 1977, SOUTHERN MED J, V70, P1225, DOI 10.1097/00007611-197710000-00020; DENNETT DC, 1991, CONSCIOUSNESS EXPLAI, P46; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; DIAMOND GA, 1981, CIRCULATION, V63, P915, DOI 10.1161/01.CIR.63.4.915; DIAMOND GA, 1983, ANN INTERN MED, V98, P385, DOI 10.7326/0003-4819-98-3-385; DIAMOND GA, 1987, AM J CARDIOL, V59, P698, DOI 10.1016/0002-9149(87)91197-0; DIAMOND GA, 1983, J AM COLL CARDIOL, V1, P444, DOI 10.1016/S0735-1097(83)80072-2; DIAMOND GA, 1992, MED DECIS MAKING, V12, P347; Doubilet P, 1985, Med Decis Making, V5, P293, DOI 10.1177/0272989X8500500305; EPSTEIN AM, 1991, ARCH INTERN MED, V151, P2147, DOI 10.1001/archinte.151.11.2147; FEINSTEIN AR, 1985, HYPERTENSION, V7, P313, DOI 10.1161/01.HYP.7.3_Pt_1.313; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P114; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P148; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P690; FERGUSON J, 1988, Journal of the American College of Cardiology, V11, p127A; FISCH C, 1991, CIRCULATION, V83, P1125; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; GITLER B, 1984, J AM COLL CARDIOL, V3, P262, DOI 10.1016/S0735-1097(84)80009-1; GLASS GV, 1972, REV EDUC RES, V42, P237, DOI 10.2307/1169991; HAND DJ, 1979, BRIT J PSYCHIAT, V135, P90, DOI 10.1192/bjp.135.1.90b; HUTCHESON F, 1729, 2 TREATISES, V2, P179; HUTCHESON F, 1929, 2 TREATISES, V1, P179; IGLEHART JK, 1984, NEW ENGL J MED, V310, P1616, DOI 10.1056/NEJM198406143102429; KAPLAN RM, 1988, J CONSULT CLIN PSYCH, V56, P382, DOI 10.1037/0022-006X.56.3.382; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; KRAKAUER H, 1991, STAT MED, V10, P521, DOI 10.1002/sim.4780100405; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LASKEY WK, 1992, ANN INTERN MED, V116, P869, DOI 10.7326/0003-4819-116-10-869; LEE YJ, 1991, STAT MED, V10, P1595, DOI 10.1002/sim.4780101011; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; Miyamoto J M, 1985, Med Decis Making, V5, P191, DOI 10.1177/0272989X8500500208; MURPHY EA, 1985, COMPANION MED STATIS, P139; MURPHY ML, 1977, NEW ENGL J MED, V297, P621, DOI 10.1056/NEJM197709222971201; PALCA J, 1992, SCIENCE, V257, P20, DOI 10.1126/science.1621086; PALCA J, 1991, SCIENCE, V254, P792, DOI 10.1126/science.1948061; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PIRSIG RM, 1991, INQUIRY MORALS, P66; Pliskin J S, 1981, Med Decis Making, V1, P10, DOI 10.1177/0272989X8100100104; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; POWERS R, 1991, GOLD BUG VARIATIONS, P30; RAHIMTOOLA SH, 1985, CIRCULATION, V72, P449, DOI 10.1161/01.CIR.72.3.449; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SIMPSON EH, 1951, J ROY STAT SOC B, V13, P238; SMITH DG, 1987, AM J MED, V83, P545, DOI 10.1016/0002-9343(87)90768-6; SOX HC, 1989, ANN INTERN MED, V110, P456, DOI 10.7326/0003-4819-110-6-456; Starr Paul, 1982, SOCIAL TRANSFORMATIO, P379; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; TOPOL EJ, 1987, J AM COLL CARDIOL, V10, pB65, DOI 10.1016/S0735-1097(87)80430-8; VARNAUSKAS E, 1982, LANCET, V2, P1173; WEINSTEIN MC, 1980, CLIN DECISION ANAL, P189; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; WONNACOTT RJ, 1985, INTRO STATISTICS, P17; 1991, 1991 HEART STROKE FA; 1990, LANCET, V335, P1315	69	57	57	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					455	464		10.7326/0003-4819-118-6-199303150-00010	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00010			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439120				2022-12-28	WOS:A1993KR81700010
J	LEVY, DN; FERNANDES, LS; WILLIAMS, WV; WEINER, DB				LEVY, DN; FERNANDES, LS; WILLIAMS, WV; WEINER, DB			INDUCTION OF CELL-DIFFERENTIATION BY HUMAN IMMUNODEFICIENCY VIRUS-1 VPR	CELL			English	Article							TRANS-ACTIVATOR GENE; VIRION-ASSOCIATED PROTEIN; OPEN READING FRAME; MUTATIONAL ANALYSIS; HTLV-III; LINE TE671; SOR GENE; INFECTION; TYPE-2; HIV-1	Cell lines from rhabdomyosarcomas, which are tumors of muscle origin, have been used as models of CD4-independent HIV infection. These cell lines can be induced to differentiate in vitro. We report here that the vpr gene of HIV1 is sufficient for the differentiation of the human rhabdomyosarcoma cell line TE671. Differentiated cells are characterized by great enlargement, altered morphology, lack of replication, and high level expression of the muscle-specific protein myosin. We have also observed the morphological differentiation and inhibition of proliferation of two other transformed cell lines. vpr-transfected cells remain fully viable in culture for extended periods. These observations elucidate a potential role for vpr in the virus life cycle and raise the possibility that some aspects of HIV-induced pathologies may be caused by a disturbance of cells by vpr.	WISTAR INST,PHILADELPHIA,PA 19104	The Wistar Institute	LEVY, DN (corresponding author), UNIV PENN,DEPT MED,INST BIOTECHNOL & ADV MOLEC MED,PHILADELPHIA,PA 19104, USA.		Weiner, David B/H-8579-2014	Williams, William/0000-0003-3611-9284				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; AGUANNO S, 1990, CANCER RES, V50, P3377; ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; BRUNI C, 1979, MUSCLE REGENERATION, P265; CANN AJ, 1989, AIDS S1, V3, P19; CHEN TR, 1989, NATURE, V340, P106, DOI 10.1038/340106b0; CHERNOFF D, 1990, AIDS KNOWLEDGE BASE; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; COHEN PT, 1990, AIDS KNOWLEDGE BASE; DALAKAS M, 1991, PEDIATRIC AIDS CHALL, P420; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DEDERA D, 1989, J VIROL, V63, P3205, DOI 10.1128/JVI.63.7.3205-3208.1989; FELIX CA, 1992, CANCER RES, V52, P2243; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GRODY WW, 1990, AM J CARDIOL, V66, P203, DOI 10.1016/0002-9149(90)90589-S; GUYADER M, 1989, EMBO J, V8, P1169, DOI 10.1002/j.1460-2075.1989.tb03488.x; HAGGERTY S, 1991, AIDS RES HUM RETROV, V7, P501, DOI 10.1089/aid.1991.7.501; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; HATTORI N, 1990, P NATL ACAD SCI USA, V87, P8080, DOI 10.1073/pnas.87.20.8080; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; KAPPES JC, 1991, VIROLOGY, V184, P197, DOI 10.1016/0042-6822(91)90836-Z; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAMPERTH L, 1990, Neurology, V40, P121; LI L, 1992, ADV CANCER RES, V58, P95, DOI 10.1016/S0065-230X(08)60292-4; Ling L L, 1991, PCR Methods Appl, V1, P63; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MCALLISTER RM, 1969, CANCER-AM CANCER SOC, V24, P520, DOI 10.1002/1097-0142(196909)24:3<520::AID-CNCR2820240313>3.0.CO;2-M; MCALLISTER RM, 1977, INT J CANCER, V20, P206, DOI 10.1002/ijc.2910200207; MILLER CW, 1990, CANCER RES, V50, P7950; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; ROULSTON A, 1992, J EXP MED, V175, P751, DOI 10.1084/jem.175.3.751; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P7727, DOI 10.1073/pnas.87.19.7727; SCHUITEMAKER H, 1992, J CLIN INVEST, V89, P1154, DOI 10.1172/JCI115697; SHIBATA R, 1990, J MED PRIMATOL, V19, P217; SHIBATA R, 1990, J VIROL, V64, P742, DOI 10.1128/JVI.64.2.742-747.1990; SIEGEL HN, 1988, DEV BRAIN RES, V44, P269, DOI 10.1016/0165-3806(88)90225-8; SODROSKI J, 1986, SCIENCE, V231, P1549, DOI 10.1126/science.3006244; SRINIVASAN A, 1988, ARCH VIROL, V99, P21, DOI 10.1007/BF01311020; STANLEY SK, 1992, J IMMUNOL, V149, P689; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; STREBEL K, 1988, SCIENCE, V241, P1221, DOI 10.1126/science.3261888; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P5163, DOI 10.1073/pnas.86.13.5163; TERWILLIGER EF, 1992, AIDS RES REV, V2, P3; TRISTEM M, 1992, EMBO J, V11, P3405, DOI 10.1002/j.1460-2075.1992.tb05419.x; TRISTEM M, 1990, NATURE, V347, P341, DOI 10.1038/347341b0; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEBER J, 1989, J GEN VIROL, V70, P2653, DOI 10.1099/0022-1317-70-10-2653; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEISS RA, 1988, J ACQ IMMUN DEF SYND, V1, P536; WERNER A, 1990, AIDS, V4, P537, DOI 10.1097/00002030-199006000-00007; WONGSTAAL F, 1987, AIDS RES HUM RETROV, V3, P33, DOI 10.1089/aid.1987.3.33; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YU XF, 1990, J VIROL, V64, P5688, DOI 10.1128/JVI.64.11.5688-5693.1990; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265	69	212	228	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					541	550		10.1016/0092-8674(93)90073-Y	http://dx.doi.org/10.1016/0092-8674(93)90073-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440020				2022-12-28	WOS:A1993KP16500009
J	LILLIEBLANTON, M; ANTHONY, JC; SCHUSTER, CR				LILLIEBLANTON, M; ANTHONY, JC; SCHUSTER, CR			PROBING THE MEANING OF RACIAL ETHNIC-GROUP COMPARISONS IN CRACK COCAINE SMOKING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To probe the meaning of reported racial and ethnic group differences in the prevalence of crack cocaine smoking and to estimate the degree to which crack cocaine smoking is associated with personal factors specific to race/ethnicity. Design.-Through reanalysis of data from the 1988 National Household Survey of Drug Abuse (NHSDA), we compared racial/ethnic group differences in crack cocaine smoking. To hold constant social and environmental risk factors that might potentially confound racial comparisons, we used an epidemiologic strategy that involves poststratification of respondents into neighborhood risk sets. A conditional logistic regression model was used to estimate the relative odds of crack use by race/ethnicity. Patients or Other Participants.-The 1988 NHSDA interviewed 8814 individuals residing within households in the United States. Subjects were selected using a multistage area probability sampling of all residents aged 12 years and older. Results.-Once respondents were grouped into neighborhood clusters, the relative odds (RO) of crack use did not differ significantly for African Americans (RO, 0.85; 95% confidence interval [CI], 0.37 to 1.93) or for Hispanic Americans (RO, 0.88; 95% CI, 0.47 to 1.67) compared with white Americans. Conclusion.-Findings of race-associated differences are often presented as if a person's race has intrinsic explanatory power. This analysis provides evidence that, given similar social and environmental conditions, crack use does not strongly depend on race-specific (eg, biologic) personal factors. Although the study finding does not refute the previous analysis, it provides evidence that prevalence estimates unadjusted for social environmental risk factors may lead to misunderstanding about the role of race or ethnicity in the epidemiology of crack use. Future research should seek to identify which characteristics of the neighborhood social environment are important and potentially modifiable determinants of drug use.	NIDA,ADDICT RES CTR,POB 5180,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MENTAL HYG,BALTIMORE,MD 21218	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins University; Maryland Department of Health & Mental Hygiene			Anthony, Jim/H-3637-2011	Anthony, Jim/0000-0001-7176-0929	NIDA NIH HHS [DA04392] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004392] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Anthony J C, 1991, NIDA Res Monogr, V110, P71; ANTHONY JC, 1989, AM J EPIDEMIOL, V129, P543, DOI 10.1093/oxfordjournals.aje.a115166; BASSETT MT, 1986, AM J PUBLIC HEALTH, V76, P1400, DOI 10.2105/AJPH.76.12.1400; HENDERSON AS, 1988, INTRO SOCIAL PSYCHIA; JONES CP, 1991, AM J EPIDEMIOL, V134, P1079, DOI 10.1093/oxfordjournals.aje.a116011; LESSE S, 1987, AM J PSYCHOTHER, V41, P336, DOI 10.1176/appi.psychotherapy.1987.41.3.336; PETRONIS KR, 1990, SOC PSYCH PSYCH EPID, V25, P193; PETRONIS KR, 1989, DRUG ALCOHOL DEPEN, V23, P219, DOI 10.1016/0376-8716(89)90084-7; Schlesselman JJ, 1982, CASE CONTROL STUDIES; 1991, HRSPDV902 US DEP HLT; 1990, ADM901692 US DEP HLT	11	140	141	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					993	997		10.1001/jama.269.8.993	http://dx.doi.org/10.1001/jama.269.8.993			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KM603	8429605				2022-12-28	WOS:A1993KM60300026
J	STRAND, CL; WAJSBORT, RR; STURMANN, K				STRAND, CL; WAJSBORT, RR; STURMANN, K			EFFECT OF LODOPHOR VS IODINE TINCTURE SKIN PREPARATION ON BLOOD CULTURE CONTAMINATION RATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEEDLES	Objective.-To determine if iodine tincture is a more effective skin antiseptic for blood culture collection than povidone-iodine, an iodophor. Design.-Pairwise comparisons across phases. In phases 1 and 3, blood culture skin preparation was performed with the iodophor; in phases 2 and 4, skin preparation was performed with iodine tincture. Setting.-Emergency department of a large urban teaching hospital. Patients.-All adult patients seen in the emergency department who had blood cultures collected because a systemic bacterial infection was suspected. Main Outcome Measure.-The blood culture contamination rate for the iodophor and iodine tincture skin preparations. Results.-A total of 8467 blood cultures were collected during the study, and 421 (4.97%) were classified as contaminated. The contamination rate for the blood cultures collected using the iodophor was 6.25%, and the contamination rate for the cultures using iodine tincture was 3.74%; this difference is statistically significant (P<.00001). Conclusions.-The effectiveness of the skin antiseptic may be an important factor in determining contamination rate in blood culturing. If these results are confirmed by others, then institutions that have a high blood culture contamination rate when using an iodophor for skin preparation should consider changing to iodine tincture.	BETH ISRAEL MED CTR,MT SINAI SCH MED,DEPT PATHOL & LAB MED & EMERGENCY MED,NEW YORK,NY 10003	Harvard University; Beth Israel Deaconess Medical Center; Icahn School of Medicine at Mount Sinai								BATES DW, 1991, JAMA-J AM MED ASSOC, V265, P365, DOI 10.1001/jama.265.3.365; ISAACMAN DJ, 1990, PEDIATR INFECT DIS J, V9, P274, DOI 10.1097/00006454-199004000-00010; KING TC, 1963, SURG GYNECOL OBSTET, V116, P361; KRUMHOLZ HM, 1990, ANN INTERN MED, V113, P290, DOI 10.7326/0003-4819-113-4-290; LEE S, 1967, AM J CLIN PATHOL, V47, P646; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; SCHIFMAN RB, IN PRESS AM J CLIN P; SELWYN S, 1972, BMJ-BRIT MED J, V1, P136, DOI 10.1136/bmj.1.5793.136; STRAND CL, 1988, BLOODSTREAM INFECTIO, P15; WAJSBORT RR, 1992, AM J CLIN PATHOL, V97, P850, DOI 10.1093/ajcp/97.6.850	10	109	111	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					1004	1006		10.1001/jama.269.8.1004	http://dx.doi.org/10.1001/jama.269.8.1004			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM603	8429580				2022-12-28	WOS:A1993KM60300028
J	FISHER, DE; PARENT, LA; SHARP, PA				FISHER, DE; PARENT, LA; SHARP, PA			HIGH-AFFINITY DNA-BINDING MYC ANALOGS - RECOGNITION BY AN ALPHA-HELIX	CELL			English	Article							LEUCINE-ZIPPER; SACCHAROMYCES-CEREVISIAE; DIMERIZATION SPECIFICITY; NEGATIVE REGULATOR; PROTEIN; FOS; JUN; TRANSCRIPTION; COMPLEX; DOMAINS	Myc and other basic-helix-loop-helix-leucine zipper (b-HLH-ZIP) proteins bind the sequence CACGTG. Exhaustive mutagenesis in the basic domain identified four amino acids critical for DNA binding with spacing suggestive of an alpha-helical face. Surprisingly, two highly conserved amino acids were nonessential for DNA binding. Circular dichroism demonstrated a DNA-induced alpha-helical transition. A series of analogs were constructed with multiple simultaneous alanine substitutions at nonessential positions and a critical lysine for arginine substitution. In this way 35-fold higher specific affinity for CACGTG was obtained as compared with the basic domain of c-Myc. These b-HLH-ZIP proteins appear to bind the same palindromic sequence and may compete for common sites in vivo. Additionally, a C-terminal basic region clamp motif was identified that was also identifiable in crystal structures from several different families of DNA-binding factors.	CHILDRENS HOSP MED CTR,DEPT PEDIAT HEMATOL & ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT HEMATOL & ONCOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	FISHER, DE (corresponding author), MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NCI NIH HHS [P01-CA42063, P30-CA14051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; FISHER DE, 1992, IN PRESS P NATL ACAD; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALEZONETIS TD, 1992, SCIENCE, V255, P464; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TALANIAN RV, 1992, BIOCHEMISTRY-US, V31, P6871, DOI 10.1021/bi00145a002; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WECHSLER DS, 1992, P NATL ACAD SCI USA, V89, P7635, DOI 10.1073/pnas.89.16.7635; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEISS MA, 1990, NATURE, V347, P545; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	53	80	81	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					467	476		10.1016/0092-8674(93)90122-7	http://dx.doi.org/10.1016/0092-8674(93)90122-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431949				2022-12-28	WOS:A1993KM16200015
J	TOLLERVEY, D; LEHTONEN, H; JANSEN, R; KERN, H; HURT, EC				TOLLERVEY, D; LEHTONEN, H; JANSEN, R; KERN, H; HURT, EC			TEMPERATURE-SENSITIVE MUTATIONS DEMONSTRATE ROLES FOR YEAST FIBRILLARIN IN PRE-RIBOSOMAL-RNA PROCESSING, PRE-RIBOSOMAL-RNA METHYLATION, AND RIBOSOME ASSEMBLY	CELL			English	Article							SMALL NUCLEOLAR RNA; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; INVITRO SYNTHESIS; PROTEIN GENES; COILED BODY; U3 SNRNA; DEPLETION; SUBUNITS; CELLS	We have generated temperature-sensitive lethal point mutations in the small nucleolar RNA-associated protein fibrillarin (encoded by the NOP1 gene in yeast) and analyzed their effects on ribosome synthesis. The five alleles tested all prevent synthesis of normal ribosomes, but in dramatically different ways. At the non-permissive temperature, the nop1.2 and nop1.5 alleles prevent synthesis of both 18S and 25S rRNA and all pre-rRNA species except the 35S primary transcript. In contrast, the nop1.3, nop1.4, and nop1.7 alleles do not strongly impair processing. In nop1.3 strains, nucleolar methylation of pre-rRNA is strongly inhibited; late, cytoplasmic methylation of 18S rRNA and tRNA methylation continue. The nop1.4 and nop1.7 alleles result in the synthesis of cytoplasmic 60S ribosomal subunits with strongly aberrant mobilities on sucrose gradients even at the permissive temperature, owing to the impairment of a late step in ribosome assembly. Thus, all major posttranscriptional activities in ribosome synthesis, pre-rRNA processing, pre-rRNA modification, and ribosome assembly are dependent on fibrillarin.			TOLLERVEY, D (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1, W-6900 HEIDELBERG, GERMANY.		Ed Hurt, Dr./AAE-8874-2019; Tollervey, David/AAR-6662-2020	Ed Hurt, Dr./0000-0002-4535-8255; Tollervey, David/0000-0003-2894-2772				ALIX JH, 1982, MICROBIOL REV, V46, P281, DOI 10.1128/MMBR.46.3.281-295.1982; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; BASERGA SJ, 1992, IN PRESS GENES DEV, V6; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; BRAND RC, 1977, EUR J BIOCHEM, V75, P311, DOI 10.1111/j.1432-1033.1977.tb11531.x; CABOCHE M, 1977, EUR J BIOCHEM, V74, P19, DOI 10.1111/j.1432-1033.1977.tb11362.x; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; CHELBIALIX MK, 1981, EUR J BIOCHEM, V115, P627; CHRISTENSEN ME, 1977, BIOCHEM BIOPH RES CO, V74, P621, DOI 10.1016/0006-291X(77)90348-5; CLARKE MW, 1990, J CELL BIOL, V11, P1741; FABIAN GR, 1987, J BACTERIOL, V169, P1571, DOI 10.1128/jb.169.4.1571-1578.1987; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HUGHES JMX, 1987, EMBO J, V6, P2145, DOI 10.1002/j.1460-2075.1987.tb02482.x; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; HURT EC, 1988, EUR J CELL BIOL, V46, P554; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; KASS S, 1990, MOL CELL BIOL, V10, P4920, DOI 10.1128/MCB.10.9.4920; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KLOOTWIJK J, 1972, FEBS LETT, V27, P102, DOI 10.1016/0014-5793(72)80419-8; KRUISWIJK T, 1978, BIOCHIM BIOPHYS ACTA, V517, P378, DOI 10.1016/0005-2787(78)90204-6; KRZYZOSIAK W, 1987, BIOCHEMISTRY-US, V26, P2353, DOI 10.1021/bi00382a042; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LEER RJ, 1984, NUCLEIC ACIDS RES, V12, P6685, DOI 10.1093/nar/12.17.6685; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1988, J MOL BIOL, V201, P289, DOI 10.1016/0022-2836(88)90139-8; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORITZ M, 1991, MOL CELL BIOL, V11, P5681, DOI 10.1128/MCB.11.11.5681; MORITZ M, 1990, J CELL BIOL, V111, P2261, DOI 10.1083/jcb.111.6.2261; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; NIERHAUS KH, 1991, BIOCHIMIE, V73, P739, DOI 10.1016/0300-9084(91)90054-5; PUVIONDUTILLEUL F, 1991, EUR J CELL BIOL, V56, P178; RASKA I, 1990, J STRUCT BIOL, V104, P120, DOI 10.1016/1047-8477(90)90066-L; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; ROSBASH M, 1981, CELL, V24, P679, DOI 10.1016/0092-8674(81)90094-5; RUSSELL ID, 1992, IN PRESS J CELL BIOL; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5466; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; Sherman F., 1986, METHODS YEAST GENETI; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; SWANN PF, 1975, BIOCHEM J, V150, P335, DOI 10.1042/bj1500335; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TRAPMAN J, 1975, EXP CELL RES, V90, P95, DOI 10.1016/0014-4827(75)90361-4; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; UDEM SA, 1973, J BIOL CHEM, V248, P1412; VAUGHAN MH, 1967, P NATL ACAD SCI USA, V58, P1527, DOI 10.1073/pnas.58.4.1527; WARNER JR, 1972, J MOL BIOL, V65, P243, DOI 10.1016/0022-2836(72)90280-X; WOLF SF, 1977, BIOCHEMISTRY-US, V16, P2783, DOI 10.1021/bi00631a031; ZAGORSKI J, 1988, MOL CELL BIOL, V8, P3282, DOI 10.1128/MCB.8.8.3282	62	413	423	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					443	457		10.1016/0092-8674(93)90120-F	http://dx.doi.org/10.1016/0092-8674(93)90120-F			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431947				2022-12-28	WOS:A1993KM16200013
J	ADAM, D; DIMITRIJEVIC, N; SCHARTL, M				ADAM, D; DIMITRIJEVIC, N; SCHARTL, M			TUMOR SUPPRESSION IN XIPHOPHORUS BY AN ACCIDENTALLY ACQUIRED PROMOTER	SCIENCE			English	Article							MELANOMA; EXPRESSION; CELLS; ONCOGENE; ELEMENTS; FISH; GENE	Melanoma formation in the teleost Xiphophorus is caused by a dominant genetic locus, Tu. This locus includes the Xmrk oncogene, which encodes a receptor tyrosine kinase. Tumor induction is suppressed in wild-type fish by a tumor suppressor locus, R. Molecular genetic analyses revealed that the Tu locus emerged by nonhomologous recombination of the Xmrk proto-oncogene with a previously uncharacterized sequence, D. This event generated an additional copy of Xmrk with a new promoter. Suppression of the new Xmrk promoter by R in parental fish and its deregulation in hybrids explain the genetics of melanoma formation in Xiphophorus.	MAX PLANCK INST BIOCHEM, GENZENTRUM, W-8033 MARTINSRIED, GERMANY; UNIV WURZBURG, THEODOR BOVERI INST BIOWISSENSCH, W-8700 WURZBURG, GERMANY	Max Planck Society; University of Wurzburg			Adam, Dieter/E-9763-2010	Adam, Dieter/0000-0002-5668-5032; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1991, ONCOGENE, V6, P73; ADAM D, UNPUB; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; BELLAMY AW, 1922, ANAT REC, V23, P98; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDENREICH H, 1990, NUCLEIC ACIDS RES, V18, P3299, DOI 10.1093/nar/18.11.3299; Gordon M, 1927, GENETICS, V12, P253; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KALLMAN KD, 1966, ZOOLOGICA-N Y, V51, P107; Kosswig C., 1928, Zeitschrift fuer Induktive Abstammungs- und Vererbungslehre, V47, P150; KUHN C, 1979, IN VITRO CELL DEV B, V15, P537, DOI 10.1007/BF02618156; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAUELER W, 1988, ONCOGENE, V3, P113; MAUELER W, 1988, ONCOGENE, V2, P421; SCHARTL M, 1992, PIGM CELL RES, P173; SCHARTL M, 1990, GENETICS, V126, P1083; STEINER C, 1989, TRENDS GENET, V5, P138; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0	23	96	96	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					816	819		10.1126/science.8430335	http://dx.doi.org/10.1126/science.8430335			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430335	Green Submitted			2022-12-28	WOS:A1993KL11000034
J	GAYLIN, DS; HELD, PJ; PORT, FK; HUNSICKER, LG; WOLFE, RA; KAHAN, BD; JONES, CA; AGODOA, LYC				GAYLIN, DS; HELD, PJ; PORT, FK; HUNSICKER, LG; WOLFE, RA; KAHAN, BD; JONES, CA; AGODOA, LYC			THE IMPACT OF COMORBID AND SOCIODEMOGRAPHIC FACTORS ON ACCESS TO RENAL-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; AGE	Objective.-To assess the impact of sociodemographic factors and comorbid conditions on access to renal transplantation for adult US dialysis patients with end-stage renal disease (ESRD). Design.-Cohort analytic study. Data on comorbid conditions at onset of ESRD were abstracted from patients' medical records and matched to sociodemographic and ESRD data from the United States Renal Data System database. Setting.-United States Medicare dialysis population. Patients.-Random, national sample of ESRD patients starting dialysis in 1986 and 1987 (n=4118). Main Outcome Measure.-Time to first renal transplant (living or cadaver donor) since onset of ESRD regressed with two nested Cox proportional hazards models, first against sociodemographic factors alone, and then against sociodemographic factors and comorbid conditions. Results.-Cardiovascular diseases are most predictive of who receives a transplant; patients with coronary heart disease, congestive heart failure, or left ventricular hypertrophy showed lower transplantation rates relative to patients without the disease (relative rate [RR]=0.65 to 0.80, P<.05 each). Obese patients and patients with peripheral vascular disease also showed lower transplantation rates (RR=0.65 to 0.75, P<.05 each). Previously reported sociodemographic effects of lower transplantation rates for older patients, women, nonwhite patients, and lower income patients were confirmed (P<.01). Sociodemographic effects remained essentially unchanged when adjusted for comorbid conditions. Conclusions.-These findings indicate that sociodemographics have strong independent effects on access to transplantation that cannot be explained away as ''surrogate'' effects related to comorbid factors. Furthermore, the results suggest that lower mortality rates for transplant recipients relative to dialysis patients are due, in part, to a healthier case mix among patients receiving transplants.	UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH PUBL HLTH,DEPT BIOSTAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48104; UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV TEXAS,SCH MED,DIV IMMUNOL & ORGAN TRANSPLANTAT,HOUSTON,TX 77025; NIDDKD,DIV KIDNEY UROL & HEMATOL DIS,BETHESDA,MD	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Iowa; University of Texas System; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	GAYLIN, DS (corresponding author), URBAN INST,2100 M ST NW,SUITE 400 USRDS,WASHINGTON,DC 20037, USA.				NIDDK NIH HHS [N0 1-DK-8-2234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK082234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COX DR, 1972, J R STAT SOC B, V34, P187; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; HELD P J, 1991, Journal of the American Society of Nephrology, V2, P328; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HELD PJ, 1992, CLIN TRANSPLANTS 199, P71; HUTCHINSON TA, 1982, ANN INTERN MED, V96, P417, DOI 10.7326/0003-4819-96-4-417; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; MORRIS PI, 1983, KIDNEY TRANSPLANTATI, P547; WEBB RL, 1991, CLIN TRANSPLANTS 199, P75; 1991, DISTRIBUTION ORGANS; 1991, USRDS1991 NIH NAT I; 1992, SURGEON GENERALS WOR; 1991, USRDS1992 NIH NAT I	14	237	237	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					603	608		10.1001/jama.269.5.603	http://dx.doi.org/10.1001/jama.269.5.603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421364				2022-12-28	WOS:A1993KJ44400026
J	MODELL, JH				MODELL, JH			CURRENT CONCEPTS - DROWNING	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CARDIAC RESUSCITATION; WATER; PRESSURE; CHILDREN; THERAPY; ASPIRATION; HYPOTHERMIA; PULMONARY; ACIDOSIS; VICTIMS				MODELL, JH (corresponding author), UNIV FLORIDA,COLL MED,DEPT ANESTHESIOL,POB 100254,GAINESVILLE,FL 32610, USA.							BERGQUIST RE, 1980, ANESTHESIOLOGY, V52, P142; BIGGART MJ, 1990, J PEDIATR-US, V117, P179, DOI 10.1016/S0022-3476(05)80526-8; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; BYNUM LJ, 1976, AM REV RESPIR DIS, V114, P1129; CALDERWOOD HW, 1975, ANESTHESIOLOGY, V43, P642, DOI 10.1097/00000542-197512000-00008; CONN AW, 1980, CAN ANAESTH SOC J, V27, P201, DOI 10.1007/BF03007429; COT C, 1931, ASPHYXIES ACCIDENTEL; CRAIG AB, 1961, J APPL PHYSIOL, V15, P583; DEAN JM, 1981, CRIT CARE MED, V9, P536; DOWNS JB, 1977, ASA REFRESHER COURSE, V5, P71; EDWARDS ND, 1990, INTENS CARE MED, V16, P336, DOI 10.1007/BF01706363; EPSTEIN SE, 1989, NEW ENGL J MED, V321, P320, DOI 10.1056/NEJM198908033210511; FRATES RC, 1981, AM J DIS CHILD, V135, P1006, DOI 10.1001/archpedi.1981.02130350010004; FULLER RH, 1963, MIL MED, V128, P22, DOI 10.1093/milmed/128.1.22; FULLER RH, 1963, P ROY SOC MED, V56, P33, DOI 10.1177/003591576305600109; GIAMMONA ST, 1967, AM J DIS CHILD, V114, P612, DOI 10.1001/archpedi.1967.02090270068005; GONZALEZROTHI RJ, 1987, HEART LUNG, V16, P474; HEIMLICH HJ, 1988, POSTGRAD MED, V84, P62; HEIMLICH HJ, 1981, ANN EMERG MED, V10, P476, DOI 10.1016/S0196-0644(81)80281-8; KETTE F, 1991, JAMA-J AM MED ASSOC, V266, P2121, DOI 10.1001/jama.266.15.2121; KETTE F, 1990, CIRCULATION, V81, P1660, DOI 10.1161/01.CIR.81.5.1660; KRINGSHOLM B, 1991, FORENSIC SCI INT, V52, P85, DOI 10.1016/0379-0738(91)90099-5; MODELL JH, 1968, ANESTHESIOLOGY, V29, P456, DOI 10.1097/00000542-196805000-00012; MODELL JH, 1986, CRIT CARE MED, V14, P593; MODELL JH, 1972, J APPL PHYSIOL, V32, P579, DOI 10.1152/jappl.1972.32.5.579; MODELL JH, 1967, ANN INTERN MED, V67, P68, DOI 10.7326/0003-4819-67-1-68; MODELL JH, 1966, ANESTHESIOLOGY, V27, P33, DOI 10.1097/00000542-196601000-00007; MODELL JH, 1966, ANESTHESIOLOGY, V27, P662, DOI 10.1097/00000542-196609000-00018; MODELL JH, 1976, CHEST, V70, P231, DOI 10.1378/chest.70.2.231; MODELL JH, 1969, ANESTHESIOLOGY, V30, P414, DOI 10.1097/00000542-196904000-00011; MODELL JH, 1981, CRIT CARE MED, V9, P351; MODELL JH, 1980, CAN ANAESTH SOC J, V27, P211, DOI 10.1007/BF03007430; MODELL JH, 1968, J AMER MED ASSOC, V203, P337, DOI 10.1001/jama.1968.03140050021005; MODELL JH, 1980, CAN ANAESTH SOC J, V27, P197, DOI 10.1007/BF03007428; MODELL JH, 1974, ANESTHESIOLOGY, V40, P376, DOI 10.1097/00000542-197404000-00013; Modell JH., 1971, PATHOPHYSIOLOGY TREA; NAGEL FO, 1990, S AFR MED J, V78, P422; NEMIROFF MJ, 1977, UNDERSEA BIOMED RES, V4, pA56; NICHTER MA, 1989, CRIT CARE MED, V17, P993, DOI 10.1097/00003246-198910000-00005; NUSSBAUM E, 1988, PEDIATRICS, V81, P630; ORLOWSKI JP, 1989, ANN EMERG MED, V18, P1044, DOI 10.1016/S0196-0644(89)80927-8; ORLOWSKI JP, 1979, JACEP-J AM COLL EMER, V8, P176, DOI 10.1016/S0361-1124(79)80121-5; ORLOWSKI JP, 1987, PEDIATR CLIN N AM, V34, P75; ORLOWSKI JP, 1987, JAMA-J AM MED ASSOC, V258, P512, DOI 10.1001/jama.1987.03400040110033; ORNATO JP, 1986, JAMA-J AM MED ASSOC, V256, P75, DOI 10.1001/jama.256.1.75; Patrick EA, 1988, POSTGRAD MED, V84, P71; RAMEY CA, 1987, J APPL PHYSIOL, V63, P665, DOI 10.1152/jappl.1987.63.2.665; RUIZ BC, 1973, ANESTH ANALG, V52, P570; SHAPIRO JI, 1990, AM J PHYSIOL, V258, pH1835, DOI 10.1152/ajpheart.1990.258.6.H1835; TABELING BB, 1983, CRIT CARE MED, V11, P693, DOI 10.1097/00003246-198309000-00004; WERNER J Z, 1982, Anesthesiology (Hagerstown), V57, pA81, DOI 10.1097/00000542-198209001-00081; WYNNE JW, 1977, ANN INTERN MED, V87, P466, DOI 10.7326/0003-4819-87-4-466; WYNNE JW, 1979, ANESTHESIOLOGY, V51, P11, DOI 10.1097/00000542-197907000-00004; 1986, JAMA-J AM MED ASSOC, V255, P2905	54	71	75	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1993	328	4					253	256						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ442	8418406				2022-12-28	WOS:A1993KJ44200007
J	BUDETTI, PP				BUDETTI, PP			ACHIEVING A UNIFORM FEDERAL PRIMARY CARE POLICY - OPPORTUNITIES PRESENTED BY NATIONAL-HEALTH REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									GEORGE WASHINGTON UNIV,DEPT HLTH SERV MANAGEMENT & POLICY,WASHINGTON,DC 20052	George Washington University	BUDETTI, PP (corresponding author), GEORGE WASHINGTON UNIV,CTR HLTH POLICY RES,2021 K ST NW,SUITE 800,WASHINGTON,DC 20052, USA.							BUDETTI P, 1990, PHS903460 DEP HLTH H, P9; CLINTON B, 1992, NEW ENGL J MED, V327, P804, DOI 10.1056/NEJM199209103271112; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; ESTES EH, 1990, PHS903460 DEP HLTH H, P5; GRAHAM R, 1990, PHS903460 DEP HLTH H, P37; HARMON RG, 1990, HRSAS VISION ITS ROL; HIBBARD H, 1991, 910011 AG HLTH CAR P, P1; HOY EW, 1991, HEALTH AFFAIR, V10, P18, DOI 10.1377/hlthaff.10.4.18; JOLIN LD, 1991, JAMA-J AM MED ASSOC, V266, P985, DOI 10.1001/jama.266.7.985; KING KM, 1992, CRS IB91116 C RES SE; KLEBE ER, 1991, CRS91769 EPW C RES S; MILLIS JS, 1966, GRADUATE ED PHYSICIA; MULLAN F, 1990, PHS903460 DEP HLTH H, P35; PETERSDORF RG, 1991, STATEMENT ASS AM MED; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; Starfield B., 1992, PRIMARY CARE CONCEPT; 1978, MANPOWER POLICY PRIM; 1992, WMCP10244 PUBL; 1980, REPORT GRADUATE MED; 1991, SOURCE BOOK HLTH INS; HCFA452 PUBL; 1992, UNPUB CHANGE PRIVATE; 1991, UNIVERSAL HLTH INSUR; 1992, ANN INTERN MED, V117, P511; 1992, PRIMARY HLTH CARE CH; 1991, MEDICARE MEDICAID GU	26	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					498	501		10.1001/jama.269.4.498	http://dx.doi.org/10.1001/jama.269.4.498			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8419669				2022-12-28	WOS:A1993KH38500034
J	TAKASAWA, S; NATA, K; YONEKURA, H; OKAMOTO, H				TAKASAWA, S; NATA, K; YONEKURA, H; OKAMOTO, H			CYCLIC ADP-RIBOSE IN INSULIN-SECRETION FROM PANCREATIC BETA-CELLS	SCIENCE			English	Article							THYROTROPIN-RELEASING-HORMONE; DNA STRAND BREAKS; INOSITOL TRISPHOSPHATE; POLY(ADP-RIBOSE) SYNTHETASE; PROINSULIN SYNTHESIS; PITUITARY-CELLS; CALCIUM RELEASE; 2ND MESSENGER; GH4C1 CELLS; CA-2+	Inositol 1,4,5-trisphosphate (IP3) is thought to be a second messenger for intracellular calcium mobilization. However, in a cell-free system of islet microsomes, cyclic adenosine diphosphate-ribose (cADP-ribose), a nicotinamide adenine dinucleotide (NAD+) metabolite, but not IP3, induced calcium release. In digitonin-permeabilized islets, cADP-ribose and calcium, but not IP3, induced insulin secretion. Islet microsomes released calcium when combined with the extract from intact islets that had been incubated with high concentrations of glucose. Sequential additions of cADP-ribose inhibited the calcium release response to extracts from islets treated with high concentrations of glucose. Conversely, repeated additions of the islet extract inhibited the calcium release response to a subsequent addition of cADP-ribose. These results suggest that cADP-ribose is a mediator of calcium release from islet microsomes and may be generated in islets by glucose stimulation, serving as a second messenger for calcium mobilization in the endoplasmic reticulum.	TOHOKU UNIV, SCH MED, DEPT BIOCHEM, SENDAI, MIYAGI 980, JAPAN	Tohoku University								BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BERRIDGE MJ, 1989, NATURE, V341, P187; BIDEN TJ, 1984, BIOCHEM J, V223, P467, DOI 10.1042/bj2230467; CHIBA T, 1987, BIOCHEM BIOPH RES CO, V145, P263, DOI 10.1016/0006-291X(87)91315-5; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; COLCA JR, 1985, BIOCHEM J, V228, P529, DOI 10.1042/bj2280529; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; JOSEPH SK, 1984, J BIOL CHEM, V259, P2952; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; KOSHIYAMA H, 1991, ENDOCRINOLOGY, V128, P2715, DOI 10.1210/endo-128-6-2715; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; MASIELLO P, 1985, DIABETOLOGIA, V28, P683, DOI 10.1007/BF00291976; MOLLARD P, 1990, BIOCHEM J, V268, P345, DOI 10.1042/bj2680345; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; OKAMOTO H, 1985, BIOESSAYS, V2, P15, DOI 10.1002/bies.950020106; Okamoto H., 2008, MOL BIOL ISLETS LANG, P209; PRENTKI M, 1985, J BIOL CHEM, V260, P9185; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PRENTKI M, 1984, NATURE, V309, P562, DOI 10.1038/309562a0; SALUJA AK, 1989, BIOCHEM BIOPH RES CO, V164, P8, DOI 10.1016/0006-291X(89)91675-6; SHIMA K, 1987, DIABETES RES CLIN PR, V3, P135, DOI 10.1016/S0168-8227(87)80019-0; TAKASAWA S, UNPUB; TASHJIAN AH, 1987, BIOCHEM J, V243, P305, DOI 10.1042/bj2430305; UCHIGATA Y, 1982, J BIOL CHEM, V257, P6084; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WOLF BA, 1985, BIOCHEM J, V227, P965, DOI 10.1042/bj2270965; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0	37	412	415	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					370	373		10.1126/science.8420005	http://dx.doi.org/10.1126/science.8420005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8420005				2022-12-28	WOS:A1993KG62400035
J	STEVENSON, HW; CHEN, CS; LEE, SY				STEVENSON, HW; CHEN, CS; LEE, SY			MATHEMATICS ACHIEVEMENT OF CHINESE, JAPANESE, AND AMERICAN CHILDREN - 10 YEARS LATER	SCIENCE			English	Article								A decade of heightened emphasis in the United States on mathematics and science education has had little influence on academic achievement or parental attitudes. American elementary school children in 1990 lagged behind their Chinese and Japanese peers to as great a degree as they did in 1980. Comparison of the performance of elementary and secondary school students between 1980 and 1990 reveals a decline from first to eleventh grade in the relative position of American students in mathematics. Parental satisfaction with American students' achievement and education remains high and standards remain low. Innate ability continues to be emphasized by Americans as a basis for achievement. American eleventh graders report more indications of stress than do their Chinese and Japanese counterparts.	UNIV CALIF IRVINE,IRVINE,CA 92717	University of California System; University of California Irvine	STEVENSON, HW (corresponding author), UNIV MICHIGAN,ANN ARBOR,MI 48109, USA.			Chen, Chuansheng/0000-0002-8224-1005				CHEN CS, 1989, CHILD DEV, V60, P551, DOI 10.2307/1130721; CRYSTAL D, UNPUB; Stevenson H. W., 1992, LEARNING GAP; STEVENSON HW, 1986, SCIENCE, V231, P693, DOI 10.1126/science.3945803; STEVENSON HW, 1990, MONOGR SOC RES C 221, V55; STEVENSON HW, IN PRESS HDB RES EAR; WESTBURY I, 1992, EDUC RES, V22, P18; 1989, KIDS COUNT DATA BOOK; 1991, STATE MATH ACHIEVEME	9	248	252	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					53	58		10.1126/science.8418494	http://dx.doi.org/10.1126/science.8418494			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KE601	8418494	Green Submitted			2022-12-28	WOS:A1993KE60100025
J	GREENSPAN, SL; RESNICK, NM				GREENSPAN, SL; RESNICK, NM			FRACTURE RISK IN WOMAN WITH OSTEOPOROSIS - MUST TENNIS CEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							POSTMENOPAUSAL OSTEOPOROSIS; WOMEN; THERAPY				GREENSPAN, SL (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.							BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003-4819-112-7-516; RESNICK NM, 1989, JAMA-J AM MED ASSOC, V261, P1025, DOI 10.1001/jama.261.7.1025; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201	7	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1306	1306						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437312				2022-12-28	WOS:A1993KP88500034
J	SWAGER, B				SWAGER, B			JERICHO-SPRINGS, MISSOURI	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1191	1191						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN611	8433478				2022-12-28	WOS:A1993KN61100038
J	COHEN, AR				COHEN, AR			ENDOSCOPIC LASER 3RD VENTRICULOSTOMY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											COHEN, AR (corresponding author), NEW ENGLAND MED CTR,BOSTON,MA 02111, USA.								0	21	22	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					552	552						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8426622				2022-12-28	WOS:A1993KP05300006
J	RAGOT, T; VINCENT, N; CHAFEY, P; VIGNE, E; GILGENKRANTZ, H; COUTON, D; CARTAUD, J; BRIAND, P; KAPLAN, JC; PERRICAUDET, M; KAHN, A				RAGOT, T; VINCENT, N; CHAFEY, P; VIGNE, E; GILGENKRANTZ, H; COUTON, D; CARTAUD, J; BRIAND, P; KAPLAN, JC; PERRICAUDET, M; KAHN, A			EFFICIENT ADENOVIRUS-MEDIATED TRANSFER OF A HUMAN MINIDYSTROPHIN GENE TO SKELETAL-MUSCLE OF MDX MICE	NATURE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; MOUSE; INVIVO; EXPRESSION; INJECTION; DNA	DUCHENNE progressive muscular dystrophy is a lethal and common X-linked genetic disease1 caused by the absence of dystrophin2,3, a 427K protein encoded by a 14 kilobase transcript4. Two approaches have been proposed to correct the dystrophin deficiency in muscle. The first, myoblast transfer therapy, uses cells from normal donors5-7, whereas the second involves direct intramuscular injection of recombinant plasmids expressing dystrophin8. Adenovirus is an efficient vector for in vivo expression of various foreign genes9-13. It has recently been demonstrated that a recombinant adenovirus expressing the lac-Z reporter gene can infect stably many mouse tissues, particularly muscle and heart12,13. We have tested the ability of a recombinant adenovirus, containing a 6.3 kilobase pair Becker-like dystrophin complementary DNA14 driven by the Rous sarcoma virus promoter to direct the expression of a 'minidystrophin' in infected 293 cells and C2 myoblasts, and in the mdx mouse15,16, after intramuscular injection. We report here that in vivo, we have obtained a sarcolemmal immunostaining in up to 50% of fibres of the injected muscle.	INST COCHIN GENET MOLEC,INSERM,U129,F-75014 PARIS,FRANCE; ICGM,INSERM,CJF 9003,F-75014 PARIS,FRANCE; INST JACQUES MONOD,CNRS,UMR 3,F-75251 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	RAGOT, T (corresponding author), INST GUSTAVE ROUSSY,CNRS,URA 1301,PR2,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.		Gilgenkrantz, Helene/G-5534-2017	gilgenkrantz, helene/0000-0001-6770-4561				ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CARTAUD A, 1992, NEUROSCIENCE, V48, P995, DOI 10.1016/0306-4522(92)90288-D; Emery A, 1988, DUCHENNE MUSCULAR DY; ENGLAND SB, 1990, NATURE, V343, P180, DOI 10.1038/343180a0; GINJAAR HB, 1992, FEBS LETT, V308, P293, DOI 10.1016/0014-5793(92)81296-X; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; HUARD J, 1992, MUSCLE NERVE, V15, P550, DOI 10.1002/mus.880150504; HUGNOT JP, 1992, P NATL ACAD SCI USA, V89, P7506, DOI 10.1073/pnas.89.16.7506; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; LEVRERO M, 1991, GENE, V101, P195, DOI 10.1016/0378-1119(91)90411-4; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; RAGOT T, 1991, HUMAN GENE TRANSFER, P249; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SHENK T, 1984, CURR TOP MICROBIOL, P1; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	28	394	449	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					647	650		10.1038/361647a0	http://dx.doi.org/10.1038/361647a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8437625				2022-12-28	WOS:A1993KM77600067
J	GURWITZ, JH; BOHN, RL; GLYNN, RJ; MONANE, M; MOGUN, H; AVORN, J				GURWITZ, JH; BOHN, RL; GLYNN, RJ; MONANE, M; MOGUN, H; AVORN, J			ANTIHYPERTENSIVE DRUG-THERAPY AND THE INITIATION OF TREATMENT FOR DIABETES-MELLITUS	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS; DIURETICS, THIAZIDE; ANTIHYPERTENSIVE AGENTS; HYPOGLYCEMIC AGENTS; INSULIN	GLUCOSE-INTOLERANCE; BLOOD-PRESSURE; HYPERTENSION; TRIAL; HYPERINSULINEMIA; DIURETICS; INSULIN; OBESITY	Objective: To quantify the risk for the occurrence of hyperglycemia requiring initiation of therapy among patients taking various antihypertensive regimens. Design: Case-control study. Setting: New Jersey Medicaid program. Patients: The study included New Jersey Medicaid enrollees 35 years of age or older. The 11 855 case patients were newly started on a hypoglycemic agent (oral agent or insulin) between 1981 and 1990. The 11 855 controls were selected randomly from among other Medicaid enrollees. Measurements and Main Results: The frequency of initiation of hypoglycemic therapy was increased for users of virtually all antihypertensive agents relative to nonusers after adjustment for age, gender, race, nursing home residency, number of days hospitalized, total number of prescriptions, and selected medication exposures. The estimated relative risk for initiation of hypoglycemic therapy was 1.40 for patients receiving thiazide diuretics (95% CI, 1.26 to 1.58) and ranged from 1.56 to 1.77 for patients receiving other antihypertensive medications, depending on the medication category. A higher risk was associated with multiple-agent regimens, whether they excluded a thiazide diuretic (odds ratio, 1.76; CI, 1.49 to 2.07) or included one (odds ratio, 1.93; CI, 1.75 to 2.13). When the analysis was restricted to users of antihypertensive agents (n = 8005), the risk associated with other single-agent antihypertensive regimens was not significantly different from that associated with thiazide diuretics. However, patients receiving multiple-agent regimens continued to be at increased risk for hyperglycemia requiring hypoglycemic therapy relative to those who used thiazide diuretic therapy alone. Conclusion: The association between antihypertensive therapy and the initiation of treatment for diabetes mellitus is more closely related to the intensity of therapy than to the individual agent used. Our data do not support the hypothesis that thiazide diuretics are more strongly associated with the initiation of hypoglycemic therapy than are other antihypertensive agents.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HEBREW REHABIL CTR AGED, BOSTON, MA USA	Harvard University; Harvard Medical School	GURWITZ, JH (corresponding author), BRIGHAM & WOMENS HOSP, PROGRAM ANAL CLIN STRATEGIES, 221 LONGWOOD AVE, SUITE 309, BOSTON, MA 02115 USA.				NIA NIH HHS [K08 AG00510, AG-08812] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG008812, K08AG000510, P60AG008812] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALDERMAN MH, 1992, JAMA-J AM MED ASSOC, V267, P2786, DOI 10.1001/jama.267.20.2786; AMERY A, 1978, LANCET, V1, P681; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1981, LANCET, V2, P539; [Anonymous], 1985, Hypertension, V7, P1008; BARRETTCONNOR E, 1981, AM J EPIDEMIOL, V113, P276, DOI 10.1093/oxfordjournals.aje.a113097; BENGTSSON C, 1988, DIABETIC MED, V5, P261, DOI 10.1111/j.1464-5491.1988.tb00981.x; Cox DR., 1970, ANAL BINARY DATA; DONAHUE RP, 1990, AM J EPIDEMIOL, V132, P827, DOI 10.1093/oxfordjournals.aje.a115725; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRARI P, 1991, AM J MED, V91, P589, DOI 10.1016/0002-9343(91)90211-F; FLETCHER AE, 1991, AM J MED, V90, pS42, DOI 10.1016/0002-9343(91)90435-Z; FURMAN BL, 1981, PHARMACOL THERAPEUT, V12, P613, DOI 10.1016/0163-7258(81)90102-9; GOLDNER MG, 1960, NEW ENGL J MED, V262, P403, DOI 10.1056/NEJM196002252620807; HELGELAND A, 1980, AM J MED, V69, P725, DOI 10.1016/0002-9343(80)90438-6; KOHNER EM, 1971, LANCET, V1, P986; LANDSBERG L, 1987, NEW ENGL J MED, V317, P378, DOI 10.1056/NEJM198708063170609; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; MOSER M, 1991, JAMA-J AM MED ASSOC, V265, P498, DOI 10.1001/jama.265.4.498; MURPHY MB, 1982, LANCET, V2, P1293; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; RAY WA, 1986, AM J MED, V81, P9, DOI 10.1016/0002-9343(86)90522-X; SCHAPPERT SM, 1992, ADV DATA VITAL HLTH, V211; SHAPIRO AP, 1961, NEW ENGL J MED, V265, P1028, DOI 10.1056/NEJM196111232652102; SKARFORS ET, 1989, BRIT MED J, V298, P1147, DOI 10.1136/bmj.298.6681.1147; WOLFF FW, 1963, JAMA-J AM MED ASSOC, V185, P568, DOI 10.1001/jama.1963.03060070036019; 1985, SAS USERS GUIDE STAT	27	77	78	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					273	278		10.7326/0003-4819-118-4-199302150-00005	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420444				2022-12-28	WOS:A1993KL45700005
J	KLEIN, RD; MEYER, BJ				KLEIN, RD; MEYER, BJ			INDEPENDENT DOMAINS OF THE SDC-3 PROTEIN CONTROL SEX DETERMINATION AND DOSAGE COMPENSATION IN C-ELEGANS	CELL			English	Article							X-CHROMOSOME DOSAGE; NEMATODE CAENORHABDITIS-ELEGANS; BINDING-PROTEINS; FINGER PROTEIN; ZINC FINGERS; GENE; SEQUENCE; MYOSIN; ATP; MUTANTS	sdc-3 is an early-acting regulatory gene that controls both sex determination and X chromosome dosage compensation in C. elegans. It is unique among sdc genes in that its sex determination and dosage compensation functions act independently. The molecular analysis reported here demonstrates that separate domains of the Sdc-3 protein control these two developmental processes. Sequence analysis of 16 sdc-3 alleles reveals that the dosage compensation mutations specifically eliminate a pair of zinc finger motifs at the carboxyl terminus of Sdc-3, while the sex determination mutations alter a region with limited homology to the ATP-binding domain of myosin. Null mutations, which disrupt both processes, abort translation of Sdc-3 prior to both domains. Analysis of site-directed changes confirms the functional significance of the two separate regions in sex determination and dosage compensation and reveals that an additional region, undetected by genetic analysis, is also required for proper dosage compensation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	KLEIN, RD (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA.			Meyer, Barbara/0000-0002-6530-4588	NIGMS NIH HHS [GM30702, R01 GM030702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030702, R01GM030702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEJSOVEC A, 1990, CELL, V60, P133, DOI 10.1016/0092-8674(90)90723-R; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P5698; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DELONG LD, 1993, IN PRESS GENETICS, V133; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HODGKIN J, 1983, MOL GEN GENET, V192, P452, DOI 10.1007/BF00392190; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1979, GENETICS, V91, P67; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KRAUSE M, 1989, J MOL BIOL, V208, P381, DOI 10.1016/0022-2836(89)90503-2; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; MONTANDON AJ, 1989, NUCLEIC ACIDS RES, V17, P3347, DOI 10.1093/nar/17.9.3347; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; NUSBAUM C, 1989, GENETICS, V122, P579; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PLENEFISCH JD, 1989, GENETICS, V121, P57; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHAUER IE, 1990, DEVELOPMENT, V110, P1303; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TRENT C, 1991, MECH DEVELOP, V34, P43, DOI 10.1016/0925-4773(91)90090-S; Villeneuve A.M., 1990, Advances in Genetics, V27, P117; VILLENEUVE AM, 1987, CELL, V48, P25, DOI 10.1016/0092-8674(87)90352-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; [No title captured]; [No title captured]	42	58	78	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					349	364		10.1016/0092-8674(93)90113-5	http://dx.doi.org/10.1016/0092-8674(93)90113-5			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431944				2022-12-28	WOS:A1993KM16200006
J	BERNSTEIN, SJ; HILBORNE, LH; LEAPE, LL; FISKE, ME; PARK, RE; KAMBERG, CJ; BROOK, RH				BERNSTEIN, SJ; HILBORNE, LH; LEAPE, LL; FISKE, ME; PARK, RE; KAMBERG, CJ; BROOK, RH			THE APPROPRIATENESS OF USE OF CORONARY ANGIOGRAPHY IN NEW-YORK-STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BYPASS-SURGERY	Objective.-To determine the appropriateness of use of coronary angiography in New York State. Design.-Retrospective randomized medical record review. Setting.-Fifteen randomly selected hospitals in New York State that provide coronary angiography. Patients.-Random sample of 1335 patients undergoing coronary angiography in New York State in 1990. Main Outcome Measures.-Percentage of patients who underwent coronary angiography for appropriate, uncertain, or inappropriate indications. Results.-Approximately 76% of coronary angiographies were rated appropriate; 20%, uncertain; and 4%, inappropriate. Inappropriate use did not vary significantly between the elderly (ie, patients aged 65 years and older) and nonelderly, 4.7% and 3.9%, respectively. Although the rate of inappropriate use varied from 0% to 9% among hospitals, the difference was not significant. Rates of appropriateness did not vary by hospital location (upstate vs downstate), volume (fewer than 750 procedures annually or at least 750 procedures annually), teaching status, or whether revascularization was available at the hospital where angiography was performed. Conclusions.-Although coronary angiography was used for few inappropriate indications in New York State, many procedures were performed for uncertain indications in which the benefit and risk were approximately equal or unknown.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL & LAB MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, LOS ANGELES, CA USA; UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Harvard T.H. Chan School of Public Health	BERNSTEIN, SJ (corresponding author), RAND CORP, 1700 MAIN ST, SANTA MONICA, CA 90406 USA.							BERNSTEIN SJ, 1992, JRA03 PUBL; BERNSTEIN SJ, IN PRESS INT J TECHN; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; Cochran W.G., 2007, SAMPLING TECHNIQUES; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; GRABOYS TB, 1992, JAMA-J AM MED ASSOC, V268, P2537, DOI 10.1001/jama.268.18.2537; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; [No title captured]; 1991, VITAL HLTH STAT 13, V108, P110	14	110	110	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					766	769		10.1001/jama.269.6.766	http://dx.doi.org/10.1001/jama.269.6.766			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423658				2022-12-28	WOS:A1993KK54400029
J	HENTSCHEL, E; BRANDSTATTER, G; DRAGOSICS, B; HIRSCHL, AM; NEMEC, H; SCHUTZE, K; TAUFER, M; WURZER, H				HENTSCHEL, E; BRANDSTATTER, G; DRAGOSICS, B; HIRSCHL, AM; NEMEC, H; SCHUTZE, K; TAUFER, M; WURZER, H			EFFECT OF RANITIDINE AND AMOXICILLIN PLUS METRONIDAZOLE ON THE ERADICATION OF HELICOBACTER-PYLORI AND THE RECURRENCE OF DUODENAL-ULCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAMPYLOBACTER-PYLORI; PEPTIC-ULCER; RELAPSE; THERAPY; TRIAL; CURE	Background. Persistent infection with Helicobacter pylori is associated with the recurrence of duodenal ulcer. Whether the efficacy of bismuth therapy in reducing the rate of recurrence of duodenal ulcer is due to its antimicrobial effects on H. pylori or to a direct protective action on the mucosa is still a matter of debate. Methods. To study the effect of the eradication of H. pylori on the recurrence of duodenal ulcer, we treated 104 patients with H. pylori infection and recurrent duodenal ulcer with either amoxicillin (750 mg three times daily) plus metronidazole (500 mg three times daily) or identical-appearing placebos, given orally for 12 days. All patients also received ranitidine (300 mg each night) for 6 or 10 weeks. Endoscopy was performed before treatment and periodically during follow-up for up to 12 months after healing. Results. Among the 52 patients given antibiotics, H. pylori was eradicated in 46, as compared with 1 of the 52 given placebo (89 percent vs. 2 percent, P<0.001). After six weeks, the ulcers were healed in 48 patients given antibiotics and 39 given placebo (92 percent vs. 75 percent, P = 0.011). Side effects, mainly diarrhea, occurred in 15 percent of the patients given antibiotics. Among the patients followed up for 12 months, duodenal ulcers recurred in 4 of 50 patients given antibiotics and 42 of 49 given placebo (8 percent vs. 86 percent, P<0.001). Ulcers recurred in 1 of 46 patients in whom H. pylori had been eradicated, as compared with 45 of 53 in whom H. pylori persisted (2 percent vs. 85 percent, P<0.001). Conclusions. In patients with recurrent duodenal ulcer, eradication of H. pylori by a regimen that does not have any direct action on the mucosa is followed by a marked reduction in the rate of recurrence, suggesting a causal role for H. pylori in recurrent duodenal ulcer.	HANUSCH HOSP, DEPT PATHOL, A-1140 VIENNA, AUSTRIA; GEN HOSP, DEPT MED 2, GRAZ, AUSTRIA; REG PUBL MED INSURANCE, DEPT OUTPATIENT S, VIENNA, AUSTRIA; UNIV VIENNA, SCH MED, INST HYG, DEPT CLIN MICROBIOL, A-1010 VIENNA, AUSTRIA; GRAZ UNIV, SCH MED, DEPT PATHOL, A-8010 GRAZ, AUSTRIA	WGKK - Hanusch Hospital; University of Vienna; University of Graz	HENTSCHEL, E (corresponding author), HANUSCH HOSP, DEPT MED 1, HEINRICH COLLINSTR 30, A-1140 VIENNA, AUSTRIA.							BORODY T, 1992, LANCET, V339, P1295, DOI 10.1016/0140-6736(92)91622-F; BORODY TJ, 1989, MED J AUSTRALIA, V151, P431, DOI 10.5694/j.1326-5377.1989.tb101251.x; CARRICK J, 1988, J CLIN GASTROENTEROL, V10, P247; CARRICK J, 1990, RE ESP ENF DIG S1, V78, P122; COGHLAN JG, 1987, LANCET, V2, P1109; COLLINS R, 1991, Gastroenterology, V100, pA48; DENT JC, 1988, EUR J CLIN MICROBIOL, V7, P555, DOI 10.1007/BF01962615; FIOCCA R, 1991, LANCET, V337, P1614, DOI 10.1016/0140-6736(91)93316-2; GEORGE LL, 1990, MED J AUSTRALIA, V153, P145, DOI 10.5694/j.1326-5377.1990.tb136833.x; GLUPCZYNSKI Y, 1992, LANCET, V339, P54; GRAHAM DY, 1991, ANN INTERN MED, V115, P266, DOI 10.7326/0003-4819-115-4-266; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; HANSKY J, 1987, GASTROENTEROLOGY, V92, P1489; HIRSCHL AM, 1988, SCAND J GASTROENTERO, V23, P76, DOI 10.3109/00365528809091718; ISAKOV VA, 1990, LANCET, V336, P755, DOI 10.1016/0140-6736(90)92254-F; LAMOULIATTE H, 1991, ITAL J GASTROENTE S2, V23, P109; LOGAN R P H, 1991, Gastroenterology, V100, pA112; MARSHALL BJ, 1988, LANCET, V2, P1437; PATCHETT S, 1990, REV ESP ENF DIG S1, V78, P121; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; RABENECK L, 1991, AM J MED, V91, P566; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SMITH AC, 1988, GASTROENTEROLOGY, V94, pA431; SOLL AH, 1990, NEW ENGL J MED, V322, P909	24	752	762	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					308	312		10.1056/NEJM199302043280503	http://dx.doi.org/10.1056/NEJM199302043280503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8419816				2022-12-28	WOS:A1993KK24700003
J	TODO, T; TAKEMORI, H; RYO, H; IHARA, M; MATSUNAGA, T; NIKAIDO, O; SATO, K; NOMURA, T				TODO, T; TAKEMORI, H; RYO, H; IHARA, M; MATSUNAGA, T; NIKAIDO, O; SATO, K; NOMURA, T			A NEW PHOTOREACTIVATING ENZYME THAT SPECIFICALLY REPAIRS ULTRAVIOLET LIGHT-INDUCED (6-4)PHOTOPRODUCTS	NATURE			English	Article							ESCHERICHIA-COLI; PYRIMIDINE DIMER; BINDING-PROTEINS; HUMAN-CELLS; DNA; SEQUENCE; PHOTOPRODUCTS; ESTABLISHMENT; PURIFICATION; DAMAGE	CYCLOBUTANE pyrimidine dimers (CPDs) and pyrimidine (6-4) pyrimidone photoproducts ((6-4)photoproducts) are the two major classes of cytotoxic, mutagenic and carcinogenic DNA photoproducts produced by ultraviolet light irradiation of cells1-4. The phenomenon of photoreactivation, the reduction of the lethal and mutagenic effects of ultraviolet radiation by simultaneous or subsequent irradiation with near ultraviolet or visible light, has been identified in several organisms and in some cases the enzymes that catalyse this process have been characterized in sufficient detail5. CPDs are the only known substrate for the photoreactivating enzymes so far analysed and enzymatic photoreactivation of (6-4)photoproducts has not yet been reported4,5. We report here that an enzyme that catalyses the light-dependent repair of (6-4)photoproduct exists in Drosophila melanogaster. This is, to our knowledge, the first report of such photoreactivating activity specific for (6-4)photoproducts in any organism.	NARA MED UNIV,DEPT BIOL,KASHIHARA,NARA 634,JAPAN; KANAZAWA UNIV,FAC PHARMACEUT SCI,DIV RADIAT BIOL,KANAZAWA,ISHIKAWA 920,JAPAN; OSAKA UNIV,SCH MED,DEPT DERMATOL,OSAKA 553,JAPAN	Nara Medical University; Kanazawa University; Osaka University	TODO, T (corresponding author), OSAKA UNIV,FAC MED,DEPT RADIAT BIOL,YAMADA OKA 2-2,SUITA,OSAKA 565,JAPAN.							[Anonymous], 1985, DNA REPAIR; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Harm W, 1980, BIOL EFFECTS ULTRAVI; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; MATSUNAGA T, 1990, MUTAT RES, V235, P187, DOI 10.1016/0921-8777(90)90073-E; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MIZUNO T, 1991, MUTAT RES, V254, P175, DOI 10.1016/0921-8777(91)90009-E; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7; TODO T, 1992, MUTAT RES, V273, P85, DOI 10.1016/0921-8777(92)90052-5; VARGHESE AJ, 1968, SCIENCE, V160, P186, DOI 10.1126/science.160.3824.186; WANG SY, 1967, BIOCHEM BIOPH RES CO, V29, P543, DOI 10.1016/0006-291X(67)90519-0	21	251	256	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					371	374		10.1038/361371a0	http://dx.doi.org/10.1038/361371a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8426655				2022-12-28	WOS:A1993KJ59000064
J	BRYANT, PJ				BRYANT, PJ			THE POLAR COORDINATE MODEL GOES MOLECULAR	SCIENCE			English	Editorial Material							IMAGINAL DISKS; DROSOPHILA; GENE; WINGLESS; EMBRYOS; LOCUS				BRYANT, PJ (corresponding author), UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717, USA.							AGNEL M, 1992, ROUX ARCH DEV BIOL, V201, P284, DOI 10.1007/BF00592109; BAKER NE, 1988, DEVELOPMENT, V102, P489; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; COHEN SM, IN PRESS DEV DROSOPH; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; Goto S., COMMUNICATION; HATANO Y, 1991, MOL GEN GENET, V226, P17, DOI 10.1007/BF00273582; HELD LI, IN PRESS DEV BIOL; HOOPER J, COMMUNICATION; HOOPER JE, 1993, EARLY EMBRYONIC DEV; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MANAK J, COMMUNICATION; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MOHLER J, 1988, GENETICS, V120, P1061; ORENIC TV, COMMUNICATION; PEIFER M, 1991, DEVELOPMENT, V111, P1029; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; SIMCOX AA, 1989, DEVELOPMENT, V107, P715; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WILLIAMS JA, IN PRESS DEVELOPMENT; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301	28	51	52	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					471	472		10.1126/science.8424169	http://dx.doi.org/10.1126/science.8424169			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424169				2022-12-28	WOS:A1993KJ07900022
J	BREIMAN, RF; DAVIS, JP; FACKLAM, RR; GRAY, BM; HOGE, CW; KAPLAN, EL; MORTIMER, EA; SCHLIEVERT, PM; SCHWARTZ, B; STEVENS, DL; TODD, JK				BREIMAN, RF; DAVIS, JP; FACKLAM, RR; GRAY, BM; HOGE, CW; KAPLAN, EL; MORTIMER, EA; SCHLIEVERT, PM; SCHWARTZ, B; STEVENS, DL; TODD, JK			DEFINING THE GROUP-A STREPTOCOCCAL TOXIC SHOCK SYNDROME - RATIONALE AND CONSENSUS DEFINITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCARLET FEVER; PYOGENES; SEPTICEMIA; INFECTION		CTR DIS CONTROL & PREVENT,RESP DIS BRANCH,MAILSTOP C-09,1600 CLIFTON RD NE,ATLANTA,GA 30333; WISCONSIN DEPT HLTH & SOCIAL SERV,BUR PUBL HLTH,MADISON,WI; UNIV ALABAMA,SCH MED,DEPT PEDIAT,BIRMINGHAM,AL 35233; UNIV MINNESOTA,SCH MED,DEPT PEDIAT,MINNEAPOLIS,MN 55455; CASE WESTERN RESERVE UNIV,DEPT EPIDEMIOL & BIOSTAT,CLEVELAND,OH 44106; UNIV MINNESOTA,DEPT MICROBIOL,MINNEAPOLIS,MN 55455; BOISE VET ADM HOSP,DEPT MED,BOISE,ID; UNIV COLORADO,SCH MED,DEPT PEDIAT,DENVER,CO 80202	Centers for Disease Control & Prevention - USA; University of Alabama System; University of Alabama Birmingham; University of Minnesota System; University of Minnesota Twin Cities; Case Western Reserve University; University of Minnesota System; University of Minnesota Twin Cities; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BARTTER T, 1988, ARCH INTERN MED, V148, P1421, DOI 10.1001/archinte.148.6.1421; BOHACH GA, 1990, CRIT REV MICROBIOL, V17, P251, DOI 10.3109/10408419009105728; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; CRUICKSHANK JG, 1981, BRIT MED J, V282, P1944, DOI 10.1136/bmj.282.6280.1944; HAUSER AR, 1991, J CLIN MICROBIOL, V29, P1562, DOI 10.1128/JCM.29.8.1562-1567.1991; HOGE CW, 1993, JAMA-J AM MED ASSOC, V269, P384, DOI 10.1001/jama.269.3.384; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; SHAUNAK S, 1988, Q J MED, V69, P921; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; WHEELER MC, 1991, JAMA-J AM MED ASSOC, V266, P533, DOI 10.1001/jama.266.4.533; 1990, MMWR, V39, P3	12	514	523	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					390	391		10.1001/jama.1993.03500030088038	http://dx.doi.org/10.1001/jama.1993.03500030088038			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418347				2022-12-28	WOS:A1993KG38100032
J	HOGE, CW; SCHWARTZ, B; TALKINGTON, DF; BREIMAN, RF; MACNEILL, EM; ENGLENDER, SJ				HOGE, CW; SCHWARTZ, B; TALKINGTON, DF; BREIMAN, RF; MACNEILL, EM; ENGLENDER, SJ			THE CHANGING EPIDEMIOLOGY OF INVASIVE GROUP-A STREPTOCOCCAL INFECTIONS AND THE EMERGENCE OF STREPTOCOCCAL TOXIC SHOCK-LIKE SYNDROME - A RETROSPECTIVE POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE RHEUMATIC-FEVER; 4-YEAR EXPERIENCE; UNITED-STATES; SCARLET FEVER; BACTEREMIA; DISEASE; MENINGITIS; CHILDREN; MORBIDITY; MORTALITY	Objective.-To determine disease incidence and changes in the epidemiology of invasive group A streptococcal infections in a community in Arizona. Design and Setting.-We retrospectively surveyed microbiology records from all 10 hospitals in Pima County, Arizona, to identify patients who had Streptococcus pyogenes isolated from blood, sterile body fluid, or tissue biopsy specimens between April 1985 and March 1990. Demographic and clinical information was abstracted from the medical records of these patients. Patients.-A total of 128 patients with a median age of 53.5 years (range, 6 months to 96 years). Outcome Measures.-Racial/ethnic differences in disease incidence; mortality and changes in the clinical spectrum of disease over the study period. Results.-The annual age-adjusted incidence was 4.3 per 100 000 but was 46.0 per 100 000 among Native Americans. Advanced age, age less than 5 years, hypotension, and multi-organ system involvement were significantly associated with increased mortality. From 1985 to 1990, the proportion of infections with hypotension, rash, desquamation, renal impairment, and gastrointestinal involvement increased significantly (chi2 for trend P less-than-or-equal-to .02 for each feature). A toxic shock-like syndrome occurred in 8% of infections since 1988, compared with none of the infections between 1985 and 1987 (P=.04). Patients with the syndrome were younger than patients with other invasive infections (median age 15 vs 54 years, P=02), and were less likely to have underlying medical conditions (P=.008). Conclusions.-Significant changes occurred in the spectrum of invasive group A streptococcal infections in Pima County, Arizona, between 1985 and 1990. Native Americans were at increased risk of acquiring these infections. Patients with the streptococcal toxic shock-like syndrome had epidemiologic features that distinguished them from patients with other invasive infections, including younger age and less underlying illness.	PIMA CTY HLTH DEPT,TUCSON,AZ; NATL CTR DIS CONTROL & PREVENT,CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,RESP DIS BRANCH,ATLANTA,GA; ARIZONA DEPT HLTH SERV,PHOENIX,AZ	Centers for Disease Control & Prevention - USA; Arizona Department of Health Services								BARTTER T, 1988, ARCH INTERN MED, V148, P1421, DOI 10.1001/archinte.148.6.1421; BEGOVAC J, 1990, PEDIATR INFECT DIS J, V9, P369, DOI 10.1097/00006454-199005000-00013; BIBLER MR, 1986, REV INFECT DIS, V8, P941; BISNO AL, 1985, JAMA-J AM MED ASSOC, V254, P538, DOI 10.1001/jama.254.4.538; BRAUNSTEIN H, 1991, REV INFECT DIS, V13, P8; BURKERT T, 1992, CLIN INFECT DIS, V14, P29, DOI 10.1093/clinids/14.1.29; CAMOSFILHO N, 1989, AM J EPIDEMIOL, V129, P439; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; COULEHAN J, 1980, PUBLIC HEALTH REP, V95, P62; COULEHAN JL, 1984, PUBLIC HEALTH REP, V99, P404; DAJANI AS, 1973, ARCH DERMATOL, V108, P517, DOI 10.1001/archderm.108.4.517; DAN M, 1990, REV INFECT DIS, V12, P537; DAVIS JP, 1982, J INFECT DIS, V145, P441, DOI 10.1093/infdis/145.4.441; DUMA RJ, 1969, MEDICINE, V48, P87, DOI 10.1097/00005792-196903000-00001; Facklam RR, 1985, MANUAL CLIN MICROBIO, V4th, P154; FRANCIS J, 1988, Q J MED, V68, P603; GIVNER LB, 1991, J PEDIATR-US, V118, P341, DOI 10.1016/S0022-3476(05)82144-4; HRIBALOVA V, 1988, ANN INTERN MED, V108, P772, DOI 10.7326/0003-4819-108-5-772_2; KOHLER W, 1987, ZBL BAKT-INT J MED M, V266, P104; LERSCH C, 1990, KLIN WOCHENSCHR, V68, P523, DOI 10.1007/BF01648248; LONGSTAFFE S, 1982, CAN MED ASSOC J, V127, P497; MARTIN PR, 1990, SCAND J INFECT DIS, V22, P421, DOI 10.3109/00365549009027073; MASSELL BF, 1988, NEW ENGL J MED, V318, P280, DOI 10.1056/NEJM198802043180504; MOODY M D, 1965, Health Lab Sci, V2, P149; QUINN RW, 1989, REV INFECT DIS, V11, P928; REDD SC, 1988, PEDIATRICS, V82, P576; SCHLIEVERT PM, 1981, J INFECT DIS, V143, P509, DOI 10.1093/infdis/143.4.509; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STROMBERG A, 1991, J INFECT DIS, V164, P595, DOI 10.1093/infdis/164.3.595; TALKINGTON DF, 1991, 91ST AM SOC MICR ANN; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WALLACE MR, 1989, JAMA-J AM MED ASSOC, V262, P2557, DOI 10.1001/jama.262.18.2557; WARD JI, 1981, LANCET, V1, P1281; WHEELER MC, 1991, JAMA-J AM MED ASSOC, V266, P533, DOI 10.1001/jama.266.4.533; WOTTON KA, 1981, CAN MED ASSOC J, V124, P887; YOST GC, 1986, AM J DIS CHILD, V140, P943, DOI 10.1001/archpedi.1986.02140230113047; 1990, COMMUNICAB DIS REP, V26, P3; 1990, MMWR, V39, P3; 1990, MMWR SRR13, V39, P1; 1990, CAN DIS WKLY REP, V16, P257; 1991, COLO DIS B, V18; 1989, TUCSON PROFILE	43	320	328	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					384	389		10.1001/jama.269.3.384	http://dx.doi.org/10.1001/jama.269.3.384			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418346				2022-12-28	WOS:A1993KG38100031
J	TIERNEY, WM; MILLER, ME; OVERHAGE, JM; MCDONALD, CJ				TIERNEY, WM; MILLER, ME; OVERHAGE, JM; MCDONALD, CJ			PHYSICIAN INPATIENT ORDER WRITING ON MICROCOMPUTER WORKSTATIONS - EFFECTS ON RESOURCE UTILIZATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL RECORD; CONTROLLED TRIAL; SYSTEM; INFORMATION; REMINDERS; CARE	Objective.-To assess the effects on health care resource utilization of a network of microcomputer workstations for writing all inpatient orders. Design.-Randomized controlled clinical trial. Setting.-Inpatient internal medicine service of an urban public hospital. Subjects.-A total of 5219 internal medicine patients and the 68 teams of house officers, medical students, and faculty internists who cared for them. Intervention.-Microcomputer workstations, linked to a comprehensive electronic medical record system, for writing all inpatient orders. Main Outcome Measures.-Total inpatient charges for each admission and charges for specific categories of orders. A time-motion study of selected interns assessed the ordering system's time consumption. Results.-Intervention teams generated charges that were $887 (12.7%) lower per admission than did control teams (P=.02). Significant reductions (P<.05) were demonstrated separately for bed charges, diagnostic test charges, and drug charges. Reductions of similar proportion and statistical significance were found for hospital costs. The mean length of stay was 0.89 day shorter for intervention resident teams (P=.11). Interns in the intervention group spent an average of 33 minutes longer (5.5 minutes per patient) during a 10-hour observation period writing orders than did interns in the control group (P<.0001). Conclusions.-A network of microcomputer workstations for writing all inpatient orders significantly lowered patient charges and hospital costs. This would amount to savings of more than $3 million in charges annually for this hospital's medicine service and potentially tens of billions of dollars nationwide. However, the system required more physician time than did the paper charts. Research at other sites and system advances to reduce time requirements are warranted.	REGENSTRIEF INST HLTH CARE, COMP SCI RES SECT, 5TH FLOOR RHC, 1001 W 10TH ST, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA; RICHARD L ROUDEBUSH VET AFFAIRS MED CTR, INDIANAPOLIS, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center				Overhage, Joseph/0000-0003-0223-0195	AHRQ HHS [HS05626] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; BARNETT GO, 1983, MED CARE, V21, P400, DOI 10.1097/00005650-198304000-00003; BARRETT JP, 1975, PB358340; CAMPBELL DT, 1966, EXPT QUASIEXPERIMENT, P22; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; EISENBERG JM, 1981, JAMA-J AM MED ASSOC, V246, P2195, DOI 10.1001/jama.246.19.2195; FITZGERALD JF, 1990, CLIN RES, V38, pA912; FRIES JF, 1974, MED CARE, V12, P871, DOI 10.1097/00005650-197410000-00006; KNAPP DE, 1979, AM J HOSP PHARM, V36, P1334, DOI 10.1093/ajhp/36.10.1334; LARSEN RA, 1989, INFECT CONT HOSP EP, V10, P316, DOI 10.2307/30146474; MCDONALD CJ, 1990, CLIN RES, V38, pA914; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDONALD CJ, 1992, M D COMPUT, V9, P206; MCDONALD CJ, 1986, WESTERN J MED, V145, P823; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; MILLIKEN GA, 1984, ANAL MESSY DATA DESI, P250; OVERHAGE JM, 1991, CLIN RES, V39, pA794; RICHART RH, 1970, COMPUT BIOMED RES, V3, P415, DOI 10.1016/0010-4809(70)90003-0; Schimmel V E, 1987, Top Health Care Financ, V13, P76; SELKER HP, 1989, MED CARE, V27, P112, DOI 10.1097/00005650-198902000-00003; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; TIERNEY WM, 1988, JAMA-J AM MED ASSOC, V259, P1194, DOI 10.1001/jama.259.8.1194; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; WEINBERGER M, 1988, MED CARE, V26, P1092, DOI 10.1097/00005650-198811000-00007; WHITINGOKEEFE QE, 1985, JAMA-J AM MED ASSOC, V254, P1185, DOI 10.1001/jama.254.9.1185; WILSON GA, 1982, AM J PUBLIC HEALTH, V72, P698, DOI 10.2105/AJPH.72.7.698; 1991, GAOIMTEC915 GEN ACC; 1991, COMPUTER BASED PATIE	29	384	394	15	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					379	383		10.1001/jama.269.3.379	http://dx.doi.org/10.1001/jama.269.3.379			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418345				2022-12-28	WOS:A1993KG38100030
J	CONSTINE, LS; WOOLF, PD; CANN, D; MICK, G; MCCORMICK, K; RAUBERTAS, RF; RUBIN, P				CONSTINE, LS; WOOLF, PD; CANN, D; MICK, G; MCCORMICK, K; RAUBERTAS, RF; RUBIN, P			HYPOTHALAMIC PITUITARY DYSFUNCTION AFTER RADIATION FOR BRAIN-TUMORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-HORMONE DEFICIENCY; CRANIAL IRRADIATION; THYROID-DYSFUNCTION; INTRACRANIAL TUMORS; ENDOCRINE SEQUELAE; LH-RH; CHILDREN; RADIOTHERAPY; CHILDHOOD; PUBERTY	Background. Patients with brain tumors who are treated with radiation frequently have growth hormone deficiency, but other neuroendocrine abnormalities are presumed to be uncommon. Methods. We studied endocrine function in 32 patients (age, 6 to 65 years) 2 to 13 years after they had received cranial radiotherapy for brain tumors. The doses of radiation to the hypothalamic-pituitary region ranged from 3960 to 7020 rad (39.6 to 70.2 Gy). Nine patients also received 1800 to 3960 rad (18.0 to 39.6 Gy) to the craniospinal axis. Serum concentrations of thyroid, gonadal, and pituitary hormones were measured at base line and after stimulation. Results. Nine patients (28 percent) had symptoms of thyroid deficiency, and 20 patients (62 percent) had low serum total or free thyroxine or total triiodothyronine concentrations. Of the 23 patients treated only with cranial radiation, 15 (65 percent) had hypothalamic or pituitary hypothyroidism. Of the nine patients who also received spinal (and thus direct thyroid) radiation, three (33 percent) had evidence of primary thyroid injury. Seven of the 10 postpubertal, premenopausal women (70 percent) had oligomenorrhea, and 5 (50 percent) had low serum estradiol concentrations. Three of the 10 men (30 percent) had low serum testosterone concentrations. Overall, 14 of the 23 postpubertal patients (61 percent) had evidence of hypogonadism. Mild hyperprolactinemia was present in 50 percent of the patients. Responses to stimulation with corticotropin-releasing hormone and corticotropin were normal in all patients except one, who had panhypothalamic dysfunction. However, serum 11-deoxycortisol responses to the administration of metyrapone were low in 11 of the 31 patients (35 percent) tested. Three of the 32 patients (9 percent) had no endocrine abnormalities, 9 (28 percent) had an abnormal result on tests of thyroid, gonadal, prolactin, or adrenal function, 8 (25 percent) had abnormalities in two axes, 8 (25 percent) in three axes, and 4 (12 percent) in all four axes. Conclusions. Cranial radiotherapy in children and adults with brain tumors frequently causes abnormal hypothalamic-pituitary function. The most frequent changes are hypothyroidism and gonadal dysfunction, although subtle abnormalities in adrenal function may also be present.	UNIV ROCHESTER, MED CTR, DEPT PEDIAT, DIV PEDIAT ONCOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT MED, DIV ENDOCRINOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT BIOSTAT, ROCHESTER, NY 14642 USA; DOVER GEN HOSP, DEPT RADIAT ONCOL, DOVER, NJ USA; SUNY HLTH SCI CTR, DEPT PEDIAT, DIV ENDOCRINOL, SYRACUSE, NY USA	University of Rochester; University of Rochester; University of Rochester; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	CONSTINE, LS (corresponding author), UNIV ROCHESTER, MED CTR, DEPT RADIAT ONCOL, ROCHESTER, NY 14642 USA.				NCRR NIH HHS [RR00044] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABAYOMI OK, 1986, INT J RADIAT ONCOL, V12, P945, DOI 10.1016/0360-3016(86)90390-1; AGRESTI A, 1984, ANAL ORDINAL CATEGOR, P161; ALMQUIST S, 1964, ACTA RADIOL THER PHY, V2, P179, DOI 10.3109/02841866409134144; BAJORUNAS DR, 1980, J CLIN ENDOCR METAB, V50, P329, DOI 10.1210/jcem-50-2-329; BRAUNER R, 1989, J CLIN ENDOCR METAB, V68, P346, DOI 10.1210/jcem-68-2-346; BRUNNER H, 1920, ARCH KLIN CHIR, V114, P332; CLAYTON PE, 1991, J PEDIATR-US, V118, P226, DOI 10.1016/S0022-3476(05)80487-1; Conover WJ, 1980, PRACTICAL NONPARAMET, P215; CONSTINE LS, 1984, CANCER-AM CANCER SOC, V53, P878, DOI 10.1002/1097-0142(19840215)53:4<878::AID-CNCR2820530411>3.0.CO;2-J; CONSTINE LS, 1987, J CLIN ONCOL, V5, P1841, DOI 10.1200/JCO.1987.5.11.1841; CROMPTON MR, 1961, BRAIN, V84, P85, DOI 10.1093/brain/84.1.85; DANOFF BF, 1982, CANCER, V48, P1580, DOI 10.1002/1097-0142(19820415)49:8<1580::AID-CNCR2820490810>3.0.CO;2-7; DEUTSCH M, 1986, MEDULLOBLASTOMAS CHI, P213; DICKERMAN Z, 1976, AM J DIS CHILD, V130, P634, DOI 10.1001/archpedi.1976.02120070060011; DUFFNER PK, 1985, CANCER-AM CANCER SOC, V56, P2189, DOI 10.1002/1097-0142(19851101)56:9<2189::AID-CNCR2820560909>3.0.CO;2-I; Fleiss J. L, 1981, STATISTICAL METHODS, P24; GARNIER PE, 1974, ACTA ENDOCRINOL-COP, V77, P422; HAJJAR RA, 1973, ARCH INTERN MED, V132, P836, DOI 10.1001/archinte.132.6.836; HARROP JS, 1976, CLIN ENDOCRINOL, V5, P313, DOI 10.1111/j.1365-2265.1976.tb01960.x; KELLY KH, 1951, J NATL CANCER I, V11, P967; LAM KSL, 1991, Q J MED, V78, P165; LANNERING B, 1987, HORM RES, V27, P13, DOI 10.1159/000180772; LITTLEY MD, 1989, CLIN ENDOCRINOL, V31, P363, DOI 10.1111/j.1365-2265.1989.tb01260.x; LIVESEY EA, 1989, ARCH DIS CHILD, V64, P593, DOI 10.1136/adc.64.4.593; LIVESEY EA, 1988, ARCH DIS CHILD, V63, P495, DOI 10.1136/adc.63.5.495; OBERFIELD SE, 1986, J PEDIATR-US, V108, P219, DOI 10.1016/S0022-3476(86)80986-6; PERRYKEENE DA, 1976, CLIN ENDOCRINOL, V5, P373, DOI 10.1111/j.1365-2265.1976.tb01965.x; QUIGLEY C, 1989, NEW ENGL J MED, V321, P143, DOI 10.1056/NEJM198907203210303; RAMSAY N, 1978, P AM ASSOC CANC RES, V19, P389; RAPPAPORT R, 1989, PEDIATR RES, V25, P561, DOI 10.1203/00006450-198906000-00001; REITER EO, 1975, PEDIATR RES, V9, P111, DOI 10.1203/00006450-197509020-00011; Rubin P., 1968, CLIN RAD PATHOLOGY; SAMAAN NA, 1987, J LAB CLIN MED, V109, P364; SAMAAN NA, 1982, INT J RADIAT ONCOL, V8, P1857, DOI 10.1016/0360-3016(82)90442-4; SCHURMEYER TH, 1984, J CLIN ENDOCR METAB, V59, P1103, DOI 10.1210/jcem-59-6-1103; SHALET SM, 1976, CLIN ENDOCRINOL, V5, P287, DOI 10.1111/j.1365-2265.1976.tb01955.x; SHALET SM, 1975, LANCET, V2, P104; SKLAR C A, 1991, Pediatrician, V18, P53; SLANINA J, 1977, INT J RADIAT ONCOL, V2, P1, DOI 10.1016/0360-3016(77)90003-7; SLATSTEI.E, 1971, J CLIN ENDOCR METAB, V32, P833, DOI 10.1210/jcem-32-6-833; SNYDER PJ, 1974, ANN INTERN MED, V81, P751, DOI 10.7326/0003-4819-81-6-751; WARA WM, 1977, INT J RADIAT ONCOL, V2, P549, DOI 10.1016/0360-3016(77)90166-3; WIGG DR, 1982, ACTA RADIOL ONCOL, V21, P49, DOI 10.3109/02841868209133984	43	442	462	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1993	328	2					87	94		10.1056/NEJM199301143280203	http://dx.doi.org/10.1056/NEJM199301143280203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG467	8416438				2022-12-28	WOS:A1993KG46700003
J	DINARELLO, CA; WOLFF, SM				DINARELLO, CA; WOLFF, SM			MECHANISMS OF DISEASE - THE ROLE OF INTERLEUKIN-1 IN DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TUMOR NECROSIS FACTOR; ACUTE MYELOBLASTIC-LEUKEMIA; IL-1 RECEPTOR ANTAGONIST; CYCLOOXYGENASE INHIBITION; RHEUMATOID-ARTHRITIS; CYTOKINE PRODUCTION; HUMAN-MONOCYTES; CELLS; INVITRO; GROWTH		TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111	Tufts University	DINARELLO, CA (corresponding author), NEW ENGLAND MED CTR,DEPT MED,750 WASHINGTON ST,BOSTON,MA 02111, USA.				NIAID NIH HHS [AI 15614] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015614, R37AI015614] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AREND WP, 1991, J IMMUNOL, V147, P1530; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; AREND WP, 1985, J IMMUNOL, V134, P3868; BAGBY GC, 1988, J CLIN INVEST, V82, P1430, DOI 10.1172/JCI113748; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BODEL P, 1967, NEW ENGL J MED, V276, P1002, DOI 10.1056/NEJM196705042761803; CANNON JG, 1992, CRIT CARE MED, V20, P1414, DOI 10.1097/00003246-199210000-00009; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; COMINELLI F, 1989, GASTROENTEROLOGY, V97, P1400, DOI 10.1016/0016-5085(89)90382-X; COZZOLINO F, 1989, P NATL ACAD SCI USA, V86, P2369, DOI 10.1073/pnas.86.7.2369; DAYER JM, 1991, J RHEUMATOL, V18, P71; DAYER-METROZ M-D, 1992, European Journal of Clinical Investigation, V22, pA50; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; EASTGATE JA, 1988, LANCET, V2, P706; ENDRES S, 1989, EUR J IMMUNOL, V19, P2327, DOI 10.1002/eji.1830191222; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; ESTROV Z, 1991, BLOOD, V78, P1476; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FISCHER E, 1991, AM J PHYSIOL, V261, pR442, DOI 10.1152/ajpregu.1991.261.2.R442; FISHER CJJ, 1991, NOV ANN M AM COLL CH; GERSHENWALD JE, 1990, P NATL ACAD SCI USA, V87, P4966, DOI 10.1073/pnas.87.13.4966; GRANOWITZ EV, 1991, LANCET, V338, P1423, DOI 10.1016/0140-6736(91)92725-H; GRANOWTIZ EV, 1992, CYTOKINE, V4, P353, DOI 10.1016/1043-4666(92)90078-6; GRIFFIN JD, 1987, BLOOD, V70, P1218; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; JACOBS CA, 1991, J IMMUNOL, V146, P2983; KRANE SM, 1990, ANN NY ACAD SCI, V580, P340, DOI 10.1111/j.1749-6632.1990.tb17943.x; KU G, 1992, J BIOL CHEM, V267, P14183; LEMAY L G, 1990, Cytokine, V2, P199, DOI 10.1016/1043-4666(90)90016-M; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; Mandrup-Poulsen T, 1989, Autoimmunity, V4, P191, DOI 10.3109/08916938909003049; MCCARTHY PL, 1991, BLOOD, V78, P1915; MILLER LC, 1992, J CLIN INVEST, V90, P906, DOI 10.1172/JCI115966; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; NETA R, 1988, J IMMUNOL, V140, P108; NICOD LP, 1992, CYTOKINE, V4, P29, DOI 10.1016/1043-4666(92)90033-N; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; OPP MR, 1991, AM J PHYSIOL, V260, pR453, DOI 10.1152/ajpregu.1991.260.2.R453; PELED T, 1992, BLOOD, V79, P1172, DOI 10.1182/blood.V79.5.1172.bloodjournal7951172; RAMBALDI A, 1991, BLOOD, V78, P3248; ROSSI V, 1985, SCIENCE, V229, P174, DOI 10.1126/science.2409598; SCHWAB JH, 1991, INFECT IMMUN, V59, P4436, DOI 10.1128/IAI.59.12.4436-4442.1991; SECKINGER P, 1987, J IMMUNOL, V139, P1546; SMITH J, 1990, AM SOC CLIN ONCOL, V9, P717; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; TEWARI A, 1990, LANCET, V336, P712, DOI 10.1016/0140-6736(90)92206-W; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VANDERMEER JWM, 1988, P NATL ACAD SCI USA, V85, P1620; VANNIER E, 1992, P NATL ACAD SCI USA, V89, P4076, DOI 10.1073/pnas.89.9.4076; WEBER PC, 1991, WORLD REV NUTR DIET, V66, P218	51	965	1020	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1993	328	2					106	113						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG467	8439348				2022-12-28	WOS:A1993KG46700007
J	BROADHURST, LE; ERICKSON, RL; KELLEY, PW				BROADHURST, LE; ERICKSON, RL; KELLEY, PW			DECREASES IN INVASIVE HAEMOPHILUS-INFLUENZAE DISEASES IN UNITED-STATES-ARMY CHILDREN, 1984 THROUGH 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							B DISEASE; CONJUGATE VACCINE; EPIDEMIOLOGY; EFFICACY; MENINGITIS; INFECTIONS; POPULATION; POLYSACCHARIDE; COUNTY; YOUNG	Objective.-To document trends in the incidence of invasive Haemophilus influenzae diseases in young children of US Army active duty soldiers following the publication of H influenzae type b immunization recommendations for young children between 1985 and 1990. Design.-A population-based surveillance of hospital discharge diagnoses for H influenzae invasive diseases. Setting.-Military and civilian medical treatment facilities around the world. Patients.-There was a mean population of nearly 200 000 US Army health care beneficiaries younger than 5 years of age each year of the study. Outcome Measures.-Annual total and age-specific incidences of the six most common H influenzae invasive diseases in this population (meningitis, epiglottitis, septicemia, pneumonia, cellulitis, and septic arthritis). Results.-The annual number of cases of H influenzae invasive diseases decreased from a high of 188 in 1986 to 43 in 1991. The incidence in the age group at highest risk for H influenzae disease, those 6 to 11 months of age, decreased from 355 per 100 000 children in 1986 to 116 per 100 000 in 1991 (P<.0001, chi2 for trend). The incidence for H influenzae meningitis declined from 59 per 100 000 children in 1986 to 6 per 100 000 in 1991 (P<.0001, chi2 for trend). Conclusions.-The decrease in H influenzae invasive diseases closely follows the dates of H influenzae type b vaccine licensure for use in progressively younger age groups. Some age groups, however, experienced a decline in disease rates even before becoming eligible for vaccination.	WALTER REED ARMY INST RES,DIV PREVENT MED,DEPT ADV PREVENT MED STUDIES,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)								ADAMS W, 1992, APR CTR DIS CONTR EP; AHONKHAI VI, 1991, VACCINE, V9, pS38, DOI 10.1016/0264-410X(91)90180-E; BLACK SB, 1991, PEDIATR INFECT DIS J, V10, P97, DOI 10.1097/00006454-199102000-00004; BLACK SB, 1992, PEDIATR INFECT DIS J, V11, P610; BROOME CV, 1987, PEDIATR INFECT DIS J, V6, P779, DOI 10.1097/00006454-198708000-00036; COCHI SL, 1986, PEDIATR INFECT DIS J, V5, P12, DOI 10.1097/00006454-198601000-00003; ESKOLA J, 1991, VACCINE, V9, pS14, DOI 10.1016/0264-410X(91)90174-5; FERRECCIO C, 1990, PEDIATR INFECT DIS J, V9, P488, DOI 10.1097/00006454-199007000-00007; GERVAIX A, 1991, PEDIATR INFECT DIS J, V10, P370, DOI 10.1097/00006454-199105000-00005; GRANOFF DM, 1991, VACCINE, V9, pS30, DOI 10.1016/0264-410X(91)90178-9; GREENBERG DP, 1991, JAMA-J AM MED ASSOC, V265, P987, DOI 10.1001/jama.265.8.987; HALFONYANIV I, 1990, PEDIATR INFECT DIS J, V9, P321, DOI 10.1097/00006454-199005000-00004; HOWARD AJ, 1991, BRIT MED J, V303, P441, DOI 10.1136/bmj.303.6800.441; MARWICK C, 1991, JAMA-J AM MED ASSOC, V266, P3398, DOI 10.1001/jama.266.24.3398; MURPHY TV, 1987, PEDIATRICS, V79, P173; MURPHY TV, 1991, 31ST INT C ANT AG CH; NELSON JD, 1991, PEDIATR INFECT DIS J, V17, P23; PELTOLA H, 1990, REV INFECT DIS, V12, P708; PELTOLA H, 1992, LANCET, V340, P592, DOI 10.1016/0140-6736(92)92117-X; PELTOLA H, 1991, 31TH INT C ANT AG CH; RICE RB, 1990, AM J PUBLIC HEALTH, V80, P215, DOI 10.2105/AJPH.80.2.215; SHAPIRO ED, 1991, EPIDEMIOL REV, V13, P113, DOI 10.1093/oxfordjournals.epirev.a036066; SHAPIRO ED, 1992, MAY SOC PED RES BALT; SHERRY B, 1989, JAMA-J AM MED ASSOC, V261, P1924, DOI 10.1001/jama.261.13.1924; SMITH EWP, 1972, PEDIATRICS, V50, P723; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P343, DOI 10.1097/00006454-198906000-00002; TAKALA AK, 1992, J INFECT DIS, V165, pS11, DOI 10.1093/infdis/165-Supplement_1-S11; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P297; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; WENGER J, 1988, 28TH INT C ANT AG CH; WENGER JD, 1991, LANCET, V338, P395; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; 1985, MMWR, V34, P201; 1990, MMWR, V39, P925; 1991, MMWR, V40, P1; 1990, MMWR, V39, P924; 1992, KY EPIDEMIOL NOT APR, P1; 1988, MMWR, V37, P13; 1990, MMWR, V39, P698	39	90	90	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					227	231		10.1001/jama.269.2.227	http://dx.doi.org/10.1001/jama.269.2.227			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417240				2022-12-28	WOS:A1993KF40500028
J	NISWANDER, L; MARTIN, GR				NISWANDER, L; MARTIN, GR			FGF-4 AND BMP-2 HAVE OPPOSITE EFFECTS ON LIMB GROWTH	NATURE			English	Article							PATTERN-FORMATION; CONTAINING GENES; MOUSE; EXPRESSION; FAMILY; EMBRYOGENESIS; RECEPTORS; MULTIPLE; SUGGESTS; FETAL	LIMB development is dependent on epithelial-mesenchymal interactions. The apical ectodermal ridge (AER), a specialized epithelium at the limb tip, stimulates proliferation of underlying mesenchyme, causing directed limb outgrowth1 (for review see ref. 2). Several genes are expressed in the mouse AER3-10, including Fgf-4 (fibroblast growth factor-4)11,12 and Bmp-2 (bone morphogenetic protein-2)13, both of which encode secreted signalling molecules. Using a culture system developed to explore the function of molecules produced by the AER, we have shown that FGF-4 protein stimulates proliferation of mesenchyme in the early mouse limb-bud. This suggests that FGF-4 serves that major function of the AER. In contrast, BMP-2 inhibits limb growth, suggesting that as a result the AER may serve a hitherto unrecognized inhibitory function. Furthermore, the extent of limb outgrowth can be modulated by mixing the two signalling molecules, suggesting that limb growth is regulated by a combination of stimulatory and inhibitory signals from the AER.	UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	NISWANDER, L (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.		Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594				AONO H, 1988, DEV BIOL, V128, P136, DOI 10.1016/0012-1606(88)90275-8; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HAUB O, 1991, DEVELOPMENT, V112, P397; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; JACKSONGRUSBY L, 1992, GENE DEV, V6, P29, DOI 10.1101/gad.6.1.29; JONES CM, 1991, DEVELOPMENT, V111, P531; LYONS KM, 1990, DEVELOPMENT, V109, P833; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Neubert D., 1977, METHODS PRENATAL TOX, P241; NISWANDER L, 1992, DEVELOPMENT, V114, P755; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PETERS KG, 1992, DEVELOPMENT, V114, P233; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TAKUWA Y, 1991, BIOCHEM BIOPH RES CO, V174, P96, DOI 10.1016/0006-291X(91)90490-X; WANEK N, 1989, J EXP ZOOL, V249, P41, DOI 10.1002/jez.1402490109; WILKINSON DG, 1989, DEVELOPMENT, V105, P131	32	365	380	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					68	71		10.1038/361068a0	http://dx.doi.org/10.1038/361068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421496				2022-12-28	WOS:A1993KF71800050
J	SACKEIM, HA; PRUDIC, J; DEVANAND, DP; KIERSKY, JE; FITZSIMONS, L; MOODY, BJ; MCELHINEY, MC; COLEMAN, EA; SETTEMBRINO, JM				SACKEIM, HA; PRUDIC, J; DEVANAND, DP; KIERSKY, JE; FITZSIMONS, L; MOODY, BJ; MCELHINEY, MC; COLEMAN, EA; SETTEMBRINO, JM			EFFECTS OF STIMULUS-INTENSITY AND ELECTRODE PLACEMENT ON THE EFFICACY AND COGNITIVE EFFECTS OF ELECTROCONVULSIVE-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEIZURE THRESHOLD; ECT; DEPRESSION; MEMORY; DOSAGE; AGE	Background. The efficacy of electroconvulsive therapy in major depression is established, but the importance of the electrical dosage and electrode placement in relation to efficacy and side effects is uncertain. Methods. In a double-blind study, we randomly assigned 96 depressed patients to receive right unilateral or bilateral electroconvulsive therapy at either a low electrical dose (just above the seizure threshold) or a high dose (2.5 times the threshold). Symptoms of depression and cognitive functioning were assessed before, during, immediately after, and two months after therapy. Patients who responded to treatment were followed for one year to assess the rate of relapse. Results. The response rate for low-dose unilateral electroconvulsive therapy was 17 percent, as compared with 43 percent for high-dose unilateral therapy (P = 0.054), 65 percent for low-dose bilateral therapy (P = 0.001), and 63 percent for high-dose bilateral therapy (P = 0.001). Regardless of electrode placement, high dosage resulted in more rapid improvement (P<0.05). Compared with the low-dose unilateral group, the high-dose unilateral group took 83 percent longer (P<0.001) to recover orientation after seizure induction, whereas the combined bilateral groups took 252 percent longer (P<0.001). During the week after treatment, there was three times more retrograde amnesia about personal information with bilateral therapy (P<0.001). There were no differences between treatment groups in cognitive effects two months after treatment. Forty-one of the 70 patients who responded to therapy (59 percent) relapsed, and there were no differences between treatment groups. Conclusions. Increasing the electrical dosage increases the efficacy of right unilateral electroconvulsive therapy, although not to the level of bilateral therapy. High electrical dosage is associated with a more rapid response, and unilateral treatment is associated with less severe cognitive side effects after treatment.	COLUMBIA UNIV COLL PHYS & SURG, DEPT PSYCHIAT, NEW YORK, NY 10032 USA	Columbia University	SACKEIM, HA (corresponding author), NEW YORK STATE PSYCHIAT INST & HOSP, DEPT BIOL PSYCHIAT, 722 W 168TH ST, NEW YORK, NY 10032 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH035636, R01MH047739] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAHAM NG, 1986, BIOCHEM ARCH, V2, P253; ABRAMS R, 1983, AM J PSYCHIAT, V140, P463; ABRAMS R, 1991, ARCH GEN PSYCHIAT, V48, P746; ABRAMS R, 1986, ANN NY ACAD SCI, V462, P50, DOI 10.1111/j.1749-6632.1986.tb51238.x; ARONSON TA, 1987, CONVULSIVE THER, V3, P251; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V254, P2103; DECINA P, 1984, AM J PSYCHIAT, V141, P298; DELIA G, 1970, ACTA PSYCHIAT SCAND, P215; FINK M, 1982, ARCH GEN PSYCHIAT, V39, P1189; Fink M, 1979, CONVULSIVE THERAPY T; GOLD PE, 1973, SCIENCE, V179, P1343, DOI 10.1126/science.179.4080.1343; GREGORY S, 1985, BRIT J PSYCHIAT, V146, P520, DOI 10.1192/bjp.146.5.520; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; HORNE RL, 1985, ARCH GEN PSYCHIAT, V42, P1087; KARLINSKY H, 1984, J AM GERIATR SOC, V32, P183, DOI 10.1111/j.1532-5415.1984.tb01999.x; MAYEUX R, 1981, NEUROLOGY, V31, P645, DOI 10.1212/WNL.31.6.645; OTTOSSON J, 1960, ACTA PSYCHIAT SCAND, P145; OTTOSSON JO, 1991, CONVULSIVE THER, V7, P190; PETTINATI HM, 1984, BIOL PSYCHIAT, V19, P539; ROBIN A, 1982, BRIT J PSYCHIAT, V141, P357, DOI 10.1192/bjp.141.4.357; SACKEIM H, 1987, ARCH GEN PSYCHIAT, V44, P355; SACKEIM HA, 1991, PSYCHIAT CLIN N AM, V14, P803; SACKEIM HA, 1987, AM J PSYCHIAT, V144, P1449; SACKEIM HA, 1986, ANN NY ACAD SCI, V462, P326, DOI 10.1111/j.1749-6632.1986.tb51267.x; SACKEIM HA, 1990, J CLIN PSYCHOPHARM, V10, P96, DOI 10.1097/00004714-199004000-00004; SACKEIM HA, 1986, ANN NY ACAD SCI, V462, P398, DOI 10.1111/j.1749-6632.1986.tb51274.x; Sackeim HA, 1992, COGNITIVE DISORDERS, P183; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; SQUIRE LR, 1979, BIOL PSYCHIAT, V14, P791; SQUIRE LR, 1986, AM J PSYCHIAT, V143, P596; STEIF BL, 1986, BIOL PSYCHIAT, V21, P921, DOI 10.1016/0006-3223(86)90266-0; WEEKS D, 1980, BRIT J PSYCHIAT, V137, P26, DOI 10.1192/bjp.137.1.26; WEINER RD, 1986, ANN NY ACAD SCI, V462, P315, DOI 10.1111/j.1749-6632.1986.tb51266.x; WELCH CA, 1989, CONVULSIVE THER, V5, P35; WELLS DG, 1988, ANAESTH INTENS CARE, V16, P368, DOI 10.1177/0310057X8801600320; ZIELINSKI RJ, IN PRESS AM J PSYCHI; ZORMETZER S, 1974, PSYCHOBIOLOGY CONVUL, P99; 1990, PRACTICE ELECTROCONV	39	746	754	0	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	1993	328	12					839	846		10.1056/NEJM199303253281204	http://dx.doi.org/10.1056/NEJM199303253281204			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT814	8441428	Bronze			2022-12-28	WOS:A1993KT81400004
J	WERLER, MM; SHAPIRO, S; MITCHELL, AA				WERLER, MM; SHAPIRO, S; MITCHELL, AA			PERICONCEPTIONAL FOLIC-ACID EXPOSURE AND RISK OF OCCURRENT NEURAL-TUBE DEFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUPPLEMENTATION; PREVENTION; PREGNANCY; FOLATE; CLEFTS	Objectives.-A recent controlled trial has established that use of a 4-mg folic acid supplement before and during early pregnancy reduces the risk of recurrent neural tube defects (NTDs) by 72%. The present study was designed to determine whether folic acid also reduces the risk of first (occurrent) NTDs. Design.-Case-control study. Setting.-Tertiary and birth hospitals in metropolitan areas of Boston, Mass, Philadelphia, Pa, and Toronto, Ontario. Participants.-Mothers of 436 occurrent cases with NTDs and mothers of 2615 controls with other major malformations. Main Outcome Measures.-The prevalence of use of multivitamins containing folic acid was compared between mothers of cases and controls. Results.-The mothers of 17% of cases and 3% of controls reported knowledge of the folic acid-NTD hypothesis and were excluded from further analysis. For daily use of multivitamins containing folic acid in the periconceptional period (28 days before through 28 days after the last menstrual period), the relative risk (RR) (and 95% confidence interval) was 0.4 (0.2 to 0.6). The most commonly used dose of folic acid was 0.4 mg, and the RR estimate was 0.3 (95% confidence interval, 0.1 to 0.6). For dietary folate, there was a dose-related decline in risk according to the quintile of intake (P for trend=.02). Conclusion.-These findings suggest that dally periconceptional intake of 0.4 mg of folic acid (the dose most commonly contained in over-the-counter multivitamin preparations) reduces the risk of occurrent NTDs by approximately 60%. A relatively high dietary intake of folate may also reduce the risk.			WERLER, MM (corresponding author), BOSTON UNIV,SCH MED,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Mitchell, Allen/0000-0003-0950-6799; Werler, Martha/0000-0003-3392-6814	PHS HHS [MCJ-2505667] Funding Source: Medline; FDA HHS [FD-U-000082-10] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); FDA HHS		BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; ELWOOD JM, 1980, EPIDEMIOLOGY ANENCEP; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; MANTEL N, 1959, J NATL CANCER I, V22, P719; MILLS JL, 1989, NEW ENGL J MED, V321, P430, DOI 10.1056/NEJM198908173210704; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; MITCHELL AA, 1981, JAMA-J AM MED ASSOC, V245, P2311; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; SMITHELLS RW, 1983, LANCET, V1, P1027; SUBAR AF, 1990, AM J EPIDEMIOL, V132, P1091, DOI 10.1093/oxfordjournals.aje.a115752; TOLAROVA M, 1987, SCAND J PLAST RECONS, V21, P19, DOI 10.3109/02844318709083574; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; YEN IH, 1992, AM J DIS CHILD, V146, P857, DOI 10.1001/archpedi.1992.02160190089028; 1991, LANCET, V338, P131; 1971, STATISTICAL ASPECTS	15	427	434	1	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1257	1261		10.1001/jama.269.10.1257	http://dx.doi.org/10.1001/jama.269.10.1257			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437302				2022-12-28	WOS:A1993KP88500023
J	COHEN, IL; LAMBRINOS, J; FEIN, IA				COHEN, IL; LAMBRINOS, J; FEIN, IA			MECHANICAL VENTILATION FOR THE ELDERLY PATIENT IN INTENSIVE-CARE - INCREMENTAL CHARGES AND BENEFITS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIFE; AGE; SURVIVAL; FAILURE; QUALITY; COSTS; UNIT	Objective.-To evaluate the cost-effectiveness of prolonged mechanical ventilation in patients 80 years of age and older in the intensive care unit (ICU). Design.-A retrospective review of consecutive ICU patients requiring 3 or more days of mechanical ventilation. Cost-effectiveness analysis was performed by assessing incremental hospital charges from hospital billing records; charges were then related to years of life saved. A telephone survey was used to follow up hospital survivors for a minimum of 4 years after discharge. Setting.-A 20-bed medical-surgical ICU in a 420-bed, tertiary-care community teaching hospital. Patients.-The study included all patients aged 80 years or older taken from a comprehensive database of all patients admitted to the ICU requiring mechanical ventilation from April 1, 1985, through October 31, 1987 (n=512). Of 59 potential candidates, 45 were found to have complete billing records and were the subject of further analysis. Results.-Of the 45 patients in the group under analysis, 10 survived to leave the hospital. Of these, two were alive and one could not be located at the time of follow-up. The charge per year of life saved is estimated to be between $51 854 and $75 090 in 1985-1987 dollars. Of 22 patients whose age in years plus duration of mechanical ventilation in days totaled 100 or greater, only two survived hospitalization and neither was alive at follow-up. The cost per year of life saved in this subset of patients was $181 308 in 1985-1987 dollars. One of these patients was discharged to a nursing home and died there 4.5 years later, after multiple hospital readmissions. The other patient died at home 2 months after hospital discharge Conclusion.-Based on hospital charges and life expectancy, the cost-effectiveness of prolonged mechanical ventilation in ICU patients age 80 years and over was poor in our population when the combination of age and duration ot mechanical ventilation exceeded 100. Further studies using this type of analysis may prove valuable in both clinical and administrative decision-making processes.	UNION UNIV, DEPT MED, ALBANY, NY 12208 USA; UNION COLL, INST GRAD MANAGEMENT, SCHENECTADY, NY 12308 USA	Union College; Union College	COHEN, IL (corresponding author), UNION UNIV, DEPT SURG, A-162, 47 NEW SCOTLAND AVE, ALBANY, NY 12208 USA.		Fein, I. Alan/J-2576-2019					BAKER R, 1991, ANESTHESIOL CLIN N A, V9, P437; BERMAN HJ, 1990, FINANC MANAGE, P109; BOUBJERG RR, 1987, IND L REV, V19, P857; CAMPION EW, 1981, JAMA-J AM MED ASSOC, V246, P2052, DOI 10.1001/jama.246.18.2052; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; CULLEN DJ, 1977, ANESTHESIOLOGY, V47, P203, DOI 10.1097/00000542-197708000-00011; DAVIS H, 1980, JAMA-J AM MED ASSOC, V243, P43; FEDULLO AJ, 1983, CRIT CARE MED, V11, P155, DOI 10.1097/00003246-198303000-00001; GIBBS J, 1982, HEW100790110 BLU CRO; GOLDBERG AI, 1988, CHEST, V94, P1277, DOI 10.1378/chest.94.6.1277; KNAUS W A, 1989, American Review of Respiratory Disease, V140, pS8; LAMBRINOS J, 1987, MANAGING CRITICAL CA, P358; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LEAF A, 1977, NEW ENGL J MED, V297, P887, DOI 10.1056/NEJM197710202971612; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; LEGALL JR, 1982, CRIT CARE MED, V10, P575; MCLEAN RF, 1985, CRIT CARE MED, V13, P625, DOI 10.1097/00003246-198508000-00002; MOORE MJ, 1988, J POLICY ANAL MANAG, V7, P476, DOI 10.2307/3323726; NUNN JF, 1979, BRIT MED J, V1, P1525, DOI 10.1136/bmj.1.6177.1525; ODONNELL A, 1991, CHEST, V100, pS29; PESAU B, 1992, CRIT CARE MED, V20, P489, DOI 10.1097/00003246-199204000-00010; ROSEN RL, 1988, CLIN CHEST MED, V9, P163; SAGE WM, 1986, CRIT CARE MED, V14, P777, DOI 10.1097/00003246-198609000-00004; SCHMIDT CD, 1983, CRIT CARE MED, V11, P407, DOI 10.1097/00003246-198306000-00001; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; SWINBURNE AJ, 1991, CHEST, V100, pS79; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; ZAREN B, 1987, CRIT CARE MED, V15, P743, DOI 10.1097/00003246-198708000-00006; 1981, FED REG         0219, V14, P13193; 1992, EC REPORT PRESIDENT, P361; 1986, GAOHRD8625 US GEN AC; 1992, NATIONAL ISSUES FORU	32	90	94	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					1025	1029		10.1001/jama.269.8.1025	http://dx.doi.org/10.1001/jama.269.8.1025			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM603	8429584				2022-12-28	WOS:A1993KM60300032
J	PARKER, R; SILICIANO, PG				PARKER, R; SILICIANO, PG			EVIDENCE FOR AN ESSENTIAL NON-WATSON-CRICK INTERACTION BETWEEN THE 1ST AND LAST NUCLEOTIDES OF A NUCLEAR PREMESSENGER RNA INTRON	NATURE			English	Article							3' SPLICE-SITE; MAMMALIAN INTRONS; YEAST; U6; RIBONUCLEOPROTEIN; MUTATIONS; RECOGNITION; TETRAHYMENA; SEQUENCES; U2	NUCLEAR pre-messenger RNA splicing requires the action of five small nuclear (sn) RNAs, U1, U2, U4, U5 and U6, and more than 50 proteins1,2. The mechanistic similarity of nuclear pre-mRNA splicing and group II self-splicing suggests that many of the central processes of nuclear pre-mRNA splicing are based on RNA-RNA interactions3,4. To understand the mechanism of pre-mRNA splicing, the interactions, and their temporal relationships, that occur between the snRNAs and the pre-mRNA during splicing must be identified. Several snRNA-snRNA5-9 and snRNA-intron9-12 interactions have been demonstrated but the putative RNA-based interactions that recognize the AG dinucleotide at the 3' splice site during 3' cleavage and exon ligation are unknown. We report here the reciprocal suppression between 5' and 3' splice site mutations in the yeast actin intron, and propose that the 3' splice site is positioned for 3' cleavage and exon ligation, at least in part, through a non-Watson-Crick interaction between the guanosines at the 5' and 3' splice sites.	UNIV MINNESOTA, SCH MED, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	PARKER, R (corresponding author), UNIV ARIZONA, DEPT MOLEC & CELLULAR BIOL, LIFE SCI S, TUCSON, AZ 85721 USA.							AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; GREEN MA, 1991, REV CELL BIOL, V7, P559; GUTHRIE C, 1989, AM ZOOL, V29, P557; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; LESSER CF, IN PRESS GENETICS; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NEWMAN AJ, 1992, CELL, V68, P734; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZHAUNG Y, 1986, CELL CAMBRIDGE, V46, P827	29	131	131	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 18	1993	361	6413					660	662		10.1038/361660a0	http://dx.doi.org/10.1038/361660a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8437627				2022-12-28	WOS:A1993KM77600071
J	SCHMIDT, CF; SVOBODA, K; LEI, N; PETSCHE, IB; BERMAN, LE; SAFINYA, CR; GREST, GS				SCHMIDT, CF; SVOBODA, K; LEI, N; PETSCHE, IB; BERMAN, LE; SAFINYA, CR; GREST, GS			EXISTENCE OF A FLAT PHASE IN RED-CELL MEMBRANE SKELETONS	SCIENCE			English	Article							HUMAN-ERYTHROCYTE MEMBRANE; TETHERED MEMBRANES; MOLECULAR-DYNAMICS; X-RAY; FLUCTUATIONS; LAMELLAR; SURFACES; SPECTRIN; SYSTEM; SHAPE	Biomolecular membranes display rich statistical mechanical behavior. They are classified as liquid in the absence of shear elasticity in the plane of the membrane and tethered (solid) when the neighboring molecules or subunits are connected and the membranes exhibit solid-like elastic behavior in the plane of the membrane. The spectrin skeleton of red blood cells was studied as a model tethered membrane. The static structure factor of the skeletons, measured by small-angle x-ray and light scattering, was fitted with a structure factor predicted with a model calculation. The model describes tethered membrane sheets with free edges in a flat phase, which is a locally rough but globally flat membrane configuration. The fit was good for large scattering vectors. The membrane roughness exponent, zeta, defined through h is-proportional-to L(zeta), where h is the average amplitude of out-of-plane fluctuations and L is the linear membrane dimension, was determined to be 0.65 +/- 0.10. Computer simulations of model red blood cell skeletons also showed this flat phase. The value for the roughness exponent, which was determined from the scaling properties of membranes of different sizes, was consistent with that from the experiments.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT PHYS,CAMBRIDGE,MA 02138; EXXON RES & ENGN CO,ANNANDALE,NJ 08801; BROOKHAVEN NATL LAB,NATL SYNCHROTRON LIGHT SOURCE,UPTON,NY 11973; UNIV CALIF SANTA BARBARA,DEPT MAT & PHYS,SANTA BARBARA,CA 93106	Harvard University; Harvard University; Exxon Mobil Corporation; State University of New York (SUNY) System; United States Department of Energy (DOE); Brookhaven National Laboratory; University of California System; University of California Santa Barbara	SCHMIDT, CF (corresponding author), ROWLAND INST SCI INC,100 CAMBRIDGE PKWY,CAMBRIDGE,MA 02142, USA.		Schmidt, Christoph F/G-3787-2011	Schmidt, Christoph F/0000-0003-2864-6973				ABRAHAM FF, 1992, EUROPHYS LETT, V19, P293, DOI 10.1209/0295-5075/19/4/008; ABRAHAM FF, 1990, SCIENCE, V249, P393, DOI 10.1126/science.249.4967.393; ABRAHAM FF, 1989, PHYS REV LETT, V62, P1757, DOI 10.1103/PhysRevLett.62.1757; ARONOVITZ JA, 1988, PHYS REV LETT, V60, P2634, DOI 10.1103/PhysRevLett.60.2634; De Gennes P.-G., 1979, SCALING CONCEPTS POL; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; GOULIAN M, 1992, PHYS REV A, V46, pR6170, DOI 10.1103/PhysRevA.46.R6170; GREST GS, 1990, J PHYS-PARIS, V51, P1415, DOI 10.1051/jphys:0199000510130141500; HAEST CWM, 1982, BIOCHIM BIOPHYS ACTA, V694, P331, DOI 10.1016/0304-4157(82)90001-6; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; HO JS, 1989, PHYS REV LETT, V63, P1324, DOI 10.1103/PhysRevLett.63.1324; KANTOR Y, 1987, PHYS REV A, V36, P4020, DOI 10.1103/PhysRevA.36.4020; LANGE Y, 1982, J CELL BIOL, V92, P714, DOI 10.1083/jcb.92.3.714; LARCHE FC, 1986, PHYS REV LETT, V56, P1700, DOI 10.1103/PhysRevLett.56.1700; LEIBLER S, 1989, STATISTICAL MECHANIC, P45; LIPOWSKY R, 1990, PHYS REV LETT, V65, P2893, DOI 10.1103/PhysRevLett.65.2893; LIPOWSKY R, 1991, NATURE, V349, P475, DOI 10.1038/349475a0; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; NELSON DR, 1987, J PHYS-PARIS, V48, P1085, DOI 10.1051/jphys:019870048070108500; NELSON DR, 1989, STATISTICAL MECHANIC; NELSON DR, 1989, STATISTICAL MECHANIC, P137; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; ROUX D, IN PRESS MODERN ATMO; SAFINYA CR, 1989, NATO ADV SCI I B-PHY, V211, P249; SAFINYA CR, 1986, PHYS REV LETT, V57, P2718, DOI 10.1103/PhysRevLett.57.2718; SAFINYA CR, 1989, PHYS REV LETT, V62, P1134, DOI 10.1103/PhysRevLett.62.1134; SHEETZ MP, 1978, J SUPRAMOL STR CELL, V8, P399, DOI 10.1002/jss.400080403; SHEN BW, 1984, J CELL BIOL, V99, P810, DOI 10.1083/jcb.99.3.810; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SINHA SK, 1988, PHYS REV B, V38, P2297, DOI 10.1103/PhysRevB.38.2297; STOKKE BT, 1985, BIOCHIM BIOPHYS ACTA, V816, P102, DOI 10.1016/0005-2736(85)90398-0; STREY R, 1990, J CHEM SOC FARADAY T, V86, P2253, DOI 10.1039/ft9908602253; SVOBODA K, 1992, BIOPHYS J, V63, P784, DOI 10.1016/S0006-3495(92)81644-2; WEN X, 1992, NATURE, V355, P426, DOI 10.1038/355426a0	34	101	101	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					952	954		10.1126/science.8438153	http://dx.doi.org/10.1126/science.8438153			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438153				2022-12-28	WOS:A1993KL80000036
J	BONE, RC				BONE, RC			A NEW THERAPY FOR THE ADULT RESPIRATORY-DISTRESS SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NITRIC-OXIDE				BONE, RC (corresponding author), RUSH MED COLL,CHICAGO,IL 60612, USA.							ANDREADIS N, 1985, AM REV RESPIR DIS, V132, P1344; ASHBAUGH DG, 1967, LANCET, V2, P319; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BONE RC, 1989, CHEST, V96, P114, DOI 10.1378/chest.96.1.114; BONE RC, 1992, CHEST, V101, P320, DOI 10.1378/chest.101.2.320; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; Jones R. C., 1991, Proceedings. Frontiers in Education. Twenty-First Annual Conference. Engineering Education in a New World Order. (Cat. No.91CH3069-2), P179, DOI 10.1109/FIE.1991.187465; MARINI JJ, 1990, CLIN CHEST MED, V11, P673; MONCADA S, 1991, PHARMACOL REV, V43, P109; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PINSKY MR, 1989, CRIT CARE CLIN, V5, P199; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SINARD JM, 1990, J CRIT CARE, V5, P265, DOI 10.1016/0883-9441(90)90048-E	15	21	26	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					431	432		10.1056/NEJM199302113280611	http://dx.doi.org/10.1056/NEJM199302113280611			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8421462				2022-12-28	WOS:A1993KL58400011
J	JECKER, NS				JECKER, NS			PRIVACY BELIEFS AND THE VIOLENT FAMILY - EXTENDING THE ETHICAL ARGUMENT FOR PHYSICIAN INTERVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY; MEDICINE; ABUSE; WOMEN	Privacy beliefs associated with the family impede physicians' response to domestic violence. As a private sphere, the family is regarded as sacred, separate, and hidden from public view. Hence, physicians who look for or uncover violence in the family risk defiling a sacred object and violating norms of noninterference. Privacy beliefs also obfuscate the ethical analysis of physicians' duties to intercede on behalf of battered patients. Ethical principles of beneficence and nonmaleficence have been invoked to justify physicians' duties to abused patients; however, the principle of justice has not been invoked. Ethical analysis of physicians' duties in this area must be broadened to include the principle of justice. Justice is at stake because establishing conditions favorable to self-respect is a requirement of justice, and the response physicians make to battered patients carries important ramifications for supporting patients' self-respect and dignity. If justice forms part of the ethical foundation for physician intervention in domestic violence, mandatory steps that do not transgress the confidentiality of the physician-patient relationship or infringe the patient's autonomy should be taken, such as requiring domestic violence training in medical education and following treatment plans and protocols to identify abuse and provide assistance to battered patients.			JECKER, NS (corresponding author), UNIV WASHINGTON,SCH MED,DEPT MED HIST & ETH,SB-20,SEATTLE,WA 98195, USA.		Jecker, Nancy/AAJ-6303-2020	Jecker, Nancy/0000-0002-5642-748X				Bograd, 1988, FEMINIST PERSPECTIVE, P249; BOWKER LH, 1987, WOMEN HEALTH, V12, P25, DOI 10.1300/J013v12n01_03; BUCHANAN A, 1987, ETHICS, V97, P558, DOI 10.1086/292866; Burge S K, 1989, Fam Med, V21, P368; CONRAD P, 1990, SOCIOLOGY HLTH ILLNE, P141; DRACHMAN VG, 1979, HLTH CARE AM ESSAYS, P67; ELSHTAIN JB, 1974, POLIT SOC, V4, P453, DOI 10.1177/003232927400400402; Elshtain Jean B., 1981, PUBLIC MAN PRIVATE W; FLITCRAFT AH, 1992, JAMA-J AM MED ASSOC, V267, P3194, DOI 10.1001/jama.267.23.3194; FRIEDMAN LS, 1992, ARCH INTERN MED, V152, P1186, DOI 10.1001/archinte.152.6.1186; GREGORY M, 1976, VIOLENCE FAMILY, P107; HABER JD, 1985, ADV PAIN RES THER, V9, P889; JECKER NS, 1991, J MED PHILOS, V16, P285, DOI 10.1093/jmp/16.3.285; Kim D S, 1986, Health Soc Work, V11, P95; KURZ D, 1987, SOC PROBL, V34, P69, DOI 10.1525/sp.1987.34.1.03a00050; LANGHINRICHSEN J, 1992, ARCH INTERN MED, V152, P1178; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; MCLEER SV, 1987, ANN EMERG MED, V16, P1155, DOI 10.1016/S0196-0644(87)80476-6; MEHTA P, 1988, AM FAM PHYSICIAN, V37, P193; NICHOLSON L, 1986, GENDER HIST; NOVELLO AC, 1992, JAMA-J AM MED ASSOC, V267, P3132, DOI 10.1001/jama.267.23.3132; Nozick Robert, 1974, ANARCHY STATE UTOPIA; Okin S. M., 1989, JUSTICE GENDER FAMIL; OKIN SM, 1989, LIBERALISM MORAL LIF, P39; OKIN SM, 1986, MORAL FDN CIVIL RIGH, P125; Okin Susan Moller, 1991, POLITICAL THEORY TOD, P67; Rawls J., 1971, THEORY JUSTICE; RHODE D, 1989, JUSTICE GENDER; RISER SJ, 1977, ETHICS MED HIST PERS, P29; ROSALDO MZ, 1980, SIGNS, V5, P389, DOI 10.1086/493727; ROSE K, 1986, HLTH CARE WOMEN INT, V17, P427; Rosenblum N.L, 1987, ANOTHER LIBERALISM; SCHECHTER S, 1990, ABUSE VICTIMIZATION, P240; Shklar J.N., 1990, FACES INJUSTICE; SIMMEL A, 1968, INT ENCYCL SOC SCI, V12, P480; SOMMERS CH, 1986, J PHILOS, V83, P435; STARK E, 1979, INT J HEALTH SERV, V9, P461, DOI 10.2190/KTLU-CCU7-BMNQ-V2KY; Starr P, 1982, SOCIAL TRANSFORMATIO; Straus M.M.A., 1980, CLOSED DOORS VIOLENC; Strauss M.A., 1990, PHYS VIOLENCE AM FAM, P29; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P3157, DOI 10.1001/jama.267.23.3157; Walker L. E., 1979, BATTERED WOMAN; Walzer M., 1983, SPHERES JUSTICE; Warshaw C, 1989, GENDER SOC, V3, P506, DOI 10.1177/089124389003004008; 1992, CURRENT OPINIONS COU, P40; 1992, CURRENT OPINIONS COU, P25; 1988, JAMA-J AM MED ASSOC, V259, P1360; 1992, JAMA-J AM MED ASSOC, V267, P3184; 1989, MMWR, V38, P17; 1992, JAMA-J AM MED ASSOC, V267, P3190; 1982, FEDERAL RESPONSE DOM; 1992, CURRENT OPINIONS COU, pR10; IN PRESS P HOUSE DEL; 1984, COMPACT EDITION OXFO, V2, P1388	54	29	29	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					776	780		10.1001/jama.269.6.776	http://dx.doi.org/10.1001/jama.269.6.776			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KK544	8423660				2022-12-28	WOS:A1993KK54400031
J	KURODA, Y; SUZUKI, N; KATAOKA, T				KURODA, Y; SUZUKI, N; KATAOKA, T			THE EFFECT OF POSTTRANSLATIONAL MODIFICATIONS ON THE INTERACTION OF RAS2 WITH ADENYLYL CYCLASE	SCIENCE			English	Article							INSECT BACULOVIRUS SYSTEM; GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; CARBOXYL TERMINUS; FILM DETECTION; A-FACTOR; YEAST; P21RAS; GENES	Ras proteins undergo a series of posttranslational modifications that are critical for their cellular function. These modifications are necessary to anchor Ras proteins to the membrane. Yeast Ras2 proteins were purified with various degrees of modification and examined for their ability to activate their effector, adenylyl cyclase. The farnesylated intermediate form of Ras2 had more than 100 times higher affinity for adenylyl cyclase than for the unprocessed form. The subsequent palmitoylation reaction had little effect. In contrast, palmitoylation was required for efficient membrane localization of the Ras2 protein. These results indicate the importance of farnesylation in the interaction of Ras2 with its effector.	KOBE UNIV, SCH MED, DEPT PHYSIOL, 7-5-1 KUSUNOKI CHO, CHUO KU, KOBE 650, JAPAN	Kobe University								BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; FUJIYAMA A, 1991, J BIOL CHEM, V266, P17926; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; KURODA Y, UNPUB; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LOWE PN, 1990, ONCOGENE, V5, P1045; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; QUI MS, 1991, J CELL BIOL, V115, P795; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WANG JC, UNPUB; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693	44	132	135	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1993	259	5095					683	686		10.1126/science.8430318	http://dx.doi.org/10.1126/science.8430318			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430318				2022-12-28	WOS:A1993KJ68800043
J	CAI, XD; GOLDE, TE; YOUNKIN, SG				CAI, XD; GOLDE, TE; YOUNKIN, SG			RELEASE OF EXCESS AMYLOID BETA-PROTEIN FROM A MUTANT AMYLOID BETA-PROTEIN PRECURSOR	SCIENCE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; SOLUBLE DERIVATIVES; GENE; MUTATION; LOCALIZATION; PEPTIDE; BRAIN; CDNA	The 4-kilodalton amyloid beta protein (Abeta), which forms fibrillar deposits in Alzheimer's disease (AD), is derived from a large protein referred to as the amyloid beta protein precursor (betaAPP). Human neuroblastoma (M17) cells transfected with constructs expressing wild-type betaAPP or a mutant, betaAPP(DELTANL), recently linked to familial AD were compared. After continuous metabolic labeling for 8 hours, cells expressing betaAPP(DELTANL) had five times more of an Abeta-bearing, carboxyl terminal, betaAPP derivative than cells expressing wild-type betaAPP and they released six times more Abeta into the medium. Thus this mutant betaAPP may cause AD because its processing is altered in a way that releases increased amounts of Abeta.	CASE WESTERN RESERVE UNIV, INST PATHOL, DIV NEUROPATHOL, CLEVELAND, OH 44106 USA	Case Western Reserve University					NATIONAL INSTITUTE ON AGING [R01AG006656] Funding Source: NIH RePORTER; NIA NIH HHS [AG06656] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BURDICK D, 1992, J BIOL CHEM, V267, P546; CAI X, UNPUB; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; COLE GM, 1990, INT CONGR SER, V884, P113; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GLENNER G, 1983, BRANBURY REPORT, V15, P137; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1992, SCIENCE, V359, P322; HARDY J, 1991, LANCET, V337, P1342; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDD M, 1964, BRAIN, V87, P307, DOI 10.1093/brain/87.2.307; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; ROBAKIS NK, 1987, LANCET, V1, P384; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SEUBERT P, 1992, SCIENCE, V359, P325; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TERRY RD, 1963, BRAIN, V311, P528; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z	36	857	922	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					514	516		10.1126/science.8424174	http://dx.doi.org/10.1126/science.8424174			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424174				2022-12-28	WOS:A1993KJ07900034
J	CHANCE, PF; ALDERSON, MK; LEPPIG, KA; LENSCH, MW; MATSUNAMI, N; SMITH, B; SWANSON, PD; ODELBERG, SJ; DISTECHE, CM; BIRD, TD				CHANCE, PF; ALDERSON, MK; LEPPIG, KA; LENSCH, MW; MATSUNAMI, N; SMITH, B; SWANSON, PD; ODELBERG, SJ; DISTECHE, CM; BIRD, TD			DNA DELETION ASSOCIATED WITH HEREDITARY NEUROPATHY WITH LIABILITY TO PRESSURE PALSIES	CELL			English	Article							MARIE-TOOTH DISEASE; ARREST-SPECIFIC GENE; LINKAGE; TYPE-1A; MYELIN; LOCALIZATION; SEQUENCE; PROTEIN; MOUSE; MAP	Hereditary neuropathy with liability to pressure palsies (HNPP) is an autosomal dominant disorder that causes episodes of focal demyelinating neuropathy following minor trauma to peripheral nerves. We assign the HNPP locus to chromosome 17p11.2 and demonstrate the presence of a large interstitial deletion associated with this disorder in three unrelated pedigrees. De novo deletion is documented in one pedigree. The deleted region appears uniform in all pedigrees and includes the gene for peripheral myelin protein 22 (PMP-22), suggesting that underexpression of PMP-22 may cause HNPP. The deletion in HNPP spans approximately 1.5 Mb and includes all markers that are known to map within the Charcot-Marie-Tooth neuropathy type 1A (CMT1A) duplication. Furthermore, the breakpoints in HNPP and CMT1A map to the same intervals in 17p11.2, suggesting that these genetic disorders may be the result of reciprocal products of unequal crossover.	UNIV UTAH,MED CTR,DEPT NEUROL,SALT LAKE CITY,UT 84112; UNIV UTAH,MED CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,MED CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,MED CTR,MUSCULAR DYSTROPHY ASSOC,MUSCLE CLIN,SALT LAKE CITY,UT 84112; VET ADM MED CTR,SALT LAKE CITY,UT 84132; UNIV WASHINGTON,SCH MED,DEPT PATHOL,DIV GENET PATHOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,DIV NEUROL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,DIV MED GENET,SEATTLE,WA 98195; VET ADM MED CTR,SEATTLE,WA 98195	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)	CHANCE, PF (corresponding author), UNIV UTAH,MED CTR,DEPT PEDIAT,DIV MED GENET,SALT LAKE CITY,UT 84112, USA.		Chance, Phillip/AAX-5826-2020					AGUAYO AJ, 1977, NATURE, V265, P73, DOI 10.1038/265073a0; BEHSE F, 1972, BRAIN, V95, P777, DOI 10.1093/brain/95.4.777; BIRD TD, 1982, AM J HUM GENET, V34, P388; BRADLEY WG, 1975, BRAIN, V98, P381, DOI 10.1093/brain/98.3.381; BUCHBERG AM, 1989, GENETICS, V122, P153; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHANCE PF, 1992, NEUROLOGY, V42, P2295, DOI 10.1212/WNL.42.12.2295; CHANCE PF, 1990, AM J HUM GENET, V47, P915; CHANCE PF, 1992, NEUROLOGY, V42, P2037, DOI 10.1212/WNL.42.10.2037; DAVIES DM, 1954, LANCET, V2, P266; DAVISSON MT, 1978, CYTOGENET CELL GENET, V22, P552, DOI 10.1159/000131022; De Jong J, 1947, PSYCHIAT NEUROL BL A, V50, P60; DEBRUYNE J, 1980, J NEUROL SCI, V47, P385, DOI 10.1016/0022-510X(80)90091-X; DYCK PJ, 1981, ANN NEUROL, V10, P222, DOI 10.1002/ana.410100304; DYCK PJ, 1992, PERIPHERAL NEUROPATH, P1094; EARL CJ, 1964, Q J MED, V33, P481; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FISCHBECK KH, 1986, ANN NEUROL, V20, P527, DOI 10.1002/ana.410200414; GAL A, 1985, HUM GENET, V70, P38, DOI 10.1007/BF00389456; GREENBERG F, 1991, AM J HUM GENET, V49, P1207; HENRY EW, 1988, SCIENCE, V241, P344, DOI 10.1126/science.3388045; HOOGENDIJK JE, 1992, LANCET, V339, P1081, DOI 10.1016/0140-6736(92)90668-S; LEBO RV, 1992, AM J HUM GENET, V50, P42; LUPSKI JR, 1992, NAT GENET, V1, P29, DOI 10.1038/ng0492-29; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MADRID R, 1975, J NEUROL SCI, V25, P415, DOI 10.1016/0022-510X(75)90263-4; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MATSUNAMI N, 1992, NAT GENET, V1, P176, DOI 10.1038/ng0692-176; MOYZIS RK, 1987, CHROMOSOMA, V95, P375, DOI 10.1007/BF00333988; ODELBERG SJ, 1989, GENOMICS, V5, P915, DOI 10.1016/0888-7543(89)90134-1; PATEL PI, 1992, NAT GENET, V1, P157; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RAEYMAEKER SP, 1991, NEUROMUSC DIS, V1, P93; RAEYMAEKERS P, 1992, J MED GENET, V29, P5, DOI 10.1136/jmg.29.1.5; Smith A.C.M.M.L., 1982, AM J HUM GENET, V34; SMITH PP, 1992, GENE CHROMOSOME CANC, V5, P150, DOI 10.1002/gcc.2870050209; SPREYER P, 1991, EMBO J, V10, P3661, DOI 10.1002/j.1460-2075.1991.tb04933.x; STAAL A, 1965, NEUROLOGY, V15, P1008, DOI 10.1212/WNL.15.11.1008; SUTER U, 1992, P NATL ACAD SCI USA, V89, P4382, DOI 10.1073/pnas.89.10.4382; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; TIMMERMAN V, 1992, NAT GENET, V1, P171, DOI 10.1038/ng0692-171; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166; VANCE JM, 1989, EXP NEUROL, V104, P186, DOI 10.1016/S0014-4886(89)80013-5; VANCE JM, 1991, GENOMICS, V9, P623, DOI 10.1016/0888-7543(91)90355-I; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WINDEBANK AJ, 1992, PERIPHERAL NEUROPATH, P1137; WRIGHT EC, 1990, GENOMICS, V7, P103, DOI 10.1016/0888-7543(90)90524-X	48	677	703	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					143	151		10.1016/0092-8674(93)90058-X	http://dx.doi.org/10.1016/0092-8674(93)90058-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422677				2022-12-28	WOS:A1993KG95500018
J	WEBSTER, A; HAY, RT; KEMP, G				WEBSTER, A; HAY, RT; KEMP, G			THE ADENOVIRUS PROTEASE IS ACTIVATED BY A VIRUS-CODED DISULFIDE-LINKED PEPTIDE	CELL			English	Article							INFECTED-CELLS; PROTEINASE; POLYPROTEIN; TYPE-2; CLEAVAGE; POLYPEPTIDE; SPECIFICITY; EXPRESSION; COMPONENT; ACIDS	In common with many other viruses, adenoviruses code for a protease essential for the development of infectivity. Recombinant adenovirus protease was active in crude in vitro complementation assays but was inactive with peptide or purified protein substrates. Activity was reconstituted by a component of adenovirus virions, which was identified as GVQSLKRRRCF, a peptide derived from the virus protein pVI. Synthetic peptides were used to demonstrate that the cysteine is essential and that the disulphide-linked dimer is required for activity. It is proposed that the adenovirus protease is a cysteine protease and that its activation by the peptide involves thiol-disulphide interchange, which serves to expose the active site cysteine. This represents a novel strategy for controlling the activity of a protease that is required for virus maturation.			WEBSTER, A (corresponding author), UNIV ST ANDREWS, SCH BIOL & MED SCI, DIV BIOCHEM & MOLEC BIOL, ST ANDREWS KY16 9ST, FIFE, SCOTLAND.		Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024				ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; ATHERTON E, 1988, TETRAHEDRON, V44, P843, DOI 10.1016/S0040-4020(01)86121-4; BHATTI AR, 1978, BIOCHEM BIOPH RES CO, V81, P973, DOI 10.1016/0006-291X(78)91446-8; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BOUDIN ML, 1980, VIROLOGY, V101, P144, DOI 10.1016/0042-6822(80)90491-2; BROCKLEHURST K, 1973, NATURE-NEW BIOL, V242, P167, DOI 10.1038/newbio242167a0; CAI F, 1992, BIOCHIM BIOPHYS ACTA, V1129, P339, DOI 10.1016/0167-4781(92)90514-Z; CHAMBERS TJ, 1991, J VIROL, V65, P6042, DOI 10.1128/JVI.65.11.6042-6050.1991; DEGROOT RJ, 1990, EMBO J, V9, P2631, DOI 10.1002/j.1460-2075.1990.tb07445.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HELLEN CUT, 1992, EXPERIENTIA, V48, P201, DOI 10.1007/BF01923512; HIERHOLZER JC, 1991, ARCH VIROL, V121, P179, DOI 10.1007/BF01316753; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HORWITZ MS, 1990, FIELDS VIROLOGY, V2, P1723; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; LIANG YK, 1983, J MOL BIOL, V167, P217, DOI 10.1016/S0022-2836(83)80044-8; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; NOIVA R, 1992, J BIOL CHEM, V267, P3553; RUSSELL WC, 1977, J GEN VIROL, V34, P19, DOI 10.1099/0022-1317-34-1-19; SCHEIDTMANN KH, 1989, PROTEIN STRUCTURE PR, P93; Summers MD, 1987, TEXAS AGR EXP STATIO, V1555; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; TEMPERLEY SM, 1991, NUCLEIC ACIDS RES, V19, P3243, DOI 10.1093/nar/19.12.3243; TREMBLAY ML, 1983, BIOCHIM BIOPHYS ACTA, V743, P239, DOI 10.1016/0167-4838(83)90220-0; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; WEBER J, 1976, J VIROL, V17, P462, DOI 10.1128/JVI.17.2.462-471.1976; WEBSTER A, 1989, J GEN VIROL, V70, P3225, DOI 10.1099/0022-1317-70-12-3225; WEBSTER A, 1989, J GEN VIROL, V70, P3215, DOI 10.1099/0022-1317-70-12-3215; WISKERCHEN M, 1991, VIROLOGY, V184, P341, DOI 10.1016/0042-6822(91)90850-B; WOLF DH, 1992, EXPERIENTIA, V48, P117, DOI 10.1007/BF01923505; WYCKOFF EE, 1990, P NATL ACAD SCI USA, V87, P9529, DOI 10.1073/pnas.87.24.9529	34	136	141	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 15	1993	72	1					97	104		10.1016/0092-8674(93)90053-S	http://dx.doi.org/10.1016/0092-8674(93)90053-S			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422686				2022-12-28	WOS:A1993KG95500013
J	BOURDILLON, P; DAVIES, ER; ENNIS, WP; EVANS, KT; HACKING, PM; LAWS, JW; MCNULTY, MR; ROBERTS, CJ; ROBERTS, GM; SUTHERLAND, R				BOURDILLON, P; DAVIES, ER; ENNIS, WP; EVANS, KT; HACKING, PM; LAWS, JW; MCNULTY, MR; ROBERTS, CJ; ROBERTS, GM; SUTHERLAND, R			INFLUENCE OF ROYAL-COLLEGE-OF-RADIOLOGISTS GUIDELINES ON REFERRAL FROM GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure the effect on general practitioner referrals for radiography of introducing guidelines of good practice together with monitoring and peer review. Design-Collection of referral data during 1 January 1989 to 31 December 1990. Guidelines were introduced on 1 January 1990. Setting-Open access radiology services provided by one non-teaching district in England. Subjects-144614 registered patients from 22 practices. Main outcome measures-Number of referrals per 1000 registered patients for radiography of the chest, skull, spine, abdomen, limbs, and joints and for barium investigation and excretion urography. Results-Overall referrals fell from 88.4/1000 registered patients to 77.2/1000 after the guidelines were introduced. The commonest reasons for referral were for examination of the chest, spine, and limbs and joints and referrals for these fell by 9.4%, 17.5%, and 13.5% respectively. Referrals for skull radiography fell by 30% (from 241 to 168). Conclusions-By helping general practitioners to be more selective in their use of diagnostic radiology, the guidelines reduced the rate of referral and thus patients' exposure to radiation.	UNIV WALES COLL MED,DEPT EPIDEMIOL & COMMUNITY MED,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University								Barker J, 1967, J Coll Gen Pract, V13, P55; BARTON E, 1987, BRIT J RADIOL, V60, P893, DOI 10.1259/0007-1285-60-717-893; Evans S M, 1969, J R Coll Gen Pract, V17, P237; FREEMAN GK, 1983, UPDATE, V26, P403; KEOGAN MT, 1992, CLIN RADIOL, V46, P51, DOI 10.1016/S0009-9260(05)80035-2; Lloyd G, 1973, J R Coll Gen Pract, V23, P326; MAIR WJ, 1974, BMJ-BRIT MED J, V3, P732, DOI 10.1136/bmj.3.5933.732; MEIRING PDV, 1990, CLIN RADIOL, V42, P327; MILLS KA, 1983, BRIT MED J, V287, P1265, DOI 10.1136/bmj.287.6401.1265; STODDART PGP, 1989, CLIN RADIOL, V40, P183, DOI 10.1016/S0009-9260(89)80088-1; 1981, J R COLL GEN PRACT, V31, P528; 1992, BMJ, V304, P740; 1991, BMJ, V303, P809; 1990, GUIDELINES DOCTORS	14	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					110	111						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435606				2022-12-28	WOS:A1993KG46500024
J	CHAN, ATC; OBRIEN, MER				CHAN, ATC; OBRIEN, MER			HYPERSENSITIVITY TO DEXAMETHASONE	BRITISH MEDICAL JOURNAL			English	Letter											CHAN, ATC (corresponding author), ROYAL MARSDEN HOSP,DEPT MED,LONDON SW3 6JJ,ENGLAND.		Chan, Anthony Tak Cheung/R-3940-2018	Chan, Anthony Tak Cheung/0000-0002-6912-8091				ASHFORD R F U, 1980, Postgraduate Medical Journal, V56, P437; FULCHER DA, 1991, MED J AUSTRALIA, V154, P210, DOI 10.5694/j.1326-5377.1991.tb121038.x; HAYHURST M, 1978, S AFR MED J, V53, P250; MENDELSON LM, 1974, J ALLERGY CLIN IMMUN, V54, P125, DOI 10.1016/0091-6749(74)90049-9; PARTRIDGE MR, 1978, BRIT MED J, V1, P1521, DOI 10.1136/bmj.1.6126.1521	5	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					109	109		10.1136/bmj.306.6870.109	http://dx.doi.org/10.1136/bmj.306.6870.109			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435604	Green Published, Bronze			2022-12-28	WOS:A1993KG46500021
J	LAUERMANN, E				LAUERMANN, E			LONDON AFTER TOMLINSON .9. MANAGING CHANGE - THE HUMAN ASPECTS OF THE NHS	BRITISH MEDICAL JOURNAL			English	Article								Whatever ministers actually decide about London following the Tomlinson report, the changes are likely to be largescale and affect many staff and patients. Therefore how well those changes are handled becomes crucial to their success. The NHS has much to learn from other industries and organisations that have been through similar changes, Firstly, there needs to be an overall strategy for the change, rather than individual units trying to manage their own parts of it in an ad hoc way. Secondly, how well those made redundant are treated is an important factor in maintaining the morale of those who stay behind. For those affected by changes the NHS needs to provide full information, imagination, time, emotional and practical support, and money. Though decisions need to be made quickly, their implementation should take as much time as is necessary.			LAUERMANN, E (corresponding author), KINGS FUND COLL,LONDON W2 4HS,ENGLAND.							BOYDELL T, 1978, SELF DEV MANAGERS; 1980, MANAGED HEART	2	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					130	132		10.1136/bmj.306.6870.130	http://dx.doi.org/10.1136/bmj.306.6870.130			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435612	Bronze, Green Published			2022-12-28	WOS:A1993KG46500031
J	Vanravenswaaijarts, CMA; Kollee, LAA; Hopman, JCW; Stoelinga, GBA; Vangeijn, HP				Vanravenswaaijarts, CMA; Kollee, LAA; Hopman, JCW; Stoelinga, GBA; Vangeijn, HP			Heart-Rate-Variability	ANNALS OF INTERNAL MEDICINE			English	Review						Heart Rate; Autonomic Nervous System; Diabetic Neuropathies; Myocardial Infarction; Death, Sudden, Cardiac	RESPIRATORY SINUS ARRHYTHMIA; POWER SPECTRAL-ANALYSIS; ACUTE MYOCARDIAL-INFARCTION; NERVOUS-SYSTEM DYSFUNCTION; CARDIAC PARASYMPATHETIC ACTIVITY; VENTRICULAR EJECTION FRACTION; DIABETIC AUTONOMIC NEUROPATHY; COMPUTER-ASSISTED ANALYSIS; PATENT DUCTUS-ARTERIOSUS; R INTERVAL VARIABILITY	Purpose: To present an overview of the applicability of heart rate variability measurements in medicine. Data Sources: During a 4-year period all new papers concerning heart rate variability were collected. A selection of the most recent publications in the presented research area was used for this review. Data Synthesis: The amount of short- and long-term variability in heart rate reflects the vagal and sympathetic function of the autonomic nervous system, respectively. Therefore heart rate variability can be used as a monitoring tool in clinical conditions with altered autonomic nervous system function. In postinfarction and diabetic patients, low heart rate variability is associated with an increased risk for sudden cardiac death. A sympathovagal imbalance is also detectable with heart rate variability analysis in coronary artery disease and essential hypertension. Besides diabetic neuropathy, in many other neurologic disorders, such as brain damage, the Guillain-Barre syndrome, and uremic neuropathy, heart rate variability analysis can provide insight into which division of the autonomic nervous system is most affected. Heart rate variability can be influenced by various groups of drugs, but it can also shed light on the mode of action of drugs. The protective effect of cardiovascular drugs in postinfarction patients has been investigated. Conclusions: Heart rate variability analysis is easily applicable in adult medicine, but physiologic influences such as age must be considered. The most important application is the surveillance of postinfarction and diabetic patients to prevent sudden cardiac death. With heart rate variability analysis, individual therapy adjustments to achieve the most favorable sympathetic-parasympathetic balance might be possible in the future.	Univ Hosp Nijmegen, Dept Pediat, POB 9101, NL-6500 HB Nijmegen, NETHERLANDS; Free Univ Amsterdam Hosp, Dept Obstet & Gynecol, NL-1007 MB Amsterdam, NETHERLANDS	Radboud University Nijmegen; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Vanravenswaaijarts, CMA (corresponding author), Univ Hosp Nijmegen, Dept Pediat, POB 9101, NL-6500 HB Nijmegen, NETHERLANDS.		Ghiami, Zeinab/G-5492-2016; Hopman, Jeroen/A-5531-2013; Kollee, L.A.A./L-4443-2015					AARIMAA T, 1988, PEDIATR RES, V24, P745; AARIMAA T, 1985, CRIT CARE MED, V13, P9; ADINOFF B, 1992, PSYCHIAT RES, V41, P89, DOI 10.1016/0165-1781(92)90101-8; AIRAKSINEN KEJ, 1987, BRIT HEART J, V58, P592; AKSELROD S, 1985, AM J PHYSIOL, V249, pH867, DOI 10.1152/ajpheart.1985.249.4.H867; ALIMELKKILA T, 1991, ACTA ANAESTH SCAND, V35, P436, DOI 10.1111/j.1399-6576.1991.tb03324.x; ALVERSON DC, 1983, J PEDIATR-US, V102, P754, DOI 10.1016/S0022-3476(83)80252-2; ANEMA JR, 1991, J NEUROL SCI, V104, P129, DOI 10.1016/0022-510X(91)90301-M; APPEL ML, 1989, J AM COLL CARDIOL, V14, P1139, DOI 10.1016/0735-1097(89)90408-7; AXELROD S, 1987, NEPHRON, V45, P202, DOI 10.1159/000184117; BEKHEIT S, 1990, AM HEART J, V119, P79, DOI 10.1016/S0002-8703(05)80085-7; BELLAVERE F, 1985, DIABETES METAB, V11, P152; BERNARDI L, 1986, ACTA DIABETOL LAT, V23, P141, DOI 10.1007/BF02624674; BIGGER JT, 1991, J AM COLL CARDIOL, V18, P1643, DOI 10.1016/0735-1097(91)90497-W; BIGGER JT, 1988, AM J CARDIOL, V61, P208, DOI 10.1016/0002-9149(88)90917-4; BIGGER JT, 1989, AM J CARDIOL, V64, P536, DOI 10.1016/0002-9149(89)90436-0; BILLMAN GE, 1982, CIRCULATION, V66, P874, DOI 10.1161/01.CIR.66.4.874; BINKLEY PF, 1991, J AM COLL CARDIOL, V18, P464, DOI 10.1016/0735-1097(91)90602-6; CASOLO G, 1989, AM J CARDIOL, V64, P1162, DOI 10.1016/0002-9149(89)90871-0; CASOLO GC, 1992, CIRCULATION, V85, P2073, DOI 10.1161/01.CIR.85.6.2073; CLOARECBLANCHARD L, 1992, KIDNEY INT, V41, pS14; COMI G, 1990, J AUTONOM NERV SYST, V30, pS45, DOI 10.1016/0165-1838(90)90100-W; COOK JR, 1991, J AM COLL CARDIOL, V17, P480, DOI 10.1016/S0735-1097(10)80119-6; COONS S, 1985, J PEDIATR-US, V107, P728, DOI 10.1016/S0022-3476(85)80401-7; COUMEL P, 1991, EUR HEART J, V12, P412, DOI 10.1093/oxfordjournals.eurheartj.a059910; DAVIDSON NS, 1976, J PHYSIOL-LONDON, V259, P523, DOI 10.1113/jphysiol.1976.sp011480; DEHAAN J, 1971, EUR J OBSTET GYN R B, V3, P103; EKERT WD, 1974, MONATSSCHR KINDERH, V122, P643; EWING DJ, 1975, NEPHRON, V15, P424, DOI 10.1159/000180525; EWING DJ, 1986, CLIN ENDOCRINOL META, V15, P855, DOI 10.1016/S0300-595X(86)80078-0; EWING DJ, 1981, DIABETOLOGIA, V21, P18, DOI 10.1007/BF03216217; EWING DJ, 1980, Q J MED, V49, P95; EWING DJ, 1980, ANN INTERN MED, V92, P308, DOI 10.7326/0003-4819-92-2-308; FAGIUS J, 1980, J NEUROL SCI, V47, P449, DOI 10.1016/0022-510X(80)90099-4; FALLEN EL, 1988, J AUTONOM NERV SYST, V23, P199, DOI 10.1016/0165-1838(88)90094-X; FARRELL TG, 1991, J AM COLL CARDIOL, V18, P687, DOI 10.1016/0735-1097(91)90791-7; FINLEY JP, 1987, CAN J PHYSIOL PHARM, V65, P2048, DOI 10.1139/y87-320; FORSSTROM J, 1986, SCAND J CLIN LAB INV, V46, P665, DOI 10.3109/00365518609083729; FRISON JC, 1980, BRIT MED J, V281, P649, DOI 10.1136/bmj.281.6241.649; FURLAN R, 1990, CIRCULATION, V81, P537, DOI 10.1161/01.CIR.81.2.537; GOLDSTEIN DS, 1983, HYPERTENSION, V5, P86, DOI 10.1161/01.HYP.5.1.86; GROSSMAN P, 1991, PSYCHOPHYSIOLOGY, V28, P201, DOI 10.1111/j.1469-8986.1991.tb00412.x; GUZZETTI S, 1991, J HYPERTENS, V9, P831, DOI 10.1097/00004872-199109000-00010; GUZZETTI S, 1988, J HYPERTENS, V6, P711, DOI 10.1097/00004872-198809000-00004; HALLIWILL JR, 1992, AM J PHYSIOL, V262, pH1719, DOI 10.1152/ajpheart.1992.262.6.H1719; HARADA N, 1990, BRIT J IND MED, V47, P263; HARPER RM, 1987, ELECTROEN CLIN NEURO, V67, P379, DOI 10.1016/0013-4694(87)90126-X; HAYANO J, 1991, AM HEART J, V121, P1070, DOI 10.1016/0002-8703(91)90664-4; HEINONEN E, 1985, ACTA NEUROL SCAN S90, V65, P232; HIRSCH JA, 1981, AM J PHYSIOL, V241, pH620, DOI 10.1152/ajpheart.1981.241.4.H620; HORNCHEN H, 1983, J PERINAT MED, V11, P32, DOI 10.1515/jpme.1983.11.1.32; HOSKING DJ, 1978, DIABETES, V27, P1043, DOI 10.2337/diab.27.10.1043; HRUSHESKY WJM, 1991, CIRCULATION, V84, P697, DOI 10.1161/01.CIR.84.2.697; HUEY JR, 1979, AM J OBSTET GYNECOL, V134, P691, DOI 10.1016/0002-9378(79)90652-5; INOUE K, 1991, AM J PHYSIOL, V260, pH842, DOI 10.1152/ajpheart.1991.260.3.H842; INOUE K, 1990, AM J PHYSIOL, V258, pH1722, DOI 10.1152/ajpheart.1990.258.6.H1722; JENKINS JG, 1980, ACTA PAEDIATR SCAND, V69, P393, DOI 10.1111/j.1651-2227.1980.tb07098.x; JENNINGS JR, 1984, EXP AGING RES, V10, P19, DOI 10.1080/03610738408258536; KATONA PG, 1975, J APPL PHYSIOL, V39, P801, DOI 10.1152/jappl.1975.39.5.801; KERO P, 1978, PEDIATRICS, V62, P307; KIENZLE MG, 1992, AM J CARDIOL, V69, P761, DOI 10.1016/0002-9149(92)90502-P; KITNEY R I, 1982, Automedica (London), V4, P155; KITNEY RI, 1975, J THEOR BIOL, V52, P231, DOI 10.1016/0022-5193(75)90054-5; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; KLEIGER RE, 1991, AM J CARDIOL, V68, P626, DOI 10.1016/0002-9149(91)90355-O; KORVENRANTA H, 1983, BIOL NEONATE, V44, P138; KRONE RJ, 1992, ANN INTERN MED, V116, P223, DOI 10.7326/0003-4819-116-3-223; KUROIWA Y, 1983, NEUROLOGY, V33, P463, DOI 10.1212/WNL.33.4.463; KUROIWA Y, 1987, J NEUROL, V235, P65, DOI 10.1007/BF00718011; LEIPZIG TJ, 1986, NEUROSURGERY, V19, P356, DOI 10.1227/00006123-198609000-00004; LEISTNER HL, 1980, J PEDIATR-US, V97, P51, DOI 10.1016/S0022-3476(80)80129-6; LINDQVIST A, 1989, CARDIOVASC RES, V23, P262, DOI 10.1093/cvr/23.3.262; LIPSITZ LA, 1990, CIRCULATION, V81, P1803, DOI 10.1161/01.CIR.81.6.1803; LISHNER M, 1987, J AUTONOM NERV SYST, V19, P119, DOI 10.1016/0165-1838(87)90005-1; LOMBARDI F, 1992, AM HEART J, V123, P1521, DOI 10.1016/0002-8703(92)90804-5; LOMBARDI F, 1987, AM J CARDIOL, V60, P1239, DOI 10.1016/0002-9149(87)90601-1; LOWENSOHN RI, 1977, LANCET, V1, P626; LOWN B, 1976, NEW ENGL J MED, V294, P1165; MACKAY JD, 1983, DIABETOLOGIA, V24, P253; MADWED JB, 1989, AM J PHYSIOL, V256, pH1573, DOI 10.1152/ajpheart.1989.256.6.H1573; MALIK M, 1990, AM J CARDIOL, V66, P1049, DOI 10.1016/0002-9149(90)90503-S; MALIK M, 1989, INT J BIOMED COMPUT, V24, P89, DOI 10.1016/0020-7101(89)90012-3; MALIK M, 1990, CARDIOVASC RES, V24, P793, DOI 10.1093/cvr/24.10.793; MALLIANI A, 1991, CIRCULATION, V84, P482, DOI 10.1161/01.CIR.84.2.482; MALPAS SC, 1990, DIABETES, V39, P1177, DOI 10.2337/diabetes.39.10.1177; MALPAS SC, 1991, BRIT HEART J, V65, P84; MARTIN CB, 1982, CLIN PERINATOL, V9, P339, DOI 10.1016/S0095-5108(18)31029-7; MAULIK D, 1983, J PERINAT MED, V11, P243, DOI 10.1515/jpme.1983.11.5.243; MCCABE PM, 1985, PSYCHOPHYSIOLOGY, V22, P195, DOI 10.1111/j.1469-8986.1985.tb01585.x; MEHLSEN J, 1987, CLIN PHYSIOL, V7, P115, DOI 10.1111/j.1475-097X.1987.tb00153.x; MOLGAARD H, 1991, EUR HEART J, V12, P1153, DOI 10.1093/eurheartj/12.11.1153; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; MULLER JE, 1984, CIRCULATION, V69, P740, DOI 10.1161/01.CIR.69.4.740; MURATA K, 1991, INT ARCH OCC ENV HEA, V63, P335, DOI 10.1007/BF00381584; MURATA K, 1991, INT ARCH OCC ENV HEA, V63, P205, DOI 10.1007/BF00381570; MURATA K, 1991, AM J IND MED, V20, P663, DOI 10.1002/ajim.4700200509; MYERS GA, 1986, IEEE T BIO-MED ENG, V33, P1149, DOI 10.1109/TBME.1986.325694; NEUBAUER B, 1978, J NEUROL NEUROSUR PS, V41, P417, DOI 10.1136/jnnp.41.5.417; NISHIDA H, 1981, J PERINAT MED, V9, P160, DOI 10.1515/jpme.1981.9.s1.160; OBRIEN JA, 1991, Q J MED, V79, P495; ODEMUYIWA O, 1991, PACE, V14, P1986, DOI 10.1111/j.1540-8159.1991.tb02803.x; ODEMUYIWA O, 1991, AM J CARDIOL, V68, P434, DOI 10.1016/0002-9149(91)90774-F; PAGANI M, 1991, CIRCULATION, V83, P43; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; PAGANI M, 1984, J HYPERTENS        S, V2, pS383; PARER WJ, 1985, AM J OBSTET GYNECOL, V153, P402, DOI 10.1016/0002-9378(85)90078-X; PENAZ J, 1978, Automedica (London), V2, P135; Penaz J, 1968, BIOKYBERNETIK, P233; PERSSON A, 1983, ACTA NEUROL SCAND, V67, P294, DOI 10.1111/j.1600-0404.1983.tb04578.x; PETRIE RH, 1978, SEMIN PERINATOL, V2, P147; PFEIFER MA, 1982, DIABETES, V31, P339, DOI 10.2337/diabetes.31.4.339; PIHA SJ, 1991, CLIN PHYSIOL, V11, P277, DOI 10.1111/j.1475-097X.1991.tb00459.x; PIPILIS A, 1991, AM J CARDIOL, V67, P1137, DOI 10.1016/0002-9149(91)90880-T; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; PRIETSCH V, 1992, BIOL NEONATE, V61, P142; RIBBERT LSM, 1991, BRIT J OBSTET GYNAEC, V98, P820, DOI 10.1111/j.1471-0528.1991.tb13489.x; RIBBERT LSM, 1991, J PERINAT MED, V19, P53, DOI 10.1515/jpme.1991.19.1-2.53; RICH MW, 1988, AM J CARDIOL, V62, P714, DOI 10.1016/0002-9149(88)91208-8; RIMOLDI O, 1990, AM J PHYSIOL, V258, pH967, DOI 10.1152/ajpheart.1990.258.4.H967; RIZZONI D, 1991, J HYPERTENS, V9, pS84; ROSENBAUM M, 1968, AM J PHYSIOL, V215, P1397, DOI 10.1152/ajplegacy.1968.215.6.1397; ROTHER M, 1988, ACTA PHYSIOL HUNG, V71, P383; ROTHSCHILD M, 1988, AM J CARDIOL, V62, P637, DOI 10.1016/0002-9149(88)90670-4; SACHIS PN, 1981, J PEDIATR-US, V98, P278, DOI 10.1016/S0022-3476(81)80661-0; SANDS KEF, 1989, CIRCULATION, V79, P76, DOI 10.1161/01.CIR.79.1.76; SAUL JP, 1988, AM J CARDIOL, V61, P1292, DOI 10.1016/0002-9149(88)91172-1; SAYERS BM, 1973, ERGONOMICS, V16, P17; SCHECHTMAN VL, 1989, EARLY HUM DEV, V19, P167, DOI 10.1016/0378-3782(89)90077-7; SCHEFFER GJ, 1990, NEUROCARDIOVASCULAR, P124; SCHREINER W, 1991, J BIOMED ENG, V13, P313, DOI 10.1016/0141-5425(91)90113-L; SCHWARTZ JB, 1991, J GERONTOL, V46, pM99, DOI 10.1093/geronj/46.3.M99; SCHWARTZ PJ, 1992, CIRCULATION, V85, P77; SHANNON DC, 1987, AM J PHYSIOL, V253, pH874, DOI 10.1152/ajpheart.1987.253.4.H874; SIASSI B, 1979, PEDIATR RES, V13, P1163, DOI 10.1203/00006450-197910000-00017; SINGER DH, 1988, J ELECTROCARDIOL, V21, pS46, DOI 10.1016/0022-0736(88)90055-6; SMITH JH, 1988, BRIT J OBSTET GYNAEC, V95, P980, DOI 10.1111/j.1471-0528.1988.tb06501.x; SMITH SA, 1982, BRIT MED J, V285, P1599, DOI 10.1136/bmj.285.6355.1599; SOPHER SM, 1990, AM J PHYSIOL, V259, pH689, DOI 10.1152/ajpheart.1990.259.3.H689; STALBERG EV, 1989, MUSCLE NERVE, V12, P993, DOI 10.1002/mus.880121207; THALER I, 1985, ACTA OBSTET GYN SCAN, V64, P47, DOI 10.3109/00016348509154687; THOMASETH K, 1990, J AUTONOM NERV SYST, V30, pS169, DOI 10.1016/0165-1838(90)90125-3; VALLBONA C, 1965, AM J CARDIOL, V16, P379, DOI 10.1016/0002-9149(65)90729-0; Van Den Akker T. J., 1983, Automedica, V4, P201; VANDERMOER PE, 1985, OBSTET GYNECOL, V65, P125; VANGEIJN HP, 1980, AM J OBSTET GYNECOL, V136, P1061, DOI 10.1016/0002-9378(80)90638-9; VANGEIJN HP, 1980, AM J OBSTET GYNECOL, V138, P246, DOI 10.1016/0002-9378(80)90242-2; VANGEIJN HP, 1980, EUR J OBSTET GYN R B, V10, P187, DOI 10.1016/0028-2243(80)90060-X; VANHOOGENHUYZE D, 1991, AM J CARDIOL, V68, P1668, DOI 10.1016/0002-9149(91)90327-H; VANRAVENSWAAIJARTS CMA, 1991, EARLY HUM DEV, V27, P207, DOI 10.1016/0378-3782(91)90195-9; VANRAVENSWAAIJARTS CMA, 1991, EARLY HUM DEV, V27, P187, DOI 10.1016/0378-3782(91)90194-8; VISSER GHA, 1990, INT J BIOMED COMPUT, V25, P239, DOI 10.1016/0020-7101(90)90027-R; VYBIRAL T, 1990, AM J CARDIOL, V65, P604, DOI 10.1016/0002-9149(90)91038-8; WEISE F, 1990, J INTERDISCIPL CYCLE, V21, P17; WEISE F, 1990, KLIN WOCHENSCHR, V68, P26, DOI 10.1007/BF01648886; WEISE F, 1986, DRUG ALCOHOL DEPEN, V17, P365, DOI 10.1016/0376-8716(86)90086-4; WHARTON JM, 1992, TRENDS CARDIOVAS MED, V2, P65, DOI 10.1016/1050-1738(92)90007-F; WHEELER T, 1973, BRIT MED J, V4, P584, DOI 10.1136/bmj.4.5892.584; WOLF MM, 1978, MED J AUSTRALIA, V2, P52, DOI 10.5694/j.1326-5377.1978.tb131339.x; YLIHANKALA A, 1991, ACTA PHYSIOL SCAND, V141, P399, DOI 10.1111/j.1748-1716.1991.tb09097.x; YOKOYAMA A, 1991, ALCOHOL CLIN EXP RES, V15, P761, DOI 10.1111/j.1530-0277.1991.tb00595.x; ZOCCALI C, 1982, CLIN SCI, V63, P285, DOI 10.1042/cs0630285	161	519	538	3	40	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					436	447		10.7326/0003-4819-118-6-199303150-00008	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00008			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439119				2022-12-28	WOS:A1993KR81700008
J	JEWETT, JF; HECHT, FM				JEWETT, JF; HECHT, FM			PREVENTIVE HEALTH-CARE FOR ADULTS WITH HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; IMMUNE-DEFICIENCY-SYNDROME; INTRAVENOUS-DRUG-USERS; HUMAN PAPILLOMAVIRUS INFECTION; AIDS-RELATED COMPLEX; PERSISTENT GENERALIZED LYMPHADENOPATHY; PELVIC INFLAMMATORY DISEASE; PLACEBO-CONTROLLED TRIAL; FINE-NEEDLE ASPIRATION	Objective.-To assess the level of evidence for preventive health interventions for adults with human immunodeficiency virus (HIV) infection. Data Sources.-A MEDLINE literature search for each intervention, supplemented by reviewing conference proceedings and the recommendations of experts. Study Selection.-English-language studies of interventions that contribute to one of the following goals were reviewed: (1) prevention of complications of HIV infection; (2) early detection of complications, before symptoms develop, at a stage in which early treatment could lead to improved outcome; (3) slowing of HIV disease progression; (4) reduction in the risk of transmission of infectious agents, such as HIV itself; and (5) prevention of psychological distress and improvement in the quality of life. Data Extraction.-The importance of interventions and quality of supporting evidence were evaluated using criteria modified from the US Preventive Services Task Force. Data Synthesis.-Existing evidence strongly supports the efficacy of some preventive measures: primary and secondary Pneumocystis carinii pneumonia prophylaxis; secondary prophylaxis of Cryptococcus, Toxoplasma, and cytomegalovirus infections; tuberculin testing, with chemotherapy for individuals with positive test results; syphilis screening; Papanicolaou tests; educational measures to reduce the transmission of HIV and other infections; T-lymphocyte monitoring; and antiretroviral therapy in selected patients. Recommended measures of possible, but less certain, effectiveness include vaccines to prevent influenza, Haemophilus influenzae, pneumococcal, and hepatitis B infections; prophylaxis for recurrent esophageal and vaginal candidiasis; primary prophylaxis of Mycobacterium avium complex; tuberculosis prophylaxis for anergic, high-risk individuals; routine physical examination; screening for gonorrhea and Chlamydia in high-risk women; monitoring Toxoplasma titers, complete blood cell counts, and serum chemistry values; attempting to maintain weight through nutritional interventions; and exercise. Mental health and substance abuse interventions are probably very important, but documentation of their benefits is limited. Some measures require further study before they can routinely be recommended, including vitamin and mineral supplementation; specific nutritional diets; and laboratory tests, other than CD4 counts, for monitoring disease progression. Conclusions.-Persons with HIV infection have different stage-specific health maintenance needs that form an important part of comprehensive care for people in all stages of infection.	UNIV CALIF SAN FRANCISCO, SFGH, DGIM, BOX 0862, 3RD & PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA; MARTHA ELIOT HLTH CTR, BOSTON, MA USA; MONTEFIORE MED CTR, RESIDENCY PROGRAM SOCIAL MED FAC, BRONX, NY USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, BOSTON, MA 02115 USA; MONTEFIORE MED CTR, DEPT MED, BRONX, NY 10467 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco				Hecht, Frederick/0000-0002-5782-1171				ALWOOD K, 1989, 5TH INT C AIDS MONTR; AMPEL NM, 1990, 6TH INT C AIDS SAN F; ANDERSON RE, 1990, ARCH INTERN MED, V150, P73, DOI 10.1001/archinte.150.1.73; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], MMWR MORB MORTAL WKL; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BALLET JJ, 1987, CLIN EXP IMMUNOL, V68, P479; BALSDON MJ, 1988, GENITOURIN MED, V64, P124; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BAUM MK, 1991, J ACQ IMMUN DEF SYND, V4, P1122; BAUM MK, 1990, 6TH INT C AIDS SAN F; BEACH RS, 1992, AIDS, V6, P701, DOI 10.1097/00002030-199207000-00013; BEACH RS, 1992, ARCH NEUROL-CHICAGO, V49, P501, DOI 10.1001/archneur.1992.00530290089016; BEACH RS, 1991, 7TH INT C AIDS FLOR; BECKER MH, 1989, AIDS SEXUAL BEHAVIOR, P259; BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; BLOOM JN, 1988, ANN INTERN MED, V109, P963, DOI 10.7326/0003-4819-109-12-963; BLUM RN, 1992, J ACQ IMMUN DEF SYND, V5, P341; BOGDEN JD, 1990, ANN NY ACAD SCI, V587, P189, DOI 10.1111/j.1749-6632.1990.tb00146.x; BOTTLES K, 1988, ANN INTERN MED, V108, P42, DOI 10.7326/0003-4819-108-1-42; Bourgoignie J J, 1988, Adv Nephrol Necker Hosp, V17, P113; BRAMS DI, 1991, AID SHIV TREATMENT D; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; BROWN LS, 1991, 7TH INT C AIDS FLOR; BRUGUERA M, 1992, J CLIN GASTROENTEROL, V14, P27, DOI 10.1097/00004836-199201000-00007; BSUKIN SE, 1992, 8TH ITN C AIDS III S; BURCHAM J, 1991, AIDS, V5, P365, DOI 10.1097/00002030-199104000-00002; BURKES RL, 1987, EUR J HAEMATOL, V38, P141; BYRNE MA, 1989, AIDS, V3, P379, DOI 10.1097/00002030-198906000-00007; CARNE CA, 1987, BRIT MED J, V294, P866, DOI 10.1136/bmj.294.6576.866; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; CARR A, 1992, AIDS, V6, P165, DOI 10.1097/00002030-199202000-00004; CASADEVALL A, 1992, AM J MED, V92, P587, DOI 10.1016/0002-9343(92)90774-6; CASTELLANO AR, 1991, JAMA-J AM MED ASSOC, V266, P820, DOI 10.1001/jama.266.6.820; CAUMES E, 1989, 5TH INT C AIDS MONTR; CAUSSY D, 1990, INT J CANCER, V46, P214, DOI 10.1002/ijc.2910460212; CEBUL RD, 1987, ANN INTERN MED, V106, P403, DOI 10.7326/0003-4819-106-3-403; CELLO JP, 1990, MED MANAGEMENT AIDS, P145; CHAISSON RE, 1992, J ACQ IMMUN DEF SYND, V5, P456; CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; CLARK R, 1988, SOUTHERN MED J, V81, P1204, DOI 10.1097/00007611-198809000-00040; COHEN M, 1990, AM J ACUPUNCTURE, V18, P111; COLLIER AC, 1988, ANN INTERN MED, V109, P101, DOI 10.7326/0003-4819-109-2-101; CONANT MA, 1988, J AM ACAD DERMATOL, V18, P186, DOI 10.1016/S0190-9622(88)70024-9; COODLEY G, 1991, J GEN INTERN MED, V6, P472, DOI 10.1007/BF02598176; COREY L, 1992, NEW ENGL J MED, V326, P484, DOI 10.1056/NEJM199202133260710; Cotton D., 1992, AIDS Clinical Care, V4, P85; CRITCHLOW CW, 1992, ARCH INTERN MED, V152, P1673, DOI 10.1001/archinte.152.8.1673; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DEW MA, 1990, ARCH GEN PSYCHIAT, V47, P737; DINUBILE MJ, 1992, ARCH INTERN MED, V152, P1324, DOI 10.1001/archinte.152.6.1324; DOVER JS, 1991, ARCH DERMATOL, V127, P1383, DOI 10.1001/archderm.127.9.1383; DOVER JS, 1991, ARCH DERMATOL, V127, P1549, DOI 10.1001/archderm.127.10.1549; Drew W L, 1988, Infect Dis Clin North Am, V2, P495; DWORKIN BM, 1988, BIOL TRACE ELEM RES, V15, P167, DOI 10.1007/BF02990135; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FARLEY MM, 1992, ANN INTERN MED, V116, P806, DOI 10.7326/0003-4819-116-10-806; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISHER M, 1989, GUIDE CLIN PREVENTIV, P147; FLEGG PJ, 1991, AIDS, V5, P1021, DOI 10.1097/00002030-199108000-00015; FORSTER SM, 1987, AIDS, V1, P235; FRAZER IH, 1986, LANCET, V2, P657; FREEDBERG KA, 1992, J GEN INTERN MED, V7, P261, DOI 10.1007/BF02598081; FRUCHTER R, 1992, 8TH INT C AIDS III S; GALGIANI JN, 1990, J INFECT DIS, V162, P1165, DOI 10.1093/infdis/162.5.1165; GAZZARD BG, 1992, BRIT MED J, V304, P456, DOI 10.1136/bmj.304.6825.456; GESEMANN M, 1988, VIRAL HEPATITIS LIVE, P1076; GOMBERT ME, 1987, JAMA-J AM MED ASSOC, V258, P2553, DOI 10.1001/jama.258.18.2553; GORDIN F, 1992, 8TH INT C AIDS III S; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; GRANT IH, 1990, AIDS, V4, P519, DOI 10.1097/00002030-199006000-00004; GREENSPAN JS, 1988, INFECT DIS CLIN N AM, V2, P387; GREMMEN T, 1992, 8TH INT C AIDS III S; GRIFFIN PM, 1988, J INFECT DIS, V158, P668, DOI 10.1093/infdis/158.3.668; GROOPMAN JE, 1992, NEW ENGL J MED, V327, P639, DOI 10.1056/NEJM199208273270912; HAAS JS, 1990, J INFECT DIS, V162, P862, DOI 10.1093/infdis/162.4.862; HADLER SC, 1988, ANN INTERN MED, V109, P92, DOI 10.7326/0003-4819-109-2-92; HADLER SC, 1991, J INFECT DIS, V163, P454, DOI 10.1093/infdis/163.3.454; HAMBLETON J, 1990, MED MANAGEMENT AIDS, P182; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARDY WD, 1991, CLIN AIDS REV 1991, P145; HARRIMAN GR, 1989, ARCH INTERN MED, V149, P2039, DOI 10.1001/archinte.149.9.2039; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; HAY P, 1989, 5TH INT C AIDS MONTR; HEALD A, 1991, ANN INTERN MED, V115, P760, DOI 10.7326/0003-4819-115-10-760; HECKER LM, 1990, NUTR REV, V48, P393, DOI 10.1111/j.1753-4887.1990.tb02888.x; HENDERLY DE, 1987, OPHTHALMOLOGY, V94, P425; HICKS CB, 1987, ANN INTERN MED, V107, P492, DOI 10.7326/0003-4819-107-4-492; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; HOEGSBERG B, 1990, AM J OBSTET GYNECOL, V163, P1135, DOI 10.1016/0002-9378(90)90671-S; HOFMANN B, 1990, AIDS, V4, P207, DOI 10.1097/00002030-199003000-00005; HOLLAND JC, 1985, ANN INTERN MED, V103, P760, DOI 10.7326/0003-4819-103-5-760; HOOVER DR, 1992, J ACQ IMMUN DEF SYND, V5, P794; HUANG KL, 1987, JAMA-J AM MED ASSOC, V257, P2047, DOI 10.1001/jama.257.15.2047; HUEBNER RE, 1992, JAMA-J AM MED ASSOC, V267, P409, DOI 10.1001/jama.267.3.409; IMAM N, 1990, AM J MED, V89, P142, DOI 10.1016/0002-9343(90)90291-K; Israelski D M, 1988, Infect Dis Clin North Am, V2, P429; JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401; JANOFF EN, 1988, J INFECT DIS, V158, P983, DOI 10.1093/infdis/158.5.983; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; JANSSEN RS, 1988, ANN NEUROL, V23, P49, DOI 10.1002/ana.410230109; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; JOHNSON JC, 1992, OBSTET GYNECOL, V79, P321, DOI 10.1097/00006250-199203000-00001; JOHNSON PDR, 1991, AIDS, V5, P419, DOI 10.1097/00002030-199104000-00010; JUSTNUBLING G, 1991, EUR J CLIN MICROBIOL, V10, P917, DOI 10.1007/BF02005444; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KARPATKIN S, 1988, SEMIN HEMATOL, V25, P219; KASLOW RA, 1989, JAMA-J AM MED ASSOC, V261, P3424, DOI 10.1001/jama.261.23.3424; Katoff L, 1988, J Palliat Care, V4, P88; Kelly Jeffrey A., 1988, AIDS HLTH CRISIS PSY; KELLY PJ, 1990, 6TH INT C AIDS SAN F; KEMPER CA, 1990, AIDS, V4, P1145, DOI 10.1097/00002030-199011000-00015; KENT RS, 1992, COMMUNICATION   0810; KIEBURTZ KD, 1991, ARCH NEUROL-CHICAGO, V48, P312, DOI 10.1001/archneur.1991.00530150082023; KLEIN RS, 1989, J INFECT DIS, V160, P826, DOI 10.1093/infdis/160.5.826; KLEIN RS, 1989, AIDS, V3, pS161, DOI 10.1097/00002030-198901001-00024; KOTLER DP, 1991, AM J GASTROENTEROL, V86, P539; KRAMER A, 1989, J ACQ IMMUN DEF SYND, V2, P291; KRUMHOLZ HM, 1989, 5TH INT C AIDS MONTR; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LAPERRIERE AR, 1990, BIOFEEDBACK SELF-REG, V15, P229, DOI 10.1007/BF01011107; LEBOVICS E, 1988, AM J GASTROENTEROL, V83, P1; LEEN CLS, 1990, J INFECTION, V21, P55, DOI 10.1016/0163-4453(90)90646-P; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LIFSON AR, 1992, LANCET, V339, P1436, DOI 10.1016/0140-6736(92)92030-J; LOKE RHT, 1990, J MED VIROL, V31, P109, DOI 10.1002/jmv.1890310207; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MACDONELL KB, 1990, AM J MED, V89, P706, DOI 10.1016/0002-9343(90)90210-5; MACGREGOR RR, 1992, AM J MED, V92, P227, DOI 10.1016/0002-9343(92)90122-R; MAIMAN M, 1990, GYNECOL ONCOL, V38, P377, DOI 10.1016/0090-8258(90)90077-X; MAIMAN M, 1991, OBSTET GYNECOL, V78, P84; MALESSA R, 1989, 5TH INT C AIDS MONTR; MALLOLAS J, 1991, LANCET, V337, P1162, DOI 10.1016/0140-6736(91)92829-Q; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; MANTEROATIENZA E, 1991, 7TH INT C AIDS FLOR; MARTIN MA, 1992, ARCH INTERN MED, V152, P523, DOI 10.1001/archinte.152.3.523; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MATORRAS R, 1991, AM J OBSTET GYNECOL, V164, P42, DOI 10.1016/0002-9378(91)90620-7; MAYER KH, 1990, 6TH INT C AIDS SAN F; MCLAUGHLIN M, 1988, PEDIATRICS, V82, P229; MCLEISH WM, 1990, OPHTHALMOLOGY, V97, P196; MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487; MEEKER HC, 1985, J LEUKOCYTE BIOL, V38, P451, DOI 10.1002/jlb.38.4.451; MELMED RN, 1989, J ACQ IMMUN DEF SYND, V2, P70; METROKA CE, 1989, 5TH INT C AIDS MONTR; Minamoto G, 1988, Infect Dis Clin North Am, V2, P447; MINDEL A, 1988, LANCET, V1, P926; MINKOFF HL, 1991, JAMA-J AM MED ASSOC, V266, P2253; MIOTTI PG, 1989, JAMA-J AM MED ASSOC, V262, P779, DOI 10.1001/jama.262.6.779; MOSESON M, 1989, J ACQ IMMUN DEF SYND, V2, P235; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MULDER C, 1992, 8TH INT C AIDS III S; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; MUSHER DM, 1990, ANN INTERN MED, V113, P872, DOI 10.7326/0003-4819-113-11-872; NELSON KE, 1988, ANN INTERN MED, V109, P383, DOI 10.7326/0003-4819-109-5-383; NELSON MR, 1989, 5TH INT C AIDS MONTR; NIELSEN TL, 1991, 7TH INT C AIDS FLOR; NIEMAN R, 1992, 8TH INT C AIDS III S; NIGHTINGALE SD, 1992, AIDS, V6, P191, DOI 10.1097/00002030-199202000-00008; OCHS HD, 1988, J CLIN IMMUNOL, V8, P57, DOI 10.1007/BF00915157; ODEH M, 1992, J INTERN MED, V231, P463, DOI 10.1111/j.1365-2796.1992.tb00961.x; OLMSTED L, 1989, BIOL TRACE ELEM RES, V20, P59, DOI 10.1007/BF02919098; OPRAVIL M, 1991, CLIN EXP IMMUNOL, V84, P185, DOI 10.1111/j.1365-2249.1991.tb08146.x; PALEFSKY JM, 1990, JAMA-J AM MED ASSOC, V263, P2911, DOI 10.1001/jama.263.21.2911; PALESTINE AG, 1984, OPHTHALMOLOGY, V91, P1092; PEDERSEN C, 1987, BRIT MED J, V295, P567, DOI 10.1136/bmj.295.6598.567; PERRY S, 1991, ARCH GEN PSYCHIAT, V48, P143; PERRY SW, 1986, HOSP COMMUNITY PSYCH, V37, P1001; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PINCHING AJ, 1988, AIDS, V2, P335, DOI 10.1097/00002030-198810000-00002; POLIS MA, 1990, AM J MED, V89, P701, DOI 10.1016/0002-9343(90)90209-V; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; RADOLF JD, 1988, J AM ACAD DERMATOL, V18, P423, DOI 10.1016/S0190-9622(88)70062-6; RAGNI MV, 1987, J LAB CLIN MED, V109, P545; REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106; REID S, 1989, 5TH INT C AIDS MONTR; REMACHA AF, 1991, EUR J HAEMATOL, V47, P60; RHOADS JL, 1987, JAMA-J AM MED ASSOC, V257, P3105, DOI 10.1001/jama.257.22.3105; RICH JD, 1992, 8TH INT C AIDS III S; ROSENBERG PR, 1983, OPHTHALMOLOGY, V90, P874; ROTH AC, 1990, GENITOURIN MED, V66, P357; ROYCE RA, 1990, AIDS, V4, P327, DOI 10.1097/00002030-199004000-00007; RUEDY J, 1990, ANN INTERN MED, V112, P721, DOI 10.7326/0003-4819-112-10-721; SACHS MK, 1992, ARCH INTERN MED, V152, P485, DOI 10.1001/archinte.152.3.485; SAFRIN S, 1990, OBSTET GYNECOL, V75, P666; SCHAFER A, 1991, AM J OBSTET GYNECOL, V164, P593, DOI 10.1016/S0002-9378(11)80029-3; SCHLAMM HT, 1989, AM J MED, V86, P11, DOI 10.1016/0002-9343(89)90222-2; SCHLENZIG C, 1989, 5TH INT C AIDS MONTR; SCHRAGER LK, 1989, J ACQ IMMUN DEF SYND, V2, P570; SEBER R, 1990, 6TH INT C AIDS SAN F; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SHAPIRO AL, 1991, OTOLARYNG HEAD NECK, V105, P419, DOI 10.1177/019459989110500312; SHCLENZIG C, 1992, 8TH INT C AIDS III S; SHORPOSNER G, 1992, 8TH INT C AIDS III S; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SOBEL JD, 1986, NEW ENGL J MED, V315, P1455, DOI 10.1056/NEJM198612043152305; SOLOWAY B, 1992, AIDS CLIN CARE, V4, P61; SPRAUER M, 1990, 6TH INT C AIDS SAN F; SPRINZ E, 1992, 8TH INT C AIDS III S; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; STEVENS DA, 1991, ARCH INTERN MED, V151, P2458, DOI 10.1001/archinte.151.12.2458; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; TERRY PM, 1988, GENITOURIN MED, V64, P219; TORRES R, 1991, 7TH INT C AIDS FLOR; TORRES RA, 1992, 8TH INT C AIDS III S; VARDINON N, 1990, J INFECT DIS, V162, P238, DOI 10.1093/infdis/162.1.238; VERMUND SH, 1991, AM J OBSTET GYNECOL, V165, P392, DOI 10.1016/0002-9378(91)90101-V; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WADHAWAN D, 1990, 6TH INT C AIDS SAN F; WEBER R, 1990, BRIT MED J, V301, P1362, DOI 10.1136/bmj.301.6765.1362; WHEAT LJ, 1990, MEDICINE, V69, P361, DOI 10.1097/00005792-199011000-00004; WOLCOTT DL, 1986, ANN ALLERGY, V57, P95; YOULE M, 1992, 8TH INT C AIDS III S; ZANGERLE R, 1991, AIDS, V5, P985, DOI 10.1097/00002030-199108000-00010; ZICH J, 1990, PSYCHOSOCIAL PERSPEC, P201; 1990, JAMA-J AM MED ASSOC, V263, P1609; 1987, MMWR S1S, V36, pS1; 1990, JAMA-J AM MED ASSOC, V263, P1606; 1988, MMWR, V37, P486; 1991, MMWR, V40, P27; 1990, LANCET, V335, P821; 1990, MMWR, V39, P5; 1988, MMWR, V37, P600; 1986, MMWR, V35, P448; 1988, MMWR, V37, P593; 1990, GLOBAL PROGRAM AIDS; 1988, MMWR, V37, P755; [No title captured]; 1986, MMWR, V34, P227; 1990, MMWR, V39, P846; 1990, MMWR, V39, P1; 1991, LANCET, V338, P86	239	53	54	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1144	1153		10.1001/jama.269.9.1144	http://dx.doi.org/10.1001/jama.269.9.1144			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN611	8433470				2022-12-28	WOS:A1993KN61100032
J	STIELL, IG; GREENBERG, GH; MCKNIGHT, RD; NAIR, RC; MCDOWELL, I; REARDON, M; STEWART, JP; MALONEY, J				STIELL, IG; GREENBERG, GH; MCKNIGHT, RD; NAIR, RC; MCDOWELL, I; REARDON, M; STEWART, JP; MALONEY, J			DECISION RULES FOR THE USE OF RADIOGRAPHY IN ACUTE ANKLE INJURIES - REFINEMENT AND PROSPECTIVE VALIDATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY EXAMINATIONS; CLINICAL-ASSESSMENT; PREDICTION RULES; EMERGENCY; PROTOCOL; FRACTURE; PROGRAM; TRAUMA; SPRAIN	Objective.-To validate and refine previously derived clinical decision rules that aid the efficient use of radiography in acute ankle injuries. Design.-Survey prospectively administered in two stages: validation and refinement of the original rules (first stage) and validation of the refined rules (second stage). Setting.-Emergency departments of two university hospitals. Patients.-Convenience sample of adults with acute ankle injuries: 1032 of 1130 eligible patients in the first stage and 453 of 530 eligible patients in the second stage. Main Outcome Measures.-Attending emergency physicians assessed each patient for standardized clinical variables and classified the need for radiography according to the original (first stage) and the refined (second stage) decision rules. The decision rules were assessed for their ability to correctly identify the criterion standard of fractures on ankle and foot radiographic series. The original decision rules were refined by univariate and recursive partitioning analyses. Main Results.-In the first stage, the original decision rules were found to have sensitivities of 1.0 (95% confidence interval [Cl], 0.97 to 1.0) for detecting 121 malleolar zone fractures, and 0.98 (95% Cl, 0.88 to 1.0) for detecting 49 midfoot zone fractures. For interpretation of the rules in 116 patients, kappa values were 0.56 for the ankle series rule and 0.69 for the foot series rule. Recursive partitioning of 20 predictor variables yielded refined decision rules for ankle and foot radiographic series.In the second stage, the refined rules proved to have sensitivities of 1.0 (95% Cl, 0.93 to 1.0) for 50 malleolar zone fractures, and 1.0 (95% Cl, 0.83 to 1.0) for 19 midfoot zone fractures. The potential reduction in radiography is estimated to be 34% for the ankle series and 30% for the foot series. The probability of fracture, if the corresponding decision rule were ''negative,'' is estimated to be 0% (95% Cl, 0% to 0.8%) in the ankle series, and 0% (95% Cl, 0% to 0.4%) in the foot series. Conclusion.-Refinement and validation have shown the Ottawa ankle rules to be 100% sensitive for fractures, to be reliable, and to have the potential to allow physicians to safely reduce the number of radiographs ordered in patients with ankle injuries by one third. Field trials will assess the feasibility of implementing these rules into clinical practice.	ONTARIO MINIST HLTH,HLTH RES PERSONNEL DEV PROGRAM,TORONTO M5W 1R5,ONTARIO,CANADA; UNIV OTTAWA,FAC MED,DIV EMERGENCY MED,OTTAWA K1N 6N5,ONTARIO,CANADA; UNIV OTTAWA,FAC MED,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA K1N 6N5,ONTARIO,CANADA	University of Ottawa; University of Ottawa			Nair, Rama C/G-5674-2011; Reardon, Michael/ABF-8880-2021	Nair, Rama C/0000-0002-9101-0516; Stiell, Ian/0000-0002-2583-6408				ABRAMS HL, 1979, NEW ENGL J MED, V300, P1213, DOI 10.1056/NEJM197905243002110; ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BATES DW, 1990, ANN INTERN MED, V113, P495, DOI 10.7326/0003-4819-113-7-495; BEAULIEU MD, 1986, CAN MED ASSOC J, V135, P1003; BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; BRAND DA, 1982, NEW ENGL J MED, V306, P333, DOI 10.1056/NEJM198202113060604; BROOKS SC, 1981, BRIT MED J, V282, P607, DOI 10.1136/bmj.282.6264.607; CHARLSON ME, 1987, ARCH INTERN MED, V147, P2155, DOI 10.1001/archinte.147.12.2155; CIAMPI A, 1988, COMPUT METH PROG BIO, V26, P239, DOI 10.1016/0169-2607(88)90004-1; Ciampi A., 1987, TIME SERIES ECONOMET, P23; COCKSHOTT WP, 1983, CAN MED ASSOC J, V129, P129; DELACEY G, 1979, BRIT MED J, V1, P1597, DOI 10.1136/bmj.1.6178.1597; DIAMOND GA, 1989, AM J CARDIOL, V63, P99, DOI 10.1016/0002-9149(89)91084-9; DIEHR P, 1988, MED DECIS MAKING, V8, P40, DOI 10.1177/0272989X8800800106; DUNLOP MG, 1986, BRIT MED J, V293, P603, DOI 10.1136/bmj.293.6547.603; FEINSTEIN AR, 1985, ARCH INTERN MED, V145, P1257, DOI 10.1001/archinte.145.7.1257; Feinstein AR, 1987, CLINIMETRICS; Fleiss JL, 1981, STAT METHODS RATES P; GERVIN AS, 1991, AJR AM J ROENTGENOL, V157, P789; GLEADHILL DNS, 1987, BRIT MED J, V294, P943, DOI 10.1136/bmj.294.6577.943; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRATTON MC, 1990, ANN EMERG MED, V19, P497, DOI 10.1016/S0196-0644(05)82175-4; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HECKERLING PS, 1990, ANN INTERN MED, V113, P664, DOI 10.7326/0003-4819-113-9-664; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; LEE TH, 1990, J GEN INTERN MED, V5, P528, DOI 10.1007/BF02600886; LLOYD S, 1986, CAN MED ASSOC J, V135, P973; LLOYD S, 1988, CAN FAM PHYSICIAN, V34, P2261; Long A E, 1985, Emerg Med Clin North Am, V3, P437; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MATTHEWS MG, 1986, BRIT MED J, V293, P959; MCCONNOCHIE KM, 1990, PEDIATRICS, V86, P45; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; MONTAGUE AP, 1985, INJURY, V16, P545, DOI 10.1016/0020-1383(85)90082-8; POZEN MW, 1980, ANN INTERN MED, V92, P238, DOI 10.7326/0003-4819-92-2-238; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA; SIMON RR, 1987, EMERGENCY ORTHOPEDIC; Sox HC, 1988, MED DECISION MAKING; STIELL IG, 1992, CAN MED ASSOC J, V147, P1671; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; STIELL IG, 1992, AM J EMERG MED, V110, P14; SUJITKUMAR P, 1986, ARCH EMERG MED, V3, P101; SVENSON J, 1988, LANCET, V1, P244; VARGISH T, 1983, INJURY, V14, P507, DOI 10.1016/0020-1383(83)90053-0; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEST A, 1988, BR J CLIN PRACT, V43, P360; 1990, ONTARIO STATISTICAL	47	355	356	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1127	1132		10.1001/jama.269.9.1127	http://dx.doi.org/10.1001/jama.269.9.1127			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN611	8433468				2022-12-28	WOS:A1993KN61100029
J	ISEMAN, MD; COHN, DL; SBARBARO, JA				ISEMAN, MD; COHN, DL; SBARBARO, JA			DIRECTLY OBSERVED TREATMENT OF TUBERCULOSIS - WE CANT AFFORD NOT TO TRY IT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									DENVER DEPT HLTH & HOSP,DENVER,CO 80204; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	ISEMAN, MD (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206, USA.							ALBERT RK, 1976, AM REV RESPIR DIS, V114, P1051; ANASTASATU C, 1982, B INT UNION TUBERC, V52, P1; [Anonymous], 1991, Am Rev Respir Dis, V143, P700; [Anonymous], 1987, Am Rev Respir Dis, V136, P1339; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; DAVIS MS, 1967, J HEALTH SOC BEHAV, V8, P265, DOI 10.2307/2948420; HAYES RB, 1979, COMPLIANCE HLTH CARE; HUDSON LD, 1973, JAMA-J AM MED ASSOC, V223, P139, DOI 10.1001/jama.223.2.139; ISEMAN MD, 1985, AM REV RESPIR DIS, V132, P735; MCFADDEN RC, 1991, NY TIMES        1117, P20; PRABHAKER R, 1987, B INT UNION TUBERC L, V62, P21; SBARBARO JA, 1986, CHEST, V90, P754, DOI 10.1378/chest.90.5.754; SBARBARO JA, 1979, CHEST, V76, P750, DOI 10.1378/chest.76.6.750; 1990, MMWR MORB MORTAL WKL, V39, P369; 1991, MMWR MORB MORTAL WKL, V40, P585; 1985, CHEST S, V87, pS115; 1992, MMWR MORB MORTAL WKL, V41; [No title captured]; 1988, AM REV RESPIR DIS, V138, P1070; 1987, AM REV RESPIR DIS, V136, P92	23	176	176	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					576	578		10.1056/NEJM199302253280811	http://dx.doi.org/10.1056/NEJM199302253280811			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8426627				2022-12-28	WOS:A1993KP05300011
J	REISER, SJ				REISER, SJ			THE ERA OF THE PATIENT - USING THE EXPERIENCE OF ILLNESS IN SHAPING THE MISSIONS OF HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTCOMES	The emergence of an era that focuses on the experiences of individuals with illness to provide an alternative voice in health care is explored. Antecedent events that caused the eclipse of the patient and challenged the authenticity of personal experience in establishing medical facts-the introduction of the concept of diseases and the technologic revolution in medicine-are examined. Recent events that returned the patient's views to the center of medical attention-the medical ethics and outcomes movements-are analyzed and connected. Recommendations are presented to make the experience of individuals with illness significant features of health care practice, education, research, and policy, and to reverse the view of patients and subjects as individuals benefited by medicine, but unable to help it.	UNIV TEXAS,HLTH SCI CTR,INST HLTH POLICY,HOUSTON,TX 77225	University of Texas System; University of Texas Health Science Center Houston	REISER, SJ (corresponding author), UNIV TEXAS,HLTH SCI CTR,PROGRAM HUMANITIES & TECHNOL HLTH CARE,POB 20708,HOUSTON,TX 77225, USA.							BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; BOK S, 1976, NEW ENGL J MED, V295, P367, DOI 10.1056/NEJM197608122950706; CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254; DELBANCO TL, 1992, ANN INTERN MED, V116, P414, DOI 10.7326/0003-4819-116-5-414; DENTZER S, 1991, DARTMOUTH ALUMNI MAY, P16; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; F. A. D, 1900, NATURE, V62, P49, DOI [10.1038/062049a0, DOI 10.1038/062049A0]; GEIGLE R, 1990, INQUIRY-J HEALTH CAR, V27, P7; Harrison T. R., 1944, J MED ASS STATE ALA, V13, P381; Havel V., 1992, NEW YORK TIMES, P15; LOHR KN, 1988, INQUIRY-J HEALTH CAR, V25, P37; Neuhauser D, 1990, Int J Technol Assess Health Care, V6, P307; PIUS XII, 1958, POPE SPEAKS, V4, P393; Reiser S., 1978, MED REIGN TECHNOLOGY; REISER SJ, 1992, JAMA-J AM MED ASSOC, V267, P1511, DOI 10.1001/jama.267.11.1511; REISER SJ, 1991, JAMA-J AM MED ASSOC, V266, P2127, DOI 10.1001/jama.266.15.2127; SANDERS D, 1968, UCLA LAW REV, V15, P366; SYDENHAM T, 1848, WORKS T SYDENHAM, V1, P15; Yankelovich D., 1991, COMING PUBLIC JUDGME; 1973, HOSPITALS, V47, P41; 1992, QUALITY CARE ISSUES; 1992, EVALUATION OREGON ME	22	90	91	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					1012	1017		10.1001/jama.269.8.1012	http://dx.doi.org/10.1001/jama.269.8.1012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KM603	8429582				2022-12-28	WOS:A1993KM60300030
J	LUSHER, JM; ARKIN, S; ABILDGAARD, CF; SCHWARTZ, RS				LUSHER, JM; ARKIN, S; ABILDGAARD, CF; SCHWARTZ, RS			RECOMBINANT FACTOR-VIII FOR THE TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH HEMOPHILIA-A - SAFETY, EFFICACY, AND DEVELOPMENT OF INHIBITORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEPATITIS-C VIRUS; ANTIHEMOPHILIC-FACTOR; NATURAL-HISTORY; CLOTTING FACTOR; VIRAL SAFETY; ANTIBODY; CONCENTRATE; INFECTION	Background. Although methods of viral attenuation in plasma-derived clotting-factor concentrates have improved, there is still a possibility that such concentrates may transmit certain blood-borne viruses. For this reason, the use of recombinant DNA-derived factor VIII (which is virus-free) to treat hemophilia A has generated considerable interest. Methods. We conducted a multicenter trial in previously untreated children with hemophilia A. They received recombinant factor VIII for all treatment or for prophylaxis and were evaluated at their respective clinics at intervals of no more than three months. Results. Between January 1, 1989, and July 1, 1992, 95 patients who could be evaluated received recombinant factor VIII. By September 1, 1992, they had received the concentrate exclusively for 2.4 months to 3.5 years (median, 1.5 years). All responded well, with no treatment failures. A total of 3315 infusions were administered; there were three reports of minor adverse reactions. Inhibitor antibodies to factor VIII developed in 16 of 81 patients tested for them, after a median of nine days of exposure to factor VIII treatment. Inhibitor titers were or became low in 9 of the 16 patients despite continued episodic treatment with the concentrate. Inhibitors disappeared completely in 4 patients and remained at a low level (<10 Bethesda units) in 5 patients receiving episodic treatment. Conclusions. Transient or low levels of inhibitor, as observed in this study, may represent part of the natural history of hemophilia in infants. In view of the transient nature and lower concentration of the inhibitors detected and the generally satisfactory response to treatment, the benefits of recombinant factor VIII for the treatment of hemophilia seem to outweigh the risks.	MILES INC, DEPT CLIN RES, BERKELEY, CA USA; CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA; UNIV CALIF DAVIS, DAVIS, CA 95616 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of California System; University of California Davis	LUSHER, JM (corresponding author), CHILDRENS HOSP MICHIGAN, 3901 BEAUBIEN BLVD, DETROIT, MI 48201 USA.		Wilson, Matthew H/K-3193-2013					ADDIEGO JE, 1992, THROMB HAEMOSTASIS, V67, P19; AZZI A, 1992, AM J HEMATOL, V39, P228, DOI 10.1002/ajh.2830390315; BERNTORP E, 1990, LANCET, V335, P1531, DOI 10.1016/0140-6736(90)93075-Z; BRACKMANN HH, 1977, LANCET, V2, P933; BUCHANAN G, 1991, 43RD ANN M NAT HEM F; CHAN SY, 1991, SEMIN HEMATOL, V28, P10; EHRENFORTH S, 1992, LANCET, V339, P594, DOI 10.1016/0140-6736(92)90874-3; EWING NP, 1988, JAMA-J AM MED ASSOC, V259, P65, DOI 10.1001/jama.259.1.65; FOURNEL MA, 1991, SEMIN HEMATOL, V28, P22; FULCHER CA, 1987, BLOOD, V69, P1475; Gill F M, 1984, Prog Clin Biol Res, V150, P19; Hoyer L W, 1984, Prog Clin Biol Res, V150, P73; HOYER LW, 1991, BLOOD COAGUL FIBRIN, V2, P11; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KLEIM JP, 1990, THROMB HAEMOSTASIS, V64, P336; KLEIN U, 1991, SEMIN HEMATOL, V28, P17; LUSHER JM, 1987, ANN NY ACAD SCI, V509, P89, DOI 10.1111/j.1749-6632.1987.tb30987.x; LUSHER JM, 1990, SEMIN HEMATOL, V27, P1; LUSHER JM, 1991, ANN HEMATOL, V63, P138, DOI 10.1007/BF01703244; LUSHER JM, 1991, BLOOD COAGUL FIBRIN, V2, P3; LUSHER JM, 1991, BLOOD S, V78, P1409; LYON DJ, 1989, LANCET, V1, P1085; MANNUCCI PM, 1989, THROMB HAEMOSTASIS, V61, P532; MANNUCCI PM, 1990, THROMB HAEMOSTASIS, V64, P232; MCMILLAN CW, 1988, BLOOD, V71, P344; RASI V, 1990, BRIT J HAEMATOL, V76, P369, DOI 10.1111/j.1365-2141.1990.tb06370.x; RIZZA CR, 1982, BRIT J HAEMATOL, V52, P13, DOI 10.1111/j.1365-2141.1982.tb03857.x; ROBERTS HR, 1991, BLOOD COAGUL FIBRIN, V2, P21; SCANDELLA D, 1989, BLOOD, V74, P1618; SCHWARTZ RS, 1990, NEW ENGL J MED, V323, P1800, DOI 10.1056/NEJM199012273232604; SCHWARZINGER I, 1987, AM J HEMATOL, V24, P241, DOI 10.1002/ajh.2830240303; VERMYLEN J, 1991, ACTA CLIN BELG, V46, P419, DOI 10.1080/17843286.1991.11718201; WHITE GC, 1989, NEW ENGL J MED, V320, P166, DOI 10.1056/NEJM198901193200307; WHITE GC, 1982, AM J HEMATOL, V13, P335, DOI 10.1002/ajh.2830130410; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.1093/jee/39.2.269	36	430	448	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1993	328	7					453	459		10.1056/NEJM199302183280701	http://dx.doi.org/10.1056/NEJM199302183280701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM417	8421474				2022-12-28	WOS:A1993KM41700001
J	HALL, LL				HALL, LL			THE BIOLOGY OF MENTAL-DISORDERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HALL, LL (corresponding author), US CONGRESS,OFF TECHNOL ASSESSMENT,BIOL APPLICAT PROGRAM,WASHINGTON,DC 20510, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					844	844						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KL474	8426436				2022-12-28	WOS:A1993KL47400004
J	KIEBER, JJ; ROTHENBERG, M; ROMAN, G; FELDMANN, KA; ECKER, JR				KIEBER, JJ; ROTHENBERG, M; ROMAN, G; FELDMANN, KA; ECKER, JR			CTR1, A NEGATIVE REGULATOR OF THE ETHYLENE RESPONSE PATHWAY IN ARABIDOPSIS, ENCODES A MEMBER OF THE RAF FAMILY OF PROTEIN-KINASES	CELL			English	Article							COMPLETE CODING SEQUENCE; POLYMORPHISM LINKAGE MAP; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE; SIGNAL TRANSDUCTION; CONSERVED FEATURES; DOMINANT MUTATION; FORMING ENZYME; ABSCISIC-ACID; MESSENGER-RNA; THALIANA	We isolated a recessive Arabidopsis mutant, ctr1, that constitutively exhibits seedling and adult phenotypes observed in plants treated with the plant hormone ethylene. The ctr1 adult morphology can be phenocopied by treatment of wild-type plants with exogenous ethylene and is due, at least in part, to inhibition of cell elongation. Seedlings and adult ctr1 plants show constitutive expression of ethylene-regulated genes. The epistasis of ctr1 and other ethylene response mutants has defined the position of CTR1 in the ethylene signal transduction pathway. The CTR1 gene has been cloned, and the DNA sequences of four mutant alleles were determined. The gene encodes a putative serine/threonine protein kinase that is most closely related to the Raf protein kinase family.	UNIV ARIZONA, DEPT PLANT SCI, TUCSON, AZ 85721 USA	University of Arizona	KIEBER, JJ (corresponding author), UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA.		Kieber, Joseph/GLN-6328-2022; Roman, Gregg/W-1586-2019; Ecker, Joseph R/B-9144-2008	Kieber, Joseph/0000-0002-5766-812X; Roman, Gregg/0000-0003-1519-4699; Ecker, Joseph R/0000-0001-5799-5895	NIGMS NIH HHS [GM R29 38820] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeles F, 1992, ETHYLENE PLANT BIOL; ADAMS DO, 1979, P NATL ACAD SCI USA, V76, P170, DOI 10.1073/pnas.76.1.170; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BEYER EM, 1976, PLANT PHYSIOL, V58, P268, DOI 10.1104/pp.58.3.268; BITOUN R, 1990, MOL GEN GENET, V220, P234, DOI 10.1007/BF00260487; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRAAM J, 1990, CELL, V60, P357, DOI 10.1016/0092-8674(90)90587-5; BROWN JWS, 1986, NUCLEIC ACIDS RES, V14, P9549, DOI 10.1093/nar/14.24.9549; CAMPRUBI P, 1979, J HORTIC SCI, V54, P225, DOI 10.1080/00221589.1979.11514874; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; DAHNOUS K, 1982, AGRON J, V74, P580, DOI 10.2134/agronj1982.00021962007400030041x; DEIKMAN J, 1988, EMBO J, V7, P3315, DOI 10.1002/j.1460-2075.1988.tb03202.x; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; ECKER JR, 1987, P NATL ACAD SCI USA, V84, P5202, DOI 10.1073/pnas.84.15.5202; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; FELDMANN KA, 1987, MOL GEN GENET, V208, P1, DOI 10.1007/BF00330414; FUNKE G. L., 1938, BIOLOGISCH JAARBOEK, V5, P335; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; GRAY J, 1992, PLANT MOL BIOL, V19, P69, DOI 10.1007/BF00015607; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HAMILTON AJ, 1991, P NATL ACAD SCI USA, V88, P7434, DOI 10.1073/pnas.88.16.7434; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HAYNES SR, 1987, P NATL ACAD SCI USA, V84, P1819, DOI 10.1073/pnas.84.7.1819; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOLDSWORTH MJ, 1989, PLANTA, V179, P17, DOI 10.1007/BF00395766; KENDE H, 1989, PLANT PHYSIOL, V91, P1, DOI 10.1104/pp.91.1.1; KIEBER JJ, 1992, PLANT PHYSIOL, V99, P1493, DOI 10.1104/pp.99.4.1493; KLEE H, 1991, ANNU REV PLANT PHYS, V42, P529, DOI 10.1146/annurev.pp.42.060191.002525; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LUTKE HA, 1987, EMBO J, V6, P43; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; Matallana E., 1992, Methods in Arabidopsis research., P144; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MCGARVEY DJ, 1992, PLANT PHYSIOL, V98, P554, DOI 10.1104/pp.98.2.554; Messing J., 1983, GENETIC ENG PLANTS A, P211; NAKAJIMA N, 1988, PLANT CELL PHYSIOL, V29, P989; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; Neljubow D., 1901, BEIHEFTE ZUM BOT ZEN, V10, P128; OELLER PW, 1991, SCIENCE, V254, P437, DOI 10.1126/science.1925603; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PICKETT FB, 1990, PLANT PHYSIOL, V94, P1462, DOI 10.1104/pp.94.3.1462; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; RAPP UR, 1991, ONCOGENE, V6, P495; ROBERTS IN, 1985, PLANTA, V164, P439, DOI 10.1007/BF00395959; ROTHENBERG M, 1993, IN PRESS SEM DEV BIO, V4; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMAC DA, 1990, PLANT PHYSIOL, V93, P907, DOI 10.1104/pp.93.3.907; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SATO T, 1989, P NATL ACAD SCI USA, V86, P6621, DOI 10.1073/pnas.86.17.6621; SATOH S, 1983, PHYSIOL PLANTARUM, V57, P521, DOI 10.1111/j.1399-3054.1983.tb02779.x; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; SCOTT IM, 1990, PHYSIOL PLANTARUM, V78, P147, DOI 10.1111/j.1399-3054.1990.tb08729.x; SISLER EC, 1990, PLANT GROWTH REGUL, V9, P157, DOI 10.1007/BF00027443; SISLER EC, 1990, PLANT HORMONE ETHYLE, P81; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SPANU P, 1991, EMBO J, V10, P2007, DOI 10.1002/j.1460-2075.1991.tb07730.x; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STEEN DA, 1981, PLANT PHYSIOL, V67, P460, DOI 10.1104/pp.67.3.460; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; THEOLOGIS A, 1992, CELL, V70, P181, DOI 10.1016/0092-8674(92)90093-R; TREWAVAS A, 1991, TRENDS GENET, V7, P356, DOI 10.1016/0168-9525(91)90255-O; VAN DER STRAETEN D, 1990, P NATL ACAD SCI USA, V87, P4859, DOI 10.1073/pnas.87.12.4859; VANANDEL OM, 1978, J EXP BOT, V29, P638; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103	84	1459	1555	11	255	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					427	441		10.1016/0092-8674(93)90119-B	http://dx.doi.org/10.1016/0092-8674(93)90119-B			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431946	hybrid			2022-12-28	WOS:A1993KM16200012
J	SOMMER, RJ; TAUTZ, D				SOMMER, RJ; TAUTZ, D			INVOLVEMENT OF AN ORTHOLOGUE OF THE DROSOPHILA PAIR-RULE GENE HAIRY IN SEGMENT FORMATION OF THE SHORT GERM-BAND EMBRYO OF TRIBOLIUM (COLEOPTERA)	NATURE			English	Article							MOLECULAR-GENETICS; KRUPPEL; EXPRESSION; REVEALS; HUNCHBACK; HOMOLOGY; PATTERN; GAP; DNA	THE segments in long germ-band insect embryos, like Drosophila, are all determined at syncytial blastoderm stage. This is in contrast to short germ-band embryos which show an early determination of only the anterior head segments, whereas the more posterior thoracic and abdominal segments are sequentially added after formation of a primary germ anlage (reviewed in ref. 1). Segment formation in Drosophila involves the pair-rule genes which define double segmental periodicities2,3 and which have been considered to represent a special adaptation to the long germ-band type development4,5 hairy belongs to the primary pair-rule genes in Drosophila which are directly regulated by the gap genes, such as Kruppel6-13. We have isolated the orthologues of hairy and Kruppel from the flour beetle Tribolium castaneum which has a short germ type development14. We show here that hairy is expressed in several stripes at blastoderm stage and later on in two stripes in the growth zone of the developing embryo. Kruppel expression overlaps hairy stripe three and four expression, very similar to Drosophila. This suggests that the segment patterning mechanism that acts in an open blastoderm in Drosophila works in a similar way in the cellularized Tribolium embryo.	UNIV MUNICH,INST ZOOL,W-8000 MUNICH 2,GERMANY	University of Munich			Tautz, Diethard/D-4304-2011; Tautz, Diethard/H-8436-2014	Tautz, Diethard/0000-0002-0460-5344				AKAM M, 1992, Current Biology, V2, P395, DOI 10.1016/0960-9822(92)90313-Y; BROWN SJ, 1990, INSECT BIOCHEM, V20, P185, DOI 10.1016/0020-1790(90)90011-I; COUNCE SJA, 1961, REV ENTOMOL, V6, P295; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; HOOPER KL, 1989, DEVELOPMENT, V107, P489; HOWARD KR, 1990, DEVELOPMENT, V110, P1223; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; INGHAM PW, 1986, EMBO J, V5, P1659, DOI 10.1002/j.1460-2075.1986.tb04409.x; KRAUSE GERHARa, 1939, BIOL ZENTMLBI, V59, P495; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PANKRATZ MJ, 1990, TRENDS GENET, V6, P287, DOI 10.1016/0168-9525(90)90234-W; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; Patel Nipam H., 1992, P377; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; RIDDIHOUGH G, 1991, GENE DEV, V5, P840, DOI 10.1101/gad.5.5.840; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sander K., 1976, Advances in insect physiology. Volume 12., P125, DOI 10.1016/S0065-2806(08)60255-6; Sokoloff A, 1972, BIOL TRIBOLIUM; SOMMER RJ, 1992, P NATL ACAD SCI USA, V89, P10782, DOI 10.1073/pnas.89.22.10782; STANLEY MSM, 1970, ANN ENTOMOL SOC AM, V63, P1248, DOI 10.1093/aesa/63.5.1248; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAUTZ D, 1986, NATURE, V322, P652, DOI 10.1038/322652a0; TREIER M, 1989, EMBO J, V8, P1517, DOI 10.1002/j.1460-2075.1989.tb03536.x	28	143	143	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					448	450		10.1038/361448a0	http://dx.doi.org/10.1038/361448a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8429884				2022-12-28	WOS:A1993KK71300060
J	GRIMALDI, CH; NELSON, RG; PETTITT, DJ; SAMPLINER, RE; BENNETT, PH; KNOWLER, WC				GRIMALDI, CH; NELSON, RG; PETTITT, DJ; SAMPLINER, RE; BENNETT, PH; KNOWLER, WC			INCREASED MORTALITY WITH GALLSTONE DISEASE - RESULTS OF A 20-YEAR POPULATION-BASED SURVEY IN PIMA-INDIANS	ANNALS OF INTERNAL MEDICINE			English	Article						CHOLELITHIASIS; INDIANS, NORTH AMERICAN; MORTALITY; ARIZONA; GALLBLADDER NEOPLASMS	CORONARY HEART-DISEASE; GALLBLADDER CANCER; HIGH PREVALENCE; COLON CANCER; BILE-ACIDS; DIABETES-MELLITUS; NATURAL-HISTORY; RISK-FACTORS; LARGE BOWEL; CHOLECYSTECTOMY	Objective: To determine if gallstone disease is associated with an increased risk for malignancy and higher total mortality in Pima Indians. Design: Inception cohort. Setting: American Indian community. Participants: Age- and sex-stratified random population-based sample. Measurements: Between 1966 and 1969, an age- and sex-stratified random sample of Pima Indians from the Gila River Indian Community in Arizona was examined to identify evidence of gallstone disease defined as either gallstones (oral cholecystography) or previous cholecystectomy. During 20 years of follow-up, deaths were recorded and underlying causes of death, according to death certificates, were determined. Results: Among 383 persons with known gallbladder status, 186 (49%) died: 133 among the 222 persons with gallstone disease and 53 among the 161 without. The overall death rate was higher in persons with gallstone disease than in those with normal gallbladders. The age- and sex-adjusted death rate ratio was 1.9 (95% CI, 1.3 to 2.7). Furthermore, the death rate attributed to malignancies was 6.6 times (CI, 1.3 to 33.1) as high in persons with gallstone disease as in those with normal gallbladders. Of the 20 fatal malignancies in persons with gallstone disease, 11 occurred in the digestive tract, of which six involved the gallbladder or bile ducts. Conclusions: Increased cancer mortality and total mortality were found in Pima Indians with gallstone disease. Although plausible explanations exist for the increased cancer mortality, the increased death rates due to other causes are unexplained. Whether cholecystectomy would change this risk is unknown.	NIDDKD, PHOENIX EPIDEMIOL & CLIN RES BRANCH, PHOENIX, AZ USA; CLEVELAND CLIN EDUC FDN, CLEVELAND, OH 44106 USA; VET AFFAIRS MED CTR, TUCSON, AZ USA; UNIV ARIZONA, TUCSON, AZ 85721 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Cleveland Clinic Foundation; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; University of Arizona	GRIMALDI, CH (corresponding author), HOP CIMIEZ, 4 AV REINE VICTORIA, F-06000 NICE, FRANCE.		Bennett, Peter/AAH-9605-2021; Nelson, Robert G/B-1470-2012					ADAMI HO, 1983, GASTROENTEROLOGY, V85, P859; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; [Anonymous], 1978, INT CLASSIFICATION D; BAGHERI SA, 1978, GASTROENTEROLOGY, V74, P188; BAKER HL, 1960, RADIOLOGY, V74, P239, DOI 10.1148/74.2.239; BARBARA L, 1987, HEPATOLOGY, V7, P913, DOI 10.1002/hep.1840070520; BENNETT PH, 1971, LANCET, V2, P125; BORTNICHAK EA, 1985, AM J EPIDEMIOL, V121, P19, DOI 10.1093/oxfordjournals.aje.a113978; BREUER NF, 1988, DIGESTION, V40, P219, DOI 10.1159/000199658; CAPRON JP, 1978, GASTROEN CLIN BIOL, V2, P383; COMESS LJ, 1967, NEW ENGL J MED, V277, P894, DOI 10.1056/NEJM196710262771702; COMFORT MW, 1948, ANN SURG, V128, P931, DOI 10.1097/00000658-194811000-00005; COX DR, 1972, J R STAT SOC B, V34, P187; DIEHL AK, 1980, J NATL CANCER I, V65, P1209; DIEHL AK, 1988, ANN INTERN MED, V108, P157, DOI 10.7326/0003-4819-108-1-157; DIEHL AK, 1987, AM J PUBLIC HEALTH, V77, P841, DOI 10.2105/AJPH.77.7.841; EHNMARK E, 1939, ACTA CHIR SCAND    S, V57, P1; ENGLAND DM, 1977, J CLIN MICROBIOL, V6, P494; Gomand L, 1966, Tijdschr Gastroenterol, V9, P594; GRACIE WA, 1982, NEW ENGL J MED, V307, P798, DOI 10.1056/NEJM198209233071305; Gracie WA, 1985, GALLSTONES, P27; HILL MJ, 1975, CANCER, V36, P2387, DOI 10.1002/1097-0142(197512)36:6<2387::AID-CNCR2820360618>3.0.CO;2-4; HYVARINEN H, 1987, HEPATO-GASTROENTEROL, V34, P280; INGELFINGER JA, 1976, DIABETES, V25, P561, DOI 10.2337/diabetes.25.7.561; KALIMA T, 1982, AM J SURG, V144, P531, DOI 10.1016/0002-9610(82)90574-8; KIMURA W, 1989, AM J GASTROENTEROL, V84, P386; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; KNOWLER WC, 1984, EPIDEMIOLOGY PREVENT, P85; LINOS DA, 1982, CANCER-AM CANCER SOC, V50, P1015, DOI 10.1002/1097-0142(19820901)50:5<1015::AID-CNCR2820500533>3.0.CO;2-8; LINOS DA, 1981, LANCET, V2, P379; LOWENFELS AB, 1982, GASTROENTEROLOGY, V83, P672; LOWENFELS AB, 1985, JNCI-J NATL CANCER I, V75, P77; LOWENFELS AB, 1980, GUT, V21, P1090, DOI 10.1136/gut.21.12.1090; LUND J, 1960, ANN SURG, V151, P153, DOI 10.1097/00000658-196002000-00001; MARINGHINI A, 1987, ANN INTERN MED, V107, P30, DOI 10.7326/0003-4819-107-1-30; MAURER KR, 1990, AM J EPIDEMIOL, V131, P836, DOI 10.1093/oxfordjournals.aje.a115574; MCSHERRY CK, 1985, ANN SURG, V202, P59; NAGENGAST FM, 1988, SCAND J GASTROENTERO, V23, P76, DOI 10.3109/00365528809095955; NELSON RG, 1990, CIRCULATION, V81, P987, DOI 10.1161/01.CIR.81.3.987; PETERSON R, 1915, SURG GYNECOL OBSTET, V20, P284; RALSTON D E, 1965, Minn Med, V48, P327; REDDY BS, 1977, CANCER-AM CANCER SOC, V39, P2533, DOI 10.1002/1097-0142(197706)39:6<2533::AID-CNCR2820390634>3.0.CO;2-X; SAMPLINER RE, 1970, NEW ENGL J MED, V283, P1358, DOI 10.1056/NEJM197012172832502; SCHWESINGER WH, 1985, ANN SURG, V201, P319, DOI 10.1097/00000658-198503000-00011; SCRAGG RKR, 1984, BRIT MED J, V288, P1113, DOI 10.1136/bmj.288.6424.1113; SHIMADA K, 1977, J INFECT DIS, V135, P850, DOI 10.1093/infdis/135.5.850; SIEVERS ML, 1967, ANN INTERN MED, V67, P800, DOI 10.7326/0003-4819-67-4-800; SIEVERS ML, 1990, J CLIN EPIDEMIOL, V43, P1231, DOI 10.1016/0895-4356(90)90024-J; THORNTON J, 1983, LANCET, V2, P819; TURNBULL PRG, 1981, BRIT J SURG, V68, P551, DOI 10.1002/bjs.1800680810; VERNICK LJ, 1981, LANCET, V2, P381; WEISS NS, 1982, CANCER-AM CANCER SOC, V48, P1713, DOI 10.1002/1097-0142(19820415)49:8<1713::AID-CNCR2820490830>3.0.CO;2-Y; WHITEHOUSE WM, 1955, SURG GYNECOL OBSTET, V100, P211; 1985, TECHNICAL REPORT SER, V727; 1968, PHS PUBLICATION, V1693	55	28	27	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					185	190		10.7326/0003-4819-118-3-199302010-00005	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8417635				2022-12-28	WOS:A1993KJ43900005
J	LOUIS, JC; MAGAL, E; TAKAYAMA, S; VARON, S				LOUIS, JC; MAGAL, E; TAKAYAMA, S; VARON, S			CNTF PROTECTION OF OLIGODENDROCYTES AGAINST NATURAL AND TUMOR NECROSIS FACTOR-INDUCED DEATH	SCIENCE			English	Article							CILIARY NEUROTROPHIC FACTOR; CENTRAL-NERVOUS-SYSTEM; RAT OPTIC-NERVE; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ASTROCYTE PROGENITOR CELLS; MULTIPLE-SCLEROSIS; REGIONAL DISTRIBUTION; NEURONAL SURVIVAL; FACTOR-ALPHA; BRAIN	A proportion of developing oligodendrocytes undergo natural cell death by apoptosis, and mature oligodendrocytes die, either by apoptosis or necrosis, in response to injurious signals such as cytotoxic cytokines and complement. Ciliary neurotrophic factor (CNTF), a trophic factor found in astrocytes in the central nervous system (CNS), promoted the survival and maturation of cultured oligodendrocytes. This trophic factor also protected oligodendrocytes from death induced by tumor necrosis factors (apoptosis) but not against complement (necrosis). These results suggest that CNTF functions in the survival of oligodendrocytes during development and may lead to therapeutic approaches for degenerative diseases of the CNS that involve oligodendrocyte destruction.			LOUIS, JC (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				NINDS NIH HHS [NS16349] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016349] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABNEY ER, 1981, DEV BIOL, V83, P301, DOI 10.1016/0012-1606(81)90476-0; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARBIN G, 1984, J NEUROCHEM, V43, P146; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARNES BA, 1992, CELL, V70, P31; COMPSTON DAS, 1991, TRENDS NEUROSCI, V14, P175; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; CUNNINGHAM TJ, 1982, INT REV CYTOL, V74, P163, DOI 10.1016/S0074-7696(08)61172-9; DUBOISDALCQ M, 1990, BIOESSAYS, V12, P569, DOI 10.1002/bies.950121203; DUBOISDALCQ M, 1987, EMBO J, V6, P2527; ELLISON MD, 1991, J NEUROIMMUNOL, V33, P245, DOI 10.1016/0165-5728(91)90112-K; FRANCIOTTA DM, 1989, ANN NEUROL, V26, P787, DOI 10.1002/ana.410260618; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GRIMALDI LME, 1991, ANN NEUROL, V29, P21, DOI 10.1002/ana.410290106; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; IP NY, 1991, J NEUROSCI, V11, P3124; JOHNSON EM, 1989, NEUROBIOL AGING, V10, P549, DOI 10.1016/0197-4580(89)90127-9; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAM A, 1991, GENE, V102, P271, DOI 10.1016/0378-1119(91)90089-T; LILLIE TH, 1988, J AM MOSQUITO CONTR, V4, P485; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; LOUIS JC, IN PRESS DEV BIOL; MAGAL E, 1991, J NEUROSCI RES, V30, P560, DOI 10.1002/jnr.490300314; MAGAL E, 1991, DEV BRAIN RES, V63, P141, DOI 10.1016/0165-3806(91)90074-S; MAIMONE D, 1991, NEUROIMMUNOL, V32, P67; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; McFarland H F, 1988, Ann N Y Acad Sci, V540, P99, DOI 10.1111/j.1749-6632.1988.tb27055.x; MCMORRIS FA, 1988, J NEUROSCI RES, V21, P199, DOI 10.1002/jnr.490210212; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MERRILL JE, 1990, ANN NY ACAD SCI, V594, P188; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MERRILL JE, 1989, J CLIN IMMUNOL, V9, P84, DOI 10.1007/BF00916935; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; MOLINA JM, 1989, J CLIN INVEST, V84, P733, DOI 10.1172/JCI114230; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; POSER CM, 1992, J NEUROL SCI, V107, P127, DOI 10.1016/0022-510X(92)90280-X; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAINE CS, 1970, J NEUROPATH EXP NEUR, V29, P177, DOI 10.1097/00005072-197004000-00002; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; REYNOLDS R, 1988, DEVELOPMENT, V102, P409; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SCOLDING NJ, 1992, NEUROSCI LETT, V135, P95, DOI 10.1016/0304-3940(92)90144-V; SCOLDING NJ, 1989, NATURE, V339, P620, DOI 10.1038/339620a0; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; SMALL RK, 1987, NATURE, V328, P155, DOI 10.1038/328155a0; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; TSUKADA N, 1991, J NEUROL SCI, V102, P230; WAKSMAN BH, 1984, ANN NY ACAD SCI, V436, P125, DOI 10.1111/j.1749-6632.1984.tb14783.x; WREN DR, 1989, P NATL ACAD SCI USA, V86, P9025, DOI 10.1073/pnas.86.22.9025	65	450	463	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					689	692		10.1126/science.8430320	http://dx.doi.org/10.1126/science.8430320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430320				2022-12-28	WOS:A1993KJ68800045
J	MAHAN, MJ; SLAUCH, JM; MEKALANOS, JJ				MAHAN, MJ; SLAUCH, JM; MEKALANOS, JJ			SELECTION OF BACTERIAL VIRULENCE GENES THAT ARE SPECIFICALLY INDUCED IN HOST TISSUES	SCIENCE			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; SEQUENCE; DETERMINANTS; MUTATIONS; AVIRULENT; STRAINS	A genetic system was devised that positively selects for bacterial genes that are specifically induced when bacteria infect their host. With the pathogen Salmonella typhimurium, the genes identified by this selection show a marked induction in bacteria recovered from mouse spleen. Mutations in all ivi (in vivo-induced) genes that were tested conferred a defect in virulence. This genetic system was designed to be of general use in a wide variety of bacterial-host systems and has several applications in both vaccine and antimicrobial drug development.			MAHAN, MJ (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115, USA.				NIAID NIH HHS [AI08245, AI26289] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026289] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASELSKI VS, 1978, INFECT IMMUN, V22, P181, DOI 10.1128/IAI.22.1.181-188.1978; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORMAN CJ, 1987, J BACTERIOL, V169, P3840, DOI 10.1128/jb.169.8.3840-3843.1987; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GLANSDORFF N, 1987, ESCHERICHIA COLI SAL, P321; HUGHES KT, 1988, GENETICS, V119, P9; IVANOVICS G, 1968, J BACTERIOL, V85, P147; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; LEUNK RD, 1982, INFECT IMMUN, V36, P1168, DOI 10.1128/IAI.36.3.1168-1174.1982; LEVINE HB, 1958, J IMMUNOL, V81, P433; LOCKMAN HA, 1992, INFECT IMMUN, V60, P491, DOI 10.1128/IAI.60.2.491-496.1992; Makela P. H., 1984, HDB ENDOTOXIN, P59; MCFARLAND WC, 1987, MICROB PATHOGENESIS, V3, P129, DOI 10.1016/0882-4010(87)90071-4; MECHULAM Y, 1985, J BACTERIOL, V163, P787, DOI 10.1128/JB.163.2.787-791.1985; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; NNALUE NA, 1990, INFECT IMMUN, V58, P2493, DOI 10.1128/IAI.58.8.2493-2501.1990; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; PLUMBRIDGE JA, 1980, J MOL BIOL, V144, P595, DOI 10.1016/0022-2836(80)90341-1; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STOCKER BAD, 1988, VACCINE, V6, P141, DOI 10.1016/S0264-410X(88)80017-3; STRALEY SC, 1984, INFECT IMMUN, V45, P649, DOI 10.1128/IAI.45.3.649-654.1984	24	551	613	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					686	688		10.1126/science.8430319	http://dx.doi.org/10.1126/science.8430319			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430319				2022-12-28	WOS:A1993KJ68800044
J	PECHURA, CM				PECHURA, CM			THE HEALTH-EFFECTS OF MUSTARD GAS AND LEWISITE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											PECHURA, CM (corresponding author), INST MED,COMM SURVEY HLTH EFFECTS MUSTARD GAS & LEWISITE,ROOM FO-3036,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.							1993, VETERANS RISK HLTH E; 1992, FED REG         0731; 1992, FED REG         0115	3	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					453	453		10.1001/jama.269.4.453	http://dx.doi.org/10.1001/jama.269.4.453			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8419656				2022-12-28	WOS:A1993KH38500005
J	PRUMMEL, MF; WIERSINGA, WM				PRUMMEL, MF; WIERSINGA, WM			SMOKING AND RISK OF GRAVES-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTOIMMUNE THYROID-DISEASE; CIGARETTE-SMOKING; OPHTHALMOPATHY; THYROGLOBULIN; ASSOCIATION; LYMPHOCYTES; GOITER	Objective.-To assess if smoking is associated with Graves' disease and, if so, to ascertain whether this association persists when controlling for confounding factors. Design.-Consecutive entry case-control study with two age- and sex-matched control subjects from two different populations per case patient. Setting.-University hospital. Patients.-Five groups were studied: (1) Graves' ophthalmopathy and Graves' hyperthyroidism (n=100; divided in four subgroups according to the severity of the eye disease); (2) Graves' hyperthyroidism without clinical eye involvement (n=100); (3) sporadic nontoxic goiter (n=100); (4) autoimmune hypothyroidism (n=75); and (5) toxic nodular goiter (n=75). The study comprised 200 subjects from a hospital-based population, and 200 from a population-based group served as control subjects. Main Outcome Measure.-Smoking status was determined from a questionnaire at the time of onset of the disease to exclude any effect of the disease itself on smoking. Results.-Smoking greatly increased the risk for Graves' ophthalmopathy (odds ratio, 7.7; 95% confidence interval, 4.3 to 13.7), but patients with Graves' hyperthyroidism alone were also more often smokers than control subjects (odds ratio, 1.9; 95% confidence interval, 1.1 to 3.2). Smoking was not associated with the other thyroid diseases studied. Essentially similar results were obtained after adjustment for differences in education between case patients and control subjects. Among the patients with Graves' ophthalmopathy, smokers had more severe eye disease than nonsmokers, but no association was found between the number of cigarettes smoked per day or the duration of smoking and the severity of the ophthalmopathy. However, there was a significant increase in the odds ratios in patients with more severe eye disease. Conclusions.-Smoking is associated with Graves' disease, and it especially increases the risk for the development of more severe ophthalmopathy. Thus, smoking appears to be one of the multiple factors inducing Graves' disease in genetically predisposed individuals.			PRUMMEL, MF (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT ENDOCRINOL,F5-258,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.							ANGELL M, 1990, NEW ENGL J MED, V323, P823, DOI 10.1056/NEJM199009203231209; BARTALENA L, 1989, J ENDOCRINOL INVEST, V12, P733, DOI 10.1007/BF03350047; BERGHOUT A, 1990, LANCET, V336, P193, DOI 10.1016/0140-6736(90)91730-X; CALKINS BM, 1989, DIGEST DIS SCI, V34, P1841, DOI 10.1007/BF01536701; CHRISTENSEN SB, 1984, J CLIN ENDOCR METAB, V58, P615, DOI 10.1210/jcem-58-4-615; DEGROOT LJ, 1989, ENDOCR REV, V10, P537, DOI 10.1210/edrv-10-4-537; FUNG HYM, 1988, BRIT MED J, V296, P241, DOI 10.1136/bmj.296.6617.241; GAMBLIN GT, 1983, NEW ENGL J MED, V308, P420, DOI 10.1056/NEJM198302243080803; HAGG E, 1987, BRIT MED J, V295, P634, DOI 10.1136/bmj.295.6599.634; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P132; Hernandez Avila M, 1990, EPIDEMIOLOGY, V1, P285; HUGHES DA, 1985, CLIN EXP IMMUNOL, V61, P459; KONISHI J, 1974, ENDOCRINOLOGY, V95, P434, DOI 10.1210/endo-95-2-434; LUDGATE M, 1986, LANCET, V2, P219; MCGREGOR AM, 1990, NEW ENGL J MED, V322, P1739, DOI 10.1056/NEJM199006143222409; PRUMMEL MF, 1989, NEW ENGL J MED, V321, P1353, DOI 10.1056/NEJM198911163212002; RATANACHAIYAVON.S, 1990, THYROID GLAND ENV AU, P167; REGIUS O, 1988, Z GERONTOL, V21, P161; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SHINE B, 1990, LANCET, V335, P1261, DOI 10.1016/0140-6736(90)91315-2; SHUKLA R, 1990, LANCET, V336, P184, DOI 10.1016/0140-6736(90)91711-I; THOMAS W, 1973, NATURE, V243, P240, DOI 10.1038/243240a0; VOLPE R, 1986, THYROID AUTOIMMUNITY, P283; WEETMAN AP, 1984, ENDOCR REV, V5, P309, DOI 10.1210/edrv-5-2-309; WERNER SC, 1974, NEW ENGL J MED, V290, P1447, DOI 10.1056/NEJM197406272902602; WERNER SC, 1977, J CLIN ENDOCR METAB, V44, P203, DOI 10.1210/jcem-44-1-203; 1990, STATISTISCH JB 1990, P425; 1990, LANCET, V335, P1561; 1990, LANCET, V335, P1127	29	327	344	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					479	482		10.1001/jama.269.4.479	http://dx.doi.org/10.1001/jama.269.4.479			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8419666				2022-12-28	WOS:A1993KH38500030
J	HESS, SD; DOROSHENKO, PA; AUGUSTINE, GJ				HESS, SD; DOROSHENKO, PA; AUGUSTINE, GJ			A FUNCTIONAL-ROLE FOR GTP-BINDING PROTEINS IN SYNAPTIC VESICLE CYCLING	SCIENCE			English	Article							SQUID GIANT SYNAPSE; TRANSMITTER RELEASE; NEUROTRANSMITTER RELEASE; CALCIUM ENTRY; MEMBRANE; TRANSMISSION; EXOCYTOSIS; INHIBITION; MODULATION; DROSOPHILA	The squid giant synapse was used to test the hypothesis that guanosine-5'-triphosphate (GTP)-binding proteins regulate the local distribution of synaptic vesicles within nerve terminals. Presynaptic injection of the nonhydrolyzable GTP analog GTPgammaS irreversibly inhibited neurotransmitter release without changing either the size of the calcium signals produced by presynaptic action potentials or the number of synaptic vesicles docked at presynaptic active zones. Neurotransmitter release was also inhibited by injection of the nonhydrolyzable guanosine diphosphate (GDP) analog GDPbetaS but not by injection of AlF4-. These results suggest that a small molecular weight GTP-binding protein directs the docking of synaptic vesicles that occurs before calcium-dependent neurotransmitter release. Depletion of undocked synaptic vesicles by GTPgammaS indicates that additional GTP-binding proteins function in the terminal at other steps responsible for synaptic vesicle replenishment.	DUKE UNIV, MED CTR, DEPT NEUROBIOL, POB 3209, DURHAM, NC 27710 USA; UNIV SO CALIF, DEPT BIOL SCI, LOS ANGELES, CA 90089 USA; MARINE BIOL LAB, WOODS HOLE, MA 02543 USA; KIEV PHYSIOL INST, KIEV, UKRAINE; MAX PLANCK INST BIOPHYS CHEM, W-3400 GOTTINGEN, GERMANY	Duke University; University of Southern California; Marine Biological Laboratory - Woods Hole; Max Planck Society			Augustine, George James/J-9228-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021624] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-21624] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER EM, 1991, J NEUROSCI, V11, P1496; ARAKI S, 1990, J BIOL CHEM, V265, P13007; AUGUSTINE GJ, 1990, J PHYSIOL-LONDON, V431, P343, DOI 10.1113/jphysiol.1990.sp018333; AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V367, P143, DOI 10.1113/jphysiol.1985.sp015818; AUGUSTINE GJ, 1984, J PHYSIOL-LONDON, V346, P257, DOI 10.1113/jphysiol.1984.sp015020; AUGUSTINE GJ, 1985, J PHYSIOL-LONDON, V367, P163, DOI 10.1113/jphysiol.1985.sp015819; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROOKS JC, 1984, LIFE SCI, V35, P569, DOI 10.1016/0024-3205(84)90251-0; CHARLTON MP, 1982, J PHYSIOL-LONDON, V323, P173, DOI 10.1113/jphysiol.1982.sp014067; CHARLTON MP, 1988, J NEUROSCI METH, V22, P195, DOI 10.1016/0165-0270(88)90040-4; CHIN GJ, 1992, BRAIN RES, V571, P89, DOI 10.1016/0006-8993(92)90512-8; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DOLPHIN AC, 1991, ANN NY ACAD SCI, V635, P139, DOI 10.1111/j.1749-6632.1991.tb36488.x; DOLPHIN AC, 1988, PFLUG ARCH EUR J PHY, V411, P628, DOI 10.1007/BF00580858; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAYDON PG, 1991, J NEUROSCI, V11, P3851; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KATZ B, 1967, J PHYSIOL-LONDON, V192, P407, DOI 10.1113/jphysiol.1967.sp008307; Katz B., 1969, RELEASE NEURAL TRANS, P33; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; LLINAS R, 1982, P NATL ACAD SCI-BIOL, V79, P2415, DOI 10.1073/pnas.79.7.2415; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; MARTIN R, 1986, PHILOS T R SOC B, V312, P355, DOI 10.1098/rstb.1986.0013; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; NGSEE JK, 1990, J NEUROSCI, V10, P317; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PUMPLIN DW, 1978, NEUROSCIENCE, V3, P685, DOI 10.1016/0306-4522(78)90065-9; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SANCHEZ ME, 1990, J EXP BIOL, V152, P369; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; VALTORTA F, 1990, NEUROSCIENCE, V35, P477, DOI 10.1016/0306-4522(90)90323-V; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; ZIPSER K, 1991, Biophysical Journal, V59, p594A	47	112	113	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 19	1993	259	5098					1169	1172		10.1126/science.8438167	http://dx.doi.org/10.1126/science.8438167			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8438167				2022-12-28	WOS:A1993KM91700041
J	JUNG, S; RAJEWSKY, K; RADBRUCH, A				JUNG, S; RAJEWSKY, K; RADBRUCH, A			SHUTDOWN OF CLASS SWITCH RECOMBINATION BY DELETION OF A SWITCH REGION CONTROL ELEMENT	SCIENCE			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; MURINE B-CELLS; SACCHAROMYCES-CEREVISIAE; INITIATION SITE; STEM-CELLS; GENE; INTERLEUKIN-4; INDUCTION; MOUSE; TRANSCRIPTS	Upon activation, B lymphocytes can change the class of the antibody they express by immunoglobulin class switch recombination. Cytokines can direct this recombination to distinct classes by the specific activation of repetitive recombinogenic DNA sequences, the switch regions. Recombination to a particular switch region (s(gamma)1) was abolished in mice that were altered to lack sequences that are 5' to the s(gamma)1 region. This result directly implicates the functional importance of 5' switch region flanking sequences in the control of class switch recombination. Mutant mice exhibit a selective agammaglobulinemia and may be useful in the assessment of the biological importance of immunoglobulin G1.			JUNG, S (corresponding author), UNIV COLOGNE,INST GENET,W-5000 COLOGNE 41,GERMANY.		Jung, Steffen/K-1409-2012	Jung, Steffen/0000-0003-4290-5716; Radbruch, Andreas/0000-0001-5753-0000				BERGSTEDTLINDQVIST S, 1988, EUR J IMMUNOL, V18, P1073, DOI 10.1002/eji.1830180716; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; BROACH JR, 1980, CELL, V21, P501, DOI 10.1016/0092-8674(80)90487-0; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; ESSER C, 1989, EMBO J, V8, P483, DOI 10.1002/j.1460-2075.1989.tb03401.x; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ILLGES H, 1992, MOL IMMUNOL, V29, P1265, DOI 10.1016/0161-5890(92)90063-4; ISAKSON PC, 1982, J EXP MED, V155, P734, DOI 10.1084/jem.155.3.734; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEBMAN DA, 1990, J IMMUNOL, V144, P952; LEUNG H, 1992, P NATL ACAD SCI USA, V89, P4154, DOI 10.1073/pnas.89.9.4154; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MILLS FC, 1992, J IMMUNOL, V149, P1075; MOWATT MR, 1986, J IMMUNOL, V136, P2674; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; ROTHMAN P, 1990, INT IMMUNOL, V2, P621, DOI 10.1093/intimm/2.7.621; Schmitz J, 1989, Int Immunol, V1, P570, DOI 10.1093/intimm/1.6.570; SCHULTES NP, 1991, MOL CELL BIOL, V11, P322, DOI 10.1128/MCB.11.1.322; SCHULTZ CL, 1992, J IMMUNOL, V149, P60; SEVERINSON E, 1990, EUR J IMMUNOL, V20, P1079, DOI 10.1002/eji.1830200520; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SIEBENKOTTEN G, 1992, EUR J IMMUNOL, V22, P1827, DOI 10.1002/eji.1830220723; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VOELKELMEIMAN K, 1987, CELL, V48, P1071, DOI 10.1016/0092-8674(87)90714-8; WILLIAMS RL, 1988, NATURE, V336, P685; Xu M, 1990, Dev Immunol, V1, P11, DOI 10.1155/1990/47659; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x	35	312	334	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					984	987		10.1126/science.8438159	http://dx.doi.org/10.1126/science.8438159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438159				2022-12-28	WOS:A1993KL80000047
J	NANAVATI, C; FERNANDEZ, JM				NANAVATI, C; FERNANDEZ, JM			THE SECRETORY GRANULE MATRIX - A FAST-ACTING SMART POLYMER	SCIENCE			English	Article							MAST-CELLS; FUSION PORE; GELS; EXOCYTOSIS; VESICLE	The secretory granule matrix is a miniature biopolymer that consists of a charged polymer network that traps peptides and transmitters when it condenses and releases them on exocytotic decondensation. Models of exocytotic fusion have treated this matrix as a short circuit and have neglected its electrical contributions. This matrix responded to negative voltages by swelling, which was accompanied by a large increase in conductance, and to positive voltages by condensing. Thus, the matrix resembled a diode. The swollen matrix exerted large pressures on the order of 12 bar. The responses took place within milliseconds of the application of the electric field. These findings suggest that matrix decondensation, and therefore product release, is controlled by potential gradients.	MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905	Mayo Clinic								ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; BRECKENRIDGE LJ, 1987, P NATL ACAD SCI USA, V84, P1945, DOI 10.1073/pnas.84.7.1945; BRECKENRIDGE LJ, 1987, NATURE, V328, P814, DOI 10.1038/328814a0; CURRAN MJ, 1991, J GEN PHYSIOL, V98, P771, DOI 10.1085/jgp.98.4.771; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; KAJIWARA K, 1992, NATURE, V355, P208, DOI 10.1038/355208a0; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; MONCK JR, 1991, BIOPHYS J, V59, P39, DOI 10.1016/S0006-3495(91)82196-8; NANAVATI C, 1992, BIOPHYS J, V63, P1118, DOI 10.1016/S0006-3495(92)81679-X; NIELSEN EH, 1990, J CELL SCI, V96, P43; OSADA Y, 1992, NATURE, V355, P242, DOI 10.1038/355242a0; Osada Y., 1991, POLYM GELS FUNDAMENT; STEINBERG IZ, 1966, NATURE, V210, P568, DOI 10.1038/210568a0; TAM PY, 1981, NATURE, V292, P340, DOI 10.1038/292340a0; TANAKA T, 1981, SCI AM, V244, P124, DOI 10.1038/scientificamerican0181-124; TANAKA T, 1982, SCIENCE, V218, P467, DOI 10.1126/science.218.4571.467; TANAKA T, 1979, J CHEM PHYS, V70, P1214, DOI 10.1063/1.437602; [No title captured]	19	111	117	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					963	965		10.1126/science.8438154	http://dx.doi.org/10.1126/science.8438154			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438154				2022-12-28	WOS:A1993KL80000040
J	GLANTZ, SA				GLANTZ, SA			REMOVING THE INCENTIVE TO SELL KIDS TOBACCO - A PROPOSAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHILDREN; CAMEL		UNIV CALIF SAN FRANCISCO,DEPT MED,DIV CARDIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	GLANTZ, SA (corresponding author), UNIV CALIF SAN FRANCISCO,MOFFITT HOSP,DEPT MED,DIV CARDIOL,ROOM 1186,SAN FRANCISCO,CA 94143, USA.							BEGAY M, 1991, U CALIFORNIA I HLTH; DIFRANZA JR, 1990, JAMA-J AM MED ASSOC, V263, P2784, DOI 10.1001/jama.263.20.2784; DIFRANZA JR, 1991, JAMA-J AM MED ASSOC, V266, P3149, DOI 10.1001/jama.266.22.3149; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; PIERCE J P, 1992, Morbidity and Mortality Weekly Report, V41, P485; PIERCE JP, 1991, JAMA-J AM MED ASSOC, V266, P3154, DOI 10.1001/jama.266.22.3154; Slade J, 1988, N J Med, V85, P102; SWEANOR DT, 1991, TAX BURDEN TOBACCO A; Tye J B, 1987, J Public Health Policy, V8, P492, DOI 10.2307/3342275; GAOHRD89119 US GEN A	10	12	12	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					793	794		10.1001/jama.269.6.793	http://dx.doi.org/10.1001/jama.269.6.793			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423664				2022-12-28	WOS:A1993KK54400035
J	FUCHS, VR				FUCHS, VR			NO PAIN, NO GAIN - PERSPECTIVES ON COST CONTAINMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNITED-STATES		STANFORD UNIV,DEPT ECON,STANFORD,CA 94305; STANFORD UNIV,DEPT HLTH RES POLICY,STANFORD,CA 94305	Stanford University; Stanford University	FUCHS, VR (corresponding author), NATL BUR ECON RES,204 JUNIPERO SERRA BLVD,STANFORD,CA 94305, USA.							AARON HJ, 1984, PAINFUL PRESCRIPTION; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1991, CANADIAN HLTH INSURA; 1991, HOSPITAL STATISTICS	5	24	24	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					631	633						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421368				2022-12-28	WOS:A1993KJ44400032
J	LEAF, A				LEAF, A			PREVENTIVE MEDICINE FOR OUR AILING HEALTH-CARE SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYOCARDIAL-INFARCTION; HEART-DISEASE; REHABILITATION; REGRESSION; MORBIDITY; MORTALITY; TRIALS		HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	LEAF, A (corresponding author), W ROXBURY VA MED CTR,DEPT MED,1400 VFW PKWY,BOSTON,MA 02132, USA.							BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P323; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; HENNEKENS CH, 1988, NEW ENGL J MED, V318, P262; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PELL S, 1985, NEW ENGL J MED, V312, P1005, DOI 10.1056/NEJM198504183121601; STEINBERG D, 1988, AM J CARDIOL, V62, pB6, DOI 10.1016/S0002-9149(88)80044-4; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; 1991, 1992 HEART STROKE FA; 1986, AM J CARDIOL, V58, P1; 1984, JAMA-J AM MED ASSOC, V251, P351; 1985, AM J CARDIOL, V55, P16	16	31	31	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					616	618		10.1001/jama.269.5.616	http://dx.doi.org/10.1001/jama.269.5.616			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421366				2022-12-28	WOS:A1993KJ44400028
J	ROGERS, BJ; BRADSHAW, MF				ROGERS, BJ; BRADSHAW, MF			VERTICAL DISPARITIES, DIFFERENTIAL PERSPECTIVE AND BINOCULAR STEREOPSIS	NATURE			English	Article							STEREOSCOPIC DEPTH; PERCEPTION; DISTANCE; MODEL	To calculate the depth difference between a pair of points on a three-dimensional surface from binocular disparities, it is necessary to know the absolute distance to the surface1,2. Traditionally, it has been assumed that this information is derived from non-visual sources such as the vergence angle of the eyes3,4. It has been shown 5,6 that the horizontal gradient of vertical disparity between the images in the two eyes also contains information about the fixation distanCe7-9. Recent results10,11, however, indicated that manipulations of the vertical disparity gradient have no effect on either the perceived shape or the perceived depth of surf aces defined by horizontal disparities. Following the reasoning of Longuet-Higgins12 and Tyler13, we suggest that vertical disparities are best understood as a consequence of perspective viewing from two different vantage points and the results we report here show that the human visual system is able to exploit vertical disparities and use them to scale the perceived depth and size of stereoscopic surfaces, if the field of view is sufficiently large.			ROGERS, BJ (corresponding author), UNIV OXFORD,DEPT EXPTL PSYCHOL,OXFORD OX1 3UD,ENGLAND.							BISHOP PO, 1989, PROC R SOC SER B-BIO, V237, P445, DOI 10.1098/rspb.1989.0059; CUMMING BG, 1991, NATURE, V349, P411, DOI 10.1038/349411a0; FOLEY JM, 1980, PSYCHOL REV, V87, P411, DOI 10.1037/0033-295X.87.5.411; FRISBY JP, 1984, NATURE, V307, P592, DOI 10.1038/307592a0; HOWARD JP, 1970, PSYCHON MONOGR S, V3, P201; KOENDERINK JJ, 1976, BIOL CYBERN, V21, P29, DOI 10.1007/BF00326670; MAYHEW J, 1982, PERCEPTION, V11, P387, DOI 10.1068/p110387; MAYHEW JEW, 1982, NATURE, V297, P376, DOI 10.1038/297376a0; Ono H., 1977, STABILITY CONSTANCY, P91; PETROV AP, 1980, VISION RES, V20, P409, DOI 10.1016/0042-6989(80)90031-0; PORRILL J, 1987, FRONTIERS VISUAL SCI, P90; ROGERS BJ, 1992, INVEST OPHTH VIS SCI, V33, P1333; ROGERS BJ, 1992, PERCEPTION, V21, P18; SOBEL EC, 1991, P ROY SOC B-BIOL SCI, V244, P87, DOI 10.1098/rspb.1991.0055; STENTON SP, 1984, NATURE, V309, P622, DOI 10.1038/309622a0; Tyler C., 1991, BINOCULAR VISION, P19; VONHELMHOLTZ H, 1925, TREATISE OPHYSIOLOGI, V3	18	204	206	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 21	1993	361	6409					253	255		10.1038/361253a0	http://dx.doi.org/10.1038/361253a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8423851				2022-12-28	WOS:A1993KH61400057
J	WELLINGER, RJ; WOLF, AJ; ZAKIAN, VA				WELLINGER, RJ; WOLF, AJ; ZAKIAN, VA			SACCHAROMYCES TELOMERES ACQUIRE SINGLE-STRAND TG(1-3) TAILS LATE IN S-PHASE	CELL			English	Article							DNA-SEQUENCES; YEAST CHROMOSOMES; REPLICATION ORIGINS; CEREVISIAE; GENE; PLASMID; TRANSFORMATION; CENTROMERES; EXPRESSION; ELEMENTS	Saccharomyces telomeres consist of approximately 300 bp of C1-3A/TG1-3 DNA. Nondenaturing Southern hybridization, capable of detecting approximately 60 to approximately 300 bases of TG1-3 DNA, revealed that yeast telomeres acquired and lost TG1-3 tails, the predicted intermediate in telomere replication, in a cell cycle-dependent manner. TG1-3 tails were also detected on the ends of a linear plasmid isolated from late S phase cells. In addition, a nonlinear form of this plasmid was detected: this structure migrated in two-dimensional agarose gels like a nicked circle of the same size as the linear plasmid, but had considerably more single-stranded character than a conventional nicked circle. The evidence indicates that these circles were formed by telomere-telomere interactions involving the TG1-3 tails. These data provide evidence for a cell cycle-dependent change in telomere structure and demonstrate that TG1-3 tails, generated during replication of a linear plasmid in vivo, are capable of mediating telomere-telomere interactions.	UNIV WASHINGTON,SEATTLE,WA 98104	University of Washington; University of Washington Seattle	WELLINGER, RJ (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.		Wellinger, Raymund/K-3207-2019	Wellinger, Raymund/0000-0001-6670-2759	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM026938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACEVEDO OL, 1991, NUCLEIC ACIDS RES, V19, P3409, DOI 10.1093/nar/19.12.3409; ANDREADIS A, 1984, J BIOL CHEM, V259, P8059; BERNARDS A, 1983, NATURE, V303, P592, DOI 10.1038/303592a0; BLAKCBURN EH, 1992, ANN REV BIOCH, V61, P113; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENIKOFF S, 1987, GENETICS, V117, P711; HOROWITZ H, 1984, NUCLEIC ACIDS RES, V12, P7105, DOI 10.1093/nar/12.18.7105; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KERR C, 1972, J BIOL CHEM, V247, P311; KROEKER WD, 1978, BIOCHEMISTRY-US, V17, P3236, DOI 10.1021/bi00609a010; LARSON DD, 1987, CELL, V50, P477, DOI 10.1016/0092-8674(87)90501-0; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; LIVINGSTON DM, 1977, J MOL BIOL, V116, P249, DOI 10.1016/0022-2836(77)90215-7; LOUIS EJ, 1990, GENETICS, V124, P533; LUSTIG AJ, 1992, NUCLEIC ACIDS RES, V20, P3021, DOI 10.1093/nar/20.12.3021; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MCNEIL JB, 1981, MOL GEN GENET, V184, P386, DOI 10.1007/BF00352510; MURRAY AW, 1988, MOL CELL BIOL, V8, P4642, DOI 10.1128/MCB.8.11.4642; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; NEWLON CS, 1974, NATURE, V247, P32, DOI 10.1038/247032a0; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; REYNOLDS AE, 1989, MOL CELL BIOL, V9, P4488, DOI 10.1128/MCB.9.10.4488; RUNGE KW, 1991, MOL CELL BIOL, V11, P2919, DOI 10.1128/MCB.11.6.2919; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; Sambrook J, 1989, MOL CLONING LABORATO; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; STINCHCOMB DT, 1982, J MOL BIOL, V158, P157, DOI 10.1016/0022-2836(82)90427-2; STINCHCOMB DT, 1980, P NATL ACAD SCI-BIOL, V77, P4559, DOI 10.1073/pnas.77.8.4559; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SUTCLIFFE JG, 1978, NUCLEIC ACIDS RES, V5, P2721, DOI 10.1093/nar/5.8.2721; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WELLINGER RJ, 1989, P NATL ACAD SCI USA, V86, P973, DOI 10.1073/pnas.86.3.973; WELLINGER RJ, 1992, IN PRESS CHROMOSOMA, V102; WELLINGER RJ, 1993, IN PRESS CHROMOSOME; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZAKIAN VA, 1990, TRENDS GENET, V6, P12, DOI 10.1016/0168-9525(90)90043-6	56	356	368	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					51	60		10.1016/0092-8674(93)90049-V	http://dx.doi.org/10.1016/0092-8674(93)90049-V			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422682				2022-12-28	WOS:A1993KG95500009
J	CARTER, NS; FAIRLAMB, AH				CARTER, NS; FAIRLAMB, AH			ARSENICAL-RESISTANT TRYPANOSOMES LACK AN UNUSUAL ADENOSINE TRANSPORTER	NATURE			English	Article							AFRICAN TRYPANOSOMES; NUCLEOSIDE TRANSPORTERS; LEISHMANIA-DONOVANI; BRUCEI; DRUGS; TRYPANOTHIONE; ALLOPURINOL; METABOLISM; PURINE; CELLS	THE melaminophenyl arsenical melarsoprol is still used to treat African sleeping sickness1-3, a disease caused by parasitic protozoa of the Trypanosoma brucei subgroup. Based on the observation that melamine antagonizes the trypanocidal activity of this class of drugs4, we investigated whether other physiological compounds could compete for the same receptor. Here we report that the in vitro trypanolytic effect of melarsen oxide can be specifically abrogated by adenine, adenosine and dipyridamole, all of which compete for uptake by an adenosine transporter. Melarsen-sensitive trypanosomes have two high-affinity adenosine transport systems: a P1 type, which also transports inosine; and a P2 type, which also transports adenine and the melaminophenyl arsenicals, Melarsen-resistant trypanosomes lack P2 adenosine transport, suggesting that resistance to these arsenicals is due to loss of uptake.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT MED PARASITOL, KEPPEL ST, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine			Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APTED FIC, 1980, PHARMACOL THERAPEUT, V11, P391, DOI 10.1016/0163-7258(80)90035-2; ARONOW B, 1987, MOL BIOCHEM PARASIT, V22, P29, DOI 10.1016/0166-6851(87)90066-1; ARONOW B, 1985, J BIOL CHEM, V260, P6226; BAER HP, 1992, AM J TROP MED HYG, V47, P87, DOI 10.4269/ajtmh.1992.47.87; CLARKSON AB, 1976, SCIENCE, V194, P204, DOI 10.1126/science.986688; DANSON MJ, 1987, BIOCHEM J, V243, P661, DOI 10.1042/bj2430661; Ehrlich P., 1956, COLLECTED PAPERS P E, P596; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; FAIRLAMB AH, 1989, PARASITOLOGY, V99, pS93, DOI 10.1017/S003118200008344X; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAIRLAMB AH, 1977, NATURE, V265, P270, DOI 10.1038/265270a0; FAIRLAMB AH, 1992, MOL BIOCHEM PARASIT, V53, P223, DOI 10.1016/0166-6851(92)90024-E; FAIRLAMB AH, 1992, MOL BIOCHEM PARASIT, V53, P213, DOI 10.1016/0166-6851(92)90023-D; FAIRLAMB AH, 1989, P NATL ACAD SCI USA, V86, P2607, DOI 10.1073/pnas.86.8.2607; FINLEY RW, 1988, MOL BIOCHEM PARASIT, V31, P133, DOI 10.1016/0166-6851(88)90164-8; FLYNN IW, 1974, COMP BIOCHEM PHYSIOL, V48, P261, DOI 10.1016/0305-0491(74)90203-X; FRIEDHEIM EAH, 1949, AM J TROP MED, V29, P173; HALLER L, 1986, AM J TROP MED HYG, V35, P94, DOI 10.4269/ajtmh.1986.35.94; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; Hawking F., 1938, Annals of Tropical Medicine and Parasitology, V32, P313; HAWKING F, 1966, EXPT CHEMOTHERAPY, V1, P129; HOEIJMAKERS JHJ, 1980, GENE, V8, P391, DOI 10.1016/0378-1119(80)90043-8; JAMES DM, 1980, PARASITOLOGY, V81, P383, DOI 10.1017/S0031182000056110; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; MARR JJ, 1978, SCIENCE, V201, P1018, DOI 10.1126/science.356267; MESHNICK SR, 1978, J EXP MED, V148, P569, DOI 10.1084/jem.148.2.569; NELSON DJ, 1979, J BIOL CHEM, V254, P1544; OGBUNUDE POJ, 1991, EXP PARASITOL, V73, P369, DOI 10.1016/0014-4894(91)90109-A; OKOCHI VI, 1983, BIOCHEM INT, V6, P129; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; RICHARME G, 1985, J BACTERIOL, V162, P286, DOI 10.1128/JB.162.1.286-293.1985; VANSCHAFTINGEN E, 1987, EUR J BIOCHEM, V166, P653; WERY M, 1991, CURR OPIN INFECT DIS, V4, P838, DOI 10.1097/00001432-199112000-00020; WILLIAMSON J, 1959, BRIT J PHARM CHEMOTH, V14, P431, DOI 10.1111/j.1476-5381.1959.tb00947.x	34	307	312	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					173	176		10.1038/361173a0	http://dx.doi.org/10.1038/361173a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421523				2022-12-28	WOS:A1993KG46600066
J	MURPHY, TV; WHITE, KE; PASTOR, P; GABRIEL, L; MEDLEY, F; GRANOFF, DM; OSTERHOLM, MT				MURPHY, TV; WHITE, KE; PASTOR, P; GABRIEL, L; MEDLEY, F; GRANOFF, DM; OSTERHOLM, MT			DECLINING INCIDENCE OF HAEMOPHILUS-INFLUENZAE TYPE-B DISEASE SINCE INTRODUCTION OF VACCINATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							POLYSACCHARIDE VACCINE; HEMOPHILUS; CHILDREN; MINNESOTA; EFFICACY	Objective.-To determine the incidence of invasive Haemophilus influenzae type b disease in children living in Minnesota and Dallas County, Texas, before and since introduction of plain polysaccharide vaccine in 1985, and conjugate vaccine in 1988. Initially, use of these vaccines was limited to infants 18 months of age and older. Design.-Identification of culture-proven cases of H influenzae type b disease was through systems of active, laboratory-based surveillance. The mean incidence of disease (cases observed/100 000 child-years) for 1983 and 1984 served as a baseline for comparison with subsequent years through 1991. Participants.-Children less than 5 years of age in Minnesota and Dallas County, Texas. Overall, there were 2557 confirmed age-eligible cases of invasive H influenzae type b disease from 1983 through 1991. Results.-Between the 1983-1984 baseline and 1991, the incidence of H influenzae type b disease decreased 85% in Minnesota and 92% in Dallas. Notably, declines in incidence were observed in children in the age group being vaccinated as well as in infants younger than 18 months of age prior to introduction of vaccination. Conclusion.-In two widely separated areas of the United States, a profound decrease in the incidence of H influenzae type b disease has occurred. The data suggest that vaccination may be protecting against disease, as well as decreasing the spread of infection to unvaccinated infants.	MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,MINNEAPOLIS,MN; ST LOUIS CHILDRENS HOSP,ST LOUIS,MO 63178; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,DIV INFECT DIS,ST LOUIS,MO 63110	Minnesota Department of Health (MHD); St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL)	MURPHY, TV (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PEDIAT,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021842] Funding Source: NIH RePORTER; NIAID NIH HHS [R0 1 AI21842] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		FLEISCHER GR, 1992, PEDIATR RES, V31, P161; GRANOFF DM, 1989, J INFECT DIS, V159, P908, DOI 10.1093/infdis/159.5.908; GRANOFF DM, 1984, CURRENT CLIN TOPICS, V5, P290; HINMAN AR, 1979, PEDIATR RES, V13, P689, DOI 10.1203/00006450-197905001-00007; JAFFE DM, 1987, NEW ENGL J MED, V317, P1175, DOI 10.1056/NEJM198711053171902; LI KI, 1987, PEDIATR INFECT DIS J, V6, P303, DOI 10.1097/00006454-198703000-00028; MURPHY TV, 1987, PEDIATRICS, V79, P173; MURPHY TV, 1992, J INFECT DIS, V165, pS7, DOI 10.1093/infdis/165-Supplement_1-S7; MURPHY TV, 1991, 31ST INT C ANT AG CH; OSTERHOLM MT, 1988, JAMA-J AM MED ASSOC, V260, P1423, DOI 10.1001/jama.260.10.1423; PELTOLA H, 1977, PEDIATRICS, V60, P730; SHAPIRO ED, 1991, EPIDEMIOL REV, V13, P113, DOI 10.1093/oxfordjournals.epirev.a036066; SHAPIRO ED, 1988, JAMA-J AM MED ASSOC, V260, P1419, DOI 10.1001/jama.260.10.1419; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982	14	177	178	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					246	248		10.1001/jama.269.2.246	http://dx.doi.org/10.1001/jama.269.2.246			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417244				2022-12-28	WOS:A1993KF40500032
J	THERIAULT, Y; LOGAN, TM; MEADOWS, R; YU, LP; OLEJNICZAK, ET; HOLZMAN, TF; SIMMER, RL; FESIK, SW				THERIAULT, Y; LOGAN, TM; MEADOWS, R; YU, LP; OLEJNICZAK, ET; HOLZMAN, TF; SIMMER, RL; FESIK, SW			SOLUTION STRUCTURE OF THE CYCLOSPORINE-A CYCLOPHILIN COMPLEX BY NMR	NATURE			English	Article							CIS-TRANS ISOMERASE; BINDING-PROTEIN; CONFORMATION	CYCLOSPORIN A, a cyclic undecapeptide, is a potent immunosuppressant that binds to a peptidyl-prolyl cis-trans isomerase1,2 of 165 amino acids, cyclophilin3. The cyclosporin A/cyclophilin complex inhibits the calcium- and calmodulin-dependent phosphatase, calcineurin4, resulting in a failure to activate genes encoding interleukin-2 and other lymphokines5,6. The three-dimensional structures of uncomplexed cyclophilin7, a tetrapeptide/cyclophilin complex8,9, and cyclosporin A when bound to cyclophilin10,11 have been reported. However, the structure of the cyclosporin A/cyclophilin complex has not been determined. Here we present the solution structure of the cyclosporin A/cyclophilin complex obtained by heteronuclear three-dimensional NMR spectroscopy. The structure, one of the largest determined by NMR, differs from proposed models of the complex12-14 and is analysed in terms of the binding interactions and structure/activity relationships for CsA analogues15,16.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064	Abbott Laboratories				Yu, Liping/0000-0003-3536-6427				ALTSCHUH D, 1992, SCIENCE, V256, P92, DOI 10.1126/science.1566062; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FESIK SW, 1992, J AM CHEM SOC, V114, P3165, DOI 10.1021/ja00034a087; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GALLION S, 1992, PROTEIN ENG, V5, P391, DOI 10.1093/protein/5.5.391; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; JAMES MNG, 1982, P NATL ACAD SCI-BIOL, V79, P6137, DOI 10.1073/pnas.79.20.6137; KALLEN J, 1992, FEBS LETT, V300, P286, DOI 10.1016/0014-5793(92)80865-E; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KESSLER H, 1990, HELV CHIM ACTA, V73, P1818, DOI 10.1002/hlca.19900730703; KOFRON JL, 1992, J AM CHEM SOC, V114, P2670, DOI 10.1021/ja00033a047; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LOOSLI HR, 1985, HELV CHIM ACTA, V68, P682, DOI 10.1002/hlca.19850680319; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NERI P, 1991, FEBS LETT, V294, P81, DOI 10.1016/0014-5793(91)81348-C; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; QUESNIAUX VFJ, 1987, EUR J IMMUNOL, V17, P1359, DOI 10.1002/eji.1830170921; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WUTHRICH K, 1991, FEBS LETT, V285, P237, DOI 10.1016/0014-5793(91)80808-G	31	175	181	9	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					88	91		10.1038/361088a0	http://dx.doi.org/10.1038/361088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421500				2022-12-28	WOS:A1993KF71800056
J	POLDERMAN, KH; STEHOUWER, CDA; VANKAMP, GJ; DEKKER, GA; VERHEUGT, FWA; GOOREN, LJG				POLDERMAN, KH; STEHOUWER, CDA; VANKAMP, GJ; DEKKER, GA; VERHEUGT, FWA; GOOREN, LJG			INFLUENCE OF SEX-HORMONES ON PLASMA ENDOTHELIN LEVELS	ANNALS OF INTERNAL MEDICINE			English	Article						ENDOTHELINS; ATHEROSCLEROSIS; HYPERTENSION; SEX HORMONES; SEX FACTORS	CARDIOVASCULAR-DISEASE; ORAL-CONTRACEPTIVES; ANABOLIC-STEROIDS; ATHEROSCLEROSIS	Objective: To determine whether a sex-associated difference in endothelin levels exists and to assess whether this difference is mediated by sex hormones. Design: Initial survey in healthy persons, followed by a nonrandomized intervention. Setting: A university teaching hospital. Patients: Twenty-three healthy men, 29 healthy women, 20 pregnant women, and 12 male-to-female and 13 female-to-male transsexual patients. Measurements: Plasma levels of endothelin were first assessed in healthy men, healthy women, and pregnant women; subsequently, endothelin levels were determined in male-to-female and female-to-male transsexual patients both before and during cross-gender hormone treatment. This treatment involves administration of testosterone esters to women and of ethinylestradiol and cyproterone acetate to men. Results: Endothelin levels were higher in men than in women (5.9 +/- 1.2 compared with 4.17 +/- 0.67 pg/mL; P < 0.01). Endothelin levels were lower in pregnant women than in age- and sex-matched nonpregnant controls (2.19 +/- 0.73 compared with 4.17 +/- 0.67 pg/mL; P < 0.01). In 12 male-to-female transsexuals treated with estradiol and the progestational agent cyproterone acetate, endothelin levels decreased from 8.1 +/- 3.0 to 5.1 +/- 2.0 pg/mL (P < 0.01). In 13 female-to-male transsexuals treated with testosterone, endothelin levels increased from 6.2 +/- 1.1 to 7.8 +/- 1.2 pg/mL (P < 0.01). Conclusion: Sex hormones may modulate plasma endothelin levels, with male hormones raising levels and female hormones lowering them. This finding may be important in explaining sex-associated differences in susceptibility to atherosclerotic cardiovascular disease.			POLDERMAN, KH (corresponding author), FREE UNIV AMSTERDAM HOSP, DEPT INTERNAL MED, POB 7057, 1007 MB AMSTERDAM, NETHERLANDS.		Stehouwer, Coen/AAB-3435-2021; Polderman, Kees H/K-3623-2012; Verheugt, F.W.A./H-8105-2014					ASSCHEMAN H, 1989, METABOLISM, V38, P869, DOI 10.1016/0026-0495(89)90233-3; COHEN JC, 1987, J CLIN ENDOCR METAB, V64, P960, DOI 10.1210/jcem-64-5-960; Gooren LJG, 1990, TESTOSTERONE ACTION, P182; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; KNOPP RH, 1988, AM J OBSTET GYNECOL, V158, P1630, DOI 10.1016/0002-9378(88)90201-3; KOHNO M, 1990, AM J MED, V88, P614, DOI 10.1016/0002-9343(90)90527-K; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; Lind T, 1979, Br J Obstet Gynaecol, V86 Suppl 3, P1, DOI 10.1111/j.1471-0528.1979.tb16232.x; MCNUTT RA, 1988, AM J CARDIOL, V62, P164, DOI 10.1016/0002-9149(88)91390-2; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; NAGELBERG SB, 1986, NEW ENGL J MED, V314, P649; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; VANE JR, 1990, NEW ENGL J MED, V323, P27; VIERHAPPER H, 1990, CIRCULATION, V81, P1415, DOI 10.1161/01.CIR.81.4.1415; VOERMAN HJ, 1992, CRIT CARE MED, V20, P1097, DOI 10.1097/00003246-199208000-00005; WREN BG, 1982, MED J AUSTRALIA, V2, P329, DOI 10.5694/j.1326-5377.1982.tb132453.x	18	286	288	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					429	432		10.7326/0003-4819-118-6-199303150-00006	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439117				2022-12-28	WOS:A1993KR81700006
J	GRINES, CL; BROWNE, KF; MARCO, J; ROTHBAUM, D; STONE, GW; OKEEFE, J; OVERLIE, P; DONOHUE, B; CHELLIAH, N; TIMMIS, GC; VLIETSTRA, RE; STRZELECKI, M; PUCHROWICZOCHOCKI, S; ONEILL, WW				GRINES, CL; BROWNE, KF; MARCO, J; ROTHBAUM, D; STONE, GW; OKEEFE, J; OVERLIE, P; DONOHUE, B; CHELLIAH, N; TIMMIS, GC; VLIETSTRA, RE; STRZELECKI, M; PUCHROWICZOCHOCKI, S; ONEILL, WW			A COMPARISON OF IMMEDIATE ANGIOPLASTY WITH THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; EMERGENCY CORONARY ANGIOPLASTY; RANDOMIZED TRIAL; INTRACORONARY STREPTOKINASE; INTRAVENOUS STREPTOKINASE; CARDIAC-CATHETERIZATION; PHASE-II; DIPYRIDAMOLE; DETERMINANTS; PREVENTION	Background. The success of thrombolytic therapy for acute myocardial infarction is limited by bleeding complications, the impossibility of reperfusing all occluded coronary arteries, recurrent myocardial ischemia, and the relatively small number of patients who are appropriate candidates for this therapy. We hypothesized that these problems could be overcome by the use of immediate percutaneous transluminal coronary angioplasty (PTCA), without previous thrombolytic therapy. Methods. At 12 clinical centers, 395 patients who presented within 12 hours of the onset of myocardial infarction were treated with intravenous heparin and aspirin and then randomly assigned to undergo immediate PTCA (without previous thrombolytic therapy, 195 patients) or to receive intravenous tissue plasminogen activator (t-PA, 200 patients) followed by conservative care. Radionuclide ventriculography was performed to assess ventricular function within 24 hours and at six weeks. Results. Among the patients randomly assigned to PTCA, 90 percent underwent the procedure; the success rate was 97 percent, and no patient required emergency coronary-artery bypass surgery. The in-hospital mortality rates in the t-PA and PTCA groups were 6.5 and 2.6 percent, respectively (P = 0.06). In a post hoc analysis, the mortality rates in the subgroups classified as ''not low risk'' were 10.4 and 2.0 percent, respectively (P = 0.01). Reinfarction or death in the hospital occurred in 12.0 percent of the patients treated with t-PA and 5.1 percent of those treated with PTCA (P = 0.02). Intracranial bleeding occurred more frequently among patients who received t-PA than among those who underwent PTCA (2.0 percent vs. 0 percent, P = 0.05). The mean (+/-SD) ejection fractions at rest (53+/-13 percent vs. 53+/-13 percent) and during exercise (56+/-13 percent vs. 56+/-14 percent) were similar in the t-PA and PTCA groups at six weeks. By six months, reinfarction or death had occurred in 32 patients who received t-PA (16.8 percent) and 16 treated with PTCA (8.5 percent, P = 0.02). Conclusions. As compared with t-PA therapy for acute myocardial infarction, immediate PTCA reduced the combined occurrence of nonfatal reinfarction or death, was associated with a lower rate of intracranial hemorrhage, and resulted in similar left ventricular systolic function.	LAKELAND REG MED CTR, LAKELAND, FL USA; CLIN PASTEUR, TOULOUSE, FRANCE; ST VINCENT HOSP, INDIANAPOLIS, IN USA; EL CAMINO HOSP, Mountain View, CA USA; MID AMER HEART INST, KANSAS CITY, MO USA; ST MARY PLAINS, LUBBOCK, TX USA; ALLEGHENY GEN HOSP, PITTSBURGH, PA 15212 USA; UNITED HOSP, GRAND FORKS, ND USA	Saint Luke's Mid America Heart Institute; Allegheny General Hospital	GRINES, CL (corresponding author), WILLIAM BEAUMONT HOSP, DIV CARDIOL, 3601 W 13 MILE RD, ROYAL OAK, MI 48073 USA.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1986, Lancet, V1, P397; BAIM DS, 1990, J AM COLL CARDIOL, V15, P1188, DOI 10.1016/0735-1097(90)90263-O; BARNATHAN ES, 1987, CIRCULATION, V76, P125, DOI 10.1161/01.CIR.76.1.125; BILAZARIAN SD, 1991, J CRIT ILLNESS, V6, P859; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CALIFF RM, 1992, CIRCULATION, V85, P839, DOI 10.1161/01.CIR.85.2.839; CARNEY RJ, 1992, J AM COLL CARDIOL, V20, P17, DOI 10.1016/0735-1097(92)90131-6; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHESEBRO JH, 1991, J AM COLL CARDIOL, V17, pB96; DAVIDSON CJ, 1989, ANN INTERN MED, V110, P119, DOI 10.7326/0003-4819-110-2-119; DEWOOD MA, 1989, CIRCULATION S2, V80, P418; DOUGHERTY KG, 1990, CIRCULATION, V82, P189; ELLIS SG, 1992, J AM COLL CARDIOL, V19, P681, DOI 10.1016/S0735-1097(10)80292-X; FERGUSON JJ, 1992, TEX HEART I J, V19, P1; FUNG AY, 1986, J AM COLL CARDIOL, V8, P496, DOI 10.1016/S0735-1097(86)80173-5; GIBBONS RJ, 1991, CIRCULATION S2, V84, P536; Glantz S.A., 1981, PRIMER BIOSTATISTICS, V2nd ed.; Grines C L, 1991, J Interv Cardiol, V4, P149; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GRINES CL, 1991, CIRCULATION, V84, P540, DOI 10.1161/01.CIR.84.2.540; GUERCI AD, 1987, NEW ENGL J MED, V317, P1613, DOI 10.1056/NEJM198712243172601; KENNEDY JW, 1983, NEW ENGL J MED, V309, P1477, DOI 10.1056/NEJM198312153092402; LeFree M. T., 1986, Proceedings of the SPIE - The International Society for Optical Engineering, V626, P334, DOI 10.1117/12.975410; LEMBO NJ, 1990, AM J CARDIOL, V65, P422, DOI 10.1016/0002-9149(90)90804-A; MILLER PF, 1987, ARCH INTERN MED, V147, P1565, DOI 10.1001/archinte.147.9.1565; MULLER DWM, 1991, J AM COLL CARDIOL, V18, P1594, DOI 10.1016/0735-1097(91)90490-Z; NICOD P, 1991, CIRCULATION, V84, P1004, DOI 10.1161/01.CIR.84.3.1004; O'Neill WW, 1991, CIRCULATION S2, V84, pII; OGILBY JD, 1991, CIRCULATION S2, V84, P592; OKEEFE JH, 1989, AM J CARDIOL, V64, P1221, DOI 10.1016/0002-9149(89)90558-4; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; ONEILL WW, 1992, CIRCULATION, V86, P1710, DOI 10.1161/01.CIR.86.6.1710; PAINE T D, 1992, Journal of the American College of Cardiology, V19, p21A; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PERRIGO E S, 1989, Medicine and Science in Sports and Exercise, V21, pS55; RIBEIRO E E, 1991, Journal of the American College of Cardiology, V17, p152A; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; ROSAMOND W D, 1992, Journal of the American College of Cardiology, V19, p20A; ROTHBAUM DA, 1987, J AM COLL CARDIOL, V10, P264, DOI 10.1016/S0735-1097(87)80006-2; ROUX S, 1992, J AM COLL CARDIOL, V19, P671, DOI 10.1016/S0735-1097(10)80290-6; RYAN T J, 1988, Journal of the American College of Cardiology, V12, P529; SCHRODER R, 1987, J AM COLL CARDIOL, V9, P197, DOI 10.1016/S0735-1097(87)80101-8; SCHRODER R, 1987, CIRCULATION, V76, P44; SIMOONS ML, 1986, J AM COLL CARDIOL, V7, P717, DOI 10.1016/S0735-1097(86)80329-1; TIMMIS GC, 1985, CIRCULATION, V72, P219; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; WALL TC, 1992, J AM COLL CARDIOL, V19, P482, DOI 10.1016/S0735-1097(10)80259-1; WILCOX RG, 1988, LANCET, V2, P525; ZIJLSTRA F, 1991, CIRCULATION S2, V84, P536	51	1648	1695	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1993	328	10					673	679		10.1056/NEJM199303113281001	http://dx.doi.org/10.1056/NEJM199303113281001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ861	8433725				2022-12-28	WOS:A1993KQ86100001
J	HAND, R; FREMGEN, A; CHMIEL, JS; RECANT, W; BERK, R; SYLVESTER, J; SENER, S				HAND, R; FREMGEN, A; CHMIEL, JS; RECANT, W; BERK, R; SYLVESTER, J; SENER, S			STAGING PROCEDURES, CLINICAL MANAGEMENT, AND SURVIVAL OUTCOME FOR OVARIAN-CARCINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMON EPITHELIAL CANCER; RANDOMIZED TRIAL; CYCLOPHOSPHAMIDE; CISPLATIN; REGIMENS; THERAPY	Objective.-To evaluate the relationship between survival and patterns of clinical management for ovarian carcinoma. Design.-Retrospective analysis of cancer registry data including follow-up, operative reports, and pathology reports. Setting.-Seventy-seven Illinois hospitals with active cancer registries. Patients.-A total of 2669 women with newly diagnosed ovarian carcinoma from 1983 through 1988. Main Outcome Measures.-Frequency of use of specific staging procedures and treatment options. Survival was estimated using the Kaplan-Meier product-limit method. Results.-Thirty percent of 632 stage I patients, 31% of 233 stage II patients, and 45% of 516 stage III patients underwent hysterectomy, bilateral salpingo-oophorectomy, omentectomy, sampled peritoneal washings, and node biopsy. Five year survival for those receiving this extensive surgery (who were therefore pathologically staged) was as follows: stage I, 80%; stage II, 63%; and stage III, 28%. For those not receiving this extensive surgery (who were therefore clinically staged), the 5-year survival at these stages was 76%, 62%, and 21%, respectively. The overall survival curves were not significantly different between those who were pathologically staged and those who were clinically staged for stage I patients (P=.27) or stage II patients (P=.47), but were for stage III patients (P=.01). Platinum-based combination chemotherapy was given to 76% of 221 patients with pathological stage III disease. Their 5-year survival-50% for the group with no residual disease and 20% for the group with residual disease-was better than for those receiving regimens without platinum-37% and 5%, respectively, for the two groups-and the overall survival curves were significantly better for those receiving platinum (P<.0005 for both groups). The groups receiving platinum had younger patients. Conclusions.-Extensive surgery for pathological staging was not usually done for management of ovarian cancer, while platinum-based chemotherapy was commonly used. Failure to undergo extensive surgery had little impact on survival for stage I and II patients. However, use of extensive surgery and platinum-based chemotherapy improved survival for stage III patients. The improved survival for this group receiving platinum-based chemotherapy may be explained in part by selection of younger patients for this treatment.	UNIV ILLINOIS, CHICAGO COLL MED, DEPT MED, CHICAGO, IL 60680 USA; NORTHWESTERN UNIV, SCH MED, CANC CTR BIOMETRY SECT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT SURG, CHICAGO, IL 60611 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University; Northwestern University; University of Chicago	HAND, R (corresponding author), AMER CANC SOCIETY, CANC INCIDENCE & END RESULTS COMM, 77 E MONROE ST, CHICAGO, IL 60603 USA.		yang, xiao-jun/B-1927-2009					ALBERTS DS, 1984, ADJUVANT THERAPY CAN, V4, P507; AVERETTE HE, 1990, CANCER-AM CANCER SOC, V65, P703, DOI 10.1002/1097-0142(19900201)65:3+<703::AID-CNCR2820651314>3.0.CO;2-4; BEECHAM JB, 1983, CLIN ONCOLOGY MULTID, P435; BEREK JS, 1985, CANCER TREATMENT, P415; BRUCKNER HW, 1983, AM J OBSTET GYNECOL, V145, P653, DOI 10.1016/0002-9378(83)90569-0; BUCHSBAUM HJ, 1989, SURG GYNECOL OBSTET, V169, P226; COX DR, 1972, J R STAT SOC B, V34, P187; EDWARDS CL, 1983, GYNECOL ONCOL, V15, P261, DOI 10.1016/0090-8258(83)90082-3; GRIFFITHS CT, 1982, CANCER MED, P1965; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LUCAS WE, 1983, PRINCIPLES PRACTICE, P885; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCGOWAN L, 1985, OBSTET GYNECOL, V65, P568; MORROW CP, 1981, GYNECOL ONCOL, P655; NEIJT JP, 1987, J CLIN ONCOL, V5, P1157, DOI 10.1200/JCO.1987.5.8.1157; OMURA G, 1986, CANCER, V57, P1725, DOI 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J; OZOLS RF, 1982, PRINCIPLES CANCER TR, P482; PETTERSON F, 1985, ANN REPORT RESULTS T, P19; Pettersson F., 1988, ANN REPORT RESULTS T, VFIGO, P20; RICHARDSON GS, 1985, NEW ENGL J MED, V312, P415, DOI 10.1056/NEJM198502143120706; RICHARDSON GS, 1985, NEW ENGL J MED, V312, P474, DOI 10.1056/NEJM198502213120804; SCHWARTZ PE, 1982, CANCER THERAPY, P525; YOUNG RC, 1983, JAMA-J AM MED ASSOC, V250, P3072, DOI 10.1001/jama.250.22.3072; YOUNG RC, 1990, NEW ENGL J MED, V322, P1021, DOI 10.1056/NEJM199004123221501; YOUNG RC, 1987, CANCER, V60, P2042, DOI 10.1002/1097-0142(19901015)60:8+<2042::AID-CNCR2820601516>3.0.CO;2-D; YOUNG RC, 1982, CANCER PRINCIPLES PR, P884; 1983, CANCER ILLINOIS 1983; 1988, MANUAL STAGING CANCE; 1986, CANCER ILLINOIS 1986; 1988, CANCER ILLINOIS 1987; 1985, CANCER ILLINOIS 1985; 1984, CANCER ILLINOIS 1984	33	23	23	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1119	1122		10.1001/jama.269.9.1119	http://dx.doi.org/10.1001/jama.269.9.1119			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN611	8433466				2022-12-28	WOS:A1993KN61100027
J	SHELTON, CA; WASSERMAN, SA				SHELTON, CA; WASSERMAN, SA			PELLE ENCODES A PROTEIN-KINASE REQUIRED TO ESTABLISH DORSOVENTRAL POLARITY IN THE DROSOPHILA EMBRYO	CELL			English	Article							NF-KAPPA-B; DORSAL-VENTRAL POLARITY; MATERNAL MESSENGER-RNA; TOLL GENE-PRODUCT; DNA-BINDING; TRANSMEMBRANE PROTEIN; NUCLEAR-LOCALIZATION; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION	The pelle gene is required for the nuclear import of dorsal protein that establishes dorsoventral polarity in Drosophila embryos. We report here the genetic mapping and molecular characterization of pelle. DNA sequence analysis revealed that pelle encodes a protein of 501 amino acids, the last 292 of which comprise a protein kinase catalytic domain. Microinjection of in vitro synthesized transcripts containing site-directed mutations indicates that the kinase catalytic domain is required for biological activity. This domain is most similar to that of the raf and mos protein kinases and is predicted to have a serine and threonine specificity. These results provide direct evidence for the role of phosphorylation in the in vivo regulation of a rel-like transcription factor.			SHELTON, CA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM07062] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CASANOVA J, 1991, MECH DEVELOP, V36, P41, DOI 10.1016/0925-4773(91)90070-M; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HECHT P M, 1992, Trends in Cell Biology, V2, P197, DOI 10.1016/0962-8924(92)90246-J; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; IP YT, 1991, CELL, V64, P439; JOWETT T, 1986, PREPARATION NUCLEIC; KALFAYAN L, 1982, CELL, V29, P91, DOI 10.1016/0092-8674(82)90093-9; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LINDSLEY DL, 1972, GENETICS, V71, P157; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MILLER M, 1991, DEVELOPMENT, V113, P569; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MULLERHOLTKAMP F, 1985, DEV BIOL, V110, P238, DOI 10.1016/0012-1606(85)90080-6; MULLERHOLTKAMP F, 1985, THESIS U TUBINGEN TU; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; OHNO S, 1990, J BIOL CHEM, V265, P6296; PAN DJ, 1991, GENE DEV, V5, P1892, DOI 10.1101/gad.5.10.1892; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PIRROTTA V, 1986, DROSOPHILA PRACTICAL; RAY RP, 1991, DEVELOPMENT, V113, P35; ROBERTSON HM, 1988, GENETICS, V118, P461; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SAMBROOK E, 1989, MOL CLONING LABORATO; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; Stein DS, 1991, CURR OPIN GENET DEV, V1, P247, DOI 10.1016/S0959-437X(05)80078-4; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STJOHNSTON D, 1992, CELL, V68, P201; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WEISCHAUS E, 1986, DROSOPHILA PRACTICAL, P199; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	80	197	202	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					515	525		10.1016/0092-8674(93)90071-W	http://dx.doi.org/10.1016/0092-8674(93)90071-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440018				2022-12-28	WOS:A1993KP16500007
J	ELDRED, GE; LASKY, MR				ELDRED, GE; LASKY, MR			RETINAL AGE PIGMENTS GENERATED BY SELF-ASSEMBLING LYSOSOMOTROPIC DETERGENTS	NATURE			English	Article							FAST ATOM BOMBARDMENT; MASS-SPECTROMETRY; EPITHELIUM	A UNIVERSAL biomarker of cellular ageing in eukaryotic post-mitotic cells is the appearance over time of autofluorescent lysosomal residual bodies called age pigments or lipofuscin granules1. Their role in the process of cellular ageing has been debated without resolution2. Neither the identity nor mechanism of formation of the fluorophores has been definitively determined. A post-mitotic cell type that accumulates large quantities of age pigments is the ocular retinal pigment epithelium2. We have now identified the major orange-emitting fluorophore of these pigments using fast-atom bombardment tandem mass spectrometry with collisional activation analysis4. It is an amphoteric quaternary amine that arises as a Schiff base reaction product of retinaldehyde and ethanolamine. This compound should display lysosomotropic detergent behaviour which would help explain many of the age-related changes shown in this cell. These results suggest a new role for Schiff base reaction products as lysosomotropic amines in the genesis of cellular age pigments.			ELDRED, GE (corresponding author), UNIV MISSOURI, SCH MED, MASON INST OPHTHALMOL, COLUMBIA, MO 65212 USA.							ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5; FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583; LYON PA, 1984, ANAL CHEM, V56, P2278, DOI 10.1021/ac00277a004; PORTA EA, 1991, ARCH GERONTOL GERIAT, V12, P303, DOI 10.1016/0167-4943(91)90036-P; SOHAL RS, 1989, ADV EXP MED BIOL, V266, P17; TOMER KB, 1989, MASS SPECTROM REV, V8, P445, DOI 10.1002/mas.1280080602	6	392	405	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					724	726		10.1038/361724a0	http://dx.doi.org/10.1038/361724a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	8441466				2022-12-28	WOS:A1993KN78900056
J	PHILIPS, MR; PILLINGER, MH; STAUD, R; VOLKER, C; ROSENFELD, MG; WEISSMANN, G; STOCK, JB				PHILIPS, MR; PILLINGER, MH; STAUD, R; VOLKER, C; ROSENFELD, MG; WEISSMANN, G; STOCK, JB			CARBOXYL METHYLATION OF RAS-RELATED PROTEINS DURING SIGNAL TRANSDUCTION IN NEUTROPHILS	SCIENCE			English	Article							GTP-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; NADPH OXIDASE; MEMBRANES; CYSTEINE; METHYLTRANSFERASE; CHEMOTAXIS; ACTIVATION; MECHANISMS; LEUKOCYTES	In human neutrophils, as in other cell types, Ras-related guanosine triphosphate binding proteins are directed toward their regulatory targets in membranes by a series of posttranslational modifications that include methyl esterification of a carboxyl-terminal prenylcysteine residue. In intact cells and in a reconstituted in vitro system, the amount of carboxyl methylation of Ras-related proteins increased in response to the chemoattractant N-formyl-methionyl-leucyl-phenylalanine (FMLP). Activation of Ras-related proteins by guanosine-5'-O-(3-thiotriphosphate) had a similar effect and induced translocation of p22rac2 from cytosol to plasma membrane. Inhibitors of prenylcysteine carboxyl methylation effectively blocked neutrophil responses to FMLP. These findings suggest a direct link between receptor-mediated signal transduction and the carboxyl methylation of Ras-related proteins.	PRINCETON UNIV, DEPT CHEM, PRINCETON, NJ 08544 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA; NYU MED CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	Princeton University; Princeton University; New York University	PHILIPS, MR (corresponding author), NYU MED CTR, DEPT MED, DIV RHEUMATOL, NEW YORK, NY 10016 USA.		Weissmann, Gerald/N-5273-2015; Staud, Roland/A-8442-2008	Pillinger, Michael/0000-0003-3168-1542; Weissmann, Gerald/0000-0002-4285-4552; Mark, Philips/0000-0002-1179-8156	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020277, T32GM008309] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-07176-18] Funding Source: Medline; NIGMS NIH HHS [GM-8309, GM 20277] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BACKLUND PS, 1992, J BIOL CHEM, V267, P18432; BACKLUND PS, 1988, J BIOL CHEM, V263, P15864; BINSTOCK J, 1984, METHOD ENZYMOL, V106, P310; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GOLDSTEIN IM, 1977, J CLIN INVEST, V59, P249, DOI 10.1172/JCI108635; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HORI Y, 1991, ONCOGENE, V6, P515; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; HUZOORAKBAR, 1991, J BIOL CHEM, V266, P4387; ISOMURA M, 1991, ONCOGENE, V6, P119; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KORCHAK HM, 1984, J BIOL CHEM, V259, P4070; MARIDONNEAUPARINI I, 1991, J CLIN INVEST, V87, P901, DOI 10.1172/JCI115096; ODEA RF, 1978, NATURE, V272, P462, DOI 10.1038/272462a0; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; PIKE MC, 1978, P NATL ACAD SCI USA, V75, P3928, DOI 10.1073/pnas.75.8.3928; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SNYDERMAN R, 1988, INFLAMMATION BASIC P, P309; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; VENKATASUBRAMANIAN K, 1980, MOL IMMUNOL, V17, P201, DOI 10.1016/0161-5890(80)90072-3; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WEISSMANN G, 1989, SPRINGER SEMIN IMMUN, V11, P235	38	208	214	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1993	259	5097					977	980		10.1126/science.8438158	http://dx.doi.org/10.1126/science.8438158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438158				2022-12-28	WOS:A1993KL80000045
J	FABRI, PJ				FABRI, PJ			REPLACEMENT OF CENTRAL VASCULAR CATHETERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											FABRI, PJ (corresponding author), UNIV S FLORIDA,TAMPA,FL 33612, USA.							POWELL C, 1988, JPEN J PARENTER ENTE, V12, P4462	1	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					445	445						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8421469				2022-12-28	WOS:A1993KL58400026
J	BLACK, RD; EARLY, TA; ROEMER, PB; MUELLER, OM; MOGROCAMPERO, A; TURNER, LG; JOHNSON, GA				BLACK, RD; EARLY, TA; ROEMER, PB; MUELLER, OM; MOGROCAMPERO, A; TURNER, LG; JOHNSON, GA			A HIGH-TEMPERATURE SUPERCONDUCTING RECEIVER FOR NUCLEAR-MAGNETIC-RESONANCE MICROSCOPY	SCIENCE			English	Article							LIMITED RESOLUTION; NMR	A high-temperature superconducting-receiver system for use in nuclear magnetic resonance (NMR) microscopy is described. The scaling behavior of sources of sample and receiver-coil noise is analyzed, and it is demonstrated that Johnson, or thermal, noise in the receiver coil is the factor that limits resolution. The behavior of superconductors in the environment of an NMR experiment is examined, and a prototypical system for imaging biological specimens is discussed. Preliminary spin-echo images are shown, and the ultimate limits of the signal-to-noise ratio of the probe are investigated.	DUKE UNIV,DEPT RADIOL,DURHAM,NC 27710; DUKE UNIV,DEPT PHYS,DURHAM,NC 27710	Duke University; Duke University	BLACK, RD (corresponding author), GE,CTR CORP RES & DEV,SCHENECTADY,NY 12301, USA.			Johnson, G.Allan/0000-0002-7606-5447	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004187] Funding Source: NIH RePORTER; NCRR NIH HHS [1P41 RR05959] Funding Source: Medline; NIEHS NIH HHS [ES0 4187] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHN CB, 1989, MED PHYS, V16, P22, DOI 10.1118/1.596393; BANSON ML, 1992, INVEST RADIOL, V27, P157, DOI 10.1097/00004424-199202000-00013; BLACK RD, 1991, 10TH P ANN M SOC MAG, P1250; BLOCH F, 1946, PHYS REV, V69, P127, DOI 10.1103/PhysRev.69.127; CALLAGHAN PT, 1990, J MAGN RESON, V87, P304, DOI 10.1016/0022-2364(90)90007-V; CALLAGHAN PT, 1988, J MAGN RESON, V78, P1, DOI 10.1016/0022-2364(88)90151-5; CHO ZH, 1988, MED PHYS, V15, P815, DOI 10.1118/1.596287; ECCLES CD, 1986, J MAGN RESON, V68, P393, DOI 10.1016/0022-2364(86)90261-1; EDELSTEIN WA, 1986, MAGNET RESON MED, V3, P604, DOI 10.1002/mrm.1910030413; HOULT DI, 1979, J MAGN RESON, V34, P425, DOI 10.1016/0022-2364(79)90019-2; HOUSE WV, 1984, IEEE T NUCL SCI, V31, P570, DOI 10.1109/TNS.1984.4333321; JOHNSON GA, 1989, VET PATHOL, V26, P303, DOI 10.1177/030098588902600403; JOHNSON GA, 1990, INVEST RADIOL, V25, P1361; Johnson JB, 1928, PHYS REV, V32, P97, DOI 10.1103/PhysRev.32.97; MANSFIELD P, 1975, PHYS REV B, V12, P3618, DOI 10.1103/PhysRevB.12.3618; MCFARLAND EW, 1992, MAGN RESON IMAGING, V10, P279, DOI 10.1016/0730-725X(92)90487-K; MCFARLAND EW, 1992, MAGN RESON IMAGING, V10, P269, DOI 10.1016/0730-725X(92)90486-J; MOGROCAMPERO A, 1991, APPL PHYS LETT, V58, P417, DOI 10.1063/1.104654; MUELLER OM, 1987, 6TH P ANN M SOC MAGN, P411; MULLER G, 1990, J SUPERCOND, V3, P235, DOI 10.1007/BF00625263; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560; STYLES P, 1989, J MAGN RESON, V84, P376, DOI 10.1016/0022-2364(89)90383-1; Terman F. E., 1943, RADIO ENG HDB, P148	23	183	199	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 5	1993	259	5096					793	795		10.1126/science.8430331	http://dx.doi.org/10.1126/science.8430331			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430331				2022-12-28	WOS:A1993KL11000026
J	GREENGARD, P; VALTORTA, F; CZERNIK, AJ; BENFENATI, F				GREENGARD, P; VALTORTA, F; CZERNIK, AJ; BENFENATI, F			SYNAPTIC VESICLE PHOSPHOPROTEINS AND REGULATION OF SYNAPTIC FUNCTION	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; TERMINAL-SPECIFIC PHOSPHOPROTEIN; SQUID GIANT SYNAPSE; FROG NEUROMUSCULAR-JUNCTION; ALPHA-LATROTOXIN RECEPTOR; EXPRESS HIGH-LEVELS; SRC GENE-PRODUCT; NEUROTRANSMITTER RELEASE; MEMBRANE-PROTEIN; RAT-BRAIN	Complex brain functions, such as learning and memory, are believed to involve changes in the efficiency of communication between nerve cells. Therefore, the elucidation of the molecular mechanisms that regulate synaptic transmission, the process of intercellular communication, is an essential step toward understanding nervous system function. Several proteins associated with synaptic vesicles, the organelles that store neurotransmitters, are targets for protein phosphorylation and dephosphorylation. One of these phosphoproteins, synapsin I, by means of changes in its state of phosphorylation, appears to control the fraction of synaptic vesicles available for release and thereby to regulate the efficiency of neurotransmitter release. This article describes current understanding of the mechanism by which synapsin I modulates communication between nerve cells and reviews the properties and putative functions of other phosphoproteins associated with synaptic vesicles.	UNIV MILAN, S RAFFAELE SCI INST,CNR,CTR CYTOPHARMACOL, DEPT MED PHARMACOL, I-20122 MILAN, ITALY; UNIV MODENA, INST HUMAN PHYSIOL, I-41100 MODENA, ITALY; UNIV ROME TOR VERGATA, DEPT EXPTL MED, ROME, ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Universita di Modena e Reggio Emilia; University of Rome Tor Vergata	GREENGARD, P (corresponding author), ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Flavia, Valtorta/F-3450-2012	Flavia, Valtorta/0000-0001-9556-4746	NIMH NIH HHS [MH 39327] Funding Source: Medline; Telethon [112] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039327, R01MH039327] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ALDER J, 1992, NEURON, V9, P759, DOI 10.1016/0896-6273(92)90038-F; ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BAHLER M, 1991, J NEUROCHEM, V57, P423, DOI 10.1111/j.1471-4159.1991.tb03769.x; BAHLER M, 1990, BIOESSAYS, V12, P259, DOI 10.1002/bies.950120603; BAINES AJ, 1986, NATURE, V319, P145, DOI 10.1038/319145a0; BAINES AJ, 1985, NATURE, V315, P410, DOI 10.1038/315410a0; BARNEKOW A, 1990, ONCOGENE, V5, P1019; BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; BENFENATI F, 1990, J BIOL CHEM, V265, P12584; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1989, J CELL BIOL, V108, P1851, DOI 10.1083/jcb.108.5.1851; BENFENATI F, 1991, P NATL ACAD SCI USA, V88, P575, DOI 10.1073/pnas.88.2.575; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENFENATI F, 1992, NEURON, V8, P377, DOI 10.1016/0896-6273(92)90303-U; BENNETT M K, 1991, Journal of Cell Biology, V115, p304A; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MK, IN PRESS J NEUROSCI; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; Burgoyne R. D., 1991, NEURONAL CYTOSKELETO; CECCALDI PE, UNPUB; CECCARELLI B, 1980, PHYSIOL REV, V60, P396, DOI 10.1152/physrev.1980.60.2.396; CHILCOTE T, UNPUB; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; DELCASTILLO J, 1956, PROG BIOPHYS MOL BIO, V6, P122, DOI 10.1016/S0096-4174(18)30106-9; DINO M R, 1991, Society for Neuroscience Abstracts, V17, P637; FERRELL JE, 1990, ONCOGENE, V5, P1033; FESCE R, 1992, J BIOL CHEM, V267, P11289; GOLDENRING JR, 1986, J BIOL CHEM, V261, P8495; GOTOW T, 1991, NEUROSCIENCE, V40, P587, DOI 10.1016/0306-4522(91)90143-C; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; HACKETT JT, 1990, J NEUROPHYSIOL, V63, P701, DOI 10.1152/jn.1990.63.4.701; HALL FL, 1990, J BIOL CHEM, V265, P6944; HAN HQ, 1991, NATURE, V349, P697, DOI 10.1038/349697a0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; HUTTNER WB, 1979, P NATL ACAD SCI USA, V76, P5402, DOI 10.1073/pnas.76.10.5402; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; KENNEDY MB, 1983, J NEUROSCI, V3, P818; KNAUS P, 1990, NEURON, V5, P453, DOI 10.1016/0896-6273(90)90084-S; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; MANDELL JW, 1992, J NEUROSCI, V12, P1736; MANDELL JW, 1990, NEURON, V5, P19, DOI 10.1016/0896-6273(90)90030-J; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; Nestler E. J., 1984, PROTEIN PHOSPHORYLAT; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NICHOLS RA, 1992, J NEUROCHEM, V58, P783, DOI 10.1111/j.1471-4159.1992.tb09788.x; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; PANG D T, 1988, Society for Neuroscience Abstracts, V14, P106; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; POPOLI M, 1988, NEUROCHEM RES, V13, P63, DOI 10.1007/BF00971856; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; RUBENSTEIN JL, 1993, SYNAPSE, V13, P161, DOI 10.1002/syn.890130207; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SEVERIN SE, 1989, FEBS LETT, V258, P223, DOI 10.1016/0014-5793(89)81658-8; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SIHRA TS, 1989, P NATL ACAD SCI USA, V86, P8108, DOI 10.1073/pnas.86.20.8108; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SIOW YL, 1992, BIOCHEMISTRY-US, V31, P4268, DOI 10.1021/bi00132a017; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TARELLI FT, 1992, NEURON, V9, P1143, DOI 10.1016/0896-6273(92)90072-L; TARELLI FT, 1991, BRAIN RES, V547, P331, DOI 10.1016/0006-8993(91)90981-Z; TARELLI FT, 1990, J CELL BIOL, V110, P449; THIEL G, 1991, P NATL ACAD SCI USA, V88, P3431, DOI 10.1073/pnas.88.8.3431; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; THOMAS L, 1990, J CELL BIOL, V111, P2041, DOI 10.1083/jcb.111.5.2041; TRIFARO JM, 1989, NEUROSCIENCE, V29, P1, DOI 10.1016/0306-4522(89)90327-8; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; VALTORTA F, 1992, J BIOL CHEM, V267, P11281; VALTORTA F, 1990, NEUROSCIENCE, V35, P477, DOI 10.1016/0306-4522(90)90323-V; VALTORTA F, 1988, NEUROSCIENCE, V24, P593, DOI 10.1016/0306-4522(88)90353-3; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; WALAAS SI, 1988, MOL BRAIN RES, V3, P215, DOI 10.1016/0169-328X(88)90044-7; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9	103	1129	1147	4	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					780	785		10.1126/science.8430330	http://dx.doi.org/10.1126/science.8430330			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430330				2022-12-28	WOS:A1993KL11000022
J	PAUKER, SG; KOPELMAN, RI				PAUKER, SG; KOPELMAN, RI			WEAK REASONING - DIAGNOSIS BY DRUG REACTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MYASTHENIA-GRAVIS; ERYTHROMYCIN; AGGRAVATION		TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GEN INTERNAL MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	PAUKER, SG (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CLIN DECIS MAKING,BOSTON,MA 02111, USA.							ABSHER JR, 1991, J PEDIATR-US, V119, P155, DOI 10.1016/S0022-3476(05)81058-3; ALBERT RK, 1992, TXB INTERNAL MED, P1874; ENGEL AG, 1992, CECIL TXB MED, P2265; HOWARD JF, 1990, SEMIN NEUROL, V10, P89, DOI 10.1055/s-2008-1041258; KASSIRER JP, 1991, LEARNING CLIN REASON, P33; LINTON DM, 1990, DM-DIS MON, V36, P593; MAY EF, 1990, ANN NEUROL, V28, P577, DOI 10.1002/ana.410280417; MURRAY JF, 1992, CECIL TXB MED, P452; 1992, DRUG EVALUATIONS ANN, P1349; 1992, DRUG FACTS COMPARISO; 1992, PHYSICIANS DESK REFE, P915	11	7	7	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					336	339		10.1056/NEJM199302043280509	http://dx.doi.org/10.1056/NEJM199302043280509			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8419820				2022-12-28	WOS:A1993KK24700009
J	DAVIES, K				DAVIES, K			CLONING THE MENKES DISEASE GENE	NATURE			English	Article																		CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; DANKS DM, 1972, LANCET, V1, P1101; HAMER DH, 1993, NAT GENET, V3, P3, DOI 10.1038/ng0193-3; Kaler S. G., 1992, American Journal of Human Genetics, V51, pA170; LEVINSON D, 1993, NATURE GENET, V3, P6; MENKES JH, 1962, PEDIATRICS, V29, P764; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7	9	12	12	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					98	98		10.1038/361098a0	http://dx.doi.org/10.1038/361098a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421503	Bronze			2022-12-28	WOS:A1993KF71800059
J	MENZIES, R; TAMBLYN, R; FARANT, JP; HANLEY, J; NUNES, F; TAMBLYN, R				MENZIES, R; TAMBLYN, R; FARANT, JP; HANLEY, J; NUNES, F; TAMBLYN, R			THE EFFECT OF VARYING LEVELS OF OUTDOOR-AIR SUPPLY ON THE SYMPTOMS OF SICK BUILDING SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OFFICE; VENTILATION; QUALITY	Background. The sick building syndrome is the term given to a constellation of symptoms reported by workers in modem office buildings, hypothesized to occur when the supply of outdoor air is reduced, because of the accumulation of contaminants arising from within the building. We undertook this study to determine the effect of changing the supply of outdoor air in four office buildings on the symptoms reported by workers and their perception of the indoor environment. Methods. Within each of three consecutive two-week blocks, the ventilation systems in each building were manipulated, in random order, to deliver to the indoor environment an intended 20 or 50 ft3 (0.57 or 1.4 m3) of outdoor air per minute per person for one week at a time. Each week, the participants, unaware of the experimental intervention, reported symptoms and the indoor environment was thoroughly evaluated. Results. Of 1838 eligible workers in the four buildings, 1546 (84 percent) participated in the study. The supply of outdoor air averaged 7 percent and 32 percent in the ventilation systems and 30 and 64 ft3 (0.85 and 1.8 m3) per minute per person in the work sites at the lower and higher ventilation levels, respectively. These changes in the supply of outdoor air were not associated with changes in the participants' ratings of the office environment or in symptom frequency (crude odds ratio, 1.0; 95 percent confidence interval, 0.9 to 1.1). After work-site measures of ventilation, temperature, humidity, and air velocity were included in the regression analysis, the adjusted odds ratio was also 1.0 (95 percent confidence interval, 0.8 to 1.2). Conclusions. Increases in the supply of outdoor air did not appear to affect workers' perceptions of their office environment or their reporting of symptoms considered typical of the sick building syndrome.	MCGILL UNIV,DEPT MED,RESP EPIDEMIOL UNIT,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,SCH OCCUPAT HLTH,MONTREAL H3A 2T5,QUEBEC,CANADA; ENGN INTERFACE LTD,TORONTO,ON,CANADA	McGill University; McGill University	MENZIES, R (corresponding author), MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,RESP EPIDEMIOL UNIT,1110 PINE AVE W,MONTREAL H3A 1A3,PQ,CANADA.		Tamblyn, Robyn/L-6010-2016					BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; Bradburn N.M., 1969, STRUCTURE PSYCHOL WE, DOI DOI 10.1037/T10756-000; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BRODER I, 1990, 5TH P INT C IND AIR, V1, P221; BURGE S, 1987, ANN OCCUP HYG, V31, P493, DOI 10.1093/annhyg/31.4A.493; Colton T., 1974, STAT MED, V1; FANGER PO, 1988, ENERG BUILDINGS, V12, P7, DOI 10.1016/0378-7788(88)90052-7; Fanger PO., 1972, THERMAL COMFORT; FARANT JP, 1990, 5TH P INT C IND AIR, V1, P581; FLEISS JL, 1982, AM J EPIDEMIOL, V115, P841, DOI 10.1093/oxfordjournals.aje.a113371; GIRMAN JR, 1989, OCCUP MED, V4, P695; HALL HI, 1991, HLTH BUILDINGS, P33; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; LEVINE H, 1991, INDOOR AIR QUALI SEP, V4, P5; NORBACK D, 1990, SCAND J WORK ENV HEA, V16, P121, DOI 10.5271/sjweh.1808; PRELLER L, 1990, 5TH P IND AIR 90 INT, V1, P227; ROBERTSON AS, 1985, BRIT MED J, V291, P373, DOI 10.1136/bmj.291.6492.373; SAMET JM, 1988, AM REV RESPIR DIS, V137, P221, DOI 10.1164/ajrccm/137.1.221; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SKOV P, 1987, ENVIRON INT, V13, P339, DOI 10.1016/0160-4120(87)90190-5; TAMBLYN RM, 1992, J CLIN EPIDEMIOL, V45, P603, DOI 10.1016/0895-4356(92)90132-7; TURIEL I, 1983, ATMOS ENVIRON, V17, P51, DOI 10.1016/0004-6981(83)90007-0; TURNER WA, 1989, HUMAN EQUATION HLTH, P117; WOODS JE, 1989, OCCUP MED, V4, P753; WYON DP, 1979, SCAND J WORK ENV HEA, V5, P352, DOI 10.5271/sjweh.2646; [No title captured]; 1983, INDOOR AIR POLLUTANT; 1989, ASHRAE621989 AM SOC; [No title captured]; [No title captured]; 1981, ASHRAE621989 AM SOC	31	112	113	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 25	1993	328	12					821	827		10.1056/NEJM199303253281201	http://dx.doi.org/10.1056/NEJM199303253281201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT814	8441426	Green Published			2022-12-28	WOS:A1993KT81400001
J	REDELMEIER, DA; FUCHS, VR				REDELMEIER, DA; FUCHS, VR			HOSPITAL EXPENDITURES IN THE UNITED-STATES AND CANADA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE SYSTEM; ONTARIO; EXPERIENCE	Background. Expenditures per capita for hospitals are higher in the United States than in Canada. If the United States had the same spending pattern as Canada, the annual savings in 1985 would have exceeded $30 billion. Methods. We used data from published sources, computer files, and institutional reports to compare 1987 costs for acute care hospitals on three levels: national (the United States vs. Canada), regional (California vs. Ontario), and institutional (two California hospitals vs. two Ontario hospitals). Expenditures per admission were adjusted for the case mix of patients, prices of labor and other resources, and outpatient visits. Results. The United States had proportionately fewer hospital beds than Canada (3.9 vs. 5.4 per 1000 population), fewer admissions (129 vs. 142 per 1000 population), and shorter mean stays (7.2 vs. 11.2 days). Higher costs per admission in the United States were explained in part by a case mix that was more complex by 14 percent and by prices for labor, supplies, and other hospital resources that were higher by 4 percent. Hospitals in the United States provided relatively less outpatient care, particularly in emergency departments (320 vs. 677 visits per 1000 population). After all adjustments, the estimate of resources used for inpatient care per admission was 24 percent higher in the United States than in Canada and 46 percent higher in California than in Ontario. The estimated differences between the two pairs of California and Ontario hospitals were 20 and 15 percent. Conclusions. Canadian acute care hospitals have more admissions, more outpatient visits, and more inpatient days per capita than hospitals in the United States, but they spend appreciably less. The reasons include higher administrative costs in the United States and more use of centralized equipment and personnel in Canada.	NATL BUR ECON RES,STANFORD,CA; UNIV TORONTO,DEPT MED,TORONTO M5S 1A1,ONTARIO,CANADA; STANFORD UNIV,DEPT ECON,STANFORD,CA 94305; STANFORD UNIV,DEPT HLTH RES & POLICY,STANFORD,CA 94305	National Bureau of Economic Research; University of Toronto; Stanford University; Stanford University	REDELMEIER, DA (corresponding author), WELLESLEY COLL HOSP,RES INST,DIV CLIN EPIDEMIOL,JONES BLDG,RM 123,160 WELLESLEY ST E,TORONTO M4Y 1J3,ONTARIO,CANADA.							CAPDEVIELLE P, 1988, MON LABOR REV, V111, P44; COYTE PC, 1991, NEW ENGL J MED, V324, P89, DOI 10.1056/NEJM199101103240204; DETSKY AS, 1986, MED CARE, V24, P89, DOI 10.1097/00005650-198601000-00010; DETSKY AS, 1983, NEW ENGL J MED, V309, P151, DOI 10.1056/NEJM198307213090306; DONHAM CS, 1989, HLTH CARE FINANC REV, V11, P113; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; HABER SG, IN PRES SJ HLTH EC; HELYAR C, 1991, NOTEBOOK DATA QUALIT; HIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441, DOI 10.1056/NEJM198602133140710; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; IGLEHART JK, 1990, NEW ENGL J MED, V322, P562, DOI 10.1056/NEJM199002223220827; KATZ SJ, 1991, JAMA-J AM MED ASSOC, V266, P1108, DOI 10.1001/jama.266.8.1108; Levit K R, 1985, Health Care Financ Rev, V6, P1; LIPSET S, 1990, CONTINENTAL DIVIDE; NAYLOR CD, 1991, HEALTH AFFAIR, V10, P110, DOI 10.1377/hlthaff.10.3.110; NEWHOUSE JP, 1988, HEALTH AFFAIR, V7, P6, DOI 10.1377/hlthaff.7.5.6; SCHIEBER GJ, 1991, HEALTH AFFAIR, V10, P22, DOI 10.1377/hlthaff.10.3.22; STEINWALD B, 1989, HEALTH AFFAIR, V8, P35, DOI 10.1377/hlthaff.8.2.35; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; 1988, CURRENT POPULATION S; 1988, CANADA YB 1988; 1990, CALIFORNIA STATISTIC; 1987, LENGTH STAY DATABASE; 1988, HOSPITAL STATISTICS; 1990, 1990 ONTARIO BUDGET; 1989, HOSPITAL STATISTICS; 1990, HOSPITAL STATISTICS; 1988, CAN DIS WKLYY REP, V14, P15; 1991, CANADA YB 1990; 1990, VITAL STATISTICS 198; 1991, HOSPITAL STATISTICS; 1991, 1990 OFF STAT HLTH P; 1990, DEP LABOR B, V2364; 1990, LIST CANADIAN HOSPIT; 1991, HOSPITAL ANN STATIST; 1990, STATISTICAL ABSTRACT; 1988, MMWR MORB MORTAL WKL, V36, P827; 1991, VITAL STATISTICS, V3; 1989, NATIONAL CTR HLTH 13, V99; 1990, AGGREGATE HOSPITAL D	41	108	108	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					772	778		10.1056/NEJM199303183281107	http://dx.doi.org/10.1056/NEJM199303183281107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KR848	8437598				2022-12-28	WOS:A1993KR84800007
J	BURNSIDE, JW				BURNSIDE, JW			PASSING STONES	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						RETIREMENT; PHYSICIANS PRACTICE; PATTERNS		An older physician consults a younger colleague for medical care. Having begun his career with good intentions and hard work, the older physician has become bitter because of the constant demands. His colleague encourages him to retire for his health, with surprising consequences.			BURNSIDE, JW (corresponding author), UNIV TEXAS, SW MED CTR, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					465	466		10.7326/0003-4819-118-6-199303150-00011	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00011			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439121				2022-12-28	WOS:A1993KR81700011
J	GIBBONS, RJ; HOLMES, DR; REEDER, GS; BAILEY, KR; HOPFENSPIRGER, MR; GERSH, BJ				GIBBONS, RJ; HOLMES, DR; REEDER, GS; BAILEY, KR; HOPFENSPIRGER, MR; GERSH, BJ			IMMEDIATE ANGIOPLASTY COMPARED WITH THE ADMINISTRATION OF A THROMBOLYTIC AGENT FOLLOWED BY CONSERVATIVE TREATMENT FOR MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; HEXAKIS 2-METHOXYISOBUTYL ISONITRILE; CORONARY ANGIOPLASTY; METHOXYISOBUTYL ISONITRILE; INTRAVENOUS STREPTOKINASE; VENTRICULAR-FUNCTION; REPERFUSION THERAPY; TC-99M ISONITRILE; BLOOD-FLOW; TRIAL	Background. Immediate angioplasty and the administration of a thrombolytic agent followed by conservative treatment are two approaches to the management of acute myocardial infarction, but these methods have not been compared prospectively. Methods. We enrolled 108 patients with acute myocardial infarction in a randomized trial designed to test the hypothesis that immediate angioplasty (without previous thrombolytic therapy) may result in greater myocardial salvage than the administration of a thrombolytic agent followed by conservative treatment. The primary end point was the change in the size of the perfusion defect as assessed at admission and discharge by tomographic imaging with technetium-99m sestamibi, a myocardial perfusion agent that can measure myocardium at risk and final infarct size. Results. End-point data were available for 56 patients randomly assigned to receive tissue plasminogen activator (mean [+/-SD] time to start of infusion, 232+/-174 minutes after the onset of chest pain) and 47 patients randomly assigned to receive angioplasty (first balloon inflation at 277+/-144 minutes). In the case of anterior infarction, myocardial salvage as assessed by imaging with technetium-99m sestamibi was 27+/-21 percent of the left ventricle for 22 patients in the thrombolysis group, as compared with 31+/-21 percent for 15 patients in the angioplasty group. For infarcts in all other locations, myocardial salvage was 7+/-13 percent for 34 patients in the thrombolysis group and 5+/-10 percent for 32 patients in the angioplasty group. After adjustment for infarct location, the difference in mean salvage between groups was 0 (P = 0.98), with a 95 percent confidence interval of +/-6 percent of the left ventricle. Conclusions. In patients with acute myocardial infarction, immediate angioplasty does not appear to result in greater myocardial salvage than the administration of a thrombolytic agent followed by conservative treatment, although a small difference between these two therapeutic approaches cannot be excluded.	MAYO CLIN & MAYO FDN, DIV STAT & HLTH SCI RES, ROCHESTER, MN 55905 USA	Mayo Clinic	GIBBONS, RJ (corresponding author), MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1986, Lancet, V1, P397; BEHRENBECK T, 1991, J AM COLL CARDIOL, V17, P365, DOI 10.1016/S0735-1097(10)80101-9; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; CHRISTIAN TF, 1991, AM J CARDIOL, V68, P21, DOI 10.1016/0002-9149(91)90703-N; CHRISTIAN TF, 1990, J AM COLL CARDIOL, V16, P1632, DOI 10.1016/0735-1097(90)90313-E; Cochran W.G, 1957, STAT METHODS, V6th ed; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; DECOSTER PM, 1990, CIRCULATION, V82, P2152, DOI 10.1161/01.CIR.82.6.2152; ELLIS SG, 1989, J AM COLL CARDIOL, V13, P1122, DOI 10.1016/0735-1097(89)90272-6; GIBBONS RJ, 1991, SEMIN NUCL MED, V21, P213, DOI 10.1016/S0001-2998(05)80041-8; GIBBONS RJ, 1989, CIRCULATION, V80, P1277, DOI 10.1161/01.CIR.80.5.1277; GIBBONS RJ, 1988, J AM COLL CARDIOL, V11, P28, DOI 10.1016/0735-1097(88)90162-3; HUNT D, 1992, LANCET, V339, P753; LI QS, 1988, J NUCL MED, V29, P1539; OCONNOR MK, 1990, EUR J NUCL MED, V17, P69, DOI 10.1007/BF00819407; OKADA RD, 1988, CIRCULATION, V77, P491, DOI 10.1161/01.CIR.77.2.491; OKEEFE JH, 1989, AM J CARDIOL, V64, P1221, DOI 10.1016/0002-9149(89)90558-4; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; OROURKE M, 1988, CIRCULATION, V77, P1311, DOI 10.1161/01.CIR.77.6.1311; PELLIKKA PA, 1990, J NUCL MED, V31, P1269; REIMER KA, 1985, CIRC RES, V56, P651, DOI 10.1161/01.RES.56.5.651; REIMER KA, 1981, CARDIOVASC RES, V15, P668, DOI 10.1093/cvr/15.11.668; RITCHIE JL, 1988, J AM COLL CARDIOL, V11, P689, DOI 10.1016/0735-1097(88)90197-0; RIVAS F, 1976, CIRC RES, V38, P439, DOI 10.1161/01.RES.38.5.439; ROTHBAUM DA, 1987, J AM COLL CARDIOL, V10, P264, DOI 10.1016/S0735-1097(87)80006-2; SANTORO GM, 1990, J AM COLL CARDIOL, V15, P301; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1986, J AM COLL CARDIOL, V7, P717, DOI 10.1016/S0735-1097(86)80329-1; SINUSAS A J, 1990, Journal of the American College of Cardiology, V15, p227A; SINUSAS AJ, 1990, CIRCULATION, V82, P1424, DOI 10.1161/01.CIR.82.4.1424; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; VERANI MS, 1988, J AM COLL CARDIOL, V12, P1573, DOI 10.1016/S0735-1097(88)80028-7; WACKERS FJT, 1989, J AM COLL CARDIOL, V14, P861, DOI 10.1016/0735-1097(89)90456-7; WILCOX RG, 1988, LANCET, V2, P525	36	725	735	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1993	328	10					685	691		10.1056/NEJM199303113281003	http://dx.doi.org/10.1056/NEJM199303113281003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ861	8433727				2022-12-28	WOS:A1993KQ86100003
J	MAHER, J; HACHINSKI, VC				MAHER, J; HACHINSKI, VC			ANTICOAGULATION FOR EMBOLIC STROKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ATRIAL-FIBRILLATION				MAHER, J (corresponding author), UNIV WESTERN ONTARIO, LONDON N6A 3K7, ONTARIO, CANADA.							[Anonymous], 1984, Stroke, V15, P779; GURWITZ JH, 1988, ARCH INTERN MED, V148, P1733, DOI 10.1001/archinte.148.8.1733; HART RG, 1983, STROKE, V14, P688, DOI 10.1161/01.STR.14.5.688; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; PETERSEN P, 1989, LANCET, V1, P175; 1983, STROKE, V14, P668	7	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1309	1309		10.1001/jama.1993.03500100109041	http://dx.doi.org/10.1001/jama.1993.03500100109041			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437313				2022-12-28	WOS:A1993KP88500035
J	VANHOY, M; LEUTHER, KK; KODADEK, T; JOHNSTON, SA				VANHOY, M; LEUTHER, KK; KODADEK, T; JOHNSTON, SA			THE ACIDIC ACTIVATION DOMAINS OF THE GCN4 AND GAL4 PROTEINS ARE NOT ALPHA-HELICAL BUT FORM BETA-SHEETS	CELL			English	Article							TRANSCRIPTIONAL ACTIVATION; YEAST; BINDING; PURIFICATION; INVITRO; VP16; GENE; LAC9	The most common class of activation domains, the so-called acidic activators, has been proposed either to adopt an amphipathic alpha-helical structure or to exist as unstructured ''acid blobs.'' However, genetic analysis of an acidic activation domain in the yeast GAL4 protein has suggested that the structure of the activation region is a beta sheet. To distinguish between these models, we conducted a biophysical analysis of peptides corresponding to the yeast GAL4 and GCN4 acidic activation domains. Circular dichroism spectroscopy shows that the peptides are not alpha helical, but that they can undergo a transition to a structure that is almost 100% beta sheet in character in slightly acidic solution. We also show that the artificial acidic activator AH has structural properties that are markedly different from the natural GAL4 and GCN4 domains and does not adopt a beta-rich structure at reduced pH.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,GENET & DEV PROGRAM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	VANHOY, M (corresponding author), UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047140, R01GM040700] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-40700, GM-47140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDL CJ, 1989, P NATL ACAD SCI USA, V86, P2652, DOI 10.1073/pnas.86.8.2652; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEGRADO WF, 1981, J AM CHEM SOC, V103, P679, DOI 10.1021/ja00393a035; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INNES MA, 1990, PCR PROTOCOLS GUIDE; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REGIER JL, 1992, IN PRESS P NATL ACAD; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SALMERON JM, 1989, MOL CELL BIOL, V9, P2950, DOI 10.1128/MCB.9.7.2950; Sambrook J, 1989, MOL CLONING LABORATO; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VANHOY M, 1992, J AM CHEM SOC, V114, P362, DOI 10.1021/ja00027a057; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOO Y, 1989, J BIOL CHEM, V264, P17078	37	136	138	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					587	594		10.1016/0092-8674(93)90077-4	http://dx.doi.org/10.1016/0092-8674(93)90077-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440022				2022-12-28	WOS:A1993KP16500013
J	REN, RB; MAYER, BJ; CICCHETTI, P; BALTIMORE, D				REN, RB; MAYER, BJ; CICCHETTI, P; BALTIMORE, D			IDENTIFICATION OF A 10-AMINO ACID PROLINE-RICH SH3 BINDING-SITE	SCIENCE			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; C-ABL; PROTEINS; MUTAGENESIS; P60C-SRC; DOMAINS	The Src homology 3 (SH3) region is a small protein domain present in a very large group of proteins, including cytoskeletal elements and signaling proteins. It is believed that SH3 domains serve as modules that mediate protein-protein associations and, along with Src homology 2 (SH2) domains, regulate cytoplasmic signaling. The SH3 binding sites of two SH3 binding proteins were localized to a nine- or ten-amino acid stretch very rich in proline residues. Similar SH3 binding motifs exist in the formins, proteins that function in pattern formation in embryonic limbs of the mouse, and one subtype of the muscarinic acetylcholine receptor. Identification of the SH3 binding site provides a basis for understanding the interaction between the SH3 domains and their targets.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University					NCI NIH HHS [CA 08875, CA 09673, CA 51462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008875, R01CA051462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, UNPUB; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DICKIE MM, 1968, MOUSE NEWS LETT, V38, P24; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Green MC, 1964, MOUSE NEWS LETT, V31, P27; GRUENEBERG H, 1963, PATHOLOGY DEV STUDY; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JENKINS NA, UNPUB; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MASS RL, 1990, NATURE, V346, P853; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; PAWSON T, 1992, NATURE, V356, P285, DOI 10.1038/356285a0; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; Potts W M, 1988, Oncogene Res, V3, P343; REN R, UNPUB; Richardson JS., 1989, PREDICT PROTEIN STRU; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Stryer L., 1988, BIOCHEMISTRY-US; SWEET HO, 1982, MOUSE NEWS LETT, V66, P66; WOYCHIK RP, 1985, NATURE, V318, P36, DOI 10.1038/318036a0; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; 1989, TRENDS PHARM SCI S, pR7	37	1136	1192	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 19	1993	259	5098					1157	1161		10.1126/science.8438166	http://dx.doi.org/10.1126/science.8438166			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8438166				2022-12-28	WOS:A1993KM91700038
J	CHELALA, CA				CHELALA, CA			A MODERN DOCTOR SCHWEITZER	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIANS ROLE; SOCIAL RESPONSIBILITY; KNOWLEDGE, ATTITUDES, PRACTICE; DEVELOPING COUNTRIES; EQUATORIAL GUINEA		A physician from Spain devotes bis life to treating patients in small village in Africa. Despite the lack of modern medical equipment and personal amenities, he finds satisfaction in caring for patients who would otherwise go without medical treatment.											0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					307	307		10.7326/0003-4819-118-4-199302150-00010	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420449				2022-12-28	WOS:A1993KL45700009
J	FUSHIMI, K; UCHIDA, S; HARA, Y; HIRATA, Y; MARUMO, F; SASAKI, S				FUSHIMI, K; UCHIDA, S; HARA, Y; HIRATA, Y; MARUMO, F; SASAKI, S			CLONING AND EXPRESSION OF APICAL MEMBRANE WATER CHANNEL OF RAT-KIDNEY COLLECTING TUBULE	NATURE			English	Article							MAJOR INTRINSIC PROTEIN; XENOPUS OOCYTES; SEQUENCE; POLYMERASE; NUCLEOTIDE; FAMILY; LENS; MIP	CONCENTRATING urine is mandatory for most mammals to prevent water loss from the body. Concentrated urine is produced in response to vasopressin by the transepithelial recovery of water from the lumen of the kidney collecting tubule through highly water-permeable membranes1,2. In this nephron segment, vasopressin regulates water permeability by endo- and exocytosis of water channels from or to the apical membrane3,4. CHIP28 is a water channel in red blood cells and the kidney proximal tubule5, but it is not expressed in the collecting tubule6. Here we report the cloning of the complementary DNA for WCH-CD, a water channel of the apical membrane of the kidney collecting tubule. WCH-CD is 42% identical in amino-acid sequence to CHIP28. WCH-CD transcripts are detected only in the collecting tubule of the kidney. Immunohistochemically, WCH-CD is localized to the apical region of the kidney collecting tubule cells. Expression of WCH-CD in Xenopus oocytes markedly increases osmotic water permeability. The functional expression and the limited localization of WCH-CD to the apical region of the kidney collecting tubule suggest that WCH-CD is the vasopressin-regulated water channel.	TOKYO MED & DENT UNIV,DEPT BIOCHEM,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU)	FUSHIMI, K (corresponding author), TOKYO MED & DENT UNIV,DEPT INTERNAL MED 2,1-5-45 YUSHIMA,BUNKYO KU,TOKYO 113,JAPAN.		Uchida, Shinichi/D-1111-2013					DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DENKER BM, 1988, J BIOL CHEM, V263, P15634; HANDLER JS, 1988, AM J PHYSIOL, V255, pF375, DOI 10.1152/ajprenal.1988.255.3.F375; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KENT NA, 1990, NUCLEIC ACIDS RES, V18, P4256, DOI 10.1093/nar/18.14.4256; KNEPPER MA, 1991, KIDNEY, P445; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOXAK M, 1987, NUCLEIC ACIDS RES, V15, P8127; KUWAHARA M, 1988, BIOPHYS J, V54, P595, DOI 10.1016/S0006-3495(88)82994-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MORIYAMA T, 1990, AM J PHYSIOL, V258, pF1470, DOI 10.1152/ajprenal.1990.258.5.F1470; ORLOFF J, 1967, AM J MED, V42, P757, DOI 10.1016/0002-9343(67)90093-9; PAO GM, 1991, MOL MICROBIOL, V5, P33, DOI 10.1111/j.1365-2958.1991.tb01823.x; PISANO MM, 1991, GENOMICS, V11, P981; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SIGEL E, 1990, J MEMBRANE BIOL, V117, P201, DOI 10.1007/BF01868451; SKOWSKY WR, 1972, J LAB CLIN MED, V80, P134; TERADA Y, 1991, AM J PHYSIOL, V261, pF1080, DOI 10.1152/ajprenal.1991.261.6.F1080; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; WISTOW GJ, 1991, TRENDS BIOCHEM SCI, V16, P170, DOI 10.1016/0968-0004(91)90065-4; ZHANG R, 1991, AM J PHYSIOL, V260, pC26, DOI 10.1152/ajpcell.1991.260.1.C26	24	891	913	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					549	552		10.1038/361549a0	http://dx.doi.org/10.1038/361549a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429910				2022-12-28	WOS:A1993KL71400065
J	KELLER, AS; LINK, RN; BICKELL, NA; CHARAP, MH; KALET, AL; SCHWARTZ, MD				KELLER, AS; LINK, RN; BICKELL, NA; CHARAP, MH; KALET, AL; SCHWARTZ, MD			DIABETIC-KETOACIDOSIS IN PRISONERS WITHOUT ACCESS TO INSULIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To assess the cause and clinical severity of diabetic ketoacidosis in male prisoners hospitalized in New York City. Design.-Retrospective chart review. Setting.-A municipal hospital in New York City. Patients.-Forty-nine adult male prisoners with a total of 54 hospital admissions for diabetic ketoacidosis between January 1, 1989, and June 30, 1991. Main Outcome Measures.-Charts were reviewed for diabetic and medical history, time from arrest until hospitalization, cause of diabetic ketoacidosis, admission laboratory data, and hospital course. Results.-Thirty-eight (70%) of the 54 admissions for diabetic ketoacidosis among prisoners occurred because prisoners had not received insulin during the period immediately following arrest (mean number of days from arrest until hospitalization was 2.5). All of these individuals had a history of insulin-dependent diabetes and were reportedly compliant with their insulin regimen at the time of arrest. Admission laboratory data for this group of prisoners included a mean serum glucose level of 27.4 mmol/L (495 mg/dL) and a mean serum bicarbonate level of 14.4 mmol/L. Mean number of days in the hospital was 3.4 including a mean of 1 day in an intensive care unit. Conclusions.-Inadequate access to medication results in serious sequelae for recently arrested prisoners in New York City with insulin-dependent diabetes. Access to health care for recently arrested prisoners needs to be improved.	NYU,SCH MED,DEPT MED,NEW YORK,NY 10003	New York University			Kalet, Adina/AAA-3440-2021	Kalet, Adina/0000-0003-4855-0223; Schwartz, Mark/0000-0002-7123-0060				Clements R S Jr, 1978, Diabetes Care, V1, P314; DUBLER NN, 1986, STANDARDS HLTH SERVI; FOSTER DW, 1983, NEW ENGL J MED, V309, P159; GANGI R, 1992, PRESENTATION TASK FO; HAMBLIN PS, 1989, MED J AUSTRALIA, V151, P439, DOI 10.5694/j.1326-5377.1989.tb101253.x; HAMBURG MA, 1992, FINAL REPORT NEW YOR; NAVARRO M, 1992, NY TIMES        0213, V13, pB3; RAAB S, 1992, NEW YORK TIMES  0305, pB1; Raab Selwyn, 1992, NY TIMES, P25; 1992, ANN INTERN MED, V117, P71; 1992, 1992 POLICY COMPENDI; 1992, DIABETES CARE S2, V15, P42	12	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					619	621		10.1001/jama.269.5.619	http://dx.doi.org/10.1001/jama.269.5.619			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421367				2022-12-28	WOS:A1993KJ44400029
J	FOLSOM, AR; KAYE, SA; SELLERS, TA; HONG, CP; CERHAN, JR; POTTER, JD; PRINEAS, RJ				FOLSOM, AR; KAYE, SA; SELLERS, TA; HONG, CP; CERHAN, JR; POTTER, JD; PRINEAS, RJ			BODY-FAT DISTRIBUTION AND 5-YEAR RISK OF DEATH IN OLDER WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; CARDIOVASCULAR-DISEASE; ABDOMINAL ADIPOSITY; DIABETES-MELLITUS; CIGARETTE-SMOKING; MASS INDEX; MEN BORN; MORTALITY; PARTICIPANTS; WEIGHT	Objective.-To test the hypothesis that both body mass index (expressed as the ratio of weight in kilograms per height in meters squared) and the ratio of waist circumference to hip circumference are positively associated with mortality risk in older women. Design.-Prospective cohort study with a 5-year follow-up period. Setting.-General community. Participants.-Random sample of 41 837 Iowa women aged 55 to 69 years. Main Outcome Measure.-Total mortality (1504 deaths). Main Results.-Body mass index, an index of relative weight, was associated with mortality in a J-shaped fashion: rates were elevated in the leanest as well as in the most obese women. In contrast, waist/hip circumference ratio was strongly and positively associated with mortality in a dose-response manner. Adjusted for age, body mass index, smoking, education level, marital status, estrogen use, and alcohol use, a 0.15-unit increase in waist/hip circumference ratio (eg, a 15-cm [6-in] increase in waist measurement in a woman with 1 00-cm [40-in] hips) was associated with a 60% greater relative risk of death. The observed associations were not explained to any great degree by bias from weight loss prior to baseline or higher early deaths among lean participants. Conclusions.-Waist/hip circumference ratio is a better marker than body mass index of risk of death in older women. Waist/hip circumference ratio should be measured as part of routine surveillance and risk monitoring in medical practice.	UNIV MIAMI, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, MIAMI, FL 33152 USA	University of Miami	FOLSOM, AR (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.			Cerhan, James/0000-0002-7482-178X; Potter, John/0000-0001-5439-1500	NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA099607, R01 CA39742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETTCONNOR E, 1989, ANN INTERN MED, V111, P783, DOI 10.7326/0003-4819-111-10-783; BJORNTORP P, 1988, ACTA MED SCAND, V723, P121; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; BOUCHARD C, 1988, INT J OBESITY, V12, P205; CORNONIHUNTLEY JC, 1991, J CLIN EPIDEMIOL, V44, P743, DOI 10.1016/0895-4356(91)90126-T; FANELLI MT, 1988, INT J OBESITY, V12, P125; FOLSOM AR, 1990, STROKE, V21, P701, DOI 10.1161/01.STR.21.5.701; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; FREEDMAN DS, 1990, CIRCULATION, V81, P1498, DOI 10.1161/01.CIR.81.5.1498; HARRIS T, 1988, Journal of the American Medical Association, V259, P1520, DOI 10.1001/jama.259.10.1520; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; HUNGER RG, 1992, AM J EPIDEMIOL, V136, P192; KAYE SA, 1991, J CLIN EPIDEMIOL, V44, P329, DOI 10.1016/0895-4356(91)90044-A; KAYE SA, 1990, INT J OBESITY, V14, P583; KUSHI LH, 1988, AM J EPIDEMIOL, V128, P740, DOI 10.1093/oxfordjournals.aje.a115027; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; PRINEAS RJ, IN PRESS ANN EPIDEMI; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V266, P1808, DOI 10.1001/jama.266.13.1808; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SHIMOKATA H, 1989, JAMA-J AM MED ASSOC, V261, P1169, DOI 10.1001/jama.261.8.1169; SIDNEY S, 1987, AM J PUBLIC HEALTH, V77, P317, DOI 10.2105/AJPH.77.3.317; SMALLEY KJ, 1990, AM J CLIN NUTR, V52, P405, DOI 10.1093/ajcn/52.3.405; WIENPAHL J, 1990, J CLIN EPIDEMIOL, V43, P949, DOI 10.1016/0895-4356(90)90078-4; WILCOSKY T, 1990, J CLIN EPIDEMIOL, V43, P743, DOI 10.1016/0895-4356(90)90232-E; [No title captured]; 1977, 9TH REV C 1975 GEN	32	466	471	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					483	487		10.1001/jama.269.4.483	http://dx.doi.org/10.1001/jama.269.4.483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8419667				2022-12-28	WOS:A1993KH38500031
J	MANDEL, EM; ROCKETTE, HE; BLUESTONE, CD; PARADISE, JL; NOZZA, RJ				MANDEL, EM; ROCKETTE, HE; BLUESTONE, CD; PARADISE, JL; NOZZA, RJ			ANTIBIOTIC-THERAPY FOR OTITIS-MEDIA WITH EFFUSION - A RESPONSE FROM PITTSBURGH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DOUBLE-BLIND; DECONGESTANT-ANTIHISTAMINE; RANDOMIZED TRIAL; CHILDREN; MYRINGOTOMY; EFFICACY; AMOXICILLIN; COMBINATION; INFANTS; PLACEBO		CHILDRENS HOSP PITTSBURGH, OTTIS MEDIA RES CTR, PITTSBURGH, PA USA; CHILDRENS HOSP PITTSBURGH, DEPT PEDIAT OTOLARYNGOL, PITTSBURGH, PA USA; CHILDRENS HOSP PITTSBURGH, DEPT AUDIOL & COMMUN DISORDERS, PITTSBURGH, PA USA; CHILDRENS HOSP PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA USA; UNIV PITTSBURGH, SCH MED, DEPT OTOLARYNGOL, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SCH MED, DEPT PEDIAT, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SCH MED, DEPT CLIN EPIDEMIOL & PREVENT MED, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT BIOSTAT, PITTSBURGH, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BROSTOFF LM, 1988, 4TH P INT S REC ADV, P47; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; CANTEKIN E I, 1991, Journal of the American Medical Association, V266, P3309, DOI 10.1001/jama.266.23.3309; CANTEKIN EI, 1980, ANN OTO RHINOL LARYN, V89, P190, DOI 10.1177/00034894800890S344; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; CANTEKIN EI, 1983, ANN OTOL RHINOL S107, V92, P6; ENGELHARD D, 1989, LANCET, V2, P141; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P54; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; HALSTED C, 1968, AM J DIS CHILD, V115, P542, DOI 10.1001/archpedi.1968.02100010544003; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; KALEIDA PH, 1991, PEDIATRICS, V87, P466; LAXDAL OE, 1970, CAN MED ASSOC J, V102, P263; LORENTZEN P, 1977, J LARYNGOL OTOL, V91, P331, DOI 10.1017/S0022215100083742; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; MYGIND N, 1981, CLIN OTOLARYNGOL, V6, P5, DOI 10.1111/j.1365-2273.1981.tb01781.x; OSTFELD E, 1988, 4TH P INT S REC ADV, P235; PARADISE JL, 1979, ANN OTO RHINOL LARYN, V88, P56, DOI 10.1177/000348947908800110; PARADISE JL, 1976, PEDIATRICS, V58, P198; PARADISE JL, 1977, NEW ENGL J MED, V296, P445, DOI 10.1056/NEJM197702242960809; SAAH AJ, 1982, JAMA-J AM MED ASSOC, V248, P1071, DOI 10.1001/jama.248.9.1071; SMITH CG, 1982, PEDIATRICS, V69, P351; Thalin A, 1986, P INT C AC SECR OT 1, P441; VAN DISHOECK H A, 1959, Acta Otolaryngol, V50, P250; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1981, LANCET, V2, P883	26	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					516	517		10.1001/jama.269.4.516	http://dx.doi.org/10.1001/jama.269.4.516			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8419673				2022-12-28	WOS:A1993KH38500038
J	LATHROP, JT; TIMKO, MP				LATHROP, JT; TIMKO, MP			REGULATION BY HEME OF MITOCHONDRIAL PROTEIN-TRANSPORT THROUGH A CONSERVED AMINO-ACID MOTIF	SCIENCE			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; ERYTHROID 5-AMINOLEVULINATE SYNTHASE; IRON-RESPONSIVE ELEMENT; MESSENGER-RNA; ERYTHROLEUKEMIA-CELLS; LIVER-MITOCHONDRIA; ESCHERICHIA-COLI; RAT-LIVER; TRANSLOCATION; PRECURSOR	A conserved motif, termed the heme regulatory motif (HRM), was identified in the presequences of the erythroid delta-aminolevulinate synthase precursors and was shown to be involved in hemin inhibition of transport of these proteins into mouse mitochondria in vitro. When the HRM was inserted into the presequence of the ornithine transcarbamoylase precursor, a normally unregulated mitochondrial protein, it conferred hemin inhibition on the transport of the chimeric protein. The conserved cysteine within the HRM was shown by site-directed mutagenesis to be required for hemin inhibition.	UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22901	University of Virginia					NIDDK NIH HHS [5 RO1 DK33304-06] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033304] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BEAUMONT C, 1984, EXP CELL RES, V154, P474, DOI 10.1016/0014-4827(84)90171-X; CHEN JJ, 1989, J BIOL CHEM, V264, P9559; CHEN WJ, 1987, J BIOL CHEM, V262, P15605; CONBOY JG, 1981, P NATL ACAD SCI-BIOL, V78, P3073, DOI 10.1073/pnas.78.5.3073; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DREW PD, 1989, BIOCHEM BIOPH RES CO, V162, P102, DOI 10.1016/0006-291X(89)91968-2; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; GARDNER LC, 1991, J BIOL CHEM, V266, P22010; GRAYZEL AI, 1966, P NATL ACAD SCI USA, V55, P650, DOI 10.1073/pnas.55.3.650; HAMILTON JW, 1991, ARCH BIOCHEM BIOPHYS, V289, P387, DOI 10.1016/0003-9861(91)90428-L; HAMPSEY DM, 1986, J BIOL CHEM, V261, P3259; HAYASHI N, 1983, BIOCHEM BIOPH RES CO, V115, P700, DOI 10.1016/S0006-291X(83)80201-0; HORWICH AL, 1984, SCIENCE, V224, P1068, DOI 10.1126/science.6372096; KENG T, 1986, MOL CELL BIOL, V6, P355, DOI 10.1128/MCB.6.2.355; KULMACZ RJ, 1984, J BIOL CHEM, V259, P6358; LATHROP JT, 1992, THESIS U VIRGINIA; LO SC, 1981, CANCER RES, V41, P864; LONDON IM, 1987, ENZYMES, V18, P359; MURAKAMI K, 1988, J BIOL CHEM, V263, P18437; NIKKILA H, 1991, BIOCHEMISTRY-US, V30, P823, DOI 10.1021/bi00217a036; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; PONKA P, 1985, J BIOL CHEM, V260, P4717; Ranu R S, 1979, Methods Enzymol, V60, P459; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROSS J, 1976, CELL, V8, P513, DOI 10.1016/0092-8674(76)90219-1; SCHATZ G, 1987, EUR J BIOCHEM, V165, P1, DOI 10.1111/j.1432-1033.1987.tb11186.x; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SCHOENHAUT DS, 1989, NUCLEIC ACIDS RES, V17, P7013, DOI 10.1093/nar/17.17.7013; SMITH KM, 1975, PORPHYRINS METALLOPO, P804; SRIVASTAVA G, 1980, BIOCHEM J, V188, P781, DOI 10.1042/bj1880781; SRIVASTAVA G, 1983, BIOCHEM BIOPH RES CO, V117, P344, DOI 10.1016/0006-291X(83)91582-6; TANAKA Y, 1990, J BIOCHEM-TOKYO, V108, P7, DOI 10.1093/oxfordjournals.jbchem.a123165; TRIGGSRAINE BL, 1988, J BACTERIOL, V170, P4415, DOI 10.1128/jb.170.9.4415-4419.1988; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; YAMAUCHI K, 1980, J BIOL CHEM, V255, P1746; YOUNG EG, 1990, THESIS U VIRGINIA	38	241	247	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					522	525		10.1126/science.8424176	http://dx.doi.org/10.1126/science.8424176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424176				2022-12-28	WOS:A1993KJ07900037
J	LIAO, XS; BUTOW, RA				LIAO, XS; BUTOW, RA			RTG1 AND RTG2 - 2 YEAST GENES REQUIRED FOR A NOVEL PATH OF COMMUNICATION FROM MITOCHONDRIA TO THE NUCLEUS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CITRATE SYNTHASE; DNA-BINDING; MESSENGER-RNA; CYTOCHROME-B; CYC1 GENE; PROTEIN; EXPRESSION; SEQUENCE; TRANSCRIPTION	The expression of some nuclear genes is sensitive to the functional state of mitochondria, a process we term retrograde regulation. Here we show that retrograde regulation of the yeast ClT2 gene encoding peroxisomal citrate synthase depends on a new class of upstream activation site element (UAS(r)) and two previously unidentified genes, RTG1 and RTG2. RTG1 encodes a protein of 177 amino acids with similarity to basic helix-loop-helix transcription factors that likely functions at the ClT2 UAS(r). RTG2 encodes a protein of 394 amino acids of unknown function. Cells containing null alleles of RTG1 and RTG2 are viable and respiratory competent. However, they are auxotrophic for glutamic or aspartic acid and cannot use acetate as a sole carbon source, suggesting that both the tricarboxylic acid and glyoxylate cycles are compromised. Thus, RTG1 and RTG2 are pivotal genes in controlling interorganelle communication between mitochondria, peroxisomes, and the nucleus.			LIAO, XS (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022525, R01GM022525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22525] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEIDA J, 1989, GENE DEV, V3, P1758, DOI 10.1101/gad.3.11.1758; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLONDEL A, 1991, NUCLEIC ACIDS RES, V19, P181, DOI 10.1093/nar/19.1.181; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BUTOW RA, 1927, PHILOS T ROY SOC B, V319, P1; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CONRADWEBB H, 1990, NUCLEIC ACIDS RES, V18, P1369, DOI 10.1093/nar/18.6.1369; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; COSTANZO MC, 1988, P NATL ACAD SCI USA, V85, P2677, DOI 10.1073/pnas.85.8.2677; COSTANZO MC, 1986, MOL CELL BIOL, V6, P3694, DOI 10.1128/MCB.6.11.3694; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIECKMANN CL, 1982, P NATL ACAD SCI-BIOL, V79, P1805, DOI 10.1073/pnas.79.6.1805; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; FOURY F, 1989, J BIOL CHEM, V264, P20552; GAMPEL A, 1987, MOL CELL BIOL, V7, P2545, DOI 10.1128/MCB.7.7.2545; GOODRICH J, 1992, CELL, V68, P955, DOI 10.1016/0092-8674(92)90038-E; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; GUARENTE L, 1984, P NATL ACAD SCI-BIOL, V81, P7860, DOI 10.1073/pnas.81.24.7860; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; KISPAL G, 1989, J BIOL CHEM, V264, P11204; KUIPER MTR, 1988, J BIOL CHEM, V263, P2840; LABOUESSE M, 1990, MOL GEN GENET, V224, P209, DOI 10.1007/BF00271554; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; MCCONNELL SJ, 1990, J CELL BIOL, V111, P967, DOI 10.1083/jcb.111.3.967; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PARIKH VS, 1989, MOL CELL BIOL, V9, P1897, DOI 10.1128/MCB.9.5.1897; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; PARTALEDIS JA, 1988, MOL CELL BIOL, V8, P3647, DOI 10.1128/MCB.8.9.3647; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; POUTRE CG, 1987, GENETICS, V115, P637; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1988, METHODS YEAST GENETI; ROSENKRANTZ M, 1986, MOL CELL BIOL, V6, P4509, DOI 10.1128/MCB.6.12.4509; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; STEWART LC, 1991, J CELL BIOL, V115, P1249, DOI 10.1083/jcb.115.5.1249; SUISSA M, 1984, EMBO J, V3, P1773, DOI 10.1002/j.1460-2075.1984.tb02045.x; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; WANG SS, 1987, MOL CELL BIOL, V7, P4431, DOI 10.1128/MCB.7.12.4431; WINKLER H, 1988, EMBO J, V7, P1799, DOI 10.1002/j.1460-2075.1988.tb03011.x	54	338	347	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					61	71		10.1016/0092-8674(93)90050-Z	http://dx.doi.org/10.1016/0092-8674(93)90050-Z			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422683				2022-12-28	WOS:A1993KG95500010
J	HWANG, KC; MAUZERALL, D				HWANG, KC; MAUZERALL, D			PHOTOINDUCED ELECTRON-TRANSPORT ACROSS A LIPID BILAYER MEDIATED BY C70	NATURE			English	Article							FULLERENES C60; MEMBRANES; CARBON	ELECTRON transport across a membrane is central to photosynthesis, to mitochondrial respiration and to the design of molecular systems for solar energy conversion. Relatively few synthetic molecules, however, have been shown to facilitate transport of electrons across a lipid bilayer1-3. We report here that C70 can act as both a photosensitizer for electron transfer from a donor molecule and a mediator for electron transport across a lipid bilayer membrane. The steady-state photocurrent density obtained from the C70-bilayer system is about 40 times higher, at comparable light intensities, than that of the carotene-porphyrin-quinone system2, previously the most efficient artificial system. The C70-bilayer system has a quantum yield of about 0.04, while the stability (tens of minutes) and turnover number (electrons transported per C70 before decay) of 10(3) are one to three orders of magnitude greater than those of other systems1-3. We anticipate that other higher fullerenes may also provide the basis for efficient transmembrane electron-transport systems.			HWANG, KC (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.		Hwang, Kuo Chu/AAG-8217-2021					AJIE H, 1990, J PHYS CHEM-US, V94, P8630, DOI 10.1021/j100387a004; ALLEMAND PM, 1991, J AM CHEM SOC, V113, P1050, DOI 10.1021/ja00003a053; ARBOGAST JW, 1992, J AM CHEM SOC, V114, P2277, DOI 10.1021/ja00032a063; BENESCH RE, 1953, SCIENCE, V11, P447; CLARK WM, 1960, OXIDATION REDUCTION, P470; DRAIN M, 1992, BIOPHYS J, V63, P1556; FELDBERG SW, 1981, BIOPHYS J, V34, P149, DOI 10.1016/S0006-3495(81)84842-4; HONG FT, 1976, J ELECTROCHEM SOC, V123, P1317, DOI 10.1149/1.2133068; HUNG RR, 1991, J PHYS CHEM-US, V95, P6073, DOI 10.1021/j100169a007; HWANG KC, 1992, J AM CHEM SOC, V114, P9705, DOI 10.1021/ja00050a086; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; ILANI A, 1981, BIOPHYS J, V35, P79, DOI 10.1016/S0006-3495(81)84775-3; KAMAT PV, 1991, J AM CHEM SOC, V113, P9705, DOI 10.1021/ja00025a064; KIM DH, 1992, J AM CHEM SOC, V114, P4429, DOI 10.1021/ja00037a075; KRASNE S, 1971, SCIENCE, V174, P412, DOI 10.1126/science.174.4007.412; MILLER B, 1991, J AM CHEM SOC, V113, P6291, DOI 10.1021/ja00016a067; MOUNTZ JM, 1978, PHOTOCHEM PHOTOBIOL, V28, P395, DOI 10.1111/j.1751-1097.1978.tb07724.x; SCHUHANNK W, 1991, J AM CHEM SOC, V113, P394; SENSION RJ, 1991, CHEM PHYS LETT, V185, P179, DOI 10.1016/S0009-2614(91)85043-V; SETA P, 1989, PHOTOCHEM PHOTOBIOL, V49, P537, DOI 10.1111/j.1751-1097.1989.tb08422.x; SETA P, 1985, NATURE, V316, P651; WANG Y, 1992, NATURE, V356, P585, DOI 10.1038/356585a0; WASIELEWSKI MR, 1991, J AM CHEM SOC, V113, P2774, DOI 10.1021/ja00007a074	23	156	161	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					138	140		10.1038/361138a0	http://dx.doi.org/10.1038/361138a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421519				2022-12-28	WOS:A1993KG46600053
J	GROVES, T				GROVES, T			COUNTDOWN TO COMMUNITY CARE .4. REACHING OUT - COMMUNITY CARE IN BASSETLAW	BRITISH MEDICAL JOURNAL			English	Article													Groves, Trish/A-9119-2009	Groves, Trish/0000-0001-7915-6419				[Anonymous], 1989, CM849; GROVES T, 1990, BRIT MED J, V300, P1128, DOI 10.1136/bmj.300.6732.1128	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					132	135		10.1136/bmj.306.6870.132	http://dx.doi.org/10.1136/bmj.306.6870.132			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KG465	8435613	Green Published, Bronze			2022-12-28	WOS:A1993KG46500032
J	JOBE, AH				JOBE, AH			DRUG-THERAPY - PULMONARY SURFACTANT THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESPIRATORY-DISTRESS SYNDROME; HYALINE-MEMBRANE DISEASE; RANDOMIZED CONTROLLED TRIAL; BIRTH-WEIGHT INFANTS; PLACEBO-CONTROLLED TRIAL; 30 WEEKS GESTATION; REPLACEMENT THERAPY; BOVINE SURFACTANT; CLINICAL-TRIAL; PREMATURE-INFANTS		UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	JOBE, AH (corresponding author), UNIV CALIF LOS ANGELES, HARBOR MED CTR, DEPT PEDIAT, 1000 W CARSON ST, RB-1, TORRANCE, CA 90509 USA.				NICHD NIH HHS [HD-12719, HD-20618, HD-11932] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011932, R37HD011932, R01HD020618] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS FH, 1970, J PEDIATR-US, V77, P833, DOI 10.1016/S0022-3476(70)80244-X; AUTEN RL, 1991, PEDIATRICS, V87, P101; AVERY ME, 1959, AMA J DIS CHILD, V97, P517, DOI 10.1001/archpedi.1959.02070010519001; BOSE C, 1990, J PEDIATR-US, V117, P947, DOI 10.1016/S0022-3476(05)80143-X; Chen J Y, 1990, J Formos Med Assoc, V89, P110; CHU J, 1967, PEDIATRICS S, P40; CLEMENTS JA, 1957, P SOC EXP BIOL MED, V95, P170; CLYMAN RI, 1982, J PEDIATR-US, V100, P101; CORBET A, 1991, J PEDIATR-US, V118, P277, DOI 10.1016/S0022-3476(05)80502-5; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; CUMMINGS JJ, 1992, AM REV RESPIR DIS, V145, P999, DOI 10.1164/ajrccm/145.5.999; DAVIS JM, 1988, NEW ENGL J MED, V319, P476, DOI 10.1056/NEJM198808253190804; DUNN M, 1990, PEDIATR RES, V27, pA204; DUNN MS, 1990, PEDIATRICS, V86, P564; DUNN MS, 1988, PEDIATRICS, V82, P543; DUNN MS, 1991, PEDIATRICS, V87, P377; EDWARDS DK, 1985, RADIOLOGY, V157, P329, DOI 10.1148/radiology.157.2.3840268; ENHORNING G, 1985, PEDIATRICS, V76, P145; ENHORNING G, 1978, AM J OBSTET GYNECOL, V132, P529, DOI 10.1016/0002-9378(78)90748-2; ENHORNING G, 1972, PEDIATRICS, V50, P58; FARRELL EE, 1989, AM J OBSTET GYNECOL, V161, P628, DOI 10.1016/0002-9378(89)90367-0; FUJIWARA T, 1990, PEDIATRICS, V86, P753; FUJIWARA T, 1980, LANCET, V1, P55; FUJIWARA T, 1984, PULMONARY SURFACTANT, P479; GITLIN JD, 1987, PEDIATRICS, V79, P31; GOLDSMITH LS, 1991, J PEDIATR-US, V119, P424, DOI 10.1016/S0022-3476(05)82057-8; GORTNER L, 1990, LUNG, V168, P864, DOI 10.1007/BF02718221; HALL SB, 1992, AM REV RESPIR DIS, V145, P24, DOI 10.1164/ajrccm/145.1.24; HALLIDAY HL, 1989, ARCH DIS CHILD-FETAL, V64, P13, DOI 10.1136/adc.64.1_Spec_No.13; HALLIDAY HL, 1984, LANCET, V1, P476; HALLMAN M, 1986, PEDIATR RES, V20, P1228, DOI 10.1203/00006450-198612000-00008; HALLMAN M, 1991, AM REV RESPIR DIS, V144, P1376, DOI 10.1164/ajrccm/144.6.1376; HALLMAN M, 1985, J PEDIATR-US, V106, P963, DOI 10.1016/S0022-3476(85)80253-5; HANSEN TN, 1979, PEDIATR RES, V13, P1167, DOI 10.1203/00006450-197910000-00018; HELDT GP, 1989, PEDIATR RES, V25, P305, DOI 10.1203/00006450-198903000-00020; HOEKSTRA RE, 1991, PEDIATRICS, V88, P10; HOFFMAN RM, 1987, AM REV RESPIR DIS, V135, P1358; HORBAR JD, 1989, NEW ENGL J MED, V320, P959; HORBAR JD, 1990, EUR J PEDIATR, V149, P416, DOI 10.1007/BF02009663; IKEGAMI M, 1980, PEDIATR RES, V14, P1082, DOI 10.1203/00006450-198009000-00013; IKEGAMI M, 1989, J APPL PHYSIOL, V67, P429, DOI 10.1152/jappl.1989.67.1.429; IKEGAMI M, 1981, J CLIN INVEST, V68, P491, DOI 10.1172/JCI110280; JOBE A, 1987, AM REV RESPIR DIS, V136, P1256, DOI 10.1164/ajrccm/136.5.1256; JOBE AH, 1989, AM REV RESPIR DIS, V139, P352, DOI 10.1164/ajrccm/139.2.352; JOBE AH, 1993, AM J OBSTET GYNECOL, V168, P508, DOI 10.1016/0002-9378(93)90483-Y; KENDIG JW, 1988, PEDIATRICS, V82, P756; KENDIG JW, 1991, NEW ENGL J MED, V324, P865, DOI 10.1056/NEJM199103283241301; King RJ, 1984, PULMONARY SURFACTANT, P1; KWONG MS, 1985, PEDIATRICS, V76, P585; LANG MJ, 1990, J PEDIATR-US, V116, P295, DOI 10.1016/S0022-3476(05)82897-5; LEWIS JF, 1991, J APPL PHYSIOL, V70, P869, DOI 10.1152/jappl.1991.70.2.869; LIECHTY EA, 1991, PEDIATRICS, V88, P19; LONG W, 1991, J PEDIATR-US, V118, P595, DOI 10.1016/S0022-3476(05)83388-8; LONG W, 1991, NEW ENGL J MED, V325, P1696, DOI 10.1056/NEJM199112123252404; MANISCALCO WM, 1989, PEDIATRICS, V83, P1; MERRITT TA, 1986, NEW ENGL J MED, V315, P785, DOI 10.1056/NEJM198609253151301; MERRITT TA, 1991, J PEDIATR-US, V118, P581, DOI 10.1016/S0022-3476(05)83387-6; MORLEY CJ, 1987, BRIT MED J, V294, P991; MUGFORD M, 1991, ARCH DIS CHILD-FETAL, V66, P757, DOI 10.1136/adc.66.7_Spec_No.757; NOACK G, 1990, RESPIRATION, V57, P1; NOTTER RH, 1985, PEDIATR RES, V19, P569, DOI 10.1203/00006450-198506000-00014; PATTLE RE, 1955, NATURE, V175, P1125, DOI 10.1038/1751125b0; PHIBBS RH, 1991, PEDIATRICS, V88, P1; POSSMAYER F, 1990, AM REV RESPIR DIS, V142, P749, DOI 10.1164/ajrccm/142.4.749; RAJU TNK, 1987, LANCET, V1, P651; REPKA MX, 1992, OPHTHALMOLOGY, V99, P531; RIDER ED, 1992, J APPL PHYSIOL, V73, P2089, DOI 10.1152/jappl.1992.73.5.2089; ROBERTSON B, 1988, PEDIATRICS, V82, P683; ROBERTSON B, 1974, LAB INVEST, V31, P54; ROBERTSON B, 1990, PROG R RES, V25, P237; Robertson B., 1984, PULMONARY SURFACTANT, P383; ROBILLARD E, 1964, CAN MED ASSOC J, V90, P55; SHAPIRO DL, 1985, PEDIATRICS, V76, P593; SHENNAN A, 1989, PEDIATR RES, V25, pA231; SOLA A, 1992, LANCET, V340, P1363; SOLL R F, 1988, Pediatric Research, V23, p525A; SOLL RF, 1990, PEDIATRICS, V85, P1092; SOLL RF, 1991, OXFORD DATABASE PERI; SPEER CP, 1992, PEDIATRICS, V89, P13; STEVENSON D, 1992, J PEDIATR-US, V120, pS3, DOI 10.1016/S0022-3476(05)81226-0; STEWARTDEHAAN PJ, 1980, BIOL NEONATE, V38, P238; TAEUSCH HW, 1986, PEDIATRICS, V77, P572; VANHOUTEN J, 1992, J PEDIATR-US, V120, pS40, DOI 10.1016/S0022-3476(05)81232-6; VANIWAARDEN JF, 1991, AM J PHYSIOL, V261, pL204, DOI 10.1152/ajplung.1991.261.2.L204; VAUCHER YE, 1988, AM J DIS CHILD, V142, P927, DOI 10.1001/archpedi.1988.02150090025015; WARE J, 1990, PEDIATRICS, V85, P1103; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WEGMAN ME, 1991, PEDIATRICS, V88, P1081; WIEDEMANN H, 1992, American Review of Respiratory Disease, V145, pA184; WILKINSON A, 1985, LANCET, V2, P287; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554; 1990, PEDIATR RES, V27, pA200	92	471	483	2	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	1993	328	12					861	868						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT814	8441430				2022-12-28	WOS:A1993KT81400008
J	SIDRANSKY, E; GINNS, EI				SIDRANSKY, E; GINNS, EI			CLINICAL HETEROGENEITY AMONG PATIENTS WITH GAUCHERS-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN GLUCOCEREBROSIDASE GENE; ASHKENAZI JEWS; MUTATION; FREQUENCY; SEQUENCE				SIDRANSKY, E (corresponding author), NIMH,CLIN NEUROSCI BRANCH,MOLEC NEUROGENET SECT,CLIN GENET UNIT,BETHESDA,MD 20892, USA.							Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BERREBI A, 1984, NOUV REV FR HEMATOL, V26, P201; BEUTLER E, 1992, SCIENCE, V256, P794, DOI 10.1126/science.1589760; BEUTLER E, 1991, P NATL ACAD SCI USA, V88, P10544, DOI 10.1073/pnas.88.23.10544; CHOUDARY PV, 1986, COLD SPRING HARB SYM, V51, P1047, DOI 10.1101/SQB.1986.051.01.121; COGAN DG, 1981, ARCH OPHTHALMOL-CHIC, V99, P1802; DAHL N, 1990, AM J HUM GENET, V47, P275; ERIKSON A, 1988, ACTA PAEDIATR SC   S, V326, P1; EYAL N, 1990, GENE, V96, P277, DOI 10.1016/0378-1119(90)90264-R; Frederickson DS, 1972, METABOLIC BASIS INHE, P730; GINNS EI, 1985, P NATL ACAD SCI USA, V82, P7101, DOI 10.1073/pnas.82.20.7101; GIRGENSOHN H, 1954, KLIN WOCHENSCHR, V32, P57, DOI 10.1007/BF01493524; HERRLIN KM, 1962, ACTA PAEDIATR SCAND, V51, P137, DOI 10.1111/j.1651-2227.1962.tb06522.x; HONG CM, 1990, DNA CELL BIOL, V9, P233, DOI 10.1089/dna.1990.9.233; HOROWITZ M, 1989, GENOMICS, V4, P87, DOI 10.1016/0888-7543(89)90319-4; LATHAM TE, 1991, DNA CELL BIOL, V10, P15, DOI 10.1089/dna.1991.10.15; LIPSON AH, 1991, ARCH DIS CHILD, V66, P667, DOI 10.1136/adc.66.5.667-a; LIU K, 1988, ARCH DIS CHILD, V68, P854; MARTIN B, 1992, AM J HUM GENET, V51, P307; Martin B M, 1989, Adv Pediatr, V36, P277; MATOTH Y, 1987, AM J MED GENET, V27, P561; NISHIMURA RN, 1980, ARCH NEUROL-CHICAGO, V37, P92, DOI 10.1001/archneur.1980.00500510050008; PCE Gaucher, 1882, EPITHELIOMA PRIMITIF; RAPPEPORT JM, 1984, NEW ENGL J MED, V311, P84, DOI 10.1056/NEJM198407123110203; SIDRANSKY E, 1992, AM J MED GENET, V42, P331, DOI 10.1002/ajmg.1320420315; SIDRANSKY E, 1992, PEDIATR RES, V32, P494, DOI 10.1203/00006450-199210000-00023; SIDRANSKY E, 1992, CLIN GENET, V41, P1; SUN CC, 1984, PATHOL RES PRACT, V179, P101, DOI 10.1016/S0344-0338(84)80069-2; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; TYBULEWICZ VLJ, 1992, NATURE, V357, P407, DOI 10.1038/357407a0; WENGER DA, 1982, J PEDIATR-US, V100, P252, DOI 10.1016/S0022-3476(82)80650-1; WHITTINGTON R, 1992, DRUGS, V44, P72, DOI 10.2165/00003495-199244010-00007; ZIMRAN A, 1991, AM J HUM GENET, V49, P855	34	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1154	1157		10.1001/jama.269.9.1154	http://dx.doi.org/10.1001/jama.269.9.1154			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN611	8433471				2022-12-28	WOS:A1993KN61100033
J	TAPPERO, JW; KOEHLER, JE; BERGER, TG; COCKERELL, CJ; LEE, TH; BUSCH, MP; STITES, DP; MOHLEBOETANI, J; REINGOLD, AL; LEBOIT, PE				TAPPERO, JW; KOEHLER, JE; BERGER, TG; COCKERELL, CJ; LEE, TH; BUSCH, MP; STITES, DP; MOHLEBOETANI, J; REINGOLD, AL; LEBOIT, PE			BACILLARY ANGIOMATOSIS AND BACILLARY SPLENITIS IN IMMUNOCOMPETENT ADULTS	ANNALS OF INTERNAL MEDICINE			English	Note						ANGIOMATOSIS, BACILLARY; SPLENITIS, BACILLARY; IMMUNOCOMPETENCE; ROCHALIMAEA-HENSELAE; ERYTHROMYCIN	INFECTION; DNA	Bacillary angiomatosis and bacillary peliosis have been described in patients with human immunodeficiency virus (HIV) infection and drug-induced immunosuppression. Patients with these vascular lesions in the absence of profound immunodeficiency have not been well characterized. We studied five patients with histologically confirmed bacillary angiomatosis or bacillary splenitis without clinical immunodeficiency. Studies to detect HIV infection, immunologic defects, and presence of Rochalimaea species DNA in infected tissues were done. Cell cultures were negative for HIV-1 replication, and HIV-1 DNA was not detected. Results of lymphocyte subsets and activation, neutrophil oxidative burst, skin testing to mumps antigen, and assays for quantitative immunoglobulins and complement were normal. DNA amplification and sequencing confirmed infection by Rochalimaea henselae, even in tissue showing bacillary splenitis without peliosis. Bacillary angiomatosis and bacillary splenitis may occur in the absence of demonstrable immunodeficiency. On the basis of the therapeutic response of these five patients, we recommend treatment with erythromycin or doxycycline for a minimum of 6 weeks.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; IRWIN MEM BLOOD CTR, SAN FRANCISCO, CA USA; UNIV CALIF BERKELEY, BERKELEY, CA 94720 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA	University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	TAPPERO, JW (corresponding author), CTR DIS CONTROL & PREVENT, MAIL STOP C09, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.		Mohle-Boetani, Janet/AAH-4221-2019		NIAMS NIH HHS [AR07175-15] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007175] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALKASSAB AS, 1990, CLIN EXP IMMUNOL, V81, P267; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; DESOUSA M, 1989, CLIN EXP IMMUNOL, V75, P1; EPLING CL, 1992, CYTOMETRY, V13, P615, DOI 10.1002/cyto.990130609; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; LEBOIT PE, 1988, LANCET, V1, P960; LEE TH, 1991, AIDS, V5, P1201, DOI 10.1097/00002030-199110000-00008; MALIUSH AE, 1986, MANUAL CLIN LABORATO, P274; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; STEVENS P, 1978, INFECT IMMUN, V22, P41, DOI 10.1128/IAI.22.1.41-51.1978; STITES DP, 1991, BASIC CLIN IMMUNOL, P263; TAPPERO JW, 1993, IN PRESS JAMA; TCHORZEWSKI H, 1989, EXP CLIN IMMUNOGENET, V6, P185; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992	15	109	112	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					363	365		10.7326/0003-4819-118-5-199303010-00007	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8430982				2022-12-28	WOS:A1993KN68800007
J	PATTERSON, DR; MILLERPERRIN, C; MCCORMICK, TR; HUDSON, LD				PATTERSON, DR; MILLERPERRIN, C; MCCORMICK, TR; HUDSON, LD			WHEN LIFE-SUPPORT IS QUESTIONED EARLY IN THE CARE OF PATIENTS WITH CERVICAL-LEVEL QUADRIPLEGIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SPINAL-CORD INJURY; DEPRESSION				PATTERSON, DR (corresponding author), UNIV WASHINGTON,SCH MED,SEATTLE,WA 98104, USA.							ABRAMS KS, 1981, PARAPLEGIA, V19, P253, DOI 10.1038/sc.1981.49; CHARLIFUE SW, 1991, ARCH PHYS MED REHAB, V72, P488; CREWE N M, 1979, Archives of Physical Medicine and Rehabilitation, V60, P252; CUSHMAN LA, 1990, ARCH PHYS MED REHAB, V71, P191; DUCHARME SH, 1980, SCI DIG, V2, P29; ELGHATIT AZ, 1975, J CHRON DIS, V28, P383, DOI 10.1016/0021-9681(75)90034-X; FINK SL, 1968, J MARRIAGE FAM, V30, P64, DOI 10.2307/350223; Fleetwood J, 1989, Nursing, V19, P62; FRANK RG, 1987, CLIN PSYCHOL REV, V7, P611, DOI 10.1016/0272-7358(87)90009-2; GARDNER BP, 1985, BRIT MED J, V291, P1620, DOI 10.1136/bmj.291.6509.1620; GEISLER WO, 1983, PARAPLEGIA, V21, P364, DOI 10.1038/sc.1983.60; MAYNARD FM, 1987, ARCH PHYS MED REHAB, V68, P862; Morris J, 1986, J HEAD TRAUMA REHAB, V1, P31; Nyquist R H, 1967, Paraplegia, V5, P22; PALMER JB, 1985, ARCH PHYS MED REHAB, V66, P253, DOI 10.1016/0003-9993(85)90164-9; PATTERSON DR, IN PRESS PSYCHOL B; Ridley B, 1989, Rehabil Nurs, V14, P250; SIEGEL M, 1969, 17TH P VET ADM SPIN, V18, P230; SIEGEL M, 1970, PSYCHOL ASPECTS DISA, V17, P9; SIEGEL M, 1971, RES UTILIZATION REHA; SIEGEL MS, 1969, MED CLIN N AM, V53, P713, DOI 10.1016/S0025-7125(16)32767-5; SKIPPER JK, 1968, J REHABIL, V34, P16; SOMERVILLE J, 1990, AM MED NEWS     0202, P6; STOVER SL, 1986, SPINAL CORD INJURY F; Trieschmann RB, 1988, SPINAL CORD INJURIES; Vargo F.A., 1984, J APPL REHABIL COUNS, V15, P28, DOI 10.1891/0047-2220.15.1.28; VARGO FA, 1984, INT J ADV COUNS, V7, P253, DOI 10.1007/BF00379147; WESTBROOK MT, 1986, REHABIL PSYCHOL, V31, P79, DOI 10.1037//0090-5550.31.2.79; WHITENECK GG, 1985, COLLABORATIVE STUDY; YORKSTON KM, 1992, AUGMENTATIVE COMMUNI; 1991, AM REV RESPIR DIS, V144, P726	31	42	42	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1993	328	7					506	509		10.1056/NEJM199302183280712	http://dx.doi.org/10.1056/NEJM199302183280712			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KM417	8421482				2022-12-28	WOS:A1993KM41700012
J	KHAN, AS; HENEINE, WM; CHAPMAN, LE; GARY, HE; WOODS, TC; FOLKS, TM; SCHONBERGER, LB				KHAN, AS; HENEINE, WM; CHAPMAN, LE; GARY, HE; WOODS, TC; FOLKS, TM; SCHONBERGER, LB			ASSESSMENT OF A RETROVIRUS SEQUENCE AND OTHER POSSIBLE RISK-FACTORS FOR THE CHRONIC FATIGUE SYNDROME IN ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article						FATIGUE SYNDROME, CHRONIC; HTLV-II; GENE PRODUCTS, GAG; RETROVIRUS INFECTIONS; RISK FACTORS	EPSTEIN-BARR VIRUS; BLOOD MONONUCLEAR-CELLS; COMMON ODDS RATIO; INFECTION; AMPLIFICATION; INTERVAL; TABLES	Objective: To assess whether the human T-lymphotropic virus type II (HTLV-II) gag gene sequence, a purportedly new laboratory marker of the chronic fatigue syndrome (CFS), and other possible risk factors for CFS, particularly those associated with retroviral transmission, are associated with well-characterized CFS. Design: Two matched case-control studies. Setting. The metropolitan Atlanta area. Patients: Twenty-one patients with CFS who were identified by the Centers for Disease Control and Prevention CFS surveillance system; 21 CDC employee controls (laboratory study) and 42 neighborhood controls (risk-factor study) who were matched to patients by age, race, and gender. Measurements: Peripheral blood lymphocytes and leukocytes were assayed for the HTLV-II gag gene sequence by polymerase chain reaction and specific Southern blot hybridization. Questionnaires elicited demographic and clinical information and a history of exposures associated with retrovirus transmission (for example, blood transfusions, sexual practices, intravenous drug use). Results: All patients were white and 86% were female. The median age at illness onset was 34 years (range, 16 to 51 years). The HTLV-II gag gene sequence was not identified in the blood of any patient or control under conditions in which the appropriate assay controls were positive. No statistical differences were observed between patients and controls in frequency of blood transfusions (10% compared with 7%), median number of sex partners before illness (3 compared with 3), bisexual or homosexual behavior (14% compared with 7%), intravenous drug use (0% compared with 0%), and other factors associated with retroviral infection. Conclusions: The HTLV-II gag gene sequence was not a marker for CFS in this small study of well-defined patients, nor did other characteristics of the patients and controls support the hypothesis that a retrovirus, transmitted by usual modes, was a cause of CFS.			KHAN, AS (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, OFF DIRECTOR, ATLANTA, GA 30333 USA.							BELL KM, 1991, REV INFECT DIS, V13, pS32; BUCHWALD D, 1990, J CLIN IMMUNOL, V10, P335, DOI 10.1007/BF00917479; BUCKNER C, 1992, J INFECT DIS, V166, P1160, DOI 10.1093/infdis/166.5.1160; Cox DR., 1970, ANAL BINARY DATA; CROOK WG, 1983, YEAST CONNECTION MED; DEFREITAS E, 1991, P NATL ACAD SCI USA, V88, P2922, DOI 10.1073/pnas.88.7.2922; DUBOIS RE, 1984, SOUTHERN MED J, V77, P1376, DOI 10.1097/00007611-198411000-00007; FLUGEL RM, 1992, CLIN INFECT DIS, V14, P623, DOI 10.1093/clinids/14.2.623; FOLKS TM, 1993, CIBA F SYMP, V173, P160; GART JJ, 1970, BIOMETRIKA, V57, P471, DOI 10.1093/biomet/57.3.471; GOLD D, 1990, JAMA-J AM MED ASSOC, V264, P48, DOI 10.1001/jama.264.1.48; GOW J, IN PRESS J CLIN PATH; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; GUNN WJ, 1993, CIBA F S, V173; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HOLMES GP, 1987, JAMA-J AM MED ASSOC, V257, P2297, DOI 10.1001/jama.257.17.2297; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; JONES JF, 1985, ANN INTERN MED, V102, P1, DOI 10.7326/0003-4819-102-1; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1988, BLOOD, V72, P1117; LAL RB, 1991, J CLIN MICROBIOL, V29, P2253, DOI 10.1128/JCM.29.10.2253-2258.1991; LANE TJ, 1991, AM J MED, V91, P335, DOI 10.1016/0002-9343(91)90150-V; LEHMANN EL, 1975, NONPARAMETRICS; Maniatis T., 1982, MOL CLONING; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; YOUSEF GE, 1988, LANCET, V1, P146	28	41	42	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					241	245		10.7326/0003-4819-118-4-199302150-00001	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420441				2022-12-28	WOS:A1993KL45700001
J	LISITSYN, N; LISITSYN, N; WIGLER, M				LISITSYN, N; LISITSYN, N; WIGLER, M			CLONING THE DIFFERENCES BETWEEN 2 COMPLEX GENOMES	SCIENCE			English	Article							DNA; DELETION; AMPLIFICATION; SEQUENCES; PATIENT	The analysis of the differences between two complex genomes holds promise for the discovery of infectious agents and probes useful for genetic studies. A system was developed in which subtractive and kinetic enrichment was used to purify restriction endonuclease fragments present in one population of DNA fragments but not in another. Application of this method to DNA populations of reduced complexity (''representations'') resulted in the isolation of probes to viral genomes present as single copies in human DNA, and probes that detect polymorphisms between two individuals. In principle, this system, called representational difference analysis (RDA), may also be used for isolating probes linked to sites of genomic rearrangements, whether occurring spontaneously and resulting in genetic disorders or cancer, or programmed during differentiation and development.	RUSSIAN ACAD SCI,INST MOLEC GENET,MOSCOW 123182,RUSSIA	Russian Academy of Sciences	LISITSYN, N (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.		Lisitsyn, Nikolai/AAO-7011-2021	Wigler, Michael/0000-0003-4396-1971; Lisitsyn, Nikolai/0000-0003-4725-2662				BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; BERNARD O, 1978, CELL, V15, P1133, DOI 10.1016/0092-8674(78)90041-7; BISHOP DT, 1983, AM J HUM GENET, V35, P795; BROOKES AJ, 1991, NUCLEIC ACIDS RES, V19, P2609; CHUN JJ, 1991, CELL, V1, P189; KUNKEL LM, 1985, P NATL ACAD SCI USA, V82, P4778, DOI 10.1073/pnas.82.14.4778; LAMAR EE, 1984, CELL, V37, P171, DOI 10.1016/0092-8674(84)90312-X; MATSUOKA M, 1991, SCIENCE, V254, P81, DOI 10.1126/science.1925563; NUSSBAUM RL, 1987, P NATL ACAD SCI USA, V84, P6521, DOI 10.1073/pnas.84.18.6521; PATANJALI SR, 1991, P NATL ACAD SCI USA, V88, P1943, DOI 10.1073/pnas.88.5.1943; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEGAL E, 1985, CELL, V40, P293, DOI 10.1016/0092-8674(85)90143-6; STRATHERN JN, 1980, P NATL ACAD SCI-BIOL, V77, P2839, DOI 10.1073/pnas.77.5.2839; STRAUS D, 1990, P NATL ACAD SCI USA, V87, P1889, DOI 10.1073/pnas.87.5.1889; VANDERPLOEG LHT, 1984, CELL, V39, P213, DOI 10.1016/0092-8674(84)90207-1; WIELAND I, 1990, P NATL ACAD SCI USA, V87, P2720, DOI 10.1073/pnas.87.7.2720; YOKOTA H, 1990, P NATL ACAD SCI USA, V87, P6398, DOI 10.1073/pnas.87.16.6398	17	1121	1303	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					946	951		10.1126/science.8438152	http://dx.doi.org/10.1126/science.8438152			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438152				2022-12-28	WOS:A1993KL80000035
J	LELIEVER, WC				LELIEVER, WC			EUSTACHIAN-TUBE DYSFUNCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											LELIEVER, WC (corresponding author), UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					809	809						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423666				2022-12-28	WOS:A1993KK54400037
J	SCHAPIRA, DV; STUDNICKI, J; BRADHAM, DD; WOLFF, P; JARRETT, A				SCHAPIRA, DV; STUDNICKI, J; BRADHAM, DD; WOLFF, P; JARRETT, A			INTENSIVE-CARE, SURVIVAL, AND EXPENSE OF TREATING CRITICALLY ILL CANCER-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS; HEMATOLOGIC MALIGNANCY; RESPIRATORY-FAILURE; PROGNOSIS	Objective.-To determine the survival and factors affecting the survival of patients with solid tumors and hematologic cancers who were admitted to the intensive care unit, the time these patients spent at home (meaningful survival) before they died, and the cost per year of life gained and per year of life gained at home Design.-Survival and cost-effectiveness analysis. Setting.-A tertiary-care cancer center at a university medical center. Patients.-Every patient admitted to the intensive care unit between July 1, 1988, and June 30,1990, was entered into the study. This group comprised 83 patients with solid tumors and 64 patients with hematologic cancers. Main Outcome Measures.-Factors affecting survival, such as age, sex, malignancy, length of stay in the intensive care unit, and necessity for mechanical ventilator assistance, as well as cost per year of life gained and cost per year of life gained at home. Results.-The only factor that significantly affected survival was the requirement for mechanically assisted ventilation for patients with hematologic cancers. More than three fourths of the patients in either group spent less than 3 months at home before dying. The cost per year of life gained for patients with solid tumors was $82 845 and for patients with hematologic cancers was $189 339. The cost per year of life gained at home was $95 142 for patients with solid tumors and $449 544 for patients with hematologic cancers. Conclusion.-The majority of patients with solid tumors and hematologic cancers admitted to the intensive care unit die before discharge, or, if they survive the hospital admission, they spend a minimal amount of time at home before dying. This limited survival is achieved at considerable cost. Physicians who treat patients with neoplastic disease should discuss potential outcomes and the possibility of withdrawing life-supportive therapy if appropriate with the patient and family, so that a reasonable strategy can be agreed on before the initiation of therapy.	UNIV S FLORIDA,COLL MED,TAMPA,FL 33612; UNIV S FLORIDA,SCH PUBL HLTH,TAMPA,FL 33620	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	SCHAPIRA, DV (corresponding author), H LEE MOFFITT CANC CTR & RES INST,CANC PREVENT SECT,12902 MAGNOLIA DR,TAMPA,FL 33612, USA.							ANDERSON G, 1990, JAMA-J AM MED ASSOC, V263, P967, DOI 10.1001/jama.263.7.967; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; ESTOPA R, 1984, CRIT CARE MED, V12, P26, DOI 10.1097/00003246-198401000-00007; GAUMER GL, 1992, HEALTH SERV RES, V26, P725; GOODWIN PJ, 1988, J CLIN ONCOL, V6, P1537, DOI 10.1200/JCO.1988.6.10.1537; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; JOHNSON MH, 1986, CRIT CARE MED, V14, P693, DOI 10.1097/00003246-198608000-00006; LLOYDTHOMAS AR, 1988, BRIT MED J, V296, P1025, DOI 10.1136/bmj.296.6628.1025; MCCUSKER J, 1983, PUBLIC HEALTH REP, V98, P170; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; PETERS SG, 1988, CHEST, V94, P99, DOI 10.1378/chest.94.1.99; RIZZO JA, 1992, HEALTH SERV RES, V26, P705; SCHUSTER DP, 1983, AM J MED, V75, P402, DOI 10.1016/0002-9343(83)90340-6; Sonnefeld S T, 1991, Health Care Financ Rev, V13, P1; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; WELCH HG, 1991, MED CARE, V29, P578, DOI 10.1097/00005650-199106000-00016; 1984, Y3T2222C822CASE28 PU, P3; 1992, CANCER FACTS FIGURES	19	165	169	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					783	786		10.1001/jama.269.6.783	http://dx.doi.org/10.1001/jama.269.6.783			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423662				2022-12-28	WOS:A1993KK54400033
J	KLAG, MJ; FORD, DE; MEAD, LA; HE, J; WHELTON, PK; LIANG, KY; LEVINE, DM				KLAG, MJ; FORD, DE; MEAD, LA; HE, J; WHELTON, PK; LIANG, KY; LEVINE, DM			SERUM-CHOLESTEROL IN YOUNG MEN AND SUBSEQUENT CARDIOVASCULAR-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISCHEMIC HEART-DISEASE	Background. The increased risk of cardiovascular disease associated with higher serum cholesterol levels in middle-aged persons has been clearly established, but there have been few opportunities to examine a potential link between serum cholesterol levels measured in young men and clinically evident premature cardiovascular disease later in life. Methods. We performed a prospective study of 1017 young men (mean age, 22 years) followed for 27 to 42 years to quantify the risk of cardiovascular disease and total mortality associated with serum cholesterol levels during early adult life. The mean serum cholesterol level at entry was 192 mg per deciliter (5.0 mmol per liter). Results. During a median follow-up of 30.5 years, there were 125 cardiovascular-disease events, 97 of which were due to coronary heart disease. The serum cholesterol level at base line was strongly associated with the incidence of events related to coronary heart disease and cardiovascular disease, as well as to total mortality and mortality due to cardiovascular disease. The risks were similar whether the events occurred before or after the age of 50. In a proportional-hazards analysis adjusted for age, body-mass index (the weight in kilograms divided by the square of the height in meters), the level of physical activity, coffee intake, change in smoking status, and the incidence of diabetes and hypertension during follow-up, a difference in the serum cholesterol level at base line of 36 mg per deciliter (0.9 mmol per liter) - the difference between the 25th and 75th percentiles of cholesterol level in the study population at base line - was associated with an increased risk of cardiovascular disease (relative risk, 1.72; 95 percent confidence interval, 1.39 to 2.14), coronary heart disease (relative risk, 2.01; 95 percent confidence interval, 1.59 to 2.53), and mortality due to cardiovascular disease (relative risk, 2.02; 95 percent confidence interval, 1.23 to 3.32). A difference in the base-line serum cholesterol level of 36 mg per deciliter was significantly associated with an increased risk of death before the age of 50 (relative risk, 1.64; 95 percent confidence interval, 1.03 to 2.61), but not with the overall risk of death (relative risk, 1.21; 95 percent confidence interval, 0.93 to 1.58). Conclusions. These findings indicate a strong association between the serum cholesterol level measured early in adult life in men and cardiovascular disease in midlife.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOSTAT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21218 USA; BEIJING UNION MED COLL, BEIJING, PEOPLES R CHINA; CHINESE ACAD MED SCI, BEIJING, PEOPLES R CHINA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College			Liang, Kung-Yee/F-8299-2011		NCRR NIH HHS [RR00035] Funding Source: Medline; NHLBI NIH HHS [HL42734] Funding Source: Medline; NIA NIH HHS [AG01760] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG001760] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COLLINS RA, 1970, AM J CLIN PATHOL, V54, P219; CORESH J, 1992, HYPERTENSION, V19, P218; COX DR, 1972, J R STAT SOC B, V34, P187; DECKERS JW, 1990, CIRCULATION, V82, P259; ENOS WF, 1953, JAMA-J AM MED ASSOC, V152, P1090, DOI 10.1001/jama.1953.03690120006002; HOLMAN RL, 1958, AM J PATHOL, V34, P209; JUDSON JJ, 1971, J AMER MED ASSOC, V216, P1185; KANNEL W B, 1981, Progress in Lipid Research, V20, P339, DOI 10.1016/0163-7827(81)90067-9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLAG MJ, 1991, CIRCULATION, V83, P14; LACROIX AZ, 1986, NEW ENGL J MED, V315, P977, DOI 10.1056/NEJM198610163151601; LIU K, 1978, J CHRON DIS, V31, P399, DOI 10.1016/0021-9681(78)90004-8; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; OBERMAN A, 1967, CIRCULATION, V36, P812, DOI 10.1161/01.CIR.36.6.812; PAFFENBARGER RS, 1966, AM J PUBLIC HEALTH N, V56, P962, DOI 10.2105/AJPH.56.6.962; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RABKIN SW, 1977, AM J CARDIOL, V39, P452, DOI 10.1016/S0002-9149(77)80104-5; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SHEKELLE RB, 1989, LANCET, V1, P1177; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; THOMAS C B, 1957, J Chronic Dis, V6, P1, DOI 10.1016/0021-9681(57)90059-0; THOMAS CB, 1951, B JOHNS HOPKINS HOSP, V89, P419; THOMAS CB, 1965, B JOHNS HOPKINS HOSP, V116, P348; THOMAS CB, 1956, AM J MED SCI, V232, P389, DOI 10.1097/00000441-195610000-00003; [No title captured]; 1980, DHHS PHS801260 PUBL; 1987, JAMA-J AM MED ASSOC, V257, P937	32	407	417	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					313	318		10.1056/NEJM199302043280504	http://dx.doi.org/10.1056/NEJM199302043280504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8419817				2022-12-28	WOS:A1993KK24700004
J	STANTON, MS; GERSH, BI; HAMMILL, SC				STANTON, MS; GERSH, BI; HAMMILL, SC			ELECTROPHYSIOLOGICALLY GUIDED ANTIARRHYTHMIC THERAPY VERSUS BETA-BLOCKER THERAPY IN PATIENTS WITH VENTRICULAR TACHYARRHYTHMIAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							TACHYCARDIA; SELECTION				STANTON, MS (corresponding author), MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905, USA.							HOROWITZ LN, 1978, CIRCULATION, V58, P986, DOI 10.1161/01.CIR.58.6.986; MASON JW, 1978, CIRCULATION, V58, P971, DOI 10.1161/01.CIR.58.6.971; WALLER TJ, 1987, J AM COLL CARDIOL, V10, P83, DOI 10.1016/S0735-1097(87)80164-X; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105	4	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					357	357						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8419829				2022-12-28	WOS:A1993KK24700024
J	TSUKADA, S; SAFFRAN, DC; RAWLINGS, DJ; PAROLINI, O; ALLEN, RC; KLISAK, I; SPARKES, RS; KUBAGAWA, H; MOHANDAS, T; QUAN, S; BELMONT, JW; COOPER, MD; CONLEY, ME; WITTE, ON				TSUKADA, S; SAFFRAN, DC; RAWLINGS, DJ; PAROLINI, O; ALLEN, RC; KLISAK, I; SPARKES, RS; KUBAGAWA, H; MOHANDAS, T; QUAN, S; BELMONT, JW; COOPER, MD; CONLEY, ME; WITTE, ON			DEFICIENT EXPRESSION OF A B-CELL CYTOPLASMIC TYROSINE KINASE IN HUMAN X-LINKED AGAMMAGLOBULINEMIA	CELL			English	Article							PHILADELPHIA-CHROMOSOME; HEMATOPOIETIC-CELLS; PROTEIN-KINASE; LYMPHOCYTES-B; ANTIGEN RECEPTOR; CLOSE LINKAGE; BONE-MARROW; SRC-FAMILY; GENE HCK; PRE-B	We describe a novel cytoplasmic tyrosine kinase, termed BPK (B cell progenitor kinase), which is expressed in all stages of the B lineage and in myeloid cells. BPK has classic SH1, SH2, and SH3 domains, but lacks myristylation signals and a regulatory phosphorylation site corresponding to tyrosine 527 of c-src. BPK has a long, basic amino-terminal region upstream of the SH3 domain. BPK was evaluated as a candidate for human X-linked agammaglobulinemia (XLA), an inherited immunodeficiency characterized by a severe deficit of B and plasma cells and profound hypogammaglobulinemia. BPK mapped to within 100 kb of a probe defining the polymorphism most closely linked to XLA at DXS178. Reduction in or the absence of BPK mRNA, protein expression, and kinase activity was observed in XLA pre-B and B cell lines. BPK is likely the XLA gene and functions in pathways critical to 8 cell expansion.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38101 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, INST MOLEC GENET, HOUSTON, TX 77030 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV ALABAMA, HOWARD HUGHES MED INST, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, HOWARD HUGHES MED INST, DEPT PEDIAT, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, HOWARD HUGHES MED INST, DEPT PATHOL, BIRMINGHAM, AL 35294 USA; UCLA TORRANCE, HARBOR MED CTR, DEPT MED GENET, TORRANCE, CA 90502 USA	University of California System; University of California Los Angeles; University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; Baylor College of Medicine; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	TSUKADA, S (corresponding author), UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA.		Belmont, John/AAH-6084-2021; PAROLINI, ORNELLA/C-7946-2013; Belmont, John W/AAI-2494-2019; PAROLINI, ORNELLA/ABI-7862-2020	PAROLINI, ORNELLA/0000-0002-5211-6430; Belmont, John W/0000-0001-7409-3578; PAROLINI, ORNELLA/0000-0002-5211-6430	NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030879, R37AI025129, R56AI025129, R01AI025129] Funding Source: NIH RePORTER; NCI NIH HHS [CA13148] Funding Source: Medline; NIAID NIH HHS [AI30879, AI25129] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RC, 1992, HUM MOL GENET, V1, P216, DOI 10.1093/hmg/1.3.216; ANKER R, 1989, J EXP MED, V169, P2109, DOI 10.1084/jem.169.6.2109; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BRUTON OC, 1952, PEDIATRICS, V9, P722; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPANA D, 1990, J IMMUNOL, V145, P1675; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; CONLEY ME, 1985, J IMMUNOL, V134, P3070; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; COOPER MD, 1993, IN PRESS PROG IMMUNO; CREMERS FPM, 1989, GENOMICS, V4, P41, DOI 10.1016/0888-7543(89)90312-1; DENNY CT, 1989, P NATL ACAD SCI USA, V86, P4254, DOI 10.1073/pnas.86.11.4254; DRISCOLL MC, 1989, P NATL ACAD SCI USA, V86, P7470, DOI 10.1073/pnas.86.19.7470; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FAUST EA, 1993, IN PRESS J EXP MED; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; FU SM, 1980, J EXP MED, V152, P1519, DOI 10.1084/jem.152.6.1519; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; GUIOLI S, 1989, HUM GENET, V84, P19, DOI 10.1007/BF00210664; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P7405, DOI 10.1073/pnas.88.16.7405; Hillyard A. L., 1992, LOCUS MAP MOUSE COMP; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KUBAGAWA H, 1988, P NATL ACAD SCI USA, V85, P875, DOI 10.1073/pnas.85.3.875; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KWAN SP, 1986, J CLIN INVEST, V77, P649, DOI 10.1172/JCI112351; KWAN SP, 1990, GENOMICS, V6, P238, DOI 10.1016/0888-7543(90)90562-9; LASSOUED K, 1992, FASEB J, V6, pA1704; Lau Y L, 1989, Clin Exp Immunol, V75, P190; LEVITT D, 1984, J CLIN IMMUNOL, V4, P143, DOI 10.1007/BF00915048; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MALCOLM S, 1987, HUM GENET, V77, P172, DOI 10.1007/BF00272387; MANO H, 1990, ONCOGENE, V5, P1781; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARU Y, 1990, ONCOGENE RES, V5, P199; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MENSINK EJBM, 1986, HUM GENET, V73, P327, DOI 10.1007/BF00279095; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MOHANDAS T, 1986, SOMAT CELL MOLEC GEN, V12, P89, DOI 10.1007/BF01560731; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nishimoto N., 1991, FED PROC, V5, P1346; OKADA M, 1991, J BIOL CHEM, V266, P24249; PAROLINI O, 1993, IN PRESS GENOMICS; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARL ER, 1978, J IMMUNOL, V120, P1169; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; Saffran D. C., 1992, CURR TOP MICROBIOL I, V182, P34; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; Sambrook J, 1989, MOL CLONING LABORATO; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TSUCHIYA S, 1980, SCAND J IMMUNOL, V11, P155, DOI 10.1111/j.1365-3083.1980.tb00221.x; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VINCENT WS, 1989, GENE DEV, V3, P334, DOI 10.1101/gad.3.3.334; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	82	1123	1152	2	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 29	1993	72	2					279	290		10.1016/0092-8674(93)90667-F	http://dx.doi.org/10.1016/0092-8674(93)90667-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	8425221				2022-12-28	WOS:A1993KK03800012
J	MILINKOVITCH, MC; ORTI, G; MEYER, A				MILINKOVITCH, MC; ORTI, G; MEYER, A			REVISED PHYLOGENY OF WHALES SUGGESTED BY MITOCHONDRIAL RIBOSOMAL DNA-SEQUENCES	NATURE			English	Article							EVOLUTION; RNA; MAMMALS; ORIGIN; EOCENE	LIVING cetaceans are subdivided into two highly distinct suborders, Odontoceti (the echolocating toothed whales) and Mysticeti (the filter-feeding baleen whales), which are believed to have had a long independent history. Here we report the determination of DNA sequences from two mitochondrial ribosomal gene segments (930 base pairs per species) for 16 species of cetaceans, a perissodactyl and a sloth, and construct the first phylogeny for whales and dolphins based on explicit cladistic methods. Our data (and earlier published myoglobin sequences) confirmed that cetaceans are closely related to artiodactyls and that all families and superfamilies of cetaceans are monophyletic. A surprising finding was that one group of toothed whales, the sperm whales, is more closely related to the baleen whales than to other odontocetes. The common ancestor of baleen whales and sperm whales might have lived only 10-15 million years ago. The suggested paraphyly of toothed whales has many implications for classification, phylogeny and our understanding of the evolutionary history of cetaceans.	SUNY STONY BROOK,DEPT ECOL & EVOLUT,STONY BROOK,NY 11794; UNIV LIBRE BRUXELLES,INST RECH INTERDISCIPLINAIRE BIOL HUMAINE & NUCL,B-1070 BRUSSELS,BELGIUM	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Universite Libre de Bruxelles			Meyer, Axel/C-9826-2009	Meyer, Axel/0000-0002-0888-8193; Orti, Guillermo/0000-0002-6886-2323; Milinkovitch, Michel/0000-0002-2553-0724				ALLARD MW, 1992, P NATL ACAD SCI USA, V89, P3972, DOI 10.1073/pnas.89.9.3972; ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ARNASON U, 1991, J MOL EVOL, V33, P556, DOI 10.1007/BF02102808; Barnes L.G., 1978, P582; BARNES LG, 1985, MAR MAMMAL SCI, V1, P15, DOI 10.1111/j.1748-7692.1985.tb00530.x; Czelusniak J., 1990, Current Mammalogy, V2, P545; EPERON IC, 1980, NATURE, V286, P460, DOI 10.1038/286460a0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FELSENSTEIN J, 1991, PHYLIP VERSION 341; Flower W. H., 1883, P ZOOL SOC LOND, V1883, P466; GATSEY J, 1992, MOL BIOL EVOL, V9, P433; GINGERICH PD, 1990, SCIENCE, V249, P154, DOI 10.1126/science.249.4965.154; GINGERICH PD, 1983, SCIENCE, V220, P403, DOI 10.1126/science.220.4595.403; GOODMAN M, 1985, Cladistics, V1, P171, DOI 10.1111/j.1096-0031.1985.tb00420.x; GUTELL RR, 1988, NUCLEIC ACIDS RES, V16, pR175, DOI 10.1093/nar/16.suppl.r175; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KRAUS F, 1991, SYST ZOOL, V40, P117, DOI 10.2307/2992252; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; MILINKOVITCH MC, 1992, J EVOLUTION BIOL, V5, P149, DOI 10.1046/j.1420-9101.1992.5010149.x; MINDELL DP, 1990, ANNU REV ECOL SYST, V21, P541, DOI 10.1146/annurev.es.21.110190.002545; MIYAMOTO MM, 1990, P NATL ACAD SCI USA, V87, P6127, DOI 10.1073/pnas.87.16.6127; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Palumbi S, 1991, SIMPLE FOOLS GUIDE P; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHLOTTERER C, 1991, NATURE, V354, P63, DOI 10.1038/354063a0; Szalay F. S., 1969, American Museum Novitates, VNo. 2361, P1; VAN VALEN LEIGH, 1966, BULL AMER MUS NATUR HIST, V132, P1; [No title captured]	31	145	154	1	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					346	348		10.1038/361346a0	http://dx.doi.org/10.1038/361346a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8426652	Green Submitted			2022-12-28	WOS:A1993KJ59000055
J	BROWMAN, GP; WONG, G; HODSON, I; SATHYA, J; RUSSELL, R; MCALPINE, L; SKINGLEY, P; LEVINE, MN				BROWMAN, GP; WONG, G; HODSON, I; SATHYA, J; RUSSELL, R; MCALPINE, L; SKINGLEY, P; LEVINE, MN			INFLUENCE OF CIGARETTE-SMOKING ON THE EFFICACY OF RADIATION-THERAPY IN HEAD AND NECK-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KILLER-CELL-ACTIVITY; ALPHA-TOCOPHEROL; BETA-CAROTENE; LUNG-CANCER; ALCOHOL-CONSUMPTION; SURVIVAL; RETINOL	Background. Smoking is a risk factor for several cancers and may also limit the efficacy of treatment. In this study, we evaluated the influence of cigarette smoking during radiation therapy on the efficacy of treatment in patients with head and neck cancer. Methods. Using a questionnaire, we obtained information on smoking behavior at base line and weekly during therapy in 115 patients with head and neck cancer who were treated with radiation therapy with or without fluorouracil. The side effects of therapy were evaluated weekly, and response was assessed 13 weeks after treatment was completed. The main outcomes measured were treatment response and survival. Results. The prognostic variables were similar among the patients who smoked and those who did not smoke during treatment. The 53 patients who continued to smoke during radiation therapy had a lower rate of complete response (45 percent vs. 74 percent, P = 0.008) and poorer two-year survival (39 percent vs. 66 percent, P = 0.005) than the 62 patients who did not smoke or who had quit before treatment. Among the nonsmoking patients, mortality was influenced by the length of time between quitting and treatment, with a risk reduction (relative to that for patients who continued to smoke) of 40 percent for patients who had quit less than 12 weeks before diagnosis and of 70 percent for patients who had quit more than 1 year before diagnosis. After adjustment for other variables with proportional-hazards regression analysis, smoking remained an independent prognostic factor (P = 0.002), with a relative risk of 2.5 (95 percent confidence interval, 1.4 to 4.4) favoring the patients who abstained from smoking. The results could not be explained by the type of chemotherapy received, the presence of coexisting morbid conditions, differences in the side effects of radiation, or the number of interruptions of treatment. Conclusions. Patients with head and neck cancer who continue to smoke during radiation therapy have lower rates of response and survival than patients who do not smoke during radiation therapy.	MCMASTER UNIV, DEPT MED, HAMILTON L8N 3Z5, ONTARIO, CANADA; ONTARIO CANC TREATMENT & RES FDN, HAMILTON REG CTR, HAMILTON, ON, CANADA; UNIV NEW MEXICO, CTR CANC, ALBUQUERQUE, NM 87131 USA	McMaster University; University of New Mexico	BROWMAN, GP (corresponding author), MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, RM HSC 2C10B, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA.							ARCHIMBAUD E, 1989, CANCER-AM CANCER SOC, V63, P2060, DOI 10.1002/1097-0142(19890515)63:10<2060::AID-CNCR2820631031>3.0.CO;2-2; BAKO G, 1982, CAN MED ASSOC J, V127, P727; BERGMAN, 1989, EUR RESPIR J, V2, P592; BERGMAN B, 1988, EUR RESPIR J, V1, P932; CHALMER J, 1975, J NATL CANCER I, V55, P1129, DOI 10.1093/jnci/55.5.1129; COMSTOCK GW, 1988, AM J EPIDEMIOL, V127, P114, DOI 10.1093/oxfordjournals.aje.a114771; COX DR, 1972, J R STAT SOC B, V34, P187; DANIELL HW, 1984, NEW ENGL J MED, V310, P1531; DANIELL HW, 1986, CANCER, V58, P784, DOI 10.1002/1097-0142(19860801)58:3<784::AID-CNCR2820580328>3.0.CO;2-N; FALK RT, 1989, CANCER RES, V49, P4024; FERSON M, 1979, INT J CANCER, V23, P603, DOI 10.1002/ijc.2910230504; HERBETH B, 1990, AM J EPIDEMIOL, V132, P394, DOI 10.1093/oxfordjournals.aje.a115672; HINDS MW, 1982, J NATL CANCER I, V68, P395; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; JOHNSTONEARLY A, 1980, JAMA-J AM MED ASSOC, V244, P2175, DOI 10.1001/jama.244.19.2175; KAMBAM JR, 1986, ANESTH ANALG, V65, P1186; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MERLETTI F, 1989, CANCER RES, V49, P4919; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PHILLIPS B, 1985, CANCER, V56, P2789, DOI 10.1002/1097-0142(19851215)56:12<2789::AID-CNCR2820561213>3.0.CO;2-2; RUGG T, 1990, BRIT J RADIOL, V63, P554, DOI 10.1259/0007-1285-63-751-554; SHAW HM, 1981, INT J CANCER, V28, P153, DOI 10.1002/ijc.2910280207; STEVENS MH, 1983, ARCH OTOLARYNGOL, V109, P746; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804	25	452	458	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1993	328	3					159	163		10.1056/NEJM199301213280302	http://dx.doi.org/10.1056/NEJM199301213280302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG625	8417381				2022-12-28	WOS:A1993KG62500002
J	SCHROEDER, JS; GAO, SZ; ALDERMAN, EL; HUNT, SA; JOHNSTONE, I; BOOTHROYD, DB; WIEDERHOLD, V; STINSON, EB				SCHROEDER, JS; GAO, SZ; ALDERMAN, EL; HUNT, SA; JOHNSTONE, I; BOOTHROYD, DB; WIEDERHOLD, V; STINSON, EB			A PRELIMINARY-STUDY OF DILTIAZEM IN THE PREVENTION OF CORONARY-ARTERY DISEASE IN HEART-TRANSPLANT RECIPIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHOLESTEROL-FED RABBITS; LONGITUDINAL DATA-ANALYSIS; CALCIUM-CHANNEL BLOCKER; ANGIOGRAPHIC PROGRESSION; ATHEROSCLEROSIS; NIFEDIPINE; VERAPAMIL; SUPPRESSION; ATHEROGENESIS; ANTAGONISTS	Background. Accelerated coronary artery disease is a major cause of late morbidity and mortality among heart-transplant recipients. Because calcium-channel blockers can suppress diet-induced atherosclerosis in laboratory animals, we assessed the efficacy of diltiazem in preventing coronary artery disease in transplanted hearts. Methods. Consecutive eligible cardiac-transplant recipients were randomly assigned to receive diltiazem (n = 52) or no calcium-channel blocker (n = 54). Coronary angiograms obtained early after cardiac transplantation and annually thereafter were used for the visual assessment of the extent of coronary artery disease. The average diameters of identical coronary artery segments were measured on the angiograms obtained at base line and at the first and second follow-up examinations. Results. In the 57 patients who had all three angiograms, the average coronary artery diameter (+/-SD) decreased in the group that received no calcium-channel blocker from 2.41+/-0.27 mm at base line to 2.19+/-0.28 mm at one year, and to 2.22+/-0.26 mm at two years (P<0.001 for both years). The average diameter in the diltiazem group changed little from the base-line value of 2.32+/-0.22 mm (2.32+/-0.27 mm at one year and 2.36+/-0.22 mm at two years). The average change in the diameter of the segment differed significantly between the two treatment groups (P<0.001), and the estimated effect of treatment changed only negligibly after adjustment for other relevant clinical variables. New angiographic evidence of coronary artery disease developed in 14 patients not given calcium-channel blockers, as compared with 5 diltiazem-treated patients (P = 0.082). Coronary stenoses greater than 50 percent of the luminal diameter developed in seven patients not given calcium-channel blockers, as compared with two patients given diltiazem; death due to coronary artery disease or retransplantation occurred in five patients in the group that did not receive calcium-channel blockers and in none of those who received diltiazem. Conclusions. Our preliminary results suggest that diltiazem can prevent the usual reduction in the diameter of the coronary artery in cardiac-transplant recipients, but further follow-up will be required to determine whether diltiazem can decrease the long-term incidence of symptomatic coronary artery disease.	STANFORD UNIV, MED CTR, SCH MED, DEPT STAT, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT CARDIOTHORAC SURG, STANFORD, CA 94305 USA	Stanford University; Stanford University	SCHROEDER, JS (corresponding author), STANFORD UNIV, MED CTR, SCH MED, CVRC, DIV CARDIOVASC MED, STANFORD, CA 94305 USA.			Boothroyd, Derek Brian/0000-0001-5387-6995				ALDERMAN EL, 1981, DIGITAL RADIOGRAPHY, P273; Becker RA, 1988, NEW S LANGUAGE PROGR; BETZ E, 1988, ANN NY ACAD SCI, V522, P399; BILLINGHAM ME, 1992, J HEART LUNG TRANSPL, V11, pS38; BLUMLEIN SL, 1984, AM J CARDIOL, V54, P884, DOI 10.1016/S0002-9149(84)80226-X; CATAPANO AL, 1988, ANN NY ACAD SCI, V522, P519; COOPER DKC, 1982, J HEART TRANSPLANT, V2, P78; DAUGHERTY A, 1987, BRIT J PHARMACOL, V91, P113, DOI 10.1111/j.1476-5381.1987.tb08989.x; ETINGIN OR, 1985, J CLIN INVEST, V75, P1554, DOI 10.1172/JCI111860; FRONEK K, 1988, ANN NY ACAD SCI, V522, P525; GAO SZ, 1987, CIRCULATION, V76, P56; GAO SZ, 1990, CIRCULATION, V82, P269; GAO SZ, 1989, CIRCULATION, V80, P100; GAO SZ, 1988, J AM COLL CARDIOL, V12, P334, DOI 10.1016/0735-1097(88)90402-0; GINSBURG R, 1983, LAB INVEST, V49, P154; HANDLEY DA, 1986, AM J PATHOL, V124, P88; HENRY PD, 1981, J CLIN INVEST, V68, P1366, DOI 10.1172/JCI110384; JAMIESON SW, 1984, HEART TRANSPLANTATIO, V3, P224; JOHNSON DE, 1989, J HEART TRANSPLANT, V8, P349; JOHNSON DE, 1991, J AM COLL CARDIOL, V17, P449, DOI 10.1016/S0735-1097(10)80114-7; KOBER G, 1989, J CARDIOVASC PHARM, V13, pS2, DOI 10.1097/00005344-198900134-00002; KRAMSCH DM, 1981, SCIENCE, V213, P1511, DOI 10.1126/science.6792706; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; LOALDI A, 1989, AM J CARDIOL, V64, P433, DOI 10.1016/0002-9149(89)90417-7; MACALPIN RN, 1973, RADIOLOGY, V108, P567, DOI 10.1148/108.3.567; NOMOTO A, 1987, ATHEROSCLEROSIS, V64, P255, DOI 10.1016/0021-9150(87)90253-X; OREKHOV AN, 1988, J CARDIOVASC PHARM, V12, pS66, DOI 10.1097/00005344-198812006-00017; PAOLETTI R, 1988, ANN NY ACAD SCI, V522, P390; PARMLEY WW, 1987, AM J MED, V82, P3, DOI 10.1016/0002-9343(87)90204-X; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; ROULEAU JL, 1983, J AM COLL CARDIOL, V1, P1453, DOI 10.1016/S0735-1097(83)80049-7; SHAO ZG, 1988, AM J CARDIOL, V62, P876, DOI 10.1016/0002-9149(88)90885-5; STEIN O, 1987, ARTERIOSCLEROSIS, V7, P585, DOI 10.1161/01.ATV.7.6.585; STEIN O, 1985, ARTERIOSCLEROSIS, V5, P35, DOI 10.1161/01.ATV.5.1.35; STENDER S, 1986, ATHEROSCLEROSIS, V61, P15, DOI 10.1016/0021-9150(86)90109-7; SUGANO M, 1988, BRIT J EXP PATHOL, V69, P515; SUGANO M, 1986, ARTERIOSCLEROSIS, V6, P237, DOI 10.1161/01.ATV.6.2.237; URETSKY BF, 1987, CIRCULATION, V76, P827, DOI 10.1161/01.CIR.76.4.827; VALANTINE H, 1992, J HEART LUNG TRANSPL, V11, P1; WATANABE N, 1987, ARTERY, V14, P283; WATERS D, 1990, CIRCULATION, V82, P1940, DOI 10.1161/01.CIR.82.6.1940; WEINSTEIN DB, 1987, AM J CARDIOL, V59, pB163, DOI 10.1016/0002-9149(87)90097-X; WILLIS AL, 1985, ARTERIOSCLEROSIS, V5, P250, DOI 10.1161/01.ATV.5.3.250; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	45	252	256	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1993	328	3					164	170		10.1056/NEJM199301213280303	http://dx.doi.org/10.1056/NEJM199301213280303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG625	8417382				2022-12-28	WOS:A1993KG62500003
J	WEINSTOCK, HS; BOLAN, G; REINGOLD, AL; POLISH, LB				WEINSTOCK, HS; BOLAN, G; REINGOLD, AL; POLISH, LB			HEPATITIS-C VIRUS-INFECTION AMONG PATIENTS ATTENDING A CLINIC FOR SEXUALLY-TRANSMITTED DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							NON-B-HEPATITIS; NON-A-HEPATITIS; POSTTRANSFUSION HEPATITIS; HEMODIALYSIS-PATIENTS; ANTIBODIES; RISK; TRANSMISSION; PREVALENCE; HIV	Objective.-To evaluate the association between hepatitis C virus (HCV) infection and sexual behavior in a sexually active population. Design.-Cross-sectional study. Setting.-Inner-city clinic for sexually transmitted diseases. Subjects.-The study included 1292 patients attending the clinic for care during a 1-month period and having syphilis serologic tests performed. Outcome Measures.-Antibody to HCV (anti-HCV) positivity as defined by a repeatedly reactive enzyme immunoassay and a positive neutralization enzyme immunoassay (Abbott Laboratories, Chicago, III). Results.-Of 1292 patients screened for anti-HCV, 99 (7.7%) were positive. Logistic regression analysis found that patients who reported intravenous drug use, were positive for antibody to hepatitis B core antigen, reported a history of a blood transfusion, were black, or reported crack cocaine use were more likely to be anti-HCV-positive. Forty-five percent of patients who were anti-HCV-positive reported intravenous drug use. Sex with an intravenous drug user and a history of gonorrhea and syphilis were associated with anti-HCV positivity in a univariate analysis, but after controlling for confounding variables, no such associations remained. While having multiple sexual partners in the previous 3 months, being homosexual or bisexual, and engaging in receptive anal intercourse were associated with being positive for antibody to hepatitis B core antigen, those behaviors were not associated with anti-HCV positivity. Conclusions.-While these results cannot exclude a role for the sexual transmission of HCV, they do suggest that, in this sexually active population, the sexual transmission of HCV occurs infrequently and that HCV is largely associated with intravenous drug use.	CTR DIS CONTROL & PREVENT,DIV STD HIV PREVENT,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,DIV VIRAL & RICKETTSIAL DIS,HEPATITIS BRANCH,ATLANTA,GA 30333; SAN FRANCISCO,DEPT PUBL HLTH,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco; University of California System; University of California Berkeley					PHS HHS [H-25CCH904371-01-2] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1989, LANCET, V2, P294; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; EYSTER ME, 1991, ANN INTERN MED, V115, P764, DOI 10.7326/0003-4819-115-10-764; HAYASHI J, 1991, AM J EPIDEMIOL, V134, P651, DOI 10.1093/oxfordjournals.aje.a116137; KALLINOWSKI B, 1991, NEPHRON, V59, P236, DOI 10.1159/000186557; KELEN GD, 1992, NEW ENGL J MED, V326, P1399, DOI 10.1056/NEJM199205213262105; KLEIN RS, 1991, LANCET, V338, P1539, DOI 10.1016/0140-6736(91)92369-D; RAKELA J, 1979, GASTROENTEROLOGY, V77, P1200; REALDI G, 1982, GUT, V23, P270, DOI 10.1136/gut.23.4.270; TOR J, 1990, BRIT MED J, V301, P1130, DOI 10.1136/bmj.301.6761.1130; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; 1987, HEPATITIS SURVEILLAN, P19	18	118	117	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					392	394						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418348				2022-12-28	WOS:A1993KG38100033
J	SINGH, R; GREEN, MR				SINGH, R; GREEN, MR			SEQUENCE-SPECIFIC BINDING OF TRANSFER-RNA BY GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE	SCIENCE			English	Article							URACIL DNA GLYCOSYLASE; NUCLEAR TRANSPORT; IMMUNOCYTOCHEMICAL LOCALIZATION; SKELETAL-MUSCLE; PROTEIN; EXPORT; SYNTHETASE; CELLS; IDENTIFICATION; TRANSCRIPTION	A transfer RNA (tRNA) binding protein present in HeLa cell nuclear extracts was purified and identified as the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Studies with mutant tRNAs indicated that GAPDH recognizes both sequence and structural features in the RNA. GAPDH discriminated between wild-type tRNA and two tRNA mutants that are defective in nuclear export, which suggests that the protein may participate in RNA export. The cofactor nicotinamide adenine dinucleotide disrupted complex formation between tRNA and GAPDH and thus may share a common binding site with the RNA. Indirect immunofluorescence experiments showed that GAPDH is present in the nucleus as well as in the cytoplasm.			SINGH, R (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NIGMS NIH HHS [GM35490] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035490] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; ALLEN RW, 1987, J BIOL CHEM, V262, P649; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BODE J, 1975, BIOCHEMISTRY-US, V14, P1146, DOI 10.1021/bi00677a008; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CASWELL AH, 1985, J BIOL CHEM, V260, P6892; COOL BL, 1989, CANCER RES, V49, P3029; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FOLK WR, 1983, CELL, V33, P585, DOI 10.1016/0092-8674(83)90439-7; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HODOR P, 1989, MICROCIRC ENDOTH LYM, V5, P485; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KARPEL RL, 1981, BIOCHIM BIOPHYS ACTA, V654, P256, DOI 10.1016/0005-2787(81)90180-5; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; LIN T, 1986, J BIOL CHEM, V261, P4594; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MCALISTER L, 1985, J BIOL CHEM, V260, P5013; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MORGENEGG G, 1986, J NEUROCHEM, V47, P54; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; PERUCHO M, 1977, EUR J BIOCHEM, V81, P557, DOI 10.1111/j.1432-1033.1977.tb11982.x; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; ROSSMANN MG, 1976, ENZYMES, P62; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RYAZANOV AG, 1985, FEBS LETT, V192, P131, DOI 10.1016/0014-5793(85)80058-2; SAMPSON JR, 1990, BIOCHEMISTRY-US, V29, P2523, DOI 10.1021/bi00462a014; SANTOS T, 1981, CELL, V23, P699, DOI 10.1016/0092-8674(81)90433-5; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Singh R., UNPUB; TOBIAN JA, 1985, CELL, V43, P415, DOI 10.1016/0092-8674(85)90171-0; TUNG KS, 1992, MOL CELL BIOL, V12, P2673, DOI 10.1128/MCB.12.6.2673; VANTUINEN E, 1987, J HISTOCHEM CYTOCHEM, V35, P327, DOI 10.1177/35.3.3546482; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZASLOFF M, 1982, NATURE, V295, P533, DOI 10.1038/295533a0; ZASLOFF M, 1982, NATURE, V300, P81, DOI 10.1038/300081a0; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	44	404	425	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					365	368		10.1126/science.8420004	http://dx.doi.org/10.1126/science.8420004			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8420004				2022-12-28	WOS:A1993KG62400033
J	KAWACHI, I; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC; MANSON, JE; ROSNER, B; SPEIZER, FE; HENNEKENS, CH				KAWACHI, I; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC; MANSON, JE; ROSNER, B; SPEIZER, FE; HENNEKENS, CH			SMOKING CESSATION AND DECREASED RISK OF STROKE IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE-SMOKING; SUBARACHNOID HEMORRHAGE; QUESTIONNAIRE; DISEASE	Objective.-To prospectively examine the relationship of time since stopping smoking with risk of stroke in middle-aged women. Design.-An ongoing prospective cohort of women with 12 years' follow-up data (1976 to 1988), in which information on smoking habits was updated every 2 years by postal questionnaire. Population Studied.-A total of 117 006 female registered nurses aged 30 to 55 years in 1976 and free of coronary heart disease, stroke, and cancer at baseline. Main Outcome Measures.-Incident strokes (fatal and nonfatal), further subdivided into ischemic stroke, subarachnoid hemorrhage, and cerebral hemorrhage. Results.-The age-adjusted relative risk of total stroke among current smokers compared with never smokers was 2.58 (95% confidence interval, 2.08 to 3.19). The corresponding relative risk among former smokers was 1.34 (95% confidence interval, 1.04 to 1.73). For total and ischemic stroke, the excess risks among former smokers largely disappeared from 2 to 4 years after cessation. The same patterns of decline were observed regardless of number of cigarettes smoked, the age at starting, or the presence of other risk factors for stroke. Conclusions.-The risk of suffering a stroke among cigarette smokers declines soon after cessation and the benefits are independent of the age at starting and the number of cigarettes smoked per day.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH & SOCIAL BEHAV, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, CHANNING LAB, DEPT PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	KAWACHI, I (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLANTYNE D, 1978, CLIN SCI MOL MED, V55, P333; BELL BA, 1979, BRIT MED J, V1, P577, DOI 10.1136/bmj.1.6163.577; CELLINA GU, 1975, AM HEART J, V89, P18, DOI 10.1016/0002-8703(75)90004-6; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; COLDITZ GA, 1987, INT J EPIDEMIOL, V16, P392, DOI 10.1093/ije/16.3.392; DONNAN GA, 1989, LANCET, V2, P643; GILL JS, 1989, ARCH INTERN MED, V149, P2053, DOI 10.1001/archinte.149.9.2053; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HENNEKENS CH, 1979, LANCET, V1, P1390; KANNEL WB, 1987, AM HEART J, V113, P1006, DOI 10.1016/0002-8703(87)90063-9; KUBOTA K, 1983, STROKE, V14, P720, DOI 10.1161/01.STR.14.5.720; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LEVINE PH, 1973, CIRCULATION, V48, P619, DOI 10.1161/01.CIR.48.3.619; LONGSTRETH WT, 1985, STROKE, V16, P377, DOI 10.1161/01.STR.16.3.377; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MYERS AH, 1987, AM J PUBLIC HEALTH, V77, P628, DOI 10.2105/AJPH.77.5.628; ROGERS RL, 1985, JAMA-J AM MED ASSOC, V253, P2970, DOI 10.1001/jama.253.20.2970; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; TAHA A, 1982, J ROY SOC MED, V75, P332; Walker A E, 1981, Stroke, V12, pI13; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; 1990, PHS CDC908416 US DEP	24	302	312	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					232	236		10.1001/jama.269.2.232	http://dx.doi.org/10.1001/jama.269.2.232			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417241				2022-12-28	WOS:A1993KF40500029
J	JARRETT, RJ				JARRETT, RJ			GESTATIONAL DIABETES - A NONENTITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLUCOSE-INTOLERANCE; TOLERANCE	Screening for gestational diabetes is commonly recommended despite the absence of a common definition of gestational diabetes. Furthermore, there is no consensus about management or treatment. Those who recommend screening do so largely on the basis of fetal morbidity, which seems to be predominantly ''macrosomia''-another term without an agreed definition. The implications of macrosomia in terms of actual morbidity are also not clear. R J Jarrett reviews the history of the subject and concludes that gestational diabetes is simply impaired glucose tolerance temporally associated with pregnancy. Its main importance is as a predictor of subsequent non-insulin dependent diabetes, but it fails the major tests for a condition suitable for a screening programme.			JARRETT, RJ (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS CAMPUS, LONDON SE1 9RT, ENGLAND.							ALES KL, 1989, LANCET, V1, P1187; COUSTAN DR, 1978, OBSTET GYNECOL, V51, P306, DOI 10.1097/00006250-197803000-00010; Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; FURMAN GI, 1987, DIABETES S1, V36, P90; GABBE SG, 1989, CARBOHYD METABOL, P309; GILBERT JAL, 1949, BRIT MED J, V1, P48, DOI 10.1136/bmj.1.4592.48; GREEN JR, 1991, OBSTET GYNECOL, V78, P235; HADDEN DR, 1980, DIABETES CARE, V3, P440, DOI 10.2337/diacare.3.3.440; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARRIS MI, 1988, DIABETES CARE, V11, P402, DOI 10.2337/diacare.11.5.402; O'Sullivan J.B., 1975, CARBOHYD METABOL, P195; OSULLIVAN JB, 1964, DIABETES, V13, P278; OSULLIVAN JB, 1966, DIABETES, V15, P466, DOI 10.2337/diab.15.7.466; OSULLIVAN JB, 1971, J REPROD MED, V7, P45; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; 1986, MANAGEMENT DIABETES, V92, P1; 1980, WHO TECHNICAL REPORT, V646; 1985, DIABETES S2, V34, P123; 1991, DIABETES CARE, V14, P5; 1979, DIABETES, V28, P1038	20	94	95	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 2	1993	306	6869					37	38		10.1136/bmj.306.6869.37	http://dx.doi.org/10.1136/bmj.306.6869.37			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435576	Bronze, Green Published			2022-12-28	WOS:A1993KE98400026
J	NOYORI, R; SUZUKI, M				NOYORI, R; SUZUKI, M			ORGANIC-SYNTHESIS OF PROSTAGLANDINS - ADVANCING BIOLOGY	SCIENCE			English	Editorial Material							3-COMPONENT COUPLING SYNTHESIS; GROWTH-INHIBITION; ISOCARBACYCLIN; ANTITUMOR; MECHANISM; SITE		NAGOYA UNIV,CTR CHEM INSTRUMENT,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University	NOYORI, R (corresponding author), NAGOYA UNIV,DEPT CHEM,CHIKUSA KU,NAGOYA 46401,JAPAN.							COREY EJ, 1991, ANGEW CHEM INT EDIT, V30, P445; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; ICHIKAWA A, 1992, LIPID BIOFACTOR, P113; ITO S, 1992, J BIOL CHEM, V267, P20326; KATO T, 1986, CANCER RES, V46, P3538; MIZUSHIMA Y, 1987, PROSTAGLANDINS, V33, P161, DOI 10.1016/0090-6980(87)90003-7; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P500; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P506; NOYORI R, 1990, SCIENCE, V248, P1194, DOI 10.1126/science.248.4960.1194; NOYORI R, 1990, CHEMTRACTS ORG CHEM, V3, P173; SHIBASAKI M, 1983, TETRAHEDRON LETT, V24, P3493, DOI 10.1016/S0040-4039(00)86021-9; SUZUKI M, 1988, J AM CHEM SOC, V110, P4718, DOI 10.1021/ja00222a033; SUZUKI M, 1990, TETRAHEDRON, V46, P4809, DOI 10.1016/S0040-4020(01)85596-4; SUZUKI M, 1988, B CHEM SOC JPN, V61, P1299, DOI 10.1246/bcsj.61.1299; SUZUKI M, 1987, J ORG CHEM, V52, P5583, DOI 10.1021/jo00234a014; SUZUKI M, 1992, TETRAHEDRON, V48, P2635, DOI 10.1016/S0040-4020(01)88526-4; TANAKA T, 1991, TETRAHEDRON, V47, P1861, DOI 10.1016/S0040-4020(01)96099-5; 1983, ADV PROSTAGLANDIN TH, V11	18	109	109	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					44	45		10.1126/science.8418493	http://dx.doi.org/10.1126/science.8418493			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418493				2022-12-28	WOS:A1993KE60100023
J	BERRIOS, X; DELCAMPO, E; GUZMAN, B; BISNO, AL				BERRIOS, X; DELCAMPO, E; GUZMAN, B; BISNO, AL			DISCONTINUING RHEUMATIC-FEVER PROPHYLAXIS IN SELECTED ADOLESCENTS AND YOUNG-ADULTS - A PROSPECTIVE-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; STREPTOCOCCAL INFECTIONS; RECURRENCE; PENICILLINS	G STREPTOCOCCAL PHARYNGITIS; GROUP-A STREPTOCOCCI; RECURRENCES; INFECTIONS; OUTBREAK; DISEASE	Objective: To assess the safety of discontinuing prophylaxis with antimicrobial agents in patients judged to be at relatively low risk for recurrence of acute rheumatic fever. Design: Observational cohort study. Setting: Public health clinics in the Southeast Health District of Santiago, Chile. Patients: Fifty-nine patients (19 men, 40 women) ranging in age at study entry from 15 to 44 years (mean, 24.5 years). Forty-eight had completed their prescribed period of prophylaxis. Eleven refused or were allergic to intramuscular benzathine penicillin G and were non-compliant with oral sulfadiazine. Intervention: In patients who did not have carditis during their previous attack(s), prophylaxis was discontinued after 5 years or at age 18, whichever was longer. In those with only mild mitral regurgitation or healed carditis, prophylaxis was stopped after 10 years or at age 25. Symptomatic intercurrent streptococcal throat infections were treated with antibiotics. Measurements: Patients were seen every 3 months during the study (July 1982 to September 1988). For the first 4.25 years, throat cultures as well as sera samples for antistreptolysin O and anti-DNAse B assays were obtained at each visit. Results: During laboratory surveillance, significant increases in antibody titers were detected in 56 instances (28.1 [95% CI, 21.7 to 36.5] per 100 patient-years), and 29 isolations of group A streptococci occurred (14.5 [CI, 10.1 to 20.8] per 100 patient-years). The patients were followed for a total of 3349 patient-months, during which time two acute rheumatic fever recurrences were observed (0.7 [CI, 0.2 to 2.6] per 100 patient-years). No recurrences occurred during an outbreak of acute rheumatic fever in 52 patients in the study area in 1986. Conclusions: These and other data indicate that acute rheumatic fever prophylaxis can safely be discontinued in young adults judged to be at low risk for recurrence and who are maintained under careful prospective surveillance.	MIAMI VET AFFAIRS MED CTR, MED SERV 111, 1201 NW 16TH ST, MIAMI, FL 33125 USA; CATHOLIC UNIV AMER, DEPT PUBL HLTH, WASHINGTON, DC 20064 USA; HOSP DR SOTERO DEL RIO, DEPT MED, SANTIAGO, CHILE; UNIV MIAMI, DEPT MED, MIAMI, FL 33152 USA	Catholic University of America; Universidad de Chile; University of Miami								ARON AM, 1965, AM J MED, V38, P83, DOI 10.1016/0002-9343(65)90162-2; BERRIOS X, 1986, J LAB CLIN MED, V108, P535; BERRIOS X, 1985, J PEDIATR-US, V107, P867, DOI 10.1016/S0022-3476(85)80177-3; BESSEN DE, 1990, J EXP MED, V172, P1757, DOI 10.1084/jem.172.6.1757; Bisno A.L., 1980, STREPTOCOCCAL DISEAS, P789; BISNO AL, 1977, J INFECT DIS, V136, P278, DOI 10.1093/infdis/136.2.278; BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; BISNO AL, 1987, INFECT IMMUN, V55, P753, DOI 10.1128/IAI.55.3.753-757.1987; COLLINS CM, 1992, INFECT IMMUN, V60, P3689, DOI 10.1128/IAI.60.9.3689-3696.1992; DAJANI AS, 1988, CIRCULATION, V78, P1082, DOI 10.1161/01.CIR.78.4.1082; FEINSTEIN AR, 1966, J AMER MED ASSOC, V197, P949, DOI 10.1001/jama.197.12.949; FEINSTEIN AR, 1960, NEW ENGL J MED, V262, P533, DOI 10.1056/NEJM196003172621101; GERBER MA, 1991, PEDIATRICS, V87, P598; JOHNSON EE, 1964, JAMA-J AM MED ASSOC, V190, P407, DOI 10.1001/jama.1964.03070180005001; JOHNSON EE, 1960, NEW ENGL J MED, V263, P105, DOI 10.1056/NEJM196007212630301; KUTTNER AG, 1963, NEW ENGL J MED, V268, P1259, DOI 10.1056/NEJM196306062682301; MAJEED HA, 1984, AM J DIS CHILD, V138, P341, DOI 10.1001/archpedi.1984.02140420007003; MASON T, 1991, ARCH INTERN MED, V151, P133, DOI 10.1001/archinte.151.1.133; MEIER FA, 1990, ARCH INTERN MED, V150, P825, DOI 10.1001/archinte.150.4.825; MOODY M D, 1965, Health Lab Sci, V2, P149; Rammelkamp C.H., 1952, RHEUMATIC FEVER, P72; SIEGEL AC, 1961, NEW ENGL J MED, V265, P559, DOI 10.1056/NEJM196109212651201; SPAGNUOL.M, 1971, NEW ENGL J MED, V285, P641, DOI 10.1056/NEJM197109162851201; Stollerman G H, 1990, Adv Intern Med, V35, P1; STOLLERMAN GH, 1975, MOD CONC CARDIOV DIS, V44, P35; STRYKER WS, 1982, AM J EPIDEMIOL, V116, P533, DOI 10.1093/oxfordjournals.aje.a113437; Swift HF, 1943, J EXP MED, V78, P127, DOI 10.1084/jem.78.2.127; TARANTA A, 1959, NEW ENGL J MED, V260, P1204, DOI 10.1056/NEJM195906112602402; TARANTA A, 1964, ANN INTERN MED, V60, P58, DOI 10.7326/0003-4819-60-2-58; TARANTA A, 1956, AM J MED, V20, P170, DOI 10.1016/0002-9343(56)90186-3; WIDDOWSON JP, 1971, J GEN MICROBIOL, V65, P69, DOI 10.1099/00221287-65-1-69; WOOD HF, 1964, ANN INTERN MED, V60, P31, DOI 10.7326/0003-4819-60-2-31	32	29	29	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					401	406		10.7326/0003-4819-118-6-199303150-00001	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439112				2022-12-28	WOS:A1993KR81700001
J	FERRIS, FL				FERRIS, FL			HOW EFFECTIVE ARE TREATMENTS FOR DIABETIC-RETINOPATHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											FERRIS, FL (corresponding author), NEI, CLIN TRIALS BRANCH, BLDG 31, ROOM 6A24, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							[Anonymous], 1988, OPHTHALMOLOGY, V95, P1307; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], 1976, Am J Ophthalmol, V81, P383; BEETHAM W P, 1963, Br J Ophthalmol, V47, P611, DOI 10.1136/bjo.47.10.611; BLANKENSHIP GW, 1991, OPHTHALMOLOGY, V98, P125; CAIRD FI, 1968, DIABETES, V17, P121, DOI 10.2337/diab.17.3.121; DECKERT T, 1967, DIABETES, V16, P728, DOI 10.2337/diab.16.10.728; DRUMMOND MF, 1992, SOC SCI MED, V34, P973, DOI 10.1016/0277-9536(92)90128-D; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; 1991, OPHTHALMOLOGY S, V98, P767; 1990, ARCH OPHTHALMOL-CHIC, V108, P958; 1989, DIABETIC RETINOPATHY	12	272	277	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1290	1291		10.1001/jama.269.10.1290	http://dx.doi.org/10.1001/jama.269.10.1290			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437309				2022-12-28	WOS:A1993KP88500030
J	LOWENBERG, B; VANPUTTEN, WLJ; TOUW, IP; DELWEL, R; SANTINI, V				LOWENBERG, B; VANPUTTEN, WLJ; TOUW, IP; DELWEL, R; SANTINI, V			AUTONOMOUS PROLIFERATION OF LEUKEMIC-CELLS INVITRO AS A DETERMINANT OF PROGNOSIS IN ADULT ACUTE MYELOID-LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background and Methods. A characteristic of acute myeloid leukemia is the frequent ability of the leukemic cells to sustain their own proliferation in vitro. To determine the clinical importance of this property, we measured the uptake of tritiated thymidine by leukemic cells in serum-free and cytokine-free cultures as a means of determining the rate of spontaneous proliferation in 114 patients with newly diagnosed acute myeloid leukemia. Proliferation was then classified according to three quantitative levels of activity and related to overall survival and to treatment outcome (the response to treatment, the actuarial probability of relapse, and disease-free survival) in 91 patients who were treated with chemotherapy to induce remission. Results. Of the 114 patients, 37 had low, 39 had intermediate, and 38 had high levels of proliferation. The probability of survival at three years was 36 percent among patients with low levels of proliferative activity and 3 percent among those with high levels (P<0.001). Among the patients treated with chemotherapy, those with low rates of proliferative activity had a 68 percent rate of complete remission and a 49 percent probability of remaining free of relapse, whereas those with high rates of proliferative activity had only a 39 percent rate of complete remission (P = 0.04) and an 11 percent probability of remaining in complete remission (P = 0.009). The probability of disease-free survival at three years among the patients in complete remission after chemotherapy was 49 percent among those with low rates of proliferative activity and 9 percent among those with high rates (P = 0.004). Accordingly, patients with low rates of proliferative activity also had a significantly higher rate of overall survival (44 percent vs. 4 percent; P = 0.002). Patients whose cells had intermediate levels of proliferation in vitro had intermediate rates of survival, relapse, and disease-free survival. Conclusions. The capacity of leukemic blasts for autonomous proliferation is associated with highly aggressive acute myeloid leukemia.	ERASMUS UNIV, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam	LOWENBERG, B (corresponding author), DR DANIEL DEN HOED CANC CTR, GROENE HILLEDIJK 301, 3075 EA ROTTERDAM, NETHERLANDS.		SANTINI, VALERIA/AAL-3135-2020	SANTINI, VALERIA/0000-0002-5439-2172				ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BEGLEY CG, 1988, EXP HEMATOL, V16, P71; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BUDEL LM, 1989, BLOOD, V74, P565; COX DR, 1972, J R STAT SOC B, V34, P187; COZZOLINO F, 1989, P NATL ACAD SCI USA, V86, P2369, DOI 10.1073/pnas.86.7.2369; DELWEL R, 1989, BLOOD, V74, P586; DELWEL R, 1988, BLOOD, V72, P1944; ELBAZ O, 1991, BLOOD, V77, P989; GOLDIE JH, 1984, CANCER RES, V44, P3643; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GRIFFIN JD, 1987, BLOOD, V70, P1218; HAGEMEIJER A, 1979, CYTOGENET CELL GENET, V23, P208, DOI 10.1159/000131327; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HOANG T, 1989, J EXP MED, V170, P15, DOI 10.1084/jem.170.1.15; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOWENBERG B, 1989, J CLIN ONCOL, V7, P1268; LOWENBERG B, 1990, J CLIN ONCOL, V8, P287; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; OSTER W, 1989, J CLIN INVEST, V84, P451, DOI 10.1172/JCI114186; PARK LS, 1989, BLOOD, V74, P56; REES JKH, 1987, SEMIN ONCOL, V14, P32; SALEM M, 1990, LEUKEMIA, V4, P37; SALEM M, 1989, BRIT J HAEMATOL, V71, P363; SCHIFFER CA, 1989, BLOOD, V73, P263; SHERR CJ, 1990, BLOOD, V75, P1; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VANDERSCHOOT CE, 1989, BLOOD, V74, P2081; YOUNG DC, 1987, J CLIN INVEST, V79, P100, DOI 10.1172/JCI112769; YOUNG DC, 1986, BLOOD, V68, P1178; ZITTOUN R, 1989, BLOOD, V73, P896	31	175	177	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1993	328	9					614	619		10.1056/NEJM199303043280904	http://dx.doi.org/10.1056/NEJM199303043280904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP680	8429853				2022-12-28	WOS:A1993KP68000004
J	LIDZ, CW; MULVEY, EP; GARDNER, W				LIDZ, CW; MULVEY, EP; GARDNER, W			THE ACCURACY OF PREDICTIONS OF VIOLENCE TO OTHERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DANGEROUSNESS; COMMITMENT; DISORDER	Objective.-To assess the accuracy of clinicians in predicting violence in mental patients. Specifically, to determine if clinicians can predict violence when variation in rates of violence attributable to age, race, and sex is controlled. Design.-Two samples of psychiatric patients, matched on age, race, sex, and admission status, were followed up in the community during a 6-month period. One group included individuals assessed by psychiatric emergency department clinicians as likely to be violent to another person during the follow-up period; the other was a comparison group. Patients provided self-reports of violent incidents, and a ''collateral,'' ie, an individual with detailed knowledge of the patient's life, provided this same information. Official records were also reviewed. Setting.-Patients were recruited in the emergency department of a metropolitan psychiatric hospital. Patients and collaterals were interviewed in their homes or in public places in the community. Patients or Other Participants.-A consecutive sample of individuals coming into a psychiatric emergency department during daylight and evening shifts was obtained. A total of 2452 patients were approached for consent and 1948 consented. A final sample of 357 patients whom clinicians assessed as likely to be violent and their matched comparison patients were included. Main Outcome Measures.-Patients', collaterals', and official records' reports of incidents in which the patient laid hands on another person or threatened someone with a weapon. Results.-Violence during the.follow-up period was reported in approximately 45% of the cases: 36% in the comparison group and 53% in the cases predicted to be violent. Overall clinical accuracy was significantly better than chance, but predictions of female patients' violence were not better than chance. Conclusions.-The level of patient violence reported using self-reports and collateral reports was higher than has been obtained using other methods. Clinical judgment adds to predictive accuracy, but overall accuracy was modest and particularly low for female patients.			LIDZ, CW (corresponding author), UNIV PITTSBURGH,WESTERN PSYCHIAT INST & CLIN,SCH MED,DEPT PSYCHIAT,3811 OHARA ST,PITTSBURGH,PA 15213, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040030] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 40030-07] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bishop YM., 2007, DISCRETE MULTIVARIAT; BLAND R, 1986, CAN J PSYCHIAT, V31, P129, DOI 10.1177/070674378603100210; COCOZZA JJ, 1976, RUTGERS LAW REV, V29, P1084; DIX GE, 1975, J PSYCHIAT LAW, V3, P327; EWING C, 1983, AM J LAW MED, V4, P407; FAUST D, 1988, SCIENCE, V241, P31, DOI 10.1126/science.3291114; GRISSO T, 1992, LAW HUMAN BEHAV, V16, P621, DOI 10.1007/BF01884019; HOLFORD TR, 1978, BIOMETRICS, V34, P665, DOI 10.2307/2530387; Jacoby Joseph E., 1979, CRIMINALLY INSANE CO; KLASSEN D, 1990, PSYCHOL ASSESSMENT, V1, P75; KOZL HL, 1972, CRIME DELINQUENCY, V18, P371; KRAKOWSKI M, 1986, COMPR PSYCHIAT, V27, P131, DOI 10.1016/0010-440X(86)90022-2; LIDZ CW, 1989, AM J PSYCHIAT, V146, P176; LIDZ CW, 1986, 12 INT C LAW PSYCH M; MEEHL PE, 1955, PSYCHOL BULL, V52, P194, DOI 10.1037/h0048070; MONAHAN J, 1988, INT J LAW PSYCHIAT, V11, P249, DOI 10.1016/0160-2527(88)90012-X; MONAHAN J, 1989, SCHIZOPHRENIA BULL, V15, P541, DOI 10.1093/schbul/15.4.541; MONAHAN J, PREDICTING VIOLENT B; Monahan John, 1981, CLIN PREDICTION VIOL; MORSE S, 1982, CALIF LAW REV, V54, P70; MORSE SJ, 1982, CALIF LAW REV, V54, P87; MULVEY EP, 1985, LAW HUMAN BEHAV, V9, P209, DOI 10.1007/BF01067052; MULVEY EP, 1984, CLIN PSYCHOL REV, V4, P379, DOI 10.1016/0272-7358(84)90018-7; MULVEY EP, IN PRESS LAW HUM BEH; POYTHRESS NG, 1990, AM J PSYCHIAT, V147, P994; QUINSEY V, 1986, J INTERPERS VIOLENCE, V1, P143, DOI DOI 10.1177/088626086001002002; QUINSEY VL, 1975, BRIT J CRIMINOL, V15, P264, DOI 10.1093/oxfordjournals.bjc.a046644; Rosen G., 1968, MADNESS SOC CHAPTERS; SAPEJAK D, 1983, B AM ACAD PSYCH LAW, V11, P171; SEGAL SP, 1988, ARCH GEN PSYCHIAT, V45, P753; Steadman H J, 1977, Bull Am Acad Psychiatry Law, V5, P200; Steadman Henry J., 1974, CAREERS CRIMINALLY I; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; TARDIFF K, 1982, AM J PSYCHIAT, V11, P13; Weinstein MC, 1980, CLIN DECISION ANAL	35	299	303	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					1007	1011		10.1001/jama.269.8.1007	http://dx.doi.org/10.1001/jama.269.8.1007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KM603	8429581				2022-12-28	WOS:A1993KM60300029
J	HEINZ, DW; BAASE, WA; DAHLQUIST, FW; MATTHEWS, BW				HEINZ, DW; BAASE, WA; DAHLQUIST, FW; MATTHEWS, BW			HOW AMINO-ACID INSERTIONS ARE ALLOWED IN AN ALPHA-HELIX OF T4-LYSOZYME	NATURE			English	Article							PROTEIN STABILITY CURVES; BACTERIOPHAGE-T4 LYSOZYME; T4 LYSOZYME; SEQUENCES; ACCESSIBILITY; ENZYME	STUDIES of extant protein sequences indicate that amino-acid insertions and deletions are preferentially located in loop regions1, which has traditionally been explained as the result of selection removing deleterious mutations within secondary structural elements from the population. But there is no a priori reason to discount the possibility that insertions within secondary structure could either be tolerated until compensatory mutations arise, or have effects that are propagated away from secondary structure into loops. Earlier studies have indicated that insertions are generally tolerated, although much less well within secondary structure elements than in loop regions2-8. Here we show that amino-acid insertions in an alpha-helix of T4 lysozyme can be accepted in two different ways. In some cases the inserted amino acids are accommodated within the helix, leading to the translocation of wild-type residues from the helix to the preceding loop. In other cases the insertion causes a 'looping-out' in the first or last turn of the helix. The individual structural responses seem to be dominated by the maintenance of the interface between the helix and the rest of the protein.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; Howard Hughes Medical Institute; University of Oregon; University of Oregon; University of Oregon								ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BARANY F, 1985, P NATL ACAD SCI USA, V82, P4202, DOI 10.1073/pnas.82.12.4202; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FREIMUTH PI, 1990, J BIOL CHEM, V265, P896; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; HEINZ DW, 1992, P NATL ACAD SCI USA, V89, P3751, DOI 10.1073/pnas.89.9.3751; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KURKEL TA, 1987, METHOD ENZYMOL, V154, P367; LADANT D, 1992, J BIOL CHEM, V267, P2244; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; MARTI T, 1992, P NATL ACAD SCI USA, V89, P1219, DOI 10.1073/pnas.89.4.1219; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MCINTOSH LP, 1990, BIOCHEMISTRY-US, V29, P6341, DOI 10.1021/bi00479a003; MILNERWHITE EJ, 1987, TRENDS BIOCHEM SCI, V12, P189; PASCARELLA S, 1992, J MOL BIOL, V224, P461, DOI 10.1016/0022-2836(92)91008-D; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; SONDEK J, 1990, PROTEINS, V7, P299, DOI 10.1002/prot.340070402; SONDEK J, 1992, PROTEINS, V13, P132, DOI 10.1002/prot.340130206; STARZYK RM, 1989, BIOCHEMISTRY-US, V28, P8479, DOI 10.1021/bi00447a031; STREISINGER G, 1961, COLD SPRING HARB SYM, V26, P25, DOI 10.1101/SQB.1961.026.01.007; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001	28	112	112	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					561	564		10.1038/361561a0	http://dx.doi.org/10.1038/361561a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429913				2022-12-28	WOS:A1993KL71400069
J	CONCATO, J; FEINSTEIN, AR; HOLFORD, TR				CONCATO, J; FEINSTEIN, AR; HOLFORD, TR			THE RISK OF DETERMINING RISK WITH MULTIVARIABLE MODELS	ANNALS OF INTERNAL MEDICINE			English	Article						MULTIVARIATE ANALYSIS; STATISTICAL MODELS; RISK FACTORS; PROPORTIONAL HAZARDS MODELS; LOGISTIC MODELS	CORONARY HEART-DISEASE; BONE-MARROW TRANSPLANTATION; CYTOMEGALO-VIRUS INFECTION; BREAST-CANCER; RANDOMIZED TRIAL; CARDIOVASCULAR MORTALITY; PROGNOSTIC PREDICTION; REGRESSION-MODELS; HOST-DISEASE; SURVIVAL	Purpose: To review the principles of multivariable analysis and to examine the application of multivariable statistical methods in general medical literature. Data Sources: A computer-assisted search of articles in The Lancet and The New England Journal of Medicine identified 451 publications containing multivariable methods from 1985 through 1989. A random sample of 60 articles that used the two most common methods-logistic regression or proportional hazards analysis-was selected for more intensive review. Data Extraction: During review of the 60 randomly selected articles, the focus was on generally accepted methodologic guidelines that can prevent problems affecting the accuracy and interpretation of multivariable analytic results. Results: From 1985 to 1989, the relative frequency of multivariable statistical methods increased annually from about 10% to 18% among all articles in the two journals. In 44 (73%) of 60 articles using logistic or proportional hazards regression, risk estimates were quantified for individual variables (''risk factors''). Violations and omissions of methodologic guidelines in these 44 articles included overfitting of data; no test of conformity of variables to a linear gradient; no mention of pertinent checks for proportional hazards; no report of testing for interactions between independent variables; and unspecified coding or selection of independent variables. These problems would make the reported results potentially inaccurate, misleading, or difficult to interpret. Conclusions: The findings suggest a need for improvement in the reporting and perhaps conducting of multivariable analyses in medical research.	YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA	Yale University								ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397; AMERY A, 1986, LANCET, V2, P589; APGAR V, 1953, Curr Res Anesth Analg, V32, P260; Armitage P, 1987, STATISTICAL METHODS, P399; BARKER DJP, 1989, LANCET, V2, P577; BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904; BAUM M, 1985, LANCET, V1, P836; BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; Breslow N, 1980, STATISTICAL METHODS, V32; Breslow N. E., 1987, STATISTICAL METHODS, VII; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHRISTENSEN E, 1987, HEPATOLOGY, V7, P1346, DOI 10.1002/hep.1840070628; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; COHEN J, 1987, LANCET, V1, P8; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; COX DR, 1972, J R STAT SOC B, V34, P187; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; DEHMER GJ, 1988, NEW ENGL J MED, V319, P733, DOI 10.1056/NEJM198809223191201; DIXON WJ, 1987, BMDP STATISTICAL SOF; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; ETTINGER B, 1986, NEW ENGL J MED, V315, P1386, DOI 10.1056/NEJM198611273152204; FEINSTEIN AR, 1977, CLIN BIOSTATISTICS, P385; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR, P396; FLEGEL KM, 1987, LANCET, V1, P526; FOGELFELD L, 1989, NEW ENGL J MED, V320, P835, DOI 10.1056/NEJM198903303201304; FRANCIS CW, 1986, LANCET, V1, P769; FREEDMAN DS, 1986, NEW ENGL J MED, V315, P721, DOI 10.1056/NEJM198609183151202; FREEDMAN LS, 1987, LANCET, V2, P294; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GELMERS HJ, 1988, NEW ENGL J MED, V318, P203, DOI 10.1056/NEJM198801283180402; GERSH BJ, 1985, NEW ENGL J MED, V313, P217, DOI 10.1056/NEJM198507253130403; GILL M, 1988, LANCET, V1, P689; Harrell F., 1983, SUGI SUPPLEMENTAL LI, P267; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HARRIS KR, 1985, LANCET, V2, P802; HARVEY EB, 1985, NEW ENGL J MED, V312, P541, DOI 10.1056/NEJM198502283120903; HAYBITTLE JL, 1985, LANCET, V1, P967; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; HOLMBERG LH, 1986, LANCET, V2, P27; HOROWITZ MM, 1989, LANCET, V1, P535; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HOSMER DW, 1989, APPL LOGISTIC REGRES, P131; HURWITZ ES, 1985, NEW ENGL J MED, V313, P849, DOI 10.1056/NEJM198510033131403; JUSTICE AC, 1989, NEW ENGL J MED, V320, P1388, DOI 10.1056/NEJM198905253202106; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; KNUTSSON A, 1986, LANCET, V2, P89; KRAUSS RM, 1987, LANCET, V2, P62; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; LEE ET, 1980, STATISTICAL METHODS; LESKO SM, 1985, NEW ENGL J MED, V313, P593, DOI 10.1056/NEJM198509053131001; LOUIK C, 1987, NEW ENGL J MED, V317, P474, DOI 10.1056/NEJM198708203170803; LUDLAM CA, 1985, LANCET, V2, P233; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; MARWICK TH, 1988, LANCET, V2, P66; MCMANUS IC, 1987, LANCET, V2, P33; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; PRICE WH, 1989, LANCET, V1, P1407; RAGLAND DR, 1988, NEW ENGL J MED, V318, P65, DOI 10.1056/NEJM198801143180201; RAHMAN M, 1985, LANCET, V2, P28, DOI 10.1016/S0140-6736(85)90068-6; REIS GJ, 1989, LANCET, V2, P177; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIOU G, 1987, LANCET, V1, P761; ROM WN, 1983, ENV OCCUPATIONAL MED, P157; RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601; SCHEIN OD, 1989, NEW ENGL J MED, V321, P773, DOI 10.1056/NEJM198909213211201; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SELIKOFF IJ, 1968, J AMER MED ASSOC, V204, P106, DOI 10.1001/jama.204.2.106; SHEINFELD J, 1989, NEW ENGL J MED, V320, P773, DOI 10.1056/NEJM198903233201205; SPYRATOS F, 1989, LANCET, V2, P1115; STADEL BV, 1985, LANCET, V2, P970; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201; THOMPSON PL, 1988, LANCET, V1, P203; VISTE A, 1986, LANCET, V2, P502; WAHRENDORF J, 1989, LANCET, V2, P1239, DOI 10.1016/S0140-6736(89)91850-3; WALTER SD, 1990, J CLIN EPIDEMIOL, V43, P349, DOI 10.1016/0895-4356(90)90121-5; WEBSTER A, 1989, LANCET, V2, P63; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WITTEMAN JCM, 1986, LANCET, V2, P1120; YUDKIN JS, 1988, LANCET, V2, P530; 1988, BRS COLLEAGUE USERS; 1988, SAS GUIDE PERSONAL C	88	921	927	0	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					201	210		10.7326/0003-4819-118-3-199302010-00009	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8417638				2022-12-28	WOS:A1993KJ43900009
J	MENDENHALL, MD				MENDENHALL, MD			AN INHIBITOR OF P34(CDC28) PROTEIN-KINASE ACTIVITY FROM SACCHAROMYCES-CEREVISIAE	SCIENCE			English	Article							XENOPUS CDC2 PROTEIN; CELL-DIVISION CYCLE; FISSION YEAST; M-PHASE; ACTIVATION; MITOSIS; P34CDC2; COMPLEX; GENE; DEPHOSPHORYLATION	The p34CDC28 protein from Saccharomyces cerevisiae is a homolog of the p34cdc2 protein kinase, a fundamental regulator of cell division in all eukaryotic cells. Once activated it initiates the visible events of mitosis (chromosome condensation, nuclear envelope breakdown, and spindle formation). The p34CDC28 protein also has a critical role in the initiation of DNA synthesis. The protein kinase activity is regulated by cycles of phosphorylation and dephosphorylation and by periodic association with cyclins. An endogenous 40-kilodalton protein (p40) originally identified as a substrate of the p34CDC28 protein kinase was purified. The p40 protein bound tightly to p34CDC28 and inhibited the activity of the kinase. The p40 protein may provide another mechanism to regulate p34CDC28 protein kinase activity.	UNIV KENTUCKY,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky	MENDENHALL, MD (corresponding author), UNIV KENTUCKY,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536, USA.							DUCOMMUN B, 1990, ANAL BIOCHEM, V187, P94, DOI 10.1016/0003-2697(90)90422-6; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HARLOW E, 1988, ANTIBODIES LABORATOR, P304; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LUCA FC, 1989, J CELL BIOL, V109, P1895, DOI 10.1083/jcb.109.5.1895; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MEIKRANTZ W, 1991, FEBS LETT, V291, P192, DOI 10.1016/0014-5793(91)81281-C; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MENDENHALL MD, UNPUB; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; YAMASHITA M, 1992, DEV BIOL, V149, P8, DOI 10.1016/0012-1606(92)90259-J	28	173	178	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					216	219		10.1126/science.8421781	http://dx.doi.org/10.1126/science.8421781			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	8421781				2022-12-28	WOS:A1993KF71900027
J	SMITH, JW; LONGO, DL; ALVORD, WG; JANIK, JE; SHARFMAN, WH; GAUSE, BL; CURTI, BD; CREEKMORE, SP; HOLMLUND, JT; FENTON, RG; SZNOL, M; MILLER, LL; SHIMIZU, M; OPPENHEIM, JJ; FIEM, SJ; HURSEY, JC; POWERS, GC; URBA, WJ				SMITH, JW; LONGO, DL; ALVORD, WG; JANIK, JE; SHARFMAN, WH; GAUSE, BL; CURTI, BD; CREEKMORE, SP; HOLMLUND, JT; FENTON, RG; SZNOL, M; MILLER, LL; SHIMIZU, M; OPPENHEIM, JJ; FIEM, SJ; HURSEY, JC; POWERS, GC; URBA, WJ			THE EFFECTS OF TREATMENT WITH INTERLEUKIN-1-ALPHA ON PLATELET RECOVERY AFTER HIGH-DOSE CARBOPLATIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT HUMAN INTERLEUKIN-3; COLONY-STIMULATING FACTOR; ENDOTHELIAL-CELLS; PHASE-I; CANCER; MICE; INVIVO; IL-1; 5-FLUOROURACIL; NEUTROPENIA	Background. Thrombocytopenia is a frequent side effect of cancer chemotherapy and commonly limits attempts to escalate drug doses. To determine whether interleukin-1alpha could ameliorate carboplatin-induced thrombocytopenia, we combined it with high-dose carboplatin in 43 patients with advanced neoplasms. Methods. High-dose carboplatin (800 mg per square meter of body-surface area) was administered alone to a control group. Subsequent patients were randomly assigned to receive the same dose of carboplatin with interleukin-1alpha, administered either before or after carboplatin. Interleukin-1alpha was given intravenously at a dose of 0.03, 0.1, or 0.3 mug per kilogram of body weight per day for five days. Results. Carboplatin alone consistently produced thrombocytopenia with a median nadir of 19,000 platelets per cubic millimeter and a median of 10 days with less than 1 00,000 platelets per cubic millimeter. All 15 patients receiving interleukin-1alpha before carboplatin had similar findings. In contrast, 5 of the 15 patients given one of the two higher doses of interleukin-1alpha after carboplatin had minimal thrombocytopenia (nadir, 91,000 to 332,000 platelets per cubic millimeter). In the 10 patients given 0.3 mug of interleukin-1alpha per kilogram after carboplatin treatment, the platelet count recovered to 100,000 per cubic millimeter significantly earlier than in either the control group (P = 0.002) or the patients who received interleukin-1alpha before carboplatin (P = 0.003), with the median times to recovery in the three groups being 16, 21, and 23 days, respectively. At the highest dose of interleukin-1alpha, toxicity was substantial (but reversible), requiring inpatient support for hypotension, supraventricular arrhythmias, and pulmonary-capillary leak. Conclusions. Interleukin-1alpha can accelerate the recovery of platelets after high-dose carboplatin therapy and may be clinically useful in preventing or treating thrombocytopenia induced by chemotherapy.	NCI,FREDERICK CANC RES & DEV CTR,DATA MANAGEMENT SERV,FREDERICK,MD 21701; FREDERICK MEM HOSP,FREDERICK,MD; PROGRAM RESOURCES INC,DYNCORP,FREDERICK,MD; NCI,CANC TREATMENT EVALUAT PROGRAM,ROCKVILLE,MD; DAINIPPON PHARMACEUT CO LTD,SUITA,OSAKA 564,JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Dainippon Sumitomo Pharmaceutical Company	SMITH, JW (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21701, USA.		Longo, Dan L./F-6022-2011	Sznol, Mario/0000-0002-4359-8749	NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADSHEAD F J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P241; BAGBY GC, 1986, J CLIN INVEST, V78, P1316, DOI 10.1172/JCI112717; BIESMA B, 1992, BLOOD, V80, P1141; CASTELLI MP, 1988, J IMMUNOL, V140, P3830; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; CROWN J, 1991, BLOOD, V78, P1420; DAVILA E, 1987, CANCER, V60, P61; DERCKSEN MW, 1992, P AM SOC CLIN ONCOL, V11, P303; DEVRIES EGE, 1992, P AM SOC CLIN ONCOL, V11, P230; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DUBOIS CM, 1991, BLOOD, V78, P2841; ELIAS A, 1991, BLOOD, V78, pA400; FIBBE WE, 1989, EXP HEMATOL, V17, P805; FUTAMI H, 1990, J IMMUNOL, V145, P4121; GANSER A, 1990, BLOOD, V76, P455; GERHARTZ HH, 1992, P AM SOC CLIN ONCOL, V11, P329; HONDT VD, 1992, P AM SOC CLIN ONCOL, V11, P381; HUAN SD, 1992, BLOOD, V79, P3388; KRITZ A, 1991, BLOOD S1, V78, pA7; KURZROCK R, 1991, J CLIN ONCOL, V9, P1241, DOI 10.1200/JCO.1991.9.7.1241; LINDEMANN A, 1991, J CLIN ONCOL, V9, P2120, DOI 10.1200/JCO.1991.9.12.2120; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MOORE MAS, 1991, BLOOD, V78, P1; MOORE MAS, 1987, P NATL ACAD SCI USA, V84, P7134, DOI 10.1073/pnas.84.20.7134; MUGGIA FM, 1989, SEMIN ONCOL, V16, P7; NAKAMURA S, 1991, CANCER RES, V51, P215; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; NETA R, 1986, J IMMUNOL, V136, P2483; OZOLS RF, 1987, J CLIN ONCOL, V5, P197, DOI 10.1200/JCO.1987.5.2.197; PETERS WP, 1991, BLOOD S, V78, pA162; POSTMUS PE, 1992, J CLIN ONCOL, V10, P1131, DOI 10.1200/JCO.1992.10.7.1131; RUSTHOVEN JJ, 1992, P AM SOC CLIN ONCOL, V11, P237; SHEA TC, 1992, J CLIN ONCOL, V10, P464, DOI 10.1200/JCO.1992.10.3.464; SIRONI M, 1989, J IMMUNOL, V142, P549; SMITH JW, 1992, J CLIN ONCOL, V10, P1141, DOI 10.1200/JCO.1992.10.7.1141; SPEYER J, 1992, P AN M AM SOC CLIN, V11, P227; STEIS R, 1991, P AN M AM SOC CLIN, V10, P211; TEPLER I, 1992, P AN M AM SOC CLIN, V11, P296; TEWARI A, 1990, LANCET, V336, P712, DOI 10.1016/0140-6736(90)92206-W; WILSON WH, 1992, P AN M AM SOC CLIN, V11, P335; ZUCALI JR, 1986, J CLIN INVEST, V77, P1857, DOI 10.1172/JCI112512; 1985, SAS USERS GUIDE STAT	42	125	125	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					756	761		10.1056/NEJM199303183281103	http://dx.doi.org/10.1056/NEJM199303183281103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8437596				2022-12-28	WOS:A1993KR84800003
J	MILETICH, JP; PRESCOTT, SM; WHITE, R; MAJERUS, PW; BOVILL, EG				MILETICH, JP; PRESCOTT, SM; WHITE, R; MAJERUS, PW; BOVILL, EG			INHERITED PREDISPOSITION TO THROMBOSIS	CELL			English	Article							PROTEIN-C DEFICIENCY; HUMAN DNA; SUBSTITUTIONS; POLYMORPHISMS; COAGULATION; SPECTRUM; FAMILIES; LINKAGE		WASHINGTON UNIV, SCH MED, DEPT HEMATOL ONCOL, ST LOUIS, MO 63110 USA; UNIV UTAH, ECCLES PROGRAM HUMAN MOLEC BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA; UNIV VERMONT, DEPT PATHOL, COLCHESTER, VT 05446 USA; UNIV VERMONT, COLCHESTER RES FACIL, COLCHESTER, VT 05446 USA	Washington University (WUSTL); Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Vermont; University of Vermont	MILETICH, JP (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PATHOL & INTERNAL MED, ST LOUIS, MO 63110 USA.							BOVILL EG, 1989, BLOOD, V73, P712; CHURCH GM, 1988, SCIENCE, V240, P185, DOI 10.1126/science.3353714; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DAVIE EW, 1986, COLD SPRING HARB SYM, V51, P509, DOI 10.1101/SQB.1986.051.01.062; DREYFUS M, 1991, NEW ENGL J MED, V325, P1565, DOI 10.1056/NEJM199111283252207; ESMON CT, 1992, ARTERIOSCLER THROMB, V12, P135, DOI 10.1161/01.ATV.12.2.135; FISCHER SG, 1983, P NATL ACAD SCI-BIOL, V80, P1579, DOI 10.1073/pnas.80.6.1579; HORELLOU MH, 1986, ANN MED INTERNE, V137, P465; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEPPERT M, 1988, J CLIN INVEST, V82, P847, DOI 10.1172/JCI113688; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; MARLAR RA, 1989, J PEDIATR-US, V114, P528, DOI 10.1016/S0022-3476(89)80688-2; MILETICH J, 1987, NEW ENGL J MED, V317, P991, DOI 10.1056/NEJM198710153171604; MORTON NE, 1955, AM J HUM GENET, V7, P277; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PENROSE LS, 1953, ANN EUGENIC, V18, P120; REITSMA PH, 1991, BLOOD, V78, P890, DOI 10.1182/blood.V78.4.890.bloodjournal784890; STENFLO J, 1991, BLOOD, V78, P1637; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; WHITE R, 1987, ADV HUM GENET, V16, P121	25	183	183	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 26	1993	72	4					477	480		10.1016/0092-8674(93)90063-V	http://dx.doi.org/10.1016/0092-8674(93)90063-V			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440014				2022-12-28	WOS:A1993KP16500001
J	VLATAKIS, G; ANDERSSON, LI; MULLER, R; MOSBACH, K				VLATAKIS, G; ANDERSSON, LI; MULLER, R; MOSBACH, K			DRUG ASSAY USING ANTIBODY MIMICS MADE BY MOLECULAR IMPRINTING	NATURE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; AMINO-ACID DERIVATIVES; ENZYME-IMMUNOASSAY; ENANTIOMERIC RESOLUTION; POLYMERS; THEOPHYLLINE; RECOGNITION; SERUM; SPECIFICITY; NONCOVALENT	LIGAND-BINDING assays are used for determination of minute amounts of substances in the bloodstream. Such assays require a receptor that specifically binds the substance of interest. The receptor used is often an antibody1-5, but antibodies require special handling and a costly production procedure5. We have used molecular imprinting, a method for creating selective recognition sites in synthetic polymers6-8, to prepare polymers that mimic antibody combining sites. Molecular imprints made against theophylline9 and diazepam10 showed strong binding and cross-reactivity profiles similar to those of antibodies. Here we describe a new radiolabelled ligand-binding assay, the molecularly imprinted sorbent assay, which uses antibody mimics. This assay accurately measures drug levels in human serum, with results comparable to those obtained using a well established immunoassay technique. Antibody mimics, which are stable and readily prepared by molecular imprinting, may provide a useful general alternative to antibodies.	UNIV LUND,CTR CHEM,DEPT PURE & APPL BIOCHEM,POB 124,S-22100 LUND,SWEDEN	Lund University			Mosbach, Klaus/L-1016-2013	Mosbach, Klaus/0000-0001-7300-3470; Andersson, Lars I./0000-0002-5257-4052				ALTUNKAYA D, 1988, FORENSIC SCI INT, V39, P23, DOI 10.1016/0379-0738(88)90115-6; ANDERSSON LI, 1990, J CHROMATOGR, V516, P313, DOI 10.1016/S0021-9673(01)89273-6; ANDERSSON LI, 1991, THESIS LUND U; BASELT RC, 1984, ADV ANAL TOXICOLOGY, V1, P81; CASTRO A, 1978, CLIN CHEM, V24, P944; CHANG J, 1982, CLIN CHEM, V28, P361; CRAM DJ, 1992, NATURE, V356, P29, DOI 10.1038/356029a0; DESLONGCHAMPS G, 1992, ANGEW CHEM INT EDIT, V31, P61, DOI 10.1002/anie.199200611; DIETZLER DN, 1980, CLIN CHIM ACTA, V101, P163, DOI 10.1016/0009-8981(80)90242-9; EKBERG B, 1989, TRENDS BIOTECHNOL, V7, P92, DOI 10.1016/0167-7799(89)90006-1; FISCHER L, 1991, J AM CHEM SOC, V113, P9358, DOI 10.1021/ja00024a046; GOSLING JP, 1990, CLIN CHEM, V36, P1408; HARVEY SC, 1985, PHARMACOL BASIS THER, P339; HENDELES L, 1978, CLIN PHARMACOKINET, V3, P294, DOI 10.2165/00003088-197803040-00003; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KURSTAK E, 1986, ENZYME IMMUNODIAGNOS, P5; MEFFIN PJ, 1980, PROGR DRUG METABOLIS, V4, P261; MURA P, 1987, J CHROMATOGR-BIOMED, V416, P303, DOI 10.1016/0378-4347(87)80513-3; OELLERICH M, 1984, J CLIN CHEM CLIN BIO, V22, P895; OSHANNESSY DJ, 1989, J CHROMATOGR, V470, P391, DOI 10.1016/S0021-9673(01)83567-6; PENG GW, 1978, CLIN CHEM, V24, P357; PONCELET SM, 1990, J IMMUNOASSAY, V11, P77, DOI 10.1080/01971529008053259; REBEK J, 1990, ANGEW CHEM INT EDIT, V29, P245, DOI 10.1002/anie.199002451; SELLERGREN B, 1988, J AM CHEM SOC, V110, P5853, DOI 10.1021/ja00225a041; SELLERGREN B, 1985, J CHROMATOGR, V347, P1, DOI 10.1016/S0021-9673(01)95464-0; SHEA KJ, 1991, J AM CHEM SOC, V113, P4109, DOI 10.1021/ja00011a009; TIJSSEN P, 1988, LABORATORY TECHNIQUE; WULFF G, 1986, ACS SYM SER, V308, P186; WULFF G, 1990, J LIQ CHROMATOGR, V13, P2987, DOI 10.1080/01483919008049082; YALOW RS, 1959, NATURE, V184, P1648, DOI 10.1038/1841648b0	30	1486	1650	22	681	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					645	647		10.1038/361645a0	http://dx.doi.org/10.1038/361645a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8437624				2022-12-28	WOS:A1993KM77600066
J	ADLER, AI; ALTMAN, J				ADLER, AI; ALTMAN, J			AN OUTBREAK OF MUD-WRESTLING INDUCED PUSTULAR DERMATITIS IN COLLEGE-STUDENTS - DERMATITIS-PALAESTRAE-LIMOSAE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							GRAM-NEGATIVE FOLLICULITIS; PSEUDOMONAS-AERUGINOSA; CITROBACTER	Objective.-To investigate an outbreak of gram-negative folliculitis in relation to a common exposure, mud wrestling, and identify risk factors for dermatitis among those who mud wrestled. Design.-Case-control study. Setting.-University of Washington, Seattle. Participants.-Two college-residence groups of students. Results.-Cultures from affected students and from mud similar to that used for wrestling yielded Enterobacteriaceae. The odds ratio associated with mud wrestling was 79.5 (95% confidence interval, 13.9 to 895.4). Increased time spent wrestling was associated with increased risk. Skin trauma during wrestling or immersion in the mud increased the risk of infection (odds ratio, 23.1; 95% confidence interval, 1.7 to 1440.4). Conclusions.-Mud wrestling is one cause of pustular follicular dermatitis. Trauma to the skin may be a necessary cofactor for the development of infection.	UNIV WASHINGTON, CTR STUDENT HLTH, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT FAMILY MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ARNOLD HA, 1990, ANDREWS DISEASES SKI; BELONGIA EA, 1991, NEW ENGL J MED, V325, P906, DOI 10.1056/NEJM199109263251302; BERGER RS, 1990, CUTIS, V45, P97; BLANKENSHIP ML, 1984, ARCH DERMATOL, V120, P1301, DOI 10.1001/archderm.120.10.1301; Braun Julius, 1875, CURATIVE EFFECTS BAT; CHANDRASEKAR PH, 1984, ARCH DERMATOL, V120, P1337, DOI 10.1001/archderm.120.10.1337; FOX AB, 1984, ARCH DERMATOL, V120, P1304, DOI 10.1001/archderm.120.10.1304; FREEMAN MJ, 1977, CUTIS, V20, P333; KELLY MT, 1985, MANUAL CLIN MICROBIO, P00263; LIPSKY BA, 1980, REV INFECT DIS, V2, P746; MOSTAFA WZ, 1989, J AM ACAD DERMATOL, V20, P504, DOI 10.1016/S0190-9622(89)80090-8; Seefelder A, 1991, Offentl Gesundheitswes, V53, P338; Tscharntke D, 1987, Offentl Gesundheitswes, V49, P589	13	6	7	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					502	504		10.1001/jama.269.4.502	http://dx.doi.org/10.1001/jama.269.4.502			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8419670				2022-12-28	WOS:A1993KH38500035
J	NISHIZAKA, T; YAGI, T; TANAKA, Y; ISHIWATA, S				NISHIZAKA, T; YAGI, T; TANAKA, Y; ISHIWATA, S			RIGHT-HANDED ROTATION OF AN ACTIN FILAMENT IN AN INVITRO MOTILE SYSTEM	NATURE			English	Article							MYOSIN; MOVEMENT; MUSCLE	MUSCLE contraction occurs by mutual sliding between thick (myosin) and thin (actin) filaments1,2. But the physical and chemical properties of the sliding force are not clear; even the precise direction of sliding force generated at each cross-bridge is not known. We report here the use of a recently developed in vitro motile assay system3-5 to show supercoiling of an actin filament in which the front part of the filament was fixed to a glass surface through cross-linked heavy-meromyosin and the rear part was able to slide on a track of heavy-meromyosin. A left-handed single turn of superhelix formed just before supercoiling, suggesting that the sliding force has a right-handed torque component that induces the right-handed rotation of an actin filament around its long axis. The presence of the torque component in the sliding force will explain several properties of the contractile system of muscle.	WASEDA UNIV,SCH SCI & ENGN,DEPT PHYS,3-4-1 OKUBO,SHINJUKU KU,TOKYO 169,JAPAN; HONDA RES & DEV CO LTD,WAKO RES CTR,SAITAMA 35101,JAPAN	Waseda University; Honda Motor Company								ANDO T, 1989, J BIOCHEM-TOKYO, V105, P818, DOI 10.1093/oxfordjournals.jbchem.a122751; CECCHI G, 1990, SCIENCE, V250, P1409, DOI 10.1126/science.2255911; GOLDSTEIN MA, 1987, FASEB J, V1, P133, DOI 10.1096/fasebj.1.2.3609610; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; JAROSCH R, 1987, NATURE FUNCTION CYTO, P231; KONDO H, 1976, J BIOCHEM-TOKYO, V79, P159, DOI 10.1093/oxfordjournals.jbchem.a131043; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; SELLERS JR, 1990, SCIENCE, V249, P406, DOI 10.1126/science.2377894; SHIMADA K, 1975, NATURE, V254, P332, DOI 10.1038/254332a0; TANAKA Y, 1992, BIOCHIM BIOPHYS ACTA, V1159, P94, DOI 10.1016/0167-4838(92)90079-S; TOYOSHIMA YY, 1989, NATURE, V341, P154, DOI 10.1038/341154a0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; VALE RD, 1988, CELL, V52, P459, DOI 10.1016/S0092-8674(88)80038-2; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8; YAMAGUCHI M, 1985, J MOL BIOL, V184, P621, DOI 10.1016/0022-2836(85)90308-0	18	109	110	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 21	1993	361	6409					269	271		10.1038/361269a0	http://dx.doi.org/10.1038/361269a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8423853				2022-12-28	WOS:A1993KH61400063
J	FRIDEN, PM; WALUS, LR; WATSON, P; DOCTROW, SR; KOZARICH, JW; BACKMAN, C; BERGMAN, H; HOFFER, B; BLOOM, F; GRANHOLM, AC				FRIDEN, PM; WALUS, LR; WATSON, P; DOCTROW, SR; KOZARICH, JW; BACKMAN, C; BERGMAN, H; HOFFER, B; BLOOM, F; GRANHOLM, AC			BLOOD-BRAIN-BARRIER PENETRATION AND INVIVO ACTIVITY OF AN NGF CONJUGATE	SCIENCE			English	Article							NERVE GROWTH-FACTOR; ANTITRANSFERRIN RECEPTOR ANTIBODY; SEPTAL CHOLINERGIC NEURONS; BASAL FOREBRAIN NEURONS; PROMOTES DEVELOPMENT; ALZHEIMERS-DISEASE; ANTERIOR-CHAMBER; ADULT-RATS; TRANSPORT; INFUSION	Nerve growth factor (NGF) is essential for the survival of both peripheral ganglion cells and central cholinergic neurons of the basal forebrain. The accelerated loss of central cholinergic neurons during Alzheimer's disease may be a determinant of dementia in these patients and may therefore suggest a therapeutic role for NGF. However, NGF does not significantly penetrate the blood-brain barrier, which makes its clinical utility dependent on invasive neurosurgical procedures. When conjugated to an antibody to the transferrin receptor, however, NGF crossed the blood-brain barrier after peripheral injection. This conjugated NGF increased the survival of both cholinergic and noncholinergic neurons of the medial septal nucleus that had been transplanted into the anterior chamber of the rat eye. This approach may prove useful for the treatment of Alzheimer's disease and other neurological disorders that are amenable to treatment by proteins that do not readily cross the blood-brain barrier.	UNIV COLORADO,SCH DENT,DEPT BASIC SCI,DENVER,CO 80262; UNIV LINKOPING,HLTH SCI CTR,DEPT CELL BIOL,LINKOPING,SWEDEN; SCRIPPS CLIN & RES FDN,DEPT NEUROPHARMACOL,LA JOLLA,CA 92037; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	University of Colorado System; University of Colorado Denver; Linkoping University; Scripps Research Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	FRIDEN, PM (corresponding author), ALKERMES INC,64 SIDNEY ST,CAMBRIDGE,MA 02139, USA.		backman, cristina/C-1276-2013	Doctrow, Susan/0000-0003-0628-9960	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R44NS029601, R43NS029601] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29601-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BJORKLUND H, 1990, ENVIRON RES, V22, P229; BLAIR AH, 1983, J IMMUNOL METHODS, V59, P129; BRIGHTMAN MW, 1977, EXP EYE RES, V25, P1, DOI 10.1016/S0014-4835(77)80008-0; BUXSER S, 1991, J NEUROCHEM, V56, P1012, DOI 10.1111/j.1471-4159.1991.tb02022.x; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; ERIKSDOTTERNILSSON M, 1989, EXP BRAIN RES, V74, P89; ERIKSDOTTERNILSSON M, 1989, NEUROSCIENCE, V30, P755, DOI 10.1016/0306-4522(89)90167-X; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; FRIDEN PM, 1991, P NATL ACAD SCI USA, V88, P4771, DOI 10.1073/pnas.88.11.4771; GAHWILER BH, 1987, NEUROSCI LETT, V75, P6, DOI 10.1016/0304-3940(87)90066-8; GOLDSTEIN GW, 1986, SCI AM, V255, P74, DOI 10.1038/scientificamerican0986-74; GREENE LA, 1980, ANNU REV NEUROSCI, V3, P353, DOI 10.1146/annurev.ne.03.030180.002033; HAGG T, 1990, J NEUROSCI, V10, P3087; HAGG T, 1988, EXP NEUROL, V101, P303, DOI 10.1016/0014-4886(88)90013-1; Haigler HJ, 1985, BRAIN RES, V362, P157; HARIK SI, 1990, P NATL ACAD SCI USA, V87, P4261, DOI 10.1073/pnas.87.11.4261; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTIKKA J, 1988, J NEUROSCI, V8, P2967; HEFTI F, 1986, J NEUROSCI, V6, P2155; HOFFMAN D, 1990, EXP NEUROL, V110, P39, DOI 10.1016/0014-4886(90)90049-X; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; JUNARD EO, 1990, EXP NEUROL, V110, P25, DOI 10.1016/0014-4886(90)90048-W; KNOBLER RL, 1992, J NEUROPATH EXP NEUR, V51, P36, DOI 10.1097/00005072-199201000-00005; KOTTLER M, 1970, INVEST OPHTH VISUAL, V9, P758; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; KUPERSMITH M, 1989, IMPLICATIONS BLOOD B, P369; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACRI FJ, 1970, ARCH OPHTHALMOL-CHIC, V83, P741; MOBLEY WC, 1986, MOL BRAIN RES, V1, P53, DOI 10.1016/0169-328X(86)90020-3; OLSON L, 1991, ARCH NEUROL-CHICAGO, V48, P373, DOI 10.1001/archneur.1991.00530160037011; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; OLSON L, 1977, BRAIN RES, V119, P87, DOI 10.1016/0006-8993(77)90093-2; PARDRIDGE WM, 1991, J PHARMACOL EXP THER, V259, P66; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; RAVIOLA G, 1977, EXP EYE RES, V25, P27, DOI 10.1016/S0014-4835(77)80009-2; RAVIOLA G, 1984, INVEST OPHTH VIS SCI, V25, P827; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; ROSSIER J, 1984, NEUROCHEM INT, V6, P183, DOI 10.1016/0197-0186(84)90090-1; SAFFRAN BN, 1989, BRAIN RES, V492, P245, DOI 10.1016/0006-8993(89)90907-4; SCHWAB ME, 1979, BRAIN RES, V168, P473, DOI 10.1016/0006-8993(79)90303-2; TRIGUERO D, 1990, J NEUROCHEM, V54, P1882, DOI 10.1111/j.1471-4159.1990.tb04886.x; WAINER BH, 1984, NEUROCHEM INT, V6, P163, DOI 10.1016/0197-0186(84)90089-5; WALUS LR, UNPUB; Wawrzyaczak E. J., 1987, IMMUNOCONJUGATES ANT, P28; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WHITTEMORE SR, 1987, BRAIN RES REV, V12, P439, DOI 10.1016/0165-0173(87)90008-7; WILL B, 1985, BEHAV BRAIN RES, V17, P17, DOI 10.1016/0166-4328(85)90004-X; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231	50	262	310	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					373	377		10.1126/science.8420006	http://dx.doi.org/10.1126/science.8420006			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8420006				2022-12-28	WOS:A1993KG62400036
J	YIANNAKIS, PH; LARNER, AJ				YIANNAKIS, PH; LARNER, AJ			VISUAL FAILURE AND OPTIC ATROPHY ASSOCIATED WITH CHLORAMBUCIL THERAPY	BRITISH MEDICAL JOURNAL			English	Letter											YIANNAKIS, PH (corresponding author), MIDLAND CTR NEUROSURG & NEUROL,SMETHWICK B67 7JX,W MIDLANDS,ENGLAND.							IMPERIA PS, 1989, SURV OPHTHALMOL, V34, P209, DOI 10.1016/0039-6257(89)90105-7; PAVANLIVINGSTON.D, 1991, HDB OCCULAR DRUG THE; VIZEL M, 1982, CANCER, V49, P1999, DOI 10.1002/1097-0142(19820515)49:10<1999::AID-CNCR2820491009>3.0.CO;2-B	3	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					109	109		10.1136/bmj.306.6870.109-b	http://dx.doi.org/10.1136/bmj.306.6870.109-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435605	Bronze, Green Published			2022-12-28	WOS:A1993KG46500023
J	GANTLEY, M; DAVIES, DP; MURCOTT, A				GANTLEY, M; DAVIES, DP; MURCOTT, A			SUDDEN-INFANT-DEATH-SYNDROME - LINKS WITH INFANT CARE PRACTICES	BRITISH MEDICAL JOURNAL			English	Article							ETHNIC-DIFFERENCES; COT DEATH; HONG-KONG	Objectives-To investigate infant care practices in a small ethnic minority population within Britain that might suggest possible factors contributing to the low incidence of the sudden infant death syndrome in Asian populations. Design-Ethnographic interviewing, a qualitative comparative method drawn from social anthropology. Setting-Central Cardiff. Subjects-Non-random sample of 60 mothers of Bangladeshi or Welsh ethnic origin and working or middle class occupational status, who had infants under one year old. None of the families interviewed had experienced a sudden infant death. Results-Broad cultural contrasts emerged as a series of themes from the interview data: living patterns, family networks, sleeping patterns, and concepts of time and dependence. Conclusion-Bangladeshi infants were cared for in a consistently rich sensory environment; Welsh infants, in contrast, were more likely to experience alternating periods of high and low sensory input. Long periods of lone quiet sleep may be one factor that contributes to a higher rate of sudden deaths in white than in Asian infants.	UNIV WALES COLL MED,DEPT CHILD HLTH,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University	GANTLEY, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH PROMOT SCI UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							Alam Fazlul, 1988, SALIENCE HOMELAND SO; Atkinson P., 1981, CLIN EXPERIENCE ETHN; BALARAJAN R, 1989, BRIT MED J, V298, P716, DOI 10.1136/bmj.298.6675.716; DAVIES DP, 1985, LANCET, V2, P1346; FAROOQI S, 1991, LANCET, V338, P1455, DOI 10.1016/0140-6736(91)92753-O; Glaser B.G., 1965, AWARENESS DYING; GOLDING J, 1985, PATTERNS PUZZLES PRO; GRETHER JK, 1990, J PEDIATR-US, V116, P525, DOI 10.1016/S0022-3476(05)81597-5; HOLTON JB, 1991, ARCH DIS CHILD, V66, P1315, DOI 10.1136/adc.66.11.1315; Janes C, 1986, ANTHR EPIDEMIOLOGY I; KYLE D, 1990, ARCH DIS CHILD, V65, P830, DOI 10.1136/adc.65.8.830; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; McKenna J J, 1990, Hum Nat, V1, P179, DOI 10.1007/BF02692151; McKenna J J, 1990, Hum Nat, V1, P145, DOI 10.1007/BF02692150; McKenna J J, 1990, Hum Nat, V1, P291, DOI 10.1007/BF02733987; MCKENNA JJ, 1990, AM J PHYS ANTHROPOL, V83, P331, DOI 10.1002/ajpa.1330830307; OAKLEY A, 1981, HERE MATERNITY BECOM; SOUTHALL DP, 1992, BMJ-BRIT MED J, V304, P265, DOI 10.1136/bmj.304.6822.265; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282; 1991, COUNTY MONITOR 1991; 1991, OPCS SERIES DH2, V17; [No title captured]; 1991, LANCET, V337, P1012	23	60	61	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1993	306	6869					16	20		10.1136/bmj.306.6869.16	http://dx.doi.org/10.1136/bmj.306.6869.16			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435569	Green Published, Bronze			2022-12-28	WOS:A1993KE98400019
J	LAW, CM; DESWIET, M; OSMOND, C; FAYERS, PM; BARKER, DJP; CRUDDAS, AM; FALL, CHD				LAW, CM; DESWIET, M; OSMOND, C; FAYERS, PM; BARKER, DJP; CRUDDAS, AM; FALL, CHD			INITIATION OF HYPERTENSION INUTERO AND ITS AMPLIFICATION THROUGHOUT LIFE	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; ADULT LIFE; FETAL; GROWTH; AGE	Objective-To determine whether the relation between high blood pressure and low birth weight is initiated in utero or during infancy, and whether it changes with age. Design-A longitudinal study of children and three follow up studies of adults. Setting-Farnborough, Preston, and Hertfordshire, England, and a national sample in Britain. Subjects-1895 children aged 0-10 years, 3240 men and women aged 36 years, 459 men and women aged 46-54 years, and 1231 men and women aged 59-71 years. The birth weight of all subjects had been recorded. Main outcome measure-Systolic blood pressure. Results-At all ages beyond infancy people who had lower birth weight had higher systolic blood pressure. Systolic blood pressure was not related to growth during infancy independently of birth weight. The relation between systolic pressure and birth weight became larger with increasing age so that, after current body mass was allowed for, systolic pressure at ages 64-71 years decreased by 5.2 mm Hg (95% confidence interval 1.8 to 8.6) for every kg increase in birth weight. Conclusions-Essential hypertension is initiated in fetal life. A raised blood pressure is then amplified from infancy to old age, perhaps by a positive feedback mechanism.	QUEEN CHARLOTTES & CHELSEA HOSP,INST OBSTET & GYNAECOL,LONDON W6 0XG,ENGLAND; MRC,CANC TRIALS OFF,CAMBRIDGE CB2 2BB,ENGLAND	Imperial College London	LAW, CM (corresponding author), SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.		Fayers, Peter M/A-5999-2010; Law, Catherine/A-1353-2009	Osmond, Clive/0000-0002-9054-4655; Fayers, Peter/0000-0003-4778-1513; Law, Catherine/0000-0002-1777-9386				Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BERRY CL, 1978, BRIT HEART J, V40, P709; CRUISE M, 1973, PEDIATRICS, V51, P322; DESWIET M, 1992, BRIT MED J, V304, P23, DOI 10.1136/bmj.304.6818.23; FERRISS JB, 1975, BMJ-BRIT MED J, V1, P135, DOI 10.1136/bmj.1.5950.135; FOLKOW B, 1978, CLIN SCI MOL MED, V55, pS3, DOI 10.1042/cs055003s; FOLKOW B, 1982, PHYSIOL REV, V62, P347, DOI 10.1152/physrev.1982.62.2.347; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LEVER AF, 1992, J HYPERTENS, V10, P101, DOI 10.1097/00004872-199202000-00001; OUNSTED MK, 1985, ARCH DIS CHILD, V60, P631, DOI 10.1136/adc.60.7.631; Owens J.A., 1989, ADV FETAL PHYSL, P263; SCOTT A, 1982, EARLY HUM DEV, V7, P17, DOI 10.1016/0378-3782(82)90004-4; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534	16	509	516	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1993	306	6869					24	27		10.1136/bmj.306.6869.24	http://dx.doi.org/10.1136/bmj.306.6869.24			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435572	Bronze, Green Published			2022-12-28	WOS:A1993KE98400021
J	GALLANT, JL; BRAUN, J; VANESSEN, DC				GALLANT, JL; BRAUN, J; VANESSEN, DC			SELECTIVITY FOR POLAR, HYPERBOLIC, AND CARTESIAN GRATINGS IN MACAQUE VISUAL-CORTEX	SCIENCE			English	Article							INFERIOR TEMPORAL NEURONS; MONKEY; FIELD; AREA; PATTERNS; SENSITIVITY; PERCEPTION; DIRECTION; SULCUS; MOTION	The neural basis of pattern recognition is a central problem in visual neuroscience. Responses of single cells were recorded in area V4 of macaque monkey to three classes of periodic stimuli that are based on spatial derivative operators: polar (concentric and radial), hyperbolic, and conventional sinusoidal (Cartesian) gratings. Of 118 cells tested, 16 percent responded significantly more to polar or hyperbolic (non-Cartesian) gratings than to Cartesian gratings and only 8 percent showed a significant preference for Cartesian gratings. Among cells selective for non-Cartesian gratings, those that preferred concentric gratings were most common. Cells selective for non-Cartesian gratings may constitute an important intermediate stage in pattern recognition and the representation of surface shape.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Braun, Jochen/F-1370-2013; Gallant, Jack L/C-4426-2011	Braun, Jochen/0000-0002-8886-078X; 	NATIONAL EYE INSTITUTE [R01EY002091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007251] Funding Source: NIH RePORTER; NEI NIH HHS [EY02091] Funding Source: Medline; NINDS NIH HHS [T32NS07251] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CAELLI TM, 1976, MATH BIOSCI, V30, P191, DOI 10.1016/0025-5564(76)90065-1; Cavanagh P., 1984, FIGURAL SYNTHESIS, P185; DESIMONE R, 1985, VISION RES, V25, P441, DOI 10.1016/0042-6989(85)90069-0; DESIMONE R, 1984, J NEUROSCI, V4, P2051; DESIMONE R, 1987, J NEUROPHYSIOL, V57, P835, DOI 10.1152/jn.1987.57.3.835; DeValois RL, 1990, SPATIAL VISION; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; DODWELL PC, 1987, VISION RES, V27, P569, DOI 10.1016/0042-6989(87)90043-5; DODWELL PC, 1990, PSYCHOL REV, V97, P78, DOI 10.1037/0033-295X.97.1.78; DODWELL PC, 1983, PERCEPT PSYCHOPHYS, V34, P1, DOI 10.3758/BF03205890; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1346, DOI 10.1152/jn.1991.65.6.1346; Eagleson Roy, 1992, Spatial Vision, V6, P183, DOI 10.1163/156856892X00073; EMERSON VF, 1985, PERCEPT PSYCHOPHYS, V37, P155, DOI 10.3758/BF03202851; EMERSON VF, 1984, CAN J PSYCHOL, V38, P551, DOI 10.1037/h0080866; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FELLEMAN DJ, 1987, J NEUROPHYSIOL, V57, P889, DOI 10.1152/jn.1987.57.4.889; FERRARO M, 1988, J OPT SOC AM A, V5, P738, DOI 10.1364/JOSAA.5.000738; GASKA JP, 1987, VISION RES, V27, P1687, DOI 10.1016/0042-6989(87)90098-8; HOFFMAN W C, 1970, Mathematical Biosciences, V6, P437, DOI 10.1016/0025-5564(70)90079-9; HOFFMAN WC, 1985, CAN J PSYCHOL, V39, P491, DOI 10.1037/h0080077; Horn BKP, 1989, SHAPE SHADING; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; KOBATAKE E, 1991, SOC NEUR ABSTR, V21, P443; KOENDERINK JJ, 1990, BIOL CYBERN, V63, P291, DOI 10.1007/BF00203452; LEYTON M, 1984, BIOL CYBERN, V51, P141, DOI 10.1007/BF00346136; OLAVARRIA JF, 1992, J NEUROPHYSIOL, V68, P164, DOI 10.1152/jn.1992.68.1.164; ORBAN GA, 1992, P NATL ACAD SCI USA, V89, P2595, DOI 10.1073/pnas.89.7.2595; PALMER SE, 1985, ACTA PSYCHOL, V59, P67, DOI 10.1016/0001-6918(85)90042-3; RICHMOND BJ, 1987, J NEUROPHYSIOL, V57, P132, DOI 10.1152/jn.1987.57.1.132; ROLLS ET, 1987, VISION RES, V27, P311, DOI 10.1016/0042-6989(87)90081-2; SAITO H, 1986, J NEUROSCI, V6, P145; SCHWARTZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P5776, DOI 10.1073/pnas.80.18.5776; TANAKA K, 1989, J NEUROPHYSIOL, V62, P626, DOI 10.1152/jn.1989.62.3.626; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170	34	417	424	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					100	103		10.1126/science.8418487	http://dx.doi.org/10.1126/science.8418487			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KE601	8418487				2022-12-28	WOS:A1993KE60100039
J	BECK, TM; CIOCIOLA, AA; JONES, SE; HARVEY, WH; TCHEKMEDYIAN, NS; CHANG, A; GALVIN, D; HART, NE				BECK, TM; CIOCIOLA, AA; JONES, SE; HARVEY, WH; TCHEKMEDYIAN, NS; CHANG, A; GALVIN, D; HART, NE			EFFICACY OF ORAL ONDANSETRON IN THE PREVENTION OF EMESIS IN OUTPATIENTS RECEIVING CYCLOPHOSPHAMIDE-BASED CHEMOTHERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						ONDANSETRON; CYCLOPHOSPHAMIDE; DOXORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ANTIEMETICS	HIGH-DOSE METOCLOPRAMIDE; CISPLATIN-INDUCED NAUSEA; DOXORUBICIN CHEMOTHERAPY; CANCER-CHEMOTHERAPY; ANTIEMETIC EFFICACY; DEXAMETHASONE; COMBINATION; ANTAGONIST; SEROTONIN; DOMPERIDONE	Objective: To evaluate the efficacy and safety of oral ondansetron (Zofran) as an antiemetic in patients receiving cyclophosphamide-based chemotherapy. Design: A multicenter, randomized, double-blind, stratified, placebo-controlled trial conducted between March 1989 and January 1990. Setting: Twenty-seven oncology centers including university hospitals, community cancer centers, and private medical oncology practices. Patients: A total of 349 chemotherapy-naive patients having their first cycle of cyclophosphamide (greater-than-or-equal-to 450 mg/m2)-based chemotherapy. Patients also received methotrexate (greater-than-or-equal-to 30 mg/m2) or doxorubicin (greater-than-or-equal-to 35 mg/m2). All patients were evaluated for safety and 318 (91%) were evaluated for efficacy. Interventions: Patients were randomly assigned to one of four treatment groups: placebo, 1 mg, 4 mg, or 8 mg of ondansetron. Assigned study medication was taken three times per day for 3 consecutive days. Measurements: Time and number of emetic episodes as well as degree of nausea were recorded by patients for each of the 3 study days. Results. Compared with placebo, all three doses of ondansetron were superior (P < 0.001) in preventing vomiting and controlling nausea. A complete response (no emetic episodes) was observed in 19%, 57%, 65%, and 66% of patients in the placebo, 1-mg, 4-mg, and 8-mg ondansetron groups, respectively. For patients who received higher-dose cyclophosphamide and doxorubicin, a dose-related trend in antiemetic efficacy of ondansetron was observed. Mild headache and constipation were the most frequently reported adverse events. No extrapyramidal reactions were observed. Conclusion: Oral ondansetron is a safe and effective antiemetic that is more efficacious than placebo for patients receiving cyclophosphamide-based chemotherapy.	GLAXO INC, RES INST, RES TRIANGLE PK, NC 27709 USA; BAYLOR UNIV, MED CTR, DALLAS, TX USA	GlaxoSmithKline; Baylor University; Baylor University Medical Center	BECK, TM (corresponding author), MT STATES TUMOR INST, 151 E BANNOCK ST, BOISE, ID 83712 USA.							ANDREWS P L R, 1987, British Journal of Pharmacology, V91, p417P; ANDREWS PLR, 1988, TRENDS PHARMACOL SCI, V9, P334, DOI 10.1016/0165-6147(88)90106-X; BARNES N M, 1987, British Journal of Pharmacology, V92, p649P; BASURTO C, 1988, AM J CLIN ONCOL-CANC, V11, P594, DOI 10.1097/00000421-198810000-00017; COATES A, 1983, EUR J CANCER CLIN ON, V19, P203, DOI 10.1016/0277-5379(83)90418-2; COSTALL B, 1987, British Journal of Pharmacology, V90, p90P; COX R, 1982, CANCER CHEMOTH PHARM, V8, P133, DOI 10.1007/BF00292884; CUBEDDU LX, 1990, J CLIN ONCOL, V8, P1721, DOI 10.1200/JCO.1990.8.10.1721; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; CUNNINGHAM D, 1987, BRIT MED J, V295, P250, DOI 10.1136/bmj.295.6592.250; DAVID M, 1984, CANCER TREAT REP, V68, P921; EDGE SB, 1987, AM J CLIN ONCOL-CANC, V10, P257, DOI 10.1097/00000421-198706000-00020; EINHORN LH, 1990, J CLIN ONCOL, V8, P731, DOI 10.1200/JCO.1990.8.4.731; FETTING JH, 1982, CANCER TREAT REP, V66, P1487; FRASCHINI G, 1991, J CLIN ONCOL, V9, P1268, DOI 10.1200/JCO.1991.9.7.1268; FRYTAK S, 1981, JAMA-J AM MED ASSOC, V245, P393, DOI 10.1001/jama.245.4.393; GAGEN M, 1984, J CLIN ONCOL, V2, P696, DOI 10.1200/JCO.1984.2.6.696; GRALLA RJ, 1987, MED CLIN N AM, V71, P289, DOI 10.1016/S0025-7125(16)30871-9; HORTOBAGYI GN, 1987, J CLIN ONCOL, V5, P354, DOI 10.1200/JCO.1987.5.3.354; KAASA S, 1990, EUR J CANCER, V26, P311, DOI 10.1016/0277-5379(90)90227-K; KRIS MG, 1985, J CLIN ONCOL, V3, P1379, DOI 10.1200/JCO.1985.3.10.1379; KRIS MG, 1989, J NATL CANCER I, V81, P42, DOI 10.1093/jnci/81.1.42; LASZLO J, 1983, DRUGS, V25, P1, DOI 10.2165/00003495-198300251-00002; LEAK RE, 1989, EUR J CANCER CLIN ON, V5, pS63; Lehmann EL, 1975, NONPARAMETRICS, P145; MARTY M, 1990, NEW ENGL J MED, V322, P816, DOI 10.1056/NEJM199003223221205; MARTY M, 1989, EUR J CANCER CLIN ON, V25, pS41; MORRAN C, 1979, BMJ-BRIT MED J, V1, P1323, DOI 10.1136/bmj.1.6174.1323-a; MORROW GR, 1984, P AN M AM SOC CLIN, V3, P408; Orr L E, 1980, Arch Intern Med, V140, P1431; PRIESTMAN TJ, 1989, EUR J CANCER CLIN ON, V25, pS29; ROEMELING RV, 1985, J CLIN ONCOL, V3, P1273, DOI 10.1200/JCO.1985.3.9.1273; STABLES R, 1987, CANCER TREAT REV, V14, P333, DOI 10.1016/0305-7372(87)90026-0; STRUM SB, 1984, J CLIN ONCOL, V2, P1057, DOI 10.1200/JCO.1984.2.9.1057; VANELTEREN P, 1960, B INT STATIST INST, V37, P351	35	89	89	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					407	413		10.7326/0003-4819-118-6-199303150-00002	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439113				2022-12-28	WOS:A1993KR81700002
J	CHOI, MJ; FERNANDEZ, PC; COUPAYEGERARD, B; DANDREA, D; SZERLIP, H; KLEYMAN, TR				CHOI, MJ; FERNANDEZ, PC; COUPAYEGERARD, B; DANDREA, D; SZERLIP, H; KLEYMAN, TR			TRIMETHOPRIM-INDUCED HYPERKALEMIA IN A PATIENT WITH AIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; TRANSTUBULAR POTASSIUM CONCENTRATION; IMMUNE-DEFICIENCY SYNDROME; NA+ CHANNEL; FROG-SKIN; THERAPY; SULFAMETHOXAZOLE; COMPLICATION; TRANSPORT; EVALUATE		PHILADELPHIA VET AFFAIRS MED CTR, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT MED, DIV RENAL & ELECTROLYTE, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA; MED COLL PENN, DEPT MED, PHILADELPHIA, PA 19129 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania; Drexel University					NIDDK NIH HHS [DK-07006] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007006] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENTLEY PJ, 1968, J PHYSIOL-LONDON, V195, P317, DOI 10.1113/jphysiol.1968.sp008460; ETHIER JH, 1990, AM J KIDNEY DIS, V15, P309, DOI 10.1016/S0272-6386(12)80076-X; FONSECA PD, 1991, EUR J PHARM-MOLEC PH, V207, P337, DOI 10.1016/0922-4106(91)90008-6; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GIEBISCH G, 1991, KIDNEY, V1, P283; GREENBLA.DJ, 1973, JAMA-J AM MED ASSOC, V225, P40, DOI 10.1001/jama.225.1.40; GREENE LW, 1984, ANN INTERN MED, V101, P497, DOI 10.7326/0003-4819-101-4-497; GUENTHNER EE, 1984, ANN INTERN MED, V100, P847, DOI 10.7326/0003-4819-100-6-847; HANDLER JS, 1991, KIDNEY, V1, P110; HANSEN KB, 1967, CLIN PHARMACOL THER, V8, P392; HOSHIKO T, 1986, J GEN PHYSIOL, V87, P425, DOI 10.1085/jgp.87.3.425; KALIN MF, 1987, AM J MED, V82, P1035, DOI 10.1016/0002-9343(87)90171-9; KAUFMAN AM, 1983, MT SINAI J MED, V50, P238; KLEYMAN TR, 1988, SEMIN NEPHROL, V8, P242; KLEYMAN TR, 1991, J BIOL CHEM, V266, P3907; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MEMBRENO L, 1987, J CLIN ENDOCR METAB, V65, P482, DOI 10.1210/jcem-65-3-482; PERKINS FM, 1981, AM J PHYSIOL, V241, pC154, DOI 10.1152/ajpcell.1981.241.3.C154; RIMMER JM, 1987, ARCH INTERN MED, V147, P867, DOI 10.1001/archinte.147.5.867; ROOT RK, 1988, WESTERN J MED, V148, P70; ROTH B, 1969, J ORG CHEM, V34, P821, DOI 10.1021/jo01256a011; SENEY FD, 1990, AM J KIDNEY DIS, V16, P1; SHARPSTONE P, 1969, POSTGRAD MED J     S, V45, P38; SIGEL CW, 1983, HDB EXPT PHARM, V64, P163; VAZIRI ND, 1985, J NATL MED ASSOC, V77, P369; WEST ML, 1986, MINER ELECTROL METAB, V12, P226; WEST ML, 1986, MINER ELECTROL METAB, V12, P234; ZETTLE RM, 1987, AM J NEPHROL, V7, P360, DOI 10.1159/000167502	29	108	109	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1993	328	10					703	706		10.1056/NEJM199303113281006	http://dx.doi.org/10.1056/NEJM199303113281006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ861	8433730	Bronze			2022-12-28	WOS:A1993KQ86100006
J	KEILANI, T; SCHLUETER, WA; LEVIN, ML; BATLLE, DC				KEILANI, T; SCHLUETER, WA; LEVIN, ML; BATLLE, DC			IMPROVEMENT OF LIPID ABNORMALITIES ASSOCIATED WITH PROTEINURIA USING FOSINOPRIL, AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR	ANNALS OF INTERNAL MEDICINE			English	Article						ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; PROTEINURIA; FOSINOPRIL; LIPOPROTEIN(A); CHOLESTEROL	NEPHROTIC SYNDROME; GLOMERULAR INJURY; DIABETES-MELLITUS; HEAVY PROTEINURIA; HYPERLIPIDEMIA; LIPOPROTEIN; LOVASTATIN; METABOLISM; RAT; ATHEROSCLEROSIS	Objective: To examine whether reducing protein excretion in patients with proteinuric renal disease using an angiotensin-converting enzyme inhibitor, fosinopril sodium, would be accompanied by an amelioration of the associated hyperlipidemia. Design: A randomized, placebo-controlled, double-blind study of 12 weeks, followed by 23 weeks of an open-label trial using fosinopril. Setting. Outpatient renal clinics. Patients: Twenty-six patients (age range, 28 to 70 years) with mild to moderate renal impairment and proteinuria associated with type II diabetes (15 patients) and other causes of nondiabetic renal disease (11 patients) completed the double-blind phase of the study. All patients except one were men. Intervention. Fosinopril, 10 mg initial oral daily dose (randomized trial), and 20 mg orally once a day (open-label phase). Measurements: Proteinuria and serum lipids (total cholesterol, high-density lipoprotein, and low-density lipoprotein [LDL] cholesterol, and lipoprotein(a) protein). Results: In a group of 17 patients treated with fosinopril, protein excretion decreased from 5.56 to 4.28 g/d, a reduction of 1.28 (95% CI, -2.49 to -0.08). The reduction was associated with a decrease in serum total cholesterol from 6.39 to 5.82 mmol/L, a decrease of 0.58 mmol/L (CI, -1.01 to -0.15 mmol/L). In a group of nine patients treated with placebo, neither protein excretion (from 5.11 to 4.81 g/d, a change of -0.29 g/d [CI, -1.78 to +1.13 g/d]) nor serum total cholesterol (from 6.08 to 5.77 mmol/L, a change of -0.31 mmol/L [CI, -0.78 to +0.13 mmol/L]) changed significantly. At the end of the double-blind phase, plasma lipoprotein(a) protein decreased in the fosinopril-treated group (from 3.94 to 3.33 mg/dL, a reduction of 0.60 mg/dL [CI, -1.02 to -0.18 mg/dL]) but not in the placebo group (from 2.85 to 3.19 mg/dL, a change of +0.34 mg/dL [CI, -0.53 to +1.2 mg/dL]). Dietary protein and fat intake were similar in the two groups throughout the study. In 16 patients who completed an extended open-label phase, fosinopril was associated with a decrease in protein excretion from 4.53 to 3.22 g/d, a reduction of 1.29 g/d (CI, -2.54 to -0.05 g/d), which was associated with a reduction in serum total cholesterol (from 6.37 to 5.54 mmol/L, a decrease of 0.84 mmol/L [CI, -1.59 to -0.08 mmol/L]), LDL cholesterol (from 4.38 to 3.72 mmol/L [a decrease of 0.68 mmol/L [CI, -1.33 to -0.03 mmol/L]), and plasma lipoprotein(a) protein (from 3.58 to 2.81 mg/dL, a reduction of 0.82 mg/dL [CI, -1.58 to -0.05 mg/dL]). Conclusion: The angiotensin-converting enzyme inhibitor, fosinopril, can result in a sustained reduction in serum total cholesterol, LDL cholesterol, and plasma lipoprotein(a) protein levels in conjunction with a partial reduction in proteinuria.	NORTHWESTERN UNIV, NW MEM HOSP,SCH MED,DEPT MED,DIV NEPHROL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA; LAKESIDE VET AFFAIRS MED CTR, CHICAGO, IL USA	Northwestern Memorial Hospital; Northwestern University								ALLEN JC, 1961, J CLIN INVEST, V40, P499, DOI 10.1172/JCI104277; ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528; APPEL GB, 1985, NEW ENGL J MED, V312, P1544, DOI 10.1056/NEJM198506133122404; BAKRIS GL, 1990, ANN INTERN MED, V112, P707, DOI 10.7326/0003-4819-112-9-707; BJORCK S, 1986, BMJ-BRIT MED J, V293, P471, DOI 10.1136/bmj.293.6545.471; Burnstein M, 1970, J LIPID RES, V11, P583; CAMERON JS, 1987, AM J KIDNEY DIS, V10, P157, DOI 10.1016/S0272-6386(87)80170-1; CURRY RC, 1977, AM J MED, V63, P183, DOI 10.1016/0002-9343(77)90231-5; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; DAVIES RW, 1990, J CLIN INVEST, V86, P600, DOI 10.1172/JCI114750; DEMARIE BK, 1990, ANN INTERN MED, V113, P987, DOI 10.7326/0003-4819-113-12-987; DIAMOND JR, 1988, KIDNEY INT, V33, P917, DOI 10.1038/ki.1988.87; FLESS GM, 1989, J LIPID RES, V30, P651; GLASSOCK RJ, 1983, TXB NEPHROLOGY, V1; GOLPER TA, 1989, AM J KIDNEY DIS, V13, P312, DOI 10.1016/S0272-6386(89)80038-1; HEEG JE, 1989, KIDNEY INT, V36, P272, DOI 10.1038/ki.1989.190; HOSTETTER TH, 1990, SEMIN NEPHROL, V10, P219; JOVEN J, 1990, NEW ENGL J MED, V323, P579, DOI 10.1056/NEJM199008303230905; KARADI I, 1989, CLIN CHEM, V35, P2121; KASISKE BL, 1988, KIDNEY INT, V33, P667, DOI 10.1038/ki.1988.51; KASISKE BL, 1990, AM J KIDNEY DIS, V15, P8, DOI 10.1016/S0272-6386(12)80586-5; KAYSEN GA, 1987, KIDNEY INT, V31, P1368, DOI 10.1038/ki.1987.151; KEANE WF, 1990, NEW ENGL J MED, V323, P603, DOI 10.1056/NEJM199008303230910; KOSTNER GM, 1989, CIRCULATION, V80, P1313, DOI 10.1161/01.CIR.80.5.1313; LEREN TP, 1988, ATHEROSCLEROSIS, V73, P135, DOI 10.1016/0021-9150(88)90034-2; MARRE M, 1987, BMJ-BRIT MED J, V294, P1448, DOI 10.1136/bmj.294.6585.1448; MARTIN MJ, 1986, LANCET, V2, P933; MEYER TW, 1987, KIDNEY INT, V31, P752, DOI 10.1038/ki.1987.62; MOORHEAD JF, 1982, LANCET, V2, P1309; REMUZZI A, 1990, J CLIN INVEST, V85, P541, DOI 10.1172/JCI114470; RUILOPE LM, 1988, J HYPERTENS, V6, pS467, DOI 10.1097/00004872-198812040-00147; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCHLUETER WA, 1989, DRUGS, V37, P900, DOI 10.2165/00003495-198937060-00005; SINGHVI SM, 1988, BRIT J CLIN PHARMACO, V25, P9, DOI 10.1111/j.1365-2125.1988.tb03275.x; STAPRANS I, 1987, METABOLISM, V36, P496, DOI 10.1016/0026-0495(87)90050-3; TAGUMA Y, 1985, NEW ENGL J MED, V313, P1617, DOI 10.1056/NEJM198512263132601; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202	38	117	119	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					246	254		10.7326/0003-4819-118-4-199302150-00002	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420442				2022-12-28	WOS:A1993KL45700002
J	NOGEE, LM; DEMELLO, DE; DEHNER, LP; COLTEN, HR				NOGEE, LM; DEMELLO, DE; DEHNER, LP; COLTEN, HR			BRIEF REPORT - DEFICIENCY OF PULMONARY SURFACTANT PROTEIN-B IN CONGENITAL ALVEOLAR PROTEINOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							FETAL LUNG; SP-A; RESPIRATORY-DISTRESS; MESSENGER-RNAS; TUBULAR MYELIN; EXPRESSION; IDENTIFICATION; NEWBORN; CDNA		WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,DIV ALLERGY & PULM MED,ST LOUIS,MO 63110; CARDINAL GLENNON MEM HOSP CHILDREN,DEPT PATHOL,ST LOUIS,MO 63104	Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL-34748, HL-37591] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037591] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOLLING TJ, 1990, BIOTECHNIQUES, V8, P488; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN M, 1980, AM REV RESPIR DIS, V121, P583, DOI 10.1164/arrd.1980.121.3.583; DEMELLO DE, 1989, AM J PATHOL, V134, P1285; FARRELL PM, 1975, AM REV RESPIR DIS, V111, P657; GLASSER SW, 1987, P NATL ACAD SCI USA, V84, P4007, DOI 10.1073/pnas.84.12.4007; GLASSER SW, 1988, J BIOL CHEM, V263, P9; HAWGOOD S, 1990, J CLIN INVEST, V86, P1, DOI 10.1172/JCI114670; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HOOK GER, 1986, LAB INVEST, V55, P194; HOROWITZ S, 1991, AM J RESP CELL MOL, V5, P511, DOI 10.1165/ajrcmb/5.6.511; KNIGHT DP, 1985, ARCH PATHOL LAB MED, V109, P529; KOBAYASHI T, 1991, J APPL PHYSIOL, V71, P530, DOI 10.1152/jappl.1991.71.2.530; KORFHAGEN TR, 1991, AM J RESP CELL MOL, V4, P463, DOI 10.1165/ajrcmb/4.5.463; LEES MB, 1972, ANAL BIOCHEM, V47, P184, DOI 10.1016/0003-2697(72)90291-6; LILEY HG, 1989, J CLIN INVEST, V83, P1191, DOI 10.1172/JCI114000; MINOO P, 1991, AM J PHYSIOL, V261, pL386, DOI 10.1152/ajplung.1991.261.6.L386; MOULTON SL, 1992, J PEDIATR-US, V120, P297, DOI 10.1016/S0022-3476(05)80448-2; NOGEE LM, 1991, AM J RESP CELL MOL, V4, P102, DOI 10.1165/ajrcmb/4.2.102; PHELPS DS, 1991, AM J PHYSIOL, V260, pL146, DOI 10.1152/ajplung.1991.260.2.L146; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; PHELPS DS, 1986, BIOCHEM J, V237, P373, DOI 10.1042/bj2370373; PRYHUBER GS, 1991, PEDIATR RES, V30, P597, DOI 10.1203/00006450-199112000-00023; RICE WR, 1989, BIOCHIM BIOPHYS ACTA, V1006, P237, DOI 10.1016/0005-2760(89)90202-6; ROBERTSON B, 1991, PEDIATR RES, V30, P239, DOI 10.1203/00006450-199109000-00007; ROSEN SH, 1958, NEW ENGL J MED, V258, P1123, DOI 10.1056/NEJM195806052582301; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P43; SARIN VK, 1990, P NATL ACAD SCI USA, V87, P2633, DOI 10.1073/pnas.87.7.2633; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUMACHER RE, 1989, PEDIATR PULM, V7, P178, DOI 10.1002/ppul.1950070312; SUZUKI Y, 1989, AM REV RESPIR DIS, V140, P75, DOI 10.1164/ajrccm/140.1.75; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WEAVER TE, 1988, SEMIN PERINATOL, V12, P213; WEAVER TE, 1988, J APPL PHYSIOL, V65, P982, DOI 10.1152/jappl.1988.65.2.982; WHITSETT JA, 1986, PEDIATR RES, V20, P460, DOI 10.1203/00006450-198605000-00016; WHITSETT JA, 1987, J BIOL CHEM, V262, P15618; WHITSETT JA, 1986, PEDIATR RES, V20, P744, DOI 10.1203/00006450-198608000-00009; WIKENHEISER KA, 1992, AM J PHYSIOL, V262, pL32, DOI 10.1152/ajplung.1992.262.1.L32; WILLIAMS MC, 1991, AM J RESP CELL MOL, V5, P41, DOI 10.1165/ajrcmb/5.1.41; YU SH, 1988, BIOCHIM BIOPHYS ACTA, V961, P337	41	485	500	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					406	410		10.1056/NEJM199302113280606	http://dx.doi.org/10.1056/NEJM199302113280606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8421459				2022-12-28	WOS:A1993KL58400006
J	RICE, WG; SCHAEFFER, CA; HARTEN, B; VILLINGER, F; SOUTH, TL; SUMMERS, MF; HENDERSON, LE; BESS, JW; ARTHUR, LO; MCDOUGAL, JS; ORLOFF, SL; MENDELEYEV, J; KUN, E				RICE, WG; SCHAEFFER, CA; HARTEN, B; VILLINGER, F; SOUTH, TL; SUMMERS, MF; HENDERSON, LE; BESS, JW; ARTHUR, LO; MCDOUGAL, JS; ORLOFF, SL; MENDELEYEV, J; KUN, E			INHIBITION OF HIV-1 INFECTIVITY BY ZINC-EJECTING AROMATIC C-NITROSO COMPOUNDS	NATURE			English	Article							MURINE LEUKEMIA-VIRUS; STRANDED NUCLEIC-ACIDS; NUCLEOCAPSID PROTEIN; DIMER FORMATION; FINGER DOMAIN; METAL-IONS; VIRAL-RNA; BINDING; POLYMERASE; SEQUENCE	RETROVIRAL nucleocapsid and gag-precursor proteins from all known strains of retroviruses contain one or two copies of an invariant sequence, Cys-X2-Cys-X4-His-X4-Cys1,2, that is populated with zinc in mature particles3. Modification of cysteine or histidine residues results in defective packaging of genomic viral RNA and formation of non-infectious particles4-8, making these structures potentially attractive targets for antiviral therapy3,8. We recently reported that aromatic C-nitroso ligands of poly(ADP-ribose) polymerase preferentially destabilize one of the two (CYS-X2-CYS-X28-His-X2-Cys) zinc-fingers with concomitant loss of enzymatic activity9,10, coincidental with selective cytocidal action of the C-nitroso substituted ligands on cancer cells11. Based on the occurrence of (3Cys, 1His) zinc-binding sites in both retroviral nucleocapsid and gag proteins and in poly(ADP-ribose) polymerase12, we reasoned that the C-nitroso compounds may also have antiretroviral effects. We show here that two such compounds, 3-nitrosobenzamide and 6-nitroso-1,2-benzopyrone, inhibit infection of human immunodeficiency virus HIV-1 in human lymphocytes and also eject zinc from isolated HIV-1 nucleocapsid zinc fingers and from intact HIV-1 virions. Thus the design of zinc-ejecting agents that target retroviral zinc fingers represents a new approach to the chemotherapy of AIDS.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,AIDS VACCINE PROGRAM,FREDERICK,MD 21702; EMORY UNIV,SCH MED,DEPT PATHOL & LAB MED,ATLANTA,GA 30322; CTR DIS CONTROL,NCID,DHA,IMMUNOL BRANCH,ATLANTA,GA 30333; OCTAMER INC,TIBURON,CA 94920; SAN FRANCISCO STATE UNIV,ROMBERG TIBURON CTR,ENVIRONM TOXICOL & CHEM LAB,TIBURON,CA 94920	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Emory University; Centers for Disease Control & Prevention - USA; California State University System; San Francisco State University	RICE, WG (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ANTIVIRAL DRUG MECHANISMS LAB,FREDERICK,MD 21702, USA.		Bess, Jr., Julian/B-5343-2012					ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; BUKI KG, 1991, FEBS LETT, V290, P181, DOI 10.1016/0014-5793(91)81255-7; CHANCE MR, 1992, P NATL ACAD SCI USA, V89, P10041, DOI 10.1073/pnas.89.21.10041; CHEN MJ, 1980, P NATL ACAD SCI USA, V77, P4961; COLE GA, 1991, BIOCHEM BIOPH RES CO, V180, P504, DOI 10.1016/S0006-291X(05)81093-9; CORNILLE F, 1990, INT J PEPT PROT RES, V36, P551; DUPRAZ P, 1990, J VIROL, V64, P4978, DOI 10.1128/JVI.64.10.4978-4987.1990; FITZGERALD DW, 1991, BIOCHEMISTRY-US, V30, P5195, DOI 10.1021/bi00235a012; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; GREEN LM, 1990, P NATL ACAD SCI USA, V87, P6403, DOI 10.1073/pnas.87.16.6403; GREEN LM, 1989, P NATL ACAD SCI USA, V86, P4047, DOI 10.1073/pnas.86.11.4047; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KUN E, 1836, Patent No. 780809; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; MCDOUGAL JS, 1985, J IMMUNOL METHODS, V76, P171, DOI 10.1016/0022-1759(85)90489-2; MERIC C, 1986, J VIROL, V60, P450; MERIC C, 1984, J MOL BIOL, V173, P531, DOI 10.1016/0022-2836(84)90396-6; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYERS G, 1991, HUMAN RETROVIRUSES A; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; RICE WG, 1992, P NATL ACAD SCI USA, V89, P7703, DOI 10.1073/pnas.89.16.7703; SMITH BJ, 1979, NUCLEIC ACIDS RES, V7, P2055; SOUTH TL, 1990, BIOCHEMISTRY-US, V29, P7786, DOI 10.1021/bi00486a002; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; SOUTH TL, 1993, PROTEIN SCI, V2, P3; SOUTH TL, 1989, J AM CHEM SOC, V111, P295; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; SUMMERS MF, 1991, J CELL BIOCHEM, V45, P41, DOI 10.1002/jcb.240450110	34	206	222	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					473	475		10.1038/361473a0	http://dx.doi.org/10.1038/361473a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8429889				2022-12-28	WOS:A1993KK71300068
J	MEIEREWERT, S; MAIER, E; AHMADI, A; CURTIS, J; LEHRACH, H				MEIEREWERT, S; MAIER, E; AHMADI, A; CURTIS, J; LEHRACH, H			AN AUTOMATED APPROACH TO GENERATING EXPRESSED SEQUENCE CATALOGS	NATURE			English	Article							DNA; HYBRIDIZATION				MEIEREWERT, S (corresponding author), IMPERIAL CANC RES FUND,GENOME ANAL LAB,44 LINCOLNS INN FIELDS,POB 123,LONDON WC2A 3PX,ENGLAND.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BELLANNECHANTELOT C, 1992, CELL, V70, P1059, DOI 10.1016/0092-8674(92)90254-A; DRMANAC R, 1989, GENOMICS, V4, P114; DRMANAC R, 1990, ELECTROPHORESIS SUPE, P60; ENDO I, 1991, NATURE, V352, P89, DOI 10.1038/352089a0; HOHEISEL JD, IN PRESS CELL; JONES P, 1992, NUCLEIC ACIDS RES, V20, P4599, DOI 10.1093/nar/20.17.4599; KAHN AS, 1992, NAT GENET, V2, P180; LEHRACH H, 1990, GENOME ANAL GENETIC, P36; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; STREZOSKA Z, 1991, P NATL ACAD SCI USA, V88, P10089, DOI 10.1073/pnas.88.22.10089; UBER DC, 1991, BIOTECHNIQUES, V5, P642	14	96	106	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					375	376		10.1038/361375a0	http://dx.doi.org/10.1038/361375a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8426656				2022-12-28	WOS:A1993KJ59000068
J	BISHOP, JM; KIRSCHNER, M; VARMUS, H				BISHOP, JM; KIRSCHNER, M; VARMUS, H			SCIENCE AND THE NEW ADMINISTRATION	SCIENCE			English	Editorial Material											BISHOP, JM (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143, USA.							BROWN G, 1992, LOS ANGELES TIM 0908, P12; THOMPSON D, 1992, TIME, V140, P84	2	9	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					444	445		10.1126/science.8424162	http://dx.doi.org/10.1126/science.8424162			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424162				2022-12-28	WOS:A1993KJ07900010
J	RAO, DS; SHIH, MS; MOHINI, R				RAO, DS; SHIH, MS; MOHINI, R			EFFECT OF SERUM PARATHYROID-HORMONE AND BONE-MARROW FIBROSIS ON THE RESPONSE TO ERYTHROPOIETIN IN UREMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; CHRONIC RENAL-FAILURE; SECONDARY HYPER-PARATHYROIDISM; PRIMARY HYPERPARATHYROIDISM; ILIAC BONE; ANEMIA; ALUMINUM; OSTEODYSTROPHY; THERAPY; DISEASE	Background and Methods. Anemia is common in patients with chronic renal insufficiency and secondary hyperparathyroidism. Erythropoietin therapy is effective, but the dose required varies greatly. One possible determinant of the efficacy of erythropoietin therapy is the extent of marrow fibrosis caused by hyperparathyroidism. We examined the relation between the erythropoietic response to erythropoietin and hyperparathyroidism in a cross-sectional study of 18 patients undergoing hemodialysis who had received erythropoietin therapy for one to three years. In 7 patients (the poor-response group) the dose of intravenous erythropoietin needed to maintain a mean (+/-SD) target hematocrit of 35+/-3 percent was >100 units per kilogram of body weight three times a week, and in 11 patients (the good-response group) it was less-than-or-equal-to 100 units per kilogram. In all patients, indexes of the adequacy of dialysis and the extent of hyperparathyroidism and aluminum toxicity were determined monthly, and bone histomorphometry was performed. Results. The mean (+/-SD) dose of erythropoietin required to maintain the target hematocrit was 174+/-33 units per kilogram three times a week in the poor-response group and 56+/-18 units per kilogram in the good-response group. The mean ages, duration and adequacy of dialysis, increment in hematocrit, iron requirements, and serum concentrations of calcium, phosphate, and aluminum were similar in the two groups. The percentages of osteoid volume and surface, the osteoid thickness, and the stainable aluminum content of bone were similar in the two groups. In contrast, the mean serum parathyroid hormone concentration, the percentages of osteoclastic and eroded bone surfaces, and the degree of marrow fibrosis were greater in the poor-response group than in the good-response group (P = 0.03, P = 0.04, P = 0.009, and P = 0.009, respectively). Conclusions. In patients with uremia, the dose of erythropoietin needed to achieve an adequate hematocrit response may depend on the severity of secondary hyperparathyroidism and the extent of bone marrow fibrosis.	HENRY FORD HOSP, DEPT MED, DIV NEPHROL, DETROIT, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	RAO, DS (corresponding author), HENRY FORD HOSP, DEPT MED, DIV BONE & MINERAL METAB, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.		Rao, Sudhaker/ABG-8204-2021					Albright F, 1934, J AMER MED ASSOC, V102, P1276, DOI 10.1001/jama.1934.02750160010003; ANDRESS DL, 1986, J BONE MINER RES, V1, P391; BARBOUR GL, 1979, ARCH INTERN MED, V139, P889, DOI 10.1001/archinte.139.8.889; BIA MJ, 1989, KIDNEY INT, V36, P852, DOI 10.1038/ki.1989.271; BOXER M, 1977, ARCH INTERN MED, V137, P588, DOI 10.1001/archinte.137.5.588; CHAN YL, 1985, MEDICINE, V64, P296, DOI 10.1097/00005792-198509000-00002; DELWICHE F, 1983, J LAB CLIN MED, V102, P613; ERSLEV AJ, 1991, NEW ENGL J MED, V324, P1339, DOI 10.1056/NEJM199105093241907; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; FALKO JM, 1976, ARCH INTERN MED, V136, P887, DOI 10.1001/archinte.136.8.887; MALLETTE LE, 1974, MEDICINE, V53, P127, DOI 10.1097/00005792-197403000-00002; MALONEY NA, 1982, J LAB CLIN MED, V99, P206; MCGONIGLE RJS, 1984, J LAB CLIN MED, V104, P1016; MEYTES D, 1981, J CLIN INVEST, V67, P1263, DOI 10.1172/JCI110154; MURPHY G, 1989, J AM SOC NEPHROL, pA262; NISSENSON AR, 1991, ANN INTERN MED, V114, P402, DOI 10.7326/0003-4819-114-5-402; PARFITT AM, 1985, J CLIN INVEST, V76, P2403, DOI 10.1172/JCI112253; RAO DS, 1991, VITAMIN D, P881; Rao DS., 1983, BONE HISTOMORPHOMETR, P3; ROGER SD, 1991, NEPHRON, V58, P33, DOI 10.1159/000186374; SCHOBER HC, 1991, CONTRIB NEPHROL, V88, P127; SHASHA SM, 1978, ISRAEL J MED SCI, V14, P328; STIVELMAN JC, 1989, SEMIN NEPHROL, V9, P8; URENA P, 1991, NEPHRON, V59, P384, DOI 10.1159/000186596; VANWYCK DB, 1989, KIDNEY INT, V35, P712, DOI 10.1038/ki.1989.43; WEINBERG SG, 1977, AM J MED, V63, P755, DOI 10.1016/0002-9343(77)90162-0; ZINGRAFF J, 1978, ARCH INTERN MED, V138, P1650, DOI 10.1001/archinte.138.11.1650	27	317	330	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 21	1993	328	3					171	175		10.1056/NEJM199301213280304	http://dx.doi.org/10.1056/NEJM199301213280304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG625	8417383				2022-12-28	WOS:A1993KG62500004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INSTRUCTIONAL VIDEOS ON FOOD SAFETY IN NURSING-HOMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, JAMA-J AM MED ASSOC, V266, P2105	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					328	328						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418328				2022-12-28	WOS:A1993KG38100006
J	STROME, S				STROME, S			DETERMINATION OF CLEAVAGE PLANES	CELL			English	Review							C-ELEGANS EMBRYOS; CAENORHABDITIS-ELEGANS; UNEQUAL CLEAVAGE; ANIMAL-CELLS; MICROFILAMENTS; ESTABLISHMENT; LOCALIZATION; CYTOKINESIS; MIGRATION; ASYMMETRY				STROME, S (corresponding author), INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034059] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN VW, 1992, DEVELOPMENT, V115, P873; Conklin EG, 1917, J EXP ZOOL, V22, P311, DOI 10.1002/jez.1400220205; DAN K, 1987, INT J INVER REP DEV, V11, P335, DOI 10.1080/01688170.1987.10510292; DAN K, 1979, DEV GROWTH DIFFER, V21, P527; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HILL DP, 1990, DEVELOPMENT, V108, P159; HIRAMOTO Y, 1956, EXP CELL RES, V11, P630, DOI 10.1016/0014-4827(56)90171-9; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; LUTZ DA, 1988, CELL MOTIL CYTOSKEL, V11, P83, DOI 10.1002/cm.970110202; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; RAPPAPORT R, 1961, J EXP ZOOL, V148, P81, DOI 10.1002/jez.1401480107; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; SCHROEDER TE, 1987, DEV BIOL, V124, P9, DOI 10.1016/0012-1606(87)90454-4; STROME S, 1986, J CELL BIOL, V103, P2241, DOI 10.1083/jcb.103.6.2241; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; WHITE JG, 1983, J THEOR BIOL, V101, P289, DOI 10.1016/0022-5193(83)90342-9	19	123	123	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					3	6		10.1016/0092-8674(93)90041-N	http://dx.doi.org/10.1016/0092-8674(93)90041-N			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422680				2022-12-28	WOS:A1993KG95500002
J	FREED, GL				FREED, GL			BREAST-FEEDING - TIME TO TEACH WHAT WE PREACH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATION		UNIV N CAROLINA,DIV COMMUNITY PEDIATR,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,CHAPEL HILL,NC 27514	University of North Carolina; University of North Carolina Chapel Hill	FREED, GL (corresponding author), UNIV N CAROLINA,CECIL G SHEPS CTR HLTH SERV RES,CB 7490,CHASE HALL,CHAPEL HILL,NC 27599, USA.							APPLEBAUM RM, 1975, J REPROD MED, V14, P98; BENTLEY JD, 1989, NEW ENGL J MED, V320, P1531, DOI 10.1056/NEJM198906083202306; Boston Women's Health Book Collective, 1973, OUR BODIES OURSELVES; CUNNINGHAM AS, 1979, J PEDIATR-US, V95, P685, DOI 10.1016/S0022-3476(79)80711-8; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; CUNNINGHAM AS, 1981, ADV INT MATERNAL CHI, V1, P128; DUNGY CI, 1992, PEDIATRICS, V90, P233; FREED GL, 1992, AM J PERINAT, V9, P420, DOI 10.1055/s-2007-999279; FREED GL, 1992, SOUTHERN MED J, V85, P483, DOI 10.1097/00007611-199205000-00006; FREED GL, 1991, AM J DIS CHILD, V145, P917, DOI 10.1001/archpedi.1991.02160080095027; GRAYDONALD K, 1985, PEDIATRICS, V75, P514; HOLLEN B K, 1976, Journal of Tropical Pediatrics and Environmental Child Health, V22, P288; JOFFE A, 1987, PEDIATRICS, V79, P689; KISTIN N, 1990, PEDIATRICS, V86, P741; LAWRENCE RA, 1989, BREASTFEEDING GUIDE; Michelman D F, 1990, Am J Health Promot, V4, P181, DOI 10.4278/0890-1171-4.3.181; OSKI FA, 1991, NEW ENGL J MED, V325, P60; REAMES ES, 1985, J AM DIET ASSOC, V85, P79; Ryan AS, 1991, PEDIATRICS, V8, P873; SAARINEN UM, 1982, ACTA PAEDIATR SCAND, V71, P567, DOI 10.1111/j.1651-2227.1982.tb09476.x; Simon J L, 1988, Fam Med, V20, P224; WINIKOFF B, 1980, AM J OBSTET GYNECOL, V138, P105, DOI 10.1016/0002-9378(80)90018-6; WINIKOFF B, 1986, PEDIATRICS, V77, P757; YEUNG DL, 1981, CAN J PUBLIC HEALTH, V72, P323; 1990, HLTH PEOPLE 2000	25	39	39	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					243	245		10.1001/jama.269.2.243	http://dx.doi.org/10.1001/jama.269.2.243			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417243				2022-12-28	WOS:A1993KF40500031
J	MORLEY, V				MORLEY, V			THE FUTURE OF FHSAS .1. EMPOWERING GPS AS PURCHASERS	BMJ-BRITISH MEDICAL JOURNAL			English	Article											MORLEY, V (corresponding author), LAMBETH SOUTHWARK & LEWISHAM FAMILY HLTH, LONDON, ENGLAND.							GLENNISTER H, 1992, 12 KINGS FUND I RES; TARNOWSKI J, 1992, PRACTICE SENSITIVE P; 1991, INTEGRATING PRIMARY; 1992, NORTHAMPTON OPTIONS; 1992, GPS VIEWS LOCAL HLTH; 1989, FUNDING GENERAL PRAC, P199	6	6	6	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 9	1993	306	6870					112	114		10.1136/bmj.306.6870.112	http://dx.doi.org/10.1136/bmj.306.6870.112			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435607	Bronze, Green Published			2022-12-28	WOS:A1993KG46500025
J	ORHOLM, M; ISELIUS, L; SORENSEN, TIA; MUNKHOLM, P; LANGHOLZ, E; BINDER, V				ORHOLM, M; ISELIUS, L; SORENSEN, TIA; MUNKHOLM, P; LANGHOLZ, E; BINDER, V			INVESTIGATION OF INHERITANCE OF CHRONIC INFLAMMATORY BOWEL DISEASES BY COMPLEX SEGREGATION ANALYSIS	BRITISH MEDICAL JOURNAL			English	Article							REGIONAL PATIENT GROUP; ULCERATIVE-COLITIS; CROHNS-DISEASE; PREVALENCE; COPENHAGEN; COUNTY; FAMILY; RELATIVES; PROGNOSIS	Objective-To investigate the mode of inheritance of ulcerative colitis and Crohn's disease by complex segregation analysis. Design-Cross sectional population based survey of familial occurrence of chronic inflammatory bowel disease. Setting-Population of the Copenhagen county in 1987. Subjects-662 patients in whom inflammatory bowel disease had been diagnosed before 1979, of whom 637 (96%) provided adequate information. Of 504 patients with ulcerative colitis, 54 had 77 relatives with ulcerative colitis and of 133 patients with Crohn's disease, five had seven relatives with Crohn's disease. Main outcome measures-Patterns of segregation of either disease as assessed by complex segregation analysis performed with the computer program POINTER. Results-The analysis suggested that a major dominant gene with a penetrance of 0.20-0.26 is present in 9-13% of adult patients with ulcerative colitis. The analysis did not allow for other components in the familial aggregation. For Crohn's disease the best fitting model included a major recessive gene with complete penetrance, for which 7% of the patients are homozygous. However, this model was not significantly different from a multifactorial model. Conclusions-The segregation pattern indicates that a major dominant gene has a role in ulcerative colitis, and suggests that a major recessive gene has a role in Crohn's disease.	UNIV COPENHAGEN,HERLEV HOSP,DEPT MED GASTROENTEROL C,DK-2730 HERLEV,DENMARK; KAROLINSKA HOSP,DEPT SURG,S-10401 STOCKHOLM 60,SWEDEN; KOMMUNE HOSP COPENHAGEN,COPENHAGEN HLTH SERV,INST PREVENT MED,COPENHAGEN,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital; Karolinska Institutet; Karolinska University Hospital			Munkholm, Pia/ABD-2432-2021					BINDER V, 1985, GUT, V26, P146, DOI 10.1136/gut.26.2.146; BINDER V, 1982, GASTROENTEROLOGY, V83, P563; FARMER RG, 1980, CLIN GASTROENTEROL, V9, P271; HENDRIKSEN C, 1985, GUT, V26, P158, DOI 10.1136/gut.26.2.158; KHOURY MJ, 1988, AM J EPIDEMIOL, V127, P674, DOI 10.1093/oxfordjournals.aje.a114842; KUSTER W, 1989, AM J MED GENET, V32, P105, DOI 10.1002/ajmg.1320320122; LALOUEL JM, 1981, HUM HERED, V31, P312, DOI 10.1159/000153231; LANGHOLZ E, 1991, SCAND J GASTROENTERO, V26, P1247, DOI 10.3109/00365529108998621; LASHNER BA, 1986, GASTROENTEROLOGY, V91, P1396, DOI 10.1016/0016-5085(86)90193-9; MCCONNELL RB, 1986, GENETICS EPIDEMIOLOG, V11, P1; MCCONNELL RB, 1980, DEV DIGESTIVE DISEAS, P129; MONSEN U, 1989, CLIN GENET, V36, P411; MONSEN U, 1991, SCAND J GASTROENTERO, V26, P302, DOI 10.3109/00365529109025046; MONSEN U, 1987, SCAND J GASTROENTERO, V22, P214, DOI 10.3109/00365528708991882; MONSEN U, 1990, THESIS CAROLINSKA ME; MUNKHOLM P, 1992, SCAND J GASTROENTERO, V27, P609, DOI 10.3109/00365529209000127; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990	18	99	101	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1993	306	6869					20	24		10.1136/bmj.306.6869.20	http://dx.doi.org/10.1136/bmj.306.6869.20			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435571	Green Published, Bronze			2022-12-28	WOS:A1993KE98400020
J	LANDRIGAN, PJ				LANDRIGAN, PJ			HEALTH RISKS OF CREOSOTES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											LANDRIGAN, PJ (corresponding author), CUNY MT SINAI SCH MED,NEW YORK,NY 10029, USA.							1990, TP9009 US DEP HLTH H; 1987, UPDATING IARC MON S7, V1	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1309	1309		10.1001/jama.1993.03500100109042	http://dx.doi.org/10.1001/jama.1993.03500100109042			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437314				2022-12-28	WOS:A1993KP88500036
J	MAZZAFERRI, EL				MAZZAFERRI, EL			MANAGEMENT OF A SOLITARY THYROID-NODULE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FINE-NEEDLE ASPIRATION; SUPPRESSIVE THERAPY; BIOPSY; DISEASE; CANCER; CARCINOMA; PREVALENCE; DIAGNOSIS; CYTOLOGY; GLAND				MAZZAFERRI, EL (corresponding author), OHIO STATE UNIV,DEPT INTERNAL MED,215 MEANS HALL,1654 UPHAM DR,COLUMBUS,OH 43210, USA.				NCRR NIH HHS [M01-RR-00034] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000034] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTAVILLA G, 1990, ACTA CYTOL, V34, P251; ASHCRAFT MW, 1981, HEAD NECK SURG, V3, P297, DOI 10.1002/hed.2890030406; BELFIORE A, 1990, J CLIN ENDOCR METAB, V70, P830, DOI 10.1210/jcem-70-4-830; BELFIORE A, 1992, AM J MED, V93, P363, DOI 10.1016/0002-9343(92)90164-7; BELL B, 1993, DIGEST DIS SCI, V38, P185, DOI 10.1007/BF01296795; BRANDER A, 1989, RADIOLOGY, V173, P507, DOI 10.1148/radiology.173.2.2678263; BRANDER A, 1992, J CLIN ULTRASOUND, V20, P37, DOI 10.1002/jcu.1870200107; BRANDER A, 1991, RADIOLOGY, V181, P683, DOI 10.1148/radiology.181.3.1947082; CADY B, 1988, SURGERY, V104, P947; Caruso D, 1991, ENDOCRINOLOGIST, V1, P194, DOI 10.1097/00019616-199106000-00009; CHEUNG PSY, 1989, WORLD J SURG, V13, P818, DOI 10.1007/BF01658447; CHRISTENSEN SB, 1984, ACTA CHIR SCAND, V150, P433; CHRISTENSEN SB, 1984, ACTA CHIR SCAND, V150, P13; CLARK OH, 1988, EUR J CANCER CLIN ON, V24, P305, DOI 10.1016/0277-5379(88)90273-8; CUSICK EL, 1990, BMJ-BRIT MED J, V301, P318, DOI 10.1136/bmj.301.6747.318; DEGROOT LJ, 1989, J CLIN ENDOCR METAB, V69, P925, DOI 10.1210/jcem-69-5-925; DEKEYSER LFM, 1985, HEAD NECK SURG, V8, P100, DOI 10.1002/hed.2890080207; DELOSSANTOS ET, 1990, ARCH INTERN MED, V150, P1422, DOI 10.1001/archinte.150.7.1422; DIAMOND T, 1991, J CLIN ENDOCR METAB, V72, P1184, DOI 10.1210/jcem-72-6-1184; FOGELFELD L, 1989, NEW ENGL J MED, V320, P835, DOI 10.1056/NEJM198903303201304; FRANKLYN JA, 1992, LANCET, V340, P9, DOI 10.1016/0140-6736(92)92423-D; GHARIB H, 1984, ANN INTERN MED, V101, P25, DOI 10.7326/0003-4819-101-1-25; GHARIB H, 1987, NEW ENGL J MED, V317, P70, DOI 10.1056/NEJM198707093170202; GIANSANTI M, 1989, TUMORI J, V75, P475, DOI 10.1177/030089168907500515; GORLIN JB, 1990, ENDOCRIN METAB CLIN, V19, P649, DOI 10.1016/S0889-8529(18)30315-3; GRANT CS, 1989, SURGERY, V106, P980; HALL TL, 1989, CANCER, V63, P718, DOI 10.1002/1097-0142(19890215)63:4<718::AID-CNCR2820630420>3.0.CO;2-N; HAMBERGER B, 1982, AM J MED, V73, P381, DOI 10.1016/0002-9343(82)90731-8; HAMBURGER JI, 1980, J CLIN ENDOCR METAB, V50, P1089, DOI 10.1210/jcem-50-6-1089; HAMMING JF, 1990, ARCH INTERN MED, V150, P113, DOI 10.1001/archinte.150.1.113; HARSOULIS P, 1986, BRIT J SURG, V73, P461, DOI 10.1002/bjs.1800730615; HOLM LE, 1985, NEW ENGL J MED, V312, P601, DOI 10.1056/NEJM198503073121001; HORLOCKER TT, 1986, FRONTIERS THYROIDOLO, V2, P1309; HRAFNKELSSON J, 1989, ACTA ONCOL, V28, P785, DOI 10.3109/02841868909092308; HUNG W, 1992, PEDIATR ANN, V21, P50, DOI 10.3928/0090-4481-19920101-09; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; LEVER EG, 1983, SURGERY, V94, P893; MAZZAFERRI EL, 1991, MAYO CLIN PROC, V66, P105, DOI 10.1016/S0025-6196(12)61179-3; MAZZAFERRI EL, 1988, MED CLIN N AM, V72, P1177, DOI 10.1016/S0025-7125(16)30736-2; MAZZAFERRI EL, 1991, WERNER INGBARS THYRO, P1138; MCCOWEN KD, 1980, AM J MED, V68, P853, DOI 10.1016/0002-9343(80)90205-3; MCHENRY C, 1988, AM SURGEON, V54, P444; MOLITCH ME, 1984, ENDOCR REV, V5, P185, DOI 10.1210/edrv-5-2-185; MORTENSEN JD, 1955, J CLIN ENDOCR METAB, V15, P1270, DOI 10.1210/jcem-15-10-1270; MURRAY D, 1991, FUNCTIONAL ENDOCRINE, P293; OERTEL J E, 1965, Med Ann Dist Columbia, V34, P75; PELIZZO MR, 1990, TUMORI, V76, P255, DOI 10.1177/030089169007600309; PEPPER GM, 1989, ARCH INTERN MED, V149, P594, DOI 10.1001/archinte.149.3.594; RALLISON ML, 1991, AM J MED, V91, P363, DOI 10.1016/0002-9343(91)90153-O; REVERTER JL, 1992, CLIN ENDOCRINOL, V36, P25, DOI 10.1111/j.1365-2265.1992.tb02898.x; RIDGWAY EC, 1992, J CLIN ENDOCR METAB, V74, P231, DOI 10.1210/jc.74.2.231; RIDGWAY EC, 1991, WERNER INGBARS THYRO, P1197; ROJESKI MT, 1985, NEW ENGL J MED, V313, P428, DOI 10.1056/NEJM198508153130707; ROSEN IB, 1986, SURGERY, V100, P606; ROSS DS, 1988, MAYO CLIN PROC, V63, P1223, DOI 10.1016/S0025-6196(12)65409-3; ROSS DS, 1992, THYROID, V2, P263, DOI 10.1089/thy.1992.2.263; SCHNEIDER AB, 1990, ENDOCRIN METAB CLIN, V19, P495, DOI 10.1016/S0889-8529(18)30307-4; SCHNEIDER AB, 1981, ANN INTERN MED, V94, P176, DOI 10.7326/0003-4819-94-2-176; TROWBRIDGE FL, 1975, PEDIATRICS, V56, P82; VANDER JB, 1968, ANN INTERN MED, V69, P537, DOI 10.7326/0003-4819-69-3-537; VANHERLE AJ, 1982, ANN INTERN MED, V96, P221, DOI 10.7326/0003-4819-96-2-221	61	1005	1050	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					553	559						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8426623				2022-12-28	WOS:A1993KP05300007
J	MAGEE, MS; WALDEN, CE; BENEDETTI, TJ; KNOPP, RH				MAGEE, MS; WALDEN, CE; BENEDETTI, TJ; KNOPP, RH			INFLUENCE OF DIAGNOSTIC-CRITERIA ON THE INCIDENCE OF GESTATIONAL DIABETES AND PERINATAL MORBIDITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUCOSE-TOLERANCE; SCREENING-TESTS; PREGNANCY; POPULATION; MELLITUS; WOMEN; MANAGEMENT; THERAPY; AGE	Objective.-To determine the incidence of gestational diabetes and its associated maternal and infant morbidity by two sets of 3-hour glucose tolerance test criteria, those recommended by the National Diabetes Data G roup or the lower, modified criteria of Carpenter and Coustan. Design.-Prospective, observational outcome cohort study. Setting.-Prepaid health maintenance organization. Subjects.-A total of 2019 pregnant women preregistered in a health maintenance organization were screened for a plasma glucose of 7.77 mmol/L (140 mg/dL) or greater, 1 hour after ingestion of a 50-g glucose drink administered after an overnight fast. Positive subjects received a 3-hour glucose tolerance test interpreted by the two criteria. Data are presented for 521 randomly selected negative screenees; 264 positive screen, negative glucose tolerance test subjects; and 101 subjects with gestational diabetes mellitus. Outcome Measures.-Maternal risk factors for diabetes, infant birth weight corrected for gestational age (birth-weight ratio), umbilical cord serum insulin levels, and 33 maternal and infant perinatal morbidities assessed from chart review. Results.-Gestational diabetes incidence was 5.0% overall based on the modified criteria and 3.2% by the recommended criteria. Maternal age and family history of diabetes were higher in both modified and recommended groups. Birth-weight ratio was 1.05 in negative screenees, 1.09 in gestational diabetes overall (P<.05 when only diet-treated subjects were considered), and 1.11 in modified and 1.08 in recommended criteria groups. Cord serum insulin levels in infants of gestational diabetic mothers by both criteria were 40% above those of negative screenees (P<.001). The average percentage incidence of 33 possible perinatal morbidities was 41 % higher in gestational diabetic pregnancies by the modified criteria. The cumulative number of morbidities was higher in both modified and recommended criteria groups (P<.01 in both instances). In contrast, subjects having a positive glucose screening test but a negative glucose tolerance test by modified criteria had none of the characteristics of gestational diabetes with the single exception of greater age. Conclusions.-Fifty percent more cases of gestational diabetes were identified using the more inclusive, modified criteria. These cases had as much excess in maternal diabetes risk factors, infant macrosomia, and cord hyperinsulinemia and nearly as much increase in perinatal morbidity as subjects diagnosed by the recommended criteria. The incidence and perinatal impact of gestational diabetes may be greater than previously appreciated. The modified criteria deserve wider verification and use.	UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT OBSTET & GYNECOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35816, DK-28130] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABSON SG, 1970, PEDIATRICS, V45, P937; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; CATALANO PM, 1986, AM J OBSTET GYNECOL, V155, P1255, DOI 10.1016/0002-9378(86)90155-9; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COUSTAN DR, 1986, AM J OBSTET GYNECOL, V154, P1031, DOI 10.1016/0002-9378(86)90744-1; COUSTAN DR, 1989, OBSTET GYNECOL, V73, P557; COUSTAN DR, 1978, OBSTET GYNECOL, V51, P306, DOI 10.1097/00006250-197803000-00010; DANDROW RV, 1966, AM J OBSTET GYNECOL, V96, P1144, DOI 10.1016/0002-9378(66)90525-4; DOOLEY SL, 1991, INT J GYNECOL OBSTET, V35, P13, DOI 10.1016/0020-7292(91)90057-C; DUNN OJ, 1964, TECHNOMETRICS, V6, P241, DOI 10.2307/1266041; EFENDIC S, 1987, DIABETES, V36, P413, DOI 10.2337/diabetes.36.4.413; GABBE SG, 1977, AM J OBSTET GYNECOL, V127, P465, DOI 10.1016/0002-9378(77)90436-7; GREEN JR, 1990, AM J OBSTET GYNECOL, V163, P86, DOI 10.1016/S0002-9378(11)90675-9; Gribble R K, 1988, Wis Med J, V87, P19; HARRIS M, 1979, DIABETES, V28, P1039; HOET JP, 1954, DIABETES, V3, P1; JACOBSON JD, 1989, AM J OBSTET GYNECOL, V161, P981, DOI 10.1016/0002-9378(89)90767-9; JOVANOVIC L, 1986, DIABETES, V35, pA216, DOI 10.2337/diab.34.2.S21; KNOPP RH, 1978, LABORATORY INDICES N, P35; LANGER O, 1989, AM J OBSTET GYNECOL, V161, P593, DOI 10.1016/0002-9378(89)90361-X; LEIKIN EL, 1987, OBSTET GYNECOL, V69, P570; MAIN DM, 1985, AM J OBSTET GYNECOL, V152, P1031, DOI 10.1016/0002-9378(85)90553-8; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; OSULLIVAN JB, 1964, DIABETES, V13, P278; OSULLIVAN JB, 1975, EARLY DIABETES EARLY, P503; OSULLIVAN JB, 1975, EARLY DIABETES EARLY, P447; PEARSON DC, 1987, PREV MED, V16, P783, DOI 10.1016/0091-7435(87)90018-1; Philipson E H, 1985, Diabetes, V34 Suppl 2, P55; ROMANO AT, 1973, CLIN CHEM, V19, P1152; SACKS DA, 1987, OBSTET GYNECOL, V70, P89; SACKS DA, 1989, AM J OBSTET GYNECOL, V161, P638, DOI 10.1016/0002-9378(89)90369-4; SIEGEL S, 1988, NONPARAMETRIC STAT, P206; Snedecor G.W., 1967, STAT METHODS, V6th, P1; TALLARIGO L, 1986, NEW ENGL J MED, V315, P989, DOI 10.1056/NEJM198610163151603; WARD WK, 1985, J CLIN ENDOCR METAB, V61, P1039, DOI 10.1210/jcem-61-6-1039; WATSON WJ, 1989, OBSTET GYNECOL, V74, P40; Zoller D P, 1988, J Am Board Fam Pract, V1, P98; 1985, DIABETES S2, V34, P123	38	155	160	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					609	615		10.1001/jama.269.5.609	http://dx.doi.org/10.1001/jama.269.5.609			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421365				2022-12-28	WOS:A1993KJ44400027
J	MILLS, JL; HOLMES, LB; AARONS, JH; SIMPSON, JL; BROWN, ZA; JOVANOVICPETERSON, LG; CONLEY, MR; GRAUBARD, BI; KNOPP, RH; METZGER, BE				MILLS, JL; HOLMES, LB; AARONS, JH; SIMPSON, JL; BROWN, ZA; JOVANOVICPETERSON, LG; CONLEY, MR; GRAUBARD, BI; KNOPP, RH; METZGER, BE			MODERATE CAFFEINE USE AND THE RISK OF SPONTANEOUS-ABORTION AND INTRAUTERINE GROWTH-RETARDATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BIRTH-WEIGHT; PREGNANCY; CONSUMPTION; ASSOCIATION; BEVERAGES; ALCOHOL; COFFEE; LENGTH	Objective.-To examine the relationship between caffeine consumption during pregnancy and the occurrence of spontaneous abortion and intrauterine growth retardation. Design, Setting, and Patients.-A cohort of 431 women, enrolled in a multicenter study within 21 days of conception, was monitored throughout pregnancy to determine (1) caffeine exposure, (2) exposure to other risk factors, (3) fetal growth as assessed by ultrasonography, and (4) pregnancy outcome. Outcome Measures.-Spontaneous abortion, intrauterine growth, birth weight, and head circumference. Results.-The mean (+/-SD) first-trimester caffeine consumption was not significantly higher in women who aborted (125.9+/-123.1 mg) than in women who delivered liveborn infants (111.6+/-107.0 mg) (P=34). The adjusted odds ratio (OR) for spontaneous abortion was 1.15 (95% confidence interval [CI], 0.89 to 1.49). Early fetal growth, assessed by crown-rump length on ultrasonographic examination, was not affected by caffeine. Although the group consuming the most caffeine (>300 mg/d) had a significantly higher proportion of babies with birth weights and head circumferences below the 10th percentile in the crude analysis, the association with caffeine was no longer significant when other risk factors (notably smoking) were taken into account. The adjusted ORs were 1.11 (95% CI, 0.88 to 1.40) for decreased birth weight and 1.09 (95% CI, 0.86 to 1.37) for smaller head circumference. Conclusions.-Close monitoring of a cohort identified very soon after conception enabled us to identify all abortions after 21 days postconception, monitor intrauterine growth prospectively, and track caffeine use. Despite this intensive surveillance, we found no evidence that moderate caffeine use increased the risk of spontaneous abortion, intrauterine growth retardation, or microcephaly after accounting for other risk factors.	BRIGHAM & WOMENS HOSP,DEPT OBSTET & GYNECOL,BOSTON,MA 02115; UNIV PITTSBURGH,MAGEE WOMENS HOSP,DEPT MED,PITTSBURGH,PA 15213; UNIV TENNESSEE CTR HLTH SCI,DEPT OBSTET & GYNECOL,MEMPHIS,TN 38163; UNIV WASHINGTON,SCH MED,DEPT OBSTET & GYNECOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; SANSUM RES FDN,SANTA BARBARA,CA; NCI,BETHESDA,MD 20892; NORTHWESTERN UNIV,SCH MED,DEPT MED,CHICAGO,IL 60611	Harvard University; Brigham & Women's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Tennessee System; University of Tennessee Health Science Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; William Sansum Diabetes Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Northwestern University	MILLS, JL (corresponding author), NICHHD,DIV EPIDEMIOL STAT & PREVENT RES,EPIDEMIOL BRANCH,BETHESDA,MD 20892, USA.			Mills, James/0000-0003-4496-332X				[Anonymous], 1989, SAS STAT USERS GUIDE, V2, P1071; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; ARMSTRONG BG, 1992, AM J PUBLIC HEALTH, V82, P85, DOI 10.2105/AJPH.82.1.85; BERGER A, 1988, J REPROD MED, V33, P945; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; BROWN ZA, 1992, DIABETES CARE, V15, P613, DOI 10.2337/diacare.15.5.613; BUNKER ML, 1979, J AM DIET ASSOC, V74, P28; CAAN BJ, 1989, AM J PUBLIC HEALTH, V79, P1299, DOI 10.2105/AJPH.79.9.1299; Fenster L, 1991, Epidemiology, V2, P168, DOI 10.1097/00001648-199105000-00002; FRIED PA, 1987, NEUROTOXICOL TERATOL, V9, P79, DOI 10.1016/0892-0362(87)90082-1; FURUHASHI N, 1985, GYNECOL OBSTET INVES, V19, P187, DOI 10.1159/000299032; GILBERT RM, 1976, CAN MED ASSOC J, V114, P205; HELLER J, 1987, BRIT J ADDICT, V82, P885; JOVANOVICPETERSON L, 1991, AM J OBSTET GYNECOL, V164, P103, DOI 10.1016/0002-9378(91)90637-7; KUZMA JW, 1982, ALCOHOL CLIN EXP RES, V6, P396, DOI 10.1111/j.1530-0277.1982.tb04998.x; LINN S, 1982, NEW ENGL J MED, V306, P141, DOI 10.1056/NEJM198201213060304; MARTIN TR, 1987, AM J EPIDEMIOL, V126, P813, DOI 10.1093/oxfordjournals.aje.a114718; MCDONALD AD, 1992, AM J PUBLIC HEALTH, V82, P87, DOI 10.2105/AJPH.82.1.87; MILLS JL, 1983, PREV MED, V12, P274, DOI 10.1016/0091-7435(83)90236-0; MUNOZ LM, 1988, AM J CLIN NUTR, V48, P645, DOI 10.1093/ajcn/48.3.645; NAROD SA, 1991, AM J OBSTET GYNECOL, V164, P1109, DOI 10.1016/0002-9378(91)90597-K; NIKLASSON A, 1991, ACTA PAEDIATR SCAND, V80, P756, DOI 10.1111/j.1651-2227.1991.tb11945.x; NILEN GA, 1991, TOXICOL APPL PHARM, V58, P171; ROBINSON HP, 1975, BRIT J OBSTET GYNAEC, V82, P702, DOI 10.1111/j.1471-0528.1975.tb00710.x; SRISUPHAN W, 1986, AM J OBSTET GYNECOL, V154, P14, DOI 10.1016/0002-9378(86)90385-6; STEIN A, 1991, EPIDEMIOLOGY, V2, P163; TRUETT J, 1967, J CHRON DIS, V20, P511, DOI 10.1016/0021-9681(67)90082-3; WATKINSON B, 1985, NEUROBEH TOXICOL TER, V7, P9; WEATHERSBEE PS, 1977, POSTGRAD MED, V62, P64, DOI 10.1080/00325481.1977.11714605; Wilcox A J, 1990, Epidemiology, V1, P382, DOI 10.1097/00001648-199009000-00008; 1980, FED REG         1021, V45, P69817	31	92	94	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					593	597		10.1001/jama.269.5.593	http://dx.doi.org/10.1001/jama.269.5.593			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8421363				2022-12-28	WOS:A1993KJ44400024
J	DEFRANCHIS, R; MEUCCI, G; VECCHI, M; TATARELLA, M; COLOMBO, M; DELNINNO, E; RUMI, MG; DONATO, MF; RONCHI, G				DEFRANCHIS, R; MEUCCI, G; VECCHI, M; TATARELLA, M; COLOMBO, M; DELNINNO, E; RUMI, MG; DONATO, MF; RONCHI, G			THE NATURAL-HISTORY OF ASYMPTOMATIC HEPATITIS-B SURFACE-ANTIGEN CARRIERS	ANNALS OF INTERNAL MEDICINE			English	Article						CARRIER STATE; HEPATITIS-B SURFACE ANTIGENS; HEPATOMA; LIVER NEOPLASMS; HEPATITIS	HEPATOCELLULAR-CARCINOMA; VIRUS-INFECTION; HBSAG-CARRIERS; FOLLOW-UP; REACTIVATION; STATE; THERAPY	Objective: To assess the long-term outcome in hepatitis B surface antigen (HBsAg) carriers who have normal liver function tests, focusing on survival and the development of severe liver disease and hepatocellular carcinoma. Design: Cohort study with a mean follow-up of 130 months. Setting: Liver clinic of a referral center. Patients: Ninety-two HBsAg-positive blood donors with normal liver function tests. Measurements: Histologic evaluation of liver specimens at baseline; clinical, biochemical, and serologic follow-up; and repeat liver biopsy if clinically indicated or after 10 years of follow-up. Results: At baseline, 69 subjects had normal histologic findings or only minor abnormalities, 18 had chronic persistent hepatitis, and 5 had mild chronic active hepatitis. Serum enzyme levels remained normal in 58 of 68 patients who had regular follow-up. Three patients had biochemical changes consistent with hepatitis B virus (HBV) infection; in one of these patients, a later histologic evaluation showed progression to chronic active hepatitis. One patient developed alcoholic cirrhosis. Six other patients had mild or transient transaminase elevations, with no evidence of HBV replication, hepatitis D virus infection, hepatitis C virus (HCV) infection, or histologic deterioration. Liver histologic findings also remained unchanged in 21 patients who showed no biochemical changes during 10 years of follow-up and consented to have repeated liver biopsy. Ten patients showed loss of HBsAg; 2 of these patients acquired antibody to hepatitis B surface antigen (anti-HBs). All patients who did not have regular follow-up, except 1, were interviewed by telephone during 1990: All denied having liver disease. No patients developed hepatocellular carcinoma. Conclusions: Italian HBsAg carriers with initially normal liver function tests have an excellent prognosis: Delta superinfection is infrequent and the risk for developing hepatocellular carcinoma is low.			DEFRANCHIS, R (corresponding author), UNIV MILAN,IST MED INTERNA,VIA PACE 9,I-20122 MILAN,ITALY.		Donato, Maria francesca/AAC-2372-2019; Meucci, Gianmichele/AFJ-8527-2022	RUMI, MARIAGRAZIA/0000-0002-5876-8528; Meucci, Gianmichele/0000-0001-9004-8195				BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BIANCHI L, 1987, PATHOLOGY LIVER DISE, P310; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DAVIS GL, 1987, GASTROENTEROLOGY, V92, P2028, DOI 10.1016/0016-5085(87)90641-X; DAVIS GL, 1984, GASTROENTEROLOGY, V86, P230; DEFRANCHIS R, 1980, GASTROENTEROLOGY, V79, P521, DOI 10.1016/0016-5085(80)90378-9; DRAGOSICS B, 1987, HEPATOLOGY, V7, P302, DOI 10.1002/hep.1840070215; FEINMAN SV, 1975, GASTROENTEROLOGY, V68, P113; FEINMAN SV, 1992, HEPATOGASTROENTEROLO, V29, P58; FLOWERS MA, 1990, ANN INTERN MED, V112, P381, DOI 10.7326/0003-4819-112-5-381; GIUSTI G, 1981, HEPATO-GASTROENTEROL, V28, P96; HOFFNAGLE JH, 1983, GASTROENTEROLOGY, V84, P422; HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424; HOWDLE PD, 1987, VOX SANG, V52, P200, DOI 10.1111/j.1423-0410.1987.tb03027.x; KORETZ RL, 1978, GASTROENTEROLOGY, V75, P860; LOK ASF, 1991, GASTROENTEROLOGY, V100, P182, DOI 10.1016/0016-5085(91)90599-G; PICCININO F, 1991, PROG CLIN BIOL RES, V364, P33; PICCININO F, 1978, ACTA HEPATO-GASTRO, V25, P171; POPPER H, 1987, HEPATOLOGY, V7, P764, DOI 10.1002/hep.1840070425; RICCI G, 1973, J INFECT DIS, V128, P125, DOI 10.1093/infdis/128.1.125; RIZZETTO M, 1991, PROG CLIN BIOL RES, V364, P1; SAKUMA K, 1982, GASTROENTEROLOGY, V83, P114; SHRAGO SS, 1977, ARCH PATHOL LAB MED, V101, P648; TAPP E, 1976, J CLIN PATHOL, V29, P884, DOI 10.1136/jcp.29.10.884; VILLA E, 1982, LANCET, V2, P1243	25	217	222	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					191	194		10.7326/0003-4819-118-3-199302010-00006	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8417636				2022-12-28	WOS:A1993KJ43900006
J	CHAPARRO, A; STROMEYER, CF; HUANG, EP; KRONAUER, RE; ESKEW, RT				CHAPARRO, A; STROMEYER, CF; HUANG, EP; KRONAUER, RE; ESKEW, RT			COLOR IS WHAT THE EYE SEES BEST	NATURE			English	Article							RETINAL GANGLION-CELLS; LATERAL GENICULATE-NUCLEUS; RED-GREEN; CHROMATIC STIMULI; MACAQUE; LUMINANCE; CONTRAST; SENSITIVITY; INTEGRATION; ADAPTATION	IT has been argued by Watson, Barlow and Robson1 that the visual stimulus that humans detect best specifies the spatial-temporal structure of the receptive field of the most sensitive visual neurons. To investigate 'what the eye sees best' they used stimuli that varied in luminance alone. Because the most abundant primate retinal ganglion cells, the P cells, are colour-opponent2-4, we might expect that a coloured pattern would also be detected well. We generalized Watson et al.'s study1 to include variations in colour as well as luminance. We report here that our best detected coloured stimulus was seen 5-9-fold better than our best luminance spot and 3-8-fold better than Watson's best luminance stimulus. The high sensitivity to colour is consistent with the prevalence and high colour contrast-gain of retinal P cells, and may compensate for the low chromatic contrasts typically found in natural scenes.	HARVARD UNIV,DEPT PSYCHOL,CAMBRIDGE,MA 02138; NORTHEASTERN UNIV,DEPT PSYCHOL,BOSTON,MA 02115	Harvard University; Northeastern University	CHAPARRO, A (corresponding author), HARVARD UNIV,DIV APPL SCI,CAMBRIDGE,MA 02138, USA.							COLE GR, 1990, J OPT SOC AM A, V7, P128, DOI 10.1364/JOSAA.7.000128; CROOK JM, 1988, J PHYSIOL-LONDON, V396, P205, DOI 10.1113/jphysiol.1988.sp016959; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P219, DOI 10.1113/jphysiol.1984.sp015498; DERRINGTON AM, 1984, J PHYSIOL-LONDON, V357, P241, DOI 10.1113/jphysiol.1984.sp015499; GOURAS P, 1968, J PHYSIOL-LONDON, V199, P533, DOI 10.1113/jphysiol.1968.sp008667; KAPLAN E, 1990, PROGR RETINAL RES, V9; KELLY DH, 1977, J OPT SOC AM, V67, P1081, DOI 10.1364/JOSA.67.001081; KINGSMITH PE, 1976, J OPT SOC AM, V66, P709, DOI 10.1364/JOSA.66.000709; LEE BB, 1989, J PHYSIOL-LONDON, V414, P223, DOI 10.1113/jphysiol.1989.sp017685; MULLEN KT, 1985, J PHYSIOL-LONDON, V359, P381, DOI 10.1113/jphysiol.1985.sp015591; NOORLANDER C, 1981, J OPT SOC AM, V71, P453, DOI 10.1364/JOSA.71.000453; Pelli D. G., 1990, VISION CODING EFFICI; PERRY VH, 1985, VISION RES, V25, P1795, DOI 10.1016/0042-6989(85)90004-5; PERRY VH, 1984, NEUROSCIENCE, V12, P1101, DOI 10.1016/0306-4522(84)90006-X; PURPURA K, 1988, P NATL ACAD SCI USA, V85, P4534, DOI 10.1073/pnas.85.12.4534; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; SCHEIN SJ, 1988, J COMP NEUROL, V269, P479, DOI 10.1002/cne.902690403; SHAPLEY RM, 1991, INVEST OPHTHALMOL S, V32, P115; SMITH VC, 1984, VISION RES, V24, P653, DOI 10.1016/0042-6989(84)90206-2; STROMEYER CF, 1985, VISION RES, V25, P219, DOI 10.1016/0042-6989(85)90116-6; STROMEYER CF, 1987, VISION RES, V27, P1113, DOI 10.1016/0042-6989(87)90026-5; THORNTON JE, 1983, SCIENCE, V219, P191, DOI 10.1126/science.6849131; TROY JB, 1991, INVEST OPHTH VIS SCI, V32, P905; Van Trees H.L., 2001, DETECTION ESTIMATION, P19; WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828; WATSON AB, 1983, NATURE, V302, P419, DOI 10.1038/302419a0; WILLIAMS DR, 1981, VISION RES, V21, P1341, DOI 10.1016/0042-6989(81)90241-8	28	125	126	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					348	350		10.1038/361348a0	http://dx.doi.org/10.1038/361348a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8426653				2022-12-28	WOS:A1993KJ59000056
J	NIGHTINGALE, SL				NIGHTINGALE, SL			AGENCY POLICY ON INDUSTRY-SUPPORTED CME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1992, FED REGISTER, V57, P56412	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					328	328						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418328				2022-12-28	WOS:A1993KG38100005
J	ROINE, RO; KAJASTE, S; KASTE, M				ROINE, RO; KAJASTE, S; KASTE, M			NEUROPSYCHOLOGICAL SEQUELAE OF CARDIAC-ARREST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY BYPASS; WECHSLER MEMORY SCALE; CEREBRAL BLOOD-FLOW; HEART-SURGERY; NIMODIPINE; AMNESIA; RESUSCITATION; RELIABILITY; INFARCTION; SYMPTOMS	Objectives.-Prospective and community-based studies on the cognitive outcome of out-of-hospital cardiac arrest have not been published. We studied prospectively the neuropsychological sequelae of cardiac arrest and evaluated the effects of nimodipine on them. Design.-Placebo-controlled, randomized, double-blind trial of nimodipine compared with placebo in out-of-hospital ventricular fibrillation. Setting.-Urban area of 500 000 inhabitants served by the physician-manned Advanced Life Support Unit of Helsinki. Patients.-A total of 155 successfully resuscitated consecutive patients out of 677 resuscitation attempts during 21/2 years. Sixty-eight survivors were examined by a neuropsychologist and a neurologist. Main Outcome Measure.-Neuropsychological outcome 3 months and 1 year after cardiac arrest. Interventions.-Nimodipine or placebo at a dosage of 10 mug/kg as an intravenous injection immediately after restoration of spontaneous circulation, followed by an infusion of 0.5 mug/kg per minute for 24 hours. Results.-Three months after cardiac arrest, 41 (60%) of 68 patients were found to have moderate to severe cognitive deficits. At 12 months, 26 (48%) of 54 survivors still had moderate to severe deficits, and the Symptom Check List 90-Revised score indicated the presence of depression in 22 patients (45%) and severe,depression in 12 patients (24%). Conclusions.-Moderate to severe neuropsychological sequelae of out-of-hospital cardiac arrest are still present in approximately one half of the survivors at 1 year and may be permanent. There seems to be no excess of increased disability in the subgroup of patients with delayed advanced life support. Nimodipine failed to show any effect on the cognitive functions tested.			ROINE, RO (corresponding author), UNIV HELSINKI, DEPT NEUROL, SF-00290 HELSINKI 29, FINLAND.			Kaste, Markku/0000-0001-6557-6412				ABIKOFF H, 1987, J CLIN EXP NEUROPSYC, V9, P435, DOI 10.1080/01688638708405063; ARMITAGE P, 1987, STATISTICAL METHODS; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BENGTSSON M, 1969, Acta Psychiatrica Scandinavica, V45, P327, DOI 10.1111/j.1600-0447.1969.tb07133.x; BENTON A L, 1981, Journal of Clinical Neuropsychology, V3, P33, DOI 10.1080/01688638108403111; BERGNER L, 1985, AM J PUBLIC HEALTH, V75, P1321, DOI 10.2105/AJPH.75.11.1321; BERTINI G, 1990, Journal of Emergency Medicine, V8, P407, DOI 10.1016/0736-4679(90)90166-S; BOTWINNICK J, 1981, HDB CLIN NEUROPSYCHO, P135; CARONNA J J, 1978, Stroke, V9, P517; Christensen AL., 1975, LURIAS NEUROPSYCHOLO, V4th; CUMMINGS JL, 1984, NEUROLOGY, V34, P679, DOI 10.1212/WNL.34.5.679; DEROGATIS LR, 1983, SCL90R ADM SCORING P, V2; DIXON WJ, 1990, BMDP STATISTICAL SOF, P1; DRUHE CM, 1989, NERVENARZT, V60, P280; FLYNN JR, 1984, PSYCHOL BULL, V95, P29, DOI 10.1037/0033-2909.95.1.29; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORSMAN M, 1990, BRIT J ANAESTH, V65, P514, DOI 10.1093/bja/65.4.514; JENKINS CD, 1983, JAMA-J AM MED ASSOC, V250, P782, DOI 10.1001/jama.250.6.782; KORNFELD DS, 1982, CIRCULATION, V66, P24; KOTILA M, 1984, ACTA NEUROL SCAND, V69, P337; LAPLANE D, 1989, BRAIN, V112, P699, DOI 10.1093/brain/112.3.699; LARRABEE GJ, 1987, J CLIN EXP NEUROPSYC, V9, P456, DOI 10.1080/01688638708405065; Lezak MD, 2012, NEUROPSYCHOLOGICAL A, V5; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; Luria AR., 1973, WORKING BRAIN; MAGNI G, 1987, ARCH INTERN MED, V147, P473, DOI 10.1001/archinte.147.3.473; NEWMAN S, 1989, J CLIN EXP NEUROPSYC, V11, P529, DOI 10.1080/01688638908400911; NUSSMEIER NA, 1986, ANESTHESIOLOGY, V64, P165, DOI 10.1097/00000542-198602000-00006; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROINE RO, 1991, ARCH NEUROL-CHICAGO, V48, P625, DOI 10.1001/archneur.1991.00530180081021; ROINE RO, 1990, JAMA-J AM MED ASSOC, V264, P3171; SAVELAND H, 1988, ACTA NEUROL SCAND, V77, P54; SHAW PJ, 1987, STROKE, V18, P700, DOI 10.1161/01.STR.18.4.700; SHINAR D, 1986, STROKE, V17, P241, DOI 10.1161/01.STR.17.2.241; SOTANIEMI KA, 1981, ARCH NEUROL-CHICAGO, V38, P2, DOI 10.1001/archneur.1981.00510010028003; VOLPE BT, 1986, NEUROLOGY, V36, P408, DOI 10.1212/WNL.36.3.408; VOLPE BT, 1985, NEUROLOGY, V35, P1793, DOI 10.1212/WNL.35.12.1793; VOLPE BT, 1983, ARCH NEUROL-CHICAGO, V40, P436, DOI 10.1001/archneur.1983.04050070066017; Wechsler D., 2008, WAIS 4 WECHSLER ADUL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; WILLANGER R, 1970, ACTA NEUROL SCAND, V46, P103; YARNELL PR, 1976, STROKE, V7, P279, DOI 10.1161/01.STR.7.3.279; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	46	224	233	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 13	1993	269	2					237	242		10.1001/jama.269.2.237	http://dx.doi.org/10.1001/jama.269.2.237			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF405	8417242				2022-12-28	WOS:A1993KF40500030
J	BLISS, TVP; COLLINGRIDGE, GL				BLISS, TVP; COLLINGRIDGE, GL			A SYNAPTIC MODEL OF MEMORY - LONG-TERM POTENTIATION IN THE HIPPOCAMPUS	NATURE			English	Review							PROTEIN KINASE-C; NMDA-RECEPTOR ACTIVATION; COLLATERAL-COMMISSURAL PATHWAY; RABBIT FOLLOWING STIMULATION; EPSP SPIKE DISSOCIATION; D-ASPARTATE ANTAGONISTS; EXCITATORY AMINO-ACIDS; MOSSY FIBER SYNAPSES; RAT HIPPOCAMPUS; DENTATE GYRUS	Long-term potentiation of synaptic transmission in the hippocampus is the primary experimental model for investigating the synaptic basis of learning and memory in vertebrates. The best understood form of long-term potentiation is induced by the activation of the N-methyl-D-aspartate receptor complex. This subtype of glutamate receptor endows long-term potentiation with Hebbian characteristics, and allows electrical events at the postsynaptic membrane to be transduced into chemical signals which, in turn, are thought to activate both pre- and postsynaptic mechanisms to generate a persistent increase in synaptic strength.	UNIV BIRMINGHAM, DEPT PHARMACOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND	University of Birmingham	BLISS, TVP (corresponding author), NATL INST MED RES, DIV NEUROPHYSIOL & NEUROPHARMACOL, MILL HILL, LONDON NW7 1AA, ENGLAND.		Collingridge, Graham L/C-4605-2015; collingridge, graham/AAI-8362-2020; Sancheti, Harsh/H-3538-2012	Collingridge, Graham L/0000-0002-9572-5359; 				ABRAHAM WC, 1991, MOL NEUROBIOL, V5, P297, DOI 10.1007/BF02935553; ABRAHAM WC, 1985, J PHYSIOL-LONDON, V363, P335, DOI 10.1113/jphysiol.1985.sp015714; AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; ALFORD S, 1992, EXCITATORY AMINO ACI, P43; ANDERSEN P, 1980, J PHYSIOL-LONDON, V302, P463; ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; ANDREASEN M, 1989, J PHYSIOL-LONDON, V414, P317, DOI 10.1113/jphysiol.1989.sp017690; ANIKSZTEJN L, 1991, NATURE, V349, P67, DOI 10.1038/349067a0; ANIKSZTEJN L, 1989, NEUROSCIENCE, V28, P387, DOI 10.1016/0306-4522(89)90185-1; ARAI A, 1992, EUR J NEUROSCI, V4, P411, DOI 10.1111/j.1460-9568.1992.tb00890.x; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASZTELY F, 1992, EUR J NEUROSCI, V4, P681, DOI 10.1111/j.1460-9568.1992.tb00177.x; ASZTELY F, 1992, SYNAPSE, V11, P342, DOI 10.1002/syn.890110409; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BAR PR, 1984, BRAIN RES, V321, P381, DOI 10.1016/0006-8993(84)90198-7; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BASHIR ZI, 1991, NATURE, V349, P156, DOI 10.1038/349156a0; BASHIR ZI, 1990, NEUROSCI LETT, V108, P261, DOI 10.1016/0304-3940(90)90651-O; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BERRETTA N, 1991, EUR J NEUROSCI, V3, P850, DOI 10.1111/j.1460-9568.1991.tb00096.x; Bliss T V, 1990, Adv Exp Med Biol, V268, P269; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1990, COLD SPRING HARB SYM, V55, P119; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1984, NEUROBIOLOGY LEARNIN; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BORTOLOTTO ZA, 1993, NEUROPHARMACOLOGY, V32, P1, DOI 10.1016/0028-3908(93)90123-K; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; CLEMENTS MP, 1991, NEUROSCIENCE, V45, P379, DOI 10.1016/0306-4522(91)90235-G; COAN EJ, 1987, NEUROSCI LETT, V80, P111, DOI 10.1016/0304-3940(87)90505-2; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; COLLINGRIDGE GL, 1992, EXP PHYSIOL, V77, P771, DOI 10.1113/expphysiol.1992.sp003645; COLLINGRIDGE GL, 1988, J PHYSIOL-LONDON, V399, P283; COLLINGRIDGE GL, 1988, J PHYSIOL-LONDON, V399, P301; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; COLLINGRIDGE GL, 1991, INT ACAD BIOMED DRUG, V2, P41; DALE N, 1985, J PHYSIOL-LONDON, V363, P35, DOI 10.1113/jphysiol.1985.sp015694; DAVIES CH, 1991, NATURE, V349, P609, DOI 10.1038/349609a0; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DESMOND NL, 1990, SYNAPSE, V5, P139, DOI 10.1002/syn.890050208; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; DOYERE V, 1992, HIPPOCAMPUS, V2, P39, DOI 10.1002/hipo.450020106; DRAGUNOW M, 1989, NEUROSCI LETT, V101, P274, DOI 10.1016/0304-3940(89)90545-4; DUFFY C, 1981, SCIENCE, V212, P1148, DOI 10.1126/science.7233208; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; FAZELI MS, 1988, BRAIN RES, V473, P51, DOI 10.1016/0006-8993(88)90314-9; FAZELI MS, 1990, BRAIN RES, V521, P247, DOI 10.1016/0006-8993(90)91549-V; FAZELI MS, IN PRESS J NEUROSCI, V13; FEASEY KJ, 1986, BRAIN RES, V364, P39, DOI 10.1016/0006-8993(86)90985-6; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; FREY U, 1989, NEUROSCI LETT, V97, P135, DOI 10.1016/0304-3940(89)90152-3; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GASIC GP, 1992, REV PHYSL, V54, P507; GEINISMAN Y, 1991, BRAIN RES, V566, P77, DOI 10.1016/0006-8993(91)91683-R; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; GROVER LM, 1990, NATURE, V347, P477, DOI 10.1038/347477a0; GUSTAFSSON B, 1988, NEUROSCI LETT, V85, P77, DOI 10.1016/0304-3940(88)90432-6; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HARVEY J, 1992, NEUROSCI LETT, V139, P197, DOI 10.1016/0304-3940(92)90551-H; HEBB DO, 1949, ORG BEHAVIOR; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; HOSOKAWA T, 1992, NEUROREPORT, V3, P477, DOI 10.1097/00001756-199206000-00005; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; HUANG YY, 1992, NEUROSCIENCE, V49, P819, DOI 10.1016/0306-4522(92)90359-A; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; IRVING AJ, 1992, CELL CALCIUM, V13, P293, DOI 10.1016/0143-4160(92)90064-Y; ISAACSON JS, 1991, P NATL ACAD SCI USA, V88, P10936, DOI 10.1073/pnas.88.23.10936; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; ITO I, 1990, J PHYSIOL-LONDON, V424, P533, DOI 10.1113/jphysiol.1990.sp018081; IZUMI Y, 1991, NEUROSCI LETT, V122, P187, DOI 10.1016/0304-3940(91)90854-M; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JEFFERY KJ, 1990, MOL BRAIN RES, V8, P267, DOI 10.1016/0169-328X(90)90039-G; JOHNSTON D, 1992, REV PHYSL, V54, P489; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; KLANN E, 1991, J BIOL CHEM, V266, P24253; Konorski J., 1948, CONDITIONED REFLEXES; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LINDEN DJ, 1988, BRAIN RES, V458, P142, DOI 10.1016/0006-8993(88)90506-9; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LOVINGER DM, 1987, BRAIN RES, V436, P177, DOI 10.1016/0006-8993(87)91573-3; LOVINGER DM, 1988, J PHYSIOL-LONDON, V400, P321, DOI 10.1113/jphysiol.1988.sp017122; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; LYNCH GS, 1976, NATURE, V263, P151, DOI 10.1038/263151a0; LYNCH MA, 1991, J NEUROCHEM, V56, P113, DOI 10.1111/j.1471-4159.1991.tb02569.x; LYNCH MA, 1986, BRAIN RES, V369, P405, DOI 10.1016/0006-8993(86)90561-5; LYNCH MA, 1990, J NEUROCHEM, V55, P215, DOI 10.1111/j.1471-4159.1990.tb08841.x; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MACKLER SA, 1992, NEURON, V9, P539, DOI 10.1016/0896-6273(92)90191-F; MALENKA RC, 1992, NEURON, V9, P121, DOI 10.1016/0896-6273(92)90227-5; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALENKA RC, 1989, TRENDS NEUROSCI, V12, P444, DOI 10.1016/0166-2236(89)90094-5; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MARKRAM H, 1992, J PHYSIOL-LONDON, V447, P513, DOI 10.1113/jphysiol.1992.sp019015; MCGUINNESS N, 1991, EUR J PHARMACOL, V197, P231, DOI 10.1016/0014-2999(91)90529-Y; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; MODY I, 1984, NEUROPHARMACOLOGY, V23, P625, DOI 10.1016/0028-3908(84)90142-4; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; MULLER D, 1988, P NATL ACAD SCI USA, V85, P9346, DOI 10.1073/pnas.85.23.9346; MULLER D, 1988, P NATL ACAD SCI USA, V85, P6997, DOI 10.1073/pnas.85.18.6997; MULLER D, 1990, P NATL ACAD SCI USA, V87, P4073, DOI 10.1073/pnas.87.11.4073; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; NIKOLAEV E, 1991, BRAIN RES, V560, P346, DOI 10.1016/0006-8993(91)91257-2; OBENAUS A, 1989, NEUROSCI LETT, V98, P172, DOI 10.1016/0304-3940(89)90505-3; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OKADA D, 1989, NEUROSCI LETT, V100, P141, DOI 10.1016/0304-3940(89)90674-5; OLIVER MW, 1989, BRAIN RES, V505, P233, DOI 10.1016/0006-8993(89)91448-0; OTANI S, 1992, NEUROSCIENCE, V47, P265, DOI 10.1016/0306-4522(92)90242-T; OTANI S, 1989, NEUROSCIENCE, V28, P519, DOI 10.1016/0306-4522(89)90001-8; Otto T, 1991, Hippocampus, V1, P181, DOI 10.1002/hipo.450010206; PUBLICOVER SJ, 1991, EXP BRAIN RES, V84, P680; RADPOUR S, 1992, NEUROSCI LETT, V138, P119, DOI 10.1016/0304-3940(92)90486-Q; REGEHR WG, 1991, NEURON, V7, P451, DOI 10.1016/0896-6273(91)90297-D; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; REYMANN KG, 1988, BRAIN RES, V440, P305, DOI 10.1016/0006-8993(88)91000-1; REYMANN KG, 1989, NEUROSCI LETT, V98, P166, DOI 10.1016/0304-3940(89)90504-1; REYMANN KG, 1988, BRAIN RES, V461, P388, DOI 10.1016/0006-8993(88)90274-0; REYMANN KG, 1990, EUR J NEUROSCI, V2, P481, DOI 10.1111/j.1460-9568.1990.tb00439.x; ROSE GM, 1986, NEUROSCI LETT, V69, P244, DOI 10.1016/0304-3940(86)90487-8; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SKREDE KK, 1981, BRAIN RES, V208, P436, DOI 10.1016/0006-8993(81)90573-4; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STAUBLI U, 1990, PSYCHOBIOLOGY, V18, P377; TANG CM, 1991, SCIENCE, V254, P288, DOI 10.1126/science.1681589; TAUBE JS, 1988, J NEUROSCI, V8, P1632; TURNER RW, 1982, NEUROSCIENCE, V7, P1411, DOI 10.1016/0306-4522(82)90254-8; VORONIN LL, 1992, EXP BRAIN RES, V89, P288; VORONIN LL, 1983, NEUROSCIENCE, V10, P1051, DOI 10.1016/0306-4522(83)90099-4; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; WILLIAMS JH, 1989, NEUROSCI LETT, V107, P301, DOI 10.1016/0304-3940(89)90835-5; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; XIE XP, 1992, J NEUROPHYSIOL, V67, P1009, DOI 10.1152/jn.1992.67.4.1009	174	9074	9354	31	1420	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 7	1993	361	6407					31	39		10.1038/361031a0	http://dx.doi.org/10.1038/361031a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421494				2022-12-28	WOS:A1993KF71800038
J	REYNOLDS, DJM; ARONSON, JK				REYNOLDS, DJM; ARONSON, JK			ABC OF MONITORING DRUG-THERAPY - MAKING THE MOST OF PLASMA DRUG CONCENTRATION MEASUREMENTS	BRITISH MEDICAL JOURNAL			English	Article											REYNOLDS, DJM (corresponding author), RADCLIFFE INFIRM,OXFORD OX2 6HE,ENGLAND.							LARKIN JG, 1991, EPILEPSIA, V32, P89, DOI 10.1111/j.1528-1157.1991.tb05618.x; MCINNES GT, 1989, BRIT J CLIN PHARMACO, V27, P281, DOI 10.1111/j.1365-2125.1989.tb05365.x; SJOQVIST F, 1985, VARIABILITY DRUG THE, P1; SPECTOR R, 1988, CLIN PHARMACOL THER, V43, P345, DOI 10.1038/clpt.1988.42; VOZEH S, 1987, CLIN PHARMACOKINET, V13, P131	5	23	24	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1993	306	6869					48	51		10.1136/bmj.306.6869.48	http://dx.doi.org/10.1136/bmj.306.6869.48			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435581	Bronze, Green Published			2022-12-28	WOS:A1993KE98400031
J	AGOFF, SN; HOU, J; LINZER, DIH; WU, B				AGOFF, SN; HOU, J; LINZER, DIH; WU, B			REGULATION OF THE HUMAN HSP70 PROMOTER BY P53	SCIENCE			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; DNA-BINDING PROTEIN; E1A GENE-PRODUCTS; GLUCOCORTICOID RECEPTOR; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; MAMMALIAN-CELLS; MUTANT P53; T-ANTIGEN	The tumor suppressor p53 is a nuclear phosphoprotein with characteristics of a transcription factor. It displays sequence-specific DNA binding, contains a potent transactivation domain, and has been implicated as both a transcriptional activator and a repressor. Transcription of the human hsp70 gene is stimulated by adenovirus E1a protein. This E1a transactivation of the hsp70 promoter is mediated by CCAAT binding factor (CBF). It is demonstrated here that p53 both represses transcription from the human hsp70 promoter and also interacts with CBF. Thus, the repression of the hsp70 promoter by p53 may be mediated by direct protein-protein interaction with CBF. These results suggest that protein-protein interaction between p53 and specific transcription factors may be an additional mechanism by which p53 regulates gene expression.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208	Northwestern University								AGOFF SN, UNPUB; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1089; GANNON JV, 1987, NATURE, V329, P429; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JONAT G, 1990, CELL, V62, P1189; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; LUM SYL, 1992, MOL CELL BIOL, V12, P2599; LUND H, 1983, NATURE, V304, P596; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1990, ONCOGENE, V5, P1683; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; WU BJ, 1985, P NATL ACAD SCI USA, V82, P6070, DOI 10.1073/pnas.82.18.6070; WU BJ, 1986, P NATL ACAD SCI USA, V83, P629, DOI 10.1073/pnas.83.3.629; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	55	310	317	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					84	87		10.1126/science.8418500	http://dx.doi.org/10.1126/science.8418500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418500				2022-12-28	WOS:A1993KE60100034
J	CRISPINO, GA; HO, PT; SHARPLESS, KB				CRISPINO, GA; HO, PT; SHARPLESS, KB			SELECTIVE PERHYDROXYLATION OF SQUALENE - TAMING THE ARITHMETIC DEMON	SCIENCE			English	Article								Osmium-catalyzed asymmetric dihydroxylation, which produces 1,2-diols of high enantiopurity from prochiral olefins, is an example of the synthetic catalysts that have been developed that rival enzymes in their efficiency and high enantioselectivity. Although the asymmetric dihydroxylation catalyst lacks an enzyme's ability to effectively distinguish among the subtly different olefinic sites in a polyolefin such as squalene, this very inability permits it to bring about the ''exhaustive'' polyhydroxylation of squalene to give a dodecahydroxy derivative. Twelve chemical and stereochemical events proceed in tandem with a remarkable average yield of 98 percent per step, giving 1 out of the 36 possible stereoisomers in (0.98)12 = 78.9 percent overall yield.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028384, R01GM028384] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28384] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURK MJ, 1991, J AM CHEM SOC, V113, P8518, DOI 10.1021/ja00022a047; CRISPINO GA, 1992, TETRAHEDRON LETT, V33, P4273, DOI 10.1016/S0040-4039(00)74236-5; HOYE TR, 1986, TETRAHEDRON, V42, P2855, DOI 10.1016/S0040-4020(01)90574-5; IrelAND, 1969, ORGANIC SYNTHESIS; MORRISON JD, 1985, ASYMMETRIC SYNTHESIS, V5; RAUTENSTRAUCH V, 1992, J AM CHEM SOC, V114, P1418, DOI 10.1021/ja00030a044; SCHREIBER SL, 1987, J AM CHEM SOC, V109, P1525, DOI 10.1021/ja00239a036; SHARPLESS KB, 1992, J ORG CHEM, V57, P2768, DOI 10.1021/jo00036a003; VIGNERON JP, 1973, TETRAHEDRON, V29, P1055, DOI 10.1016/0040-4020(73)80060-2	9	67	67	5	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					64	66		10.1126/science.8418495	http://dx.doi.org/10.1126/science.8418495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	KE601	8418495				2022-12-28	WOS:A1993KE60100027
J	LACHS, M				LACHS, M			TACRINE IN ALZHEIMERS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											LACHS, M (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06510, USA.							FARLOW M, 1992, JAMA-J AM MED ASSOC, V268, P2523, DOI 10.1001/jama.268.18.2523; RABINS PV, 1982, JAMA-J AM MED ASSOC, V248, P333, DOI 10.1001/jama.248.3.333	2	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					809	809						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8437606				2022-12-28	WOS:A1993KR84800017
J	LIAW, YF; HUANG, MJ; FAN, KD; LI, KL; WU, SS; CHEN, TJ				LIAW, YF; HUANG, MJ; FAN, KD; LI, KL; WU, SS; CHEN, TJ			HEPATIC-INJURY DURING PROPYLTHIOURACIL THERAPY IN PATIENTS WITH HYPERTHYROIDISM - A COHORT STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						HYPOTHYROIDISM; PROPYLTHIOURACIL; LIVER DISEASES; HYPERBILIRUBINEMIA; HEPATITIS, TOXIC	LIVER	Objective: To evaluate the incidence, severity, and course of propylthiouracil-induced hepatic injury in patients with hyperthyroidism. Design: Cohort study. Setting: Outpatient clinic of a university-based hospital. Patients: Fifty-four patients with normal aspartate aminotransferase (AST) and alanine aminotransferase (ALT) values and a definite diagnosis of hyperthyroidism. Intervention: Treatment,with propylthiouracil, 300 mg/d for 2 months followed by 100 to 150 mg/d for 3 months and a subsequent maintenance dose of 100 mg/d. Measurements: Liver biochemical tests were studied before therapy and 2 months and 5 months after starting propylthiouracil therapy. The patients were monitored with clinical evaluation and weekly liver biochemical tests after AST or ALT levels became abnormal. Serologic markers of hepatitis A, B, C, and delta virus infection were also studied when appropriate. Results: Fifteen (28%; 95% CI, 16% to 42%) of the 54 patients showed ALT elevations 2 months after propylthiouracil therapy. The mean peak ALT level for these patients was 1.35 mukat/L (range, 0.65 3.85 mukat/L). None of these patients had symptoms or hyperbilirubinemia. Liver biopsy in three patients showed mild perivenular focal necrosis or ill-defined granuloma composed of foamy histiocytes with ceroid pigment and mild fatty metamorphosis. Despite continued propylthiouracil therapy at a reduced dose, ALT levels returned to normal in 13 of 15 patients in the following 3 months. None of these ALT elevations resulted from hepatitis A, B, C, or delta virus infection. No statistical difference was seen in the pretreatment characteristics between patients with and those without ALT elevation, except that the former had a higher pretreatment T4 level (270 +/- 12.9 compared with 237 +/- 7.72 nmol/L, P = 0.027) and T3 level (7.22 +/- 0.72 compared with 5.85 +/- 0.39 nmol/L, P = 0.048). Conclusions: Propylthiouracil-induced subclinical liver injury is common and is usually transient and asymptomatic. Therapy with propylthiouracil may be continued with caution in the absence of symptoms and hyperbilirubinemia.	CHANG GUNG MED COLL, TAIPEI, TAIWAN	Chang Gung University	LIAW, YF (corresponding author), CHANG GUNG MEM HOSP, 199 TUNG HWA N RD, TAIPEI 105, TAIWAN.		Liaw, Yun-Fan/B-4305-2009					BENICHOU C, 1990, J HEPATOL, V11, P272; COOPER DS, 1979, ANN INTERN MED, V90, P164, DOI 10.7326/0003-4819-90-2-164; EISEN MJ, 1953, NEW ENGL J MED, V249, P814, DOI 10.1056/NEJM195311122492007; FEDOTIN MS, 1975, ARCH INTERN MED, V135, P319, DOI 10.1001/archinte.135.2.319; GARTY BZ, 1985, DRUG INTEL CLIN PHAR, V19, P740, DOI 10.1177/106002808501901009; GEUBEL AP, 1987, PHARMACOL THERAPEUT, V33, P193, DOI 10.1016/0163-7258(87)90050-7; HANSON JS, 1984, ARCH INTERN MED, V144, P994, DOI 10.1001/archinte.144.5.994; HAYASHIDA CY, 1990, J ENDOCRINOL INVEST, V13, P937, DOI 10.1007/BF03349663; HUNTER AL, 1975, BIOCHEM PHARMACOL, V24, P2199, DOI 10.1016/0006-2952(75)90052-0; JONAS MM, 1988, J PEDIATR GASTR NUTR, V7, P776, DOI 10.1097/00005176-198809000-00027; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LIMAYE A, 1987, AM J GASTROENTEROL, V82, P152; MADDREY WC, 1977, GASTROENTEROLOGY, V72, P1348; MIHAS AA, 1976, GASTROENTEROLOGY, V70, P770; PARKER LN, 1975, ANN INTERN MED, V82, P228, DOI 10.7326/0003-4819-82-2-228_2; PARKER W A, 1982, Clinical Pharmacy, V1, P471; PETER SA, 1991, J NATL MED ASSOC, V83, P75; SAFANI MM, 1982, ARCH INTERN MED, V142, P838, DOI 10.1001/archinte.1982.00340170198033; SALATA R, 1985, SEMIN LIVER DIS, V5, P29, DOI 10.1055/s-2008-1041755; VITUG AC, 1985, HORM RES, V21, P229, DOI 10.1159/000180054; WEISS M, 1980, ARCH INTERN MED, V140, P1184, DOI 10.1001/archinte.140.9.1184; ZIMMERMAN HJ, 1978, HEPATOTOXICITY, P487; ZIMMERMAN HJ, 1978, HEPATOTOXICITY ADVER, P459	23	93	96	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					424	428		10.7326/0003-4819-118-6-199303150-00005	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439116				2022-12-28	WOS:A1993KR81700005
J	KERNAN, NA; BARTSCH, G; ASH, RC; BEATTY, PG; CHAMPLIN, R; FILIPOVICH, A; GAJEWSKI, J; HANSEN, JA; HENSLEEDOWNEY, J; MCCULLOUGH, J; MCGLAVE, P; PERKINS, HA; PHILLIPS, GL; SANDERS, J; STRONCEK, D; THOMAS, ED; BLUME, KG				KERNAN, NA; BARTSCH, G; ASH, RC; BEATTY, PG; CHAMPLIN, R; FILIPOVICH, A; GAJEWSKI, J; HANSEN, JA; HENSLEEDOWNEY, J; MCCULLOUGH, J; MCGLAVE, P; PERKINS, HA; PHILLIPS, GL; SANDERS, J; STRONCEK, D; THOMAS, ED; BLUME, KG			ANALYSIS OF 462 TRANSPLANTATIONS FROM UNRELATED DONORS FACILITATED BY THE NATIONAL-MARROW-DONOR-PROGRAM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background and Methods. Allogeneic bone marrow transplantation is curative in a substantial number of patients with hematologic cancers, marrow-failure disorders, immunodeficiency syndromes, and certain metabolic diseases. Unfortunately, only 25 to 30 percent of potential recipients have HLA-identical siblings who can act as donors. In 1986 the National Marrow Donor Program was created in the United States to facilitate the finding and procurement of suitable marrow from unrelated donors for patients lacking related donors. Results. During the first four years of the program, 462 patients with acquired and congenital lymphohematopoietic disorders or metabolic diseases received marrow transplants from unrelated donors. The probability of engraftment by 100 days after transplantation was 94 percent, although 8 percent of patients later had secondary graft failure. The probability of grade II, III, or IV acute graft-versus-host disease was 64 percent, and the probability of chronic graft-versus-host disease at one year was 55 percent. The rate of disease-free survival at two years among patients with leukemia and good prognostic factors was 40 percent and among patients at higher risk, 19 percent. Twenty-nine percent of the patients with aplastic anemia were alive at two years, and the rate of two-year disease-free survival among patients with myelodysplasia was 18 percent. For patients with congenital immunologic or nonimmunologic disorders, the probability of survival was 52 percent. Conclusions. The National Marrow Donor Program has benefited a substantial number of patients in need of marrow transplants from closely HLA-matched unrelated donors and has facilitated the recruitment of unrelated donors into the donor pool and the access to suitable marrow.	FRED HUTCHINSON CANC CTR, SEATTLE, WA USA; IRWIN MEM BLOOD CTR, SAN FRANCISCO, CA USA; UNIV TEXAS, HOUSTON, TX 77025 USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; MED COLL WISCONSIN, MILWAUKEE, WI 53226 USA; UNIV UTAH, SCH MED, SALT LAKE CITY, UT 84112 USA; UNIV KENTUCKY, LEXINGTON, KY 40506 USA; VANCOUVER GEN HOSP, VANCOUVER V5Z 1M9, BC, CANADA; STANFORD UNIV, MED CTR, STANFORD, CA 94305 USA	Fred Hutchinson Cancer Center; University of Texas System; University of California System; University of California Los Angeles; University of Minnesota System; University of Minnesota Twin Cities; Medical College of Wisconsin; Utah System of Higher Education; University of Utah; University of Kentucky; University of British Columbia; Stanford University	KERNAN, NA (corresponding author), MEM SLOAN KETTERING CANC CTR, 1275 YORK AVE, NEW YORK, NY 10021 USA.							ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; ANGELINI G, 1986, P NATL ACAD SCI USA, V83, P4489, DOI 10.1073/pnas.83.12.4489; ANGELINI G, 1986, P NATL ACAD SCI USA, V83, P6664; APPELBAUM FR, 1990, ANN INTERN MED, V112, P590, DOI 10.7326/0003-4819-112-8-590; ASH RC, 1991, BONE MARROW TRANSPL, V7, P443; ASH RC, 1990, NEW ENGL J MED, V322, P485, DOI 10.1056/NEJM199002223220801; ATKINSON K, 1982, BLOOD, V60, P714; BACIGALUPO A, 1988, BONE MARROW TRANSPL, V3, P531; BAXTERLOWE LA, 1991, TRANSPLANT P, V23, P1699; BEATTY PG, 1985, NEW ENGL J MED, V313, P765, DOI 10.1056/NEJM198509263131301; BEATTY PG, 1988, TRANSPLANTATION, V45, P714, DOI 10.1097/00007890-198804000-00010; BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BORTIN MM, 1989, TRANSPLANTATION, V48, P453, DOI 10.1097/00007890-198909000-00021; BOZDECH MJ, 1985, EXP HEMATOL, V13, P1201; BRADLEY B, 1986, Bone Marrow Transplantation, V1, P146; BROCHSTEIN JA, 1987, NEW ENGL J MED, V317, P1618, DOI 10.1056/NEJM198712243172602; BUCKNER CD, 1991, SEMIN HEMATOL, V28, P32; BUNIN NJ, 1988, J CLIN ONCOL, V6, P1851, DOI 10.1200/JCO.1988.6.12.1851; CAHN JY, 1988, BRIT J HAEMATOL, V69, P345, DOI 10.1111/j.1365-2141.1988.tb02372.x; CAMITTA B, 1989, BLOOD, V74, P1852; CASPER JT, 1990, AM J PEDIAT HEMATOL, V12, P434; CHAMPLIN RE, 1989, BLOOD, V73, P606; CHOO SY, 1986, IMMUNOGENETICS, V23, P24, DOI 10.1007/BF00376518; CLAY TM, 1991, LANCET, V337, P1049, DOI 10.1016/0140-6736(91)91704-X; CLIFT RA, 1991, BLOOD, V77, P1660; COX DR, 1972, J R STAT SOC B, V34, P187; DEWITTE T, 1989, TRANSPLANT P, V21, P2958; DUQUESNOY RJ, 1983, TRANSPLANTATION, V35, P566, DOI 10.1097/00007890-198306000-00010; GAJEWSKI JL, 1990, TRANSPLANTATION, V50, P244, DOI 10.1097/00007890-199008000-00015; GINGRICH RD, 1988, BLOOD, V71, P1375; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GORDON BG, 1991, AM J PEDIAT HEMATOL, V13, P29; GORDONSMITH EC, 1982, BRIT MED J, V285, P835, DOI 10.1136/bmj.285.6345.835; GUINAN EC, 1989, BLOOD, V73, P619; HANSEN JA, 1980, NEW ENGL J MED, V303, P565, DOI 10.1056/NEJM198009043031007; HOPKINS KA, 1990, LAB MANUAL, P195; HOROWITZ SD, 1975, LANCET, V2, P431; HOWARD MR, 1990, TRANSPLANTATION, V49, P547, DOI 10.1097/00007890-199003000-00015; HOWS JM, 1986, BLOOD, V68, P1322; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERNAN NA, 1987, TRANSPLANTATION, V43, P842, DOI 10.1097/00007890-198743060-00014; LOHRMANN HP, 1975, BLUT, V31, P347, DOI 10.1007/BF01634000; LONGMORE G, 1990, J CLIN ONCOL, V8, P1707, DOI 10.1200/JCO.1990.8.10.1707; MACKINNON S, 1990, EXP HEMATOL, V18, P421; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCCULLOUGH J, 1986, TRANSFUSION, V26, P315, DOI 10.1046/j.1537-2995.1986.26486262737.x; MCCULLOUGH J, 1982, TRANSFUSION, V22, P78; MCCULLOUGH J, 1989, UCLA S MOL CELLULAR, V91, P641; MCELLIGOTT MC, 1986, TRANSFUSION, V26, P309, DOI 10.1046/j.1537-2995.1986.26486262736.x; MCGLAVE, 1990, BLOOD, V76, P654; MCGLAVE P, 1987, BLOOD, V70, P877; MCGLAVE P, 1990, SEMIN HEMATOL, V27, P23; MCGLAVE PB, 1990, BLOOD, V75, P1728; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NOREEN HJ, 1989, TRANSPLANT P, V21, P2968; OREILLY RJ, 1977, NEW ENGL J MED, V297, P1311, DOI 10.1056/NEJM197712152972403; OREILLY RJ, 1983, BLOOD, V62, P941; OREILLY RJ, 1985, TRANSPLANT P, V17, P455; OREILLY RJ, 1984, SEMIN HEMATOL, V21, P188; POWLES RL, 1983, LANCET, V1, P612; RAFFOUX C, 1988, BONE MARROW TRANSPL, V3, P163; SANDERS JE, 1986, PEDIATRICS, V77, P179; SANTOS GW, 1982, SEMIN HEMATOL, V19, P227; SHAPIRO RS, 1990, J CLIN ONCOL, V8, P371, DOI 10.1200/JCO.1990.8.3.371; SONDEL PM, 1986, EXP HEMATOL, V14, P278; SPECK B, 1973, TRANSPLANTATION, V16, P24, DOI 10.1097/00007890-197307000-00005; STORB R, 1984, SEMIN HEMATOL, V21, P27; SULLIVAN, 1989, BLOOD, V74, P1180; SULLIVAN KM, 1989, BLOOD, V73, P1720; THOMAS ED, 1983, J CLIN ONCOL, V1, P517, DOI 10.1200/JCO.1983.1.9.517; TIERCY JM, 1991, P NATL ACAD SCI USA, V88, P7121, DOI 10.1073/pnas.88.16.7121; TRIGG ME, 1985, CANCER TREAT REP, V69, P377; VASILOV RG, 1983, IMMUNOGENETICS, V17, P333, DOI 10.1007/BF00372454; WEIDEN PL, 1981, NEW ENGL J MED, V304, P1529, DOI 10.1056/NEJM198106183042507; 1977, LANCET, V1, P210	76	719	733	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1993	328	9					593	602		10.1056/NEJM199303043280901	http://dx.doi.org/10.1056/NEJM199303043280901			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP680	8429851				2022-12-28	WOS:A1993KP68000001
J	SHINKAI, Y; KOYASU, S; NAKAYAMA, K; MURPHY, KM; LOH, DY; REINHERZ, EL; ALT, FW				SHINKAI, Y; KOYASU, S; NAKAYAMA, K; MURPHY, KM; LOH, DY; REINHERZ, EL; ALT, FW			RESTORATION OF T-CELL DEVELOPMENT IN RAG-2 DEFICIENT MICE BY FUNCTIONAL TCR TRANSGENES	SCIENCE			English	Article							ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODY; SCID MUTATION; V(D)J RECOMBINATION; EXPRESSION; REPAIR; CHAIN; DIFFERENTIATION; THYMOCYTES; BIOLOGY	Introduction of TCRalpha transgene, TCRbeta transgene, or both into RAG-2-/- mice differentially rescues T cell development. RAG-2-/- mice have small numbers of TCR-CD4-CD8- (double negative, DN) thymocytes that express CD3gammadeltaepsilon and zeta proteins intracellularly. Introduction of a TCRbeta transgene, but not a TCRalpha transgene, into the RAG-2-/- background restored normal numbers of thymocytes. These cells were CD4+CD8+ (double positive, DP) and expressed small amounts of surface TCRbeta chain dimers in association with CD3gammadeltaepsilon but not zeta. RAG-2-/- mice that expressed alpha and beta TCR transgenes developed both DP and single positive thymocytes. Thus, the TCRbeta subunit, possibly in association with a novel CD3 complex, participates in the DN to the DP transition.	CHILDRENS HOSP MED CTR, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DEPT GENET, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, IMMUNOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Koyasu, Shigeo/J-5583-2015; Shinkai, Yoichi/N-3909-2014	Koyasu, Shigeo/0000-0001-9585-3038; Shinkai, Yoichi/0000-0002-6051-2484	NIAID NIH HHS [AI19807, AI20047] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI019807, R37AI020047, R37AI019807, R01AI020047, R01AI019807] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, J BIOL CHEM, V264, P10327; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CLAYTON LK, 1990, J EXP MED, V172, P1243, DOI 10.1084/jem.172.4.1243; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HUSSEY RE, IN PRESS J IMMUNOL; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KOSUGI A, 1992, P NATL ACAD SCI USA, V89, P9494, DOI 10.1073/pnas.89.20.9494; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOH DY, 1991, NEW BIOL, V3, P924; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	33	369	371	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					822	825		10.1126/science.8430336	http://dx.doi.org/10.1126/science.8430336			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8430336				2022-12-28	WOS:A1993KL11000036
J	LARSON, SB; KOSZELAK, S; DAY, J; GREENWOOD, A; DODDS, JA; MCPHERSON, A				LARSON, SB; KOSZELAK, S; DAY, J; GREENWOOD, A; DODDS, JA; MCPHERSON, A			DOUBLE-HELICAL RNA IN SATELLITE TOBACCO MOSAIC-VIRUS	NATURE			English	Article							PHENYLALANINE TRANSFER-RNA; HUMAN RHINOVIRUS-14; ICOSAHEDRAL VIRUS; NECROSIS VIRUS; RESOLUTION; REFINEMENT; SEQUENCE; CRYSTALS; STRATEGY; PROGRAMS	SATELLITE tobacco mosaic virus (STMV) is the spherical satellite to an obligatory rod-shaped helper tobacco mosaic virus (TMV), which is required for replication1,2. STMV has 60 protein subunits of M(r) 17,500 on a T = 1 icosahedral capsid3 containing a single-stranded RNA genome of 1,059 bases4-6. STMV appears similar to another virus, STNV7,8, but is approximately 20 per cent smaller. It shows no amino-acid homology or immunological cross-reactivity with either STNV or its host TMV4,9. Here we report the X-ray crystal structure of STMV, which shows that the coat protein of STMV contains a 'Swiss roll' beta-barrel. An amino-terminal strand extends more than 60angstrom and is primarily responsible for quaternary interactions. Each capsid dimer is associated with a segment of genomic RNA double helix comprising seven base pairs. The dyad of each protein dimer is coincident with that of the central base pair of the associated RNA segment whose helix axis is directed along an icosahedral edge. Protein-nucleic acid interactions are extensive. The RNA helices, which have additional stacked bases at their 3' termini, differ significantly from canonical nucleic acid helical forms.	UNIV CALIF RIVERSIDE, DEPT PLANT PATHOL, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside	LARSON, SB (corresponding author), UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA.							ABADZAPATERO C, 1981, ACTA CRYSTALLOGR B, V37, P2002, DOI 10.1107/S0567740881007863; ARNOLD E, 1987, ACTA CRYSTALLOGR A, V43, P346, DOI 10.1107/S0108767387099306; ARNOLD E, 1988, ACTA CRYSTALLOGR A, V44, P270, DOI 10.1107/S0108767387011875; BENEVIDES JM, 1991, BIOCHEMISTRY-US, V30, P4855, DOI 10.1021/bi00234a004; BENTLEY GA, 1987, J MOL BIOL, V194, P129, DOI 10.1016/0022-2836(87)90722-4; BRANDEN C, 1991, INTRO PROTEIN STRUCT, pCH11; BRANDEN CI, 1991, INTRO PROTEIN STRUCT, P70; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, VA 30, P395, DOI 10.1107/S0567739474010722; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; DAY J, 1992, PROTEIN SCI, V1, P1254, DOI 10.1002/pro.5560011004; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKERSON RE, 1985, BIOL MACROMOLECULES, V2; DODDS JA, 1991, CAN J PLANT PATHOL, V13, P192, DOI 10.1080/07060669109500954; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; JONES TA, 1984, J MOL BIOL, V177, P735, DOI 10.1016/0022-2836(84)90047-0; JONES TA, 1982, COMPUTATIONAL CRYSTA, P307; KIM KS, 1989, J ULTRA MOL STRUCT R, V102, P196, DOI 10.1016/0889-1605(89)90014-1; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KOSZELAK S, 1989, J MOL BIOL, V209, P323, DOI 10.1016/0022-2836(89)90281-7; LILJAS L, 1982, J MOL BIOL, V159, P93, DOI 10.1016/0022-2836(82)90033-X; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; MIRKOV TE, 1989, VIROLOGY, V170, P139, DOI 10.1016/0042-6822(89)90361-9; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; TERWILLIGER T, 1964, ACTA CRYSTALLOGR A, V39, P813; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; VALVERDE RA, 1986, J GEN VIROL, V67, P1875, DOI 10.1099/0022-1317-67-9-1875; VALVERDE RA, 1987, J GEN VIROL, V68, P965, DOI 10.1099/0022-1317-68-4-965; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	38	97	97	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 14	1993	361	6408					179	182		10.1038/361179a0	http://dx.doi.org/10.1038/361179a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421525				2022-12-28	WOS:A1993KG46600068
J	QIAN, HH; DOWLING, JE				QIAN, HH; DOWLING, JE			NOVEL GABA RESPONSES FROM ROD-DRIVEN RETINAL HORIZONTAL CELLS	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; RECEPTOR SUBTYPES; MOLECULAR-BIOLOGY; XENOPUS-OOCYTES; RAT-BRAIN; PHARMACOLOGY; NEURONS; EXPRESSION; INVITRO; CAT	Gamma-AMINOBUTYRIC acid (GABA) is the main inhibitory neurotransmitter in the central nervous system. Two classes of GABA receptors (GABA(A) and GABA(B)) have been identified. GABA(A) receptors are ligand-gated chloride channels that are competitively antagonized by bicuculline, noncompetitively blocked by picrotoxin, and often allosterically modulated by barbiturates and benzodiazepines1-3. GABA(B) receptors regulate potassium and calcium channels through G-protein and intracellular second-messenger pathways2,3, are selectively activated by baclofen, and are antagonized by phaclofen and 2-hydroxysaclofen4,5. For some years, evidence has accumulated that there are GABA receptors, especially prominent along visual pathways, which are neither antagonized by bicuculline nor activated by baclofen, but are activated by certain conformationally restricted analogues of GABA, including cis-4-aminocrotonic acid (CACA)6-9. These receptors have been designated GABA(C) receptors9. As yet, membrane current responses from isolated neurons that reflect this novel pharmacology have not been reported, although such responses have been recorded from oocytes injected with retinal messenger RNA10-13. Here we describe a chloride-mediated current response from isolated rod-driven horizontal cells (H4) of the white perch retina that has this novel pharmacology.			QIAN, HH (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,16 DIV AVE,CAMBRIDGE,MA 02138, USA.							AKAIKE N, 1985, J PHYSIOL-LONDON, V360, P367, DOI 10.1113/jphysiol.1985.sp015622; ARAKAWA T, 1988, EUR J PHARMACOL, V158, P217, DOI 10.1016/0014-2999(88)90070-2; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CURTIS DR, 1980, BRAIN RES, V194, P255, DOI 10.1016/0006-8993(80)91339-6; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; Dowling J. E., 1987, RETINA APPROACHABLE; DOWLING JE, 1985, BRAIN RES, V360, P331, DOI 10.1016/0006-8993(85)91250-8; DREW CA, 1984, NEUROSCI LETT, V52, P317, DOI 10.1016/0304-3940(84)90181-2; GALLAGHER JP, 1978, J PHYSIOL-LONDON, V275, P263, DOI 10.1113/jphysiol.1978.sp012189; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; HOUAMED KM, 1984, NATURE, V310, P318, DOI 10.1038/310318a0; ITABASHI S, 1992, J NEUROPHYSIOL, V67, P1367, DOI 10.1152/jn.1992.67.5.1367; JOHNSTON GA, 1975, J NEUROCHEM, V24, P157, DOI 10.1111/j.1471-4159.1975.tb07642.x; Johnston GA, 1986, RECEPTOR BIOCH METHO, V5, P57; KERR DIB, 1988, NEUROSCI LETT, V92, P92, DOI 10.1016/0304-3940(88)90748-3; MATHISON RD, 1980, BRAIN RES, V187, P476, DOI 10.1016/0006-8993(80)90219-X; NAKAGAWA T, 1991, AM J PHYSIOL, V260, pC745, DOI 10.1152/ajpcell.1991.260.4.C745; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OLSEN RW, 1982, ANNU REV PHARMACOL, V22, P245, DOI 10.1146/annurev.pa.22.040182.001333; POLENZANI L, 1991, P NATL ACAD SCI USA, V88, P4318, DOI 10.1073/pnas.88.10.4318; SEEBURG PH, 1990, COLD SH Q B, V55, P29; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SIVILOTTI L, 1989, EUR J PHARMACOL, V164, P205, DOI 10.1016/0014-2999(89)90460-3; SIVILOTTI L, 1991, PROG NEUROBIOL, V36, P35, DOI 10.1016/0301-0082(91)90036-Z; WOODWARD RM, 1992, MOL PHARMACOL, V42, P165	27	255	261	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					162	164		10.1038/361162a0	http://dx.doi.org/10.1038/361162a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421521				2022-12-28	WOS:A1993KG46600062
J	CHAPMAN, S; WOODWARD, S				CHAPMAN, S; WOODWARD, S			AUSTRALIAN COURT DECISION ON PASSIVE SMOKING UPHELD ON APPEAL	BRITISH MEDICAL JOURNAL			English	Article							INDUSTRY		ACT SMOKING & HLTH LTD,WOOLLOOMOOLOO 2011,AUSTRALIA		CHAPMAN, S (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,WESTMEAD 2145,AUSTRALIA.							CHAPMAN S, 1987, COMMUNITY HEALTH ST, V11, P139; CHAPMAN S, 1991, BRIT MED J, V302, P943, DOI 10.1136/bmj.302.6782.943; CHAPMAN S, 1990, INT J HEALTH SERV, V20, P417, DOI 10.2190/YYKC-PGTC-VUMM-3A5P; DOYLE AE, 1988, MED J AUSTRALIA, V148, P152, DOI 10.5694/j.1326-5377.1988.tb112788.x; MACASKILL P, 1992, AM J PUBLIC HEALTH, V82, P96, DOI 10.2105/AJPH.82.1.96; WARNER KE, 1991, AM J PUBLIC HEALTH, V81, P839, DOI 10.2105/AJPH.81.7.839; 1990, TOBACCO AUSTR SUMMAR, P12	7	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					120	122		10.1136/bmj.306.6870.120	http://dx.doi.org/10.1136/bmj.306.6870.120			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KG465	8435609	Bronze, Green Published			2022-12-28	WOS:A1993KG46500027
J	CHENG, TL; SAVAGEAU, JA; SATTLER, AL; DEWITT, TG				CHENG, TL; SAVAGEAU, JA; SATTLER, AL; DEWITT, TG			CONFIDENTIALITY IN HEALTH-CARE - A SURVEY OF KNOWLEDGE, PERCEPTIONS, AND ATTITUDES AMONG HIGH-SCHOOL-STUDENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADOLESCENTS	Objective.-To assess adolescent knowledge, perceptions, and attitudes about health care confidentiality. Design.-Anonymous self-report survey with 64 items addressing confidentiality issues in health care. Setting.-Rural, suburban, and urban high schools in central Massachusetts. Participants.-Students in ninth through 12th grades from three schools. Results.-A total of 1295 students (87%) completed the survey: 58% had health concerns that they wished to keep private from their parents, and 69% from friends and classmates; 25% reported that they would forgo health care in some situations if their parents might find out. There were differences in response by gender, race, and school. About one third were aware of a right to confidentiality for specific health issues. Of those with a regular source of care, 86% would go to their regular physician for a physical illness, while only 57% would go there for questions about pregnancy, the acquired immunodeficiency syndrome, or substance abuse that they wished to keep private. Sixty-eight percent had concerns about the privacy of a school health center. Conclusions.-A majority of adolescents have concerns they wish to keep confidential and a striking percentage report they would not seek health services because of these concerns. Interventions to address confidentiality issues are thus crucial to effective adolescent health care.			CHENG, TL (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT PEDIAT,55 LAKE AVE N,WORCESTER,MA 01605, USA.							COOLEY CH, 1980, J ADOLESC HLTH CARE, V1, P140; ENGLISH A, 1990, MED CLIN N AM, V74, P1097, DOI 10.1016/S0025-7125(16)30504-1; Hofmann A D, 1980, J Adolesc Health Care, V1, P9, DOI 10.1016/S0197-0070(80)80003-9; HOLDER AR, 1987, JAMA-J AM MED ASSOC, V257, P3400, DOI 10.1001/jama.257.24.3400; Jellinek B, 1980, Pediatr Nurs, V6, P21; KLEIN JD, 1992, J ADOLESCENT HEALTH, V13, P162, DOI 10.1016/1054-139X(92)90084-O; LEIKIN SL, 1983, J PEDIATR-US, V102, P169, DOI 10.1016/S0022-3476(83)80514-9; LOVETT J, 1985, J PEDIATR-US, V106, P517, DOI 10.1016/S0022-3476(85)80696-X; MARKS A, 1983, J PEDIATR-US, V102, P456, DOI 10.1016/S0022-3476(83)80677-5; Resnick M, 1980, J Adolesc Health Care, V1, P137, DOI 10.1016/S0197-0070(80)80039-8; TORRES A, 1978, FAM PLANN PERSPECT, V10, P280, DOI 10.2307/2134380; TORRES A, 1980, FAM PLANN PERSPECT, V12, P284, DOI 10.2307/2134659; ZABIN LS, 1991, J ADOLESCENT HEALTH, V12, P225, DOI 10.1016/0197-0070(91)90015-E; 1991, POLICY REFERENCE GUI, P97; 1991, OTAH467 OFF TECHN AS	15	224	224	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1404	1407		10.1001/jama.269.11.1404	http://dx.doi.org/10.1001/jama.269.11.1404			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ857	8441216				2022-12-28	WOS:A1993KQ85700035
J	TONNESEN, P; NORREGAARD, J; MIKKELSEN, K; JORGENSEN, S; NILSSON, F				TONNESEN, P; NORREGAARD, J; MIKKELSEN, K; JORGENSEN, S; NILSSON, F			A DOUBLE-BLIND TRIAL OF A NICOTINE INHALER FOR SMOKING CESSATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHEWING GUM; PATCH; MG	Objective.-To evaluate the efficacy of a new nicotine inhaler system for smoking cessation. Design.-A 1 -year, randomized, double-blind, placebo-controlled study. Setting.-Medical outpatient clinic with physicians experienced in smoking cessation assistance. Subjects.-A total of 286 volunteers who smoked at least 10 cigarettes daily recruited through a local newspaper. Intervention.-Subjects were randomly allocated to nicotine inhalers (n=l45) or placebo (n=l41) to be used for 3 months followed by tapering for 3 months in the context of minimal levels of advice and support. Main Outcome Measure.-Continuous smoking abstinence at weeks 6,12, 24, and 52, verified by measurements of carbon monoxide in expired air. Results.-Continuous smoking abstinence was significantly higher for the active nicotine inhaler group compared with the placebo inhaler group. The respective success rates were 28% and 12% after 6 weeks, 21% and 9% after 12 weeks, 17% and 8% after 6 months, and 15% and 5% after 1 year (P=.02 to .001). The mean nicotine substitution based on cotinine determinations after 2 weeks was 43% (SD, 45%) of smoking levels. The treatment was well tolerated, and no serious adverse events were reported. Conclusions.-In this setting the nicotine inhaler appeared safe to use and increased success rates of smoking cessation attempts.	KABI PHARMACIA THERAPEUT,HELSINGBORG,SWEDEN; BISPEBJERG HOSP,DEPT PULM MED,DK-2400 COPENHAGEN,DENMARK	University of Copenhagen; Bispebjerg Hospital				Mikkelsen, Kim Lyngby/0000-0001-7325-7040				ABELIN T, 1989, LANCET, V1, P7; FAGERSTROM KO, 1989, J BEHAV MED, V12, P159, DOI 10.1007/BF00846549; FALKMAN SE, 1975, ANALYST, V100, P99, DOI 10.1039/an9750000099; GRUNBERG N E, 1989, Annals of Behavioral Medicine, V11, P154, DOI 10.1207/s15324796abm1104_5; JARVIS MJ, 1980, BRIT MED J, V281, P484, DOI 10.1136/bmj.281.6238.484; KORNITZER M, 1987, J PSYCHOSOM RES, V31, P171, DOI 10.1016/0022-3999(87)90073-0; LEISCHOW SJ, 1991, BRIT J ADDICT, V86, P577; MCNABB ME, 1984, CAN MED ASSOC J, V131, P589; MCNABB ME, 1982, JAMA-J AM MED ASSOC, V248, P865, DOI 10.1001/jama.248.7.865; NEMETHCOSLETT R, 1987, 95TH ANN CONV AM PSY; ROSE JE, 1988, NICOTINE REPLACEMENT, P95; RUSSELL MAH, 1987, JAMA-J AM MED ASSOC, V257, P3262, DOI 10.1001/jama.257.23.3262; SEPKOVIC DW, 1986, AM J PUBLIC HEALTH, V76, P1343, DOI 10.2105/AJPH.76.11.1343; SUTHERLAND G, 1992, LANCET, V340, P324, DOI 10.1016/0140-6736(92)91403-U; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; TONNESEN P, 1988, NEW ENGL J MED, V318, P15, DOI 10.1056/NEJM198801073180104; TONNESEN P, 1988, ADDICT BEHAV, V13, P17, DOI 10.1016/0306-4603(88)90021-4; TONNESEN P, 1988, NICOTINE REPLACEMENT, P129; 1991, JAMA-J AM MED ASSOC, V266, P3133; 1988, HLTH CONSEQUENCES SM	20	160	163	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1268	1271		10.1001/jama.269.10.1268	http://dx.doi.org/10.1001/jama.269.10.1268			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KP885	8437304				2022-12-28	WOS:A1993KP88500025
J	VALDEZ, RB; MORGENSTERN, H; BROWN, ER; WYN, R; WANG, C; CUMBERLAND, W				VALDEZ, RB; MORGENSTERN, H; BROWN, ER; WYN, R; WANG, C; CUMBERLAND, W			INSURING LATINOS AGAINST THE COSTS OF ILLNESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEXICAN-AMERICANS; HEALTH-INSURANCE; CARE UTILIZATION; REGRESSION	Objective.-To examine the determinants of health insurance coverage for Latinos in the United States and how different targeted strategies for health care reform differentially affect the country's major ethnic groups, focusing on the implications for the Latino population. Design.-Data from the 1980 and 1990 Current Population Surveys were used to compare the insurance status of nonelderly (<65 years) Latinos with the Anglo (non-Hispanic white), black, and Asian and other populations by estimating the attributable fraction for selected covariates. The effects of health care reform strategies on the coverage of the major ethnic groups were simulated from these data. Main Outcome Measures.-Percentage uninsured, percentage insured by Medicaid, and attributable fraction for covariates. Results.-Latinos have the worst health insurance coverage of any ethnic group in the country. Approximately 39% of Latinos are uninsured compared with 13.8% for the Anglo and 24% for the black population. Providing coverage to all the poor could reduce the uninsured rate for Anglos by about 23%, whereas the reduction among Latinos could be about 37% and among blacks about 42%. Similar reductions could be achieved by covering all workers and their minor dependents. Regardless of the approach to reform, however, Latinos would remain with high absolute rates of uninsured. Conclusions.-Differences in Medicaid eligibility, labor force characteristics, and family composition between Latinos and other ethnic groups suggest that policy initiatives may affect Latinos differently. Targeted strategies, such as employer mandates, ''pay-or-play'' programs, or Medicaid expansions, can improve coverage, but many Latinos could still remain uninsured.	UNIV CALIF LOS ANGELES, RAND CTR HLTH POLICY STUDIES, SANTA MONICA, CA USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT COMMUNITY HLTH SCI, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT BIOSTAT, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	VALDEZ, RB (corresponding author), UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT HLTH SERV, LOS ANGELES, CA 90024 USA.		Potter, Joseph E/A-3122-2008					Aday LA, 1980, HLTH CARE US EQUITAB; BROWN ER, 1991, CALIFORNIA POLICY SE; CARNOY M, 1990, LATINOS CHANGING US; ESTRADA AL, 1990, AM J PUBLIC HEALTH, V80, P27, DOI 10.2105/AJPH.80.Suppl.27; GABEL J, 1990, HEALTH AFFAIR, V9, P161, DOI 10.1377/hlthaff.9.3.161; GREENLAND S, 1991, EPIDEMIOLOGY, V2, P387, DOI 10.1097/00001648-199109000-00015; GUENDELMAN S, 1986, MED CARE, V24, P925, DOI 10.1097/00005650-198610000-00006; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KOOPERBERG C, 1991, EPIDEMIOLOGY, V2, P363, DOI 10.1097/00001648-199109000-00009; Marquis M S, 1983, Health Care Financ Rev, V5, P65; MCCARTHY KF, 1986, RAND R3365 PUBL; MOYER ME, 1989, HEALTH AFFAIR, V8, P102, DOI 10.1377/hlthaff.8.2.102; ROWLAND D, 1988, ANNU REV PUBL HEALTH, V9, P427; SHORT PF, 1988, HEALTH AFFAIR, V7, P186, DOI 10.1377/hlthaff.7.3.186; SOFAER S, 1990, HOSP HEALTH SERV ADM, V35, P189; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; VALDEZ RB, 1991, DOES HLTH CARE SYSTE; WALDEN DC, 1982, CONSUMERS KNOWLEDGE; 1990, ACCESS ALL MED HISPA; 1985, 03216 HLTH CAR FIN A	20	45	47	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					889	894		10.1001/jama.269.7.889	http://dx.doi.org/10.1001/jama.269.7.889			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL474	8426448				2022-12-28	WOS:A1993KL47400027
J	BONINI, NM; LEISERSON, WM; BENZER, S				BONINI, NM; LEISERSON, WM; BENZER, S			THE EYES ABSENT GENE - GENETIC-CONTROL OF CELL-SURVIVAL AND DIFFERENTIATION IN THE DEVELOPING DROSOPHILA EYE	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELLS; CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; VISUAL-SYSTEM; C-ELEGANS; MELANOGASTER; DEATH; APOPTOSIS; SEQUENCE	The eyes absent (eya) gene is required at an early stage in development of the D. melanogaster compound eye. In eya mutants, progenitor cells in the eye disc undergo programmed cell death anterior to the morphogenetic furrow, rather than proceeding into the pathway of retinal differentiation. A low level of cell death normally occurs at this stage, suggesting that eya activity influences the distribution of cells between differentiation and death. Molecular analysis identifies a nuclear protein expressed in progenitor cells prior to differentiation. Transformation with the cDNA prevents progenitor cell death and allows the events that generate the eye to proceed. eya activity is required for the survival of eye progenitor cells at a critical stage in morphogenesis.			BONINI, NM (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.		Leiserson, William/A-5721-2013	Leiserson, William/0000-0001-5477-0674; Bonini, Nancy/0000-0003-0226-5291	NATIONAL EYE INSTITUTE [R01EY009278] Funding Source: NIH RePORTER; NEI NIH HHS [EY09278] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; APPLE DJ, 1991, OCULAR PATHOLOGY CLI; ASKEW DS, 1991, ONCOGENE, V6, P1915; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BODENSTEIN D, 1953, INSECT PHYSL, P822; BOLWIG N, 1946, VIDENSK MEDD FRA DAN, V109, P80; BOWTELL DDL, 1989, CELL, V56, P931, DOI 10.1016/0092-8674(89)90626-0; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; BROWN NL, 1991, DEVELOPMENT, V113, P1245; Bryant PJ., 1978, GENET BIOL DROSOPHIL, P229; CARR VM, 1981, DEV BRAIN RES, V2, P157, DOI 10.1016/0165-3806(81)90066-3; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOE CQ, 1985, DEV BIOL, V111, P193, DOI 10.1016/0012-1606(85)90445-2; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EISENBERG JC, 1991, DROS INF SERV, V70, P266; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FESUS L, 1991, IMMUNOL LETT, V30, P277, DOI 10.1016/0165-2478(91)90038-C; FISCHBACH KF, 1983, DEV BIOL, V95, P1, DOI 10.1016/0012-1606(83)90002-7; FRISTROM D, 1969, MOL GEN GENET, V103, P363, DOI 10.1007/BF00383486; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; GATEFF EA, 1975, ROUX ARCH DEV BIOL, V176, P171, DOI 10.1007/BF00576800; GELBART WM, 1982, P NATL ACAD SCI-BIOL, V79, P2636, DOI 10.1073/pnas.79.8.2636; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GOLDSTEIN P, 1991, IMMUNOL REV, V121, P29; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HAMBURGER V, 1949, J EXP ZOOL, V111, P457, DOI 10.1002/jez.1401110308; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; HARTE PJ, 1982, GENETICS, V101, P477; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; ITOH N, 1986, P NATL ACAD SCI USA, V83, P4081, DOI 10.1073/pnas.83.11.4081; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KARLIN S, 1990, ONCOGENE, V5, P85; Kerr J.F.R., 1987, P93; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MEYEROWITZ EM, 1978, DEV BIOL, V62, P112, DOI 10.1016/0012-1606(78)90096-9; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PANNESE E, 1976, NEUROPATH APPL NEURO, V2, P247, DOI 10.1111/j.1365-2990.1976.tb00501.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Power ME, 1943, J EXP ZOOL, V94, P33, DOI 10.1002/jez.1400940103; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; RENFRANZ PJ, 1989, DEV BIOL, V136, P411, DOI 10.1016/0012-1606(89)90267-4; ROBERTSON HM, 1988, GENETICS, V118, P461; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; Sambrook J, 1989, MOL CLONING LABORATO; SAMPEDRO J, 1991, NATURE, V353, P187, DOI 10.1038/353187a0; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPREIJ T E, 1971, Netherlands Journal of Zoology, V21, P221; STELLER H, 1985, EMBO J, V4, P3765, DOI 10.1002/j.1460-2075.1985.tb04146.x; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Sved J, 1986, DROSOPH INF SERV, V63, P169; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TRENT C, 1983, GENETICS, V104, P619; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; VANDERMEERDEJONG R, 1990, GENOMICS, V7, P270, DOI 10.1016/0888-7543(90)90550-E; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WADDINGTON CH, 1960, PROC R SOC SER B-BIO, V153, P155, DOI 10.1098/rspb.1960.0094; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WHITE RH, 1961, J EXP ZOOL, V148, P223, DOI 10.1002/jez.1401480305; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WOLFF T, 1991, DEVELOPMENT, V113, P825; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	106	442	453	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					379	395		10.1016/0092-8674(93)90115-7	http://dx.doi.org/10.1016/0092-8674(93)90115-7			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431945				2022-12-28	WOS:A1993KM16200008
J	HARADA, H; KITAGAWA, M; TANAKA, N; YAMAMOTO, H; HARADA, K; ISHIHARA, M; TANIGUCHI, T				HARADA, H; KITAGAWA, M; TANAKA, N; YAMAMOTO, H; HARADA, K; ISHIHARA, M; TANIGUCHI, T			ANTI-ONCOGENIC AND ONCOGENIC POTENTIALS OF INTERFERON REGULATORY FACTOR-I AND FACTOR-II	SCIENCE			English	Article							BETA-GENE; FACTOR-I; TRANSCRIPTIONAL ACTIVATOR; INDUCIBLE ENHANCER; GROWTH-INHIBITION; NUDE-MICE; IRF-1; EXPRESSION; IFN; INDUCTION	Interferon regulatory factor-1 (IRF-1), a transcriptional activator, and IRF-2, its antagonistic repressor, have been identified as regulators of type I interferon and interferon-inducible genes. The IRF-1 gene is itself interferon-inducible and hence may be one of the target genes critical for interferon action. When the IRF-2 gene was overexpressed in NIH 3T3 cells, the cells became transformed and displayed enhanced tumorigenicity in nude mice. This transformed phenotype was reversed by concomitant overexpression of the IRF-1 gene. Thus, restrained cell growth depends on a balance between these two mutually antagonistic transcription factors.			HARADA, H (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,YAMADAOKA 1-3,SUITA,OSAKA 565,JAPAN.		Kitagawa, Motoo/W-8468-2019; Harada, Hisashi/H-2815-2019	Kitagawa, Motoo/0000-0003-1036-840X; Harada, Hisashi/0000-0001-5993-1289; Tanaka, Nobuyuki/0000-0002-6373-2220				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Demaeyer E., 1988, INTERFERONS OTHER RE; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DYSON N, 1989, MOL DIAGNOSTICS HUMA, P235; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GRESSER I, 1989, ACTA ONCOL, V28, P347, DOI 10.3109/02841868909111205; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, UNPUB; HARADA K, UNPUB; HARLOW E, 1988, ANTIBODIES; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORI T, UNPUB; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; ITOH S, UNPUB; ITOH S, 1990, THESIS OSAKA U; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KIMURA T, UNPUB; Kirchhoff S., 1992, Journal of Interferon Research, V12, pS102; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEURS EF, IN PRESS P NATL ACAD; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MIYASHITA K, 1975, CELL, V5, P131, DOI 10.1016/0092-8674(75)90021-5; NAF D, 1991, P NATL ACAD SCI USA, V88, P1369, DOI 10.1073/pnas.88.4.1369; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; Shin S, 1979, Methods Enzymol, V58, P370; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; Tanaka N., UNPUB; TANIGUCHI T, 1991, ORIGINS OF HUMAN CANCER, P501; VANHEYNINGEN V, 1992, TRENDS GENET, V8, P16, DOI 10.1016/0168-9525(92)90019-Z; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VILCEK J, 1990, HDB EXPT PHARM, P3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; Watanabe N., UNPUB; WELLS V, 1985, EXP CELL RES, V159, P27, DOI 10.1016/S0014-4827(85)80034-3; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532; YONEMA M, UNPUB; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	56	439	452	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					971	974		10.1126/science.8438157	http://dx.doi.org/10.1126/science.8438157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438157				2022-12-28	WOS:A1993KL80000043
J	MILES, SA; BALDEN, E; MAGPANTAY, L; WEI, L; LEIBLEIN, A; HOFHEINZ, D; TOEDTER, G; STIEHM, ER; BRYSON, Y				MILES, SA; BALDEN, E; MAGPANTAY, L; WEI, L; LEIBLEIN, A; HOFHEINZ, D; TOEDTER, G; STIEHM, ER; BRYSON, Y			RAPID SEROLOGIC TESTING WITH IMMUNE-COMPLEX DISSOCIATED HIV P24 ANTIGEN FOR EARLY DETECTION OF HIV-INFECTION IN NEONATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; CHILDREN; DIAGNOSIS; INFANTS; ZIDOVUDINE; MOTHERS; ASSAY; THERAPY; TYPE-1	Background. Serologic detection of human immunodeficiency virus (HIV) infection in neonates is complicated by the presence of immune complexes, consisting of passively transferred maternal antibodies and HIV antigens. A new, rapid assay has been designed to disrupt these immune complexes in order to permit the detection of a specific HIV antigen. We evaluated the efficacy of this assay in detecting HIV infection in neonates. Methods. We measured p24 antigen in blood samples from both infected and uninfected children of HIV-infected mothers. The samples were treated with glycine hydrochloride to dissociate the immune complexes, followed by neutralization with TRIS-hydrochloric acid. A commercial HIV p24 antigen assay was then used, with an optical density greater than 0.120 at a wavelength of 450 nm defined as indicating a positive result. Results. Of eight cord-blood samples from neonates with proved HIV infection, five were positive for immune-complex-dissociated p24 antigen. For two other neonates the first postnatal sample, obtained on days 12 and 18, was positive. There was no follow-up sample for the eighth neonate. Of 22 uninfected neonates, 20 were negative on the cord-blood assay. Two neonates had positive cord-blood samples, but the first postnatal sample was negative. Thus, the tests with early postnatal samples identified the HIV-infection status correctly for all 29 children who could be evaluated. In a separate group of 78 children (median age, 188 weeks), the specificity of the test was 100 percent and the sensitivity 81 percent. Conclusions. The immune-complex-dissociated HIV p24 antigen assay is a rapid, simple serologic test that may be of value in diagnosing HIV infection in neonates born to HIV-infected women.	UNIV CALIF LOS ANGELES, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; COULTER CORP, HIALEAH, FL USA	University of California System; University of California Los Angeles	MILES, SA (corresponding author), UNIV CALIF LOS ANGELES, CTR CARE, RM BH-412C, CHS, LOS ANGELES, CA 90024 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697, U01AI027660] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28697, AI27660] Funding Source: Medline; NICHD NIH HHS [HD26621] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALIMENTI A, 1991, J PEDIATR-US, V119, P225, DOI 10.1016/S0022-3476(05)80731-0; ARPADI S, 1990, PEDIATR ANN, V19, P409, DOI 10.3928/0090-4481-19900701-05; ARPADI S, 1990, PEDIATR ANN, V19, P412; ARPADI S, 1990, PEDIATR ANN, V19, P417; BRANDT CD, 1992, J CLIN MICROBIOL, V30, P36, DOI 10.1128/JCM.30.1.36-40.1992; BROUWERS P, 1990, J PEDIATR-US, V117, P980, DOI 10.1016/S0022-3476(05)80150-7; BRYSON Y, 1991, 7TH INT C AIDS FL S2, V7, P185; CASSOL SA, 1992, J ACQ IMMUN DEF SYND, V5, P113; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; EDWARDS JR, 1989, J PEDIATR-US, V115, P200, DOI 10.1016/S0022-3476(89)80065-4; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; KAGEYAMA S, 1988, J VIROL METHODS, V22, P125; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; MILES SA, 1991, BLOOD, V77, P2109; NISHANIAN P, 1990, J INFECT DIS, V162, P21, DOI 10.1093/infdis/162.1.21; PALOMBA E, 1992, J INFECT DIS, V165, P394, DOI 10.1093/infdis/165.2.394; PIZZO PA, 1990, J PEDIATR-US, V117, P799, DOI 10.1016/S0022-3476(05)83348-7; QUINN TC, 1991, JAMA-J AM MED ASSOC, V266, P3439, DOI 10.1001/jama.266.24.3439; RAKUSAN TA, 1991, J ACQ IMMUN DEF SYND, V4, P116; RUDIN C, 1991, EUR J CLIN MICROBIOL, V10, P146, DOI 10.1007/BF01964447; SCARLATTI G, 1991, AIDS, V5, P1173, DOI 10.1097/00002030-199110000-00003; WEINTRUB PS, 1991, AIDS, V5, P881, DOI 10.1097/00002030-199107000-00014; WILLIAMS P, 1990, AIDS, V4, P393, DOI 10.1097/00002030-199005000-00003	25	132	135	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					297	302		10.1056/NEJM199302043280501	http://dx.doi.org/10.1056/NEJM199302043280501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK247	8419814	Bronze			2022-12-28	WOS:A1993KK24700001
J	YAWN, BP; JACOTT, WE				YAWN, BP; JACOTT, WE			MINNESOTACARE (HEALTHRIGHT) - MYTHS AND MIRACLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									OLMSTED MED FDN, DEPT CLIN RES, ROCHESTER, MN USA; OLMSTED MED FDN, DEPT INTERNAL MED, ROCHESTER, MN USA; UNIV MINNESOTA, DEPT FAMILY MED, MINNEAPOLIS, MN 55455 USA	Olmsted Medical Center; Olmsted Medical Center; University of Minnesota System; University of Minnesota Twin Cities								BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2509, DOI 10.1001/jama.267.18.2509; CHUN R, 1992, MNCARE HLTH RIGHT IN; LUNDBERG GD, 1992, JAMA-J AM MED ASSOC, V267, P2521; PRIESTER R, 1992, MINN MED, V75, P17; 1992, HLTH RIGHT ENROLLMEN	5	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	1993	269	4					511	515		10.1001/jama.269.4.511	http://dx.doi.org/10.1001/jama.269.4.511			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH385	8419672				2022-12-28	WOS:A1993KH38500037
J	FISHER, AJ; JOHNSON, JE				FISHER, AJ; JOHNSON, JE			ORDERED DUPLEX RNA CONTROLS CAPSID ARCHITECTURE IN AN ICOSAHEDRAL ANIMAL VIRUS	NATURE			English	Article							BUSHY STUNT VIRUS; 3.0-A RESOLUTION	SMALL spherical viruses are among the simplest replicating systems in biology, yet the factors affecting their assembly, stability and disassembly are still poorly understood. A molecular switch is required for the assembly of icosahedral virus particles containing more than 60 identical subunits because strict symmetry cannot be maintained in subunit packing1. All previously reported viruses with this type of structure use a portion of the capsid protein to regulate interactions between chemically equivalent but structurally distinct interfaces2-4. We have investigated the T = 3 quasi-equivalent5 nodaviruses, which are small non-enveloped viruses with a single-stranded RNA genome that infect insects6, mice7 and fish8. They undergo a well-characterized series of steps in assembly and maturation9,10, which in some respects are similar to the picornaviruses11, despite their different capsid architecture. Here we report the X-ray structure of Flock House virus at 3.0 angstrom resolution, which reveals an ordered RNA duplex of 20 nucleotides and a protein segment that control the subunit interactions in this animal virus. The RNA interacts with a helical protein domain of the subunit that lies inside the capsid shell. One of the helices that binds the RNA is part of a 44-amino-acid polypeptide which is autocatalytically cleaved from the initial subunit translation product after virion assembly. The structure indicates that RNA associated with the cleaved polypeptide may be important in the infection process.	UNIV WISCONSIN,DEPT BIOL SCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Fisher, Andrew/0000-0003-3488-6594				ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; ARNOLD E, 1987, ACTA CRYSTALLOGR A, V43, P346, DOI 10.1107/S0108767387099306; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; CASPAR DLD, 1980, BIOPHYS J, V32, P103, DOI 10.1016/S0006-3495(80)84929-0; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; FERNANDEZTOMAS CB, 1973, J VIROL, V12, P1122, DOI 10.1128/JVI.12.5.1122-1130.1973; FISHER AJ, 1992, ACTA CRYSTALLOGR B, V48, P515, DOI 10.1107/S0108768192000053; GALLAGHER TM, 1988, J VIROL, V62, P3399, DOI 10.1128/JVI.62.9.3399-3406.1988; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HENDRY DA, 1991, VIRUSES INVERTEBRATE, P227; HOGLE J, 1983, J MOL BIOL, V171, P95, DOI 10.1016/S0022-2836(83)80315-5; HOGLE JM, 1986, J MOL BIOL, V191, P625, DOI 10.1016/0022-2836(86)90450-X; HOSUR MV, 1987, PROTEINS, V2, P167, DOI 10.1002/prot.340020302; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAESBERG P, 1990, J MOL BIOL, V214, P423, DOI 10.1016/0022-2836(90)90191-N; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI TS, 1990, BIOCHEMISTRY-US, V29, P5018, DOI 10.1021/bi00473a004; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; MORI KI, 1992, VIROLOGY, V187, P368, DOI 10.1016/0042-6822(92)90329-N; NEWMAN JFE, 1973, J GEN VIROL, V21, P371, DOI 10.1099/0022-1317-21-2-371; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; SILVA AM, 1987, J MOL BIOL, V197, P69, DOI 10.1016/0022-2836(87)90610-3; SMITH TJ, 1990, J APPL CRYSTALLOGR, V23, P141; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420	24	226	231	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					176	179		10.1038/361176a0	http://dx.doi.org/10.1038/361176a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421524				2022-12-28	WOS:A1993KG46600067
J	DUMENCO, LL; ALLAY, E; NORTON, K; GERSON, SL				DUMENCO, LL; ALLAY, E; NORTON, K; GERSON, SL			THE PREVENTION OF THYMIC LYMPHOMAS IN TRANSGENIC MICE BY HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE	SCIENCE			English	Article							METHYL-N-NITROSOUREA; MAMMALIAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; DNA ALKYLTRANSFERASE; ALKYLATING-AGENTS; MAMMARY CARCINOGENESIS; HUMAN-LYMPHOCYTES; HUMAN-FIBROBLASTS; CELL-LINES; REPAIR; O-6-METHYLGUANINE	Nitrosoureas form O6-alkylguanine-DNA adducts that are converted to G to A transitions, the mutation found in the activated ras oncogenes of nitrosourea-induced mouse lymphomas and rat mammary tumors. These adducts are removed by the DNA repair protein O6-alkylguanine-DNA alkyltransferase. Transgenic mice that express the human homolog of this protein in the thymus were found to be protected from developing thymic lymphomas after exposure to N-methyl-N-nitrosourea. Thus, transgenic expression of a single human DNA repair gene is sufficient to block chemical carcinogenesis. The transduction of DNA repair genes in vivo may unravel mechanisms of carcinogenesis and provide therapeutic protection from known carcinogens.	UNIV HOSP CLEVELAND,IRELAND CANC CTR,CLEVELAND,OH 44106; UNIV HOSP CLEVELAND,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106	University Hospitals of Cleveland; University Hospitals of Cleveland; Case Western Reserve University					NATIONAL CANCER INSTITUTE [P30CA043703, P01CA051183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006288] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA51183, P30CA43703] Funding Source: Medline; NIEHS NIH HHS [R01ES06288] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BOGDEN JM, 1981, NUCLEIC ACIDS RES, V9, P3089; BOICE JD, 1983, NEW ENGL J MED, V309, P1079, DOI 10.1056/NEJM198311033091802; BRONSTEIN SM, 1991, CANCER RES, V51, P5188; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; CRADDOCK VM, 1987, CHEM-BIOL INTERACT, V53, P283; DEROSSI A, 1981, J NATL CANCER I, V67, P1241; DEVEREUX S, 1990, BRIT MED J, V301, P1077, DOI 10.1136/bmj.301.6760.1077; DEVITA VT, 1965, CANCER RES, V25, P1876; DOLAN ME, 1991, P NATL ACAD SCI USA, V12, P2305; DOMORADZKI J, 1985, CARCINOGENESIS, V6, P1823, DOI 10.1093/carcin/6.12.1823; DUMENCO LL, 1991, CANCER RES, V51, P3391; EADIE JS, 1984, NATURE, V308, P201, DOI 10.1038/308201a0; ELLISON KS, 1989, P NATL ACAD SCI USA, V86, P8620, DOI 10.1073/pnas.86.22.8620; ERICKSON LC, 1978, CANCER RES, V38, P3379; FONG LYY, 1990, CARCINOGENESIS, V11, P411, DOI 10.1093/carcin/11.3.411; FREI JV, 1975, CHEM-BIOL INTERACT, V10, P413, DOI 10.1016/0009-2797(75)90072-1; FREI JV, 1978, BIOCHEM J, V174, P1031, DOI 10.1042/bj1741031; FREI JV, 1980, J NATL CANCER I, V64, P845; GERSON SL, 1985, J CLIN INVEST, V76, P2106, DOI 10.1172/JCI112215; GERSON SL, 1992, BIOCHEM PHARMACOL, V43, P1101, DOI 10.1016/0006-2952(92)90618-S; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; GERSON SL, 1987, CANCER RES, V47, P89; GERSON SL, 1970, CANCER RES, V30, P11; GONZAGA PE, 1989, NUCLEIC ACIDS RES, V17, P6581, DOI 10.1093/nar/17.16.6581; GRESON SL, UNPUB; HANSEN MF, 1987, CANCER RES, V47, P5518; HARRIS CC, 1991, CANCER RES, V51, pS5023; HATZOGLOU M, 1988, J BIOL CHEM, V263, P17798; HAYAKAWA H, 1990, J MOL BIOL, V213, P739, DOI 10.1016/S0022-2836(05)80260-8; HITTELMAN WN, 1988, CANCER RES, V48, P276; KAINA B, 1991, CARCINOGENESIS, V12, P1857; LOEB LA, 1991, CANCER RES, V51, P3075; LUKASH LL, 1991, MUTAT RES, V250, P397, DOI 10.1016/0027-5107(91)90196-U; NEWCOMB EW, 1988, CANCER RES, V48, P5514; PEGG AE, 1984, CANCER INVEST, V2, P223, DOI 10.3109/07357908409104376; PEGG AE, 1990, CANCER RES, V50, P6119; PETERSON LA, 1991, CANCER RES, V51, P5557; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; SHIRAISHI A, 1992, CARCINOGENESIS, V13, P289, DOI 10.1093/carcin/13.2.289; SINGER B, 1979, J NATL CANCER I, V62, P1329; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; TERRACINI B, 1967, European Journal of Cancer, V3, P435, DOI 10.1016/0014-2964(67)90028-X; TIMME TL, 1988, AM J MED SCI, V295, P40, DOI 10.1097/00000441-198801000-00009; TOPAL MD, 1988, CARCINOGENESIS, V9, P691, DOI 10.1093/carcin/9.5.691; TREY JE, 1989, CANCER RES, V49, P1899; TSUJIMURA T, 1987, JPN J CANCER RES, V78, P1207; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WIENCKE JK, 1985, CANCER RES, V45, P4798; WOYCHIK RP, 1984, P NATL ACAD SCI-BIOL, V81, P3944, DOI 10.1073/pnas.81.13.3944; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	51	262	269	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					219	222		10.1126/science.8421782	http://dx.doi.org/10.1126/science.8421782			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	8421782				2022-12-28	WOS:A1993KF71900028
J	IGARASHI, M; STRITTMATTER, SM; VARTANIAN, T; FISHMAN, MC				IGARASHI, M; STRITTMATTER, SM; VARTANIAN, T; FISHMAN, MC			MEDIATION BY G-PROTEINS OF SIGNALS THAT CAUSE COLLAPSE OF GROWTH CONES	SCIENCE			English	Article							NEURITE GROWTH; MYELIN; MEMBRANES; GUIDANCE; SYSTEM; REGENERATION; INHIBITION; MECHANISM; CHANNELS; BRAIN	During development, motion of nerve growth cones ceases on contact with particular targets. The signaling mechanism is unknown. In culture, growth cone collapse can be caused by solubilized embryonic brain membranes, central nervous system myelin, a 35-kilodalton protein isolated from myelin, and mastoparan. Collapse induced by each of these is blocked by pertussis toxin. Thus, collapse of growth cones is mediated by G protein-coupled receptors, which may be activated by proteins associated with the cell surface as well as by soluble ligands.	MASSACHUSETTS GEN HOSP E,DEV BIOL LAB,BOSTON,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School			Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				AVELDANO MI, 1991, J NEUROCHEM, V57, P250, DOI 10.1111/j.1471-4159.1991.tb02122.x; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BANDTLOW CE, 1993, SCIENCE, V259; BIRNBAUMER L, 1990, CRIT REV BIOCHEM MOL, V25, P225, DOI 10.3109/10409239009090610; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cellbio.7.1.117; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DAVIES JA, 1991, BIOESSAYS, V13, P11, DOI 10.1002/bies.950130103; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1992, DEVELOPMENT, V115, P892; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EDMONDS BT, 1990, DEV BRAIN RES, V56, P131, DOI 10.1016/0165-3806(90)90172-U; HAYDON PG, 1984, SCIENCE, V226, P561, DOI 10.1126/science.6093252; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Keynes R J, 1992, Curr Opin Neurobiol, V2, P55, DOI 10.1016/0959-4388(92)90162-E; LANKFORD KL, 1988, P NATL ACAD SCI USA, V85, P4567, DOI 10.1073/pnas.85.12.4567-a; MENDELL L M, 1992, Current Biology, V2, P259, DOI 10.1016/0960-9822(92)90378-N; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; SCHMIDT M F, 1991, Society for Neuroscience Abstracts, V17, P927; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SCHWAB ME, 1990, TRENDS NEUROSCI, V13, P452, DOI 10.1016/0166-2236(90)90098-U; STRITTMATTER SM, 1991, BIOESSAYS, V13, P127, DOI 10.1002/bies.950130306; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T	30	179	186	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					77	79		10.1126/science.8418498	http://dx.doi.org/10.1126/science.8418498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	8418498				2022-12-28	WOS:A1993KE60100032
J	IGLEHART, JK				IGLEHART, JK			THE AMERICAN HEALTH-CARE SYSTEM - MEDICAID	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		ANDERSON GF, 1992, HEALTH AFFAIR, V11, P95, DOI 10.1377/hlthaff.11.4.95; AZEVEDO D, 1992, MED ECON, V69, P126; BUCHANAN JL, 1992, R4225HCFA RAND CORP; CORNELIUS L, 1991, AHCPR910042 AG HLTH; DOBSON A, 1992, HEALTH AFFAIR, V11, P72, DOI 10.1377/hlthaff.11.4.72; FEDER J, 1992, MEDICAID COST EXPLOS; FOX MH, 1992, HEALTH AFFAIR, V11, P150, DOI 10.1377/hlthaff.11.4.150; GOLDSTEIN A, 1993, WASHINGTON POST 0201, pD1; GRAY J, 1993, NY TIMES        0207, pA41; IGLEHART JK, 1992, NEW ENGL J MED, V326, P962, DOI 10.1056/NEJM199204023261426; IGLEHART JK, 1992, NEW ENGL J MED, V327, P1467, DOI 10.1056/NEJM199211123272027; IGLEHART JK, 1992, NEW ENGL J MED, V326, P1715, DOI 10.1056/NEJM199206183262526; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; IGLEHART JK, 1993, NEW ENGL J MED, V328, P366, DOI 10.1056/NEJM199302043280528; Joe T C, 1985, Health Aff (Millwood), V4, P59, DOI 10.1377/hlthaff.4.1.59; KASSIRER JP, 1992, NEW ENGL J MED, V326, P945, DOI 10.1056/NEJM199204023261408; LONG SH, 1992, CAUSES SOARING MEDIC; MCGINLEY L, 1993, WALL ST J       0602, pA16; MILLER VJ, 1992, MEDICAID PROVIDER TA; MORGAN D, 1993, WASH POST       0207, pA23; MORGAN D, 1993, WASHINGTON POST 1119, pA1; STEVENS R, 1974, WELFARE MED AM STUDY; SULLIVAN LW, 1992, INTERIM REPORT C PAT; YUDKOWSKY BK, 1990, PEDIATRICS, V85, P567; 1991, PHYSICIAN MARKETPLAC, V2; 1993, DRAFT STRATEGIC PLAN; 1992, CBO STAFFING MEMORAN; 1991, 914 PHYS PAYM REV CO; 1992, MEDICAID PROVIDER TA; 1992, KAISER COMMISSION FU; 1993, NY TIMES        0104, pA13; 1993, MEDICAID SOURCE BOOK; 1993, GAOHRD9328 GEN ACC O	33	39	39	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 25	1993	328	12					896	900		10.1056/NEJM199303253281226	http://dx.doi.org/10.1056/NEJM199303253281226			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT814	8441449				2022-12-28	WOS:A1993KT81400035
J	SHIVDASANI, RA; HALUSKA, FG; DOCK, NL; DOVER, JS; KINEKE, EJ; ANDERSON, KC				SHIVDASANI, RA; HALUSKA, FG; DOCK, NL; DOVER, JS; KINEKE, EJ; ANDERSON, KC			GRAFT-VERSUS-HOST DISEASE ASSOCIATED WITH TRANSFUSION OF BLOOD FROM UNRELATED HLA-HOMOZYGOUS DONORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							AUTOLOGOUS BONE-MARROW; IMMUNOCOMPETENT PATIENT; NEURO-BLASTOMA; FATAL GRAFT; PRODUCTS; IRRADIATION; PREVENTION; SURGERY; CHILD		HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV IMMUNOGENET,BOSTON,MA 02115; NEW ENGLAND DEACONESS HOSP,DIV DERMATOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; AMER RED CROSS,BLOOD SERV,SYRACUSE,NY	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; American Red Cross								AKAHOSHI M, 1992, TRANSFUSION, V32, P169, DOI 10.1046/j.1537-2995.1992.32292180149.x; ANDERSON K, 1991, J CLIN ONCOL, V9, P1727, DOI 10.1200/JCO.1991.9.10.1727; ANDERSON KC, 1991, BLOOD, V77, P2096; ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; Anderson KC, 1992, IRRADIATION BLOOD CO, P31; ARSURA EL, 1988, ARCH INTERN MED, V148, P1941, DOI 10.1001/archinte.148.9.1941; BRUBAKER DB, IN PRESS SCI BASIS T; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; CAPON SM, 1991, ANN INTERN MED, V114, P1025, DOI 10.7326/0003-4819-114-12-1025; CHARPENTIER F, 1990, TRANSFUSION, V30, P850, DOI 10.1046/j.1537-2995.1990.30991048796.x; COLLINS RH, 1992, ANN INTERN MED, V116, P391, DOI 10.7326/0003-4819-116-5-391; DEEG HJ, 1989, BLOOD, V74, P2592; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; GREENBAUM BH, 1991, J CLIN ONCOL, V9, P1889, DOI 10.1200/JCO.1991.9.10.1889; JUJI T, 1989, NEW ENGL J MED, V321, P56; KANTER MH, 1992, TRANSFUSION, V32, P323, DOI 10.1046/j.1537-2995.1992.32492263445.x; KASLOW RA, 1987, ANN INTERN MED, V107, P474, DOI 10.7326/0003-4819-107-4-474; KENNEDY JS, 1986, J PEDIATR SURG, V21, P1108, DOI 10.1016/0022-3468(86)90019-9; KESSINGER A, 1987, J SURG ONCOL, V36, P206, DOI 10.1002/jso.2930360311; LANE TA, 1992, ANN INTERN MED, V117, P151, DOI 10.7326/0003-4819-117-2-151; MATSUSHITA H, 1988, VIRCHOWS ARCH B, V55, P237; MULDER NH, 1989, LANCET, V1, P735; OCONNOR NTJ, 1992, J CLIN PATHOL, V45, P621, DOI 10.1136/jcp.45.7.621; OHTO H, 1992, TRANSFUSION, V32, P691, DOI 10.1046/j.1537-2995.1992.32792391051.x; OTSUKA S, 1989, TRANSFUSION, V29, P544, DOI 10.1046/j.1537-2995.1989.29689318456.x; PERKINS HA, 1992, TRANSFUSION, V32, P302, DOI 10.1046/j.1537-2995.1992.32492263440.x; POSTMUS PE, 1988, EUR J CANCER CLIN ON, V24, P889, DOI 10.1016/0277-5379(88)90198-8; SUZUKI K, 1992, TRANSFUSION, V32, P358, DOI 10.1046/j.1537-2995.1992.32492263452.x; THALER M, 1989, NEW ENGL J MED, V321, P25, DOI 10.1056/NEJM198907063210105; TKAAHASHI K, 1991, TRANSFUS SCI, V12, P281; TWOMEY JJ, 1980, SEMIN ONCOL, V7, P114; VOGELSANG GB, 1990, TRANSFUSION, V30, P101, DOI 10.1046/j.1537-2995.1990.30290162892.x; WOODS WG, 1981, PEDIATRICS, V67, P217	33	61	63	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					766	770		10.1056/NEJM199303183281105	http://dx.doi.org/10.1056/NEJM199303183281105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8437597				2022-12-28	WOS:A1993KR84800005
J	PARDI, G; CETIN, I; MARCONI, AM; LANFRANCHI, A; BOZZETTI, P; FERRAZZI, E; BUSCAGLIA, M; BATTAGLIA, FC				PARDI, G; CETIN, I; MARCONI, AM; LANFRANCHI, A; BOZZETTI, P; FERRAZZI, E; BUSCAGLIA, M; BATTAGLIA, FC			DIAGNOSTIC-VALUE OF BLOOD-SAMPLING IN FETUSES WITH GROWTH-RETARDATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RETARDED HUMAN FETUSES; FOR-GESTATIONAL-AGE; HEART-RATE PATTERNS; UMBILICAL ARTERY; DOPPLER VELOCIMETRY; CORDOCENTESIS; LACTATE; GASES	Background. Fetuses with intrauterine growth retardation are delivered if they have evidence of distress, as manifested by abnormalities in the fetal heart rate and umbilical-artery blood flow. We studied whether umbilical-blood sampling might provide further information useful for management. Methods. We measured hemoglobin and lactate concentrations, oxygen content, pH, blood gas levels, and base deficit in umbilical-vein blood and correlated these measurements with the heart rate and umbilical-artery wave forms recorded by Doppler velocimetry in 56 fetuses with growth retardation. Twenty-one fetuses had normal heart rates and normal results of velocimetry, 24 had normal heart rates and abnormal results of velocimetry (indicative of decreased diastolic flow), and 11 had abnormal heart rates and abnormal results of velocimetry. Results. None of the 21 fetuses with normal heart rates and velocimetry had hypoxia or acidemia. Of the 24 fetuses with normal heart rates and abnormal velocimetry, 4 (17 percent) had moderate lactic acidosis, 1 (4 percent) had a low pH value, and 3 (12 percent) had hypoxia. Of the 11 fetuses with abnormal heart rates and velocimetry, 7 (64 percent) had lactic acidosis, low blood oxygen content, and low pH values. The absence of end-diastolic flow increased the risk of hypoxia and acidemia. The proportion of fetuses with elevated hemoglobin concentrations was similar among the three groups. Conclusions. Assessment of fetal oxygenation and acid-base balance is not indicated in fetuses with growth retardation if their heart rates and the results of velocimetry are normal. If the results of velocimetry are abnormal, fetal-blood sampling can distinguish fetuses that have growth retardation alone from those that also have hypoxia and acidosis, and thus may aid in determining the optimal time of delivery.	UNIV COLORADO,SCH MED,DEPT PEDIAT,DIV PERINATAL MED,DENVER,CO 80202	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	PARDI, G (corresponding author), UNIV MILAN,H SAN PAOLO,SAN PAOLO INST BIOMED SCI,DEPT OBSTET & GYNECOL,VIA A DI RUDINI 8,I-20142 MILAN,ITALY.		Ferrazzi, Enrico Mario/AAB-9416-2019; cetin, irene/K-6112-2016; marconi, anna maria/O-2580-2017	Ferrazzi, Enrico Mario/0000-0001-5243-0537; cetin, irene/0000-0002-9217-3034; marconi, anna maria/0000-0001-6295-1854	NICHD NIH HHS [HD-20761] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD020761, P50HD020761] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMON E, 1987, AM J OBSTET GYNECOL, V156, P1380, DOI 10.1016/0002-9378(87)90004-4; BEKEDAM DJ, 1990, EARLY HUM DEV, V24, P79, DOI 10.1016/0378-3782(90)90008-7; CETIN I, 1990, AM J OBSTET GYNECOL, V162, P253, DOI 10.1016/0002-9378(90)90860-A; FERRAZZI E, 1991, EUR J OBSTET GYN R B, V38, P189, DOI 10.1016/0028-2243(91)90290-2; FERRAZZI E, 1991, J ULTRAS MED, V10, P309, DOI 10.7863/jum.1991.10.6.309; FERRAZZI E, 1988, AM J OBSTET GYNECOL, V159, P1081, DOI 10.1016/0002-9378(88)90418-8; GILES WB, 1985, BRIT J OBSTET GYNAEC, V92, P31, DOI 10.1111/j.1471-0528.1985.tb01045.x; Gosling R.G., 1974, CARDIOVASCULAR APPLI, P266; MARCONI AM, 1992, PLACENTA, V13, P115, DOI 10.1016/0143-4004(92)90026-P; MARCONI AM, 1990, PEDIATR RES, V28, P652, DOI 10.1203/00006450-199012000-00022; NICOLAIDES KH, 1989, AM J OBSTET GYNECOL, V161, P996, DOI 10.1016/0002-9378(89)90770-9; PARDI G, 1987, AM J OBSTET GYNECOL, V157, P1221, DOI 10.1016/S0002-9378(87)80298-3; RIBBERT LSM, 1991, BRIT J OBSTET GYNAEC, V98, P820, DOI 10.1111/j.1471-0528.1991.tb13489.x; SCHAUSEILZIPF U, 1989, EUR J OBSTET GYN R B, V30, P1, DOI 10.1016/0028-2243(89)90087-7; SCHULMAN H, 1984, AM J OBSTET GYNECOL, V148, P985, DOI 10.1016/0002-9378(84)90541-6; THORPEBEESTON JG, 1991, BRIT J OBSTET GYNAEC, V98, P1163, DOI 10.1111/j.1471-0528.1991.tb15371.x; VISSER GHA, 1990, AM J OBSTET GYNECOL, V162, P698, DOI 10.1016/0002-9378(90)90989-K; WEINER CP, 1991, AM J OBSTET GYNECOL, V165, P1020, DOI 10.1016/0002-9378(91)90462-Z; WEINER CP, 1990, AM J OBSTET GYNECOL, V162, P1198, DOI 10.1016/0002-9378(90)90016-Z; 1980, RIV ITAL PED, V6, P153	20	249	249	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1993	328	10					692	696		10.1056/NEJM199303113281004	http://dx.doi.org/10.1056/NEJM199303113281004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ861	8433728				2022-12-28	WOS:A1993KQ86100004
J	COSMAN, F; SHEN, V; XIE, F; SEIBEL, M; RATCLIFFE, A; LINDSAY, R				COSMAN, F; SHEN, V; XIE, F; SEIBEL, M; RATCLIFFE, A; LINDSAY, R			ESTROGEN PROTECTION AGAINST BONE RESORBING EFFECTS OF PARATHYROID-HORMONE INFUSION - ASSESSMENT BY USE OF BIOCHEMICAL MARKERS	ANNALS OF INTERNAL MEDICINE			English	Article						ESTROGEN REPLACEMENT THERAPY; SKELETON; OSTEOPOROSIS, POSTMENOPAUSAL; BONE RESORPTION; PARATHYROID HORMONES	OSTEOBLAST-LIKE CELLS; POSTMENOPAUSAL OSTEOPOROSIS; PYRIDINIUM CROSSLINKS; CIRCADIAN-RHYTHM; MESSENGER-RNA; HUMAN-SERUM; CYCLIC-AMP; WOMEN; OSTEOCALCIN; OSTEOCLASTS	Objective: Because parathyroid hormone (PTH) stimulates bone resorption, resistance to its actions might help maintain bone mass. We tested the hypothesis that the effects of estrogen on bone are accomplished in part by decreasing the sensitivity of the skeleton to the resorbing effects of PTH. Study Design: Comparison of response to PTH infusion in untreated and estrogen-treated postmenopausal women with osteoporosis. Intervention: (1-34) human PTH, 0.55 U/(kg.h), was infused intravenously over 20 hours. Setting: The inpatient clinical research unit of a referral hospital. Patients: Women with primary postmenopausal osteoporosis who were untreated (n = 15) or treated with estrogen (n = 17). Main Outcome Measures: Skeletal turnover indices including hydroxyproline, deoxypyridinoline, pyridinoline, tartrate-resistant acid phosphatase, alkaline phosphatase, bone Gla protein, and insulin-like growth factor-1. Results: All basal indices were higher in untreated than in estrogen-treated women, but statistical differences were seen only for deoxypyridinoline and pyridinoline. During the 20-hour infusion, hydroxyproline/creatinine increased 0.023 mumol/mumol in untreated women but only 0.010 mumol/mumol in estrogen-treated women (P < 0.05). Corresponding changes for deoxypyridinoline/creatinine were 14.6 mumol/mumol and 3.5 mumol/mumol (P = 0.06). Tartrate-resistant acid phosphatase and pyridinoline increased only in the untreated group. A circadian rhythm in circulating bone Gla protein was seen in both groups without clear PTH-induced effects or differences between groups. Alkaline phosphatase levels and insulin-like growth factor-1 decreased in both groups with no distinction between untreated and estrogen-treated women. Conclusion: The estrogenized postmenopausal osteoporotic skeleton is less sensitive to the bone resorbing effects of acutely administered PTH. There are no differential effects on bone formation.	COLUMBIA UNIV, NEW YORK, NY 10027 USA	Columbia University	COSMAN, F (corresponding author), HELEN HAYES HOSP, REG BONE CTR, ROUTE 9W, W HAVERSTRAW, NY 10993 USA.			Seibel, Markus J/0000-0002-2701-378X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042892] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00645] Funding Source: Medline; NIAMS NIH HHS [AR-39191] Funding Source: Medline; NIDDK NIH HHS [R01-DK-42892] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNETT TR, 1986, J BONE MINER RES, V1, pA99; BARON R, 1981, METAB BONE DIS RELAT, V2, P339, DOI 10.1016/0221-8747(81)90020-5; BLACK D, 1988, ANAL BIOCHEM, V169, P197, DOI 10.1016/0003-2697(88)90274-6; CANALIS E, 1989, ENDOCRIN METAB CLIN, V18, P903, DOI 10.1016/S0889-8529(18)30348-7; COSMAN F, 1991, J CLIN ENDOCR METAB, V73, P1345, DOI 10.1210/jcem-73-6-1345; DAUGHADAY WH, 1980, J CLIN ENDOCR METAB, V51, P781, DOI 10.1210/jcem-51-4-781; DELMAS PD, 1990, ENDOCRIN METAB CLIN, V19, P1; DELMAS PD, 1990, J BONE MINER RES, V5, P5, DOI 10.1002/jbmr.5650050104; DELMAS PD, 1983, J CLIN INVEST, V71, P1316, DOI 10.1172/JCI110882; DELMAS PD, 1991, J BONE MINER RES, V6, P639; EASTELL R, 1988, OSTEOPOROSIS ETIOLOG, P373; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; ERNST M, 1991, MOL ENDOCRINOL, V5, P1081, DOI 10.1210/mend-5-8-1081; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; GARCIACARRASCO M, 1988, CALCIFIED TISSUE INT, V42, P13, DOI 10.1007/BF02555833; GREENBERG C, 1986, ENDOCRINOLOGY, V118, P2594, DOI 10.1210/endo-118-6-2594; GRIFFIN JE, 1985, TXB ENDOCRINOLOGY, P147; GUNDBERG CM, 1985, J CLIN ENDOCR METAB, V60, P736, DOI 10.1210/jcem-60-4-736; HEANEY RP, 1965, AM J MED, V39, P877, DOI 10.1016/0002-9343(65)90109-9; JOBORN C, 1991, CLIN ENDOCRINOL, V34, P335, DOI 10.1111/j.1365-2265.1991.tb00302.x; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526; KRAENZLIN ME, 1990, J CLIN ENDOCR METAB, V71, P442, DOI 10.1210/jcem-71-2-442; KUMEGAWA M, 1984, CALCIFIED TISSUE INT, V36, P72, DOI 10.1007/BF02405296; LEGGATE J, 1984, CLIN ENDOCRINOL, V20, P85, DOI 10.1111/j.1365-2265.1984.tb00062.x; LINDSAY R, 1986, J BONE MINER RES, V1, P121; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; LINDSAY R, 1988, OSTEOPOROSIS ETIOLOG, P333; LINKHART TA, 1989, ENDOCRINOLOGY, V125, P1484, DOI 10.1210/endo-125-3-1484; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; MARCUS R, 1984, ANN INTERN MED, V100, P633, DOI 10.7326/0003-4819-100-5-633; MURRILLS RJ, 1990, ENDOCRINOLOGY, V127, P2648, DOI 10.1210/endo-127-6-2648; NODA M, 1988, J BIOL CHEM, V263, P18574; ORIMO H, 1972, ENDOCRINOLOGY, V90, P760, DOI 10.1210/endo-90-3-760; OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613; Parfitt A.M., 1988, OSTEOPOROSIS ETIOLOG, P45; PIETSCHMANN P, 1990, EUR J CLIN INVEST, V20, P310, DOI 10.1111/j.1365-2362.1990.tb01861.x; PILBEAM CC, 1989, BIOCHEM BIOPH RES CO, V163, P1319, DOI 10.1016/0006-291X(89)91122-4; QUIGLEY MET, 1987, AM J OBSTET GYNECOL, V156, P1516; RECKER RR, 1977, ANN INTERN MED, V87, P649, DOI 10.7326/0003-4819-87-6-649; RIGGS BL, 1972, J CLIN INVEST, V51, P1659, DOI 10.1172/JCI106967; ROTH GS, 1990, ENDOCRINE FUNCTION AND AGING, P26; SEIBEL MJ, 1989, J RHEUMATOL, V16, P964; SELBY PL, 1986, NEW ENGL J MED, V314, P1481, DOI 10.1056/NEJM198606053142304; STEINICHE T, 1989, BONE, V10, P313, DOI 10.1016/8756-3282(89)90126-9; STEVENSON JC, 1983, EUR J CLIN INVEST, V13, P481, DOI 10.1111/j.1365-2362.1983.tb00133.x; TOBIAS JH, 1991, ACTA ENDOCRINOL-COP, V124, P121, DOI 10.1530/acta.0.1240121; TSAI KS, 1989, J CLIN ENDOCR METAB, V69, P1024, DOI 10.1210/jcem-69-5-1024; TSAI KS, 1984, J CLIN INVEST, V73, P1668, DOI 10.1172/JCI111373	49	107	110	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					337	343		10.7326/0003-4819-118-5-199303010-00003	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8430979				2022-12-28	WOS:A1993KN68800003
J	BRUNNER, HG; JANSEN, G; NILLESEN, W; NELEN, MR; DEDIE, CEM; HOWELER, CJ; VANOOST, BA; WIERINGA, B; ROPERS, HH; SMEETS, HJM				BRUNNER, HG; JANSEN, G; NILLESEN, W; NELEN, MR; DEDIE, CEM; HOWELER, CJ; VANOOST, BA; WIERINGA, B; ROPERS, HH; SMEETS, HJM			REVERSE MUTATION IN MYOTONIC-DYSTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DINUCLEOTIDE REPEAT POLYMORPHISM; SIMPLE SEQUENCE MOTIFS; DNA; GENE; DIAGNOSIS; MARKERS; LOCUS; CELLS		UNIV LIMBURG HOSP,DEPT NEUROL,MAASTRICHT,NETHERLANDS; UNIV HOSP NIJMEGEN,DEPT CELL BIOL & HISTOL,NIJMEGEN,NETHERLANDS; UNIV LIMBURG HOSP,DEPT HUMAN GENET,MAASTRICHT,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC); Radboud University Nijmegen; Maastricht University; Maastricht University Medical Centre (MUMC)	BRUNNER, HG (corresponding author), UNIV HOSP NIJMEGEN,DEPT HUMAN GENET,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		Brunner, Han/C-9928-2013; Jansen, Gert/HCI-8852-2022; Nelen, Marcel R./L-4542-2015; Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020; Jansen, Gert/0000-0002-7524-171X				ANTONARAKIS SE, 1989, NEW ENGL J MED, V320, P153, DOI 10.1056/NEJM198901193200305; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BRETT PM, 1991, NUCLEIC ACIDS RES, V19, P6978, DOI 10.1093/nar/19.24.6978-a; BREWSTER ES, 1991, NUCLEIC ACIDS RES, V19, P4022, DOI 10.1093/nar/19.14.4022; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; DEINARD AS, 1992, NUCLEIC ACIDS RES, V20, P1171, DOI 10.1093/nar/20.5.1171-a; Fleiseher B., 1918, ALBRECHT GRAEFES ARC, V96, P91, DOI DOI 10.1007/BF02018704; FORNAGE M, 1992, GENOMICS, V12, P63, DOI 10.1016/0888-7543(92)90407-J; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; HARLEY HG, 1991, AM J HUM GENET, V49, P68; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARPER PS, 1989, MAJOR PROBLEMS NEURO, V21; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; JANSEN G, 1992, GENOMICS, V13, P509, DOI 10.1016/0888-7543(92)90118-C; KOURILSKY P, 1986, TRENDS GENET, V2, P60, DOI 10.1016/0168-9525(86)90179-4; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MUTIRANGURA A, 1992, HUM MOL GENET, V1, P67, DOI 10.1093/hmg/1.1.67; Mutirangura A., 1992, Human Molecular Genetics, V1, P139, DOI 10.1093/hmg/1.2.139-a; NIJENHUIS LE, 1983, INCLUSION PROBABILIT, P551; OLIPHANT AR, 1991, NUCLEIC ACIDS RES, V19, P4794; RICHARDS RI, 1992, NAT GENET, V1, P7, DOI 10.1038/ng0492-7; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; SMEETS HJM, 1991, GENOMICS, V9, P257, DOI 10.1016/0888-7543(91)90250-I; SMEETS HJM, 1989, HUM GENET, V83, P245, DOI 10.1007/BF00285165; SUTHERLAND GR, 1991, LANCET, V338, P289, DOI 10.1016/0140-6736(91)90426-P; VANKOOIJ RJ, 1992, FERTIL STERIL, V58, P384; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H	31	91	96	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1993	328	7					476	480		10.1056/NEJM199302183280705	http://dx.doi.org/10.1056/NEJM199302183280705			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM417	8421477				2022-12-28	WOS:A1993KM41700005
J	GIOVANNUCCI, E; ASCHERIO, A; RIMM, EB; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC				GIOVANNUCCI, E; ASCHERIO, A; RIMM, EB; COLDITZ, GA; STAMPFER, MJ; WILLETT, WC			A PROSPECTIVE COHORT STUDY OF VASECTOMY AND PROSTATE-CANCER IN UNITED-STATES MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN SEMINAL PLASMA; RISK; ETIOLOGY; ANTIGENS; SPERM; MOUSE	Objective.-To examine prospectively the relationship between vasectomy and prostate cancer. Design.-Cohort study. Setting.-Health professionals (dentists, veterinarians, osteopaths, optometrists, pharmacists, and podiatrists) in the United States. Participants.-There were 10055 male members of the Health Professionals Follow-up Study, aged 40 to 75 years, who had had a vasectomy, and 37 800 members who had not had a vasectomy at the time of study entry in 1986. These participants had provided detailed information on various life-style variables including diet. Main Outcome Measure.-Diagnosis of prostate cancer. Results.-Between 1986 and 1990, 300 new cases of prostate cancer were diagnosed in participants who were initially free of diagnosed cancer. Vasectomy was associated with an elevated risk of prostate cancer (age-adjusted relative risk, 1.66; 95% confidence interval, 1.25 to 2.21; P=.0004). This elevated risk persisted after excluding 21 stage A1 cases (age-adjusted relative risk, 1.56; 95% confidence interval, 1.15 to 2.11; P=.004). Among men who had their vasectomy at least 22 years in the past (before 1965), the risk of prostate cancer was even higher (relative risk, 1.85; 95% confidence interval, 1.26 to 2.72; P=.002). This elevated risk among men with vasectomy did not appear to be caused by detection bias and persisted when we controlled for diet, level of physical activity, smoking, alcohol consumption, educational level, body mass index, and geographical area of residence. Conclusions.-These results support evidence from other epidemiologic studies that vasectomy increases risk of prostate cancer. The consistency of results among various epidemiologic studies, the increase of risk over time following vasectomy, the apparent lack of confounding or bias, and the existence of physiological changes in the prostate following vasectomy suggest that the association may be causal.	HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	GIOVANNUCCI, E (corresponding author), HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adamopoulos D A, 1976, Acta Eur Fertil, V7, P219; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; FREUND M, 1969, FERTIL STERIL, V20, P163; GACHELIN G, 1977, DEV BIOL, V57, P199, DOI 10.1016/0012-1606(77)90365-7; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P878, DOI 10.1001/jama.269.7.878; GIOVANNUCCI E, 1992, NEW ENGL J MED, V326, P1392, DOI 10.1056/NEJM199205213262104; GOLDBERG EH, 1977, TRANSPLANT P, V9, P1363; GUESS HA, 1990, AM J EPIDEMIOL, V132, P1062, DOI 10.1093/oxfordjournals.aje.a115748; HONDA GD, 1988, BRIT J CANCER, V57, P326, DOI 10.1038/bjc.1988.74; ISAACS JT, 1983, PROSTATE, V4, P351, DOI 10.1002/pros.2990040405; JAKOBSEN H, 1988, PROSTATE, V13, P57, DOI 10.1002/pros.2990130107; JAKOBSEN H, 1989, J REPROD FERTIL, V87, P39; JOSHI UM, 1981, ARCH ANDROLOGY, V7, P187, DOI 10.3109/01485018108999306; JOUANNET P, 1978, FERTIL STERIL, V29, P435; KINSON GA, 1977, RES COMMUN CHEM PATH, V18, P561; LELANNOU D, 1980, INT J ANDROL, V3, P502; LOHIYA N K, 1987, Acta Europaea Fertilitatis, V18, P207; MENDIRATTA R, 1980, INDIAN J EXP BIOL, V18, P409; MENGE AC, 1978, DEV BIOL, V63, P111, DOI 10.1016/0012-1606(78)90117-3; METTLIN C, 1990, AM J EPIDEMIOL, V132, P1056, DOI 10.1093/oxfordjournals.aje.a115747; NAG DSK, 1984, ANDROLOGIA, V16, P451; NAIK VK, 1980, J REPROD FERTIL, V58, P289; NIENHUIS H, 1992, BRIT MED J, V304, P743, DOI 10.1136/bmj.304.6829.743; NOMURA AMY, 1991, AM J EPIDEMIOL, V13, P200; PERLMAN JA, 1991, AM J EPIDEMIOL, V134, P107, DOI 10.1093/oxfordjournals.aje.a115985; PIERREPOINT CG, 1975, J REPROD FERTIL, V44, P395; PURVIS K, 1976, CLIN ENDOCRINOL, V5, P263, DOI 10.1111/j.1365-2265.1976.tb01952.x; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSENBERG L, 1990, AM J EPIDEMIOL, V132, P1051, DOI 10.1093/oxfordjournals.aje.a115746; ROSS RK, 1983, PROSTATE, V4, P333, DOI 10.1002/pros.2990040403; Rothman K, 1986, MODERN EPIDEMIOLOGY; SHETH AR, 1982, MED HYPOTHESES, V8, P237, DOI 10.1016/0306-9877(82)90118-9; SIDNEY S, 1991, CANCER CAUSE CONTROL, V2, P113, DOI 10.1007/BF00053130; SIDNEY S, 1987, J UROLOGY, V138, P795, DOI 10.1016/S0022-5347(17)43377-5; SKINNER JD, 1968, J ENDOCRINOL, V42, P355, DOI 10.1677/joe.0.0420355; SOLTER D, 1977, DEV BIOL, V57, P199; SPITZ MR, 1991, AM J EPIDEMIOL, V134, P108, DOI 10.1093/oxfordjournals.aje.a115986; SRIVASTAVA A, 1986, ACTA ENDOCRINOL-COP, V113, P440, DOI 10.1530/acta.0.1130440; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; YING W, 1983, INT J ANDROL, V6, P116, DOI 10.1111/j.1365-2605.1983.tb00330.x	42	165	168	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					873	877		10.1001/jama.269.7.873	http://dx.doi.org/10.1001/jama.269.7.873			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL474	8426446				2022-12-28	WOS:A1993KL47400024
J	MILLER, HI				MILLER, HI			FOODS OF THE FUTURE - THE NEW BIOTECHNOLOGY AND FDA REGULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MILLER, HI (corresponding author), US FDA,OFF BIOTECHNOL,ROCKVILLE,MD 20857, USA.							1992, FED REG         0529, V57, P22984; 1989, FIELD TESTING GENETI	2	5	5	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					910	912						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL474	8426451				2022-12-28	WOS:A1993KL47400031
J	BLOOM, BS; HILLMAN, AL; FENDRICK, AM; SCHWARTZ, JS				BLOOM, BS; HILLMAN, AL; FENDRICK, AM; SCHWARTZ, JS			A REAPPRAISAL OF HEPATITIS-B VIRUS VACCINATION STRATEGIES USING COST-EFFECTIVENESS ANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS-B; VIRAL HEPATITIS VACCINES; HEPATITIS-B VIRUS; COST-BENEFIT ANALYSIS; VACCINATION	POSITIVE CARRIER MOTHERS; LONG-TERM IMMUNOGENICITY; YUPIK ESKIMO POPULATION; HOMOSEXUAL MEN; HEPATOCELLULAR-CARCINOMA; VIRAL-HEPATITIS; IMMUNE GLOBULIN; PREGNANT-WOMEN; UNITED-STATES; INFANTS BORN	Objective: To determine clinical and economic consequences of alternative vaccination strategies for preventing hepatitis B virus infection (HBV). Methods: Decision analysis was used to evaluate costs, outcomes, and cost-effectiveness of three HBV management strategies (''no vaccination,'' ''universal vaccination,'' and ''screen and vaccinate'') in four populations (newborns, 10-year-old adolescents, a high-risk adult population, and the general adult U.S. population). Information on HBV incidence and prevalence, clinical course, and management of acute illness and chronic sequelae was obtained from the literature and a panel of experts. Actual payments (costs) were obtained from Blue Cross/Blue Shield and local pharmacies. Incremental cost-effectiveness was calculated from the perspective of the payer of medical care and subjected to sensitivity analysis. Results: Vaccination (with or without screening) prevents more disease at somewhat increased cost than no vaccination for the neonatal, adolescent, and adult populations. Vaccination (with or without screening) is a dominant strategy in adult high-risk populations (lower cost and greater benefit than no vaccination). Optimal cost-effectiveness, with nonmonetary benefits not discounted, results if all pregnant women are screened for active HBV infection, and HBV vaccine and hepatitis B immune globulin are administered to babies born to mothers with positive screening tests. Then HBV vaccine is administered to all children at age 10 and again 10 years later (incremental cost-per-year-of-life-saved relative to the ''no vaccination'' strategy is $375). A strategy of universal newborn vaccination alone leads to an incremental cost-per-year-of-life saved of $3332. If adolescents are vaccinated at age 10, incremental cost-per-year-of-life saved is $13 938; for the general adult population, the incremental cost-per-year-of-life saved of universal vaccination is $54 524. Discounting benefits will increase cost-per-year-of-life saved 7 to 12 times for all strategies. Conclusions: HBV vaccine is most cost-effective when a strategy of screening newborns is combined with routine administration to 10-year-old children. The means to achieve substantial improvements in the health of the public in a cost-effective fashion are now available and should be pursued aggressively.	UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, WHARTON SCH, PHILADELPHIA, PA 19104 USA; UNIV PENN, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	BLOOM, BS (corresponding author), UNIV PENN, SCH DENT MED, 2L NURSING EDUC BLDG, PHILADELPHIA, PA 19104 USA.							ALTER MJ, 1987, AM J EPIDEMIOL, V125, P133, DOI 10.1093/oxfordjournals.aje.a114496; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDRE FE, 1987, POSTGRAD MED J, V63, P169; ANDRE FE, 1989, AM J MED, V87, pS14, DOI 10.1016/0002-9343(89)90525-1; AREVALO JA, 1988, JAMA-J AM MED ASSOC, V259, P365, DOI 10.1001/jama.259.3.365; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BEASLEY RP, 1983, LANCET, V2, P1099; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; CADRANEL S, 1987, POSTGRAD MED J, V63, P159; DELAPLANE D, 1983, PEDIATRICS, V72, P176; GOILAV C, 1989, AM J MED, V87, pS21, DOI 10.1016/0002-9343(89)90526-3; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; HILLMAN AL, 1991, NEW ENGL J MED, V324, P1362, DOI 10.1056/NEJM199105093241911; Hoofnagle J H, 1981, Semin Liver Dis, V1, P7, DOI 10.1055/s-2008-1063925; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KUMAR ML, 1987, ANN INTERN MED, V107, P273, DOI 10.7326/0003-4819-107-2-273; LAUKAMMJOSTEN U, 1987, POSTGRAD MED J, V63, P143; LO KJ, 1988, HEPATOLOGY, V8, P1647, DOI 10.1002/hep.1840080629; MARGOLIS HS, 1990, VACCINE, V8, pS81, DOI 10.1016/0264-410X(90)90224-A; MCQUILLAN GM, 1989, AM J MED, V87, pS5; MEHEUS A, 1987, POSTGRAD MED J, V63, P139; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; ODAKA N, 1988, JAMA-J AM MED ASSOC, V260, P3635, DOI 10.1001/jama.260.24.3635; PERILLO RP, 1981, SEMIN LIVER DIS, V1, P15; PIAZZA M, 1988, LANCET, V2, P1132; POOVORAWAN Y, 1989, JAMA-J AM MED ASSOC, V261, P3278, DOI 10.1001/jama.261.22.3278; PRINSEN H, 1987, POSTGRAD MED J, V63, P147; REDEKER AG, 1975, AM J MED SCI, V270, P9, DOI 10.1097/00000441-197507000-00003; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; SAMPLINER RE, 1979, ARCH INTERN MED, V139, P145, DOI 10.1001/archinte.139.2.145; SHERLOCK S, 1987, POSTGRAD MED J, V63, P7; SINATRA FR, 1982, PEDIATRICS, V70, P557; SISK JE, 1986, ANN INTERN MED, V104, P79, DOI 10.7326/0003-4819-104-1-79; STEVENS CE, 1987, JAMA-J AM MED ASSOC, V257, P2612, DOI 10.1001/jama.257.19.2612; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; Szmuness W, 1978, Prog Med Virol, V24, P40; SZMUNESS W, 1973, J INFECT DIS, V127, P17, DOI 10.1093/infdis/127.1.17; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; WAINWRIGHT RB, 1991, ARCH INTERN MED, V151, P1634, DOI 10.1001/archinte.151.8.1634; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; Weinstein MC, 1980, CLIN DECISION ANAL; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; 1990, MMWR MORBID MORTAL W, V39, P1; 1989, MMWR MORBID MORTAL W, V36, P353; 1989, PHS52 CTR DIS CONTR; 1989, MMWR MORBID MORTAL W, V38, P818; 1991, MMWR MORBID MORTAL W, V40, P1; 1987, WHOHEP871 PUB; 1991, USDL91618 US DEP LAB	50	152	152	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					298	306		10.7326/0003-4819-118-4-199302150-00009	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420448				2022-12-28	WOS:A1993KL45700008
J	WASSER, KB				WASSER, KB			INFORMED CONSENT	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						INFORMED CONSENT; MUSCULAR DYSTROPHY; RESUSCITATION ORDERS		A mother faces the dilemma of either continuing medical care of her hopelessly ill child or putting an end to what she considers his ''high-tech medical torture.'' Finally, a wise clinician helps release her from her terrible conflict.										WASSER KB, 1993, ANN INTERN MED, V118, P224, DOI 10.7326/0003-4819-118-3-199302010-00012	1	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					224	224		10.7326/0003-4819-118-3-199302010-00012	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8417640				2022-12-28	WOS:A1993KJ43900012
J	BORKMAN, M; STORLIEN, LH; PAN, DA; JENKINS, AB; CHISHOLM, DJ; CAMPBELL, LV				BORKMAN, M; STORLIEN, LH; PAN, DA; JENKINS, AB; CHISHOLM, DJ; CAMPBELL, LV			THE RELATION BETWEEN INSULIN SENSITIVITY AND THE FATTY-ACID COMPOSITION OF SKELETAL-MUSCLE PHOSPHOLIPIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NORMAL GLUCOSE-TOLERANCE; DIETARY-FAT; RESISTANCE; MEMBRANE; SERUM; CELLS; HYPERINSULINEMIA; DISEASE; BINDING; HYPERTENSION	Background. Insulin resistance and hyperinsulinemia are features of obesity, non-insulin-dependent diabetes mellitus, and other disorders. Skeletal muscle is a major site of insulin action, and insulin sensitivity may be related to the fatty-acid composition of the phospholipids within the muscle membranes involved in the action of insulin. Methods. We determined the relation between the fatty-acid composition of skeletal-muscle phospholipids and insulin sensitivity in two groups of subjects. In one study, we obtained samples of the rectus abdominis muscle from 27 patients undergoing coronary artery surgery; fasting serum insulin levels provided an index of insulin sensitivity. In the second study, a biopsy of the vastus lateralis muscle was performed in 13 normal men, and insulin sensitivity was assessed by euglycemic-clamp studies. Results. In the patients undergoing surgery, the fasting serum insulin concentration (a measure of insulin resistance) was negatively correlated with the percentage of individual long-chain polyunsaturated fatty acids in the phospholipid fraction of muscle, particularly arachidonic acid (r = -0.63, P<0.001); the total percentage of C20-22 polyunsaturated fatty acids (r = -0.68, P<0.001); the average degree of fatty-acid unsaturation (r = -0.61, P<0.001); and the ratio of the percentage of C20:4 n-6 fatty acids to the percentage of C20:3 n-6 fatty acids (r = -0.55, P<0.01), an index of fatty-acid desaturase activity. In the normal men, insulin sensitivity was positively correlated with the percentage of arachidonic acid in muscle (r = 0.76, P<0.01), the total percentage of C20-22 polyunsaturated fatty acids (r = 0.76, P<0.01), the average degree of fatty-acid unsaturation (r = 0.62, P<0.05), and the ratio of C20:4 n-6 to C20:3 n-6 (rho = 0.78, P = 0.007). Conclusions. Decreased insulin sensitivity is associated with decreased concentrations of polyunsaturated fatty acids in skeletal-muscle phospholipids, raising the possibility that changes in the fatty-acid composition of muscles modulate the action of insulin.	ST VINCENTS HOSP,GARVAN INST MED RES,DARLINGHURST,NSW 2010,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney			Jenkins, Arthur B/D-4533-2012; Campbell, Lesley V/B-2271-2008; Chisholm, Donald J/J-9332-2013	Jenkins, Arthur B/0000-0003-1310-264X; Chisholm, Donald J/0000-0002-5349-5735				ALLAIN CC, 1974, CLIN CHEM, V20, P470; BUCOLO G, 1973, CLIN CHEM, V19, P476; BURSTEIN M, 1970, J LIPID RES, V11, P583; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; ELBOUSTANI S, 1989, METABOLISM, V38, P315, DOI 10.1016/0026-0495(89)90117-0; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FAAS FH, 1980, LIPIDS, V15, P953, DOI 10.1007/BF02534421; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FIELD CJ, 1988, BIOCHEM J, V253, P417, DOI 10.1042/bj2530417; FOLCH J, 1957, J BIOL CHEM, V226, P497; GINSBERG BH, 1982, BIOCHIM BIOPHYS ACTA, V690, P157, DOI 10.1016/0005-2736(82)90318-2; Ginsberg BH, 1987, DIABETES S1, V36, p51A; GRUNFELD C, 1981, BIOCHEM BIOPH RES CO, V103, P219, DOI 10.1016/0006-291X(81)91682-X; HAGVE TA, 1988, SCAND J CLIN LAB INV, V48, P381, DOI 10.3109/00365518809085746; HOLLENBECK C, 1987, J CLIN ENDOCR METAB, V64, P1169, DOI 10.1210/jcem-64-6-1169; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; LILLIOJA S, 1986, J CLIN ENDOCR METAB, V62, P922, DOI 10.1210/jcem-62-5-922; LITHELL HOL, 1991, DIABETES CARE, V14, P203, DOI 10.2337/diacare.14.3.203; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NANKERVIS A, 1985, DIABETOLOGIA, V28, P427, DOI 10.1007/BF00280885; PELIKANOVA T, 1989, METABOLISM, V38, P188, DOI 10.1016/0026-0495(89)90261-8; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RIZZA RA, 1985, DIABETOLOGIA, V28, P70; ROWE JW, 1983, J CLIN INVEST, V71, P1581, DOI 10.1172/JCI110914; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SALTIEL AR, 1990, DIABETES CARE, V13, P244, DOI 10.2337/diacare.13.3.244; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; STRALFORS P, 1988, NATURE, V335, P554, DOI 10.1038/335554a0; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V779, P89, DOI 10.1016/0304-4157(84)90005-4; TILVIS RS, 1985, J CLIN ENDOCR METAB, V61, P741, DOI 10.1210/jcem-61-4-741; VOELKER DR, 1991, MICROBIOL REV, V55, P543, DOI 10.1128/MMBR.55.4.543-560.1991; WAHLE KWJ, 1991, LIPIDS, V26, P16, DOI 10.1007/BF02544018; WHITCOMB RW, 1988, J CLIN INVEST, V81, P185, DOI 10.1172/JCI113292; WILLIS AL, 1984, NUTR REV PRESENT KNO, P90; YKIJARVINEN H, 1984, METABOLISM, V33, P1011, DOI 10.1016/0026-0495(84)90229-4; YOREK M, 1989, INVEST OPHTH VIS SCI, V30, P2087; ZAVARONI I, 1985, ATHEROSCLEROSIS, V55, P259, DOI 10.1016/0021-9150(85)90105-4; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	42	727	746	1	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1993	328	4					238	244		10.1056/NEJM199301283280404	http://dx.doi.org/10.1056/NEJM199301283280404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ442	8418404				2022-12-28	WOS:A1993KJ44200004
J	DANISHEFSKY, S				DANISHEFSKY, S			CATALYTIC ANTIBODIES AND DISFAVORED REACTIONS	SCIENCE			English	Editorial Material							RING				DANISHEFSKY, S (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511, USA.							ABRAMOWICZ DA, 1990, BIOCATALYSIS; BALDWIN JE, 1982, TETRAHEDRON, V38, P2939, DOI 10.1016/0040-4020(82)85023-0; BEAK P, 1992, ACCOUNTS CHEM RES, V25, P215, DOI 10.1021/ar00017a002; BURGI HB, 1983, ACCOUNTS CHEM RES, V16, P168; DANISHEFSKY S, 1974, J AM CHEM SOC, V96, P1256, DOI 10.1021/ja00811a068; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JOHNSSON K, 1990, MOL MECHANISMS BIOOR; KIM PS, 1988, PROTEIN ENG, V2, P249, DOI 10.1093/protein/2.4.249; KNIPE AC, 1968, J CHEM SOC, V67; Knowles J.R., 1989, ALDRICHIM ACTA, V22, P59; LERNER RA, 1991, SCIENCE, V252, P695; NICOLAOU KC, 1989, J AM CHEM SOC, V111, P5330, DOI 10.1021/ja00196a043; Pauling L, 1944, J AM CHEM SOC, V66, P784, DOI 10.1021/ja01233a039; POWELL MJ, 1989, PROTEIN ENG, V3, P69, DOI 10.1093/protein/3.2.69; STORK G, 1974, J AM CHEM SOC, V96, P5268, DOI 10.1021/ja00823a052; Tenud L., 1970, HELV CHIM ACTA, V53, P2059, DOI [10.1002/hlca.19700530816, DOI 10.1002/HLCA.19700530816]; Trost B M, 1991, COMPREHENSIVE ORGANI, V1-9	18	11	16	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					469	470		10.1126/science.8424168	http://dx.doi.org/10.1126/science.8424168			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424168				2022-12-28	WOS:A1993KJ07900021
J	LOCALIO, AR; LAWTHERS, AG; BENGTSON, JM; HEBERT, LE; WEAVER, SL; BRENNAN, TA; LANDIS, JR				LOCALIO, AR; LAWTHERS, AG; BENGTSON, JM; HEBERT, LE; WEAVER, SL; BRENNAN, TA; LANDIS, JR			RELATIONSHIP BETWEEN MALPRACTICE CLAIMS AND CESAREAN DELIVERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; SECTION RATES; MULTIVARIATE-ANALYSIS; BIRTH-RATE; MORTALITY; LABOR; RISE; CALIFORNIA; REGRESSION; SEVERITY	Objective.-To investigate whether an association exists between the probability of a cesarean delivery and the level of malpractice claims risk faced by hospitals and physicians. Design.-Survey of computerized discharge data linked with physician and hospital malpractice claims records based on stratified, random sample of hospitals. Setting.-Acute care hospitals in New York State in 1984. Population.-All deliveries (60490) at 31 hospitals. Results.-After controlling for the clinical risk of a cesarean delivery, patient socioeconomic status, and physician and hospital characteristics, cesarean delivery was positively associated with physician malpractice premiums (odds ratio [OR], 3.00; 95% confidence interval [CI], 2.13 to 4.24 for the difference between upstate and New York City levels), with the number of physician claims opened per 100 physicians at the hospital level (OR, 1.15; 95% CI, 1.02 to 1.30 for a 1-SD change), and with the number of hospital claims opened per 1000 discharges (OR, 1.26; 95% CI, 1.10 to 1.43 for a 1-SD change). Measures of physician-perceived risk of suit also showed a significant association with cesarean delivery (OR, 1.96; 95% CI, 1.53 to 2.52, upstate vs New York City). Within hospitals, there was no significant association (OR, 1.15; P=.126) between the odds of cesarean delivery and the claims history (none vs one or more) of an individual physician. Conclusion.-Results support previous speculations of a positive association between malpractice claims risk and the rate of cesarean delivery.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,CTR BIOSTAT & EPIDEMIOL,HERSHEY,PA 17033; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT OBSTET & GYNECOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; RUSH PRESBYTERIAN ST LUKES MED CTR,CTR RES HLTH & AGING,CHICAGO,IL 60612	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Rush University			Landis, J. Richard/A-9330-2010	Landis, J Richard/0000-0001-8099-0988	AHRQ HHS [1 R03 HS 07070-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON GM, 1984, NEW ENGL J MED, V311, P887, DOI 10.1056/NEJM198410043111405; Barnard GA, 1982, ENCY STAT SCI, V1, P387; BARROS FC, 1991, LANCET, V338, P167, DOI 10.1016/0140-6736(91)90149-J; BLUMBERG MS, 1991, JAMA-J AM MED ASSOC, V265, P2965; CARPENTER MW, 1987, OBSTET GYNECOL, V70, P657; DANFORTH DN, 1985, JAMA-J AM MED ASSOC, V253, P811, DOI 10.1001/jama.253.6.811; DANZON PM, 1986, LAW CONTEMP PROBL, V49, P57, DOI 10.2307/1191415; DAVIS LK, 1984, CESAREAN BIRTHS MASS; DEMOTT RK, 1990, AM J OBSTET GYNECOL, V162, P1593, DOI 10.1016/0002-9378(90)90925-W; DEREGT RH, 1986, NEW ENGL J MED, V315, P619, DOI 10.1056/NEJM198609043151005; ERICKSON ML, 1977, AM SOCIOL REV, V42, P305, DOI 10.2307/2094607; FEINSTEIN AR, 1985, ARCH INTERN MED, V145, P1257, DOI 10.1001/archinte.145.7.1257; FLOOD B, 1987, HOSPITAL STRUCTURE P; FRASER W, 1987, AM J OBSTET GYNECOL, V156, P300, DOI 10.1016/0002-9378(87)90272-9; FREEMAN DH, 1980, BIOMETRICS, V36, P195, DOI 10.2307/2529971; FRIEDMAN EA, 1986, NEW ENGL J MED, V315, P641, DOI 10.1056/NEJM198609043151010; GLEICHER N, 1985, JAMA-J AM MED ASSOC, V253, P3248, DOI 10.1001/jama.1985.03350460043008; GOULD JB, 1989, NEW ENGL J MED, V321, P233, DOI 10.1056/NEJM198907273210406; GOYERT GI, 1989, NEW ENGL J MED, V320, P106; GREENWALD B, 1978, EC MED MALPRACTICE, P65; GUTHEIL TG, 1984, NEW ENGL J MED, V311, P49, DOI 10.1056/NEJM198407053110110; HSIEH FY, 1989, STAT MED, V8, P795, DOI 10.1002/sim.4780080704; IEZZONI II, 1990, INT J TECHNOL ASSESS, V6, P272; JESSEE WF, 1982, MED CARE, V20, P75, DOI 10.1097/00005650-198201000-00006; JONAS HS, 1989, JAMA-J AM MED ASSOC, V262, P1512; Kalton G, 1986, SURV METHODOL, V12, P1; KENNELL J, 1991, JAMA-J AM MED ASSOC, V265, P2197, DOI 10.1001/jama.265.17.2197; KIWANUKA AI, 1987, BRIT J OBSTET GYNAEC, V94, P440, DOI 10.1111/j.1471-0528.1987.tb03122.x; KNOX RA, 1984, BOSTON GLOBE MA 1028, V13, P30; KOTT PS, 1991, AM STAT, V45, P107, DOI 10.2307/2684369; LANGWELL KM, 1980, J HEALTH POLIT POLIC, V5, P498; LAWTHERS AG, 1992, J HEALTH POLIT POLIC, V17, P463, DOI 10.1215/03616878-17-3-463; MARIESKIND H, 1979, EVALUATION CESAREAN; MARTEL M, 1987, AM J OBSTET GYNECOL, V156, P305, DOI 10.1016/0002-9378(87)90273-0; McCullagh P., 1989, GEN LINEAR MODELS, P124; MILLER ME, 1991, BIOMETRICS, V47, P33, DOI 10.2307/2532493; MOLD JW, 1986, NEW ENGL J MED, V314, P512, DOI 10.1056/NEJM198602203140809; MOSES LE, 1986, JAMA-J AM MED ASSOC, V255, P2801; Myers S A, 1991, QRB Qual Rev Bull, V17, P162; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NEUHAUS JM, 1991, INT STAT REV, V59, P25, DOI 10.2307/1403572; NOTZON FC, 1990, JAMA-J AM MED ASSOC, V263, P3286, DOI 10.1001/jama.263.24.3286; NOTZON FC, 1987, NEW ENGL J MED, V316, P386, DOI 10.1056/NEJM198702123160706; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; PEARSE WH, 1983, AM J PUBLIC HEALTH, V73, P843, DOI 10.2105/AJPH.73.8.843; PHILLIPS RN, 1982, JAMA-J AM MED ASSOC, V248, P1082, DOI 10.1001/jama.248.9.1082; PLACEK PJ, 1988, OBSTET GYN CLIN N AM, V15, P607; PLACEK PJ, 1983, AM J PUBLIC HEALTH, V73, P861, DOI 10.2105/AJPH.73.8.861; PLACEK PJ, 1988, AM J PUBLIC HEALTH, V78, P562, DOI 10.2105/AJPH.78.5.562; PORRECO RP, 1985, OBSTET GYNECOL, V65, P307; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; ROCK SM, 1988, PUBLIC HEALTH REP, V103, P459; SACHS BP, 1989, MEDICAL PROFESSIONAL LIABILITY AND THE DELIVERY OF OBSTETRICAL CARE, VOL 2, P27; SHAH BV, 1991, SUDAAN VERSION 541; SHIONO PH, 1987, JAMA-J AM MED ASSOC, V257, P494, DOI 10.1001/jama.257.4.494; SILVER L, 1989, UNNECESSARY CESAREAN; SLOAN FA, 1985, J HEALTH POLIT POLIC, V9, P629, DOI 10.1215/03616878-9-4-629; STAFFORD RS, 1991, JAMA-J AM MED ASSOC, V265, P59, DOI 10.1001/jama.265.1.59; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; TAFFEL SM, 1987, AM J PUBLIC HEALTH, V77, P955, DOI 10.2105/AJPH.77.8.955; TAFFEL SM, 1985, AM J PUBLIC HEALTH, V75, P190, DOI 10.2105/AJPH.75.2.190; TANCREDI LR, 1978, SCIENCE, V200, P879, DOI 10.1126/science.644329; WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268; WEISMAN CS, 1989, MED CARE, V27, P16, DOI 10.1097/00005650-198901000-00002; WILLIAMS RL, 1983, AM J PUBLIC HEALTH, V73, P863, DOI 10.2105/AJPH.73.8.863; WILLIAMS RL, 1979, AM J PUBLIC HEALTH, V69, P864, DOI 10.2105/AJPH.69.9.864; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; 1988, 14 STAT NEW YORK INS; 1984, LANCET, V2, P852; 1990, PATIENTS DOCTORS LAW; 1983, OTABPH22 OFF TECHN A, P13	71	154	155	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					366	373		10.1001/jama.269.3.366	http://dx.doi.org/10.1001/jama.269.3.366			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KG381	8418343				2022-12-28	WOS:A1993KG38100028
J	MICHAELS, MG; FRADER, J; ARMITAGE, J				MICHAELS, MG; FRADER, J; ARMITAGE, J			ETHICAL CONSIDERATIONS IN LISTING FETUSES AS CANDIDATES FOR NEONATAL HEART-TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ORTHOTOPIC CARDIAC TRANSPLANTATION; PATIENTS EVER; RECIPIENTS; DIAGNOSIS; ISSUES; LIFE		CHILDRENS HOSP PITTSBURGH,PITTSBURGH,PA; UNIV PITTSBURGH,SCH MED,CTR MED ETH,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH MED,DEPT SURG,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	MICHAELS, MG (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15261, USA.		Frader, Joel/A-8610-2010	Frader, Joel/0000-0001-5620-2400				ADDONIZIO LJ, 1989, CIRCULATION, V80, P84; BACKER CL, 1991, J THORAC CARDIOV SUR, V101, P826; BAILEY LL, 1989, ARCH SURG-CHICAGO, V124, P1221; Beauchamp TL, 1989, PRINCIPLES BIOMEDICA, P290; Bernstein D, 1990, Adv Pediatr, V37, P413; BOUCEK MM, 1990, J PEDIATR-US, V116, P171, DOI 10.1016/S0022-3476(05)82870-7; CAPLAN AL, 1987, CIRCULATION, V75, P10, DOI 10.1161/01.CIR.75.1.10; Cooley D A, 1969, Ann Thorac Surg, V8, P30; Field M A, 1989, Law Med Health Care, V17, P114; JOHNSTON J, 1990, WESTERN J MED, V152, P70; JONASSON O, 1989, TRANSPLANT P, V21, P3390; KANTROWITZ A, 1968, AM J CARDIOL, V22, P782, DOI 10.1016/0002-9149(68)90173-2; KAYE M, 1991, INFANT HEART TRANSPL; KOLDER VEB, 1987, NEW ENGL J MED, V316, P1192, DOI 10.1056/NEJM198705073161905; MACKLIN R, 1989, TRANSPLANT P, V21, P3395; MAVROUDIS C, 1988, J THORAC CARDIOV SUR, V96, P912; NELSON LJ, 1988, JAMA-J AM MED ASSOC, V259, P1060, DOI 10.1001/jama.259.7.1060; Rhoden N K, 1987, Law Med Health Care, V15, P118; ROBERTSON JA, 1987, CIRCULATION, V75, P77, DOI 10.1161/01.CIR.75.1.77; STRONG C, 1987, CLIN PERINATOL, V14, P313, DOI 10.1016/S0095-5108(18)30767-X; WERTZ DC, 1989, PEDIATR ANN, V18, P739, DOI 10.3928/0090-4481-19891101-09; 1990, JAMA-J AM MED ASSOC, V264, P2663	22	11	11	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					401	403		10.1001/jama.269.3.401	http://dx.doi.org/10.1001/jama.269.3.401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418350				2022-12-28	WOS:A1993KG38100035
J	GOTTLIEB, TM; JACKSON, SP				GOTTLIEB, TM; JACKSON, SP			THE DNA-DEPENDENT PROTEIN-KINASE - REQUIREMENT FOR DNA ENDS AND ASSOCIATION WITH KU ANTIGEN	CELL			English	Article							RNA POLYMERASE-II; VIRUS-40 T-ANTIGEN; HELA-CELL NUCLEI; BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; AUTOANTIGEN-KU; AUTO-ANTIGEN; PHOSPHORYLATION; PURIFICATION; INITIATION	The DNA-dependent protein kinase (DNA-PK) phosphorylates Sp1 and several other nuclear proteins. Here, we show that Sp1 and the DNA-PK must be colocalized on the same DNA molecule for efficient phosphorylation to occur. Interestingly, we find that the DNA-PK binds to and is activated by the ends of DNA molecules. Furthermore, we show that the DNA binding properties of the DNA-PK are identical to those of Ku, a well-characterized human autoimmune antigen. We demonstrate that the DNA-PK can be fractionated into two components, one of which is Ku and the other of which is a polypeptide of approximately 350 kd. DNA cross-linking and coimmunoprecipitation studies indicate that the catalytic 350 kd DNA-PK component is directed to DNA by protein-protein interactions with Ku. The implications of the unusual DNA binding mode and multicomponent nature of the DNA-PK are discussed.			GOTTLIEB, TM (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLAWAY GP, 1990, BIOCHEM BIOPH RES CO, V168, P747, DOI 10.1016/0006-291X(90)92385-D; ANDERSON CW, 1992, IN PRESS CRIT REV EU; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHAN JYC, 1989, J BIOL CHEM, V264, P3651; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; COUREY AJ, 1992, IN PRESS TRANSCRIPTI; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IIJIMA S, 1992, EUR J BIOCHEM, V205, P595; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PORGES AJ, 1990, J IMMUNOL, V145, P4222; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REEVES WH, 1989, J BIOL CHEM, V264, P5047; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STUIVER MH, 1990, J EXP MED, V172, P1049, DOI 10.1084/jem.172.4.1049; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WALKER AI, 1985, EMBO J, V4, P139, DOI 10.1002/j.1460-2075.1985.tb02328.x; WANG TSF, 1980, BIOCHEMISTRY-US, V19, P1782, DOI 10.1021/bi00550a009; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; YANEVA M, 1989, J BIOL CHEM, V264, P13407; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	48	1031	1047	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					131	142		10.1016/0092-8674(93)90057-W	http://dx.doi.org/10.1016/0092-8674(93)90057-W			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422676				2022-12-28	WOS:A1993KG95500017
J	MARSDEN, PD				MARSDEN, PD			LETTER FROM BRASILIA - OBSTRUCTIVE LYMPHATIC FILARIASIS	BRITISH MEDICAL JOURNAL			English	Article											MARSDEN, PD (corresponding author), UNIV BRASILIA,CP 102382,BR-70840 BRASILIA,DF,BRAZIL.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					136	136		10.1136/bmj.306.6870.136	http://dx.doi.org/10.1136/bmj.306.6870.136			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG465	8435614	Bronze, Green Published			2022-12-28	WOS:A1993KG46500033
J	SWALES, JD				SWALES, JD			LONDON AFTER TOMLINSON .8. THE TOMLINSON REPORT AND POSTGRADUATE MEDICAL-EDUCATION	BRITISH MEDICAL JOURNAL			English	Article								The postgraduate hospitals of London grew up in the nineteenth century and offered a unique national specialist service. Since then specialist services have developed in undergraduate hospitals throughout Britain as well as in London, but the postgraduate hospitals have nevertheless preserved their high levels of staffing. Although numbers of medical posts in the provinces have grown, this has not been by redistribution of London posts but merely differential growth. The fact identified by Tomlinson-that Londoners are not receiving the most appropriate clinical care-is in fact the strongest argument for changing postgraduate medical education. Such education needs to be rooted first in clinical care, though Tomlinson underestimates the importance to education of such care being sited in a shared environment with strong scientific activity.			SWALES, JD (corresponding author), UNIV LEICESTER,DEPT MED,LEICESTER LE2 7LX,W YORKSHIRE,ENGLAND.							DAINTON F, 1990, INT S SERIES, V171, P7; 1992, REPORT YEAR 1990 91; 1992, LONDON HLTH CARE 212; 1992, ENQUIRY LONDONS HLTH; 1989, COMPENDIUM HLTH STAT	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 2	1993	306	6869					42	44		10.1136/bmj.306.6869.42	http://dx.doi.org/10.1136/bmj.306.6869.42			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KE984	8435579	Green Published, Bronze			2022-12-28	WOS:A1993KE98400029
J	NAKAGAWARA, A; ARIMANAKAGAWARA, M; SCAVARDA, NJ; AZAR, CG; CANTOR, AB; BRODEUR, GM				NAKAGAWARA, A; ARIMANAKAGAWARA, M; SCAVARDA, NJ; AZAR, CG; CANTOR, AB; BRODEUR, GM			ASSOCIATION BETWEEN HIGH-LEVELS OF EXPRESSION OF THE TRK GENE AND FAVORABLE OUTCOME IN HUMAN NEUROBLASTOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NERVE GROWTH-FACTOR; HUMAN NEURO-BLASTOMA; PEDIATRIC-ONCOLOGY-GROUP; N-MYC ONCOGENE; FACTOR RECEPTOR; NGF RECEPTOR; CELL-LINES; DEVELOPMENTAL EXPRESSION; PHEOCHROMOCYTOMA CELLS; PROTOONCOGENE PRODUCT	Background and Methods. The nerve growth factor receptor is expressed in some neuroblastomas, in which its primary component is encoded by the TRK proto-oncogene. To determine the relation of the expression of TRK messenger RNA in neuroblastomas to other clinical and laboratory variables, we studied frozen tumor samples from 77 patients. In addition, we tested two primary neuroblastomas that expressed TRK for responsiveness to nerve growth factor. Results. TRK expression strongly correlated with favorable tumor stage (I, II, and IVS vs. III and IV), younger age (<1 year vs. greater-than-or-equal-to 1 year), normal N-myc copy number, and low level of N-myc expression. N-myc amplification (indicated by a high copy number) correlated with advanced tumor stage, older age, an adrenal site of the primary tumor, low level of expression of TRK, and high level of expression of N-myc. Analysis of five-year cumulative-survival rates demonstrated an association of a very favorable outcome with a high level of TRK expression (86 percent vs. 14 percent) and with normal N-myc copy number (84 percent vs. 0 percent). Univariate analysis showed that these two variables were the most powerful predictors of outcome (chi-square = 51.30, P<0.001; and chi-square = 93.61, P<0.001, respectively). TRK expression still had significant prognostic value when the analysis was restricted to tumors without N-myc amplification. In primary cultures of neuroblastoma cells expressing TRK, exposure to nerve growth factor induced early gene expression and neurite outgrowth, but deprivation of nerve growth factor led to neuronal cell death. Conclusions. A high level of expression of the TRK proto-oncogene in a neuroblastoma is strongly predictive of a favorable outcome. A tumor with a functional nerve growth factor receptor may be dependent on the neurotrophin nerve growth factor for survival and may regress in its absence, allowing a new approach to the treatment of certain patients with neuroblastoma.	WASHINGTON UNIV, SCH MED, DEPT PEDIAT, 1 CHILDRENS PL, ST LOUIS, MO 63110 USA; PEDIAT ONCOL GRP, STAT OFF, GAINESVILLE, FL USA; PEDIAT ONCOL GRP, ST LOUIS, MO USA	Washington University (WUSTL)					NCI NIH HHS [CA-05587, CA-39771, CA-49712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039771, U10CA005587, P01CA049712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BAKER DL, 1991, AM J PATHOL, V139, P115; BARTRAM CR, 1987, EUR J PEDIATR, V146, P162, DOI 10.1007/BF02343225; BILL AH, 1969, J NATL CANCER I, V43, P1221; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BOWMAN LC, 1990, MED PEDIATR ONCOL, V18, P364; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CASTLEBERRY RP, 1991, J CLIN ONCOL, V9, P789, DOI 10.1200/JCO.1991.9.5.789; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; COX DR, 1972, J R STAT SOC B, V34, P187; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; EICHLER ME, 1989, BRAIN RES, V482, P340, DOI 10.1016/0006-8993(89)91197-9; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GODFREY EW, 1986, J NEUROSCI, V6, P2543; GOLDSTEIN MN, 1964, JNCI-J NATL CANCER I, V32, P165; GRAHAMPOLE J, 1991, J CLIN ONCOL, V9, P152; GREEN AA, 1981, CANCER, V48, P2310, DOI 10.1002/1097-0142(19811115)48:10<2310::AID-CNCR2820481029>3.0.CO;2-W; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HASKELL BE, 1987, CELL TISSUE RES, V247, P67, DOI 10.1007/BF00216548; HAYASHI Y, 1987, CANCER GENET CYTOGEN, V29, P175, DOI 10.1016/0165-4608(87)90047-1; HEMPSTEAD B, 1988, COLD SPRING HARB SYM, V53, P477, DOI 10.1101/SQB.1988.053.01.055; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; IKEDA K, 1989, J PEDIATR SURG, V24, P189, DOI 10.1016/S0022-3468(89)80247-7; KANEKO Y, 1987, CANCER RES, V47, P311; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARCHETTI D, 1987, J NEUROCHEM, V49, P475, DOI 10.1111/j.1471-4159.1987.tb02889.x; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NAKAGAWARA A, 1987, J PEDIATR SURG, V22, P895, DOI 10.1016/S0022-3468(87)80583-3; NAKAGAWARA A, 1990, CANCER, V65, P1960, DOI 10.1002/1097-0142(19900501)65:9<1960::AID-CNCR2820650914>3.0.CO;2-4; NAKAGAWARA A, 1991, CANCER, V68, P2037, DOI 10.1002/1097-0142(19911101)68:9<2037::AID-CNCR2820680932>3.0.CO;2-C; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NITSCHKE R, 1991, J CLIN ONCOL, V9, P1181, DOI 10.1200/JCO.1991.9.7.1181; OTA K, 1980, HISTOLOGICAL CLASSIF; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAGSDALE C, 1991, NATURE, V350, P660, DOI 10.1038/350660a0; REDDY UR, 1991, J NEUROCHEM, V56, P67, DOI 10.1111/j.1471-4159.1991.tb02563.x; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1985, HUM PATHOL, V16, P471, DOI 10.1016/S0046-8177(85)80085-X; SLAVC I, 1990, CANCER RES, V50, P1459; SONNENFELD KH, 1985, J NEUROSCI, V5, P1717; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TAKEDA T, 1989, MED PEDIATR ONCOL, V17, P361; TAYLOR SR, 1988, CANCER, V62, P749, DOI 10.1002/1097-0142(19880815)62:4<749::AID-CNCR2820620418>3.0.CO;2-W; TISCHLER AS, 1984, CANCER, V54, P1344, DOI 10.1002/1097-0142(19841001)54:7<1344::AID-CNCR2820540718>3.0.CO;2-J; TSOKOS M, 1987, AM J PATHOL, V128, P484; WARIS T, 1973, EXPERIENTIA, V29, P1128, DOI 10.1007/BF01946760; YAN Q, 1987, DEV BIOL, V121, P139, DOI 10.1016/0012-1606(87)90147-3; YAN Q, 1988, J NEUROSCI, V8, P3481	73	590	608	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	1993	328	12					847	854		10.1056/NEJM199303253281205	http://dx.doi.org/10.1056/NEJM199303253281205			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT814	8441429				2022-12-28	WOS:A1993KT81400005
J	LANGE, RA; HILLIS, LD				LANGE, RA; HILLIS, LD			IMMEDIATE ANGIOPLASTY FOR ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRIAL				LANGE, RA (corresponding author), UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA.		Lange, Richard/AAM-9594-2021					[Anonymous], 1991, BMJ, V302, P555; ELLIS SG, 1992, CIRCULATION, V86, P1400, DOI 10.1161/01.CIR.86.5.1400; FEIT F, 1990, J AM COLL CARDIOL, V16, P1529, DOI 10.1016/0735-1097(90)90295-Z; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; SIMOONS ML, 1988, LANCET, V1, P199; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; TOPOL EJ, 1992, CIRCULATION, V85, P2090, DOI 10.1161/01.CIR.85.6.2090; WILLIAMS DO, 1992, CIRCULATION, V85, P533, DOI 10.1161/01.CIR.85.2.533; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1992, HOSPITAL STATISTICS, P208	12	50	52	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 11	1993	328	10					726	728		10.1056/NEJM199303113281010	http://dx.doi.org/10.1056/NEJM199303113281010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ861	8433733				2022-12-28	WOS:A1993KQ86100010
J	BRAVEMAN, P; BENNETT, T; LEWIS, C; EGERTER, S; SHOWSTACK, J				BRAVEMAN, P; BENNETT, T; LEWIS, C; EGERTER, S; SHOWSTACK, J			ACCESS TO PRENATAL-CARE FOLLOWING MAJOR MEDICAID ELIGIBILITY EXPANSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT; INSURANCE; HEALTH; WOMEN	Objective.-To determine whether lack of financial access was a significant barrier to prenatal care following major expansions of Medicaid eligibility in California. Design.-Retrospective analysis of birth certificates, assessing risks of inadequate prenatal care by insurance, controlling for maternal race/ethnicity, birthplace, age, parity, education, and marital status. Sample.-Singleton live births to California residents occurring in-state in 1990 (N=593510). Outcome Measures.-Untimely initiation of care, too few visits, and no prenatal care. Results.-Despite major Medicaid expansions, nearly 11% of live births were uninsured for prenatal care. Being uninsured and having Medi-Cal were both risk factors of sizable magnitude, controlling for,maternal characteristics. Compared with women who had private fee-for-service coverage, uninsured women were at elevated risk of untimely initiation (odds ratio [OR], 2.54; 95% confidence interval [Cl], 2.47 to 2.60) and too few visits (OR, 2.49; 95% Cl, 2.44 to 2.55). Women with Medi-Cal had a high risk of untimely care (OR, 3.33; 95% Cl, 3.26 to 3.40); their risk of too few visits was also elevated (OR, 1.63; 95% Cl, 1.60 to 1.66) but less than for the uninsured. Lack of private insurance was a strong risk factor for no care (OR, 6.70; 95% Cl, 6.00 to 7.47). Conclusions.-In spite of major Medicaid expansions, access to prenatal care was limited for women without private insurance. Medicaid was associated with untimely entry but with improved continuity. The findings suggest that financial barriers were salient even when controlling for many factors related to care-seeking behavior. Policy initiatives need to address continuing financial barriers along with other obstacles.	UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BRAVEMAN, P (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,BOX 0900,SAN FRANCISCO,CA 94143, USA.		Showstack, Jonathan/L-6556-2013	Showstack, Jonathan/0000-0002-1367-419X				BRAVEMAN P, 1988, WESTERN J MED, V149, P708; BROWN ER, 1988, CHANGES HLTH INSURAN; BROWN SS, 1989, FAM PLANN PERSPECT, V21, P73, DOI 10.2307/2135557; COONEY JP, 1985, MED CARE, V23, P986, DOI 10.1097/00005650-198508000-00006; DAVID RJ, 1980, AM J PUBLIC HEALTH, V70, P964, DOI 10.2105/AJPH.70.9.964; GREENBERG RS, 1983, AM J OBSTET GYNECOL, V145, P797, DOI 10.1016/0002-9378(83)90681-6; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; HUGHES D, 1988, HLTH AM CHILDREN MAT; JAMISON H, UNPUB BIRTH CERTIFIC; KOTELCHUCK M, 1987, 115TH ANN M AM PUBL; MURRAY JL, 1988, NEW ENGL J MED, V319, P1385, DOI 10.1056/NEJM198811243192105; Oberg C N, 1991, J Health Care Poor Underserved, V2, P270; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; SCHWETHELM B, 1989, AM J PREV MED, V5, P157, DOI 10.1016/S0749-3797(18)31097-3; WILLIAMS RL, 1982, OBSTET GYNECOL, V59, P624; [No title captured]; 1985, SAS USERS GUIDE STAT; 1987, PRENATAL CARE MEDICA; [No title captured]; 1988, PRENATAL CARE REACHI	20	105	105	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	1993	269	10					1285	1289		10.1001/jama.269.10.1285	http://dx.doi.org/10.1001/jama.269.10.1285			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP885	8437308				2022-12-28	WOS:A1993KP88500029
J	HELZLSOUER, KJ; BUSH, TL; ALBERG, AJ; BASS, KM; ZACUR, H; COMSTOCK, GW				HELZLSOUER, KJ; BUSH, TL; ALBERG, AJ; BASS, KM; ZACUR, H; COMSTOCK, GW			PROSPECTIVE-STUDY OF SERUM CA-125 LEVELS AS MARKERS OF OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MONOCLONAL-ANTIBODY; RISK	Objective.-To evaluate prospectively the sensitivity and specificity of serum CA-125 levels for the detection of ovarian cancer. Design.-Case-control study nested within a cohort of women who donated blood to a community-based serum bank established in 1974. Setting.-Washington County, Maryland. Population.-Cases consisted of 37 women who developed ovarian cancer from 1975 through 1989. Controls consisted of 73 women, matched on age and time since last menstrual period, and free of cancer until the cases' diagnoses. Study Variable.-Serum CA-125 levels. Outcome Measure.-Histologically confirmed ovarian cancer. Results.-Levels of serum CA-1 25 among cases were higher than among controls for each 3-year interval up to 12 years prior to the time of the cases' diagnoses. The median level for cases diagnosed within the first 3 years of follow-up was 35.4 U/mL compared with 9.0 U/mL for controls (P=.002). The sensitivity of a serum CA-1 25 level greater than 35 U/mL within the first 3 years was 57% (95% confidence interval, 20% to 88%) and the specificity was 100% (95% confidence interval lower limit, 73%). Sensitivity and specificity decreased with increasing time to diagnosis. Conclusions.-Measurement of serum CA-125 levels, particularly at a reference value of 35 U/mL, is not sufficiently sensitive to be used alone as a screening test for the detection of ovarian cancer. Lower CA-125 reference values could identify women at higher risk of developing ovarian cancer, but CA-125 measurement cannot be recommended for this purpose because of the high proportion of women who would be falsely classified as being at high risk for developing ovarian cancer.	FRANCIS SCOTT KEY MED CTR,DEPT GYNECOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,DEPT GYNECOL & OBSTET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,CTR ONCOL,SCH HYG & PUBL HLTH,DEPT IMMUNOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine			zacur, howard/W-2170-2019		NCI NIH HHS [CA36390] Funding Source: Medline; NICHD NIH HHS [HD-06268] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD006268] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA036390, R55CA036390] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; EINHORN N, 1992, OBSTET GYNECOL, V80, P14; GLATTRE E, 1989, INT J EPIDEMIOL, V18, P45, DOI 10.1093/ije/18.1.45; HAGA Y, 1986, AM J MED SCI, V292, P25, DOI 10.1097/00000441-198607000-00005; HELZLSOUER KJ, 1992, OCT NAT CANC I WORKS; JACOBS I, 1988, LANCET, V1, P268; JACOBS I, 1989, HUM REPROD, V4, P1; KLUG TL, 1984, CANCER RES, V44, P1048; KWA HG, 1981, INT J CANCER, V28, P673, DOI 10.1002/ijc.2910280603; MILLER AB, 1985, SCREENING CANCER, P3; NILOFF JM, 1984, OBSTET GYNECOL, V64, P703; RIES LAG, 1991, NCI NIH912789 PUBL; SZKLO M, 1990, Journal of General Internal Medicine, V5, pS47, DOI 10.1007/BF02600841; ZURAWSKI VR, 1988, INT J CANCER, V42, P677, DOI 10.1002/ijc.2910420507; 1988, NCI NIH882789 PUBL	18	71	73	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1123	1126		10.1001/jama.269.9.1123	http://dx.doi.org/10.1001/jama.269.9.1123			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN611	8433467				2022-12-28	WOS:A1993KN61100028
J	LEUTHER, KK; SALMERON, JM; JOHNSTON, SA				LEUTHER, KK; SALMERON, JM; JOHNSTON, SA			GENETIC-EVIDENCE THAT AN ACTIVATION DOMAIN OF GAL4 DOES NOT REQUIRE ACIDITY AND MAY FORM A BETA-SHEET	CELL			English	Article							YEAST TRANSCRIPTIONAL ACTIVATORS; NEGATIVE REGULATORY PROTEIN; DNA-BINDING PROTEINS; NF-KAPPA-B; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; MAMMALIAN-CELLS; POLYMERASE-II; AMINO-ACIDS; INVITRO	Regulation of gene expression in eukaryotes relies on intricate protein-protein interactions. Transcription of the galactose genes in yeast has been a productive model for this type of interaction. The positive activator in this system, GAL4, has a bifunctional C-terminus. It contains both a prototypic acidic activation domain and a region that binds the negative regulator, GAL80. We have taken advantage of this colocalization of functions to subject the region to a constrained mutagenesis analysis: one function was maintained, while the other one was altered. This analysis and the experiments it suggested have led us to two conclusions: first, the acidic amino acids are not, as commonly thought, required for activation; second, this region is not unstructured or alpha helical, but its function may require a beta sheet.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LEUTHER, KK (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.							BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOSTIAN K, 1980, P NATL ACAD SCI USA, V77, P4505; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; DOSTATNI N, 1991, GENE DEV, V5, P1657, DOI 10.1101/gad.5.9.1657; DOUGLAS HC, 1966, GENETICS, V54, P911; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HARDWICK JM, 1992, J VIROL, V66, P5500, DOI 10.1128/JVI.66.9.5500-5508.1992; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HERMES JD, 1989, GENE, V84, P143, DOI 10.1016/0378-1119(89)90148-0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; INOSTROZA JA, 1992, CELL, V70, P477; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON SA, 1982, P NATL ACAD SCI-BIOL, V79, P6971, DOI 10.1073/pnas.79.22.6971; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUCHE RM, 1992, P NATL ACAD SCI USA, V89, P7412, DOI 10.1073/pnas.89.16.7412; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MATSUMOTO K, 1980, J BACTERIOL, V141, P508, DOI 10.1128/JB.141.2.508-527.1980; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NOGI Y, 1989, MOL CELL BIOL, V9, P3009, DOI 10.1128/MCB.9.7.3009; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PLATT T, 1984, MOL CELL BIOL, V4, P994, DOI 10.1128/MCB.4.5.994; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REGIER JL, 1993, IN PRESS P NATL ACAD; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SALMERON JM, 1990, GENETICS, V125, P21; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SALMERON JM, 1989, MOL CELL BIOL, V9, P2950, DOI 10.1128/MCB.9.7.2950; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; SHERMAN F, 1986, LABORATORY COURSE MA; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; TREACY MN, 1992, NATURE, V68, P491; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; VANHOY M, 1992, J AM CHEM SOC, V114, P362, DOI 10.1021/ja00027a057; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILLIAMS TM, 1991, SCIENCE, V254, P1791, DOI 10.1126/science.1840704; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P21	79	130	130	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					575	585		10.1016/0092-8674(93)90076-3	http://dx.doi.org/10.1016/0092-8674(93)90076-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440021				2022-12-28	WOS:A1993KP16500012
J	SANDVIK, L; ERIKSSEN, J; THAULOW, E; ERIKSSEN, G; MUNDAL, R; RODAHL, K				SANDVIK, L; ERIKSSEN, J; THAULOW, E; ERIKSSEN, G; MUNDAL, R; RODAHL, K			PHYSICAL-FITNESS AS A PREDICTOR OF MORTALITY AMONG HEALTHY, MIDDLE-AGED NORWEGIAN MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; EXERCISE; TRIAL; ATHEROSCLEROSIS; LIPOPROTEINS; INFARCTION; SMOKING; DEATH; LIFE	Background. Despite many studies suggesting that poor physical fitness is an independent risk factor for death from cardiovascular causes, the matter has remained controversial. We studied this question in a 16-year follow-up investigation of Norwegian men that began in 1972. Methods. Our study included 1960 healthy men 40 to 59 years of age (84 percent of those invited to participate). Conventional coronary risk factors and physical fitness were assessed at base line, with physical fitness measured as the total work performed on a bicycle ergometer during a symptom-limited exercise-tolerance test. Results. After an average follow-up time of 16 years, 271 men had died, 53 percent of them from cardiovascular disease. The relative risk of death from any cause in fitness quartile 4 (highest) as compared with quartile 1 (lowest) was 0.54 (95 percent confidence interval, 0.32 to 0.89; P = 0.015) after adjustment for age, smoking status, serum lipids, blood pressure, resting heart rate, vital capacity, body-mass index, level of physical activity, and glucose tolerance. Total mortality was similar among the subjects in fitness quartiles 1, 2, and 3 when the data were adjusted for these same variables. The adjusted relative risk of death from cardiovascular causes in fitness quartile 4 as compared with quartile 1 was 0.41 (95 percent confidence interval, 0.20 to 0.84; P = 0.013). The corresponding relative risks for quartiles 3 and 2 (as compared with quartile 1) were 0.45 (95 percent confidence interval, 0.22 to 0.92; P = 0.026) and 0.59 (95 percent confidence interval, 0.28 to 1.22; P = 0.15), respectively. Conclusions. Physical fitness appears to be a graded, independent, long-term predictor of mortality from cardiovascular causes in healthy, middle-aged men. A high level of fitness was also associated with lower mortality from any cause.	CENT HOSP AKERSHUS,DEPT MED,N-1474 NORDBYHAGEN,NORWAY; NATL UNIV OSLO HOSP,OSLO,NORWAY; ULLEVAL HOSP,OSLO 1,NORWAY; UNIV OSLO,DEPT WORK PHYSIOL,OSLO 3,NORWAY	University of Oslo; University of Oslo; University of Oslo								ASTRAND PO, 1986, TSB WORK PHYSL PHYSL; BEERE PA, 1984, SCIENCE, V226, P180, DOI 10.1126/science.6484569; BERKSON DM, 1970, ATHEROSCLEROSIS, P382; BILLMAN GE, 1984, CIRCULATION, V69, P1182, DOI 10.1161/01.CIR.69.6.1182; BLAIR S N, 1985, Physician and Sportsmedicine, V13, P153; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BONJER FH, 1966, FED PROC, V5, P1363; BOUCHARD C, 1986, MED SCI SPORT EXER, V18, P639; BOVE AA, 1985, CIRCULATION, V71, P620, DOI 10.1161/01.CIR.71.3.620; BRUCE RA, 1983, J AM COLL CARDIOL, V2, P565, DOI 10.1016/S0735-1097(83)80286-1; COX DR, 1972, J R STAT SOC B, V34, P187; CROW RS, 1986, AM J CARDIOL, V57, P1075, DOI 10.1016/0002-9149(86)90677-6; DYER AR, 1980, AM J EPIDEMIOL, V112, P736, DOI 10.1093/oxfordjournals.aje.a113046; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; ENGER SC, 1977, SCAND J CLIN LAB INV, V37, P251, DOI 10.3109/00365517709091490; ERIKSSEN J, 1977, SCAND J CLIN LAB INV, V37, P243, DOI 10.3109/00365517709091489; ERIKSSEN J, 1982, ANN NY ACAD SCI, V382, P438, DOI 10.1111/j.1749-6632.1982.tb55236.x; ERIKSSEN J, 1977, ACTA MED SCAND, V202, P357; ERIKSSEN J, 1978, THESIS U HOSPITAL OS; FEARNLEY GR, 1955, BRIT J HAEMATOL, V1, P189, DOI 10.1111/j.1365-2141.1955.tb05500.x; GORDON DJ, 1987, AM J EPIDEMIOL, V125, P587, DOI 10.1093/oxfordjournals.aje.a114572; KEMMER FW, 1983, INT J SPORTS MED, V4, P77, DOI 10.1055/s-2008-1026017; KENNEY WL, 1985, MED SCI SPORT EXER, V17, P451, DOI 10.1249/00005768-198508000-00008; KRAMSCH DM, 1981, NEW ENGL J MED, V305, P1483, DOI 10.1056/NEJM198112173052501; LIE H, 1985, EUR HEART J, V6, P147, DOI 10.1093/oxfordjournals.eurheartj.a061829; MUNDAL R, 1987, EUR J APPL PHYSIOL O, V56, P245, DOI 10.1007/BF00690888; NOAKES TD, 1983, CIRCULATION, V67, P24, DOI 10.1161/01.CIR.67.1.24; PETERS RK, 1983, JAMA-J AM MED ASSOC, V249, P3052, DOI 10.1001/jama.249.22.3052; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; RAURAMAA R, 1984, BRIT MED J, V288, P603, DOI 10.1136/bmj.288.6417.603; RAURAMAA R, 1986, CIRCULATION, V74, P939, DOI 10.1161/01.CIR.74.5.939; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; ROSING DR, 1970, CIRC RES, V27, P171, DOI 10.1161/01.RES.27.2.171; SCHWANE JA, 1979, METABOLISM, V28, P771, DOI 10.1016/0026-0495(79)90184-7; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; SOBOLSKI J, 1987, AM J EPIDEMIOL, V125, P601, DOI 10.1093/oxfordjournals.aje.a114573; TAYLOR HL, 1962, AM J PUBLIC HEALTH N, V52, P1697, DOI 10.2105/AJPH.52.10.1697; WILHELMSEN L, 1981, CARDIOLOGY, V68, P1, DOI 10.1159/000173310; WYATT HL, 1978, J APPL PHYSIOL, V45, P619, DOI 10.1152/jappl.1978.45.4.619; 1971, PRINCIPLES MED STATI, P309; 1986, SUGI SUPPLEMENTAL LI	41	580	590	1	40	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					533	537		10.1056/NEJM199302253280803	http://dx.doi.org/10.1056/NEJM199302253280803			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8426620	Bronze			2022-12-28	WOS:A1993KP05300003
J	BREO, DL				BREO, DL			THE DOUBLE HELIX - WATSON AND CRICK FREAK FIND OF HOW LIKE BEGETS LIKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		BRONOWSKI J, NATION; BRONOWSKI J, ASCENT MAN; COMFORT A, MANCHESTER GUARDIAN; COMFORT A, JOY SEX; CRICK, 1974, NATURE; MEDAWAR, NEW YORK REV BOOKS; Watson James, 1968, DOUBLE HELIX; WILKINS M, 1953, NATURE          0425; SCI CITATION INDEX	9	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					1040	1045		10.1001/jama.269.8.1040	http://dx.doi.org/10.1001/jama.269.8.1040			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM603	8429587				2022-12-28	WOS:A1993KM60300036
J	BIEGLER, R; MORRIS, RGM				BIEGLER, R; MORRIS, RGM			LANDMARK STABILITY IS A PREREQUISITE FOR SPATIAL BUT NOT DISCRIMINATION-LEARNING	NATURE			English	Article							MEMORY; HIPPOCAMPUS; RATS	NEURONS sensitive to both place and direction from distinct regions of the hippocampal formation1,2, allometric relationships between spatial learning and hippocampal structure3,4 and pronounced impairments in spatial learning after lesions in this area5-8, indicate that the hippocampal formation subserves allocentric spatial learning9,10. To learn more about the process of spatial representation, we have developed a task that provides independent control of both landmark and directional cues. On the basis of physiological11 and behavioural12 work, this task also makes it possible to investigate the relevance of associative learning principles, such as predictability13, to the spatial domain. We report here that although rats learn to discriminate between landmarks on the basis of their proximity to a reliably predicted food reward, they will only learn to use them to represent its location if they maintain stable locations within a geometric frame of reference.	UNIV EDINBURGH,SCH MED,DEPT PHARMACOL,NEUROSCI LAB,1 GEORGE SQ,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Morris, Richard G M/C-9982-2013	Biegler, Robert/0000-0003-4679-4224	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BINGMAN VP, 1987, BEHAV BRAIN RES, V24, P147, DOI 10.1016/0166-4328(87)90252-X; BROWN PL, 1968, J EXP ANAL BEHAV, V11, P1, DOI 10.1901/jeab.1968.11-1; COLLETT TS, 1986, J COMP PHYSIOL A, V158, P835, DOI 10.1007/BF01324825; Craik K. J. W., 1943, NATURE EXPLANATION; DICKINSON A, 1978, ANNU REV PSYCHOL, V29, P587, DOI 10.1146/annurev.ps.29.020178.003103; DIEZCHAMIZO V, 1985, Q J EXP PSYCHOL-B, V37, P235, DOI 10.1080/14640748508402098; Johnson-Laird, 1983, MENTAL MODELS; KREBS JR, 1989, P NATL ACAD SCI USA, V86, P1388, DOI 10.1073/pnas.86.4.1388; LIPP HP, 1989, HIPPOCAMPUS NEW VIST, P395; Mackintosh N. J, 1983, CONDITIONING ASS LEA; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1990, COLD SPRING HARB SYM, V55, P161; Nadel L., 1991, Hippocampus, V1, P221, DOI 10.1002/hipo.450010302; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1987, EXP BRAIN RES, V68, P1; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; PARKINSON JK, 1988, J NEUROSCI, V8, P4159; REID IC, 1992, P ROY SOC B-BIOL SCI, V247, P137, DOI 10.1098/rspb.1992.0020; SHERRY DF, 1987, PSYCHOL REV, V94, P439, DOI 10.1037/0033-295X.94.4.439; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; TAUBE JS, 1990, J NEUROSCI, V10, P420; WORDEN R, 1992, HIPPOCAMPUS, V2, P165, DOI 10.1002/hipo.450020208	22	116	120	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					631	633		10.1038/361631a0	http://dx.doi.org/10.1038/361631a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KM776	8437622				2022-12-28	WOS:A1993KM77600062
J	WILLMAN, CL; SEVER, CE; PALLAVICINI, MG; HARADA, H; TANAKA, N; SLOVAK, ML; YAMAMOTO, H; HARADA, K; MEEKER, TC; LIST, AF; TANIGUCHI, T				WILLMAN, CL; SEVER, CE; PALLAVICINI, MG; HARADA, H; TANAKA, N; SLOVAK, ML; YAMAMOTO, H; HARADA, K; MEEKER, TC; LIST, AF; TANIGUCHI, T			DELETION OF IRF-1, MAPPING TO CHROMOSOME 5Q31.1 IN HUMAN LEUKEMIA AND PRELEUKEMIC MYELODYSPLASIA	SCIENCE			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; ACUTE NONLYMPHOCYTIC LEUKEMIA; REGULATORY FACTOR-I; TRANSCRIPTION FACTOR; LONG ARM; GM-CSF; GENE; 5Q; IDENTIFICATION; EXPRESSION	One of the most frequent cytogenetic abnormalities in human leukemia and myelodysplasia is an interstitial deletion within chromosome 5q. A tumor suppressor gene has been hypothesized to lie in 5q31, the smallest commonly deleted region. IRF-1, a gene whose product manifests anti-oncogenic activity, was mapped to 5q31.1. IRF-1 lies between IL-5 and CDC25C and is centromeric to IL-3 and GM-CSF. Among these genes, only IRF-1 was consistently deleted at one or both alleles in 13 cases of leukemia or myelodysplasia with aberrations of 5q31. Inactivating rearrangements of one IRF-1 allele, accompanied by deletion of the second allele, were also identified in one case of acute leukemia. Thus, IRF-1 may be a critically deleted gene in human leukemia and myelodysplasia.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; CITY HOPE NATL MED CTR,DEPT PATHOL,DUARTE,CA 91010; UNIV NEW MEXICO,SCH MED,DEPT CELL BIOL,ALBUQUERQUE,NM 87131; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,DIV MOLEC CYTOMETRY,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV ARIZONA,CTR CANC,TUCSON,AZ 85724	Osaka University; City of Hope; University of New Mexico; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Arizona	WILLMAN, CL (corresponding author), UNIV NEW MEXICO,SCH MED,DEPT PATHOL,900 CAMINO SALUD NE,ALBUQUERQUE,NM 87131, USA.		Harada, Hisashi/H-2815-2019	Harada, Hisashi/0000-0001-5993-1289; Tanaka, Nobuyuki/0000-0002-6373-2220; LIST, ALAN/0000-0002-1647-2972	NATIONAL CANCER INSTITUTE [U10CA032102, U10CA032734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043042] Funding Source: NIH RePORTER; NCI NIH HHS [CA-32102, CA-32734] Funding Source: Medline; NIDDK NIH HHS [DK-43042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOTT C, 1989, GENOMICS, V4, P606, DOI 10.1016/0888-7543(89)90286-3; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; DEWALD GW, 1985, BLOOD, V66, P189; DISCIPIO RG, 1984, P NATL ACAD SCI-BIOL, V81, P7298, DOI 10.1073/pnas.81.23.7298; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, UNPUB; HUEBNER K, 1985, SCIENCE, V230, P1282, DOI 10.1126/science.2999978; KERIM S, 1990, LEUKEMIA, V4, P12; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KUO WL, 1991, AM J HUM GENET, V49, P112; LEBEAU MM, 1987, P NATL ACAD SCI USA, V84, P5913; LEBEAU MM, 1986, SCIENCE, V231, P984, DOI 10.1126/science.3484837; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; MEEKER TR, UNPUB; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NIENHUIS AW, 1985, CELL, V42, P421, DOI 10.1016/0092-8674(85)90099-6; NIMER SD, 1987, BLOOD, V70, P1705; PEDERSEN B, 1991, LEUKEMIA, V5, P566; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; Sambrook J, 1989, MOL CLONING LABORATO; SARTOR H, 1992, GENOMICS, V13, P911, DOI 10.1016/0888-7543(92)90190-4; SUTHERLAND GR, 1988, BLOOD, V71, P1150; Tanaka N., UNPUB; VANDENBERGHE H, 1974, NATURE, V251, P437, DOI 10.1038/251437a0; VANDENBERGHE H, 1985, CANCER GENET CYTOGEN, V17, P189, DOI 10.1016/0165-4608(85)90016-0; WARRINGTON JA, 1992, GENOMICS, V13, P803, DOI 10.1016/0888-7543(92)90156-M; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532; 1982, CANCER GENET CYTOGEN, V11, P296	40	363	374	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					968	971		10.1126/science.8438156	http://dx.doi.org/10.1126/science.8438156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8438156				2022-12-28	WOS:A1993KL80000042
J	MANDEL, LJ; BACALLAO, R; ZAMPIGHI, G				MANDEL, LJ; BACALLAO, R; ZAMPIGHI, G			UNCOUPLING OF THE MOLECULAR FENCE AND PARACELLULAR GATE FUNCTIONS IN EPITHELIAL TIGHT JUNCTIONS	NATURE			English	Article							MDCK CELLS; POLARITY; PERMEABILITY; RESISTANCE; MEMBRANE	DURING epithelial morphogenesis, the establishment of tight junctions precedes the development of both the asymmetry in protein and lipid composition between apical and basolateral cell surfaces (the 'fence' function) and the restriction in the transport of ions and nonelectrolytes through the extracellular clefts between cells (the 'gate' function)1,2. Molecular models that explain both functions envision strands of particles extending as rings in the cell's perimeter that interact with similar strands located at the apposing cell2-5. This model accounts for the 'fence' function, because the strands prevent diffusion of protein and lipids, and also for the 'gate' function, because the interaction between strands minimizes the width of the extracellular clefts, increasing transepithelial resistance to ions and decreasing non-electrolyte permeability. Here we describe the results of energy depletion, which for the first time separates both functions: it abolishes the gate function, as determined by the dramatic decrease in transepithelial resistance, but it leaves the fence function intact, as determined by the maintenance of lipid polarity.	NORTHWESTERN UNIV,DEPT MOLEC CELLULAR & STRUCT BIOL,DIV NEPHROL & HYPERTENS,CHICAGO,IL 60611; UNIV CALIF LOS ANGELES,DEPT ANAT & CELL BIOL,LOS ANGELES,CA 90024	Northwestern University; University of California System; University of California Los Angeles	MANDEL, LJ (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,DIV PHYSIOL,DURHAM,NC 27710, USA.			Bacallao, Robert/0000-0002-5703-5701				BACALLAO R, 1990, HDB BIOL CONFOCAL MI, P197; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; CEREIJIDO M, 1989, J MEMBRANE BIOL, V110, P1, DOI 10.1007/BF01870987; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; CLAUDE P, 1973, J CELL BIOL, V58, P390, DOI 10.1083/jcb.58.2.390; Diamond J M, 1977, Physiologist, V20, P10; DRAGSTEN PR, 1981, NATURE, V294, P718, DOI 10.1038/294718a0; GUMBINER B, 1987, AM J PHYSIOL, V253, pC749, DOI 10.1152/ajpcell.1987.253.6.C749; LADINO C, 1991, EUR J CELL BIOL, V55, P217; MADARA JL, 1989, J CLIN INVEST, V83, P1089, DOI 10.1172/JCI113987; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MANDEL LJ, 1988, J CLIN INVEST, V81, P1255, DOI 10.1172/JCI113443; MOLITORIS BA, 1989, J CLIN INVEST, V84, P1334, DOI 10.1172/JCI114302; MUCKTER H, 1987, EUR J CELL BIOL, V44, P258; MULLIN JM, 1986, AM J PHYSIOL, V251, pC597, DOI 10.1152/ajpcell.1986.251.4.C597; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; OJAKIAN GK, 1981, CELL, V23, P95, DOI 10.1016/0092-8674(81)90274-9; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; STEVENSON BR, 1988, MOL CELL BIOCHEM, V83, P129; STEVENSON BR, 1988, J CELL BIOL, V107, P2401, DOI 10.1083/jcb.107.6.2401; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; ZAMPIGHI G, 1988, J CELL BIOL, V106, P1667, DOI 10.1083/jcb.106.5.1667	23	236	237	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					552	555		10.1038/361552a0	http://dx.doi.org/10.1038/361552a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429911				2022-12-28	WOS:A1993KL71400066
J	HITCHCOCK, ER				HITCHCOCK, ER			FETAL TRANSPLANT UPDATE	SCIENCE			English	Letter											HITCHCOCK, ER (corresponding author), UNIV BIRMINGHAM,MIDLAND CTR NEUROSURG & NEUROL,BIRMINGHAM B67 7JX,W MIDLANDS,ENGLAND.							HENDERSON BS, UNPUB; THOMPSON L, 1992, SCIENCE, V257, P868, DOI 10.1126/science.1502548	2	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					442	443						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424161				2022-12-28	WOS:A1993KJ07900008
J	MANGEL, WF; MCGRATH, WJ; TOLEDO, DL; ANDERSON, CW				MANGEL, WF; MCGRATH, WJ; TOLEDO, DL; ANDERSON, CW			VIRAL-DNA AND A VIRAL PEPTIDE CAN ACT AS COFACTORS OF ADENOVIRUS VIRION PROTEINASE ACTIVITY	NATURE			English	Article							TYPE-2	HUMAN adenovirus (Ad2), like many other viruses1, contains a virion-associated proteinase essential for the synthesis of infectious virus particles2-4. We observed proteinase activity in wild-type virus but not in the ts-1 virus2, which contains a mutation in the Ad2 L3 endoprotease gene5 that confers temperature-sensitive processing of virion precursor proteins. Unexpectedly, we did not observe proteinase activity with purified recombinant6,7 endoprotease protein (M(r) 23 K). Purified recombinant endoprotease protein, however, complemented the mutation in ts-1 virions, restoring proteinase activity when mixed together. This implied that cofactors may be required. Here we reconstitute proteinase activity in vitro with three purified viral components: (1) the recombinant endoprotease protein; (2) an 11-amino-acid peptide that originates from the carboxy terminus of pVI, the precursor to virion component VI; and (3) adenovirus DNA. The use of DNA for a proteinase activity is unprecedented.			MANGEL, WF (corresponding author), BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA.			McGrath, William/0000-0002-9375-624X				AKUSJARVI G, 1981, J VIROL, V38, P469; ANDERSON CW, 1993, PROTEIN EXPRES PURIF, V4, P8, DOI 10.1006/prep.1993.1002; ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; HANNAN C, 1983, INTERVIROLOGY, V19, P213, DOI 10.1159/000149363; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LEYTUS SP, 1983, BIOCHEM J, V215, P253, DOI 10.1042/bj2150253; LIANG YK, 1983, J MOL BIOL, V167, P217, DOI 10.1016/S0022-2836(83)80044-8; MIRZA A, 1980, INTERVIROLOGY, V13, P307, DOI 10.1159/000149139; WEBER J, 1976, J VIROL, V17, P462, DOI 10.1128/JVI.17.2.462-471.1976; WEBSTER A, 1989, J GEN VIROL, V70, P3225, DOI 10.1099/0022-1317-70-12-3225; WEBSTER A, 1989, J GEN VIROL, V70, P3215, DOI 10.1099/0022-1317-70-12-3215	11	148	151	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1993	361	6409					274	275		10.1038/361274a0	http://dx.doi.org/10.1038/361274a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8423855				2022-12-28	WOS:A1993KH61400065
J	SUKEGAWA, J; BLOBEL, G				SUKEGAWA, J; BLOBEL, G			A NUCLEAR-PORE COMPLEX PROTEIN THAT CONTAINS ZINC FINGER MOTIFS, BINDS DNA, AND FACES THE NUCLEOPLASM	CELL			English	Article							LINKED N-ACETYLGLUCOSAMINE; GLUCOCORTICOID RECEPTOR; ENVELOPE PROTEIN; STRUCTURAL MOTIF; DOMAIN; GLYCOPROTEINS; IDENTIFICATION; EXPRESSION; CDNA; P62	We have molecularly cloned and sequenced a cDNA for a rat liver nucleoporin with a molecular mass of 152.8 kd, termed nup153, that shares a repetitive degenerate pentapeptide motif with a subgroup of nucleoporins of yeast and vertebrates. However, its most striking feature is a novel 4-fold repeat of a Cys2-Cys2-type zinc finger motif. When expressed in E. coli, the zinc finger domain of nupl53 binds DNA in a zinc-dependent fashion. Immunoelectron microscopy localized nup153 exclusively to the nucleoplasmic side of the nuclear pore complex. We suggest that nup153 recognizes a specific DNA sequence to organize the genome three-dimensionally and to gate transcribable genes to nuclear pore complexes.			SUKEGAWA, J (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021, USA.							Akey C W, 1991, Semin Cell Biol, V2, P167; BERG JM, 1990, J BIOL CHEM, V265, P6513; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; CORDES V, 1991, EUR J CELL BIOL, V55, P31; DAHLMAN K, 1989, J BIOL CHEM, V264, P804; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P466; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HURT EC, 1988, EMBO J, V7, P4323, DOI 10.1002/j.1460-2075.1988.tb03331.x; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Marston F. A. O., 1987, DNA CLONING, P59; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RIS H, 1989, SEM I PHYS C SER, V98, P657; RIS H, 1991, EMSA B, V21, P54; Sambrook J, 1989, MOL CLONING LABORATO; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STARR CM, 1991, BIOESSAYS, V13, P145, DOI 10.1002/bies.950130309; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	45	280	286	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					29	38		10.1016/0092-8674(93)90047-T	http://dx.doi.org/10.1016/0092-8674(93)90047-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422679				2022-12-28	WOS:A1993KG95500007
J	POL, S; ROMANA, CA; RICHARD, S; AMOUYAL, P; DESPORTESLIVAGE, I; CARNOT, F; PAYS, JF; BERTHELOT, P				POL, S; ROMANA, CA; RICHARD, S; AMOUYAL, P; DESPORTESLIVAGE, I; CARNOT, F; PAYS, JF; BERTHELOT, P			MICROSPORIDIA INFECTION IN PATIENTS WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS AND UNEXPLAINED CHOLANGITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BOWEL BACTERIAL OVERGROWTH; INTESTINAL MICROSPORIDIOSIS; SCLEROSING CHOLANGITIS; AIDS; DIAGNOSIS; DISEASE; RATS	Background. Cholangitis in patients with the acquired immunodeficiency syndrome (AIDS) is usually associated with opportunistic infections by cryptosporidium species or cytomegalovirus, but in about a third of cases no opportunistic agent is identified. We suspected some of these cases of biliary disease might be explained by infection with the microsporidia species Enterocytozoon bieneusi, an obligate intracellular protozoan that causes chronic diarrhea in patients infected with the human immunodeficiency virus (HIV). Methods. We studied eight HIV-infected homosexual men (in either group IV of the classification of the Centers for Disease Control and Prevention or group II, with a CD4 cell count of less-than-or-equal-to 10 per cubic millimeter) who were referred because of cholangitis for which no causative agent had been found by standard tests. All the patients underwent abdominal ultrasonography and endoscopic ultrasonography or endoscopic retrograde cholangiopancreatography with collection of bile from the common bile duct. One patient had transhepatic biliary catheterization, and two others had cholecystectomy. Bile samples, duodenal- and liver-biopsy specimens, and gallbladder tissue were studied by light and electron microscopy. Results. All eight patients with unexplained AIDS-related cholangitis had biliary microsporidiosis. Intraepithelial E bieneusi spores (1 to 2 mum) and supranuclear plasmodia (3 to 8 mum) were identified in the six duodenal-biopsy specimens. May-Grunwald-Giemsa staining of bile samples revealed free forms of microsporidia in all eight patients, and the presence of E. bieneusi was confirmed by electron microscopy. E. bieneusi was also identified in ductal biliary cells on a liver biopsy, in one common-bile-duct smear, and in gallbladder epithelium (in two patients). Four patients were found to have associated but previously undetected biliary or duodenal cryptosporidiosis, whereas another had biliary infection associated with cytomegalovirus. Conclusions. Infection of the biliary tract with E. bieneusi is associated with and may be a cause of AIDS-related cholangitis.	HOP LA PITIE SALPETRIERE,SERV NEUROHISTOL,PARIS,FRANCE; INSERM,U313,F-75005 PARIS,FRANCE; INSERM,U99,F-75005 PARIS,FRANCE; HOP NECKER LAENNEC,HEPATOL UNIT,PARIS,FRANCE; HOP NECKER LAENNEC,PARASITOL UNIT,PARIS,FRANCE; HOP NECKER LAENNEC,ANAT & PATHOL UNIT,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)			RICHARD, Stéphane/O-1005-2017	RICHARD, Stéphane/0000-0002-9859-9773; desportes, isabelle/0000-0002-8472-449X				BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BOUCHE H, IN PRESS J HEPATOL; CANNING EU, 1990, T ROY SOC TROP MED H, V84, P181, DOI 10.1016/0035-9203(90)90247-C; CELLO JP, 1989, AM J MED, V86, P539, DOI 10.1016/0002-9343(89)90381-1; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P334; DESPORTES I, 1985, J PROTOZOOL, V32, P250; DOWSETT JF, 1988, SCAND J GASTROENTERO, V23, P1267, DOI 10.3109/00365528809090203; KORNFELD H, 1982, NEW ENGL J MED, V307, P729, DOI 10.1056/NEJM198209163071206; LICHTMAN SN, 1991, GASTROENTEROLOGY, V100, P513, DOI 10.1016/0016-5085(91)90224-9; LICHTMAN SN, 1991, HEPATOLOGY, V13, P766, DOI 10.1002/hep.1840130425; MARGULIS SJ, 1986, ANN INTERN MED, V105, P207, DOI 10.7326/0003-4819-105-2-207; MCWHINNEY PHM, 1991, AIDS, V5, P1394, DOI 10.1097/00002030-199111000-00024; ORENSTEIN JM, 1990, HUM PATHOL, V21, P475; PEACOCK CS, 1991, J CLIN PATHOL, V44, P558, DOI 10.1136/jcp.44.7.558; PITLIK SD, 1983, NEW ENGL J MED, V308, P967; POL S, 1992, GASTROENTEROLOGY, V102, P1778, DOI 10.1016/0016-5085(92)91743-N; RIJPSTRA AC, 1988, J INFECT DIS, V157, P827, DOI 10.1093/infdis/157.4.827; SCHATTENKERK JKME, 1991, LANCET, V337, P895, DOI 10.1016/0140-6736(91)90215-B; SHADDUCK JA, 1989, REV INFECT DIS, V11, P203; SIMON D, 1991, GASTROENTEROLOGY, V100, P271, DOI 10.1016/0016-5085(91)90613-P; SUNG JY, 1991, HEPATOLOGY, V14, P313, DOI 10.1016/0270-9139(91)91421-V; WEBER R, 1992, NEW ENGL J MED, V326, P161, DOI 10.1056/NEJM199201163260304	22	165	168	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1993	328	2					95	99		10.1056/NEJM199301143280204	http://dx.doi.org/10.1056/NEJM199301143280204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG467	8416439				2022-12-28	WOS:A1993KG46700004
J	PICCIRILLI, JA; VYLE, JS; CARUTHERS, MH; CECH, TR				PICCIRILLI, JA; VYLE, JS; CARUTHERS, MH; CECH, TR			METAL-ION CATALYSIS IN THE TETRAHYMENA RIBOZYME REACTION	NATURE			English	Article							PHOSPHORYL-TRANSFER-REACTIONS; RNA CLEAVAGE; ENDORIBONUCLEASE ACTIVITY; THERMOPHILA RIBOZYME; KINETIC DESCRIPTION; ESCHERICHIA-COLI; DNA; SUBSTRATE; BINDING; SITE	ALL catalytic RNAs (ribozymes) require or are stimulated by divalent metal ions, but it has been difficult to separate the contribution of these metal ions to formation of the RNA tertiary structure1 from a more direct role in catalysis. The Tetrahymena ribozyme catalyses cleavage of exogenous RNA2,3 or DNA4,5 substrates with an absolute requirement for Mg2+ or Mn2+ (ref. 6). A DNA substrate, in which the bridging 3' oxygen atom at the cleavage site is replaced by sulphur, is cleaved by the ribozyme about 1,000 times more slowly than the corresponding unmodified DNA substrate when Mg2+ is present as the only divalent metal ion. But addition of Mn2+ or Zn2+ to the reaction relieves this negative effect, with the 3' S-P bond being cleaved nearly as fast as the 3' O-P bond. Considering that Mn2+ and Zn2+ coordinate sulphur more strongly than Mg2+ does7,8, these results indicate that the metal ion contributes directly to catalysis by coordination to the 3' oxygen atom in the transition state, presumably stabilizing the developing negative charge on the leaving group. We conclude that the Tetrahymena ribozyme is a metalloenzyme, with mechanistic similarities to several protein enzymes9-12.	UNIV COLORADO, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA; UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder			Vyle, Joseph S/A-6077-2013					BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BROWNE KA, 1992, J AM CHEM SOC, V114, P4951, DOI 10.1021/ja00039a001; CECH TR, 1992, J BIOL CHEM, V267, P17479; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; COSSTICK R, 1990, NUCLEIC ACIDS RES, V8, P2295; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FREY PA, 1989, ADV ENZYMOL RAMB, V62, P119; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERSCHLAG D, 1987, J AM CHEM SOC, V109, P4665, DOI 10.1021/ja00249a033; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; JAFFE EK, 1978, J BIOL CHEM, V253, P4823; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MILSTIEN S, 1967, J AM CHEM SOC, V89, P5820, DOI 10.1021/ja00999a016; NAKAMAYE KL, 1988, NUCLEIC ACIDS RES, V16, P9947, DOI 10.1093/nar/16.21.9947; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; VYLE JS, 1992, BIOCHEMISTRY-US, V31, P3012, DOI 10.1021/bi00126a024; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	39	377	382	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 7	1993	361	6407					85	88		10.1038/361085a0	http://dx.doi.org/10.1038/361085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421499				2022-12-28	WOS:A1993KF71800055
J	MITCHELL, EA; STEWART, AW; SCRAGG, R; FORD, RPK; TAYLOR, BJ; BECROFT, DMO; THOMPSON, JMD; HASSALL, IB; BARRY, DMJ; ALLEN, EM; ROBERTS, AP				MITCHELL, EA; STEWART, AW; SCRAGG, R; FORD, RPK; TAYLOR, BJ; BECROFT, DMO; THOMPSON, JMD; HASSALL, IB; BARRY, DMJ; ALLEN, EM; ROBERTS, AP			ETHNIC-DIFFERENCES IN MORTALITY FROM SUDDEN-INFANT-DEATH-SYNDROME IN NEW-ZEALAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives-To examine the factors which might explain the higher mortality from sudden infant death syndrome in Maori infants (7.4/1000 live births in 1986 compared with 3.6 in non-Maori children). Design-A large nationwide case control study. Setting-New Zealand. 485 infants who died of sudden infant death syndrome were compared with 1800 control infants. There were 229 Maori and 240 non-Maori cases of sudden infant death syndrome (16 cases unassigned) and 353 Maori and 1410 non-Maori controls (37 unassigned). Results-Maori infants had 3.81 times the risk (95% confidence interval 3.06 to 4.76) of sudden infant death syndrome compared with non-Maori infants. The risk factors for sudden infant death syndrome within groups were remarkably similar. When Maori and non-Maori controls were compared the prevalence of many of the known risk factors was higher in Maori infants. In particular, mothers were socioeconomically disadvantaged, younger, and more likely to smoke and their infants were of lower birth weight and more likely to share a bed with another person. Multivariate analysis controlling for potential confounders found that simply being Maori increased the risk of sudden infant death syndrome by only 1.37 (95% CI=0.95 to 2.01), not statistically significantly different from 1. Population attributable risk was calculated for prone sleeping position, maternal smoking, not breast feeding, and infants sharing a bed with another person. In total these four risk factors for accounted for 89% of deaths from sudden infant death syndrome in Maori infants and 79% in non-Maori infants. Conclusion-The high rate of sudden infant death syndrome among Maori infants is based largely on the high prevalence in the Maori population of the major risk factors. Other risk factors, not related to ethnicity, probably explain remaining differences between Maori and non-Maori children.	UNIV OTAGO, DUNEDIN, NEW ZEALAND; PRINCESS MARY HOSP CHILDREN, AUCKLAND, NEW ZEALAND	University of Otago	MITCHELL, EA (corresponding author), UNIV AUCKLAND, DEPT PAEDIAT, AUCKLAND 1, NEW ZEALAND.		Taylor, Barry j/G-1410-2010	Scragg, Robert/0000-0003-0013-2620; Taylor, Barry/0000-0002-6450-8677				BALARAJAN R, 1989, BRIT MED J, V298, P716, DOI 10.1136/bmj.298.6675.716; BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BLACK L, 1986, J PEDIATR-US, V108, P209, DOI 10.1016/S0022-3476(86)80984-2; BORMAN B, 1988, NEW ZEAL MED J, V101, P413; BRESLOW NE, 1980, STAT METHODS CANC RE, V1, P74; KRAUS JF, 1989, INT J EPIDEMIOL, V18, P113, DOI 10.1093/ije/18.1.113; KYLE D, 1990, ARCH DIS CHILD, V65, P830, DOI 10.1136/adc.65.8.830; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; Mitchison TJ, 1989, CURR OPIN CELL BIOL, V1, P67, DOI 10.1016/S0955-0674(89)80039-0; TANGERMANN R, 1987, MONATSSCHR KINDERH, V135, P679; 1988, FETAL INFANT DEATHS	13	72	73	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 2	1993	306	6869					13	16		10.1136/bmj.306.6869.13	http://dx.doi.org/10.1136/bmj.306.6869.13			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE984	8435568	Bronze, Green Published			2022-12-28	WOS:A1993KE98400018
J	MANNING, WJ; SILVERMAN, DI; GORDON, SPF; KRUMHOLZ, HM; DOUGLAS, PS				MANNING, WJ; SILVERMAN, DI; GORDON, SPF; KRUMHOLZ, HM; DOUGLAS, PS			CARDIOVERSION FROM ATRIAL-FIBRILLATION WITHOUT PROLONGED ANTICOAGULATION WITH USE OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY TO EXCLUDE THE PRESENCE OF ATRIAL THROMBI	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TWO-DIMENSIONAL ECHOCARDIOGRAPHY; ANATOMIC CORRELATIONS; CLINICAL-APPLICATIONS; RECOMMENDATIONS; COMPLICATIONS; PREDICTORS; EMBOLISM; CONTRAST; PATIENT; SAFETY	Background. Because atrial thrombi are poorly detected by conventional noninvasive techniques such as transthoracic echocardiography, patients with prolonged atrial fibrillation usually receive several weeks of oral anticoagulation therapy before cardioversion is attempted. We wondered whether transesophageal echocardiography, an accurate method of detecting atrial thrombi, would allow early cardioversion to be performed safely if no thrombi were identified. Methods. A total of 669 consecutive patients admitted with the diagnosis of atrial fibrillation were screened. Patients were excluded if they were receiving long-term anti-coagulation, if the duration of atrial fibrillation was two days or less, if they were not candidates for cardioversion, or if transesophageal echocardiography was contraindicated. Of 119 qualifying patients, 94 agreed to participate; the average duration of atrial fibrillation was 4.5 weeks. Participating patients underwent transthoracic echocardiography and transesophageal echocardiography followed by cardioversion if no thrombi were seen. Short-term anticoagulation with heparin was used in 80 patients before cardioversion, and 60 patients received warfarin for one month after cardioversion. Results. Fourteen atrial thrombi were identified in 12 patients (13 percent), and 12 of the 14 thrombi were visualized only on transesophageal echocardiography. Cardioversion was deferred in all 12 patients. Two of these 12 patients died suddenly; 4 of the 10 surviving patients underwent uneventful cardioversion after prolonged oral anticoagulation. Seventy-eight of the 82 patients without thrombi underwent successful cardioversion to sinus rhythm (47 by means of antiarrhythmic drugs and 31 by electrical cardioversion), all without long-term oral anticoagulation. None of these patients (95 percent confidence interval, 0 to 4.6 percent) had an embolic event. Conclusions. In patients with atrial fibrillation of unknown or prolonged duration who are not receiving long-term anticoagulation, atrial thrombi are detected by transesophageal echocardiography in only a small minority (13 percent in our study). Our preliminary data suggest that if transesophageal echocardiography excludes the presence of thrombi, early cardioversion can be performed safely without the need for prolonged oral anticoagulation before the procedure.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; BETH ISRAEL HOSP,THORNDIKE LAB,CHARLES A DANA RES INST,BOSTON,MA 02215; UNIV CONNECTICUT,CTR HLTH,DIV CARDIOL,FARMINGTON,CT 06032	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Connecticut	MANNING, WJ (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,DEPT MED,DIV CARDIOVASC,THORNDIKE LAB,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		, Harlan/AAI-2875-2020	Douglas, Pamela/0000-0001-9876-4049	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K12AG000294] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07374] Funding Source: Medline; NIA NIH HHS [AG00294] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOTT WM, 1982, AM J SURG, V143, P460, DOI 10.1016/0002-9610(82)90196-9; ABERG H, 1969, ACTA MED SCAND, V185, P373; ARNOLD AZ, 1992, J AM COLL CARDIOL, V19, P851, DOI 10.1016/0735-1097(92)90530-Z; ASCHENBERG W, 1986, J AM COLL CARDIOL, V7, P163, DOI 10.1016/S0735-1097(86)80275-3; BJERKELUND CJ, 1969, AM J CARDIOL, V23, P208, DOI 10.1016/0002-9149(69)90068-X; CASTELLO R, 1990, AM J CARDIOL, V65, P1149, DOI 10.1016/0002-9149(90)90330-4; DAJANI AS, 1990, JAMA-J AM MED ASSOC, V264, P2919, DOI 10.1001/jama.264.22.2919; DANIEL WG, 1991, CIRCULATION, V83, P817, DOI 10.1161/01.CIR.83.3.817; DANIEL WG, 1988, J AM COLL CARDIOL, V11, P1204, DOI 10.1016/0735-1097(88)90283-5; DETHY M, 1988, AM J CARDIOL, V62, P723, DOI 10.1016/0002-9149(88)91210-6; DITTRICH HC, 1989, AM J CARDIOL, V63, P193, DOI 10.1016/0002-9149(89)90284-1; DUNN M, 1989, CHEST, V95, pS118, DOI 10.1378/chest.95.2_Supplement.118S; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; HINTON RC, 1977, AM J CARDIOL, V40, P509, DOI 10.1016/0002-9149(77)90064-9; KANNEL WB, 1992, ATRIAL FIBRILLATION, P81; LOWN B, 1963, NEW ENGL J MED, V269, P325, DOI 10.1056/NEJM196308152690701; MANNING WJ, 1989, J AM COLL CARDIOL, V13, P617, DOI 10.1016/0735-1097(89)90602-5; MANNING WJ, 1992, BRIT HEART J, V67, P170; MORRIS JJ, 1965, CIRCULATION, V31, P670, DOI 10.1161/01.CIR.31.5.670; MUGGE A, 1990, American Journal of Cardiac Imaging, V4, P173; OSTRANDER LD, 1965, CIRCULATION, V31, P888, DOI 10.1161/01.CIR.31.6.888; PEARSON AC, 1990, AM HEART J, V119, P1083, DOI 10.1016/S0002-8703(05)80238-8; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622; PETERSEN P, 1990, STROKE, V21, P4, DOI 10.1161/01.STR.21.1.4; PRITCHETT ELC, 1992, NEW ENGL J MED, V326, P1264; RESNEKOV L, 1967, BRIT HEART J, V29, P926; ROKSETH R, 1963, ARCH INTERN MED, V111, P184, DOI 10.1001/archinte.1963.03620260044008; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Seward J B, 1992, J Am Soc Echocardiogr, V5, P288; SEWARD JB, 1990, MAYO CLIN PROC, V65, P1193, DOI 10.1016/S0025-6196(12)62744-X; SEWARD JB, 1988, MAYO CLIN PROC, V63, P649, DOI 10.1016/S0025-6196(12)65529-3; SHAPIRO EP, 1988, AM J CARDIOL, V62, P1202, DOI 10.1016/0002-9149(88)90260-3; STRATTON JR, 1982, CIRCULATION, V66, P156, DOI 10.1161/01.CIR.66.1.156; WANG XF, 1992, AM HEART J, V124, P961, DOI 10.1016/0002-8703(92)90979-6; WANG XF, 1992, AM HEART J, V123, P1027, DOI 10.1016/0002-8703(92)90714-7; WEINBERG DM, 1989, AM J CARDIOL, V63, P745, DOI 10.1016/0002-9149(89)90264-6; ZABALGOITIA M, 1990, AM HEART J, V120, P1147, DOI 10.1016/0002-8703(90)90129-L; 1981, STATISTICAL METHODS, P33	38	273	275	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					750	755		10.1056/NEJM199303183281102	http://dx.doi.org/10.1056/NEJM199303183281102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8437595				2022-12-28	WOS:A1993KR84800002
J	GOBLE, M; ISEMAN, MD; MADSEN, LA; WAITE, D; ACKERSON, L; HORSBURGH, CR				GOBLE, M; ISEMAN, MD; MADSEN, LA; WAITE, D; ACKERSON, L; HORSBURGH, CR			TREATMENT OF 171 PATIENTS WITH PULMONARY TUBERCULOSIS RESISTANT TO ISONIAZID AND RIFAMPIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SHORT-COURSE CHEMOTHERAPY; DRUG-RESISTANT; CHILDREN	Background and Methods. The frequency of infection with multidrug-resistant Mycobacterium tuberculosis is increasing. We reviewed the clinical courses of 171 patients with pulmonary disease due to M. tuberculosis resistant to rifampin and isoniazid who were referred to our hospital between 1973 and 1983. The patients' records were analyzed retrospectively. Their regimens were selected individually and preferably included three medications that they had not been given previously and to which the strain was fully susceptible. Results. The 171 patients (median age, 46 years) had previously received a median of six drugs and shed bacilli that were resistant to a median of six drugs. Thus, their regimens were frequently not optimal. Of 134 patients with sufficient follow-up data, 87 (65 percent) responded to chemotherapy (as indicated by negative sputum cultures for at least three consecutive months); 47 patients (35 percent) had no response, as shown by continually positive cultures. The median stay in the hospital was more than seven months. In a multivariate analysis, an unfavorable response was significantly associated with a greater number of drugs received before the current course of therapy (odds ratio, 4.0; 95 percent confidence interval, 1.6 to 9.9; P<0.001) and with male sex (odds ratio, 2.5; 95 percent confidence interval, 1.1 to 6.2; P<0.03). Twelve of the patients with responses subsequently had relapses. The overall response rate was 56 percent over a mean period of 51 months. Of the 171 patients, 63 (37 percent) died, and 37 of these deaths were attributed to tuberculosis. Conclusions. For patients with pulmonary tuberculosis that is resistant to rifampin and isoniazid, even the best available treatment is often unsuccessful. Only about half of such patients eventually have negative sputum cultures despite carefully selected regimens administered for extended periods. Failure to control this resistant infection is associated with high mortality and ominous implications for the public health.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT BIOSTAT, DENVER, CO 80206 USA	National Jewish Health	GOBLE, M (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, 1400 JACKSON ST ANNEX, RM J203, DENVER, CO 80206 USA.			Horsburgh, C./0000-0001-6838-7895				[A Hong Kong Tuberculosis Treatment Services Brompton Hospital British Medical Research Council investigation], 1974, TUBERCLE, V55, P1; ADDINGTON WW, 1979, CHEST, V76, P741, DOI 10.1378/chest.76.6_Supplement.741; CARPENTER JL, 1983, AM REV RESPIR DIS, V128, P1055; CAUTHEN G M, 1988, American Review of Respiratory Disease, V137, P260; DAVIDSON PT, 1972, CHEST, V61, P574, DOI 10.1016/S0012-3692(15)39158-3; FISCHER D, 1965, 4TH P INT C ANT AG C, P699; FISCHER DA, 1968, AM REV RESPIR DIS, V97, P392; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FOX W, 1981, BRIT J DIS CHEST, V75, P331, DOI 10.1016/0007-0971(81)90022-X; HEIFETS L, 1988, AM REV RESPIR DIS, V137, P1217, DOI 10.1164/ajrccm/137.5.1217; Heifets L B, 1986, Semin Respir Infect, V1, P242; HOBBY GL, 1974, AM REV RESPIR DIS, V110, P95; HOBBY GL, 1972, 31ST T VA ARM FORC P, P36; ISEMAN MD, 1987, AM REV RESPIR DIS, V136, P1326, DOI 10.1164/ajrccm/136.6.1325; JANCIK E, 1963, Tubercle, V44, P443, DOI 10.1016/S0041-3879(63)80085-9; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12; LEES AW, 1972, CHEST, V61, P579, DOI 10.1016/S0012-3692(15)39159-5; Lester W, 1971, Dis Mon, P1; MCCLATCHY JK, 1986, ANTIBIOTICS LABORATO, P181; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; REVES R, 1981, AM J EPIDEMIOL, V113, P423, DOI 10.1093/oxfordjournals.aje.a113110; SCHIFFMAN PL, 1977, AM REV RESPIR DIS, V116, P821; SHARBARO JA, 1979, CHEST S, V76, P750; SNIDER DE, 1985, AM REV RESPIR DIS, V132, P125; SOMNER A R, 1962, Tubercle, V43, P345, DOI 10.1016/S0041-3879(62)80003-8; STEINER P, 1983, AM REV RESPIR DIS, V128, P425, DOI 10.1164/arrd.1983.128.3.425; STEINER P, 1986, AM REV RESPIR DIS, V134, P446; SUNDERAM G, 1987, AM REV RESPIR DIS, V136, P1475, DOI 10.1164/ajrccm/136.6.1475; SWAI OB, 1988, TUBERCLE, V69, P5, DOI 10.1016/0041-3879(88)90035-9; VALLSPINOSA A, 1970, NEW ENGL J MED, V283, P616, DOI 10.1056/NEJM197009172831202; 1990, MMWR MORB MORTAL WKL, V39, P369; 1991, MMWR MORB MORTAL WKL, V40, P585; 1990, SAS STAT USERS GUIDE; 1990, MMWR MORB MORTAL WKL, V39, P718	34	605	633	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					527	532		10.1056/NEJM199302253280802	http://dx.doi.org/10.1056/NEJM199302253280802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8426619	Bronze			2022-12-28	WOS:A1993KP05300002
J	ZHOU, XL; SASAKI, H; LOWE, L; HOGAN, BLM; KUEHN, MR				ZHOU, XL; SASAKI, H; LOWE, L; HOGAN, BLM; KUEHN, MR			NODAL IS A NOVEL TGF-BETA-LIKE GENE EXPRESSED IN THE MOUSE NODE DURING GASTRULATION	NATURE			English	Article							CPG ISLANDS; FATE	DURING gastrulation, the three germ layers of the embryo are formed and organized along the anterior-posterior body axis. In the mouse, gastrulation involves the delamination of ectodermal cells through the primitive streak and their differentiation into mesoderm1. These processes do not occur in embryos homozygous for a retrovirally induced recessive prenatal lethal mutation, the strain 413-d insertional mutation2,3. Instead of giving rise to mesoderm, embryonic ectoderm in 413-d mutants overproliferates and then rapidly degenerates, although extraembryonic lineages remain viable2. Here we isolate a candidate for the mutated gene which encodes a new member of the transforming growth factor-beta (TGF-beta) superfamily4 . Expression is first detected in primitive streak-stage embryos at about the time of mesoderm formation. It then becomes highly localized in the node at the anterior of the primitive streak. This region is analogous to chick Hensen's node and Xenopus dorsal lip (Spemann's organizer), which can induce secondary body axes when grafted into host embryos (reviewed in refs 5 and 6). Our findings suggest that this gene, named nodal, encodes a signalling molecule essential for mesoderm formation and subsequent organization of axial structures in early mouse development.	NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University			Kuehn, Michael R/A-4573-2014	Kuehn, Michael R/0000-0002-7703-9160; Sasaki, Hiroshi/0000-0001-8752-6846				BELLAIRS R, 1986, ANAT EMBRYOL, V174, P1, DOI 10.1007/BF00318331; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; CONLON FL, 1991, DEVELOPMENT, V111, P969; CONLON RA, 1992, DEVELOPMENT, V116, P357; EVANS GA, 1989, GENE, V79, P9, DOI 10.1016/0378-1119(89)90088-7; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HERRMANN BG, 1987, GUIDE MOL CLONING TE, P180; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LAWSON KA, 1992, POSTIMPLANTATION DEV, P3; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; Massague J., 1990, REV CELL BIOL, V6, P597; NAKAMURA O, 1978, ORG MILESTONE HALF C; SELIGER B, 1986, MOL CELL BIOL, V6, P286, DOI 10.1128/MCB.6.1.286; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH JC, 1989, DEVELOPMENT, V105, P665; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; TAM PPL, 1992, POSTIMPLANTATION DEV, P27; [No title captured]	22	522	568	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					543	547		10.1038/361543a0	http://dx.doi.org/10.1038/361543a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429908	Green Published			2022-12-28	WOS:A1993KL71400063
J	CAVALLISFORZA, LL; MENOZZI, P; PIAZZA, A				CAVALLISFORZA, LL; MENOZZI, P; PIAZZA, A			DEMIC EXPANSIONS AND HUMAN-EVOLUTION	SCIENCE			English	Article							INDO-EUROPEAN LANGUAGES; MITOCHONDRIAL-DNA; GENETIC-VARIATION; CLIMATE; POPULATIONS; FREQUENCIES; DIFFUSION; HISTORY; MAPS	Geographic expansions are caused by successful innovations, biological or cultural, that favor local growth and movement. They have had a powerful effect in determining the present patterns of human genetic geography. Modern human populations expanded rapidly across the Earth in the last 100,000 years. At the end of the Paleolithic (10,000 years ago) only a few islands and other areas were unoccupied. The number of inhabitants was then about one thousand times smaller than it is now. Population densities were low throughout the Paleolithic, and random genetic drift was therefore especially effective. Major genetic differences between living human groups must have evolved at that time. Population growths that began afterward, especially with the spread of agriculture, progressively reduced the drift in population and the resulting genetic differentiation. Genetic traces of the expansions that these growths determined are still recognizable.	UNIV PARMA, IST ECOL, I-43100 PARMA, ITALY; UNIV TURIN, CNR, CTR IMMUNOGENET & ISTOCOMPATIBIL, I-10124 TURIN, ITALY	University of Parma; Consiglio Nazionale delle Ricerche (CNR); University of Turin	CAVALLISFORZA, LL (corresponding author), STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA.		MENOZZI, PAOLO/A-6234-2012	MENOZZI, PAOLO/0000-0001-8638-7370; Piazza, Alberto/0000-0002-2355-4183	NIGMS NIH HHS [GM 10452, GM 20467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010452, R01GM020467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ammerman A.J., 1973, EXPLANATION CULTURE, P343; AMMERMAN AJ, 1984, NEOLITHIC TRANSITION; BARINAGA M, 1992, SCIENCE, V255, P686, DOI 10.1126/science.1738842; BIRABEN JN, 1980, POPULATION, V4, P1; BIRDSELL JB, 1957, COLD SPRING HARB SYM, V22, P47, DOI 10.1101/SQB.1957.022.01.008; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; BRAUER G, 1989, HUMAN REVOLUTION, P123; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; Cavalli-Sforza L.L., 1971, GENETICS HUMAN POPUL; CAVALLI-SFORZA L.L, 1981, CULTURAL TRANSMISSIO; Cavalli-Sforza LL, 1988, MUNIBE S, V6, P129; CAVALLISFORZA LL, 1988, P NATL ACAD SCI USA, V85, P6002, DOI 10.1073/pnas.85.16.6002; CAVALLISFORZA LL, 1993, EUR J HUM GENET, V1, P3; CAVALLISFORZA LL, 1991, SCI AM, V265, P72, DOI 10.1038/scientificamerican1191-104; CAVALLISFORZA LL, IN PRESS HIST GEOGRA; CULBERT TP, 1983, ANCIENT S AM, pCH2; DIAMOND JM, 1991, NATURE, V350, P275, DOI 10.1038/350275a0; Dolgopolsky A, 1988, MEDITERR LANG REV, V3, P7; Eldredge N., 1972, P82; Fisher RA, 1937, ANN EUGENIC, V7, P355, DOI 10.1111/j.1469-1809.1937.tb02153.x; GAMKRELIDZE TV, 1990, SCI AM, V262, P110, DOI 10.1038/scientificamerican0390-110; GIMBUTAS M, 1991, CIVILIZATION GODDESS, pCH10; GREENBERG JH, 1986, CURR ANTHROPOL, V27, P477, DOI 10.1086/203472; GREENBERG JH, 1963, LANGUAGES AFRICA; GUGLIELMINO CR, 1990, AM J PHYS ANTHROPOL, V83, P57, DOI 10.1002/ajpa.1330830107; GUGLIELMINOMATESSI CR, 1979, AM J PHYS ANTHROPOL, V50, P549, DOI 10.1002/ajpa.1330500407; HASSAN FA, 1981, DEMOGRAPHIC ARCHAEOL; HEDGES SB, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1738849; HEWLETT BS, 1986, AM ANTHROPOL, V88, P922; Howells W. W., 1973, PAPERS PEABODY MUSEU, V67; Howells W. W., 1989, PAP PEABODY MUS, V79, P1; ISAAC GL, 1976, ANN NY ACAD SCI, V280, P275, DOI 10.1111/j.1749-6632.1976.tb25494.x; JONES R, 1989, HUMAN REVOLUTION, P743; Jones R., 1977, SUNDA SAHUL PREHISTO, P113; KAISER M, 1988, ANNU REV ANTHROPOL, V17, P309; Khazanov Anatoly M., 1984, NOMADS OUTSIDE WORLD; KLEIN RG, 1989, HUMAN REVOLUTION, P529; Koyama S., 1978, SENRI ETHNOL STUD, V2, P1; Lathrap DW., 1977, ORIGINS AGR, P713, DOI [10.1515/9783110813487.713, DOI 10.1515/9783110813487.713]; Livingstone FB, 1967, ABNORMAL HEMOGLOBINS; Mallory J. P., 1989, SEARCH INDOEUROPEANS; MATESSI CRG, 1983, MONOGR CONSIGLIO NAZ, V383; MENOZZI P, 1978, SCIENCE, V201, P786, DOI 10.1126/science.356262; MOUNTAIN JL, 1992, PHILOS T ROY SOC B, V337, P159, DOI 10.1098/rstb.1992.0093; OROURKE DH, 1985, AM J PHYS ANTHROPOL, V67, P241, DOI 10.1002/ajpa.1330670309; OROURKE DH, 1986, ANN HUM BIOL, V13, P13, DOI 10.1080/03014468600008171; PIAZZA A, 1988, ANN HUM GENET, V52, P203, DOI 10.1111/j.1469-1809.1988.tb01098.x; PIAZZA A, 1981, P NATL ACAD SCI-BIOL, V78, P2638, DOI 10.1073/pnas.78.4.2638; PIAZZA A, UNPUB; RENDINE S, 1986, AM NAT, V128, P681, DOI 10.1086/284597; RENFREW C, 1989, SCI AM, V261, P106, DOI 10.1038/scientificamerican1089-106; RENFREW C, 1987, ARCHAEOLOGY LANGUAGE; RIGHTMIRE PG, 1989, HUMAN REVOLUTION BEH, P109; SAITOU N, 1991, ISOLATION MIGRATION; Salzano FM, 1988, S AM INDIANS CASE ST; SGARAMELLAZONTA L, 1973, GENETIC STRUCTURE PO, P128; SOKAL RR, 1982, AM NAT, V119, P1, DOI 10.1086/283886; SOKAL RR, 1991, NATURE, V351, P143, DOI 10.1038/351143a0; SOKAL RR, 1992, NATURE, V355, P214, DOI 10.1038/355214b0; STRINGER CB, 1989, HUMAN REVOLUTION, P232; TEMPLETON AR, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1590849; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WEIDENREICH F, 1965, LIVING RACES MAN; WOLPOFF MH, 1989, HUMAN REVOLUTION, P62; ZVELEBIL M, 1980, CAMBRIDGE ENCY ARCHA, pCH38; [No title captured]	66	308	311	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1993	259	5095					639	646		10.1126/science.8430313	http://dx.doi.org/10.1126/science.8430313			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430313				2022-12-28	WOS:A1993KJ68800032
J	BROADIE, K; BATE, M				BROADIE, K; BATE, M			INNERVATION DIRECTS RECEPTOR SYNTHESIS AND LOCALIZATION IN DROSOPHILA EMBRYO SYNAPTOGENESIS	NATURE			English	Article							ACETYLCHOLINE-RECEPTORS; CELL; PROSPERO; PROTEIN; AGRIN	IN the Drosophila embryo, motor neurons form stereotyped synapses (neuromuscular junctions) on identified muscles1-3. We have used a mutant (prospero) that removes or delays innervation4,5 to assay the role of the presynaptic motor neuron in the development of the receptive field of the postsynaptic muscle. prospero (pros) is not expressed in the muscles or their precursors. Here we find that the muscle defines the correct synaptic zone in the absence of the motor neuron by restricting putative guidance molecules to this specialized membrane region. Furthermore, the muscle expresses functional transmitter receptors at the correct developmental time without innervation. On the other hand, the muscle does not localize receptors to the synapse without instruction from the motor neuron, nor does a second, much larger, synthesis of receptors occur in muscles deprived of innervation. In muscles receiving delayed innervation, or muscles innervated at aberrant synaptic sites, both receptor clustering and receptor synthesis are delayed or redirected, consistent with the new pattern of innervation. We conclude that the muscle autonomously defines the synaptic site, whereas the motor neuron directs the development of the muscle's receptive field by stimulating the synthesis and localization of transmitter receptors.			BROADIE, K (corresponding author), UNIV CAMBRIDGE,DEPT ZOOL,DOWNING ST,CAMBRIDGE CB2 3EJ,ENGLAND.							ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P757, DOI 10.1113/jphysiol.1977.sp011880; BROADIE KS, 1993, J NEUROSCI, V13, P144; CAMPANELLI JT, 1991, CELL, V67, P909, DOI 10.1016/0092-8674(91)90364-5; CAMPOSORTEGA JA, 1992, ROUX ARCH DEV BIOL, V201, P1, DOI 10.1007/BF00188770; DAHM LM, 1991, J NEUROSCI, V11, P238; DENNIS MJ, 1981, ANNU REV NEUROSCI, V4, P43, DOI 10.1146/annurev.ne.04.030181.000355; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HORTSCH M, 1991, ANNU REV CELL BIOL, V7, P505, DOI 10.1146/annurev.cb.07.110191.002445; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JOHANSEN J, 1989, J NEUROSCI, V9, P4318; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LIU DWC, 1992, J NEUROSCI, V12, P1859; MARTINOU JC, 1991, J NEUROSCI, V11, P1291; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SANES JR, 1991, DEVELOPMENT, V113, P1181; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; SIMON AM, 1992, DEVELOPMENT, V114, P545; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; TOSNEY K, 1988, DEV BIOL, V114, P427; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8	25	105	105	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					350	353		10.1038/361350a0	http://dx.doi.org/10.1038/361350a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8426654				2022-12-28	WOS:A1993KJ59000057
J	ELFERINK, LA; PETERSON, MR; SCHELLER, RH				ELFERINK, LA; PETERSON, MR; SCHELLER, RH			A ROLE FOR SYNAPTOTAGMIN (P65) IN REGULATED EXOCYTOSIS	CELL			English	Article							SYNAPTIC VESICLE; SECRETORY GRANULE; ENDOCRINE-CELLS; PROTEINS; IDENTIFICATION; SYNAPTOPHYSIN; BIOGENESIS; BINDING	Proteins that are specifically localized to synaptic vesicles in the nervous system have been proposed to mediate aspects of synaptic transmission. Antibodies raised against the cytoplasmic domains of five of these proteins, vamp, rab3A, synaptophysin, synaptotagmin, and SV2, were used to investigate their function. Microinjection of monoclonal and polyclonal antibodies raised against synaptotagmin (p65), but not the other vesicle proteins, decreases K+/Ca2+-mediated dopamine beta-hydroxylase surface staining, a measure of regulated secretion in PC12 cells. Microinjection of a soluble fragment of synaptotagmin encompassing one of the domains homologous to the C2 regulatory region of protein kinase C, but lacking the membrane anchor, also inhibits evoked dopamine beta-hydroxylase surface staining. These results provide support for the hypothesis that synaptotagmin, a Ca2+- and phospholipid-binding protein, is important for regulated exocytosis in neurons.			ELFERINK, LA (corresponding author), STANFORD UNIV,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305, USA.							BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MK, 1993, IN PRESS J NEUROSCI; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; CUTLER DF, 1990, J CELL BIOL, V110, P721, DOI 10.1083/jcb.110.3.721; GRAESSMANN A, 1980, METHOD ENZYMOL, V65, P817; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; KELLY RB, 1988, NEURON, V1, P431, DOI 10.1016/0896-6273(88)90174-2; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; SCHEUNER D, 1992, J CELL BIOL, V116, P359, DOI 10.1083/jcb.116.2.359; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WIEDENMANN B, 1986, P NATL ACAD SCI USA, V83, P3500, DOI 10.1073/pnas.83.10.3500	24	234	235	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					153	159		10.1016/0092-8674(93)90059-Y	http://dx.doi.org/10.1016/0092-8674(93)90059-Y			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422678				2022-12-28	WOS:A1993KG95500019
J	VERSHON, AK; JOHNSON, AD				VERSHON, AK; JOHNSON, AD			A SHORT, DISORDERED PROTEIN REGION MEDIATES INTERACTIONS BETWEEN THE HOMEODOMAIN OF THE YEAST ALPHA-2 PROTEIN AND THE MCM1 PROTEIN	CELL			English	Article							DNA-BINDING; REPRESSOR ALPHA-2; TRANSCRIPTION FACTORS; REGULATORY PROTEINS; DROSOPHILA EMBRYOS; CRYSTAL-STRUCTURE; HOMEO DOMAIN; GENE; EXPRESSION; OPERATOR	Homeodomains are folded into a characteristic three-dimensional structure capable of recognizing DNA in a sequence-specific manner. We show that correct target site selection by the yeast alpha2 protein requires, as well as its homeodomain, an adjacent short and apparently unstructured region of the protein. This flexible homeodomain extension is responsible for specifying an interaction with a second regulatory protein, MCM1, which permits the cooperative binding of the two proteins to an operator. Two additional experiments suggest that this extension-homeodomain arrangement is likely to have some generality. First, when the extension of alpha2 is grafted onto the Drosophila engrailed homeodomain, it yields a protein with the DNA binding specificity of engrailed and the ability to bind cooperatively to DNA with MCM1. Second, the alpha2 extension specifies interaction not only with the yeast MCM1 protein, but also with the related human protein SRF.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NIGMS NIH HHS [GM37049] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037049] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B., 1989, MOL BIOL CELL; AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; QIAN YQ, IN PRESS P NATL ACAD; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WILDE CD, 1987, EMBO J, V6, P1393, DOI 10.1002/j.1460-2075.1987.tb02380.x; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	34	117	118	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					105	112		10.1016/0092-8674(93)90054-T	http://dx.doi.org/10.1016/0092-8674(93)90054-T			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422672				2022-12-28	WOS:A1993KG95500014
J	THYSSEN, EP; WEINSTOCK, LB; BALFE, DM; SHATZ, BA				THYSSEN, EP; WEINSTOCK, LB; BALFE, DM; SHATZ, BA			MEDICAL-TREATMENT OF BENIGN GASTROCOLIC FISTULA	ANNALS OF INTERNAL MEDICINE			English	Note						GASTRIC FISTULA; ANTIINFLAMMATORY AGENTS; SURGERY, OPERATIVE; RANITIDINE; CIMETIDINE	GASTRIC-ULCER	Benign gastrocolic fistula has been reported in patients taking anti-inflammatory drugs and has been traditionally managed with surgery. We describe two patients taking nonsteroidal anti-inflammatory medications who were found to have a benign gastrocolic fistual. Because of the relatively mild symptoms, a trial of medical therapy was initiated with documented successful closure of the fistula. These findings show that some patients with benign gastrocolic fistula can be managed medically.			THYSSEN, EP (corresponding author), WASHINGTON UNIV, SCH MED, 660 S EUCLID AVE, BOX 8124, ST LOUIS, MO 63110 USA.							CARVER N, 1990, BRIT J CLIN PRACT, V44, P759; CASEY J, 1986, J NATL MED ASSOC, V78, P330; EKBOM A, 1982, ACTA CHIR SCAND, V148, P551; FRIKKER MJ, 1986, AM SURGEON, V52, P446; HANSEN CP, 1988, ACTA CHIR SCAND, V154, P287; MADSEN RE, 1978, J AM OSTEOPATH ASSOC, V77, P684; MORGAN MDL, 1981, POSTGRAD MED J, V57, P463, DOI 10.1136/pgmj.57.669.463; SOYBEL DI, 1989, BRIT J SURG, V76, P1298, DOI 10.1002/bjs.1800761226; STRANG GI, 1977, ARCH SURG-CHICAGO, V112, P651	9	12	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					433	435		10.7326/0003-4819-118-6-199303150-00007	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439118				2022-12-28	WOS:A1993KR81700007
J	FITZGERALD, FT				FITZGERALD, FT			THE CASE FOR INTERNAL-MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											FITZGERALD, FT (corresponding author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,MED CTR,SACRAMENTO,CA 95817, USA.								0	18	18	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1993	328	9					654	656		10.1056/NEJM199303043280912	http://dx.doi.org/10.1056/NEJM199303043280912			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP680	8429860				2022-12-28	WOS:A1993KP68000012
J	SIMONS, M; LECLERC, G; SAFIAN, RD; ISNER, JM; WEIR, L; BAIM, DS				SIMONS, M; LECLERC, G; SAFIAN, RD; ISNER, JM; WEIR, L; BAIM, DS			RELATION BETWEEN ACTIVATED SMOOTH-MUSCLE CELLS IN CORONARY-ARTERY LESIONS AND RESTENOSIS AFTER ATHERECTOMY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOSIN HEAVY-CHAINS; VASCULAR-DISEASE; EXPRESSION; PROLIFERATION; ANGIOPLASTY; MECHANISMS; STENOSIS; ISOFORM; GRAFTS; KINASE	Background. Neointimal proliferation leading to restenosis frequently develops after coronary angioplasty. This process is associated with a change in vascular smooth-muscle cells from a contractile (quiescent) phenotype to a synthetic or proliferating (activated) one. We investigated whether the presence of activated smooth-muscle cells in coronary lesions at the time of coronary atherectomy predisposes patients to subsequent restenosis. Methods. We used in situ hybridization to study the expression of messenger RNA in coronary-atherectomy specimens from 20 patients. Plaque material was hybridized with a probe for the B isoform of human non-muscle myosin heavy chain, a major nonmuscle myosin isoform in activated, but not quiescent, smooth-muscle cells. Angiographic follow-up data were obtained a mean (+/-SD) of 174+/-54 days after atherectomy in 16 of the 20 patients, and the extent of recurrent luminal narrowing was analyzed quantitatively. The presence of restenosis was assessed by exercise thallium scintigraphy in the other four patients. Results. Atherectomy specimens from 10 of the 20 patients showed hybridization with the probe, defined as the clustering of more than 20 silver grains per cell nucleus in more than 10 nuclei in five high-power fields (x250); specimens from the other 10 patients showed no such hybridization. At follow-up, restenosis had developed in 8 of the 10 patients with positive hybridization results, but was absent in 9 of the 1 0 patients with negative results (P = 0.007). The degree of late loss in luminal diameter was significantly higher in patients with positive hybridization results than in those with negative results (ratio of late loss to immediate gain after atherectomy, 0.76+/-0.3 vs. 0.36+/-0.3; P<0.001). Conclusions. We conclude that the expression of the B isoform of nonmuscle myosin heavy chain is increased in some coronary atherosclerotic plaques and that this increase in expression identifies a group of lesions at high risk for restenosis after atherectomy.	CHARLES A DANA RES INST,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA 02115; ST ELIZABETH HOSP,DIV CARDIOL,BOSTON,MA	Harvard University; Harvard University; Harvard Medical School	SIMONS, M (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,DEPT MED,DIV CARDIOVASC,THORNDIKE LAB,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032747, R01HL040518] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-40518, HL-32747] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P369, DOI 10.1016/S0735-1097(85)80174-1; CALIFF RM, 1990, TXB INTERVENTIONAL C, P333; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DILLEY RJ, 1988, ARCH SURG-CHICAGO, V123, P691; FANELLI C, 1990, AM HEART J, V119, P357, DOI 10.1016/S0002-8703(05)80028-6; FISHMAN RF, 1992, J AM COLL CARDIOL, V20, P1101, DOI 10.1016/0735-1097(92)90365-T; GARRATT KN, 1991, J AM COLL CARDIOL, V17, P442, DOI 10.1016/S0735-1097(10)80113-5; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KERRICK WGL, 1984, P NATL ACAD SCI-BIOL, V81, P165, DOI 10.1073/pnas.81.1.165; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KOCHER O, 1991, LAB INVEST, V65, P459; KUNTZ RE, 1993, J AM COLL CARDIOL, V21, P15, DOI 10.1016/0735-1097(93)90712-A; KUROO M, 1991, J BIOL CHEM, V266, P3768; LECLERC G, 1992, CIRCULATION, V85, P543, DOI 10.1161/01.CIR.85.2.543; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; SAFIAN RD, 1990, CIRCULATION, V82, P69, DOI 10.1161/01.CIR.82.1.69; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SCHWARTZ SM, 1987, HUM PATHOL, V18, P240, DOI 10.1016/S0046-8177(87)80006-0; SCOBLIONKO DP, 1984, AM J CARDIOL, V53, P689, DOI 10.1016/0002-9149(84)90387-4; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SIMPSON JB, 1988, AM J CARDIOL, V61, pG96, DOI 10.1016/S0002-9149(88)80040-7; ZANELLATO AMC, 1990, ARTERIOSCLEROSIS, V10, P996, DOI 10.1161/01.ATV.10.6.996	26	104	109	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1993	328	9					608	613		10.1056/NEJM199303043280903	http://dx.doi.org/10.1056/NEJM199303043280903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP680	8429852				2022-12-28	WOS:A1993KP68000003
J	CARROZZA, JP; KUNTZ, RE; FISHMAN, RF; BAIM, DS				CARROZZA, JP; KUNTZ, RE; FISHMAN, RF; BAIM, DS			RESTENOSIS AFTER ARTERIAL INJURY CAUSED BY CORONARY STENTING IN PATIENTS WITH DIABETES-MELLITUS	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS; CORONARY DISEASE; STENTING, CORONARY; RESTENOSIS; CORONARY VASOSPASM	TRANS-LUMINAL ANGIOPLASTY; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; BIOLOGY; MODEL; PROLIFERATION; ATHERECTOMY; REGISTRY; HISTORY	Objective: To determine whether diabetic patients, when compared with nondiabetic patients, have a higher incidence of restenosis after coronary stenting, and, if so, whether restenosis is attributable to lesion or procedural differences or to a greater biologic tendency for late loss of minimum diameter in diabetic patients. Design: Case series. Setting: Tertiary care referral center. Patients: Two hundred twenty consecutive patients with coronary artery disease who were referred for placement of a Palmaz-Schatz stent in either a native coronary artery or a saphenous vein graft. Results. Based on a traditional dichotomous definition of restenosis (greater-than-or-equal-to 50% stenosis at follow-up), lesions in diabetic patients had a significantly greater restenosis rate (55%) than lesions in nondiabetic patients (20%; P = 0.001). Vessel size, lesion length, pre-procedure lesion severity, procedural outcome, and acute gain (the difference between minimum lumen diameter before and after the procedure) were similar in the diabetic and nondiabetic groups. However, at follow-up, stents in diabetic patients had a smaller lumen diameter (1.66 +/- 1.18 mm) compared with those in nondiabetic patients (2.24 +/- 0.93 mm; P = 0.004), as well as a greater percent stenosis (49% compared with 32%; P = 0.002). Thus, the increased restenosis rate in stents in diabetic patients (55% compared with 20%; P = 0.001) is secondary to increased late loss of minimum lumen diameter (1.66 +/- 1.28 mm compared with 1.23 +/- 0.97 mm; P = 0.04). Conclusions: After arterial injury produced by stent placement, diabetic patients have a significantly greater incidence of restenosis because of greater late loss at the treatment site. Because elastic recoil or vasospasm contributes little to stent restenosis, the increased late loss of minimum lumen diameter in diabetic patients suggests that they have a greater predisposition to intimal hyperplasia.			CARROZZA, JP (corresponding author), BETH ISRAEL HOSP, DIV CARDIOVASC, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P369, DOI 10.1016/S0735-1097(85)80174-1; BARBANO EF, 1989, ATHEROSCLEROSIS, V78, P183, DOI 10.1016/0021-9150(89)90222-0; BAUGHMAN KL, 1981, AM J CARDIOL, V48, P1044, DOI 10.1016/0002-9149(81)90318-0; BLOCK PC, 1980, CIRCULATION, V61, P778, DOI 10.1161/01.CIR.61.4.778; CALIFF RM, 1991, J AM COLL CARDIOL, V17, pB2; CARRICO TJ, 1984, SURG CLIN N AM, V64, P721; CARROZZA JP, 1992, J AM COLL CARDIOL, V20, P328, DOI 10.1016/0735-1097(92)90098-8; CRIQUI MH, 1986, AM J CARDIOL, V57, pC18, DOI 10.1016/0002-9149(86)91022-2; DETRE K, 1989, CIRCULATION, V80, P421, DOI 10.1161/01.CIR.80.3.421; EHRLICHMAN RJ, 1991, SURG CLIN N AM, V71, P1323; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; FOSTER DW, 1987, HARRISONS PRINCIPLES, P1778; GUITERAS VP, 1987, AM J CARDIOL S, V60, pB50; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; HOLMES DR, 1984, AM J CARDIOL, V53, pC77, DOI 10.1016/0002-9149(84)90752-5; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KING GL, 1985, METABOLISM, V34, P17, DOI 10.1016/S0026-0495(85)80005-6; KING SB, 1991, J AM COLL CARDIOL, V17, pA345; KOSCHINSKY T, 1981, ATHEROSCLEROSIS, V39, P313, DOI 10.1016/0021-9150(81)90018-6; KUNTZ RE, 1992, J AM COLL CARDIOL, V19, P1493, DOI 10.1016/0735-1097(92)90609-Q; LEVINE MJ, 1990, J AM COLL CARDIOL, V16, P332, DOI 10.1016/0735-1097(90)90582-A; MULLER DWM, 1992, J AM COLL CARDIOL, V19, P418, DOI 10.1016/0735-1097(92)90500-M; MYLER RK, 1987, CATHETER CARDIO DIAG, V13, P1, DOI 10.1002/ccd.1810130102; PFEIFLE B, 1987, ENDOCRINOLOGY, V120, P2251, DOI 10.1210/endo-120-6-2251; QUIGLEY PJ, 1989, AM J CARDIOL, V63, P409, DOI 10.1016/0002-9149(89)90309-3; RENSING BJ, 1991, J AM COLL CARDIOL, V17, pB34; SAFIAN RD, 1990, CIRCULATION, V82, P69, DOI 10.1161/01.CIR.82.1.69; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; STEELE PM, 1985, CIRC RES, V57, P105, DOI 10.1161/01.RES.57.1.105; UCHIDA Y, 1989, AM HEART J, V117, P769, DOI 10.1016/0002-8703(89)90611-X; WALKER LN, 1986, P NATL ACAD SCI USA, V83, P7311, DOI 10.1073/pnas.83.19.7311; WALLER BF, 1991, J AM COLL CARDIOL, V17, pB58; WRIGHT BD, 1989, J FUTURES MARKETS, V9, P1, DOI 10.1002/fut.3990090102	35	229	239	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					344	349		10.7326/0003-4819-118-5-199303010-00004	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8430980				2022-12-28	WOS:A1993KN68800004
J	LESKO, SM; ROSENBERG, L; SHAPIRO, S				LESKO, SM; ROSENBERG, L; SHAPIRO, S			A CASE-CONTROL STUDY OF BALDNESS IN RELATION TO MYOCARDIAL-INFARCTION IN MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; DIHYDROTESTOSTERONE; TESTOSTERONE; LIPOPROTEINS; ANDROGENS	Objective.-To examine the relationship between male pattern baldness and the risk of myocardial infarction in men under the age of 55 years. Design and Participants.-A hospital-based, case-control study was conducted in eastern Massachusetts and Rhode Island. Cases were men admitted to a hospital for a first nonfatal myocardial infarction (n=665); controls were men admitted to the same hospitals with noncardiac diagnoses (n=772). Extent of baldness was assessed using the 12-point modified Hamilton Baldness Scale; other information was obtained by personal interview. Among the controls, the prevalence of any baldness was 34%, while the prevalence of baldness involving the vertex scalp was 23%. Results.-After allowing for age, the relative risk estimate for frontal baldness compared with no hair loss was 0.9 (95% confidence interval, 0.6 to 1.3), for baldness involving the vertex scalp it was 1.4 (95% confidence interval, 1.2 to 1.9). Risk of myocardial infarction increased as the degree of vertex baldness increased (P<.01); for severe vertex baldness the relative risk was 3.4 (95% confidence interval, 1.7 to 7.0). The relationship between vertex baldness and myocardial infarction was consistent within strata defined by age and other risk factors for coronary artery disease. Conclusion.-These data support the hypothesis that male pattern baldness involving the vertex scalp is associated with coronary artery disease in men under the age of 55 years.			LESKO, SM (corresponding author), BOSTON UNIV,SCH MED,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Rosenberg, Lynn/0000-0003-2760-2987				ARMITAGE P, 1971, STATISTICAL METHODS, P319; BALAZS T, 1971, TOXICOL APPL PHARM, V20, P442, DOI 10.1016/0041-008X(71)90287-0; BUECHNER HOWARD A., 1964, J LOUISIANA STATE MED SOC, V116, P329; COOKE NT, 1979, BRIT J DERMATOL, V101, P455, DOI 10.1111/j.1365-2133.1979.tb00026.x; COTTON SG, 1972, BRIT HEART J, V34, P458, DOI 10.1136/hrt.34.5.458; GORMLEY GJ, 1990, J CLIN ENDOCR METAB, V70, P1136, DOI 10.1210/jcem-70-4-1136; GREGER NG, 1990, METABOLISM, V39, P919, DOI 10.1016/0026-0495(90)90301-R; Halim M M, 1978, Br J Dermatol, V98, P63, DOI 10.1111/j.1365-2133.1978.tb07334.x; HAMALAINEN E, 1986, METABOLISM, V35, P535, DOI 10.1016/0026-0495(86)90011-9; Hamilton JB, 1942, AM J ANAT, V71, P451, DOI 10.1002/aja.1000710306; HAYNES SG, 1978, AM J EPIDEMIOL, V107, P362, DOI 10.1093/oxfordjournals.aje.a112556; HELLER RF, 1981, BRIT MED J, V282, P438, DOI 10.1136/bmj.282.6262.438; HERMAN EH, 1979, TOXICOL APPL PHARM, V47, P493, DOI 10.1016/0041-008X(79)90520-9; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCGILL HC, 1980, SCIENCE, V207, P775, DOI 10.1126/science.6766222; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; NORWOOD OT, 1975, SOUTHERN MED J, V68, P1359, DOI 10.1097/00007611-197511000-00009; PERSSON B, 1984, ACTA MED SCAND, V216, P485; PHILLIPS GB, 1976, LANCET, V2, P14; REYNOLDS JEF, 1989, MARTINDALE EXTRA PHA, P491; SHERIDAN PJ, 1989, ANAT REC, V223, P414, DOI 10.1002/ar.1092230410; TENOVER JS, 1991, ENDOCRIN METAB CLIN, V20, P893, DOI 10.1016/S0889-8529(18)30249-4; TREVISON M, 1990, CIRCULATION, V81, P18; VERMEULEN A, 1985, MATURITAS, V7, P281, DOI 10.1016/0378-5122(85)90051-9; 1972, BMJ, V4, P3; 1971, ISCHEMIC HEART DISEA	26	89	90	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					998	1003		10.1001/jama.269.8.998	http://dx.doi.org/10.1001/jama.269.8.998			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM603	8429606				2022-12-28	WOS:A1993KM60300027
J	GHARIB, H; GOELLNER, JR				GHARIB, H; GOELLNER, JR			FINE-NEEDLE ASPIRATION BIOPSY OF THE THYROID - AN APPRAISAL	ANNALS OF INTERNAL MEDICINE			English	Article						BIOPSY, NEEDLE; THYROID NODULE; THYROID NEOPLASMS; COST-BENEFIT ANALYSIS; THYROIDECTOMY	SUPPRESSIVE THERAPY; DIAGNOSTIC-ACCURACY; FOLLOW-UP; NODULES; MANAGEMENT; CYTOLOGY; GLAND; CANCER; CARE; LIMITATIONS	Objective: To review the literature on the utility of fine-needle aspiration biopsy in the diagnostic management of nodular thyroid disease. Data Sources. Relevant articles published in major English-language medical journals during the last 10 years. Data Extraction: Articles were reviewed to assess the results of fine-needle aspiration biopsy and its effect on thyroid management and cost of care. Data Synthesis: Fine-needle aspiration biopsy of the thyroid gland is safe, inexpensive, minimally invasive, and highly accurate in the diagnosis of nodular thyroid disease. Four cytologic diagnostic categories are used. Rates for these categories, based on data pooled from seven series, were as follows: benign, 69%; suspicious, 10%; malignant, 4%; and nondiagnostic, 17%. Analysis of recent data suggests a false-negative rate of 1% to 11%, a false-positive rate of 1% to 8%, a sensitivity of 65% to 98%, and a specificity of 72% to 100%. Limitations of fine-needle aspiration are related to the skill of the aspirator, the expertise of the cytologist, and the difficulty in distinguishing some benign cellular adenomas from their malignant counterparts. The introduction of fine-needle aspiration has had a substantial effect on the management of patients with thyroid nodules. The percentage of patients undergoing thyroidectomy has decreased by 25%, and the yield of carcinoma in patients who undergo surgery has increased from 15% to at least 30%. Fine-needle aspiration has decreased the cost of care by 25%. Conclusions: Fine-needle aspiration biopsy is safe, accurate, and cost-effective. The procedure has a central role in the management of thyroid nodules and should be used as the initial diagnostic test.			GHARIB, H (corresponding author), MAYO CLIN & MAYO FDN, DIV ENDOCRINOL METAB & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							AKERMAN M, 1985, ACTA CYTOL, V29, P850; ALTAVILLA G, 1990, ACTA CYTOL, V34, P251; ANDERSON JB, 1987, BRIT J SURG, V74, P292, DOI 10.1002/bjs.1800740422; ASHCRAFT MW, 1981, HEAD NECK SURG, V3, P297, DOI 10.1002/hed.2890030406; ASHCRAFT MW, 1981, HEAD NECK SURG, V3, P216, DOI 10.1002/hed.2890030309; ASP AA, 1987, AM J MED, V83, P489, DOI 10.1016/0002-9343(87)90759-5; BACKDAHL M, 1987, SURG CLIN N AM, V67, P197; BASKIN HJ, 1987, SOUTHERN MED J, V80, P702, DOI 10.1097/00007611-198706000-00009; Block M A, 1980, World J Surg, V4, P737; BLOCK MA, 1983, AM J SURG, V146, P72, DOI 10.1016/0002-9610(83)90262-3; BOEY J, 1986, WORLD J SURG, V10, P623, DOI 10.1007/BF01655540; CAMPBELL JP, 1989, HEAD NECK-J SCI SPEC, V11, P414, DOI 10.1002/hed.2880110507; Caplan R H, 1991, Wis Med J, V90, P285; Caruso D, 1991, ENDOCRINOLOGIST, V1, P194, DOI 10.1097/00019616-199106000-00009; CHEUNG PSY, 1989, WORLD J SURG, V13, P818, DOI 10.1007/BF01658447; CRISTALLINI E G, 1989, Applied Pathology, V7, P149; CUSICK EL, 1990, BMJ-BRIT MED J, V301, P318, DOI 10.1136/bmj.301.6747.318; DELOSSANTOS ET, 1990, ARCH INTERN MED, V150, P1422, DOI 10.1001/archinte.150.7.1422; DWARAKANATHAN AA, 1989, ARCH INTERN MED, V149, P2007, DOI 10.1001/archinte.149.9.2007; FITZPATRICK D, 1986, POSTGRAD MED, V80, P62, DOI 10.1080/00325481.1986.11699532; GAGNETEN CB, 1987, ACTA CYTOL, V31, P595; GARDINER GW, 1986, J OTOLARYNGOL, V15, P161; GHARIB H, 1988, ENDOCRIN METAB CLIN, V17, P511, DOI 10.1016/S0889-8529(18)30414-6; GHARIB H, 1984, ANN INTERN MED, V101, P25, DOI 10.7326/0003-4819-101-1-25; GHARIB H, 1987, NEW ENGL J MED, V317, P70, DOI 10.1056/NEJM198707093170202; GIANSANTI M, 1989, TUMORI J, V75, P475, DOI 10.1177/030089168907500515; GOELLNER JR, 1987, ACTA CYTOL, V31, P587; GRANT CS, 1989, SURGERY, V106, P980; GRIFFIN JE, 1988, AM J MED SCI, V296, P336, DOI 10.1097/00000441-198811000-00008; HALL TL, 1989, CANCER, V63, P718, DOI 10.1002/1097-0142(19890215)63:4<718::AID-CNCR2820630420>3.0.CO;2-N; HAMAKER RC, 1983, ARCH OTOLARYNGOL, V109, P225; HAMBERGER B, 1982, AM J MED, V73, P381, DOI 10.1016/0002-9343(82)90731-8; HAMBURGER JI, 1989, ARCH PATHOL LAB MED, V113, P1035; HAMBURGER JI, 1986, NEW YORK STATE J MED, V86, P241; HAMMING JF, 1990, ARCH INTERN MED, V150, P113, DOI 10.1001/archinte.150.1.113; HANNI CL, 1984, AM SURGEON, V50, P485; HANSON GA, 1983, SURGERY, V94, P984; HARSOULIS P, 1986, BRIT J SURG, V73, P461, DOI 10.1002/bjs.1800730615; HAWKINS F, 1987, CANCER, V59, P1206, DOI 10.1002/1097-0142(19870315)59:6<1206::AID-CNCR2820590629>3.0.CO;2-7; HSU C, 1987, ACTA CYTOL, V31, P699; JAYARAM G, 1985, ACTA CYTOL, V29, P967; KAPOOR VK, 1989, POSTGRAD MED J, V65, P642, DOI 10.1136/pgmj.65.767.642; KENDALL CH, 1989, J CLIN PATHOL, V42, P23, DOI 10.1136/jcp.42.1.23; KHAFAGI F, 1988, MED J AUSTRALIA, V149, P302, DOI 10.5694/j.1326-5377.1988.tb120629.x; LAROSA GL, 1991, CANCER, V67, P2137, DOI 10.1002/1097-0142(19910415)67:8<2137::AID-CNCR2820670822>3.0.CO;2-Y; LIEL Y, 1988, ACTA CYTOL, V32, P866; LOGERFO P, 1985, SURGERY, V98, P1197; LOWHAGEN T, 1979, SURG CLIN N AM, V59, P3; MAZZAFERRI EL, 1988, MED CLIN N AM, V72, P1177, DOI 10.1016/S0025-7125(16)30736-2; MILLER J M, 1980, Henry Ford Hospital Medical Journal, V28, P145; MILLER JM, 1985, MED CLIN N AM, V69, P1063; MOLITCH ME, 1984, ENDOCR REV, V5, P185, DOI 10.1210/edrv-5-2-185; NATHAN AR, 1988, CANCER, V62, P1337, DOI 10.1002/1097-0142(19881001)62:7<1337::AID-CNCR2820620716>3.0.CO;2-9; NGUYEN GK, 1991, PATHOL ANNU, V26, P63; NUNEZ C, 1989, PATHOL ANNU, V24, P161; PEPPER GM, 1989, ARCH INTERN MED, V149, P594, DOI 10.1001/archinte.149.3.594; RAMACCIOTTI CE, 1984, ARCH INTERN MED, V144, P1169, DOI 10.1001/archinte.144.6.1169; RAVINSKY E, 1990, ACTA CYTOL, V34, P813; REEVE TS, 1986, MED J AUSTRALIA, V145, P308, DOI 10.5694/j.1326-5377.1986.tb113833.x; RIDGWAY EC, 1992, J CLIN ENDOCR METAB, V74, P231, DOI 10.1210/jc.74.2.231; ROJESKI MT, 1985, NEW ENGL J MED, V313, P428, DOI 10.1056/NEJM198508153130707; SILVERMAN JF, 1986, CANCER-AM CANCER SOC, V57, P1164, DOI 10.1002/1097-0142(19860315)57:6<1164::AID-CNCR2820570617>3.0.CO;2-S; SMITH SA, 1987, ARCH INTERN MED, V147, P311, DOI 10.1001/archinte.147.2.311; SMITH SA, 1991, ADV ENDOCRINOLOGY ME, V2, P107; STOFFER RP, 1960, ARCH INTERN MED, V106, P62, DOI 10.1001/archinte.1960.03820010012004; TANI EM, 1988, ANNU REV MED, V39, P255, DOI 10.1146/annurev.me.39.020188.001351; TREECE GL, 1983, ARCH INTERN MED, V143, P2285; VANDER JB, 1968, ANN INTERN MED, V69, P537, DOI 10.7326/0003-4819-69-3-537; VANHERLE AJ, 1982, ANN INTERN MED, V96, P221, DOI 10.7326/0003-4819-96-2-221; VIGNERI R, 1988, J ENDOCRINOL INVEST, V11, P831, DOI 10.1007/BF03350239; WETZIG NR, 1989, ANN ROY COLL SURG, V71, P316	71	913	947	1	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					282	289		10.7326/0003-4819-118-4-199302150-00007	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8420446				2022-12-28	WOS:A1993KL45700007
J	JOHNSTON, DE; KAPLAN, MM				JOHNSTON, DE; KAPLAN, MM			MEDICAL PROGRESS - PATHOGENESIS AND TREATMENT OF GALLSTONES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SHOCK-WAVE LITHOTRIPSY; BILE-DUCT STONES; TERT-BUTYL ETHER; CHOLESTEROL GALLSTONES; LAPAROSCOPIC CHOLECYSTECTOMY; ENDOSCOPIC SPHINCTEROTOMY; URSODEOXYCHOLIC ACID; GALLBLADDER BILE; CHENODEOXYCHOLIC ACID; NATURAL-HISTORY		NEW ENGLAND MED CTR,DEPT MED,DIV GASTROENTEROL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University								ABEI M, 1992, Gastroenterology, V102, pA770; ADMIRAND WH, 1968, J CLIN INVEST, V47, P1043, DOI 10.1172/JCI105794; ALIPERTI G, 1991, ANN INTERN MED, V115, P783, DOI 10.7326/0003-4819-115-10-783; ALLEN MJ, 1985, NEW ENGL J MED, V312, P217, DOI 10.1056/NEJM198501243120406; ALTMAN LK, 1992, NY TIMES        0614, V141, P1; AMARAL JF, 1985, AM J SURG, V149, P551, DOI 10.1016/S0002-9610(85)80055-6; Apstein M. D., 1989, PATHOPHYSIOLOGY GAST, P489; APSTEIN MD, 1987, GASTROENTEROLOGY, V92, P966, DOI 10.1016/0016-5085(87)90971-1; ASHUR H, 1978, ARCH SURG-CHICAGO, V113, P594; BARKUN ANG, 1990, ANN INTERN MED, V112, P126, DOI 10.7326/0003-4819-112-2-126; BASS EB, 1991, GASTROENTEROLOGY, V101, P189, DOI 10.1016/0016-5085(91)90477-3; BAZZOLI F, 1992, Gastroenterology, V102, pA302; BOLONDI L, 1985, GUT, V26, P734, DOI 10.1136/gut.26.7.734; BROOMFIELD PH, 1988, NEW ENGL J MED, V319, P1567, DOI 10.1056/NEJM198812153192403; BURNSTEIN MJ, 1983, GASTROENTEROLOGY, V85, P801; CABRAL DJ, 1989, SALIVARY HDB PHYSL 6, V3, P621; CAREY MC, 1988, GASTROENTEROLOGY, V95, P508, DOI 10.1016/0016-5085(88)90513-6; COHEN BI, 1991, GASTROENTEROLOGY, V101, P1109, DOI 10.1016/0016-5085(91)90741-3; COOPER AD, 1991, GASTROENTEROL CLIN N, V20, P21; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2; COTTON PB, 1987, GASTROINTEST ENDOSC, V33, P411, DOI 10.1016/S0016-5107(87)71675-7; DANZINGER RG, 1972, NEW ENGL J MED, V286, P1, DOI 10.1056/NEJM197201062860101; DAVIDSON BR, 1988, GUT, V29, P114, DOI 10.1136/gut.29.1.114; DAVROS WJ, 1991, RADIOLOGY, V178, P397, DOI 10.1148/radiology.178.2.1987600; DIEHL AK, 1990, AM J MED, V89, P29, DOI 10.1016/0002-9343(90)90094-T; DIEHL AK, 1991, GASTROENTEROL CLIN N, V20, P1; DOLGIN SM, 1981, NEW ENGL J MED, V304, P808, DOI 10.1056/NEJM198104023041402; DOMINGO N, 1992, Gastroenterology, V102, pA802; DONOVAN JM, 1990, HEPATOLOGY, V12, pS94; DONOVAN JM, 1991, GASTROENTEROL CLIN N, V20, P47; DUANE WC, 1990, HOSP PRACT, V25, P65; DUANE WC, 1990, HOSP PRACT OFF ED, V25, P79; EINARSSON K, 1985, NEW ENGL J MED, V313, P277, DOI 10.1056/NEJM198508013130501; ELL C, 1990, GASTROENTEROLOGY, V99, P1439, DOI 10.1016/0016-5085(90)91173-4; ESCH O, 1992, Gastroenterology, V102, pA311; EVERSON GT, 1991, GASTROENTEROL CLIN N, V20, P85; EVERSON GT, 1991, J CLIN INVEST, V87, P237, DOI 10.1172/JCI114977; FOERSTER EC, 1990, GASTROINTEST ENDOSC, V36, P444; FRIEDMAN GD, 1989, J CLIN EPIDEMIOL, V42, P1127; GADACZ TR, 1990, SURG CLIN N AM, V70, P1249; GIBNEY EJ, 1990, BRIT J SURG, V77, P368, DOI 10.1002/bjs.1800770405; GILLILAND TM, 1990, SURG GYNECOL OBSTET, V170, P39; GLEESON D, 1992, GASTROENTEROLOGY, V102, P1707, DOI 10.1016/0016-5085(92)91734-L; GRACIE WA, 1982, NEW ENGL J MED, V307, P798, DOI 10.1056/NEJM198209233071305; GREINER L, 1990, GASTROENTEROLOGY, V98, P1620, DOI 10.1016/0016-5085(90)91099-R; GROEN AK, 1992, GASTROENTEROLOGY S, V102, pA323; HALPERN Z, 1986, GASTROENTEROLOGY, V90, P875, DOI 10.1016/0016-5085(86)90863-2; HARVEY PRC, 1991, J BIOL CHEM, V266, P13996; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; HENRIKSSON P, 1989, J CLIN INVEST, V84, P811, DOI 10.1172/JCI114240; HIROTA I, 1992, GASTROENTEROLOGY, V102, P1668, DOI 10.1016/0016-5085(92)91728-M; HOFMANN AF, 1989, AM J SURG, V158, P198, DOI 10.1016/0002-9610(89)90252-3; HOFMANN AF, 1991, GASTROENTEROL CLIN N, V20, P183; HOLAN KR, 1979, GASTROENTEROLOGY, V77, P611; HOLOHANTV, 1991, LANCET, V338, P801; HOLZBACH RT, 1991, GASTROENTEROL CLIN N, V20, P67; HOLZBACH RT, 1989, GASTROINTESTINAL DIS, V2, P1668; INGOLDBY CJH, 1989, GUT, V30, P1129, DOI 10.1136/gut.30.8.1129; JENSEN KH, 1991, GASTROENTEROLOGY, V100, P790, DOI 10.1016/0016-5085(91)80027-7; JUNGST D, 1991, GASTROENTEROLOGY, V100, P1724; JUTTNER HU, 1982, RADIOLOGY, V142, P465; KOCH JP, 1964, NEW ENGL J MED, V271, P657, DOI 10.1056/NEJM196409242711304; LAI ECS, 1992, NEW ENGL J MED, V326, P1582, DOI 10.1056/NEJM199206113262401; LAMONT JT, 1984, HEPATOLOGY, V4, pS51, DOI 10.1002/hep.1840040809; LEAHY AL, 1991, BRIT J SURG, V78, P1321, DOI 10.1002/bjs.1800781116; LEE SP, 1981, J CLIN INVEST, V67, P1712, DOI 10.1172/JCI110209; LEE SP, 1992, NEW ENGL J MED, V326, P589, DOI 10.1056/NEJM199202273260902; LEE SP, 1981, SCIENCE, V211, P1429, DOI 10.1126/science.7466399; LEVY PF, 1984, GASTROENTEROLOGY, V87, P270; LIDDLE RA, 1989, ARCH INTERN MED, V149, P1750, DOI 10.1001/archinte.149.8.1750; LONG CA, 1991, RADIOLOGY, V180, P47, DOI 10.1148/radiology.180.1.2052721; LOPEZ AJ, 1991, ANN INTERN MED, V115, P712, DOI 10.7326/0003-4819-115-9-712; LOWENFELS AB, 1985, JNCI-J NATL CANCER I, V75, P77; LOWENFELS AB, 1989, INT J EPIDEMIOL, V18, P50, DOI 10.1093/ije/18.1.50; MAGLINTE DDT, 1991, RADIOLOGY, V178, P49, DOI 10.1148/radiology.178.1.1984325; MARINGHINI A, 1987, J HEPATOL, V5, P218, DOI 10.1016/S0168-8278(87)80576-7; MARTON KI, 1988, ANN INTERN MED, V109, P722, DOI 10.7326/0003-4819-109-9-722; MCSHERRY CK, 1989, AM J SURG, V158, P174, DOI 10.1016/0002-9610(89)90246-8; MCSHERRY CK, 1985, ANN SURG, V202, P59; MESSING B, 1983, GASTROENTEROLOGY, V84, P1012; MOORE EW, 1990, HEPATOLOGY, V12, pS206; MORRISSEY JF, 1991, NEW ENGL J MED, V325, P1214, DOI 10.1056/NEJM199110243251705; NEOPTOLEMOS JP, 1987, BRIT MED J, V294, P470, DOI 10.1136/bmj.294.6570.470; NILSELL K, 1985, GASTROENTEROLOGY, V89, P287, DOI 10.1016/0016-5085(85)90328-2; NILSELL K, 1983, GASTROENTEROLOGY, V85, P1248; ODONNELL LDJ, 1988, GUT, V29, P655, DOI 10.1136/gut.29.5.655; OFFNER GD, 1991, HEPATOLOGY, V14, pA92; PATTINSON NR, 1991, GASTROENTEROLOGY, V101, P1339, DOI 10.1016/0016-5085(91)90086-Z; PAUMGARTNER G, 1991, LANCET, V338, P1117, DOI 10.1016/0140-6736(91)91972-W; PESSA ME, 1987, ANN SURG, V205, P389, DOI 10.1097/00000658-198704000-00008; PETITTI DB, 1988, GASTROENTEROLOGY, V94, P91, DOI 10.1016/0016-5085(88)90614-2; PETRONI M L, 1992, Gastroenterology, V102, pA328; PITT HA, 1990, SURG CLIN N AM, V70, P1197; PODDA M, 1989, GASTROENTEROLOGY, V96, P222, DOI 10.1016/0016-5085(89)90784-1; POKORNY WJ, 1984, AM J SURG, V148, P742, DOI 10.1016/0002-9610(84)90428-8; PONCHON T, 1989, GASTROENTEROLOGY, V97, P457, DOI 10.1016/0016-5085(89)90083-8; PONCHON T, 1991, GASTROENTEROLOGY, V100, P1730, DOI 10.1016/0016-5085(91)90676-C; PRYSTOWSKY JB, 1990, SURG CLIN N AM, V70, P1231; RANSOHOFF DF, 1983, ANN INTERN MED, V99, P199, DOI 10.7326/0003-4819-99-2-199; RANSOHOFF DF, 1987, ANN INTERN MED, V106, P829, DOI 10.7326/0003-4819-106-6-829; RANSOHOFF DF, 1990, AM J MED, V88, P154, DOI 10.1016/0002-9343(90)90466-Q; RIGAS B, 1990, J CLIN GASTROENTEROL, V12, P409, DOI 10.1097/00004836-199008000-00011; ROS E, 1991, GASTROENTEROLOGY, V101, P1701, DOI 10.1016/0016-5085(91)90410-M; SACKIER JM, 1991, ARCH SURG-CHICAGO, V126, P1021; SACKIER JM, 1991, AM SURGEON, V57, P323; SACKMANN M, 1990, GASTROENTEROLOGY, V98, P392, DOI 10.1016/0016-5085(90)90830-T; SACKMANN M, 1992, GASTROENTEROLOGY, V102, P988, DOI 10.1016/0016-5085(92)90187-4; SACKMANN M, 1988, NEW ENGL J MED, V318, P393, DOI 10.1056/NEJM198802183180701; SALEN G, 1991, GASTROENTEROL CLIN N, V20, P171; SANDLER RS, 1986, GASTROENTEROLOGY, V91, P157, DOI 10.1016/0016-5085(86)90452-X; SAUERBRUCH T, 1992, HEPATOLOGY, V15, P208, DOI 10.1002/hep.1840150207; SAUERBRUCH T, 1986, NEW ENGL J MED, V314, P818, DOI 10.1056/NEJM198603273141304; SAUERBRUCH T, 1991, LANCET, V338, P1121, DOI 10.1016/0140-6736(91)91973-X; SAUERBRUCH T, 1989, AM J SURG, V158, P188, DOI 10.1016/0002-9610(89)90249-3; SCHNEIDER HT, 1992, GASTROENTEROLOGY, V102, P640, DOI 10.1016/0016-5085(92)90114-E; SCHOENFIELD LJ, 1990, NEW ENGL J MED, V323, P1239, DOI 10.1056/NEJM199011013231804; SCHOENFIELD LJ, 1981, ANN INTERN MED, V95, P257, DOI 10.7326/0003-4819-95-3-257; SENIOR JR, 1990, GASTROENTEROLOGY, V99, P243, DOI 10.1016/0016-5085(90)91254-4; SHIFFMAN ML, 1990, GASTROENTEROLOGY, V99, P1772, DOI 10.1016/0016-5085(90)90486-K; SHIFFMAN ML, 1990, GASTROENTEROLOGY, V99, P1452, DOI 10.1016/0016-5085(90)91175-6; SHLAER WJ, 1981, AM J ROENTGENOL, V136, P337, DOI 10.2214/ajr.136.2.337; SIVAK MV, 1989, AM J SURG, V158, P228, DOI 10.1016/0002-9610(89)90256-0; SMITH BF, 1985, J CLIN INVEST, V76, P439, DOI 10.1172/JCI111991; SOMJEN GJ, 1985, J LIPID RES, V26, P699; STRASBERG SM, 1990, HEPATOLOGY, V12, pS1; STRASBERG SM, 1992, HEPATOLOGY, V16, P820, DOI 10.1002/hep.1840160332; STRASBERG SM, 1990, GASTROENTEROLOGY, V98, P739, DOI 10.1016/0016-5085(90)90297-E; TALAMINI MA, 1990, SURG CLIN N AM, V70, P1217; THIJS C, 1990, GASTROENTEROLOGY, V99, P843, DOI 10.1016/0016-5085(90)90978-A; THISTLE JL, 1989, NEW ENGL J MED, V320, P633, DOI 10.1056/NEJM198903093201004; TINT GS, 1992, GASTROENTEROLOGY, V102, P2042, DOI 10.1016/0016-5085(92)90330-2; TROTMAN BW, 1991, GASTROENTEROL CLIN N, V20, P111; TROTMAN BW, 1975, GASTROENTEROLOGY, V68, P1563; VAIRA D, 1989, LANCET, V2, P431; VANSONNENBERG E, 1991, GASTROENTEROLOGY, V100, P1718, DOI 10.1016/0016-5085(91)90674-A; VITALE GC, 1991, AM J SURG, V161, P396, DOI 10.1016/0002-9610(91)90606-E; WARD A, 1984, DRUGS, V27, P95, DOI 10.2165/00003495-198427020-00001; WARE R, 1988, ANN SURG, V208, P17, DOI 10.1097/00000658-198807000-00003; WAY LW, 1989, AM J SURG, V158, P251, DOI 10.1016/0002-9610(89)90259-6; WAY LW, 1989, GASTROINTESTINAL DIS, V2, P1691; WETTER LA, 1991, GASTROENTEROL CLIN N, V20, P157; WILSON P, 1991, LANCET, V338, P795, DOI 10.1016/0140-6736(91)90674-E; YIO XY, 1992, GASTROENTEROLOGY, V102, P1000, DOI 10.1016/0016-5085(92)90189-6; ZAKKO SF, 1990, GASTROENTEROLOGY, V99, P1807, DOI 10.1016/0016-5085(90)90491-I; ZEMAN RK, 1991, GASTROENTEROL CLIN N, V20, P127; Zeman RK, 1987, GALLBLADDER BILE DUC; 1992, DHHS PHS921774 NAT C; 1992, 1992 DRUG TOPICS RED, P66; 1988, HEPATOLOGY, V8, P908; 1991, NEW ENGL J MED, V324, P1073	150	159	165	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					412	421		10.1056/NEJM199302113280608	http://dx.doi.org/10.1056/NEJM199302113280608			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8421460				2022-12-28	WOS:A1993KL58400008
J	LEE, JM				LEE, JM			SCREENING AND INFORMED CONSENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CANCER				LEE, JM (corresponding author), MERRITHEW MEM HOSP,MARTINEZ,CA 94553, USA.							BARSKY AJ, 1988, NEW ENGL J MED, V318, P414, DOI 10.1056/NEJM198802183180705; BLAKESLEE S, 1992, NY TIMES        0315, V4, P1; CAIRNS J, 1985, SCI AM, V253, P51, DOI 10.1038/scientificamerican1185-51; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; Kaplan R.M., 1982, HEALTH PSYCHOL, V1, P61, DOI [DOI 10.1037/0278-6133.1.1.61, 10.1037/0278-6133.1.1.61]; KELLY PT, 1991, UNDERSTANDING BREAST, P30; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; PAULOS JA, 1990, INNUMERACY MATH ILLI, P162; STANGE KC, 1992, J FAM PRACTICE, V34, P409	10	42	42	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					438	440		10.1056/NEJM199302113280613	http://dx.doi.org/10.1056/NEJM199302113280613			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8421464				2022-12-28	WOS:A1993KL58400013
J	ORR, HA				ORR, HA			HALDANE RULE HAS MULTIPLE GENETIC CAUSES	NATURE			English	Article								HALDANE'S rule states that ''When in the F1 offspring of two different animal races one sex is absent, rare, or sterile, that sex is the heterozygous [heterogametic or XY] sex''1. This rule represents one of the few patterns characterizing animal speciation2,3. Traditional explanations of Haldane's rule1,4-6 claim that heterogametic hybrids are unfit because they lack an X chromosome that is 'compatible' with the autosomes of one species. Recent work2,7 shows that this explanation is incorrect for hybrid sterility: contrary to prediction, homogametic hybrids carrying both X chromosomes from the same species remain fertile. Until now, similar tests have not been performed for hybrid inviability. Here I show that homogametic hybrids who carry both X chromosomes from the same species are inviable. These results show that the genetic causes of Haldane's rule differ for hybrid sterility versus inviability. Haldane's rule does not, therefore, have a single genetic basis.			ORR, HA (corresponding author), UNIV CALIF DAVIS,CTR POPULAT BIOL,DAVIS,CA 95616, USA.							Ashburner M, 1989, DROSOPHILA LAB HDB, P1; Biddle RL, 1932, GENETICS, V17, P0153; Coyne J.A., 1989, P180; COYNE JA, 1985, NATURE, V314, P736, DOI 10.1038/314736a0; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; Dobzhansky T., 1937; Haldane JBS, 1922, J GENET, V12, P101, DOI 10.1007/BF02983075; HUTTER P, 1990, GENETICS, V124, P909; Huxley J, 1940, NEW SYSTEMATICS, P185; LEE WH, 1987, JPN J GENET, V62, P225, DOI 10.1266/jjg.62.225; Muller HJ, 1942, BIOL S, V6, P71; ORR HA, 1992, GENET RES, V59, P73, DOI 10.1017/S0016672300030275; Sturtevant AH, 1920, GENETICS, V5, P488; STURTEVANT AH, 1929, PUBL CARNEG I WASH, V399, P1; WU CI, 1992, EVOLUTION, V46, P1584, DOI 10.1111/j.1558-5646.1992.tb01152.x	15	90	90	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					532	533		10.1038/361532a0	http://dx.doi.org/10.1038/361532a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429905				2022-12-28	WOS:A1993KL71400058
J	HILBORNE, LH; LEAPE, LL; BERNSTEIN, SJ; PARK, RE; FISKE, ME; KAMBERG, CJ; ROTH, CP; BROOK, RH				HILBORNE, LH; LEAPE, LL; BERNSTEIN, SJ; PARK, RE; FISKE, ME; KAMBERG, CJ; ROTH, CP; BROOK, RH			THE APPROPRIATENESS OF USE OF PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY IN NEW-YORK-STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine the appropriateness of use of percutaneous transluminal coronary angioplasty (PTCA) in New York State. Design.-Retrospective randomized medical record. Setting.-Fifteen randomly selected hospitals in New York State that provide PTCA. Patients.-Random sample of 1306 patients undergoing PTCA in New York State in 1990. Main Outcome Measures.-Percentage of patients who underwent PTCA for indications rated appropriate, uncertain, and inappropriate. Results.-The majority of patients received PTCA for chronic stable angina, unstable angina, and in the post-myocardial infarction period (up to 3 weeks). Fifty-eight percent of PTCAs were rated appropriate; 38%, uncertain; and 4%, inappropriate. The inappropriate rate varied by hospital from 1% to 9% (P=.12); the uncertain rate, from 26% to 50% (P=.02); and the combined inappropriate and uncertain rate, from 29% to 57% (P<.001). There was no difference in appropriateness when the institutions were grouped by volume (fewer than 300 procedures annually or at least 300 procedures annually), location (upstate vs downstate), or by teaching status. Conclusions.-Few PTCAs were performed for inappropriate indications in New York State. However, the large number of procedures performed for indications that were rated uncertain as to their net benefit requires further study and justification at both clinical and policy levels.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL & LAB MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, LOS ANGELES, CA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48104 USA; VALUE HLTH SCI INC, SANTA MONICA, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Harvard University; Harvard T.H. Chan School of Public Health; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	HILBORNE, LH (corresponding author), RAND CORP, 1700 MAIN ST, MAIL STOP 3F, SANTA MONICA, CA 90406 USA.			Bernstein, Steven/0000-0003-3359-7168; Hilborne, Lee/0000-0001-7246-7847				ANDERSON HV, 1985, AM J CARDIOL, V56, P712; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; Cochran W.G., 2007, SAMPLING TECHNIQUES; HILBORNE LH, 1991, JRA01 PUBL; KING SB, 1988, AM J CARDIOL, V62, pK2, DOI 10.1016/0002-9149(88)90098-7; Kish L, 1965, SURVEY SAMPLING; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; RYAN TJ, 1988, CIRCULATION, V78, P486, DOI 10.1161/01.CIR.78.2.486; SHAPIRO TA, 1992, CURR OPIN RADIOL, V4, P55; TUZCU EM, 1989, AM HEART J, V117, P1374; VACEK JL, 1991, CATHETER CARDIO DIAG, V24, P161, DOI 10.1002/ccd.1810240304; VLIETSTRA RE, 1991, INT J CARDIOL, V32, P175, DOI 10.1016/0167-5273(91)90325-J; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; 1991, VITAL HLTH STAT 13, V109; 1991, ANN REPORT CARDIAC D; 1990, LANCET, V335, P1315	17	126	126	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					761	765		10.1001/jama.269.6.761	http://dx.doi.org/10.1001/jama.269.6.761			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423657				2022-12-28	WOS:A1993KK54400028
J	DEVRIES, SH; BAYLOR, DA				DEVRIES, SH; BAYLOR, DA			SYNAPTIC CIRCUITRY OF THE RETINA AND OLFACTORY-BULB	CELL			English	Review							GAMMA-AMINOBUTYRIC ACID; ROD BIPOLAR CELLS; ISOLATED HORIZONTAL CELLS; TURTLE RETINA; CARP RETINA; ACTIVATED CONDUCTANCE; DEPOLARIZING BIPOLAR; PROTEIN-KINASE; RABBIT RETINA; CYCLIC-AMP				DEVRIES, SH (corresponding author), STANFORD UNIV, MED CTR, SCH MED, FAIRCHILD SCI CTR, DEPT NEUROBIOL, STANFORD, CA 94305 USA.				NEI NIH HHS [EY01543, EY05750, EY06387] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005750, R37EY001543, F32EY006387, R01EY001543] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASHMORE JF, 1980, J PHYSIOL-LONDON, V300, P115, DOI 10.1113/jphysiol.1980.sp013155; ATTWELL D, 1987, NATURE, V328, P522, DOI 10.1038/328522a0; Barlow H B, 1971, Vision Res, VSuppl 3, P87; BARLOW HB, 1953, J PHYSIOL-LONDON, V119, P69, DOI 10.1113/jphysiol.1953.sp004829; BAYLOR DA, 1971, J PHYSIOL-LONDON, V214, P265, DOI 10.1113/jphysiol.1971.sp009432; BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529; BAYLOR DA, 1977, J PHYSIOL-LONDON, V271, P425, DOI 10.1113/jphysiol.1977.sp012007; BIALEK W, 1990, BIOPHYS J, V58, P1227, DOI 10.1016/S0006-3495(90)82463-2; BRENNAN P, 1990, SCIENCE, V250, P1223, DOI 10.1126/science.2147078; BUCHSBAUM G, 1983, PROC R SOC SER B-BIO, V220, P89, DOI 10.1098/rspb.1983.0090; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; BUONVISO N, 1990, J NEUROPHYSIOL, V63, P447, DOI 10.1152/jn.1990.63.3.447; COREY DP, 1984, J PHYSIOL-LONDON, V354, P557, DOI 10.1113/jphysiol.1984.sp015393; DACHEUX RF, 1986, J NEUROSCI, V6, P331; DAVIS BJ, 1991, J COMP NEUROL, V314, P493, DOI 10.1002/cne.903140307; DEARRY A, 1990, J NEUROCHEM, V54, P1367, DOI 10.1111/j.1471-4159.1990.tb01971.x; DETWILER PB, 1979, J PHYSIOL-LONDON, V291, P75, DOI 10.1113/jphysiol.1979.sp012801; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; DEVRIES SH, 1989, J PHYSIOL-LONDON, V414, P351, DOI 10.1113/jphysiol.1989.sp017692; DONG CJ, 1991, J PHYSIOL-LONDON, V440, P291, DOI 10.1113/jphysiol.1991.sp018709; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRAY EG, 1971, BRAIN RES, V35, P1, DOI 10.1016/0006-8993(71)90591-9; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HAMPSON ECG, 1992, IN PRESS J NEUROSCI; Hecht S, 1942, J GEN PHYSIOL, V25, P819, DOI 10.1085/jgp.25.6.819; HEIDELBERGER R, 1992, J PHYSIOL-LONDON, V447, P235, DOI 10.1113/jphysiol.1992.sp019000; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HOPFIELD JJ, 1991, P NATL ACAD SCI USA, V88, P6462, DOI 10.1073/pnas.88.15.6462; JAHR CE, 1982, J PHYSIOL-LONDON, V326, P213, DOI 10.1113/jphysiol.1982.sp014187; KAUER JS, 1988, NATURE, V331, P166, DOI 10.1038/331166a0; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KENDRICK KM, 1992, SCIENCE, V256, P833, DOI 10.1126/science.1589766; KNAPP AG, 1987, NATURE, V325, P437, DOI 10.1038/325437a0; KRAFT TW, 1990, COLD SH Q B, V55, P635; KUFFLER SW, 1953, J NEUROPHYSIOL, V16, P37, DOI 10.1152/jn.1953.16.1.37; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMB TD, 1976, J PHYSIOL-LONDON, V263, P257, DOI 10.1113/jphysiol.1976.sp011631; LANCET D, 1992, SOC GEN PHY, V47, P73; LASATER EM, 1985, P NATL ACAD SCI USA, V82, P3025, DOI 10.1073/pnas.82.9.3025; LASATER EM, 1987, P NATL ACAD SCI USA, V84, P7319, DOI 10.1073/pnas.84.20.7319; LEVEY MS, 1992, NEUROSCI LETT, V140, P265, DOI 10.1016/0304-3940(92)90117-P; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; MANDELL JW, 1990, NEURON, V5, P19, DOI 10.1016/0896-6273(90)90030-J; MANGEL SC, 1991, J PHYSIOL-LONDON, V442, P211, DOI 10.1113/jphysiol.1991.sp018790; MATSUTANI S, 1989, J COMP NEUROL, V280, P577, DOI 10.1002/cne.902800408; MEISTER M, 1989, OPHTHALMOL VIS SCI S, V30, P68; MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4; MORI K, 1992, J NEUROPHYSIOL, V67, P786, DOI 10.1152/jn.1992.67.3.786; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NAWY S, 1991, NEURON, V7, P677, DOI 10.1016/0896-6273(91)90380-I; NAWY S, 1987, NATURE, V325, P56, DOI 10.1038/325056a0; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NEGISHI K, 1988, NEUROSCI LETT, V94, P247, DOI 10.1016/0304-3940(88)90025-0; NOWYCKY MC, 1981, J NEUROPHYSIOL, V46, P649, DOI 10.1152/jn.1981.46.3.649; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; OMALLEY DM, 1989, P NATL ACAD SCI USA, V86, P3414, DOI 10.1073/pnas.86.9.3414; OMALLEY DM, 1992, J NEUROSCI, V12, P1394; PICCOLINO M, 1984, J NEUROSCI, V4, P2477; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; REYHER CKH, 1991, J NEUROSCI, V11, P1485; SAITO T, 1979, J GEN PHYSIOL, V73, P73, DOI 10.1085/jgp.73.1.73; SCHAEFFER SF, 1978, J CELL BIOL, V79, P802, DOI 10.1083/jcb.79.3.802; SCHWARTZ EA, 1975, J PHYSIOL-LONDON, V246, P617, DOI 10.1113/jphysiol.1975.sp010907; SCHWARTZ EA, 1982, J PHYSIOL-LONDON, V323, P211, DOI 10.1113/jphysiol.1982.sp014069; SCHWARTZ EA, 1987, SCIENCE, V238, P350, DOI 10.1126/science.2443977; SCHWARTZ EA, 1986, J PHYSIOL-LONDON, V376, P411, DOI 10.1113/jphysiol.1986.sp016160; SHEPHERD GM, 1992, SOC GEN PHY, V47, P19; SHIELLS RA, 1992, P ROY SOC B-BIOL SCI, V247, P21, DOI 10.1098/rspb.1992.0004; SHIELLS RA, 1990, P ROY SOC B-BIOL SCI, V242, P91, DOI 10.1098/rspb.1990.0109; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; TACHIBANA M, 1984, P NATL ACAD SCI-BIOL, V81, P7961, DOI 10.1073/pnas.81.24.7961; TACHIBANA M, 1991, J NEUROSCI, V11, P2199; TERANISHI T, 1983, NATURE, V301, P243, DOI 10.1038/301243a0; TROMBLEY PQ, 1990, J NEUROPHYSIOL, V64, P598, DOI 10.1152/jn.1990.64.2.598; VANBUSKIRK R, 1981, P NATL ACAD SCI-BIOL, V78, P7825; Vaney D.I., 1990, PROGR RETINAL RES, V9, P49, DOI [10.1016/0278-4327(90)90004-2, DOI 10.1016/0278-4327(90)90004-2]; WERBLIN FS, 1969, J NEUROPHYSIOL, V32, P339, DOI 10.1152/jn.1969.32.3.339; WIESEL TN, 1966, J NEUROPHYSIOL, V29, P1115, DOI 10.1152/jn.1966.29.6.1115; WITKOVSKY P, 1988, BRAIN RES, V449, P332, DOI 10.1016/0006-8993(88)91048-7; WITKOVSKY P, 1991, PROG RETIN RES, V11, P247, DOI 10.1016/0278-4327(91)90031-V; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	84	85	87	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN	1993	72			S			139	149		10.1016/S0092-8674(05)80033-9	http://dx.doi.org/10.1016/S0092-8674(05)80033-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KL707	8428375				2022-12-28	WOS:A1993KL70700009
J	GOODMAN, CS; SHATZ, CJ				GOODMAN, CS; SHATZ, CJ			DEVELOPMENTAL MECHANISMS THAT GENERATE PRECISE PATTERNS OF NEURONAL CONNECTIVITY	CELL			English	Review							LONG-TERM POTENTIATION; OCULAR DOMINANCE COLUMNS; CENTRAL-NERVOUS-SYSTEM; RAT VISUAL-CORTEX; CELL-ADHESION MOLECULES; RETINAL GANGLION-CELLS; GROWTH CONE GUIDANCE; REGENERATING RETINOTECTAL PROJECTION; EXTRACELLULAR-MATRIX MOLECULES; SELECT APPROPRIATE PATHWAYS		UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT MOLEC & CELL BIOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco	GOODMAN, CS (corresponding author), UNIV CALIF SAN FRANCISCO, DIV NEUROBIOL, LIFE SCI ADDIT, SAN FRANCISCO, CA 94143 USA.				NATIONAL EYE INSTITUTE [R01EY002858, R37EY002858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER; NEI NIH HHS [EY02858] Funding Source: Medline; NIMH NIH HHS [MH48108] Funding Source: Medline; NINDS NIH HHS [NS18366] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], [No title captured]; ANTONINI A, 1992, INVEST OPHTH VIS SCI, V33, P1217; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BAILEY CH, 1989, J NEUROBIOL, V20, P356, DOI 10.1002/neu.480200508; BALL EE, 1985, J NEUROSCI, V5, P1808; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BASTIANI MJ, 1986, J NEUROSCI, V6, P3518; BASTIANI MJ, 1984, J NEUROSCI, V4, P2311; BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BATE CM, 1976, J EMBRYOL EXP MORPH, V35, P107; BEAR MF, 1990, J NEUROSCI, V10, P909; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BENTLEY D, 1992, NERVE GROWTH CONE, P265; BERNHARDT RR, 1990, J COMP NEUROL, V302, P603, DOI 10.1002/cne.903020315; BERNHARDT RR, 1992, NEURON, V8, P869, DOI 10.1016/0896-6273(92)90201-N; BIXBY JL, 1990, J CELL BIOL, V111, P2725, DOI 10.1083/jcb.111.6.2725; BIXBY JL, 1992, J NEUROBIOL, V23, P468, DOI 10.1002/neu.480230503; BOLZ J, 1990, NATURE, V346, P359, DOI 10.1038/346359a0; BONHOEFFER F, 1982, EMBO J, V1, P427, DOI 10.1002/j.1460-2075.1982.tb01186.x; BONHOEFFER F, 1985, NATURE, V315, P408, DOI 10.1038/315409a0; BONHOEFFER F, 1980, NATURE, V288, P162, DOI 10.1038/288162a0; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; BROCHER S, 1992, P NATL ACAD SCI USA, V89, P123, DOI 10.1073/pnas.89.1.123; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; Cajal SR., 1893, CELLULE, V9, P119; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; CASH S, 1992, IN  PRESS J NEUROSCI; CHANG S, 1992, DEVELOPMENT, V114, P815; CHITNIS AB, 1990, J NEUROSCI, V10, P1892; CHITNIS AB, 1991, NEURON, V7, P277, DOI 10.1016/0896-6273(91)90266-3; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COHEN J, 1989, DEVELOPMENT, V107, P381; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; COOK JE, 1990, EUR J NEUROSCI, V2, P162, DOI 10.1111/j.1460-9568.1990.tb00408.x; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; DAHM LM, 1991, J NEUROSCI, V11, P238; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; DECARLOS JA, 1992, J NEUROSCI, V12, P1194; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; Detwiler SR, 1934, J EXP ZOOL, V67, P395, DOI 10.1002/jez.1400670303; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DULAC S, 1986, J NEUROSCI, V6, P3532; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EISEN JS, 1989, NEURON, V2, P1097, DOI 10.1016/0896-6273(89)90234-1; EISEN JS, 1986, NATURE, V320, P269, DOI 10.1038/320269a0; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; ESGUERRA M, 1992, VISUAL NEUROSCI, V8, P545, DOI 10.1017/S0952523800005642; FAWCETT JW, 1985, TRENDS NEUROSCI, V8, P201, DOI 10.1016/0166-2236(85)90079-7; FERGUSON BA, 1983, J NEUROSCI, V3, P1760; FOX K, 1989, J NEUROSCI, V9, P2443; FRANK E, 1990, J NEUROSCI, V10, P2250; FRASER SE, 1990, J NEUROBIOL, V21, P51, DOI 10.1002/neu.480210105; FRASER SE, 1980, DEV BIOL, V79, P453, DOI 10.1016/0012-1606(80)90130-X; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GATCHALIAN CL, 1992, NEURON, V9, P105, DOI 10.1016/0896-6273(92)90225-3; GAZE R M, 1970, Experimental Brain Research, V10, P171; GHOSH A, 1992, SCIENCE, V255, P1441, DOI 10.1126/science.1542795; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; GOODMAN CS, 1981, J PHYSIOL-LONDON, V313, P385, DOI 10.1113/jphysiol.1981.sp013672; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; GOODMAN CS, 1979, NATURE, V280, P208, DOI 10.1038/280208a0; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; GUTHRIE S, 1992, DEVELOPMENT, V114, P663; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HALL DE, 1987, J CELL BIOL, V104, P623, DOI 10.1083/jcb.104.3.623; HALPERN ME, 1991, J NEUROSCI, V11, P3227; Hamburger V, 1939, J EXP ZOOL, V80, P347, DOI 10.1002/jez.1400800302; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HARRIS WA, 1984, J NEUROSCI, V4, P1153; HARRIS WA, 1980, J COMP NEUROL, V194, P303, DOI 10.1002/cne.901940203; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HEBB DO, 1949, ORG BEHAVIOR; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; HOLT CE, 1983, NATURE, V301, P150, DOI 10.1038/301150a0; HOLT CE, 1984, J NEUROSCI, V4, P1130; HORTSCH M, 1991, ANNU REV CELL BIOL, V7, P505, DOI 10.1146/annurev.cb.07.110191.002445; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JOHANSEN J, 1989, J NEUROSCI, V9, P710; JOHANSEN J, 1989, J NEUROSCI, V9, P4318; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P1595; KAPFHAMMER JP, 1986, J NEUROSCI, V6, P2527; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P201; KATER SB, 1991, J NEUROSCI, V11, P891; KATZ LC, 1991, EUR J NEUROSCI, V3, P1, DOI 10.1111/j.1460-9568.1991.tb00805.x; Keynes R J, 1992, Curr Opin Neurobiol, V2, P55, DOI 10.1016/0959-4388(92)90162-E; KEYNES RJ, 1984, NATURE, V310, P786, DOI 10.1038/310786a0; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; KLOSE M, 1989, SCIENCE, V245, P982, DOI 10.1126/science.2772651; KOBAYASHI T, 1990, DEV BRAIN RES, V57, P29, DOI 10.1016/0165-3806(90)90181-W; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; KUFFLER DP, 1989, J COMP NEUROL, V281, P416, DOI 10.1002/cne.902810307; Kuwada John Y., 1992, Current Opinion in Neurobiology, V2, P31, DOI 10.1016/0959-4388(92)90158-H; KUWADA JY, 1986, SCIENCE, V233, P740, DOI 10.1126/science.3738507; KUWADA JY, 1990, J NEUROSCI, V10, P1299; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P19, DOI 10.1098/rspb.1981.0080; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P559; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P1, DOI 10.1098/rspb.1981.0079; LANCEJONES C, 1980, J PHYSIOL-LONDON, V302, P581; LANCEJONES C, 1991, DEV BIOL, V143, P93, DOI 10.1016/0012-1606(91)90057-A; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P391, DOI 10.1113/jphysiol.1978.sp012546; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LANDMESSER LT, 1980, ANNU REV NEUROSCI, V3, P279, DOI 10.1146/annurev.ne.03.030180.001431; LASKOWSKI MB, 1989, J NEUROSCI, V9, P175; LASKOWSKI MB, 1987, J NEUROSCI, V7, P252; LEMMON V, 1992, J NEUROSCI, V12, P818; LEMMON V, 1981, J NEUROSCI, V1, P83, DOI 10.1523/JNEUROSCI.01-01-00083.1981; LETOURNEAU PC, 1975, DEV BIOL, V44, P92, DOI 10.1016/0012-1606(75)90379-6; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LIU DWC, 1990, J NEUROSCI, V10, P3947, DOI 10.1523/JNEUROSCI.10-12-03947.1990; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LUMSDEN AGS, 1986, NATURE, V323, P538, DOI 10.1038/323538a0; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P2861, DOI 10.1073/pnas.87.7.2861; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MCCAIG CD, 1986, J PHYSIOL-LONDON, V375, P39, DOI 10.1113/jphysiol.1986.sp016104; MCCONNELL SK, 1989, SCIENCE, V245, P978, DOI 10.1126/science.2475909; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MCLOON SC, 1991, J NEUROSCI, V11, P1470; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; Menesini Chen M G, 1978, Arch Ital Biol, V116, P53; MEYER RL, 1982, SCIENCE, V218, P589, DOI 10.1126/science.7123262; MEYER RL, 1983, DEV BRAIN RES, V6, P293, DOI 10.1016/0165-3806(83)90068-8; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MILLER KD, 1989, P NATL ACAD SCI USA, V86, P5183, DOI 10.1073/pnas.86.13.5183; MOLNAR Z, 1991, NATURE, V351, P475, DOI 10.1038/351475a0; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MOORMAN SJ, 1990, J NEUROSCI, V10, P3158; MOSHER HS, 1964, SCIENCE, V144, P1100, DOI 10.1126/science.144.3622.1100; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1993, IN PRESS COLD SPRING, V57; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OKAMOTO H, 1991, DEV BIOL, V146, P62, DOI 10.1016/0012-1606(91)90446-A; OKAMOTO H, 1991, DEV BIOL, V146, P49, DOI 10.1016/0012-1606(91)90445-9; OLEARY DDM, 1990, COLD SH Q B, V55, P453; OLEARY DDM, 1989, J NEUROSCI, V9, P2230; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PATTERSON PH, 1988, NEURON, V1, P263, DOI 10.1016/0896-6273(88)90074-8; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; PERKINS AT, 1988, BRAIN RES, V439, P222; PHELAN KA, 1990, J NEUROSCI, V10, P2699; PIKE SH, 1990, J NEUROSCI, V10, P44; PLACZEK M, 1990, DEVELOPMENT, V110, P19; POCKETT S, 1990, EXP BRAIN RES, V80, P196; PURVES D, 1986, J NEUROSCI, V6, P1051; PURVES D, 1980, SCIENCE, V210, P153, DOI 10.1126/science.7414326; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; RAPER JA, 1990, EXP NEUROL, V109, P70, DOI 10.1016/S0014-4886(05)80009-3; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; RAPER JA, 1983, J NEUROSCI, V3, P20; RAPER JA, 1983, COLD SPRING HARB SYM, V48, P587, DOI 10.1101/SQB.1983.048.01.063; RAPER JA, 1984, J NEUROSCI, V4, P2329; RAPER JA, 1983, J NEUROSCI, V3, P31; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; REDIES C, 1992, J NEUROSCI, V12, P3525; REH TA, 1984, J NEUROSCI, V4, P442; REH TA, 1985, J NEUROSCI, V5, P1132; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RICKMANN M, 1985, J EMBRYOL EXP MORPH, V75, P31; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SCHERER WJ, 1989, J NEUROSCI, V9, P3837; SCHMIDT JT, 1983, BRAIN RES, V269, P29, DOI 10.1016/0006-8993(83)90959-9; SCHMIDT JT, 1990, J NEUROSCI, V10, P233; SCHMIDT JT, 1978, J COMP NEUROL, V177, P279, DOI 10.1002/cne.901770207; SCHMIDT JT, 1985, NEUROSCIENCE, V14, P535, DOI 10.1016/0306-4522(85)90308-2; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SEEGER M, 1993, IN PRESS NEURON; SHATZ CJ, 1990, COLD SPRING HARB SYM, V55, P469; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHULZ D, 1992, J NEUROSCI, V12, P1301; SINK H, 1991, DEVELOPMENT, V113, P701; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SINK H, 1991, DEVELOPMENT, V112, P307; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; SRETAVAN DW, 1990, J NEUROSCI, V10, P1995; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; STANTON PK, 1989, NATURE, V339, P215, DOI 10.1038/339215a0; STEVENS C F, 1992, Current Biology, V2, P108, DOI 10.1016/0960-9822(92)90237-5; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; STIRLING RV, 1985, J EMBRYOL EXP MORPH, V85, P251; STRYKER MP, 1986, J NEUROSCI, V6, P2117; STUERMER CAO, 1988, J NEUROSCI, V8, P4513; STUERMER CAO, 1990, J NEUROSCI, V10, P3615; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; TANG J, 1992, NEURON, V8, P1031, DOI 10.1016/0896-6273(92)90125-W; Tessier-Lavigne M, 1992, Curr Opin Neurobiol, V2, P60, DOI 10.1016/0959-4388(92)90163-F; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOMPSON W, 1983, NATURE, V302, P614, DOI 10.1038/302614a0; THOMPSON W, 1979, NEUROSCIENCE, V4, P271, DOI 10.1016/0306-4522(79)90088-5; THOMPSON WJ, 1986, TRENDS NEUROSCI, V9, P25, DOI 10.1016/0166-2236(86)90010-X; TOSNEY KW, 1987, DEV BIOL, V122, P540, DOI 10.1016/0012-1606(87)90318-6; TOSNEY KW, 1985, J NEUROSCI, V5, P2336; TOSNEY KW, 1985, J NEUROSCI, V5, P2345; TOSNEY KW, 1988, DEV BIOL, V127, P266, DOI 10.1016/0012-1606(88)90314-4; TOSNEY KW, 1984, J NEUROSCI, V4, P2518; TRISLER GD, 1981, P NATL ACAD SCI-BIOL, V78, P2145, DOI 10.1073/pnas.78.4.2145; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; Twitty VC, 1934, SCIENCE, V80, P78, DOI 10.1126/science.80.2064.78; Twitty VC, 1934, J EXP ZOOL, V68, P247, DOI 10.1002/jez.1400680206; Twitty VC, 1937, J EXP ZOOL, V76, P67, DOI 10.1002/jez.1400760105; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1987, DEVELOPMENT, V101, P909; WESTERFIELD M, 1990, NEURON, V4, P867, DOI 10.1016/0896-6273(90)90139-7; WESTERFIELD M, 1988, TRENDS NEUROSCI, V11, P18, DOI 10.1016/0166-2236(88)90044-6; WHITE CA, 1992, P NATL ACAD SCI USA, V89, P9850, DOI 10.1073/pnas.89.20.9850; WHITELAW V, 1983, J NEUROSCI, V3, P1226; WIGSTROM H, 1985, ACTA PHYSIOL SCAND, V123, P519, DOI 10.1111/j.1748-1716.1985.tb07621.x; WILLSHAW DJ, 1976, PROC R SOC SER B-BIO, V194, P431, DOI 10.1098/rspb.1976.0087; WILSON SW, 1991, DEVELOPMENT, V112, P723; WILSON SW, 1990, DEVELOPMENT, V108, P121; YAGINUMA H, 1991, J NEUROSCI, V11, P2598; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMAMOTO N, 1992, NEURON, V9, P217, DOI 10.1016/0896-6273(92)90161-6; YOON M, 1971, EXP NEUROL, V33, P395, DOI 10.1016/0014-4886(71)90031-8; YOON MG, 1972, EXP NEUROL, V37, P451, DOI 10.1016/0014-4886(72)90088-X; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379	256	1177	1192	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN	1993	72			S			77	98		10.1016/S0092-8674(05)80030-3	http://dx.doi.org/10.1016/S0092-8674(05)80030-3			22	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KL707	8428376				2022-12-28	WOS:A1993KL70700006
J	CURHAN, GC; WILLETT, WC; RIMM, EB; STAMPFER, MJ				CURHAN, GC; WILLETT, WC; RIMM, EB; STAMPFER, MJ			A PROSPECTIVE-STUDY OF DIETARY CALCIUM AND OTHER NUTRIENTS AND THE RISK OF SYMPTOMATIC KIDNEY-STONES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTHY-SUBJECTS; EXCRETION; OXALATE; UROLITHIASIS; FREQUENCY; FORMERS; NEPHROLITHIASIS; HYPERCALCIURIA; HYPEROXALURIA; EPIDEMIOLOGY	Background. A high dietary calcium intake is strongly suspected of increasing the risk of kidney stones. However, a high intake of calcium can reduce the urinary excretion of oxalate, which is thought to lower the risk. The concept that a higher dietary calcium intake increases the risk of kidney stones therefore requires examination. Methods. We conducted a prospective study of the relation between dietary calcium intake and the risk of symptomatic kidney stones in a cohort of 45,619 men, 40 to 75 years of age, who had no history of kidney stones. Dietary calcium was measured by means of a semiquantitative food-frequency questionnaire in 1986. During four years of follow-up, 505 cases of kidney stones were documented. Results. After adjustment for age, dietary calcium intake was inversely associated with the risk of kidney stones; the relative risk of kidney stones for men in the highest as compared with the lowest quintile group for calcium intake was 0.56 (95 percent confidence interval, 0.43 to 0.73; P for trend, <0.001). This reduction in risk decreased only slightly (relative risk, 0.66; 95 percent confidence interval, 0.49 to 0.90) after further adjustment for other potential risk factors, including alcohol consumption and dietary intake of animal protein, potassium, and fluid. intake of animal protein was directly associated with the risk of stone formation (relative risk for men with the highest intake as compared with those with the lowest, 1.33; 95 percent confidence interval, 1.00 to 1.77); potassium intake (relative risk, 0.49; 95 percent confidence interval, 0.35 to 0.68) and fluid intake (relative risk, 0.71; 95 percent confidence interval, 0.52 to 0.97) were inversely related to the risk of kidney stones. Conclusions. A high dietary calcium intake decreases the risk of symptomatic kidney stones.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, DIV RENAL, MED SERV, BOSTON, MA USA; HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	CURHAN, GC (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARILLA DE, 1978, AM J MED, V64, P579, DOI 10.1016/0002-9343(78)90576-4; BATAILLE P, 1983, J UROLOGY, V130, P218, DOI 10.1016/S0022-5347(17)51073-3; BORSATTI A, 1991, KIDNEY INT, V39, P1283, DOI 10.1038/ki.1991.162; BRESLAU NA, 1988, J CLIN ENDOCR METAB, V66, P140, DOI 10.1210/jcem-66-1-140; COE FL, 1982, AM J MED, V72, P25, DOI 10.1016/0002-9343(82)90567-8; COE FL, 1976, J CHRON DIS, V29, P793, DOI 10.1016/0021-9681(76)90053-9; COE FL, 1988, NEPHROLITHIASIS PATH; Drach GW, 1986, CAMPBELLS UROLOGY, VII, P1094; EARNEST DL, 1974, GASTROENTEROLOGY, V66, P1114; FELLSTROM B, 1989, BRIT J UROL, V63, P575, DOI 10.1111/j.1464-410X.1989.tb05248.x; GOLDFARB S, 1988, KIDNEY INT, V34, P544, DOI 10.1038/ki.1988.216; GRIFFITH HM, 1981, BRIT J UROL, V53, P416, DOI 10.1111/j.1464-410X.1981.tb03220.x; HIATT RA, 1982, AM J EPIDEMIOL, V115, P255, DOI 10.1093/oxfordjournals.aje.a113297; JOHANSSON G, 1980, J UROLOGY, V124, P770, DOI 10.1016/S0022-5347(17)55655-4; JOHNSON CM, 1979, KIDNEY INT, V16, P624, DOI 10.1038/ki.1979.173; KASIDAS GP, 1980, J HUM NUTR, V34, P255; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; LARSSON L, 1987, MINER ELECTROL METAB, V13, P242; LEMANN J, 1991, KIDNEY INT, V39, P973, DOI 10.1038/ki.1991.123; LEMANN J, 1979, NEW ENGL J MED, V301, P535, DOI 10.1056/NEJM197909063011008; LEMANN J, 1969, NEW ENGL J MED, V280, P232, DOI 10.1056/NEJM196901302800502; LINGEMAN JE, 1986, MED CARE, V24, P1151, DOI 10.1097/00005650-198612000-00007; Lingeman JE, 1989, URINARY CALCULI ESWL; MARSHALL RW, 1972, CLIN SCI, V43, P91, DOI 10.1042/cs0430091; MULDOWNEY FP, 1982, KIDNEY INT, V22, P292, DOI 10.1038/ki.1982.168; NORLIN A, 1976, SCAND J UROL NEPHROL, V10, P150, DOI 10.3109/00365597609179677; PAK CYC, 1988, J UROLOGY, V140, P461, DOI 10.1016/S0022-5347(17)41692-2; POWER C, 1984, BRIT J UROL, V56, P456; RAO PN, 1982, BRIT J UROL, V54, P578, DOI 10.1111/j.1464-410X.1982.tb13600.x; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; ROBERTSON WG, 1979, J CHRON DIS, V32, P469, DOI 10.1016/0021-9681(79)90107-3; Rothman K, 1986, MODERN EPIDEMIOLOGY; SIERAKOWSKI R, 1978, INVEST UROL, V15, P438; TRINCHIERI A, 1991, BRIT J UROL, V67, P230, DOI 10.1111/j.1464-410X.1991.tb15124.x; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W, 1990, NUTRITIONAL EPIDEMIO; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; YOSHIDA O, 1990, UROL INT, V45, P104, DOI 10.1159/000281680; ZAREMBSK.PM, 1969, CLIN CHIM ACTA, V25, P1, DOI 10.1016/0009-8981(69)90218-6	40	800	833	0	68	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	1993	328	12					833	838		10.1056/NEJM199303253281203	http://dx.doi.org/10.1056/NEJM199303253281203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT814	8441427				2022-12-28	WOS:A1993KT81400003
J	BENCHETRIT, E				BENCHETRIT, E			LUCKY LADY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							LUPUS NEPHRITIS; THERAPY				BENCHETRIT, E (corresponding author), HADASSAH UNIV HOSP,DIV MED,RHEUMATOL UNIT,POB 12000,JERUSALEM,ISRAEL.							ASMAR BI, 1981, AM J DIS CHILD, V135, P1100, DOI 10.1001/archpedi.1981.02130360008004; AUSTIN HA, 1983, AM J MED, V75, P382, DOI 10.1016/0002-9343(83)90338-8; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; FRIES JF, 1978, ARCH INTERN MED, V138, P1386, DOI 10.1001/archinte.138.9.1386; PORGES AJ, 1992, J RHEUMATOL, V19, P1191; STEINBERG AD, 1989, TXB RHEUMATOLOGY, P1130; VILLAR MA, 1988, OBSTET GYN CLIN N AM, V15, P355; WHIGINTOKEEFE Q, 1982, ANN INTERN MED, V96, P723	8	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1993	328	9					636	639		10.1056/NEJM199303043280908	http://dx.doi.org/10.1056/NEJM199303043280908			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP680	8429856				2022-12-28	WOS:A1993KP68000008
J	INMAN, KJ; SIBBALD, WJ; RUTLEDGE, FS; CLARK, BJ				INMAN, KJ; SIBBALD, WJ; RUTLEDGE, FS; CLARK, BJ			CLINICAL UTILITY AND COST-EFFECTIVENESS OF AN AIR SUSPENSION BED IN THE PREVENTION OF PRESSURE ULCERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine, in critically ill patients at risk, both the clinical utility and cost-effectiveness of using an air suspension bed in the prevention of pressure ulcers. Design.-Randomized, parallel group, controlled clinical trial with accompanying cost-effectiveness analysis. Setting.-30-bed multidisciplinary intensive care unit. Patients.-100 consecutive patients at risk for the development of pressure ulcers randomly assigned to receive treatment on either an air suspension bed or a standard intensive care unit bed. Patients considered at risk were those at least 17 years of age with an Acute Physiology and Chronic Health Evaluation II (APACHE II) score greater than 15 who had an expected intensive care unit stay of at least 3 days. Main Outcome Measures.-The development of pressure ulcers by site and severity and the costs associated with each of the two programs. Results.-The air suspension bed was associated with fewer patients developing single, multiple, or severe pressure ulcers. In patients at risk, the use of an air suspension bed in the prevention of pressure ulcers was a cost-effective therapy. Conclusions.-Despite intense nursing care, pressure ulcers are more prevalent in the critically ill patient population than in the general hospital population. Air suspension therapy provides a clinically effective means of preventing pressure ulcers in these patients. In patients at risk, air suspension therapy was a cost-effective means of managing pressure ulcers compared with the standard hospital bed.	VICTORIA HOSP,RICHARD IVEY CRIT CARE TRAUMA CTR,LONDON,ON,CANADA; UNIV WESTERN ONTARIO,FAC MED,PROGRAM CRIT CARE MED,LONDON N6A 3K7,ONTARIO,CANADA	University of Victoria; Western University (University of Western Ontario); Western University (University of Western Ontario)	INMAN, KJ (corresponding author), VICTORIA HOSP,MANAGEMENT & EVALUAT RES GRP,ROOM 482 NW,375 S ST,LONDON N6A 4G5,ON,CANADA.							ALLMAN RM, 1987, ANN INTERN MED, V107, P641, DOI 10.7326/0003-4819-107-5-641; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; DRUMMOND MF, 1990, METHODS EC EVALUATIO, P40; FLAM E, 1991, J EXTENDED PATIENT C, V33, P28; FUCHS VR, 1990, NEW ENGL J MED, V323, P673, DOI 10.1056/NEJM199009063231011; Herman L.E., 1989, J INTENSIVE CARE MED, V4, P117, DOI [10.1177/088506668900400306, DOI 10.1177/088506668900400306]; HULL R, 1981, NEW ENGL J MED, V304, P1561, DOI 10.1056/NEJM198106253042602; HULL RD, 1982, CAN MED ASSOC J, V127, P990; JESTER J, 1990, J EXTENDED PATIENT C, V26, P39; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; MAKLEBUST J, 1987, NURS CLIN N AM, V22, P359; MANLEY MT, 1978, S AFR MED J, V53, P147; PETERSEN N C, 1971, Scandinavian Journal of Plastic and Reconstructive Surgery, V5, P62; REULER JB, 1981, ANN INTERN MED, V94, P661, DOI 10.7326/0003-4819-94-5-661; SHEA JD, 1975, CLIN ORTHOPAEDICS, V112, P89; WALTON RL, 1989, J INTENSIVE CARE MED, V4, P97; 1982, TECHNOLOGY TRANSFER	20	93	93	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	1993	269	9					1139	1143						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN611	8433469				2022-12-28	WOS:A1993KN61100031
J	MACKLIS, RM				MACKLIS, RM			MAGNETIC HEALING, QUACKERY, AND THE DEBATE ABOUT THE HEALTH-EFFECTS OF ELECTROMAGNETIC-FIELDS	ANNALS OF INTERNAL MEDICINE			English	Article						QUACKERY; ELECTROMAGNETIC FIELDS; HISTORY OF MEDICINE; MAGNETICS; RADIATION	CHILDHOOD-CANCER; EXPOSURE; CELLS; MEDICINE	Although the biological effects of low-frequency electromagnetic radiation have been studied since the time of Paracelsus, there is still no consensus on whether these effects are physiologically significant. The recent discovery of deposits of magnetite within the human brain as well as recent, highly publicized tort litigation charging adverse effects after exposure to magnetic fields has rekindled the debate. New data suggest that electromagnetic radiation generated from power lines may lead to physiologic effects with potentially dangerous results. Whether these effects are important enough to produce major epidemiologic consequences remains to be established. The assumption of quackery that has attended this subject since the time of Mesmer's original ''animal magnetism'' investigations continues to hamper efforts to compile a reliable data base on the health effects of electromagnetic fields.			MACKLIS, RM (corresponding author), HARVARD UNIV, SCH MED, JOINT CTR RADIAT THERAPY, 50 BINNEY ST, BOSTON, MA 02115 USA.				NCI NIH HHS [CA-49017] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA049017] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG D, 1991, GREAT AM MED SHOW, P185; BADASH L, 1978, P AM PHILOS SOC, V122, P145; BAKER J, 1843, HUMAN MAGNETISM ITS; Barnothy M.F., 1969, BIOL EFFECTS MAGNETI; BARNOTHY MF, 1969, BIOL EFFECTS MAGNETI, V1; BARRETT S, 1976, HLTH ROBBERS, P232; BARTHOLOW R, 1887, MED ELECTRICITY; BASSETT CAL, 1989, CRIT REV BIOMED ENG, V17, P451; BECKER RO, 1990, CROSS CURRENTS PROMI; BELL GB, 1991, LANCET, V338, P1521, DOI 10.1016/0140-6736(91)92336-Z; BUTTERFIELD J, 1991, LANCET, V338, P1576; Darnton R., 1968, MESMERISM END ENLIGH; DARNTON R, 1972, DICT SCI BIOGRAPHY, P325; DOCCHIEPPO KF, DICT SCI BIOGRAPHY, V197, P233; FLORIG HK, 1992, SCIENCE, V257, P468, DOI 10.1126/science.1636078; FOSTER KR, 1992, HEALTH PHYS, V62, P429, DOI 10.1097/00004032-199205000-00007; FRANKLIN B, 1784, REPORT COMMISSION CH; GOLDBERG RB, 1991, MED HYPOTHESES, V35, P265, DOI 10.1016/0306-9877(91)90244-S; GOODMAN R, 1988, P NATL ACAD SCI USA, V85, P3928, DOI 10.1073/pnas.85.11.3928; HELL M, 1762, INTRO AD UTILEM USUM; HOLBROOK SH, 1959, GOLDEN AGE QUACKERY, P18; HUBER PW, 1991, GALILEOS REVENGE JUN; JACKSON JD, 1992, P NATL ACAD SCI USA, V89, P3508, DOI 10.1073/pnas.89.8.3508; JAUCHEM JR, 1990, LANCET, V336, P884, DOI 10.1016/0140-6736(90)92397-Z; JAUCHEM JR, 1991, J CLIN EPIDEMIOL, V44, P895, DOI 10.1016/0895-4356(91)90052-B; KIRSCHVINK JL, 1992, P NATL ACAD SCI USA, V89, P7683, DOI 10.1073/pnas.89.16.7683; Landefeld S, 1976, J Hist Med Allied Sci, V31, P368; LAWRENCE RM, 1910, PRIMITIVE PSYCHOTHER, P140; LIBOFF AR, 1984, SCIENCE, V223, P818, DOI 10.1126/science.6695183; LUBEN RA, 1982, P NATL ACAD SCI-BIOL, V79, P4180, DOI 10.1073/pnas.79.13.4180; Lyons AS, 1978, MED ILLUSTRATED HIST; Mackay C., 1852, EXTRAORDINARY POPULA; Mesmer FA, 1779, MEMOIRE DECOUVERTE M; Mesmer FranzAnton., 1980, MESMERISM; MICHAELSON SM, 1987, ANN NY ACAD SCI, V502, P55, DOI 10.1111/j.1749-6632.1987.tb37646.x; MILHAM S, 1982, NEW ENGL J MED, V307, P249; MILSTEAD KL, 1963, 2ND P NAT AMA FDA C; MIZUSHIMA Y, 1975, EXPERIENTIA, V31, P1411, DOI 10.1007/BF01923216; MOORHEAD JJ, 1918, TRAUMATIC SURGERY, P439; MORGAGNI JB, 1761, SEDIBAS CAUSIS MORBO; MOURINO MR, 1991, RADIOLOGY, V180, P593, DOI 10.1148/radiology.180.3.1871268; NEWMAN ME, 1991, J NATL CANCER I, V83, P164, DOI 10.1093/jnci/83.3.164; Parish D, 1990, N J Med, V87, P108; PEREGRINUS P, 1289, EPISTOLA PETRI PEREG; Peterson F., 1892, NY MED J, V56, P729; POOL R, 1990, SCIENCE, V249, P1096, DOI 10.1126/science.2204111; QUINAN J, 1885, MARYLAND MED J, V14, P460; REESE JA, 1988, BIOELECTROMAGNETICS, V9, P237, DOI 10.1002/bem.2250090305; Roth N, 1977, Med Instrum, V11, P118; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SHORE RE, 1988, CANCER, V62, P1747, DOI 10.1002/1097-0142(19881015)62:1+<1747::AID-CNCR2820621311>3.0.CO;2-3; SHULMAN S, 1990, NATURE, V346, P597, DOI 10.1038/346597b0; SUTTON G, 1981, ISIS, V72, P375, DOI 10.1086/352788; THACHER CJ, 1986, PLAIN ROAD HLTH USEL; WALLECZEK J, 1990, FEBS LETT, V271, P157, DOI 10.1016/0014-5793(90)80396-Z; Walmsley D. M., 1967, A MESMER; WEART SR, 1988, NUCLEAR FEAR HIST IM; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WINDLE BC, 1894, J ANAT PHYSL, V29, P346; WOOD HC, 1890, THERAPEUTICS ITS PRI, P72; YOUNG JH, 1967, MED MESSIAHS, P239; YOUNG JH, 1961, TOADSTOOL MILLIONAIR, P17	62	44	45	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1993	118	5					376	383		10.7326/0003-4819-118-5-199303010-00009	http://dx.doi.org/10.7326/0003-4819-118-5-199303010-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN688	8430983				2022-12-28	WOS:A1993KN68800009
J	ROTZSCHKE, O; FALK, K; STEVANOVIC, S; GRAHOVAC, B; SOLOSKI, MJ; JUNG, G; RAMMENSEE, HG				ROTZSCHKE, O; FALK, K; STEVANOVIC, S; GRAHOVAC, B; SOLOSKI, MJ; JUNG, G; RAMMENSEE, HG			QA-2 MOLECULES ARE PEPTIDE RECEPTORS OF HIGHER STRINGENCY THAN ORDINARY CLASS-I MOLECULES	NATURE			English	Article							HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL-ANTIBODIES; MHC MOLECULES; EXPRESSION; REGION; MOUSE; CELLS; IDENTIFICATION; HLA-B27; HLA-A2	CLASS I molecules of the major histocompatibility complex (MHC) transport peptides to the cell surface for surveillance by T cells1. Ligand specificity is stringent and differs from allele to allele2-4. Here we report analysis of natural ligands of 'unconventional' glycophosphatidyl-anchored mouse class I molecules, Qa-2. The function of these molecules is unclear5,6; they can serve as recognition structures for 'unrestricted' cytotoxic T cells but have not been found to present peptides to T cells, although the DNA sequence suggests a similar peptide binding groove to that of 'conventional' class I molecules7, and other unconventional class I molecules can present antigens in a few cases8-10. Pool sequencing of natural Qa-2 ligands shows that Qa-2 molecules are indeed peptide receptors, having ligand specificity similar to that of conventional class I molecules, that is, a predominant length of nine amino acids, anchor positions, and hydrophobic termination of peptides. But ligand specificity is much more stringent than with other class I molecules: of the nine positions, two are anchors and four have rather limited occupancy.	MAX PLANCK INST BIOL,IMMUNGENET ABT,CORRENSSTR 42,W-7400 TUBINGEN,GERMANY; UNIV TUBINGEN,INST ORGAN CHEM,W-7400 TUBINGEN 1,GERMANY; JOHNS HOPKINS UNIV MED,DIV MOLEC & CLIN RHEUMATOL,BALTIMORE,MD 21205	Max Planck Society; Eberhard Karls University of Tubingen; Johns Hopkins University			Roetzschke, Olaf/GXH-0012-2022; Grahovac, Blazenka/AAN-7200-2020; Grahovac, Blazenka/S-2679-2018	Grahovac, Blazenka/0000-0001-7783-2081				ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; DARLINGTON G, 1990, J NATL CANCER I, V64, P809; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FLAHERTY L, 1990, CRIT REV IMMUNOL, V10, P131; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HASENKRUG KJ, 1987, IMMUNOGENETICS, V25, P136, DOI 10.1007/BF00364282; HERMEL E, 1991, INT IMMUNOL, V3, P407, DOI 10.1093/intimm/3.4.407; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KURLANDER RJ, 1992, SCIENCE, V257, P678, DOI 10.1126/science.1496381; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MELLOR AL, 1991, INT IMMUNOL, V3, P493, DOI 10.1093/intimm/3.5.493; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MILLIGAN GN, 1991, J EXP MED, V174, P133, DOI 10.1084/jem.174.1.133; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; PAMER EG, 1992, CELL, V70, P215, DOI 10.1016/0092-8674(92)90097-V; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SHARROW SO, 1989, J IMMUNOL, V142, P3495; SHAWAR SM, 1991, J EXP MED, V174, P941, DOI 10.1084/jem.174.4.941; SOLOSKI MJ, 1988, P NATL ACAD SCI USA, V85, P3100, DOI 10.1073/pnas.85.9.3100; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; WU M, 1991, J EXP MED, V174, P213, DOI 10.1084/jem.174.1.213	27	107	107	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					642	644		10.1038/361642a0	http://dx.doi.org/10.1038/361642a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8437623				2022-12-28	WOS:A1993KM77600065
J	KAMBARA, H; TAKAHASHI, S				KAMBARA, H; TAKAHASHI, S			MULTIPLE-SHEATHFLOW CAPILLARY ARRAY DNA ANALYZER	NATURE			English	Article							ELECTROPHORESIS				KAMBARA, H (corresponding author), HITACHI LTD,CENT RES LAB,KOKUBUNJI,TOKYO 185,JAPAN.							ANSORGE W, 1986, J BIOCHEM BIOPH METH, V13, P315, DOI 10.1016/0165-022X(86)90038-2; DROSSMAN H, 1990, ANAL CHEM, V62, P900, DOI 10.1021/ac00208a003; GUTTMAN A, 1990, ANAL CHEM, V62, P137, DOI 10.1021/ac00201a010; HOOD L E, 1987, Genomics, V1, P201, DOI 10.1016/0888-7543(87)90046-2; HUANG XHC, 1992, ANAL CHEM, V64, P967, DOI 10.1021/ac00032a025; KAMBARA H, 1991, BIO-TECHNOL, V9, P648, DOI 10.1038/nbt0791-648; KAMBARA H, 1992, ELECTROPHORESIS, V13, P542, DOI 10.1002/elps.11501301111; KAMBARA H, 1988, BIO-TECHNOL, V6, P816, DOI 10.1038/nbt0788-816; MIDDENDORF LR, 1992, ELECTROPHORESIS, V13, P487, DOI 10.1002/elps.11501301103; NISHIKAWA T, 1992, ELECTROPHORESIS, V13, P495, DOI 10.1002/elps.11501301104; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; WADA A, 1987, NATURE, V325, P771, DOI 10.1038/325771a0	12	134	147	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					565	566		10.1038/361565a0	http://dx.doi.org/10.1038/361565a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	8429915				2022-12-28	WOS:A1993KL71400073
J	BLUNTZER, MEH				BLUNTZER, MEH			THE INTERNIST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					718	718		10.1001/jama.269.6.718	http://dx.doi.org/10.1001/jama.269.6.718			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423639				2022-12-28	WOS:A1993KK54400001
J	DAVIES, K				DAVIES, K			OF MICE AND MEN (AND COWS AND CATS)	NATURE			English	Article																		DIETRICH W, 1992, GENETICS, V131, P423; GOODFELLOW PN, 1992, NATURE, V359, P777, DOI 10.1038/359777a0; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; O'Brien S.J., 1991, Current Opinion in Genetics & Development, V1, P105, DOI 10.1016/0959-437X(91)80050-V; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WOMACK JE, 1992, NATURE, V360, P108, DOI 10.1038/360108a0	7	7	7	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					478	478		10.1038/361478a0	http://dx.doi.org/10.1038/361478a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8429890	Bronze			2022-12-28	WOS:A1993KK71300070
J	KOMAROMY, M; BINDMAN, AB; HABER, RJ; SANDE, MA				KOMAROMY, M; BINDMAN, AB; HABER, RJ; SANDE, MA			SEXUAL HARASSMENT IN MEDICAL-TRAINING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WOMEN; WORK	Background. Sexual harassment has become a national concern and one that is increasingly recognized in the field of medicine. Although there are reports of the sexual harassment of medical trainees, there is little information on the prevalence of this problem and whether it is adequately addressed by training institutions. Methods. Surveys with descriptions and examples of sexual harassment were mailed to 133 internal medicine residents in a university training program. The residents were asked to report anonymously whether they had encountered sexual harassment during medical school or residency, the frequency and type of harassment, its effect on them, whether they chose to report it to a person in authority, and the factors that influenced this decision. Results. Surveys were returned by 82 residents (response rate, 62 percent) - 33 women and 49 men. Twenty-four women (73 percent) and 11 men (22 percent) reported that they had been sexually harassed at least once during their training. The women were more likely than the men to have been physically harassed, and the women's harassers were of higher professional status. Among those harassed, 19 of the women (79 percent) and 5 of the men (45 percent) thought that the experience created a hostile environment or interfered with their performance at work, but only 2 women and no men reported their experiences to an authority. The women cited a lack of confidence that they would be helped as the main reason for not reporting the experience, whereas men most commonly said that they had dealt with the problem without the need for outside assistance. Conclusions. Many medical trainees encounter what they believe to be sexual harassment during medical school or residency, and this often creates a hostile learning and work environment. Training institutions need to address the adverse effects this may have on medical education and patient care.	UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94110	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	KOMAROMY, M (corresponding author), UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SUITE C-126,SAN FRANCISCO,CA 94143, USA.							BALDWIN DWC, 1991, WESTERN J MED, V155, P140; BICKEL J, 1988, NEW ENGL J MED, V319, P1579, DOI 10.1056/NEJM198812153192405; COTTON P, 1992, JAMA-J AM MED ASSOC, V267, P778, DOI 10.1001/jama.267.6.778; ESTRICH S, 1991, STANFORD LAW REV, V43, P813, DOI 10.2307/1228921; FIRTHCOZENS J, 1990, BRIT MED J, V301, P89, DOI 10.1136/bmj.301.6743.89; GARTRELL N, 1988, AM J PSYCHIAT, V145, P690; GOLDBERG SB, 1985, DISPUTE RESOLUTION, P371; GORDON GH, 1992, J GEN INTERN MED, V7, P443, DOI 10.1007/BF02599165; Grant L, 1988, J Am Med Womens Assoc (1972), V43, P109; GRANT L, 1988, J AM MED WOMEN ASSOC, V43, P115; GROSS J, 1991, NY TIME         0714, P10; GUTEK BA, 1982, J SOC ISSUES, V38, P55, DOI 10.1111/j.1540-4560.1982.tb01910.x; KOZINSKI A, 1992, RECORDER        0527, P8; Lenhart S A, 1991, J Am Med Womens Assoc (1972), V46, P77; Lenhart S A, 1991, J Am Med Womens Assoc (1972), V46, P121; LEVINSON W, 1989, NEW ENGL J MED, V321, P1511, DOI 10.1056/NEJM198911303212205; LEWIS NA, 1991, NY TIMES        0702, P1; McGoldrick K E, 1992, J Am Med Womens Assoc (1972), V47, P4; POPOVICH PM, 1986, J PSYCHOL, V120, P387, DOI 10.1080/00223980.1986.9712637; REILLY T, 1982, J SOC ISSUES, V38, P99, DOI 10.1111/j.1540-4560.1982.tb01912.x; RICHMAN JA, 1992, JAMA-J AM MED ASSOC, V267, P692, DOI 10.1001/jama.267.5.692; RIGER S, 1991, AM PSYCHOL, V46, P497, DOI 10.1037/0003-066X.46.5.497; ROWE MP, 1981, HARVARD BUS REV, V59, P42; Sandler B., 1990, INITIATIVES, V52, P5; SCHNEIDER BE, 1987, J HIGH EDUC, V58, P46, DOI 10.2307/1981390; Tannen Deborah, 1991, YOU JUST DONT UNDERS; WOLF TM, 1991, MED EDUC, V25, P182, DOI 10.1111/j.1365-2923.1991.tb00050.x; 1992, GUIDELINES ESTABLISH, P1; 1986, CASE SEXUAL HARASSME, P1; 1986, WRITING LETT SEXUAL	30	172	174	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1993	328	5					322	326		10.1056/NEJM199302043280507	http://dx.doi.org/10.1056/NEJM199302043280507			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KK247	8419819	Bronze			2022-12-28	WOS:A1993KK24700007
J	MOYA, M; ROBERTS, D; NOVICK, P				MOYA, M; ROBERTS, D; NOVICK, P			DSS4-1 IS A DOMINANT SUPPRESSOR OF SEC4-8 THAT ENCODES A NUCLEOTIDE EXCHANGE PROTEIN THAT AIDS SEC4P FUNCTION	NATURE			English	Article							PLASMA-MEMBRANE; RAS PROTEINS; YEAST; DNA; SECRETION; SEQUENCES; BINDING	THE protein Sec4p plays an essential role at the final stage of the yeast secretory pathway and belongs to the ras superfamily of GTP-binding proteins1, more specifically to a branch that includes Ypt1p in Saccharomyces cerevisiae and rab proteins in mammalian cells. GTP-binding proteins change conformation depending on whether GTP or GDP is bound2 and can thus act as a regulatory switch. The protein remains in its inactive, GDP-bound form until exchange of GTP for GDP allows it to stimulate a downstream effector. This interaction is curtailed by GTP hydrolysis. The rates of nucleotide exchange and GTP hydrolysis can be regulated by interaction with accessory proteins3. Although GDP dissociation stimulators (GDS) have been identified that act on members of the ras and rho branches of the superfamily, less is known regarding GDSs that act on members of the Sec4/Ypt1/Rab subgroup. A preliminary characterization of a Rab3A GDP dissociation stimulating activity has been presented4. We report here the use of suppressor analysis to clone a gene, dss4, encoding a 17K protein that aids Sec4p action in vivo by functioning as a GDP dissociation stimulator.	YALE UNIV, SCH MED, DEPT CELL BIOL, 333 CEDAR ST, NEW HAVEN, CT 06510 USA	Yale University								BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BURNSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154; BURTON J, IN PRESS NATURE; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; EMANUEL JR, 1986, MOL CELL BIOL, V6, P2476, DOI 10.1128/MCB.6.7.2476; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUESDON JL, 1976, J IMMUNOL METHODS, V11, P129, DOI 10.1016/0022-1759(76)90140-X; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NAIR J, 1990, J CELL BIOL, V110, P1897, DOI 10.1083/jcb.110.6.1897; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; NOVICK P, 1992, METHOD ENZYMOL, V219, P352; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017	25	103	104	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 4	1993	361	6411					460	463		10.1038/361460a0	http://dx.doi.org/10.1038/361460a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8429886				2022-12-28	WOS:A1993KK71300064
J	COHEN, NL; WALTZMAN, SB; FISHER, SG				COHEN, NL; WALTZMAN, SB; FISHER, SG			A PROSPECTIVE, RANDOMIZED STUDY OF COCHLEAR IMPLANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-TRIAL; COMPLICATIONS; PERFORMANCE; RECOGNITION; ADULTS	Background. Cochlear implants restore some degree of hearing in patients with severe hearing impairment, but the efficacy of different implants has not been compared. We conducted a prospective trial to compare several cochlear implants. Methods. We studied 82 patients who were randomly assigned to receive one of three cochlear implants: the Ineraid multichannel implant (implant 1), the Nucleus multichannel implant (implant 2), and the 3M/Vienna single-channel implant (implant 3). All the patients had profound deafness, and none had derived benefit from hearing aids. The assigned device was successfully implanted in 80 patients. Twenty-four hearing tests were used to assess the patients' performance before implantation and 12 and 24 months after implantation. The tests were grouped into five categories according to their content, and a weighted composite index was developed to provide a single numerical indicator of the overall auditory response. Results. All the patients were able to hear with their implants. Nineteen of the 30 patients (63 percent) who received implant 2,18 of the 30 patients (60 percent) who received implant 1, and 1 of the 20 patients (5 percent) who received implant 3 were able to distinguish some words and sentences. The scores for the composite index were similar in the patients who received implant 1 and those who received implant 2, and were higher in both these groups than in the patients who received implant 3 (P = 0.02). When 24 patients with implant 2 were given an improved speech processor, their composite index increased significantly within 3 months (P<0.001); their score at that time was also significantly higher (P = 0.04) than the score of the patients with implant 1 at 24 months. Age at implantation, lip-reading ability, and IQ were prognostic indicators of the patients' performance with a cochlear implant. Conclusions. Multichannel cochlear implants are superior to single-channel implants, especially for understanding speech. Changes in speech processing can improve patients' performance.	HINES VET AFFAIRS MED CTR,HINES,IL	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	COHEN, NL (corresponding author), NYU,SCH MED,DEPT OTOLARYNGOL,550 1ST AVE,NEW YORK,NY 10016, USA.			Waltzman, Susan/0000-0001-7569-392X				CLARK GM, 1991, EAR HEARING, V12, pS15, DOI 10.1097/00003446-199108001-00004; COHEN NL, 1991, ANN OTO RHINOL LARYN, V100, P823, DOI 10.1177/000348949110001007; COHEN NL, 1991, ANN OTO RHINOL LARYN, V100, P708, DOI 10.1177/000348949110000903; DORMAN MF, 1989, EAR HEARING, V10, P44, DOI 10.1097/00003446-198902000-00008; DOWELL RC, 1986, ARCH OTOLARYNGOL, V112, P1054; GANTZ BJ, 1987, ANN OTOL RHINOL LA S, V128, P145; HENDERSON WG, 1990, CONTROL CLIN TRIALS, V11, P199, DOI 10.1016/0197-2456(90)90014-S; Hochmair-Desoyer I. J., 1985, COCHLEAR IMPLANTS, P291; SCHINDLER RA, 1987, AM J OTOL, V8, P247; SKINNER MW, 1991, EAR HEARING, V12, P3, DOI 10.1097/00003446-199102000-00002; WANG RC, 1990, ANN OTO RHINOL LARYN, V99, P791, DOI 10.1177/000348949009901007; WEBB RL, 1991, ANN OTO RHINOL LARYN, V100, P131, DOI 10.1177/000348949110000208	12	101	105	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1993	328	4					233	237		10.1056/NEJM199301283280403	http://dx.doi.org/10.1056/NEJM199301283280403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ442	8418403				2022-12-28	WOS:A1993KJ44200003
J	EISENBERG, DM; KESSLER, RC; FOSTER, C; NORLOCK, FE; CALKINS, DR; DELBANCO, TL				EISENBERG, DM; KESSLER, RC; FOSTER, C; NORLOCK, FE; CALKINS, DR; DELBANCO, TL			UNCONVENTIONAL MEDICINE IN THE UNITED-STATES - PREVALENCE, COSTS, AND PATTERNS OF USE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALTERNATIVE MEDICINE; PRIMARY CARE; PRACTITIONERS; THERAPIES; REMEDIES; PATIENT	Background. Many people use unconventional therapies for health problems, but the extent of this use and the costs are not known. We conducted a national survey to determine the prevalence, costs, and patterns of use of unconventional therapies, such as acupuncture and chiropractic. Methods. We limited the therapies studied to 16 commonly used interventions neither taught widely in U.S. medical schools nor generally available in U.S. hospitals. We completed telephone interviews with 1539 adults (response rate, 67 percent) in a national sample of adults 18 years of age or older in 1990. We asked respondents to report any serious or bothersome medical conditions and details of their use of conventional medical services; we then inquired about their use of unconventional therapy. Results. One in three respondents (34 percent) reported using at least one unconventional therapy in the past year, and a third of these saw providers for unconventional therapy. The latter group had made an average of 19 visits to such providers during the preceding year, with an average charge per visit of $27.60. The frequency of use of unconventional therapy varied somewhat among sociodemographic groups, with the highest use reported by nonblack persons from 25 to 49 years of age who had relatively more education and higher incomes. The majority used unconventional therapy for chronic, as opposed to life-threatening, medical conditions. Among those who used unconventional therapy for serious medical conditions, the vast majority (83 percent) also sought treatment for the same condition from a medical doctor; however, 72 percent of the respondents who used unconventional therapy did not inform their medical doctor that they had done so. Extrapolation to the U.S. population suggests that in 1990 Americans made an estimated 425 million visits to providers of unconventional therapy. This number exceeds the number of visits to all U.S. primary care physicians (388 million). Expenditures associated with use of unconventional therapy in 1990 amounted to approximately $13.7 billion, three quarters of which ($10.3 billion) was paid out of pocket. This figure is comparable to the $12.8 billion spent out of pocket annually for all hospitalizations in the United States. Conclusions. The frequency of use of unconventional therapy in the United States is far higher than previously reported. Medical doctors should ask about their patients' use of unconventional therapy whenever they obtain a medical history.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV MICHIGAN,INST SOCIAL RES,ANN ARBOR,MI 48109; NEW ENGLAND DEACONESS HOSP,DEPT MED,DIV GEN MED,BOSTON,MA 02215; CHICAGO COLL OSTEOPATH MED,CHICAGO,IL 60615	Harvard University; Harvard Medical School; University of Michigan System; University of Michigan; Midwestern University; Midwestern University - Chicago College of Osteopathic Medicine	EISENBERG, DM (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV GEN MED & PRIMARY CARE,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Fahimifar, Sepideh/M-5303-2019					BRIGDEN ML, 1987, POSTGRAD MED, V81, P271, DOI 10.1080/00325481.1987.11699682; CASSILETH BR, 1989, CANCER, V63, P1247, DOI 10.1002/1097-0142(19890401)63:7<1247::AID-CNCR2820630703>3.0.CO;2-3; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; CHERKIN DC, 1989, WESTERN J MED, V150, P351; CLEARY PD, 1982, AM J PUBLIC HEALTH, V72, P727, DOI 10.2105/AJPH.72.7.727; COHEN CJ, 1990, CLIN RES, V38, pA692; COOK C, 1986, SOUTH MED J, V79, P1098, DOI 10.1097/00007611-198609000-00014; CRONAN TA, 1989, ARTHRITIS RHEUM, V32, P1604, DOI 10.1002/anr.1780321217; Gevitz N, 1988, OTHER HEALERS UNORTH, P1; GILLICK MR, 1985, NEW ENGL J MED, V313, P700, DOI 10.1056/NEJM198509123131120; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; KRONENFELD JJ, 1982, SOC SCI MED, V16, P1119, DOI 10.1016/0277-9536(82)90114-9; LEPKOWSKI JM, 1988, TELEPHONE SURVEY MET, P73; Levit K R, 1991, Health Care Financ Rev, V13, P29; McGuire Meredith, 1988, RITUAL HEALING SUBUR; MURRAY RH, 1992, NEW ENGL J MED, V326, P61, DOI 10.1056/NEJM199201023260113; Schappert SM, 1992, ADV DATA VITAL HLTH, V213; SMART HL, 1986, GUT, V27, P826, DOI 10.1136/gut.27.7.826; SNYDER P, 1983, CULT MED PSYCHIAT, V7, P57, DOI 10.1007/BF00249999; VERHOEF MJ, 1990, CAN MED ASSOC J, V142, P121; YAGER J, 1989, J NERV MENT DIS, V177, P632, DOI 10.1097/00005053-198910000-00006; 1984, SUBCOMMITTEE HLTH LO; 1987, NZ MED J, V100, P110; 1989, SUDAAN PROFESSIONAL; 1987, HLTH INFORMATION USE; 1990, OTAH405 US C OFF TEC; 1984, HLTH NUTRITION EXAMI; 1980, PATIENTS HEALERS CON, P50; 1989, NATIONAL HLTH INTERV	29	2925	2975	5	201	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1993	328	4					246	252		10.1056/NEJM199301283280406	http://dx.doi.org/10.1056/NEJM199301283280406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ442	8418405	Bronze			2022-12-28	WOS:A1993KJ44200006
J	GOLDSMITH, MF				GOLDSMITH, MF			TREATMENT OF MILD HYPERTENSION STUDY SHOWS RESULTS BETTER WHEN DRUGS ABET LIFE-STYLE CHANGES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note																		1992, CIRCULATION, V86, P1475	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					323	&		10.1001/jama.1993.03500030015004	http://dx.doi.org/10.1001/jama.1993.03500030015004			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418327				2022-12-28	WOS:A1993KG38100003
J	KASISKE, BL; HEIMDUTHOY, K; MA, JZ				KASISKE, BL; HEIMDUTHOY, K; MA, JZ			ELECTIVE CYCLOSPORINE WITHDRAWAL AFTER RENAL-TRANSPLANTATION - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SHORT-TERM CYCLOSPORINE; LONG-TERM; ALLOGRAFT RECIPIENTS; KIDNEY-TRANSPLANTATION; RANDOMIZED TRIAL; CONVENTIONAL IMMUNOSUPPRESSION; TRIPLE THERAPY; SAFE CONVERSION; GRAFT FAILURE; FOLLOW-UP	Objective.-To determine whether it is safe to electively discontinue cyclosporine therapy after renal transplantation. Data Sources.-MEDLINE and bibliographies from recent publications. Study Selection.-Controlled trials assessing the rate of acute rejection, graft loss, and mortality after elective cyclosporine withdrawal. Data Extraction.-We compared outcomes in patients who underwent withdrawal from cyclosporine treatment with patients who were not withdrawn (part 1), and in a separate analysis (part 2), with patients who never received cyclosporine. Data Synthesis.-In part 1 of the meta-analysis, consisting of 10 randomized and seven nonrandomized trials, there was a greater combined rate of acute rejection among patients in whom cyclosporine was withdrawn compared with control patients who continued to receive cyclosporine (weighted difference in episodes per patient, 126; 95% confidence interval [CI], 0.085 to 0.167; P<.001). However, there were no differences in graft loss (weighted difference in grafts lost per patient per year, -0.009; 95% CI, -0.022 to 0.004; P=0.19) or mortality (weighted difference in deaths per patient per year, -0.005; 95% CI, -0.016 to 0.006; P=.40) attributable to cyclosporine withdrawal. In part 2 of the meta-analysis, consisting of three randomized and three nonrandomized trials, the combined rate of graft loss for patients who were withdrawn from cyclosporine was not significantly different vs control patients who never received cyclosporine (weighted difference in grafts lost per patient per year, -0.020; 95% CI, 0.043 to 0.003; P=.08). However, when the three randomized trials were analyzed separately, graft survival was better in patients who were withdrawn from cyclosporine (weighted difference in grafts lost per patient per year, 0.0382; 95% CI, 0.0002 to 0.0762; P=.049). None of the outcomes was affected by the timing or manner of the cyclosporine withdrawal. Conclusions.-The increased incidence of acute rejection following elective cyclosporine withdrawal does not affect short-term graft or patient survival after renal transplantation. Whether long-term consequences will outweigh the benefits of elective withdrawal remains to be determined.	UNIV MINNESOTA, HENNEPIN CTY MED CTR, COLL PHARM, DRUG EVALUAT UNIT, MINNEAPOLIS, MN 55415 USA; UNIV MINNESOTA, HENNEPIN CTY MED CTR, REG KIDNEY DIS PROGRAM, MINNEAPOLIS, MN 55415 USA	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	KASISKE, BL (corresponding author), UNIV MINNESOTA, HENNEPIN CTY MED CTR, DEPT MED, 701 PK AVE, MINNEAPOLIS, MN 55415 USA.							ABBUDFILHO M, 1988, TRANSPLANT P, V20, P164; ABBUDFILHO M, 1989, TRANSPLANT P, V21, P1638; ADAMS PL, 1987, TRANSPLANT P, V19, P2010; ADU D, 1985, LANCET, V1, P392; BARCLAY PG, 1992, TRANSPLANT P, V24, P165; BERTANI T, 1991, KIDNEY INT, V40, P243, DOI 10.1038/ki.1991.206; Bradley B A, 1989, Clin Transpl, P175; BUSING M, 1989, TRANSPLANT P, V21, P1601; CANAFAX DM, 1983, TRANSPLANT P, V15, P2874; CANAFAX DM, 1985, TRANSPLANT P, V17, P1176; CASSIDY MJD, 1986, S AFR MED J, V70, P317; CHAPMAN JR, 1986, TRANSPLANT P, V18, P186; CHAPMAN JR, 1989, TRANSPLANT P, V21, P1631; CURTIS JJ, 1986, LANCET, V2, P477, DOI 10.1016/S0140-6736(86)90355-7; DELMONICO FL, 1990, TRANSPLANTATION, V49, P899, DOI 10.1097/00007890-199005000-00013; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FLECHNER SM, 1984, TRANSPLANT P, V17, P276; FLECHNER SM, 1983, TRANSPLANT P, V15, P2869; FREEDMAN BI, 1991, TRANSPL P, V23, P1020; GONWA TA, 1987, TRANSPLANTATION, V43, P225, DOI 10.1097/00007890-198702000-00012; GONWA TA, 1987, TRANSPLANT P, V19, P2018; GONWA TA, 1988, CLIN TRANSPLANT, V2, P91; HALL BM, 1988, NEW ENGL J MED, V318, P1499, DOI 10.1056/NEJM198806093182304; HARDER F, 1983, Lancet, V2, P986; HELLING TS, 1990, AM J KIDNEY DIS, V15, P137, DOI 10.1016/S0272-6386(12)80510-5; HIESSE C, 1991, TRANSPLANT P, V23, P987; HOITSMA AJ, 1987, LANCET, V1, P584; ISONIEMI H, 1990, TRANSPLANT INT, V3, P121; ISONIEMI H, 1991, TRANSPLANT INT, V4, P31, DOI 10.1111/j.1432-2277.1991.tb01942.x; JUNOR BJR, 1989, TRANSPLANT P, V21, P1677; KAISER BA, 1989, PEDIATR NEPHROL, V3, P401, DOI 10.1007/BF00850215; KASISKE BL, 1991, AM J KIDNEY DIS, V17, P700, DOI 10.1016/S0272-6386(12)80355-6; KOOTTE AMM, 1988, TRANSPLANTATION, V46, P677, DOI 10.1097/00007890-198811000-00010; KOOTTE AMM, 1989, TRANSPLANT P, V21, P1585; KRAMER NC, 1985, TRANSPL P, V17, P2196; LAND W, 1988, TRANSPLANT P, V20, P73; LAND W, 1983, TRANSPLANT P, V15, P2857; LENNARD TWJ, 1987, TRANSPLANT P, V19, P3594; LORBER MI, 1987, AM J KIDNEY DIS, V9, P476, DOI 10.1016/S0272-6386(87)80074-4; MACDONALD AS, 1985, TRANSPLANT P, V17, P1940; MADDUX MS, 1987, TRANSPLANT P, V19, P2007; MADDUX MS, 1988, TRANSPLANT P, V20, P152; MORRIS PJ, 1987, LANCET, V1, P586; MORRIS PJ, 1983, TRANSPLANTATION, V36, P273, DOI 10.1097/00007890-198309000-00009; MYERS BD, 1988, TRANSPLANTATION, V46, P694, DOI 10.1097/00007890-198811000-00014; MYERS BD, 1991, TRANSPL P, V23, P41; MYERS BD, 1988, KIDNEY INT, V33, P590, DOI 10.1038/ki.1988.38; NORUSIS MJ, 1988, STATISTICAL PACKAGE; OKA T, 1989, TRANSPLANT P, V21, P1628; OKA T, 1987, TRANSPLANT P, V19, P2012; PARAISO AR, 1989, TRANSPLANT P, V21, P1627; PORTER GA, 1990, ARCH INTERN MED, V150, P280; PRIETO C, 1992, TRANSPLANT P, V24, P35; RAO KV, 1985, TRANSPLANTATION, V40, P631, DOI 10.1097/00007890-198512000-00011; ROCHER LL, 1984, TRANSPLANTATION, V38, P669, DOI 10.1097/00007890-198412000-00024; ROLLES K, 1983, TRANSPLANT P, V15, P2878; SAGALOWSKY AI, 1988, TRANSPL P, V20, P157; SHEN SY, 1989, TRANSPLANTATION, V47, P223, DOI 10.1097/00007890-198902000-00005; SHEN SY, 1987, TRANSPLANT P, V19, P2032; SHOWSTACK J, 1990, JAMA-J AM MED ASSOC, V264, P1818, DOI 10.1001/jama.264.14.1818; SINCLAIR NR, 1986, NEW ENGL J MED, V314, P1219; SOBH M A, 1987, Nephrology Dialysis Transplantation, V2, P258; SPIELBERGER M, 1988, TRANSPLANT P, V20, P169; STILLER CR, 1991, TRANSPLANT P, V23, P36; SWENY P, 1990, TRANSPLANT INT, V3, P19, DOI 10.1007/BF00333197; TEGZESS AM, 1987, TRANSPLANT P, V19, P2000; TEGZESS AM, 1989, TRANSPLANT P, V21, P1635; THISTLETHWAITE JR, 1985, HUM IMMUNOL, V14, P314, DOI 10.1016/0198-8859(85)90239-3; UBHI CS, 1988, NEPHROL DIAL TRANSPL, V3, P453, DOI 10.1093/oxfordjournals.ndt.a091697; VANDORP WT, 1991, TRANSPLANTATION, V51, P193, DOI 10.1097/00007890-199101000-00031; VANRENTERGHEM Y, 1985, TRANSPLANT P, V17, P1162; VEITCH PS, 1987, TRANSPLANT P, V19, P2017; VENNING MC, 1989, TRANSPLANT P, V21, P1633; VERSLUIS DJ, 1987, TRANSPLANTATION, V44, P387, DOI 10.1097/00007890-198709000-00012; VERSLUIS DJ, 1989, INT J IMMUNOPHARMACO, V11, P157, DOI 10.1016/0192-0561(89)90067-2; VERSLUIS DJ, 1987, TRANSPLANT P, V19, P3592; WATSON MA, 1989, TRANSPLANT P, V21, P1583; WEIMAR W, 1987, TRANSPLANT P, V19, P1998; WOOD RFM, 1985, TRANSPLANT P, V17, P1164; WOOD RFM, 1983, TRANSPLANT P, V15, P2862; WOODLE ES, 1989, TRANSPLANT P, V21, P1641	81	89	92	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1993	269	3					395	400		10.1001/jama.269.3.395	http://dx.doi.org/10.1001/jama.269.3.395			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KG381	8418349				2022-12-28	WOS:A1993KG38100034
J	ROMBERG, L; VALE, RD				ROMBERG, L; VALE, RD			CHEMOMECHANICAL CYCLE OF KINESIN DIFFERS FROM THAT OF MYOSIN	NATURE			English	Article							MUSCLE-CONTRACTION; DYNEIN; MICROTUBULES; MECHANISM; MOLECULES; MOVEMENT; MOTILITY; SYSTEMS; ATPASE	MOTOR proteins move unidirectionally along cytoskeletal polymers by coupling translocation to cycles of ATP hydrolysis. The energy from ATP is required both to generate force and to dissociate the motor-filament complex in order to begin a new chemomechanical cycle1,2. For myosin, force production is associated with phosphate release following ATP hydrolysis, whereas dissociation of actomyosin is tightly coupled to the binding of ATP3. Dynein, a microtubule motor, uses a similar cycle4, suggesting that all cytoskeletal motors might operate by a common mechanism. Here we investigate kinesin's chemomechanical cycle by assaying microtubule movement by single kinesin molecules when intermediate states in the hydrolysis cycle are prolonged with ATP analogues or inhibitors. In contrast to myosin and dynein, kinesin with bound ADP dissociates from microtubules during translocation, whereas kinesin with unhydrolysed nucleotide remains tightly associated with the polymer. These findings imply that kinesin converts ATP energy into mechanical work by a pathway distinct from that of myosin or dynein.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; COHN SA, 1989, J BIOL CHEM, V264, P4290; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; GOODY RS, 1975, PROTEIN LIGAND INTER; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HOLZBAUR ELF, 1986, BIOCHEMISTRY-US, V25, P428, DOI 10.1021/bi00350a023; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; JENCKS WP, 1988, ROOTS MODERN BIOCH, P571; JOHNSON KA, 1985, ANNU REV BIOPHYS BIO, V14, P161, DOI 10.1146/annurev.bb.14.060185.001113; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8350; LYMM RW, 1971, BIOCHEMISTRY-US, V10, P4617; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; OMOTO CK, 1986, BIOCHEMISTRY-US, V25, P419, DOI 10.1021/bi00350a022; PATE E, 1991, J MUSCLE RES CELL M, V12, P376, DOI 10.1007/BF01738593; PORTER ME, 1983, J BIOL CHEM, V258, P6582; SADHU A, 1992, J BIOL CHEM, V267, P11352; SHIMIZU T, 1989, BIOCHEMISTRY-US, V28, P7022, DOI 10.1021/bi00443a036; TAYLOR EW, 1992, HEART CARDIOVASCULAR, P1281; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4	20	92	95	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					168	170		10.1038/361168a0	http://dx.doi.org/10.1038/361168a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8421522				2022-12-28	WOS:A1993KG46600064
J	RINCHIK, EM; BULTMAN, SJ; HORSTHEMKE, B; LEE, ST; STRUNK, KM; SPRITZ, RA; AVIDANO, KM; JONG, MTC; NICHOLLS, RD				RINCHIK, EM; BULTMAN, SJ; HORSTHEMKE, B; LEE, ST; STRUNK, KM; SPRITZ, RA; AVIDANO, KM; JONG, MTC; NICHOLLS, RD			A GENE FOR THE MOUSE PINK-EYED DILUTION LOCUS AND FOR HUMAN TYPE-II OCULOCUTANEOUS ALBINISM	NATURE			English	Article							PRADER-WILLI SYNDROME; RECEPTOR; PROTEINS	THE mouse pink-eyed dilution (p) locus on chromosome 7 is associated with defects of skin, eye and coat pigmentation1. Mutations at p cause a reduction of eumelanin (black-brown) pigment and altered morphology of black pigment granules (eumelanosomes), but have little effect on pheomelanin (yellow-red) pigment2. We show here that the human complementary DNA DN10, linked to the p locus in mice3-5, identifies the human homologue (P) of the mouse p gene, and appears to encode an integral membrane transporter protein. The expression pattern of this gene in various p mutant mice correlates with the pigmentation phenotype; moreover, an abnormally sized messenger RNA is detected in one mutant, p(un), which reverts to the normal size in p(un) revertants. The human P gene corresponds to the D15S12 locus within the chromosome segment 15q11-q13, which is typically deleted in patients with Prader-Willi and Angelman syndrome (see ref. 5 for review). These disorders are phenotypically distinct, depending on the parent of origin of the deleted chromosome5-7, but both syndromes are often associated with hypopigmentation of the skin, hair and eyes (see ref. 8 for review), and deletion of the P gene may be responsible for this hypopigmentation. In addition, we report a mutation in both copies of the human P gene in one case of tyrosinase-positive (type II) oculocutaneous albinism, recently linked to 15q11-q13 (ref. 9).	UNIV FLORIDA,COLL MED,DEPT NEUROSCI,BOX 100244 JHMHC,GAINESVILLE,FL 32610; OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; UNIV TENNESSEE,OAK RIDGE NATL LAB,OAK RIDGE GRAD SCH BIOMED SCI,OAK RIDGE,TN 37831; UNIV ESSEN GESAMTHSCH KLINIKUM,INST HUMANGENET,W-4300 ESSEN 1,GERMANY; UNIV WISCONSIN,DEPT MED GENET,MADISON,WI 53706	State University System of Florida; University of Florida; United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; University of Duisburg Essen; University of Wisconsin System; University of Wisconsin Madison				Lee, Seung-Taek/0000-0001-7300-9784				BRILLIANT MH, 1991, SCIENCE, V252, P566, DOI 10.1126/science.1673574; Cassidy S B, 1984, Curr Probl Pediatr, V14, P1; CLAYTONSMITH J, 1992, J MED GENET, V29, P412, DOI 10.1136/jmg.29.6.412; DAUMER C, 1991, MED GENETIK, V3, P27; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; FRYBURG JS, 1991, AM J MED GENET, V38, P58, DOI 10.1002/ajmg.1320380114; GARDNER JM, 1992, SCIENCE, V257, P1121, DOI 10.1126/science.257.5073.1121; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LODISH HF, 1988, TRENDS BIOCHEM SCI, V13, P332, DOI 10.1016/0968-0004(88)90101-6; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; NAKATSU Y, 1992, MAMM GENOME, V2, P69, DOI 10.1007/BF00570442; NICHOLLS RD, IN PRESS AM J MED GE; NICHOLLS RD, 1989, MOUSE NEWS LETT, V84, P87; NICHOLLS RD, 1992, GENOMIC IMPRINTING M, V3, P139; RAMSAY M, 1992, AM J HUM GENET, V51, P879; Rinchik E.M., 1990, GENOME ANAL, P121; RINCHIK EM, 1989, GENOMICS, V4, P251, DOI 10.1016/0888-7543(89)90328-5; RUSSELL ES, 1949, GENETICS, V34, P146; Russell L. B., 1983, Cytogenetics of the mammalian X chromosome. Part A. Basic mechanisms of X chromosome behavior., P205; Sambrook J, 1989, MOL CLONING LABORATO; SCRABLE HJ, 1990, P NATL ACAD SCI USA, V87, P2182, DOI 10.1073/pnas.87.6.2182; SHIBAHARA S, 1991, J BIOL CHEM, V266, P15895; SIDMAN RL, 1965, DEV BIOL, V12, P93, DOI 10.1016/0012-1606(65)90023-0; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; TANTRAVAHI U, 1989, AM J MED GENET, V33, P78, DOI 10.1002/ajmg.1320330110; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WALLIS CE, 1989, J MED GENET, V26, P337, DOI 10.1136/jmg.26.5.337; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WOOKEY PJ, 1988, J BACTERIOL, V170, P4946, DOI 10.1128/jb.170.10.4946-4949.1988; [No title captured]	32	316	327	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					72	76		10.1038/361072a0	http://dx.doi.org/10.1038/361072a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	8421497				2022-12-28	WOS:A1993KF71800051
J	FRENKEL, LM; GARRATTY, EM; SHEN, JP; WHEELER, N; CLARK, O; BRYSON, YJ				FRENKEL, LM; GARRATTY, EM; SHEN, JP; WHEELER, N; CLARK, O; BRYSON, YJ			CLINICAL REACTIVATION OF HERPES-SIMPLEX VIRUS TYPE-2 INFECTION IN SEROPOSITIVE PREGNANT-WOMEN WITH NO HISTORY OF GENITAL HERPES	ANNALS OF INTERNAL MEDICINE			English	Article						HERPES GENITALIS; PREGNANCY COMPLICATIONS, INFECTIONS; VIRUS SHEDDING; INFANT, NEWBORN, DISEASES	UNITED-STATES; EPIDEMIOLOGY; VIDARABINE; DELIVERY; RISK; TIME	Objective: To determine the risk for genital herpes and asymptomatic herpes simplex virus (HSV) shedding in late pregnancy and delivery in a population of HSV type 2 (HSV-2)-seropositive but previously asymptomatic pregnant women. Design: A prospective inception cohort study. Participants: A total of 1355 pregnant women with no history of genital herpes referred from three private obstetrics practices between November 1985 and June 1988. Main Outcome Measures: Confidential questionnaires evaluated sexual risk factors in relation to HSV-2 serologic status as determined by Western blot analysis. Herpes simplex virus shedding was determined by viral culture of the cervix and vulva and of any suspicious lesions. Results: Antibody to HSV-2 was detected in 439 of 1355 pregnant women (32%) with no history of genital herpes. Asymptomatic HSV shedding was detected in 5 of 1160 cultures (0.43%) obtained in late pregnancy and during delivery. A first episode of clinical genital herpes was recognized by 43 of 264 HSV-2-seropositive women (16%) during their pregnancy. Conclusions: Serologic evidence of unknown HSV-2 infection was common in pregnant women without a history of genital herpes. Asymptomatic viral shedding in these women occurred at a rate similar to that seen in women with symptomatic genital HSV-2 infection. To improve recognition of genital herpes near term, obstetricians should counsel pregnant women about the high prevalence and mild and diverse symptoms of genital HSV-2 infection.	UNIV CALIF LOS ANGELES, DEPT PEDIAT, DIV INFECT DIS & BIOMATH, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles								ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; BECKER TM, 1986, J REPROD MED, V31, P359; BERNSTEIN DI, 1985, J MED VIROL, V15, P223, DOI 10.1002/jmv.1890150303; BOLOGNESE RJ, 1976, OBSTET GYNECOL, V48, P507; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; CORY L, 1990, SEXUALLY TRANSMITTED, P391; FIFE KH, 1990, SEXUALLY TRANSMITTED, P941; FLEISS JL, 1981, STATISTICAL METHODS, P64; GIBBS RS, 1988, OBSTET GYNECOL, V71, P779; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; GOLDSMITH MF, 1989, JAMA-J AM MED ASSOC, V261, P678, DOI 10.1001/jama.1989.03420050020007; HARDY DA, 1990, J INFECT DIS, V162, P1031, DOI 10.1093/infdis/162.5.1031; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; KULHANJIAN JA, 1992, NEW ENGL J MED, V326, P916, DOI 10.1056/NEJM199204023261403; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; RAWLS WE, 1971, AM J OBSTET GYNECOL, V110, P682, DOI 10.1016/0002-9378(71)90254-7; STAVRAKY KM, 1983, AM J EPIDEMIOL, V118, P109, DOI 10.1093/oxfordjournals.aje.a113612; WHITLEY R, 1991, NEW ENGL J MED, V324, P450, DOI 10.1056/NEJM199102143240704; WHITLEY R, 1991, NEW ENGL J MED, V324, P444, DOI 10.1056/NEJM199102143240703; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109; WHITLEY RJ, 1983, PEDIATRICS, V72, P778	24	73	76	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1993	118	6					414	418		10.7326/0003-4819-118-6-199303150-00003	http://dx.doi.org/10.7326/0003-4819-118-6-199303150-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR817	8439114				2022-12-28	WOS:A1993KR81700003
J	HAHN, S				HAHN, S			STRUCTURE(QUESTIONABLE) AND FUNCTION OF ACIDIC TRANSCRIPTION ACTIVATORS	CELL			English	Article							RNA POLYMERASE-II; BINDING; PROTEIN; MUTANTS; DOMAINS; REGION; VP16				HAHN, S (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.			Hahn, Steven/0000-0001-7240-2533				BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; HERSCHLAG D, 1993, IN PRESS GENES DEV; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; INOSTROZA JA, 1992, CELL, V70, P477; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	30	140	143	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					481	483		10.1016/0092-8674(93)90064-W	http://dx.doi.org/10.1016/0092-8674(93)90064-W			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8440015				2022-12-28	WOS:A1993KP16500002
J	RANSICK, A; DAVIDSON, EH				RANSICK, A; DAVIDSON, EH			A COMPLETE 2ND GUT INDUCED BY TRANSPLANTED MICROMERES IN THE SEA-URCHIN EMBRYO	SCIENCE			English	Article							CELL FATE; GASTRULATION; MESOMERES; LINEAGE; ARCHENTERON; MECHANISMS; PROTEIN	Founder cells for most early lineages of the sea urchin embryo are probably specified through inductive intercellular interactions. It is shown here that a complete respecification of cell fate occurs when 16-cell stage micromeres from the vegetal pole of a donor embryo are implanted into the animal pole of an intact recipient embryo. Animal pole cells adjacent to the transplanted micromeres are respecified from presumptive ectoderm into vegetal plate founder cells. These induced vegetal plate cells express the entire battery of genes characteristic of the endogenous vegetal plate cells. The ectopic vegetal plate invaginates during gastrulation to form a second archenteron which differentiates properly into a tripartite gut, as shown by the spatial pattern of expression of an endoderm-specific marker gene. Thus, transplanted micromeres can signal neighboring cells to induce them to change their fate.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology					NICHD NIH HHS [HD-07257, HD-05753] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005753, R37HD005753] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CAMERON RA, 1991, DEVELOPMENT, V113, P1085; CAMERON RA, 1987, GENE DEV, V1, P75, DOI 10.1101/gad.1.1.75; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DAVIDSON EH, 1989, DEVELOPMENT, V105, P421; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; DAVIDSON EH, 1986, GENE ACTIVITY EARLY, pCH4; Driesch H, 1891, Z WISS ZOOL ABT A, V53, P160; ETTENSOHN CA, 1990, SCIENCE, V248, P1115, DOI 10.1126/science.2188366; ETTENSOHN CA, 1984, AM ZOOL, V24, P571; ETTENSOHN CA, 1986, DEV BIOL, V117, P380, DOI 10.1016/0012-1606(86)90307-6; HARDIN J, 1990, DEV BIOL, V142, P86, DOI 10.1016/0012-1606(90)90153-A; HARDIN JD, 1986, DEV BIOL, V115, P490, DOI 10.1016/0012-1606(86)90269-1; HARKEY MA, 1983, DEV BIOL, V100, P12, DOI 10.1016/0012-1606(83)90196-3; HARKEY MA, 1992, MECH DEVELOP, V37, P173, DOI 10.1016/0925-4773(92)90079-Y; HENRY JJ, 1989, DEV BIOL, V136, P140, DOI 10.1016/0012-1606(89)90137-1; Horstadius S, 1939, BIOL REV CAMB PHILOS, V14, P132, DOI 10.1111/j.1469-185X.1939.tb00929.x; HORSTADIUS S, 1973, EXPT EMBRYOLOGY ECHI, pCH6; HORSTADIUS S, 1935, PUBBL STN ZOOL NAPOL, V14, P1; KHANER O, 1991, DEVELOPMENT, V112, P881; KHANER O, 1990, DEVELOPMENT, V109, P625; LIVINGSTON BT, 1990, DEVELOPMENT, V108, P403; NOCENTEMCGRATH C, 1989, DEV BIOL, V136, P264, DOI 10.1016/0012-1606(89)90147-4; NOCENTEMCGRATH C, 1991, DEV BIOL, V147, P445, DOI 10.1016/0012-1606(91)90302-J; OKAZAKI K, 1975, AM ZOOL, V15, P567; PEHRSON JR, 1986, DEV BIOL, V113, P522, DOI 10.1016/0012-1606(86)90188-0; RANSICK A, IN PRES MECH DEV; WILT FH, 1987, DEVELOPMENT, V100, P559	27	170	171	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 19	1993	259	5098					1134	1138		10.1126/science.8438164	http://dx.doi.org/10.1126/science.8438164			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8438164				2022-12-28	WOS:A1993KM91700031
J	LANZER, M; DEBRUIN, D; RAVETCH, JV				LANZER, M; DEBRUIN, D; RAVETCH, JV			TRANSCRIPTIONAL DIFFERENCES IN POLYMORPHIC AND CONSERVED DOMAINS OF A COMPLETE CLONED PLASMODIUM-FALCIPARUM CHROMOSOME	NATURE			English	Article							PARASITE PLASMODIUM-FALCIPARUM; HISTIDINE-RICH PROTEIN; INVOLVE DELETIONS; GENE; SEQUENCE; REARRANGEMENT; EXPRESSION; CROSS	CLASSICAL genetic studies on the human malaria parasite Plasmodium falciparum have been hampered by a complex life cycle which alternates between vertebrate and invertebrate hosts. Consequently, only a few genetic crosses have been performed so far1-4. In addition, molecular genetics has provided only limited access to the genes of this pathogen, a consequence of an unusually high A + T content5,6. To overcome these limitations we have constructed an ordered telomere-to-telomere contig map of P. falciparum chromosome 2 by isolating overlapping yeast artificial chromosome clones. This approach was used to examine the strain-dependent polymorphisms commonly observed for P. falciparum chromosomes7,8. Our analysis reveals that polymorphisms of chromosome 2 are restricted to regions at either end, representing 20% of the chromosome. Transcription mapping of the entire chromosome suggests a compartmentalization of chromosome 2 into a transcribed central domain and silent polymorphic ends.			LANZER, M (corresponding author), SLOAN KETTERING INST CANC RES,DEWITT WALLACE RES LAB,DIV MOLEC BIOL,1275 YORK AVE,NEW YORK,NY 10021, USA.		Ravetch, Jeffrey/Z-1596-2019; Lanzer, Michael/E-9752-2013	Ravetch, Jeffrey/0000-0003-2024-9041; Lanzer, Michael/0000-0002-0220-6526				BIGGS BA, 1989, P NATL ACAD SCI USA, V86, P2428, DOI 10.1073/pnas.86.7.2428; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BZIK DJ, 1988, MOL BIOCHEM PARASIT, V30, P279, DOI 10.1016/0166-6851(88)90097-7; CORCORAN LM, 1986, CELL, V44, P87, DOI 10.1016/0092-8674(86)90487-3; DEBRUIN D, 1992, GENOMICS, V14, P332, DOI 10.1016/S0888-7543(05)80223-X; FENTON B, 1991, MOL CELL BIOL, V11, P963, DOI 10.1128/MCB.11.2.963; GOMAN M, 1982, MOL BIOCHEM PARASIT, V5, P391, DOI 10.1016/0166-6851(82)90012-3; KEMP DJ, 1985, NATURE, V315, P347, DOI 10.1038/315347a0; LANZER M, 1992, EMBO J, V11, P1949, DOI 10.1002/j.1460-2075.1992.tb05248.x; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; PATARAPOTIKUL J, 1988, NUCLEIC ACIDS RES, V16, P4331, DOI 10.1093/nar/16.10.4331; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9115; POLLACK Y, 1982, NUCLEIC ACIDS RES, V10, P539, DOI 10.1093/nar/10.2.539; POLOGE LG, 1986, NATURE, V322, P474, DOI 10.1038/322474a0; POLOGE LG, 1988, CELL, V55, P869, DOI 10.1016/0092-8674(88)90142-0; SMYTHE JA, 1988, P NATL ACAD SCI USA, V85, P5159; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRIGLIA T, 1987, EMBO J, V6, P1413, DOI 10.1002/j.1460-2075.1987.tb02382.x; VANDERPLOEG LHT, 1985, SCIENCE, V229, P658, DOI 10.1126/science.3895435; WALKERJONAH A, 1992, MOL BIOCHEM PARASIT, V51, P313, DOI 10.1016/0166-6851(92)90081-T; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0	24	61	62	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					654	657		10.1038/361654a0	http://dx.doi.org/10.1038/361654a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8437626				2022-12-28	WOS:A1993KM77600069
J	SHELBOURNE, P; DAVIES, J; BUXTON, J; ANVRET, M; BLENNOW, E; BONDUELLE, M; SCHMEDDING, E; GLASS, I; LINDENBAUM, R; LANE, R; WILLIAMSON, R; JOHNSON, K				SHELBOURNE, P; DAVIES, J; BUXTON, J; ANVRET, M; BLENNOW, E; BONDUELLE, M; SCHMEDDING, E; GLASS, I; LINDENBAUM, R; LANE, R; WILLIAMSON, R; JOHNSON, K			DIRECT DIAGNOSIS OF MYOTONIC-DYSTROPHY WITH A DISEASE-SPECIFIC DNA MARKER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOCUS; CHROMOSOME-19; PROBE; NCOI; CKMM	Background. Myotonic dystrophy is the most common inherited form of muscular dystrophy affecting adults. Its symptoms are not confined to muscle, and variability in their nature and in the patient's age at their onset can make diagnosis difficult. A specific unstable DNA sequence associated with myotonic dystrophy has recently been identified. We describe the use of a DNA probe (p5B1.4) that can detect this mutation directly, improving the accuracy and speed of diagnosis. Methods. We analyzed DNA extracted from the peripheral-blood lymphocytes of 112 unrelated patients with myotonic dystrophy and their families, using molecular genetic techniques. Southern blot analysis and amplification with the polymerase chain reaction were used to determine the extent of expansion of the unstable DNA sequence. Results. Probe p5B1.4 allowed direct identification of the myotonic dystrophy mutation in 108 of the 112 unrelated patients. In three families for whom the clinical and genetic data obtained with linked probes were ambiguous, the probe identified persons at risk for symptoms of this disorder and demonstrated that a possible sporadic case of myotonic dystrophy was familial. In one of these families the size of the unstable myotonic dystrophy-specific fragment decreased on transmission to offspring, who remained asymptomatic. Conclusions. The diagnosis of myotonic dystrophy is improved by the use of a probe that detects directly the mutation responsible for this disorder.	CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,FULHAM PALACE RD,LONDON W6 8RF,ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP MED SCH,DEPT BIOCHEM & MOLEC GENET,LONDON SW7 2AZ,ENGLAND; CHARING CROSS HOSP,DEPT NEUROL,LONDON W6 8RP,ENGLAND; KAROLINSKA HOSP,DEPT CLIN GENET,S-10401 STOCKHOLM 60,SWEDEN; VRIJE UNIV BRUSSELS,DEPT MED GENET,B-1050 BRUSSELS,BELGIUM; CHURCHILL HOSP,DEPT MED GENET,OXFORD OX3 7LJ,ENGLAND	Imperial College London; Imperial College London; Imperial College London; Karolinska Institutet; Karolinska University Hospital; Vrije Universiteit Brussel; University of Oxford			Buxton, Jessica/L-9849-2019; Buxton, Jessica L/I-4033-2014	Buxton, Jessica L/0000-0002-0918-9335; johnson, keith/0000-0002-8578-5921				ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BARTLETT RJ, 1987, SCIENCE, V235, P1648, DOI 10.1126/science.3029876; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; COERWINKELDRIESSEN M, 1988, NUCLEIC ACIDS RES, V16, P8743, DOI 10.1093/nar/16.17.8743; DAVIES J, 1992, J MED GENET, V29, P766, DOI 10.1136/jmg.29.11.766; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GRIGGS RC, 1989, NEUROLOGY, V39, P420, DOI 10.1212/WNL.39.3.420; HARLEY HG, 1991, AM J HUM GENET, V49, P68; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARPER PS, 1989, MAJOR PROBLEMS NEURO, V21; JOHNSON K, 1990, AM J HUM GENET, V46, P1073; LAVEDAN C, 1990, GENOMICS, V8, P739, DOI 10.1016/0888-7543(90)90265-V; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; NAKAMURA Y, 1988, Genomics, V3, P67, DOI 10.1016/0888-7543(88)90161-9; PERRYMAN MB, 1988, NUCLEIC ACIDS RES, V16, P8744, DOI 10.1093/nar/16.17.8744; SHELBOURNE P, 1992, HUM MOL GENET, V1, P467, DOI 10.1093/hmg/1.7.467	17	67	67	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1993	328	7					471	475		10.1056/NEJM199302183280704	http://dx.doi.org/10.1056/NEJM199302183280704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM417	8421476	Bronze			2022-12-28	WOS:A1993KM41700004
J	HAWLEY, RS; ARBEL, T				HAWLEY, RS; ARBEL, T			YEAST GENETICS AND THE FALL OF THE CLASSICAL VIEW OF MEIOSIS	CELL			English	Review							MEIOTIC CHROMOSOME SEGREGATION; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; SYNAPTONEMAL COMPLEX; RECOMBINATION; CONVERSION; SYNAPSIS; INITIATION; SEQUENCES; PATHWAY				HAWLEY, RS (corresponding author), UNIV CALIF DAVIS,DEPT GENET,DAVIS,CA 95616, USA.			Hawley, R. Scott/0000-0002-6478-0494				CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CONLEY EC, 1989, CELL, V56, P987, DOI 10.1016/0092-8674(89)90632-6; DAWSON DS, 1986, SCIENCE, V234, P713, DOI 10.1126/science.3535068; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; GIROUX CN, 1988, GENETIC RECOMBINATIO, P465; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; KLECKNER N, 1991, COLD SH Q B, V56, P729; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; NICKLAS RB, 1974, GENETICS, V78, P205; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; ROCKMILL B, 1990, GENETICS, V126, P563; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROSS LO, 1992, GENETICS, V131, P541; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; SEARS DD, 1992, P NATL ACAD SCI USA, V89, P5296, DOI 10.1073/pnas.89.12.5296; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SYM M, 1993, CELL, V72; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x	23	127	128	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					301	303		10.1016/0092-8674(93)90108-3	http://dx.doi.org/10.1016/0092-8674(93)90108-3			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8431941				2022-12-28	WOS:A1993KM16200001
J	BARRY, M				BARRY, M			VACCINATIONS FOR TRAVELERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BARRY, M (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06510, USA.							SHWATZ B, 1989, CLIN MICROBIOL REV S, V2, pS118; 1991, HHS918280 CTR DIS CO	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					809	809						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423667				2022-12-28	WOS:A1993KK54400038
J	LEAPE, LL; HILBORNE, LH; PARK, RE; BERNSTEIN, SJ; KAMBERG, CJ; SHERWOOD, M; BROOK, RH				LEAPE, LL; HILBORNE, LH; PARK, RE; BERNSTEIN, SJ; KAMBERG, CJ; SHERWOOD, M; BROOK, RH			THE APPROPRIATENESS OF USE OF CORONARY-ARTERY BYPASS GRAFT-SURGERY IN NEW-YORK-STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To determine the appropriateness of use of coronary artery bypass graft surgery in New York State. Design.-Retrospective randomized medical record review. Setting.-Fifteen randomly selected hospitals in New York State that provide coronary artery bypass graft surgery. Patients.-Random sample of 1338 patients undergoing isolated coronary artery bypass graft surgery in New York State in 1990. Main Outcome Measures.-Percentage of patients who had bypass surgery for appropriate, inappropriate, or uncertain indications; operative (30-day) mortality and complications. Results.-Nearly 91% of the bypass operations were rated appropriate; 7%, uncertain; and 2.4%, inappropriate. This low inappropriate rate differs substantially from the 14% rate found in a previous study of patients operated on in 1979, 1980, and 1982. The difference in rates was not due to more lenient criteria but to changes in practice, the most important being that the fraction of patients receiving coronary artery bypass grafts for one- and two-vessel disease fell from 51% to 24% Individual hospital rates of inappropriateness (0% to 5%) did not vary significantly. Rates of appropriateness also did not vary by hospital location, volume, or teaching status. Operative mortality was 2.0%; 17% of patients suffered a complication. Complication rates varied significantly among hospitals (P<.01) and were higher in downstate hospitals. Conclusions.-The rates of inappropriate and uncertain use of coronary artery bypass graft surgery in New York State were very low. Rates of inappropriate use did not vary significantly among hospitals, or according to region, volume of bypass operations performed, or teaching status.	RAND CORP, 1700 MAIN ST, SANTA MONICA, CA 90406 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT PATHOL & LAB MED, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, LOS ANGELES, CA USA; UNIV MICHIGAN, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48104 USA; VALUE HLTH SCI INC, SANTA MONICA, CA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Harvard T.H. Chan School of Public Health				Bernstein, Steven/0000-0003-3359-7168				ALDERMAN E, 1990, CIRCULATION, V82, P1; [Anonymous], 1982, LANCET, V2, P1173; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CHASSIN MR, 1986, R32042CWFHFHCFAPMTRW; Cochran W.G., 2007, SAMPLING TECHNIQUES; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; Kish L, 1965, SURVEY SAMPLING; LEAPE LL, 1991, JRA02 PUBL; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; PARSONNET V, 1989, CIRCULATION, V79, P3; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; 1991, ANN REPORT CARDIAC D; 1991, VITAL HLTH STAT 13, V108; 1982, CIRCULATION, V23, P67	16	200	200	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					753	760		10.1001/jama.269.6.753	http://dx.doi.org/10.1001/jama.269.6.753			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423656				2022-12-28	WOS:A1993KK54400027
J	STEIN, MD; RUBENSTEIN, L; WACHTEL, TJ				STEIN, MD; RUBENSTEIN, L; WACHTEL, TJ			WHO PAYS FOR PUBLISHED RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To determine the extent of unfunded research published in major medical journals. Design.-Review of original research completed in the United States and published in 23 official journals of internal medicine and neurology during 1 month in 1991. Investigators were contacted to confirm lack of funding. Main Outcome Measure.-Percentage of unfunded, published original research. Results.-One hundred ninety-six articles were evaluated. There was at least one unfunded study in 78% of journals. Forty-five published studies (23%) were unfunded. Among those 45 studies, 7% were clinical trials, 9% were cohort studies, 18% were cross-sectional or case-control studies, 53% were case series, and 13% were surveys. Thirteen unfunded studies involved procedures that presumably were performed for research purposes and not as part of routine patient care. Conclusions.-Nearly one quarter of original research published in major medical journals was unfunded. Seven percent of published research involved direct clinical costs that were not accounted for by the investigators. These costs may have been passed on to study participants or third-party payers.	BROWN UNIV,SCH MED,DEPT MED,PROVIDENCE,RI 02912	Brown University								BEATY HN, 1986, ANN INTERN MED, V104, P90, DOI 10.7326/0003-4819-104-1-90; HEALY BP, 1992, J GEN INTERN MED, V7, P228, DOI 10.1007/BF02598021; KELLEY WN, 1992, ANN INTERN MED, V116, P654, DOI 10.7326/0003-4819-116-8-654	3	38	40	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	1993	269	6					781	782		10.1001/jama.269.6.781	http://dx.doi.org/10.1001/jama.269.6.781			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK544	8423661				2022-12-28	WOS:A1993KK54400032
J	BURTON, J; ROBERTS, D; MONTALDI, M; NOVICK, P; DECAMILLI, P				BURTON, J; ROBERTS, D; MONTALDI, M; NOVICK, P; DECAMILLI, P			A MAMMALIAN GUANINE-NUCLEOTIDE-RELEASING PROTEIN ENHANCES FUNCTION OF YEAST SECRETORY PROTEIN SEC4	NATURE			English	Article							GTP-BINDING PROTEINS; EXCHANGE FACTOR; TRANSFORMATION; BUD5; GENE	SMALL GTP-binding proteins of the ras superfamily are important for exocytosis from eukaryotic cells1-5. GTP-binding proteins can exist in two different conformations depending on whether they are bound to GDP or GTP, and are thought to function as molecular switches that regulate a variety of cellular processes1,3. The GTP-GDP cycle is controlled by accessory proteins that promote the exchange of bound GDP or the hydrolysis of GTP. The protein Sec4, a member of the Sec4/Ypt1/Rab branch of the Ras superfamily, is involved in a late stage of the secretory pathway in yeast6. Here we report the isolation of a mammalian complementary DNA, mss4, encoding a GDP-releasing protein that enhances Sec4 function. The Mss4 protein also stimulates GDP release from Ypt1 and from the mammalian protein Rab3a, but not from Ras2. Mss4 shows sequence similarity to Dss4, a yeast protein with similar biochemical properties.7	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University	BURTON, J (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; Battey, 1986, BASIC METHODS MOL BI; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; BURNSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; SALMINEN A, 1987, CELL, V49, P5527; Sambrook J, 1989, MOL CLONING LABORATO; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7	22	115	119	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					464	467		10.1038/361464a0	http://dx.doi.org/10.1038/361464a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8429887				2022-12-28	WOS:A1993KK71300065
J	AYER, DE; KRETZNER, L; EISENMAN, RN				AYER, DE; KRETZNER, L; EISENMAN, RN			MAD - A HETERODIMERIC PARTNER FOR MAX THAT ANTAGONIZES MYC TRANSCRIPTIONAL ACTIVITY	CELL			English	Article							DNA-BINDING PROTEINS; LOOP-HELIX PROTEIN; C-MYC; LEUCINE ZIPPER; ACTIVATES TRANSCRIPTION; CELL-DIFFERENTIATION; N-MYC; SEQUENCE; GENE; DIMERIZATION	Myc family proteins appear to function through heterodimerization with the stable, constitutively expressed bHLH-Zip protein, Max. To determine whether Max mediates the function of regulatory proteins other than Myc, we screened a lambdagt11 expression library with radiolabeled Max protein. One cDNA identified encodes a new member of the bHLH-Zip protein family, Mad. Human Mad protein homodimerizes poorly but binds Max in vitro, forming a sequence-specific DNA binding complex with properties very similar to those of Myc-Max. Both Myc-Max and Mad-Max heterocomplexes are favored over Max homodimers, and, unlike Max homodimers, the DNA binding activity of the heterodimers is unaffected by CKII phosphorylation. Mad does not associate with Myc or with representative bHLH, bZip, or bHLH-Zip proteins. In vivo transactivation assays suggest that Myc-Max and Mad-Max complexes have opposing functions in transcription and that Max plays a central role in this network of transcription factors.			AYER, DE (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, SEATTLE, WA 98104 USA.			Ayer, Donald/0000-0002-5595-3269	NCI NIH HHS [R01 CA57138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERBERICH S, 1992, ONCOGENE, V7, P775; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EISENMAN RN, 1989, ONCOGENES MOL ORIGIN, P175; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HENIKOFF S, 1987, GENETICS, V117, P711; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; IDZERDA RL, 1989, P NATL ACAD SCI USA, V86, P4659, DOI 10.1073/pnas.86.12.4659; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SMITH DB, 1989, CURRENT PROTOCOLS MO; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	52	676	691	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 29	1993	72	2					211	222		10.1016/0092-8674(93)90661-9	http://dx.doi.org/10.1016/0092-8674(93)90661-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	8425218				2022-12-28	WOS:A1993KK03800006
J	LALLIER, T; BRONNERFRASER, M				LALLIER, T; BRONNERFRASER, M			INHIBITION OF NEURAL CREST CELL ATTACHMENT BY INTEGRIN ANTISENSE OLIGONUCLEOTIDES	SCIENCE			English	Article							AMINO-ACID SEQUENCE; ACETYLTRANSFERASE GENE-EXPRESSION; ADHESION MOLECULE-1 EXPRESSION; H INDEPENDENT MECHANISM; 2 DISTINCT MECHANISMS; HUMAN BREAST-CANCER; C-MYC EXPRESSION; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; TRANSLATION INITIATION; ALKYL PHOSPHOTRIESTER	Neural crest cell interactions with extracellular matrix molecules were analyzed with the use of antisense oligonucleotides to block synthesis of integrin subunits. When added to the culture medium of quail neural crest cells, selected antisense phosphorothiol oligonucleotides reduced the amounts of cell surface alpha1 or beta1, integrin subunits by up to 95 percent and inhibited neural crest cell attachment to laminin or fibronectin substrata. Differential effects on specific alpha integrins were noted after treatment with alpha-specific oligonucleotides. Cells recovered the ability to bind to substrata 8 to 16 hours after treatment with inhibitory oligonucleotides. The operation of at least three distinct alpha integrin subunits is indicated by substratum-selective inhibition of cell attachment.	UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717	University of California System; University of California Irvine			Lallier, Thomas E/K-5977-2015	Lallier, Thomas/0000-0001-6577-6676; Bronner, Marianne/0000-0003-4274-1862	PHS HHS [15527] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790; AKHTAR S, 1991, LIFE SCI, V49, P1793, DOI 10.1016/0024-3205(91)90480-Y; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BOIZIAU C, 1991, NUCLEIC ACIDS RES, V19, P1113, DOI 10.1093/nar/19.5.1113; BOSSY B, 1991, EMBO J, V10, P2375, DOI 10.1002/j.1460-2075.1991.tb07776.x; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; BRONNERFRASER M, 1986, DEV BIOL, V117, P528, DOI 10.1016/0012-1606(86)90320-9; BRONNERFRASER M, 1988, J CELL BIOL, V106, P1321, DOI 10.1083/jcb.106.4.1321; BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; BRONNERFRASER M, 1988, J NEUROSCI RES, V21, P135, DOI 10.1002/jnr.490210206; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; BURCH RM, 1991, J CLIN INVEST, V88, P1190, DOI 10.1172/JCI115421; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; COTTEN M, 1991, NUCLEIC ACIDS RES, V19, P2629, DOI 10.1093/nar/19.10.2629; DECURTIS I, 1991, J CELL BIOL, V113, P405, DOI 10.1083/jcb.113.2.405; HAYASHI Y, 1991, CELL STRUCT FUNCT, V16, P241, DOI 10.1247/csf.16.241; HEINO J, 1989, J BIOL CHEM, V264, P380; HICKSTEIN DD, 1989, P NATL ACAD SCI USA, V86, P257, DOI 10.1073/pnas.86.1.257; HOKE GD, 1991, NUCLEIC ACIDS RES, V19, P5743, DOI 10.1093/nar/19.20.5743; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; LALLIER T, 1991, DEVELOPMENT, V113, P1069; LALLIER T, 1992, J CELL BIOL, V119, P1335, DOI 10.1083/jcb.119.5.1335; Lallier T., 1990, Seminars in Developmental Biology, V1, P35; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEONETTI JP, 1991, P NATL ACAD SCI USA, V88, P2702, DOI 10.1073/pnas.88.7.2702; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; MANSON J, 1990, LYMPHOKINE RES, V9, P35; MARCUSSEKURA CJ, 1987, NUCLEIC ACIDS RES, V15, P5749, DOI 10.1093/nar/15.14.5749; MCCLAY DR, 1981, P NATL ACAD SCI-BIOL, V78, P4975, DOI 10.1073/pnas.78.8.4975; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; SYFRIG J, 1991, EXP CELL RES, V194, P165, DOI 10.1016/0014-4827(91)90349-Y; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TEICHMANWEINBERG A, 1988, GENE, V72, P297, DOI 10.1016/0378-1119(88)90155-2; WATSON PH, 1991, CANCER RES, V51, P3996; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1743	44	94	101	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 29	1993	259	5095					692	695		10.1126/science.8430321	http://dx.doi.org/10.1126/science.8430321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8430321				2022-12-28	WOS:A1993KJ68800046
J	WEINER, AM				WEINER, AM			MESSENGER-RNA SPLICING AND AUTOCATALYTIC INTRONS - DISTANT COUSINS OR THE PRODUCTS OF CHEMICAL DETERMINISM	CELL			English	Article							SMALL NUCLEAR-RNA; BINDING-SITE; GUANOSINE; MODEL; YEAST				WEINER, AM (corresponding author), YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510, USA.							ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHAPDELAINE Y, 1991, CELL, V65, P465, DOI 10.1016/0092-8674(91)90464-A; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MAIZELS N, 1993, IN PRESS RNA WORLD; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WOODSON SA, 1988, BIOCHEMISTRY-US, V27, P3130, DOI 10.1021/bi00409a004; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3	27	103	103	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					161	164		10.1016/0092-8674(93)90654-9	http://dx.doi.org/10.1016/0092-8674(93)90654-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	8425215				2022-12-28	WOS:A1993KK03800001
J	ZERVOS, AS; GYURIS, J; BRENT, R				ZERVOS, AS; GYURIS, J; BRENT, R			MXI1, A PROTEIN THAT SPECIFICALLY INTERACTS WITH MAX TO BIND MYC-MAX RECOGNITION SITES	CELL			English	Article							HUMAN C-MYC; DNA-BINDING; LEUCINE ZIPPER; CELL-DIFFERENTIATION; TRANSFORMATION; EXPRESSION; YEAST; ACTIVATION; TRANSCRIPTION; ONCOGENE	We used the interaction trap to isolate a novel human protein that specifically interacts with Max. This protein, Mxi1 (for Max interactor 1), contains a bHLH-Zip motif that is similar to that found in Myc family proteins. Mxi1 interacts specifically with Max to form heterodimers that efficiently bind to the Myc-Max consensus recognition site. When bound to DNA by a LexA moiety in yeast, Mxi1 does not stimulate transcription. mxi1 mRNA is expressed in many tissues, and its expression is elevated in U-937 myeloid leukemia cells that have been stimulated to differentiate. These facts are consistent with a model in which Mxi1-Max heterodimers indirectly inhibit Myc function in two ways: first, by sequestering Max, thus preventing the formation of Myc-Max heterodimers, and second, by competing with Myc-Max heterodimers for binding to target sites.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	ZERVOS, AS (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.							ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Ausubel FM, 1992, CURRENT PROTOCOLS MO; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DANG CV, 1992, P NATL ACAD SCI USA, V89, P559; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EDINA Y, 1983, J BIOL CHEM, V258, P13258; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; GUTHRIE C, 1992, METHOD ENZYMOL, V194, P1; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALAZONETIS TD, 1992, SCIENCE, V255, P464, DOI 10.1126/science.1734524; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HASS R, 1991, CELL GROWTH DIFFER, V2, P541; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; Miller J.H., 1972, EXPT MOL GENETICS; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMITH DB, 1989, CURRENT PROTOCOLS MO; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TOKUNAGA K, 1987, CANCER RES, V47, P5616; VINSON CR, 1992, NEW BIOL, V4, P396; WATANABE T, 1985, BIOCHEM BIOPH RES CO, V126, P999, DOI 10.1016/0006-291X(85)90284-0	58	726	900	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					223	232		10.1016/0092-8674(93)90662-A	http://dx.doi.org/10.1016/0092-8674(93)90662-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	8425219				2022-12-28	WOS:A1993KK03800007
J	HOBSON, RW; WEISS, DG; FIELDS, WS; GOLDSTONE, J; MOORE, WS; TOWNE, JB; WRIGHT, CB				HOBSON, RW; WEISS, DG; FIELDS, WS; GOLDSTONE, J; MOORE, WS; TOWNE, JB; WRIGHT, CB			EFFICACY OF CAROTID ENDARTERECTOMY FOR ASYMPTOMATIC CAROTID STENOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSIENT ISCHEMIC ATTACKS; ARTERY STENOSIS; DISEASE; BRUITS; MORTALITY; STROKE	Background. The efficacy of carotid endarterectomy in patients with asymptomatic carotid stenosis has not been confirmed in randomized clinical trials, despite the widespread use of operative intervention in such patients. Methods. We conducted a multicenter clinical trial at 11 Veterans Affairs medical centers to determine the effect of carotid endarterectomy on the combined incidence of transient ischemic attack, transient monocular blindness, and stroke. We studied 444 men with asymptomatic carotid stenosis shown arteriographically to reduce the diameter of the arterial lumen by 50 percent or more. The patients were randomly assigned to optimal medical treatment including antiplatelet medication (aspirin) plus carotid endarterectomy (the surgical group; 211 patients) or optimal medical treatment alone (the medical group; 233 patients). All the patients at each center were followed independently by a vascular surgeon and a neurologist for a mean of 47.9 months. Results. The combined incidence of ipsilateral neurologic events was 8.0 percent in the surgical group and 20.6 percent in the medical group (P<0.001), giving a relative risk (for the surgical group vs. the medical group) of 0.38 (95 percent confidence interval, 0.22 to 0.67). The incidence of ipsilateral stroke alone was 4.7 percent in the surgical group and 9.4 percent in the medical group, An analysis of stroke and death combined within the first 30 postoperative days showed no significant differences. Nor were there significant differences between groups in an analysis of all strokes and deaths (surgical, 41.2 percent; medical, 44.2 percent; relative risk, 0.92; 95 percent confidence interval, 0.69 to 1.22). Overall mortality, including postoperative deaths, was primarily due to coronary atherosclerosis. Conclusions. Carotid endarterectomy reduced the overall incidence of ipsilateral neurologic events in a selected group of male patients with asymptomatic carotid stenosis. We did not find a significant influence of carotid endarterectomy on the combined incidence of stroke and death, but because of the size of our sample, a modest effect could not be excluded.	VET AFFAIRS COOPERAT STUDIES PROGRAM COORDINATING CTR,PERRY POINT,MD									Anderson R J, 1991, Ann Vasc Surg, V5, P111, DOI 10.1007/BF02016741; [Anonymous], 1975, Stroke, V6, P564; AWAD I, 1986, STROKE, V17, P399, DOI 10.1161/01.STR.17.3.399; BARNETT HJM, 1984, STROKE, V15, P941, DOI 10.1161/01.STR.15.6.941; BLACKSHEAR WM, 1979, SURGERY, V86, P698; BROTT T, 1984, STROKE, V15, P950, DOI 10.1161/01.STR.15.6.950; BUSUTTIL RW, 1981, JAMA-J AM MED ASSOC, V245, P1438, DOI 10.1001/jama.245.14.1438; CALLOW AD, 1988, AM J MED, V85, P835; CHAMBERS BR, 1984, STROKE, V15, P964, DOI 10.1161/01.STR.15.6.964; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; CHIKOS PM, 1983, STROKE, V14, P885, DOI 10.1161/01.STR.14.6.885; CULLEN SJ, 1983, CIRCULATION, V68, P83; EASTON JD, 1977, STROKE, V8, P565, DOI 10.1161/01.STR.8.5.565; GEE W, 1975, AM J SURG, V130, P121, DOI 10.1016/0002-9610(75)90359-1; JAVID H, 1971, ARCH SURG-CHICAGO, V102, P389; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; MOORE DJ, 1985, ANN SURG, V202, P491, DOI 10.1097/00000658-198510000-00009; PERRONE P, 1979, EUR NEUROL, V18, P217, DOI 10.1159/000115079; Pocock SJ., 2013, CLIN TRIALS PRACTICA; ROEDERER GO, 1984, STROKE, V15, P605, DOI 10.1161/01.STR.15.4.605; THOMPSON JE, 1978, ANN SURG, V188, P308, DOI 10.1097/00000658-197809000-00005; TOOLE JF, 1991, STROKE, V22, P99, DOI 10.1161/01.STR.22.1.99; TOWNE JB, 1990, J VASC SURG, V11, P252, DOI 10.1067/mva.1990.16484; Treiman R L, 1990, Ann Vasc Surg, V4, P29, DOI 10.1007/BF02042685; WYLIE EJ, 1980, ARTERIOPATHIES CEREB, P231; 1991, LANCET, V337, P1235; 1989, STROKE, V20, P844; 1985, NEW ENGL J MED, V313, P1191; 1986, STROKE, V17, P534; 1991, STROKE, V22, P1229; 1991, NEW ENGL J MED, V325, P445	31	1069	1097	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	1993	328	4					221	227		10.1056/NEJM199301283280401	http://dx.doi.org/10.1056/NEJM199301283280401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ442	8418401	Bronze			2022-12-28	WOS:A1993KJ44200001
J	CUENOUD, B; SCHEPARTZ, A				CUENOUD, B; SCHEPARTZ, A			ALTERED SPECIFICITY OF DNA-BINDING PROTEINS WITH TRANSITION-METAL DIMERIZATION DOMAINS	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATOR PROTEIN; LEUCINE ZIPPER PROTEINS; YEAST GCN4; GEL-ELECTROPHORESIS; COILED COIL; FOS; JUN; DESIGN; C/EBP; MOTIF	The bZIP motif is characterized by a leucine zipper domain that mediates dimerization and a basic domain that contacts DNA. A series of transition metal dimerization domains were used to alter systematically the relative orientation of basic domain peptides. Both the affinity and the specificity of the peptide-DNA interaction depend on domain orientation. These results indicate that the precise configuration linking the domains is important; dimerization is not always sufficient for DNA binding. This approach to studying the effect of orientation on protein function complements mutagenesis and could be used in many systems.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511	Yale University								AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CUENOUD B, 1991, TETRAHEDRON LETT, V28, P3325; CUENOUD B, IN PRESS P NATL ACAD; CUENOUD B, UNPUB; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DEVORE JL, 1987, PROBABILITY STATISTI; Fasman G. D., 1975, HDB BIOCH MOL BIOL, V1; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GHADIRI MR, 1992, J AM CHEM SOC, V114, P825, DOI 10.1021/ja00029a004; GUTTE B, 1979, NATURE, V281, P650, DOI 10.1038/281650a0; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JONES MW, 1992, INORG CHEM, V31, P1308, DOI 10.1021/ic00033a036; KAISER ET, 1987, TRENDS BIOCHEM SCI, V12, P305, DOI 10.1016/0968-0004(87)90147-2; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIEBERMAN M, 1991, J AM CHEM SOC, V113, P1470, DOI 10.1021/ja00004a090; MANIATIS T, 1987, MOL CLONING; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; MORGAN GT, 1932, J CHEM SOC, V134, P20; MUTTER M, 1989, ANGEW CHEM INT EDIT, V28, P535, DOI 10.1002/anie.198905353; OAKLEY MG, 1990, SCIENCE, V248, P847, DOI 10.1126/science.2111578; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RASMUSSEN R, 1991, P NATL ACAD SCI USA, V88, P561, DOI 10.1073/pnas.88.2.561; RICHARDSON JS, 1989, TRENDS BIOCHEM SCI, V14, P304, DOI 10.1016/0968-0004(89)90070-4; SAUDEK V, 1991, PROTEIN ENG, V4, P519, DOI 10.1093/protein/4.5.519; SCHEPARTZ A, 1989, J AM CHEM SOC, V111, P5976, DOI 10.1021/ja00197a088; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TALANIAN RV, 1992, BIOCHEMISTRY-US, V31, P6871, DOI 10.1021/bi00145a002; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004	60	126	126	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					510	513		10.1126/science.8424173	http://dx.doi.org/10.1126/science.8424173			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8424173				2022-12-28	WOS:A1993KJ07900033
J	LEE, DY; HAYES, JJ; PRUSS, D; WOLFFE, AP				LEE, DY; HAYES, JJ; PRUSS, D; WOLFFE, AP			A POSITIVE ROLE FOR HISTONE ACETYLATION IN TRANSCRIPTION FACTOR ACCESS TO NUCLEOSOMAL DNA	CELL			English	Article							5S RNA GENE; CHROMATIN CORE PARTICLES; LINKING NUMBER CHANGE; TUMOR VIRUS PROMOTER; SILENT MATING LOCI; FACTOR-IIIA; 5S-RNA GENE; C-FOS; BINDING; REPRESSION	Acetylation of the N-terminal tails of the core histones directly facilitates the recognition by TFIIIA of the 5S RNA gene within model chromatin templates. This effect is independent of a reduction in the extent of histone-DNA interactions or a change in DNA helical repeat; it is also independent of whether a histone tetramer or octamer inhibits TFIIIA binding. Removal of the N-terminal tails from the core histones also facilitates the association of TFIIIA with nucleosomal templates. We suggest that the histone tails have a major role in restricting transcription factor access to DNA and that their acetylation releases this restriction by directing dissociation of the tails from DNA and/or inducing a change in DNA configuration on the histone core to allow transcription factor binding. Acetylation of core histones might be expected to exert a major influence on the accessibility of chromatin to regulatory molecules.			LEE, DY (corresponding author), NICHHD, MOLEC EMBRYOL LAB, BETHESDA, MD 20892 USA.							ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BOLUND LA, 1973, EUR J BIOCHEM, V35, P546, DOI 10.1111/j.1432-1033.1973.tb02871.x; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CARY PD, 1982, EUR J BIOCHEM, V127, P137, DOI 10.1111/j.1432-1033.1982.tb06847.x; CARY PD, 1978, EUR J BIOCHEM, V89, P475, DOI 10.1111/j.1432-1033.1978.tb12551.x; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHRISTENSEN ME, 1984, NUCLEIC ACIDS RES, V12, P4575, DOI 10.1093/nar/12.11.4575; CLARK DJ, 1991, EMBO J, V10, P3419, DOI 10.1002/j.1460-2075.1991.tb04906.x; DABAN JR, 1982, J MOL BIOL, V156, P749, DOI 10.1016/0022-2836(82)90140-1; DELCUVE GP, 1992, ANAL BIOCHEM, V200, P339, DOI 10.1016/0003-2697(92)90475-M; DELRIO S, 1991, NUCLEIC ACIDS RES, V19, P6197; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FITZGERALD PC, 1985, J BIOL CHEM, V260, P5318; GOLDBLATT D, 1975, BIOCHEMISTRY-US, V14, P1689, DOI 10.1021/bi00679a022; GOTTESFELD JM, 1987, MOL CELL BIOL, V7, P1612, DOI 10.1128/MCB.7.5.1612; GRIGORYEV SA, 1982, EUR J BIOCHEM, V129, P119, DOI 10.1111/j.1432-1033.1982.tb07029.x; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HAYES JJ, 1992, P NATL ACAD SCI USA, V89, P1229, DOI 10.1073/pnas.89.4.1229; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KLUG A, 1981, NUCLEIC ACIDS RES, V9, P4267, DOI 10.1093/nar/9.17.4267; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; NORTON VG, 1990, J BIOL CHEM, V265, P19848; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PERLMANN T, 1992, P NATL ACAD SCI USA, V89, P3884, DOI 10.1073/pnas.89.9.3884; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PERRY CA, 1989, NUCLEIC ACIDS RES, V17, P4275, DOI 10.1093/nar/17.11.4275; PERRY M, 1981, J BIOL CHEM, V256, P3313; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROBERGE M, 1991, FEBS LETT, V288, P215, DOI 10.1016/0014-5793(91)81037-9; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; SUNG MT, 1970, P NATL ACAD SCI USA, V67, P1616, DOI 10.1073/pnas.67.3.1616; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WALKER IO, 1984, BIOCHEMISTRY-US, V23, P5622, DOI 10.1021/bi00318a037; WALKER J, 1990, J BIOL CHEM, V265, P5736; WATERBORG JH, 1984, EUR J BIOCHEM, V142, P329, DOI 10.1111/j.1432-1033.1984.tb08290.x; WHITE JH, 1989, J MOL BIOL, V207, P193, DOI 10.1016/0022-2836(89)90450-6; WHITEWAY M, 1985, CELL, V43, P483, DOI 10.1016/0092-8674(85)90178-3; WHITLOCK JP, 1977, J BIOL CHEM, V252, P6516; WINSOR WT, 1988, J BIOL CHEM, V263, P10272; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WOLFFE AP, 1987, CELL, V51, P732, DOI 10.1016/0092-8674(87)90096-1; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	75	967	1000	0	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 15	1993	72	1					73	84		10.1016/0092-8674(93)90051-Q	http://dx.doi.org/10.1016/0092-8674(93)90051-Q			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8422685				2022-12-28	WOS:A1993KG95500011
J	POWLES, JW; GIFFORD, S				POWLES, JW; GIFFORD, S			HEALTH OF NATIONS - LESSONS FROM VICTORIA, AUSTRALIA	BRITISH MEDICAL JOURNAL			English	Article							MEDIA	In its white paper The Health of the Nation the government has announced its intention to give more priority to preventive health care. Two examples from Victoria, Australia, show how coordinated legislative and voluntary sector action can have a substantial impact on public behaviour. The introduction and enforcement of strict drink-driving laws and speed limits backed up by forceful television advertisements produced a large reduction in deaths from road traffic accidents, the death rate in relation to the number of vehicles in 1991 being among the lowest in the world. Smoking has also declined in parallel with a phased ban on advertising and use of taxes from tobacco sales to replace tobacco sponsorship of sports and arts and fund health promotion.	MONASH UNIV,DEPT SOCIAL & PREVENT MED,PRAHRAN,VIC 3181,AUSTRALIA	Monash University	POWLES, JW (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,FORVIE SITE,CAMBRIDGE CB2 2SR,ENGLAND.			Powles, John/0000-0002-0766-7989				BRUCE D, 1991, AGE MELBOURNE   0914, P5; DESPAIGNET ET, 1991, MORTALITY SERIES AUS, V1; EGGER G, 1983, BRIT MED J, V287, P1125, DOI 10.1136/bmj.287.6399.1125; HARPER G, 1991, SOCIAL ADVERTISING T; HAWTHORNE G, 1991, PERSONAL TRANSPORT A; HILL DJ, 1991, MED J AUSTRALIA, V154, P800; HILL DJ, 1990, IN PRESS MED J AUST; LADER D, 1991, SMOKING SECONDARY SC; MACASKILL P, 1992, AM J PUBLIC HEALTH, V82, P96, DOI 10.2105/AJPH.82.1.96; MULLINS R, QUIT EVALUATION STUD, V6; PIERCE JP, 1990, AM J PUBLIC HEALTH, V80, P565, DOI 10.2105/AJPH.80.5.565; RAW M, 1990, CLEARING AIR GUIDE A, P59; Smeed R.J., 1972, ACCIDENT ANAL PREV, V4, P303, DOI [10.1016/0001-4575(72)90029-2, DOI 10.1016/0001-4575(72)90029-2]; SMITH R, 1991, HLTH NATION BMJ VIEW; STONE D, 1992, SUNDAY AGE MELB 0531, P6; 1992, AUSTR HLTH 1992; 1991, 1991 VICT HLTH PROM; 1991, 1989 90 NATIONAL HLT; [No title captured]; 1991, TRANSPORT STATISTICS, P258; 1992, GHS21 OFF POP CENS S, P113; 1992, ROAD TRAFFIC ACCIDEN	22	21	21	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1993	306	6870					125	127		10.1136/bmj.306.6870.125	http://dx.doi.org/10.1136/bmj.306.6870.125			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KG465	8435611	Green Published, Bronze			2022-12-28	WOS:A1993KG46500029
J	HALL, ZW; SANES, JR				HALL, ZW; SANES, JR			SYNAPTIC STRUCTURE AND DEVELOPMENT - THE NEUROMUSCULAR-JUNCTION	CELL			English	Review							GENE-RELATED PEPTIDE; ACETYLCHOLINE-RECEPTOR CLUSTERS; CULTURED MUSCLE-CELLS; ADULT SKELETAL-MUSCLE; SUBUNIT MESSENGER-RNA; TORPEDO POSTSYNAPTIC MEMBRANES; HEPARAN-SULFATE PROTEOGLYCAN; DYSTROPHIN-RELATED PROTEIN; FIBROBLAST GROWTH-FACTOR; SPINAL-CORD MOTONEURONS		WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	HALL, ZW (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA.							ALLEN F, 1991, NEURON, V6, P101, DOI 10.1016/0896-6273(91)90125-J; ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P757, DOI 10.1113/jphysiol.1977.sp011880; ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; ANDERSON MJ, 1983, J CELL BIOL, V97, P1396, DOI 10.1083/jcb.97.5.1396; ANDERSON MJ, 1991, DEV BIOL, V147, P464, DOI 10.1016/0012-1606(91)90305-M; ANDERSON MJ, 1986, J CELL BIOL, V102, P863, DOI 10.1083/jcb.102.3.863; ANGLISTER L, 1991, J CELL BIOL, V115, P755, DOI 10.1083/jcb.115.3.755; ANGLISTER L, 1985, J CELL BIOL, V101, P735, DOI 10.1083/jcb.101.3.735; ASTROW SH, 1992, J NEUROSCI, V12, P1602; AVILA OL, 1989, J NEUROSCI, V9, P2902; AXELROD D, 1976, P NATL ACAD SCI USA, V73, P4594, DOI 10.1073/pnas.73.12.4594; BAKER LP, 1992, J CELL SCI, V102, P543; BALICEGORDON RJ, 1992, IN PRESS J NEUROSCI; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MR, 1975, COLD SPRING HARB SYM, V40, P409, DOI 10.1101/SQB.1976.040.01.039; BERG DK, 1975, J PHYSIOL-LONDON, V244, P659, DOI 10.1113/jphysiol.1975.sp010818; BERG DK, 1975, J PHYSIOL-LONDON, V252, P771, DOI 10.1113/jphysiol.1975.sp011169; BETZ WJ, 1980, J PHYSIOL-LONDON, V303, P265, DOI 10.1113/jphysiol.1980.sp013284; BEVAN S, 1977, J PHYSIOL-LONDON, V267, P195, DOI 10.1113/jphysiol.1977.sp011808; BEWICK GS, 1992, NEUROREPORT, V3, P857, DOI 10.1097/00001756-199210000-00009; BIRKS R, 1960, J PHYSIOL-LONDON, V150, P145, DOI 10.1113/jphysiol.1960.sp006379; BIRNBAUM M, 1980, PFLUG ARCH EUR J PHY, V385, P37, DOI 10.1007/BF00583913; BIXBY JL, 1987, P NATL ACAD SCI USA, V84, P2555, DOI 10.1073/pnas.84.8.2555; BLOCH RJ, 1991, J CELL BIOL, V115, P435, DOI 10.1083/jcb.115.2.435; BLOCH RJ, 1989, J CELL BIOL, V108, P481, DOI 10.1083/jcb.108.2.481; BLOCH RJ, 1983, J CELL BIOL, V97, P217, DOI 10.1083/jcb.97.1.217; BLOCH RJ, 1981, DEV BIOL, V81, P386, DOI 10.1016/0012-1606(81)90305-5; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; BOURNE H, 1993, CELL NEURON S, V72; BOZYCZKO D, 1989, EXP CELL RES, V183, P72, DOI 10.1016/0014-4827(89)90419-9; BREHM P, 1988, DEV BIOL, V129, P1, DOI 10.1016/0012-1606(88)90156-X; BRENNER HR, 1989, J PHYSIOL-LONDON, V410, P501, DOI 10.1113/jphysiol.1989.sp017546; BRENNER HR, 1987, J PHYSIOL-LONDON, V388, P367, DOI 10.1113/jphysiol.1987.sp016619; BRENNER HR, 1992, DEVELOPMENT, V116, P41; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; BRENNER HR, 1983, J PHYSIOL-LONDON, V337, P159, DOI 10.1113/jphysiol.1983.sp014617; BRENNER HR, 1988, NEUROSCI LETT, V88, P161, DOI 10.1016/0304-3940(88)90119-X; BROCKES JP, 1984, PROC R SOC SER B-BIO, V222, P121, DOI 10.1098/rspb.1984.0053; BROCKES JP, 1975, P NATL ACAD SCI USA, V72, P1368, DOI 10.1073/pnas.72.4.1368; BROWN MC, 1981, ANNU REV NEUROSCI, V4, P17, DOI 10.1146/annurev.ne.04.030181.000313; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; BUCHANAN J, 1989, J NEUROSCI, V9, P1540; BURDEN S, 1977, DEV BIOL, V57, P317, DOI 10.1016/0012-1606(77)90218-4; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; BURDEN SJ, 1985, P NATL ACAD SCI USA, V82, P8270, DOI 10.1073/pnas.82.23.8270; CALLAWAY EM, 1987, NATURE, V328, P422, DOI 10.1038/328422a0; CARONI P, 1990, J CELL BIOL, V110, P1307, DOI 10.1083/jcb.110.4.1307; CARONI P, 1992, J NEUROSCI, V12, P3849; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CARTAUD A, 1989, J CELL BIOL, V109, P1745, DOI 10.1083/jcb.109.4.1745; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHAMPANERIA S, 1992, DEV BIOL, V149, P261, DOI 10.1016/0012-1606(92)90283-M; CHANG CC, 1975, NATURE, V253, P643, DOI 10.1038/253643a0; CHANGEUX JP, 1991, NEW BIOL, V3, P413; CHIU AY, 1984, DEV BIOL, V103, P456, DOI 10.1016/0012-1606(84)90333-6; CHOW I, 1983, J PHYSIOL-LONDON, V339, P553, DOI 10.1113/jphysiol.1983.sp014733; COHEN MW, 1992, J NEUROSCI, V12, P2982, DOI 10.1523/JNEUROSCI.12-08-02982.1992; COHEN MW, 1991, J NEUROSCI, V11, P1032; CONNOLD AL, 1986, DEV BRAIN RES, V28, P99, DOI 10.1016/0165-3806(86)90069-6; CONNOR EA, 1987, J CELL BIOL, V104, P109, DOI 10.1083/jcb.104.1.109; COUTEAUX R, 1973, STRUCTURE FUNCTION M, V2, P483; COVAULT J, 1986, J CELL BIOL, V102, P731, DOI 10.1083/jcb.102.3.731; COVAULT J, 1986, J CELL BIOL, V102, P716, DOI 10.1083/jcb.102.3.716; COVAULT J, 1985, P NATL ACAD SCI USA, V82, P4544, DOI 10.1073/pnas.82.13.4544; COVAULT J, 1987, J CELL BIOL, V105, P2479, DOI 10.1083/jcb.105.6.2479; DAHM LM, 1991, J NEUROSCI, V11, P238; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; DAN Y, 1992, NATURE, V359, P733, DOI 10.1038/359733a0; DANIELS MP, 1990, J CELL SCI, V97, P615; DAVEY DF, 1986, J NEUROSCI, V6, P673; DECKER ER, 1990, J NEUROSCI, V10, P3413; DELAPORTE S, 1986, DEV BIOL, V116, P69, DOI 10.1016/0012-1606(86)90044-8; DENNIS MJ, 1981, ANNU REV NEUROSCI, V4, P43, DOI 10.1146/annurev.ne.04.030181.000355; DUBINSKY JM, 1989, J CELL BIOL, V109, P1733, DOI 10.1083/jcb.109.4.1733; EDWARDS C, 1976, J NEUROBIOL, V7, P377, DOI 10.1002/neu.480070409; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; Elsberg CA, 1917, SCIENCE, V45, P318, DOI 10.1126/science.45.1161.318; ENGEL AG, 1986, MYOLOGY BASIC CLIN, P209; ENGLANDER LL, 1987, J CELL BIOL, V104, P87, DOI 10.1083/jcb.104.1.87; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; EVERS J, 1989, J NEUROSCI, V9, P1523; FALLS DL, 1990, COLD SPRING HARB SYM, V55, P397; FAMBROUGH DM, 1979, PHYSIOL REV, V59, P165, DOI 10.1152/physrev.1979.59.1.165; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1992, CELL, V70, P1, DOI 10.1016/0092-8674(92)90525-H; FESTOFF BW, 1991, J CELL PHYSIOL, V147, P76, DOI 10.1002/jcp.1041470111; FISCHBACH GD, 1972, DEV BIOL, V28, P407, DOI 10.1016/0012-1606(72)90023-1; FISCHBACH GD, 1973, DEV BIOL, V31, P147, DOI 10.1016/0012-1606(73)90326-6; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; FONTAINE B, 1987, J CELL BIOL, V105, P1337, DOI 10.1083/jcb.105.3.1337; FONTAINE B, 1988, EMBO J, V7, P603, DOI 10.1002/j.1460-2075.1988.tb02853.x; FONTAINE B, 1986, NEUROSCI LETT, V71, P59, DOI 10.1016/0304-3940(86)90257-0; FRAIL DE, 1987, P NATL ACAD SCI USA, V84, P6302, DOI 10.1073/pnas.84.17.6302; FRANK E, 1975, COLD SPRING HARB SYM, V40, P275, DOI 10.1101/SQB.1976.040.01.028; FRANK E, 1979, J CELL BIOL, V83, P143, DOI 10.1083/jcb.83.1.143; FRANK E, 1975, J PHYSIOL-LONDON, V247, P725, DOI 10.1113/jphysiol.1975.sp010954; FROEHNER SC, 1981, P NATL ACAD SCI-BIOL, V78, P5230, DOI 10.1073/pnas.78.8.5230; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; FUMAGALLI G, 1990, NEURON, V4, P563, DOI 10.1016/0896-6273(90)90114-U; GATCHALIAN CL, 1989, J CELL BIOL, V108, P1873, DOI 10.1083/jcb.108.5.1873; GLICKSMAN MA, 1983, J NEUROCYTOL, V12, P661, DOI 10.1007/BF01181529; GODFREY EW, 1991, EXP CELL RES, V195, P99, DOI 10.1016/0014-4827(91)90504-N; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GOLDMAN D, 1989, NEURON, V3, P219, DOI 10.1016/0896-6273(89)90035-4; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GORDON H, 1993, IN PRESS J NEUROSCI; GREEN TL, 1992, J BIOL CHEM, V267, P2014; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; GUNNING P, 1991, FASEB J, V5, P3064, DOI 10.1096/fasebj.5.15.1835946; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HAHN CG, 1992, J NEUROSCI, V12, P4677; HALL ZW, 1981, J CELL BIOL, V90, P789, DOI 10.1083/jcb.90.3.789; HALL ZW, 1973, J NEUROBIOL, V4, P343, DOI 10.1002/neu.480040404; HAN HQ, 1991, NATURE, V349, P697, DOI 10.1038/349697a0; HARISH OE, 1992, NEURON, V9, P1201, DOI 10.1016/0896-6273(92)90077-Q; HARTZELL HC, 1973, DEV BIOL, V30, P153, DOI 10.1016/0012-1606(73)90054-7; HENDERSON LP, 1984, J NEUROSCI, V4, P3140; HEUSER JE, 1981, J CELL BIOL, V88, P564, DOI 10.1083/jcb.88.3.564; HIROKAWA N, 1982, J NEUROCYTOL, V11, P487, DOI 10.1007/BF01257990; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; HUGHES RA, 1993, IN PRESS NEURON; HUME RI, 1983, NATURE, V305, P632, DOI 10.1038/305632a0; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER DD, 1991, J NEUROSCI, V11, P3960; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JAHROMI BS, 1992, NEURON, V8, P1069, DOI 10.1016/0896-6273(92)90128-Z; JANSEN JKS, 1990, PROG NEUROBIOL, V34, P39, DOI 10.1016/0301-0082(90)90025-C; JARAMILLO F, 1988, NATURE, V335, P66, DOI 10.1038/335066a0; JASMIN BJ, 1990, NATURE, V344, P673, DOI 10.1038/344673a0; JIA HT, 1992, CELL MOL NEUROBIOL, V12, P241, DOI 10.1007/BF00712929; JO SA, 1992, DEVELOPMENT, V115, P673; KELLY AM, 1969, J CELL BIOL, V42, P154, DOI 10.1083/jcb.42.1.154; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KIDOKORO Y, 1982, P NATL ACAD SCI-BIOL, V79, P6727, DOI 10.1073/pnas.79.21.6727; KLARSFELD A, 1985, P NATL ACAD SCI USA, V82, P4558, DOI 10.1073/pnas.82.13.4558; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; KUFFLER D, 1977, BRAIN RES, V138, P353, DOI 10.1016/0006-8993(77)90752-1; KUFFLER DP, 1986, J COMP NEUROL, V250, P228, DOI 10.1002/cne.902500209; KULLBERG RW, 1977, DEV BIOL, V60, P101, DOI 10.1016/0012-1606(77)90113-0; KUROMI H, 1984, DEV BIOL, V103, P53, DOI 10.1016/0012-1606(84)90006-X; LAROCHELLE WJ, 1989, DEV BIOL, V132, P130, DOI 10.1016/0012-1606(89)90211-X; LAROCHELLE WJ, 1986, J BIOL CHEM, V261, P5270; LAUFER R, 1991, EUR J BIOCHEM, V202, P813, DOI 10.1111/j.1432-1033.1991.tb16437.x; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; LETINSKY MS, 1976, J NEUROCYTOL, V5, P691, DOI 10.1007/BF01181582; LEUNG DW, 1992, NEURON, V8, P1045, DOI 10.1016/0896-6273(92)90126-X; LI JY, 1992, MUSCLE NERVE, V15, P984, DOI 10.1002/mus.880150903; LI L, 1992, ADV CANCER RES, V58, P95, DOI 10.1016/S0065-230X(08)60292-4; LIETH E, 1992, DEV BIOL, V149, P41, DOI 10.1016/0012-1606(92)90262-F; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LOMO T, 1972, J PHYSIOL-LONDON, V221, P493, DOI 10.1113/jphysiol.1972.sp009764; LOMO T, 1980, J PHYSIOL-LONDON, V303, P191, DOI 10.1113/jphysiol.1980.sp013280; LOMO T, 1975, COLD SPRING HARB SYM, V40, P263; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; LUPA MT, 1989, J NEUROSCI, V9, P3937; MAGILLSOLC C, 1990, J EXP BIOL, V153, P1; MAGILLSOLC C, 1988, J CELL BIOL, V107, P1825, DOI 10.1083/jcb.107.5.1825; MAN NT, 1991, J CELL BIOL, V115, P1695; MARAZZI G, 1989, J CELL BIOL, V109, P2337, DOI 10.1083/jcb.109.5.2337; MARTINOU JC, 1991, J NEUROSCI, V11, P1291; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MASSOULIE J, 1988, HDB EXP PHARM, V86, P167; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; MATTEOLI M, 1990, J MOL NEUROSCI, V2, P175, DOI 10.1007/BF02896842; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MERLIE JP, 1984, J CELL BIOL, V99, P332, DOI 10.1083/jcb.99.1.332; MERLIE JP, 1989, NEURON, V2, P1295, DOI 10.1016/0896-6273(89)90067-6; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MITRA AK, 1989, J CELL BIOL, V109, P755, DOI 10.1083/jcb.109.2.755; MOSS BL, 1987, J NEUROBIOL, V18, P101, DOI 10.1002/neu.480180108; MOSS SJ, 1989, J BIOL CHEM, V264, P20199; NAKAJIMA Y, 1980, DEV BIOL, V77, P52, DOI 10.1016/0012-1606(80)90456-X; NASTUK MA, 1991, NEURON, V7, P807, DOI 10.1016/0896-6273(91)90283-6; NEVILLE CM, 1992, IN PRESS CELL MOL NE; NEW HV, 1986, NATURE, V323, P809, DOI 10.1038/323809a0; NOAKES PG, 1992, IN PRESS DEV BIOL, V154; OGATA T, 1988, ARCH HISTOL CYTOL, V51, P385, DOI 10.1679/aohc.51.385; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PENG HB, 1986, J NEUROSCI, V6, P581; PENG HB, 1989, J COMP NEUROL, V290, P533; PENG HB, 1991, NEURON, V6, P237; PENG HB, 1982, J NEUROSCI, V2, P1760; Peters A., 1991, FINE STRUCTURE NERVO; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; PIETTE J, 1992, MECH DEVELOP, V37, P95, DOI 10.1016/0925-4773(92)90018-F; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; REINESS CG, 1981, DEV BIOL, V84, P247, DOI 10.1016/0012-1606(81)90392-4; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; REIST NE, 1992, P NATL ACAD SCI USA, V89, P7625, DOI 10.1073/pnas.89.16.7625; REYNOLDS ML, 1992, J NEUROCYTOL, V21, P50, DOI 10.1007/BF01206897; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; RIDGE RMAP, 1984, J NEUROSCI, V4, P2614; RIEGER F, 1985, J CELL BIOL, V101, P285, DOI 10.1083/jcb.101.1.285; ROBERTS WM, 1987, J PHYSIOL-LONDON, V388, P213, DOI 10.1113/jphysiol.1987.sp016611; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROLE LW, 1985, J NEUROSCI, V5, P2197; ROTZLER S, 1991, NATURE, V349, P337, DOI 10.1038/349337a0; ROUSSELET A, 1982, EMBO J, V1, P439, DOI 10.1002/j.1460-2075.1982.tb01188.x; RUBIN LL, 1980, NATURE, V283, P264, DOI 10.1038/283264a0; RUBIN LL, 1985, P NATL ACAD SCI USA, V82, P7121, DOI 10.1073/pnas.82.20.7121; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SALPETER MM, 1983, J CELL BIOL, V96, P1781, DOI 10.1083/jcb.96.6.1781; SALPETER MM, 1988, J CELL BIOL, V106, P2087, DOI 10.1083/jcb.106.6.2087; SALPETER MM, 1992, J NEUROSCI, V12, P35; SALVATERRA PM, 1989, INT REV NEUROBIOL, V31, P81; SANES JR, 1990, COLD SH Q B, V55, P419; SANES JR, 1991, DEVELOPMENT, V113, P1181; SANES JR, 1984, J NEUROSCI, V4, P464; SANES JR, 1983, COLD SPRING HARB SYM, V48, P667, DOI 10.1101/SQB.1983.048.01.070; SANES JR, 1986, J CELL BIOL, V102, P420, DOI 10.1083/jcb.102.2.420; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANES JR, 1978, J CELL BIOL, V78, P176, DOI 10.1083/jcb.78.1.176; SANES JR, 1980, REINNERVATIOIN SKELE, P131; SCHERER SS, 1984, J NEUROCYTOL, V13, P519, DOI 10.1007/BF01148079; SCHUETZE SM, 1984, J NEUROSCI, V4, P2297; SCHUETZE SM, 1987, ANNU REV NEUROSCI, V10, P403, DOI 10.1146/annurev.ne.10.030187.002155; SCOTT LJC, 1988, J NEUROSCI, V8, P932; SCOTT LJC, 1990, J NEUROSCI, V10, P346; SEALOCK R, 1984, J CELL BIOL, V98, P2239, DOI 10.1083/jcb.98.6.2239; SEALOCK R, 1989, SYNAPSE, V3, P315, DOI 10.1002/syn.890030404; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SEALOCK R, 1986, EXP CELL RES, V163, P143, DOI 10.1016/0014-4827(86)90566-5; SHYNG SL, 1991, NEURON, V6, P469, DOI 10.1016/0896-6273(91)90254-W; SHYNG SL, 1990, J NEUROSCI, V10, P3905, DOI 10.1523/JNEUROSCI.10-12-03905.1990; SIMON AM, 1992, DEVELOPMENT, V114, P545; SMITH MA, 1983, J NEUROCYTOL, V12, P993, DOI 10.1007/BF01153346; SMITH MA, 1992, IN PRESS CELL MOL NE; STEINBACH JH, 1981, DEV BIOL, V84, P267, DOI 10.1016/0012-1606(81)90394-8; STEVENS C, 1993, CELL NEURON S, V72; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUN YA, 1987, P NATL ACAD SCI USA, V84, P2540, DOI 10.1073/pnas.84.8.2540; TAKAHASHI T, 1987, J NEUROSCI, V7, P473; TELLO JF, 1907, TRAB LAB INVEST BIOL, V5, P117; THOMPSON J, 1989, GENE DEV, V3, P348, DOI 10.1101/gad.3.3.348; THOMPSON WJ, 1985, CELL MOL NEUROBIOL, V5, P167, DOI 10.1007/BF00711091; TORRITARELLI F, 1990, J CELL BIOL, V110, P449, DOI 10.1083/jcb.110.2.449; TOYOSHIMA C, 1988, NATURE, V336, P247, DOI 10.1038/336247a0; TSAY HJ, 1989, J CELL BIOL, V108, P1523, DOI 10.1083/jcb.108.4.1523; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; TURNER CE, 1991, EXP CELL RES, V192, P651, DOI 10.1016/0014-4827(91)90090-H; UCHIDA S, 1990, J NEUROCHEM, V54, P1000, DOI 10.1111/j.1471-4159.1990.tb02349.x; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; USDIN TB, 1986, J CELL BIOL, V103, P493, DOI 10.1083/jcb.103.2.493; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; VANESSEN DC, 1990, J NEUROBIOL, V21, P223, DOI 10.1002/neu.480210115; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; VERGARA J, 1985, P NATL ACAD SCI USA, V82, P6352, DOI 10.1073/pnas.82.18.6352; VILLAR MJ, 1989, EUR J NEUROSCI, V1, P269, DOI 10.1111/j.1460-9568.1989.tb00795.x; WALLACE BG, 1990, J NEUROSCI, V10, P3576; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WEINBERG CB, 1979, DEV BIOL, V68, P631, DOI 10.1016/0012-1606(79)90233-1; WEINBERG CB, 1981, DEV BIOL, V84, P255, DOI 10.1016/0012-1606(81)90393-6; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEIS J, 1991, J CELL BIOL, V113, P1385, DOI 10.1083/jcb.113.6.1385; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WITZEMANN V, 1989, FEBS LETT, V242, P419, DOI 10.1016/0014-5793(89)80514-9; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125; WITZEMANN V, 1991, FEBS LETT, V282, P259, DOI 10.1016/0014-5793(91)80490-T; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YEE WC, 1988, J NEUROCYTOL, V17, P649, DOI 10.1007/BF01260992; YOUNG SH, 1983, J NEUROSCI, V3, P225; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0; ZISKINDCONHAIM L, 1984, DEV BIOL, V103, P369, DOI 10.1016/0012-1606(84)90325-7; ZISKINDCONHAIM L, 1984, J NEUROSCI, V4, P2346	285	671	680	0	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN	1993	72			S			99	121		10.1016/S0092-8674(05)80031-5	http://dx.doi.org/10.1016/S0092-8674(05)80031-5			23	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KL707	8428377				2022-12-28	WOS:A1993KL70700007
